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1.1 Medicinal plants and phytochemicals
The living plant functions as a laboratory for the production of not only primary metabolites such as carbohydrates, amino
acids, fatty acids, etc., which are utilized as food by man, but also secondary metabolites having great pharmaceutical
signiﬁcance such as glycoside, alkaloids, ﬂavonoids, volatile oils, and so on [1]. Growth and development of a plant is the
major function of primary metabolites, whereas secondary metabolites are useful in plant defense mechanism, inducing
characteristics color, signaling, and regulation of primary metabolic pathways that help the plant to uphold a balance with
the external environment. Plant metabolites that are responsible for producing color in plants are good example of
secondary metabolites, as the color in plant attracts pollinators and also defends against attack by animals.
The World Health Organization (WHO) estimated that about 65% of the population of the world depends on
plant-derived medicines for their primary health care [2]. Most of the recent research on secondary plant metabolism is
focused on the understanding of the formation of secondary metabolites in plants and their synthesis in large quantity.
A number of factors are also associated, which is detailed in Chapter 2. Although the elucidation of the various metabolic
pathways associated with secondary metabolites has partly been successful as a result of advances made in the use of tracer
techniques, the advances in computer-aided drug discovery (CADD) have also been valuable in the discovery of novel
phytocompounds and their mechanism of actions. Details on CADD were presented in Chapter 3. Based on the biosynthetic origin, secondary metabolites in plants can be divided into the following groups: nitrogen-containing compounds,
terpenoids, and compounds without nitrogen (Fig. 1.1).
The most important intermediates employed in the biosynthesis of secondary metabolites are derived from shikimic
acid, acetyl coenzyme A, mevalonic acid, and 1-deoxyxylulose-5-phosphate, and these are utilized, respectively, in the
shikimate pathway, acetate pathway, mevalonate pathway, and deoxyxylulose phosphate pathway (Fig. 1.2).
Some important examples of drug development from plant origin are galegine from Galega ofﬁcinalis L., which
was used as a model for the synthesis of metformin and other biguanides-type antidiabetic drugs (see Chapter 8 for
more information). Examples of other antidiabetic leads, which can be further explored as possible drug candidates,

Phytochemicals as Lead Compounds for New Drug Discovery. https://doi.org/10.1016/B978-0-12-817890-4.00001-9
Copyright © 2020 Elsevier Inc. All rights reserved.

3

4 PART | I Plants as natural sources of drugs

FIGURE 1.1 Secondary metabolites.

FIGURE 1.2 Biosynthetic pathways of primary and secondary metabolites in plants.

are given in Table 1.1. Other drug development from plants include khellin from Ammi visnaga (L.) Lam., which led to the
development of sodium cromoglycate (cromolyn) as a bronchodilator, and papaverine from Papaver somniferum (as a
source of morphine and codeine), which formed the basis for development of verapamil as an antihypertensive agent
(Fig. 1.3) [22,23].
The antimalarial drug quinine from Cinchona plant formed the basis for the synthesis of chloroquine and meﬂoquine,
which proved to be more successful than quinine in the treatment of malaria (see Chapters 19 and 20 for more information).
However, because of the emergence of resistance against both drugs, this paved way for the discovery of artemisinin, a
plant-derived antimalarial drug [24]. In an attempt to improve the activity and utility of artemisinin, many analogues were
prepared. Two of the most promising analogues are arterolane or OZ277 and the dimeric analogue (Fig. 1.4) [23]. A single
dose of the dimeric analogue has shown to cure malaria-infected mice better than artemisinin. Artemisinin and related
compounds have also shown signiﬁcant antitumor activity in vitro, which gives a clue for further research.
Drug development from some traditional medicinal plants include the antihypertensive agent reserpine from Rauwolﬁa
serpentina (an Ayurvedic medicine for the treatment of snakebite and other ailments); ephedrine, from Ephedra sinica
(a traditional Chinese medicinal plant), which form the basis for the synthesis of the antiasthmatic agents, salbutamol, and
salmeterol as b-receptor agonists; and tubocurarine (historically used as arrow poison) from Chondrodendron and Curare
species used as muscle relaxant. Chapter 6 of this book presented comprehensive details on anticardiovascular disease
agents.
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TABLE 1.1 Antidiabetic agents from plant origin.
S/No.

Compound name

Source

1

Bellidifolin [3]

Swertia japonica
Makino
(Gentianaceae)

Structure

Use
Bellidifolin showed a
dose-dependent hypoglycemic
activity in streptozotocin
(STZ)-induced diabetic rats.

2

()-Epicatechin [4]

Pterocarpus
marsupium Roxb.
(Leguminosae)

It is useful as hypoglycemic
agents in the treatment of
diabetes mellitus.

3

Fagasterol [5]

Phyllanthus
emblica H. B. K.
(Euphorbiaceae)

Reduction of blood glucose
level was observed when fagasterol was injected i.p. to
alloxan-induced
hyperglycemic mice.

4

Gymnemic
acid [6]

Gymnema sylvestre R. Br.
(Asclepiadaceae)

It suppresses selectively the
sweet taste sensation in man
and also
inhibits the glucose absorption
in the rat small intestine, leading to a reduction in plasma
glucose in the oral glucose
tolerance test.

5

Ginsenoside [7]

Panax ginseng
Meyer
(Araliaceae)

Ginseng saponins had a
hypoglycemic action in rats
with STZ-induced diabetes.

6

Kaempferol-3-Orhamnoside [8]

Ziziphus rugosa
Lam.
(Rhamnaceae)

The flavonoids kaempferol-3-Orhamnoside produced hypoglycemic effect in rabbits.

7

Kolaflavanone [9]

Garcinia kola
Hook F.
(Guttiferae)

This compound produces a
significant hypoglycemic effect
in normal and alloxan-induced
diabetes mice.

8

Leucocyanidin [10]

Ficus benghalensis L. (Moraceae)

It is used in traditional medicine
for the management of diabetes
mellitus.

Continued
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TABLE 1.1 Antidiabetic agents from plant origin.dcont’d
S/No.

Compound name

Source

9

Lupeol acetate [11]

Phoenix dactylifera L.
(Palmaceae)

Structure

Use
It showed hypoglycemic activity
in rabbits.

10

Oleanolic acid [12]

Momordica
cochinchinensis
Sprengel
(Cucurbitaceae)

It decreased the amount of water consumption and urine volume in diabetic rats.

11

Quercetin [13]

Bauhinia purpurea L.
(Leguminosae)

It enhances insulin release via
changes in Caþ2 metabolism.

12

Saccharol [14]

Stevia rebaudiana
L. (Compositae)

At the level of 50-fold sucrose
sweetness, saccharol inhibited
oxidative phosphorylation in hepatic tissues.

13

Sapogenol [15]

Bumelia sartorum
L. (Sapotaceae)

Sapogenol elicited a hypoglycemic effect in normal and
alloxan-induced
hyperglycemic mice.

14

Sitosterol-Dglucoside
5,25Stigmastadienolglucoside
Vicine [16]

Momordica
charantia L.
(Cucurbitaceae)

Sitosterol and stigmastadienol
glucosides when administered
i.p. to normal rabbits produced
a gradual but significant fall in
blood sugar.
Vicine on i.p. administration
caused a hypoglycemic
response in normal fasting albino rats.

15

b-Sitosterol [17]

Coffea arabica L.
(Rubiaceae)

It exhibited significant hypoglycemic activity in normal and
hyperglycemic mice.

16

Swerchirin [18]

Swertia chirayita
Roxb.
(Gentianaceae)

It showed blood sugar lowering
effect in fasted, fed, glucoseloaded, and tolbutamidepretreated albino rat models.

Plant secondary metabolites as lead compounds for the production of potent drugs Chapter | 1

7

TABLE 1.1 Antidiabetic agents from plant origin.dcont’d
S/No.

Compound name

Source

17

Tormentic acid [19]

Poterium ancistroides Desf.
(Rosaceae)

Structure

Use
Similar to glibenclamide, it may
act by increasing insulin secretion from islets of Langerhans.

18

Tecomine
Tecostanine [20]

Tecoma stans
H.B.K. Leaf
(Bignoniaceae)

Administration of tecomine and
tecostanine caused reduction in
the blood glucose level in mice.

19

Ursolic acid [21]

Cornus officinalis
Sieb, (Cornaceae)

Ursolic acid produced hypoglycemic activity in rats with diabetes induced by STZ.

FIGURE 1.3 Traditional medicine leads (galegine, khellin, and papaverin).

Examples of the plant-derived anticancer drugs are vincristine and vinblastine from the Catharanthus roseus; etoposide
and teniposide from Podophyllum; paclitaxel from bark of the Paciﬁc yew, Taxus brevifolia; topotecan, irinotecan, and
belotecan from Chinese ornamental tree Camptotheca acuminata, and many others (see Chapters 6 & 7 for more details).
Paclitaxel was the most exciting discovery from plant origin, which acts by stabilizing the microtubule polymer and
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FIGURE 1.4 Analogues of natural antimalarial agents quinine and artemisinin.

protects it from disassembly. It was approved by the FDA for the treatment of ovarian cancer in 1992 and against breast
cancer in 1994. Further research on Taxol results in the development of docetaxel and cabazitaxel. Other examples of
anticancer agent from plant origin are given in Table 1.2, which can be further explored to develop novel anticancer agents.
To further describe the role of secondary metabolites in the synthesis of more potent drugs, few case studies have been
discussed in detail, which are as follows.

1.1.1 Case Study 1: development of new analogues of combretastatins as tubulin inhibitors
The Combretaceae plant family is divided into 20 genera, among which the Combretum genus covers the largest number
(250 species). Only the compounds from Combretum latifolium of the Indian origin have been proved as potent anticancer
agents. Several natural products isolated from Combretum caffrum functions as inhibitors of tubulin polymerization,
inhibitors against human cancer cell lines, vascular targeting agents, and antiangiogenesis agents having remarkable
biological activity. Combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are the most active naturally occurring
combretastatin from C. caffrum having potent anticancer activity via inhibition of tubulin assembly. Because of the poor
solubility of CA4 and CA1, their corresponding phosphate prodrugs (CA4P and CA1P, respectively) were developed,
which also have potent anticancer activity (Fig. 1.5). The common structural features of combretastatin are a trimethoxy
substituted “A”-ring, a “B”-ring containing substituents at C30 and C40 , and an ethene bridge between the two rings which
renders structural rigidity [34,35].
A synthetic strategy for combretastatin is as follows: 1-Bromomethyl-3,4,5-trimethoxybenzene undergoes an SN2
reaction with triphenylphosphine, which yields a phosphonium salt. This compound, through a ylide intermediate, is
coupled to a benzaldehyde-derived B-ring resulting to the desired substituents using a Wittig oleﬁnation. The Wittig
reaction produces varying amounts of E and Z isomers depending mainly on solvent polarity, temperature, electronic effect
of substituents, and metal cation coordination effects. Generally, cis-combretastatin shows improved ability over
trans-combretastatin to inhibit tubulin polymerization and cytotoxicity. To directly generate the cis forms, a Perkin
condensation reaction can be used [36].
The discovery small-molecule inhibitor of tubulin assembly was initiated with colchicine. Thereafter, several other
naturally occurring tubulin inhibitors were identiﬁed such as dolastatin and CA4, epothilone A, paclitaxel, vinblastine, etc.
Based on the above scaffolds, several synthetic analogues were also developed. To enhance the efﬁcacy of combretastatins
CA4 and CA1, many compounds have been synthesized by doing modiﬁcation in the functional group in A and B aryl rings,

TABLE 1.2 Anticancer agents from plant origin.
S/
No.

Compound name

Source

1

Camptothecin [25]

Camptotheca
acuminata
(Nyssaceae)

Remarkable activity against L1210
leukemia. Several analogues of
Camptothecin, i.e., exatecan mesylate
dihydrate (DX-8951f), CKD-602,
NX211, 9-AC (IDEC-132), 9-NC
(rubitecan), karenitecin (BNP-1350),
gimatecan, diflomotecan (BN-80915),
etc., are under evaluation.

2

Combretastatins
[26]

Combretum
latifolium
(Combretaceae)

Combretastatin A-4 (a tubulin inhibitor)
is the most potent naturally occurring
combretastatin. Its phosphate prodrug
(CA-4-P) and other analogues of CA-4
such as ombrabulin are currently being
investigated in clinical trials.

3

Epigallocatechin-3gallate [27]

Catechin; green tea

It is antioxidant, decreases DNA
damage from oxidative stress,
antiproliferative effects, inhibition of
specific kinases, inhibits carcinogenesis
induced chemically or by UV.

4

Flavopiridol [28]

Dysoxylum binectariferum Hook.f.
(Meliaceae)

It has various activities like
antiinflammatory, immunomodulatory
activity, tyrosine kinase activity, growth
inhibitory effects, etc.

5

Homoharringtonine
[29]

Cephalotaxus
harringtonii
(Cephalotaxaceae)

Homoharringtonine is active against
number of murine tumors, including
B26 melanoma, CD8F1 mammary
carcinoma, L1210 leukemia, and
especially colon 38 tumor and P388
leukemia.

6

Noscapine [30]

Papaver somniferum

It has various roles like antiproliferative
properties, microtubule interfering,
inhibition of tumor growth and
progression, etc.

7

Podophyllotoxin
[31]

Podophyllum
peltatum
(Berberidaceae)

It is effective against ascitic tumors,
testicular tumors, ovarian and
gestational carcinomas, different types
of lung cancer (small cell, squamous,
adenocarcinoma, Lewis carcinoma),
leukemias (monocytic and refractory),
malignant and recurrent lymphomas,
urogenital tumors, sarcomas,
melanomas, and experimentally
induced colon cancer.

8

Pomiferin [27]

Maclura pomifera
(Moraceae); Dereeis
Malaccensis

It has various roles like proapoptotic
effects, DNA fragmentation, inhibition
of oxidative damage of DNA,
antioxidant activity, inhibition of
histone deacetylases, cytotoxicity of
cancer cells, growth inhibition in six
human cancer cell lines i.e., ACHN
(kidney), NCIeH23 (lung), PC-3
(prostate), MDA-MB-231 (breast),
LOX-IMVI (melanoma), HCT-15
(colon).

Structure

Uses

Continued
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TABLE 1.2 Anticancer agents from plant origin.dcont’d
S/
No.

Compound name

Source

9

Roscovitine [29]

Raphanus sativus L.
(Brassicaceae)

It inhibits cyclin-dependent kinases
and causes reduction of cell cycle
progression.

10

Taxol [32]

Taxus brevifolia
(Taxaceae)

Taxol and its analogues are used for
the treatment of breast, lung, and
ovarian carcinomas and also for
AIDS-related Kaposi’s sarcoma.

11

Vinca alkaloid [33]

Catharanthus roseus
(Apocynaceae)

It plays a major role in combination
chemotherapy in the treatment of acute
lymphoblastic leukemias, lymphomas,
bladder, and breast cancers and is an
essential component in the curative
regimen for Hodgkin’s disease (see
Chapter 6 for more information).

Structure

Uses

FIGURE 1.5 Structures of combretastatins, its phosphate prodrugs, and colchicine.

which resulted in the generation of 3-nitro, 3-amino, 3-amino acid salts, 2-nitrogen substituted derivatives, 3-azido,
3,4-methylenedioxy-3-amino derivatives, 3-ﬂuoro, 4-methyl, and 3,4,5-trimethyl combretastatin analogues. In addition,
many combretastatin analogues were also generated via structural modiﬁcation from the basic stilbenoid molecular
core. Examples include phenstatin, hydroxyphenstatin, hetero-combretastatins, combretatropones, aza-combretastatins,
bridge-modiﬁed vicinal diols, combretadioxolane analogues, chalcone derivatives, disubstituted imidazole analogues,
pyridone analogues, and sulfonamide analogues (Fig. 1.6).
This study led to the discovery and development of a large number of structurally distinct combretastatin analogues.
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FIGURE 1.6 Combretastatin derivatives.

1.1.2 Case Study 2: development of coumarin analogues as antiretroviral agents
Coumarins are naturally occurring active constituents of various plants such as Dipteryx odorata, Anthoxanthum odoratum,
Galium odoratum, etc., which have important applications in pharmaceuticals, food, cosmetic, and dye industries.
In plants, coumarins act as antioxidants and enzyme inhibitors and control the actions of growth regulators and
photosynthesis, as well as defense against infection. Owing to wide range of biological activities such as antithrombotics,
anticoagulants, antimicrobial, antibacterial activities, antioxidant, antimalarial, antiinﬂammatory, hepatoprotective,
anticancer, anti-HIV activity, etc., coumarin attracts the scientiﬁc community for further research [37e43] (Fig. 1.7).
The coumarins containing phenolic hydroxyl group act as potent metal chelators and antioxidants which prevent the
formation of free radicals. Owing to possibility of substitution in the structure, coumarins are very variable in structure and
biological activity. Several synthetic routes have been developed for synthesis of coumarins via various named reactions
such as Perkin reaction, Pechmann reaction, Reformatsky reaction, Knoevenagel condensation, Wittig reaction, etc.
To explore the antiretroviral activity of coumarins, a quantitative structureeactivity relationship and docking study was
performed, and several coumarin analogues were designed and synthesized which possess remarkable antiretroviral
activity [44,45]. The reaction was conducted with a Lewis acid such as AlCl3, which catalyzes transesteriﬁcation and
ketoeenol tautomerization reactions. A Michael addition led to the formation of coumarin skeleton followed by
rearomatization, and subsequent acid-induced elimination of water gives 6-acetyl-coumarin, which condenses with
substituted bezaldehydes lacking an a-hydrogen (via ClaiseneSchmidt condensation) using silica sulfuric acid as a catalyst
to form coumarin analogues (Fig. 1.8).
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FIGURE 1.7 Pharmacological properties of coumarins.

FIGURE 1.8 Synthesis of coumarin analogues.

1.1.3 Case Study 3: oseltamivir phosphate as an antiinfluenza drug
Oseltamivir phosphate (Tamiﬂu) was the ﬁrst neuraminidase inhibitor approved by the FDA in 1999 as the only orally
available drug for both prophylaxis and treatment of human inﬂuenza and H5N1 avian ﬂu or bird ﬂu. According to the WHO
records since 2003, numerous people have been killed because of human inﬂuenza and the H5N1 avian ﬂu in many countries,
and the pathogenicity is gradually increasing which can threaten human health in the future. This situation urges a great need
of oseltamivir phosphate, which should be manufactured and stocked in every country to protect people from the attack of
human inﬂuenza or H5N1 avian ﬂu. A practical synthetic route was developed by the scientists of Gilead Sciences, Inc. and
F. HoffmaneLa Roche Ltd. that is currently used for the manufacture of oseltamivir phosphate. However, the current method
has some drawbacks such as long synthetic route and relatively low total yield. Thus, a better synthetic method for
oseltamivir phosphate was reported via a novel eight-step synthesis starting from ()-shikimic acid [46] (Fig. 1.9).
()-Shikimic acid was ﬁrst converted to ethyl shikimate 2 as per the reported procedure [47]. Compound 2 was then
reacted with 4.5 equiv of methanesulfonyl chloride and 5 equiv of triethylamine in ethyl acetate in the presence of a
catalytic amount of DMAP and resulted the trimesylate 3 with 93% yield. Reaction of compound 3 with four equiv of
sodium azide in aqueous acetone (acetone:water::5:1) at 0 C for 4 h gave an azide compound 4 in 92% yield. A lower
temperature was crucial in this step, otherwise compound 5 would be formed from 4 via elimination and aromatization.
Compound 4 was treated with 1.1 equiv of triphenylphosphine, 3 equiv of triethylamine, and a large excess of water at
room temperature to afford aziridine 6 in 84% yield. Compound 6 was then reacted with 2 equiv of acetic anhydride and 3
equiv of triethylamine in ethyl acetate to produce N-acetyl aziridine 7. Compound 7 was then treated with 1.5 equiv of
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FIGURE 1.9 Synthesis of oseltamivir from shikimic acid.

boron triﬂuoride etherate in 3-pentanol to furnish a ring-opening product 8 in 86% yield. Compound 8 was then treated
with 4 equiv of sodium azide in aqueous ethanol (EtOH:H2O:: 5:1) under reﬂuxing (around 75 C) for 8 h to afford
compound 9 in 88% yield, and the (R)-conﬁguration of C-5 is reversed to the (S)-conﬁguration. Finally, azide 9 was
transformed into the title compound 1 according to the reported procedure [48] in 91% yield.
This example is quoted here just because the starting material used for the synthesis of oseltamivir phosphate is a plant
secondary metabolite, i.e., shikimic acid, obtained by extraction from Illicium verum (Chinese star anise). It is like a boon
that ()-shikimic acid is found in abundant quantity in the Chinese star anise [1.1 kg of ()-shikimic acid from 30 kg of
the dried plant] and commercially available in large quantities in China. It is the best example of drug development from
plant secondary metabolite, which gave an important drug oseltamivir phosphate to human being to continue the battle
against human inﬂuenza and H5N1 avian ﬂu till its eradication. For more information, please see Chapter 16.

1.2 Conclusion
Since antiquity, the plant kingdom has been playing a key role in fulﬁlling various needs of humans. Various systems of
medicines such as Ayurveda, Unani, and Homeopathy depend majorly on plants for their medicines. This is largely because
of the diverse chemical nature of plant secondary metabolites with its corresponding pharmacological properties. In this
chapter, important drug developments have been described. Knowledge on the synthesis of plant secondary metabolites is
essential for new drug development. From this knowledge, novel routes of synthesis can be designed to produce the products
in large quantities. Tracer techniques, high-throughput screening, and combinatorial chemistry are the important tools that can
help in new drug development. Some case studies have been discussed, which shows how the modiﬁcation of plant
metabolite structures can result in compounds with better pharmacodynamic and pharmacokinetic properties.
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2.1 Introduction
Natural products have an astonishing array of structural diversity [1]. With the rapid growth and advancement in the
knowledge of drug discoveryerelated disciplines such as medicinal chemistry, the pharmaceutical and biotech industries
are increasingly reverting to products from nature in search for new therapeutically useful chemical entities or derivatives
[2]. Studies on drug efﬁcacy, stability, pharmacokinetics, and formulation are required to identify compounds of interest
for clinical applications [3].
Although there are challenges from different novel drug discovery methods, natural products continue to produce
additional clinical candidates and medicinal compounds. These compounds remain an important foundation of novel
medicines [2]. Consequently, many of such compounds have progressed into clinical trials and the medicine market [4].
Natural products are highly valuable for the production of a wide array of lead components ranging from simple to
highly complex entities [5]. They can speciﬁcally mimic the activity of various metabolites including hormones and
naturally occurring ligands [3]. They also possess immense structural diversity, which is a prerequisite crucial for drug
discovery.

2.1.1 The process of drug discovery
Drug discovery entails the identiﬁcation of new, potentially therapeutic compounds. These are often extracted from natural
sources through isolation, chemical synthesis, or both methods [6]. The pharmaceutical industry is increasingly reverting to
traditional medicines in search for novel drugs [7].
Currently, the main steps in drug discovery from natural products are geared toward isolation, puriﬁcation, and
screening of drug candidates. The successful development of lead compounds into clinically viable drugs is dependent on
the employment of industrial-scale extraction and the use of biotechnology [2].
The drug discovery process is long, complex, and expensive. It often results in more failures than successes, with more
funds pumped in than the returns realized in terms of new drugs developed [8,9]. The direct costs of introducing a new
drug to the market are estimated to be over US$ 1 billion [10]. It is not surprising, therefore, that the pharmaceutical
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industry has recently come under scrutiny for the high failure rates in drug development coupled with low rates of
production and approval of new chemical entities as medicines [11]. This is evident from the fact that only about 10% of
molecules entering phase 1 clinical trials are approved by the United States Food and Drug Administration [12,13]. This
has led to what has been termed the pharmaceutical research and development productivity gap [10]. The low success rates
have been partly attributed to the current pharmaceutical industry approach of a single disease being targeted by a single
drug. The complexity of the human body makes the inhibition of a single target ineffective [14]. There are several factors
that are considered critical in the process of drug discovery from natural compounds. The key factors discussed in
this chapter are efﬁcacy of plant material, molecular size and stability of natural compounds, pharmacokinetics and
pharmacodynamics, toxicity and ease of structural modiﬁcation.

2.1.2 Efficacy of plant material
The efﬁcacy of the plant material is of great importance in drug discovery. Efﬁcacy not only depends on the composition
and quality of the plant material but also on the sensitivity of the in vitro or in vivo assay. Bioactive constituents differ both
in terms of quality and quantity even for same species in different or same geographical areas [15,16]. This difference is
attributed to many factors that may be biotic or abiotic. They include ecological factors such as climate, edaphic factors,
mechanical injury, season and time of harvest, preparation and storage, extraction, and isolation process.
Storage and preparation of the plant sample before extraction is a very important aspect in preservation and availability
of the bioactive principles. Plant samples can be used either in their fresh or dried state. If fresh samples are to be used,
extraction has to be done immediately after harvest before deterioration occurs. In most research, dried samples are
preferred as they can be kept for a long time.
If dried samples are to be used, then drying has to take place in favorable conditions to avoid chemical degradation and
loss of mostly the volatile constituents. Moreover, some compounds degrade when exposed to direct sunlight and heat.
Plant samples should therefore be air-dried, oven-dried at low temperatures (<40), microwave-dried, or freeze-dried
[17,18]. The storage of the dried samples is also another aspect, which can lead to contamination, degradation, or loss
of bioactive principles. Stored samples can get infested with fungi, bacteria, and insects causing contamination and
degradation of plant chemicals.
The choice to use either fresh or dried sample depends on the researcher’s interest and the kind of research they intend
to conduct. There may be variations in the chemical compositions in the plant material before and after drying. Vongsak
[19], for instance, observed that fresh and dried Moringa oleifera leaves showed no signiﬁcant difference in total phenolics,
but the dried sample had higher ﬂavonoids content. Also, fresh and dried leaf extracts of 16 species of Scutellaria showed
varying antioxidant capacity. In some species, the dried leaves exhibited higher antioxidant capacity, and in others, the
fresh leaves had higher antioxidant activity [20]. Besides being either fresh or dried, the particle size of the plant material is
very important in ensuring maximum bioactive compounds extraction. Both the grounded and powdered samples are used;
however, powdered samples have shown high efﬁciency in extraction because of the presence of small particle sizes, which
enhance solventesample interaction [17].
The method of extraction and type of solvent is very important when it comes to chemical composition of the plant
material. Several methods of extraction including the conventional maceration, Soxhlet extraction, infusion, decoction, and
percolation do exist besides the modern supercritical ﬂuid extraction (SFE) and microwave-assisted extractions (MAE).
The conventional methods are simple and easy; however, they result into large volumes of waste solvents, which may not
be environmentally friendly, in addition to being expensive and time-consuming to remove. The modern SFE and MAE
use small volumes of solvents and are selective to particular groups of compounds especially polar ones.
For all these methods, the solvent used in the extraction will affect the chemical composition of the extracts, and it is upon
the researcher to select the appropriate solvent. In general, a good solvent should have low toxicity, be easy to evaporate at
low temperature, enhance quick absorption of the extract, have preservative action, and not cause the extract to complex or
dissociate [21]. Other factors that inﬂuence chemical composition and quality are the primary ecological factors such as
climate and soil types. Ecological factors have been found to affect the production of bioactive compounds in plant materials
[22]. Studies by Liu et al. [23,24] found that climate affected the active ingredients of Sinopodophyllum hexandrum
(an anticancer plant) more than the soil type and the composition varied from region to region. Also, environmental stresses,
such as mechanical wounding, ultraviolet light, drought, low temperatures, etc., cause accumulation of certain chemicals such
as anthocyanins in plants [25,26].
Besides composition and quality of the plant material, the sensitivity of the in vitro and in vivo methods determines the
efﬁcacy of the plant material. In vivo assays are either done in humans or animal models, while the in vitro assays are
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performed on cultured pathogens or cells. It has been observed that some in vitro results do not match with the in vivo data.
This has been attributed to host factors such as level of immunity, pharmacodynamics, and pharmacokinetics for the
in vivo assays [27]. Besides the intrinsic nature of human and animal systems, results from in vitro assays are sometimes
unreliable. False results from in vitro studies can arise because of presence of reactive chemical groups, precipitation of the
test substrate, and presence of compounds that change the concentration of the analyte [27].
Compounds that interfere in assays have chemical reactive groups. These include among others catechols, quinones,
phenolic Mannich bases, hydroxyphenylhydrazones, and b-lactams. These compounds (1) react by natural modiﬁcation of
protein residues, (2) react with reagents in the assay through oxidation of sulfur in cysteine residues, (3) act as Michael
acceptor through nucleophilic substitution and form disulﬁde bonds by reaction of two thiol-containing molecules, etc.
[28]. Another example of natural product able to interfere in assays is curcumin. Despite several studies indicating its use in
the treatment of several diseases, curcumin has not been approved as a drug because of its instability. It chelates metals,
labels proteins, exhibits redox activity, and perturbs membranes [29,30].
In cellular assays where cell death is not involved in the endpoint, the presence of toxic compounds in an extract can
increase its activity [31]. Currently, the modern high-throughput screening (HTS) advocates for quick and efﬁcient
bioactivity detection of plant extracts and identifying of potent pure compounds, but this has not had great success with
natural products. This is because some natural products have ﬂuorescent quenching compounds, and this interferes with the
ﬂuorescent HTS endpoint measurements [5,31]. Therefore, there is need to modify the assays or remove the interfering
compounds before screening is done. In all these cases, there is requirement of time and ﬁnances.

2.1.3 Molecular size
Although natural products are diverse in the structures of their compounds, their choice is affected by the molecular size of
the compounds. Natural products have a range of structural diversity (Fig. 2.1), from compounds with simple structures,
such as menthol, a constituent of essential oils from Mentha species, morphine isolated from Papaver somniferum,
artemisinin from Artemisia annua, quinine from Cinchona species, to compounds with big chromospheres such as
paclitaxel from Taxus brevifolia, kahalalide from green algae Bryopsis species [32e35].
There are natural products that have a greater number of chiral centers and increased steric complexity than either
synthetic drugs or combinatorial libraries [36e38]. An example of complex structures that have been elucidated is that of
palytoxins (Fig. 2.2) of molecular weight greater than 2650 Da with more than 60 chiral centers present [39]. Such
structures, which often have chiral centers, are difﬁcult to elucidate, and their synthesis or formation of their derivatives is
hindered, and yet this is a crucial step in drug development.
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2.1.4 Stability of natural compounds
The stability of plant-based products has affected their choice in drug discovery especially because of the physicochemical
properties of the compounds in in vivo studies. Their absorption, metabolism, and excretion remain a big problem inhibiting
their clinical use. Compounds such as caffeic acid and thymol have shown good antiinﬂammatory activities, but they are
unstable [40]. The instability of chemical compounds has called for organic chemists to modify the unstable compounds
through synthesis. In this way, many compounds have been modiﬁed, improving their stability and efﬁcacy [1].
The physicochemical properties of natural compounds often lead to poor chemical stability and lack of in vivo
bioavailability [41]. The molecular dissection of large and complex chemical structures has been used as a method for
improving both stability and activity of some natural products [1].
For instance, the alkaloid cocaine, which has traditionally been used in eye and nasal surgery as a topical anesthetic,
posed a high risk for cardiovascular toxicity. This led to the modiﬁcation and simpliﬁcation of its structure into procaine,
tetracaine, and lidocaine, which are synthetic local anesthetics (Fig. 2.3). Another example involved the modiﬁcation of
another naturally occurring alkaloid, physostigmine, because of its chemical instability. The modiﬁcation involved the
conversion of physostigmine to simple and nonchiral compounds. These include pyridostigmine bromide and neostigmine
bromide (Fig. 2.4), which both have lower adverse effects than physostigmine [1].
Isosteric replacement is also a strategy to improve metabolic stability of natural leads [42]. A case in point is the
substitution of the ester oxygen in epothilone B with a nitrogen atom to produce ixabepilone, which is more resistant to
cellular esterases than epothilone B, and consequently has better metabolic stability and higher efﬁciency as an anticancer
agent [43].
Another approach that has been variously used in the stabilization of natural products, especially with regard to
enhancing oxidative and even thermal stability, is the use of natural antioxidants. Antioxidants have been shown to
increase stability of sunﬂower oil [44].

2.1.5 Pharmacokinetics and pharmacodynamics
When natural products have good results, safety tests are done to ﬁnd out the time and mechanism(s) of its absorption,
distribution, metabolism, and excretion (ADME), which are pharmacokinetic parameters. Also, studies on their biological
effects and mechanism(s) of action are done (pharmacodynamics). Both studies aim at establishing what the body does to
the drug and what the drug does to the body.
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In some cases, natural products possess unacceptable pharmacokinetic properties. The optimization of leads from
natural structures is geared toward the enhancement of drug efﬁcacy to optimize absorption, distribution, metabolism,
excretion, and toxicity proﬁles and to improve chemical accessibility [42]. Only a handful of human clinical trials have
addressed absorption, distribution, metabolism, and excretion of natural compounds in relation to efﬁcacy, thus limiting
their use in clinical settings [41].
It is always desirous to optimize the ADME proﬁle of compounds. This can be achieved by modulation of the physicochemical properties of the small molecules. This approach is three-pronged and involves direct chemical manipulation of
functional groups, establishment and optimization of structureeactivity relationships (SARs), and pharmacophore-oriented
molecular design based on the natural template [42]. For instance, substitution of the deoxyribose in deoxycytidine by an
arabinose sugar yielded cytarabine, a chemotherapy agent mainly for treating acute myeloid leukemia and non-Hodgkin
lymphoma [45].
Secondary metabolites from plants have various pharmacological effects on the body. These include the alkaloid
vinblastine from Catharanthus roseus, which acts by binding to tubulin and inhibits microtubule formation. It acts as a
DNA intercalator and is useful in cancer therapy. Harpagoside and Harpagide, both iridiods from Harpagophytum
procumbens, have analgesic and antirheumatic properties, and cardiac glycosides inhibiting Naþ/Kþ eATPase are used to
treat heart conditions among others [46].

2.1.6 Factors affecting the collection of plant samples
Several factors affect both the quality and quantity of the medicinal plants and their ingredients pre- and postharvesting.
These include the following:
(i) Seasonality: In some species, the composition of the essential oil also changes with the time of year, and thus the
right time of harvest may be of major importance. For instance, in Achillea millefolium, the sesquiterpene hydrocarbons were the dominant components of the essential oil during the vegetative period, while in the ﬂowering
period the monoterpene hydrocarbons were the major constituents of the oil [46].
(ii) Plant age: Through research, the optimum age for harvesting different medicinal plants has been established. The
plant yields the highest concentration of the particular constituents at particular ages. For instance, it is frequent that
the higher levels of secondary metabolites are found in young organs compared with old ones [46].
(iii) Plant part: Phytochemical constituents are not evenly distributed throughout the plant.
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(iv) Temperature: This is a major controlling factor in the development and metabolism of plants. Each species has
adapted to its own natural environment, but many are able to exist in a considerable temperature range. For instance,
although the optimum temperature for nicotine production from Nicotiana rustica is 20 C, it can grow between 11
and 30 C [47].
(v) Rainfall: The important effects of rainfall must be looked at in terms of distribution throughout the year, annual
rainfall, and the effect of rainfall on humidity [47]. The content of asiaticoside from Centella asiatica was higher
during the rainy season and lower during the dry season [48].
(vi) Geographic variation: The yield and composition of essential oils from several species varies geographically,
leading to the existence of distinct chemotypes/chemical races. Such variations have been widely studied in the
essential oils of Zingiber ofﬁcinale [49].
(vii) Soil type: Edaphic factors, which include soil type and composition, are important elements in determining the
secondary metabolites composition, especially of essential oils [49].
(viii) Altitude: Different plant species grow best or produce the best yields at different altitudes. For instance, sugarcane
is a lowland plant, whereas coconut does well in maritime climates [47].
The most dominant natural medicine source is plants because of their chemical and structural diversity and their
biodiversity [2]. The success of any screening program for biologically active plant constituents greatly depends on the
selection of the plant species to be screened. Three main approaches used in the selection process are (1) random selection
of plant material, (2) targeted collection based on consideration of chemotaxonomic relationships, and (3) the ethnomedical
approach [41]. The ethnobotanical method has been proven to give a higher hit rate than other methods [50].
The growing demand for medicinal plants in traditional medicine is also threatening their survival [51]. The collection
of large quantities of material from the wild can be very destructive, even when done for screening purposes [52]. In one
case, a Swiss pharmaceutical company requested for 8 tons of the seeds of Voacanga grandifolia, with no regard to the fact
that this is a rare species with light seeds. Moreover, the company was offering a high price for the seeds. In another case, a
French ﬁrm sought 100 kg of the ﬁne hairs of Cibotium barometz per year [52]. Such requests by pharmaceutical
companies are dangerous to the survival of medicinal plant species because they can quickly lead to the extinction of
different species. To ensure the sustainable utilization and conservation of global biodiversity across the globe, it is
paramount to cultivate medicinal plants using good agricultural practices to ensure that medicinal plant material of the right
quality is availed [51].

2.1.7 Toxicity
The toxicity of a compound during the drug discovery process is seldom used as the single reason for failure of a
compound to make it as a suitable drug candidate. Compounds usually fail for a number of reasons, but nonclinical toxicity
is normally a default category. As such, a speciﬁc toxicity may be acceptable if observed at a comfortable predicted safety
margin in an investigational new drug [10].
The main toxicities driving nonclinical safety-related attrition are variable depending on the company [10]. Most
companies usually report liver and cardiac toxicities as two of the most common toxicities [53,54].
It is a challenging task to predict the toxicity of compounds during early stages, especially during lead optimization
because key pieces of information are often unknown or poorly estimated, in particular efﬁcacious exposures or tissue
concentrations. It is also extremely difﬁcult to quantify or simulate in vivo exposure to compounds in tissues and to
estimate the kinetics of compounds within tissues. Interpreting quantitative data points generated with standard in vitro
assays without this information is most often inaccurate and may lead to the termination of potentially useful compounds,
even with the emergence of new technologies over the last 20 years, which have had little impact on overall nonclinical
safety-related attrition [10].

2.1.8 Ease of structural modification
Although naturally active substances are good lead compounds for the discovery of new drugs, the majority have certain
undesirable attributes such as structural complexity, poor stability, and solubility [55]. Structural modiﬁcation is needed to
develop novel compounds with speciﬁc desirable properties [55,56]. Despite many deﬁciencies associated with natural
products, the total synthesis, semisynthetic modiﬁcation, SAR-based modiﬁcation, sometimes even the alteration of a
single atom may lead to the discovery of a novel drug [55].
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Natural products are synthesized in organisms by enzymatic catalysis, which take place with stereochemical speciﬁcity.
This yields stereospeciﬁc compounds with chiral centers, chiral axes, or cis/trans-conﬁgurations. These asymmetrical
factors signiﬁcantly contribute to the pharmacological activity of the compounds. In manipulating or simplifying natural
products, as much of the unnecessary chirality that does not participate in binding to targets and stereochemistry has to be
removed because compounds that lack chirality make the simpliﬁed analogues easy and economical to synthesize [1].
In summary, structural modiﬁcation may be done to
(i) Increase activity or selectivity
(ii) Increase metabolic stability [1]
(iii) Improve physicochemical properties, e.g., artemisinin to dihydroartemisinin, artemether, artesunate, and arteether,
from the Artemisia annua [3].
(iv) Simplify structures: The solubility, absorption, and metabolism of natural products are hindered if they are large in
size and complex in structure. One of the modiﬁcation strategies is to decrease the molecular size and to remove the
redundant functional groups. A successful example has been demonstrated with the modiﬁcation of the natural
compound schizandrin C to the smaller and more effective diphenyl bicarboxylate (Fig. 2.5) and its intermediates
in murine models, from another traditional Chinese medicinal plant, Schizandra sinensis [1].
The chemical manipulation and modiﬁcation of natural products is determined by their structural and biological
properties. However, not all natural products can be completely synthesized because of their structural complexity, in
addition to the cost and time-consuming nature of the process [1].
Organic synthesis is a major contributor in the development of novel drugs because it offers the platform for modifying
chemical structures of naturally active biological compounds and their resultant biological activity. The modiﬁcation of
active molecules may result in an increase, decrease, or alteration of their biological response to receptor sites. This can
lead to the development of superior therapeutic and novel agents [57].
However, drugs that are commercially produced from complex structures are mostly based on modiﬁcation where parts
of the original structure that possess the activity are identiﬁed. This can reduce the size and chiral centers of the natural
product precursor but retain or increase the bioactivity and reduce toxicity [1]. Of course this is time-consuming, but
nowadays there are new technologies in computational drug design and target prediction, which have made big impact on
drug development especially with complex structures [58]. The various concepts of computer-aided drug discovery were
discussed in Chapter 3 of this book.
The ﬁeld of organic synthesis has developed novel methodologies to fast track the discovery of novel molecules. These
include combinational synthesis based on privileged structures, chemical synthesis based on rational design, and diverseoriented synthesis. Privileged structures are chemical structures containing a speciﬁc skeleton, which is responsible for the
known biological activity [57].
The clinical development of natural product tanshinone I for cancer therapy from a popular traditional Chinese medicinal
plant for treating cardio- and cerebrovascular diseases, Salvia miltiorrhiza, was impeded by its low potency and poor druglike properties. After extensive and systemic structural modiﬁcation, new tanshinone derivatives were generated, one of
which is a lactam derivative that showed potent (13- to 49-fold) antiproliferative activity against different cancer cells than
the original compound. In addition, it had signiﬁcantly improved solubility, metabolic stability, and pharmacokinetic
characters, with signiﬁcantly suppression of tumor growth [61].
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2.2 Conclusion
There are several key factors that should be considered before venturing into the search for new drugs, especially of plant
origin. It is clear that these factors that have been discussed are not considered in isolation but collectively contribute
toward the ﬁnal decision taken by the pharmaceutical company on whether to continue developing the potential drug
candidate or discontinue the process. However, some factors may carry more weight than others, especially efﬁcacy and
toxicity.
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3.1 Introduction
Pharmacology, the scientiﬁc study of drugs, encompasses the preparation, properties, use, and effects. Drug discovery
process is an essential aspect of pharmacology. Based on the current situation, especially in the ﬁeld of information and
communication technology, which is now widely used in the drug discovery process, two approaches have been identiﬁed.
The ﬁrst is a conventional approach, also called the forward approach. A summarized explanation of this approach is “drug
to gene,” meaning the molecular mechanism of the drugs is discovered after design. The basis is phenotypic effects of the
compounds which are screened in vivo in disease subjects or animal models. Of the several compounds being tested, those
that have beneﬁcial therapeutic effects are further studied [1,2]. This was the routine before the elucidation of the human
genome. The expenses incurred, the duration, possible drugedrug interactions, and multiple targets are shortcomings of the
conventional approach.
The second approach is termed reverse pharmacology and is summarized as the “gene to drug” approach [2,3]. Modern
drug discovery adopts this approach because it offers great relief from the duration, cost, and possible failures in the
conventional approach. It is, however, important to note that the information obtained via the in silico approach in the
pharmacological process must be experimented in vivo in animal models and pass through all regulatory agencies,
documentation, and clinical trials before approval.
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FIGURE 3.1 The chemical structures of artemisinin [5], pilocarpine [6], quinine [7], and aspirin [8].

3.1.1 Bioactive compounds as sources of drugs
Natural bioactive compounds from plants in both terrestrial and aquatic habitats have been used since time immemorial,
and till date forms the main basis of traditional herbal medicine practice. Advances in synthetic chemistry, combinatorial
chemistry, and the introduction of bioinformatics to drug discovery process have greatly improved current understanding
and their use. Over the past two decades, there is a reawakened interest in herbal remedies mostly because of negative side
effects associated with the use of synthetic drugs.
Since 1826, when the ﬁrst natural chemical compound morphine was ﬁrst used directly as drug, several bioactive
compounds have been screened, isolated, modiﬁed, and used for disease treatment [4]. Aspirin, digitoxin, quinine, pilocarpine (Fig. 3.1), and many other compounds followed, some of which still have pharmacological applications today. In
the last few decades, a frontline example of modern drug derived from plant source is artemisinin (Fig. 3.1), obtained from
Artemisia annua for treating multidrug-resistant malaria (see Chapters 19 and 20 for more information). Botanical data
indicate vast structural diversity among phytochemicals, most of which are still largely untapped.

3.1.2 Chemical structure determination
A critical aspect of computer-based drug discovery is a good understanding of the molecular structure of drug candidates.
To achieve this, the bioactive molecule usually a component of a mixture of many compounds is ﬁrst puriﬁed using
appropriate separation techniques. X-ray crystallography and nuclear magnetic resonance spectroscopy (NMR) are
powerful tools for explaining the chemical structure of many compounds [9]. The choice of method is usually among other
factors based on the ability to crystallize. Compounds that do not crystallize in solution even at high concentrations can be
examined by NMR spectroscopy, while the chemical structures of those capable of forming ordered crystals are examined
by X-ray crystallography. Both methods combined can help to obtain complementary information that help generate a
more accurate structure.
X-ray crystallography is based on the fact that when X-rays strike macromolecular crystals, atoms produce scattered
X-rays which combine to form complex diffraction patterns consisting of measurable waves with different amplitudes. The
structure is constructed by summing up the waves that register correctly with other waves to give an image. Phase values
are assigned from which an electron density map of the molecule is drawn in three dimensions.
Unlike X-ray crystallography, NMR measures the interaction of atomic nuclei and provides the position of all atoms
including hydrogen. The ﬁnal product of NMR determination is usually a series of distances between atomic nuclei, which
show bound and unbound elements that are close enough to interact in a molecule. Details of these techniques are presented by Jaeger [10], Ladd and Palmer [11], Mlynarik [12], and Nabuurs et al. [13].

3.1.3 Reverse pharmacology
Reverse pharmacology is an approach to drug discovery that can be summarized as the gene to drug approach [2]. Relevant
factors such as genes, enzymes, transport systems, biochemical pathways, and membrane proteins that are associated with a
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FIGURE 3.2 Summarized ﬂow chart for reverse approach in drug discovery and design.

disease mechanism are ﬁrst studied following the application of the traditional drug, for example, a herbal remedy [3].
Once a target is identiﬁed and validated, high-throughput screening of leads with speciﬁc afﬁnity for the target that can
positively modify target activity is done (Fig. 3.2). This approach is adopted because it offers great relief from the duration,
cost, and possible failures associated with the conventional approach. Several aspects of this new approach, available tools,
and working principles are the focus of this chapter. It is, however, important to note that the information obtained via the
in silico approach in the pharmacological process must be experimented in vivo in animal models and pass through all
regulatory agencies’ documentation and clinical trials before approval.

3.1.4 Computer-aided drug discovery process
Natural products with enormous chemical diversities and extensive bioactivities continue to play crucial roles in drug
discovery [14,15]. To harness this huge potential of natural products in drug development to meet up with increasing
pharmaceutical demands, the use of computational methodologies is gaining more attention especially with the vast arrays
of bioactivity databases now available [16]. In this approach, several methods and tools are deployed in the identiﬁcation
and validation of therapeutic targets for the bioactive molecules that will progress to the development of a new drug with
savings on cost and time [17].
Computer-aided drug design (CADD) as a discipline draws on computational methods and technologies to simulate
drugereceptor interactions. CADD is heavily reliant on tools such as computational chemistry, bioinformatics, combinatorial library design, information management technology, molecular biology, genomics, and other new and emerging
areas [18,19].
CADD uses two main modeling strategies: the direct or indirect designs. The direct methods involve the use of threedimensional characters of the drug target, whereas the indirect methods involve the use of structural features of known
active and inactive compounds usually derived from libraries or databases of compounds [18].
There are two main approaches to CADD. It can be ligand or structure based. The former is referred to as ligand-based
drug design and the latter as structure-based drug design (SBDD) [16].

3.1.4.1 Target identification
In pharmacology, targets are important intervention points in a disease [2]. Targets include biological entities such as
proteins, cell membrane receptors, RNA, ion channels, and enzymes. The human genome project has further expanded the
scope to include genes. Identifying a new target starts by deﬁning its relationship with the disease process via several
relevant assays. A drug target must be accessible by the drug and have special afﬁnity for the drug, and the binding of the
drug must elicit a biochemical response.
Multiple targets may be relevant in a disease process. This means that more than one drug lead or bioactive molecule
may be used. Many leads can also bind to a particular target, and the key feature in selection of a suitable lead is speciﬁcity.
However, if negative side effects are observed with the most speciﬁc binding lead, a less speciﬁc molecule with positive
therapeutic effect is selected. For example, the inhibition of cyclooxygenase is required to reduce prostaglandin synthesis
in inﬂammation (see Chapter 21 for detailed information). Rofecoxib a speciﬁc binder was withdrawn from circulation
because of the associated negative effects, and aspirin is used [20].
Based on the available information about targets, they are classiﬁed as either established or potential targets, the former
so-called because the role in normal physiology and in the disease process is known. Several methods have been developed
to identify targets, which are summarized based on the approach in this text.
3.1.4.1.1 Genomic techniques
This approach includes methods such as molecular proﬁling using the DNA microarrays and system-based techniques
including representational difference analysis (RDA) and serial analysis of gene expression (SAGE).
DNA microarray technology is applied in drug discovery process to detect genetic mutations that can contribute to a
disease process. Testing for these mutations can be difﬁcult because most genes can have many sections where different
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mutations can occur. For example, about 800 different mutations can occur in BRCA1 gene. The mutations in BRCA1 and
BRCA2 genes have been linked with about 60% of cases of hereditary cancers in the breast and ovaries resulting from
several mutations. DNA microarray is a tool for investigating whether a patient’s DNA contains mutations by monitoring
gene expression of the genes on a chip. The chip is a DNA template that contains thousands of short, synthetic singlestranded DNA. An overview of DNA microarray technique and applications is provided by Bumgarner [21]. A typical
microarray experiment involves hybridizing the mRNA molecule into the DNA template, and the number of mRNA
associated with each site in the array shows the expression level of various genes. Expression levels are determined, and
the data are used to generate cellular expression proﬁles [1,21].
3.1.4.1.2 Forward and reverse genetics
Forward genetics entails the induction of a mutation in the DNA throughout the genome using a chemical agent or by
random integration of retroviruses or transposons. Mutagenesis induced by the integration of retroviruses or transposons
generates a molecular ﬁngerprint for the mutated gene, thus enhancing identiﬁcation. The observed cellular and phenotypic
changes are a function of relevance of the target [1]. Reverse genetics on the other hand uses the gene knockout approach
for the determination of the biological relevance of the target [22]. Knocking off the target gene eliminates the effect of
target inhibition of the desired future drug lead and gives room to monitor interaction with other possible metabolic
processes. Autoimmune diseases in animal models have also been employed for these studies in the validation of
immunotherapies with the advantage of helping to understand the underlying mechanisms of pathogenesis both at the
molecular and cellular levels. One limitation of this approach is that not all human diseases can be mimicked in animal
models. In such cases, however, the speciﬁc pathological or physiological process can be modeled.
3.1.4.1.3 Proteomics
Disease expression is at the protein or phenotypic level. This makes proteomics, the study of proteins and protein
pathways, relevant in target identiﬁcation [23]. Parameters of interest at this level include proteineprotein interaction,
post-translational protein modiﬁcation, and enzyme activity, which cannot be directly predicted at the molecular level.
Proteomics further validate genomic studies. An advantage of proteomic study is that its complexity can be resolved by
studying subcellular protein fractions of the proteome separately. The identiﬁcation of a target in proteomic studies is
achieved by a combination of several approaches to reduce bias. The genomic techniques, DNA microarray, and SAGE
have been combined with proteomic techniques to identify pancreatic cancer markers [1]. The details of these protocols are
not covered in this chapter.

3.1.4.2 Target validation
After the identiﬁcation of drug targets, the next crucial step is validation. Validation of drug targets is the process of
physiological, pathological, and pharmacological evaluation of a biomolecule, both at the molecular and phenotypic levels
[24]. The process generally comprises understanding the relationship between target and the disease as well as designing a
bioassay to measure biological activity [25]. The failure or emergence of a drug candidate during or after clinical trials is
dependent on efﬁcacy that is largely hinged on the relationship of target to disease process and molecular interactions
between targets and leads.
Several genetic approaches including the use of antibodies, antisense oligonucleotides, locked nucleic acids, ribozymes,
and small interfering RNA (siRNA) are used in target validation. RNA interference (RNAi) technology offers several
advantages including increased speciﬁcity. Selecting gene-speciﬁc siRNA and delivery to human cells are limitations to its
use. Transgenic knockout animal models that no longer express the target of interest are also useful in target validation
[1,26].

3.1.4.3 Lead identification
The generation and identiﬁcation of bioactive compounds that are potential drug candidates is next in the drug discovery
process following the identiﬁcation and validation of targets [13]. Several computational tools dictated by the nature of the
target and available information are used to provide essential help in decision-making in the drug discovery process to
achieve a reduction in cost and time with higher success rate [27]. This is advancement over the traditional high-throughput
screening technique [17,28].
The various computational approaches employed are broadly classiﬁed into structure-based design and ligand-based
design [16]. The structure-based design is the method of choice if the three-dimensional structure of the target is
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known [9]. It is used to design target-speciﬁc compounds that bind tightly to the active site of the target that are mostly
proteins. The test compounds are screened by the application of computational tools such as molecular docking, pharmacophore modeling, and molecular dynamics simulation [9,17].
When no information about the structure of the target is available, the ligand-based design is used; this relies on the
computational utilization of the information of the chemical similarity of a known active or inactive compound or
pharmacophore mapping to direct the de novo synthesis of new molecules with desired pharmacological properties [27].
As there is no information on the structure of the target, computation tools are used to also explore its binding site. In
addition, quantitative structureeactivity relationship (QSAR) modeling may also be used to establish correlation between
the ligand and the response of the target [17].

3.1.4.4 Lead optimization
The goal of CADD is to develop drug molecules with desirable therapeutic properties. To achieve this, several lead
compounds are generated in the process, which require optimization to increase their potency [29]. A number of
computational molecular modeling tools are employed to modify the drug leads, especially the ones with low pharmaceutical effectiveness to increase bioactivity and physiological properties such as absorption, distribution, metabolism,
excretion, and toxicitydADME-Tox [27,30,31]. Activity proﬁling and QSAR are useful in this regard.

3.1.5 Structural considerations in drug discovery
Understanding the mechanism of binding drugs to their targets is an important aspect of drug discovery. As explained by
the “Fischer Lock and Key Model” together with “Koshland induced-ﬁt model” in enzymology, complementarity is critical
irrespective of the binding mechanism. This factor makes afﬁnity and speciﬁcity essential parameters in drug discovery and
design. However, some drugs with low afﬁnity or non-binding can evoke a biological response.

3.1.5.1 Affinity profiling
Afﬁnity-based technologies are useful in the characterization of molecular interactions using recombinant target proteins.
They are a promising way to identify drug leads that are related to speciﬁc targets and can change biochemical activities.
Several technologies are available, and selecting the appropriate one is fundamental to obtaining the required biophysical
information about the ligand-binding process [32].
These technologies are categorized in a review by Mayr [29] as labeled methods, label-free methods, direct and indirect
ligand detection methods, heterogeneous and homogeneous formats, and multiplexing (afﬁnity-based screening). The
protocols, advantages, and disadvantages of the various techniques used are presented by Holdgate et al. [32], Annis et al.
[33], and Kahmann et al. [34]. The volume of data usually generated by these processes can be easily analyzed using
computer software.

3.1.5.2 Target specificity
Beyond afﬁnity, biomolecular recognition, an essential part of modern molecular biology, requires speciﬁcity. This is a
vital phase in modern drug discovery. Understanding this concept unravels the mechanism of action of a drug lead. In the
premolecular era, drug leads where tested at the phenotypic level and about 7% of those drugs still do not have wellestablished targets today.
Research efforts to deﬁne molecular recognition currently comprise afﬁnity and speciﬁcity. Yan and Wang [35]
developed a novel method based on funneled energy landscape theory called SPeciﬁcity and Afﬁnity (SPA). The idea is to
optimize the quantitative speciﬁcity of “native” proteineligand complexes, distinguishing “non-native” binding modes,
and to predict afﬁnity at the same time [35].
The chemo-informatic Similarity Ensemble Approach (SEA) of linking drugs to targets, followed by experimental
testing in direct binding assays, has also been applied in determining speciﬁc targets for orphan drugs. The SEA can
thoroughly and systematically interrogate all targets that have known ligands [36].

3.1.5.3 Quantitative structureeactivity relationships
For this purpose, statistical methods are used to establish mathematical relationships between molecular descriptors or
chemical structures and biological activity of drug molecules [37]. QSAR follows a stepwise procedure beginning with the
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selection of a set of training compounds based on experimental activities; this is followed by establishing a mathematical
relationship to describe the structural and physicochemical features of the compounds. A correlation between the descriptors and the biological properties of the compounds is derived from a model that is generated. The model is thereafter
used to foretell the action of a set of test compounds in the same way as the training compounds [9,38]. QSAR techniques
are therefore able to include combinatorial chemistry tools in the determination of structural details of a drug molecule and
elicit speciﬁc or desired response while also forecasting the biological properties of the test molecules [38,39].
QSAR study is an “important rational shortcut” to drug discovery because it eliminates or signiﬁcantly reduces the
wastefulness of the traditional approach that involved massive synthesis and testing of compounds [40].
The main purpose of QSAR methods is to increase the probability of ﬁnding active compounds from a pool of synthesized compounds and maintaining minimum effort in terms of time and other resources while yielding maximum
success [41].
Previously, QSAR methods were categorized into three groups: (1) 1D-QSAR, (2) 2D-QSAR, and (3) 3D-QSAR [40].
However, new developments have led to the advent of new categories of multidimensional QSAR (nD-QSAR) such as
4D-QSAR, 5D-QSAR, and 6D-QSAR.
3.1.5.3.1 1D-QSAR
The most popular QSAR technique is a mathematical approach known as the Hansch analysis. Introduced by Hansch Corwin
in the early 1960s, the Hansch analysis is mainly used to measure the solubility of a drug molecule by a factor known as logP.
LogP is the octanolewater partition coefﬁcient and is used to adduce how a drug molecule partitions itself into the lipid
surroundings of the receptor microenvironment. The physicochemical characteristics of drug distribution from time of
application to the time of effect as well as drugereceptor interaction are considered during the Hansch analysis.
The Hansch approach has facilitated the simultaneous investigation of the effects of a huge quantity of variables of drug
activity which was previously not possible with the traditional methods. It relies on regression analysis of the effects of
various substituents on a molecule. Using the Hansch approach is very useful, saving much time and effort in the synthesis
and testing of new drugs. As the Hansch method relies on regression analysis, there is an inherent disadvantage when using
it because good ﬁts can be obtained by simply manipulating the constants. This necessitates curve ﬁtting for a multitude of
compounds to ensure that all descriptors are considered. Biological systems are sometimes very crude as models for the
application of the model and not all the electronic effects operating in a drug molecule are well-understood or precise [40].
3.1.5.3.2 2D-QSAR
2D- and 3D-QSAR methods have gradually replaced the 1D-QSAR, which is no longer widely used. The Hansch analysis
generated the FreeeWilson method and the Topliss decision tree method for molecule optimization. The FreeeWilson
method is based on the premise that biological activity can be explained by the additive properties of substituents in the
parent structure of molecules. The Topliss solution method is an empirical method in which each compound is tested
before analogues are planned and compared with analogues planned previously with physical properties.
2D-QSAR is a more advanced method for correlating biological activity and structure. A common example is pattern
recognition analysis. The ﬁrst step in implementing 2D-QSAR is to choose a set of training sessions that are different
subset of molecules in their structure and biological activity. Ideally, the available compounds cover the full spectrum of
bioactivity, ranging from the active ones (complete and incomplete, covering the range of 103-fold receptor-binding afﬁnity) to inactivity. The more molecules the better, but a reasonable start can be made with as few as 10 compounds. Sets
with different molecules are used in different tests. Results from each test set are then used to validate any prediction
algorithm that is developed through the study.
Numerous descriptors are used to characterize each and every molecule within the training set. These descriptors can be
grouped into four classes: (1) electronic (e.g., charge densities on individual atoms and molecular dipole), (2) topological
(number of rings in the molecule, quantity of aromatic rings in the molecule, KiereHall indices, and ad hoc indices), (3)
physicochemical (number of hydrogen bonding donor and acceptor sites, octanolewater partition coefﬁcients, logP,
hydrogen bonding number, number of hydrogen bonding acceptor sites), and (4) geometric (bond lengths, bond angles,
and interatomic distances) [40].
Many descriptors not listed here are all calculated for each compound within the training set Prior to this, the construction of a 2D data array is carried out. It is then subjected to statistical analyses such as pattern recognition and cluster
analysis to determine the least quantity of descriptors that differentiate active compounds from inactive compounds, to
obtain a predictive algorithm to quantify bioactivity in terms of the relevant descriptors. The algorithm is then tested on set
compounds before being applied to guide syntheses of optimized compounds [40,42].
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3.1.5.3.3 3D-QSAR
Comparative Molecular Field Analysis (CoMFA) was the ﬁrst novel 3D-QSAR method [40,42], introduced by Cramer and
coworkers in 1988 [42]. Similar to other forms of QSAR, 3D-QSAR starts with a series of compounds with identiﬁed
structures and known biological activities, with the initial step being alignment of molecular structures with alignment algorithms. Calculation of the molecular ﬁeld around each molecule in the training set follows next. Similar with 2D-QSAR,
descriptors for each of the molecular ﬁelds are used. The ﬁeld points are then ﬁtted to predict the bioactivity using statistical
algorithms. The predictions from the molecular ﬁeld calculations are then put to test on a set of compounds [40].
In 3D-QSAR, each ligand molecule is represented by a single 3D entity. The identiﬁcation of the bioactive conformation, orientation, and the protonation state is a crucial step in the procedure. If the underlying pharmacophore hypothesis
is based on incorrect assumptions, the resulting surrogate is hardly of any use for predictive purposes [43]. The CoMFA
method laid the groundwork for the development of other 3D-QSAR methods such as comparative molecular similarity
analysis (CoMSIA), self-organizing molecular ﬁeld analysis (SOMFA), and comparative molecular moment analysis
(CoMMA) [42].
3.1.5.3.4 Multidimensional quantitative structureeactivity relationship
The 3D-QSAR CoMFA method previously discussed also led to the evolution of multidimensional (nD)-QSAR methods
such as 4D-QSAR, 5D-QSAR, and 6D-QSAR among others. These developments arose as a matter of need to solve the
problems associated with 3D-QSAR, such as subjective molecular alignment and determination of bioactive conformation
[42]. The use of multidimensional QSAR reduces the bias linked with the selection of ligand conformation and alignment
(4D) and the choice of a suitable induced-ﬁt model (5D) [43]. Multidimensional QSAR techniques provide well-designed
approach for the estimation of free energies of ligand binding. For instance, the modeling software Quasar, which is based
on 5D-QSAR, explicitly allows for the simulation of induced ﬁt [44].
4D-QSAR technologies take into consideration the problem of molecular alignment associated with 3D-QSAR [45].
4D-QSAR approach greatly reduces the bias with selecting a bioactive conformer, orientation, or protonation state by
permitting multiple conformation, orientation, and protonation state representation of ligand molecules. It, however, still
requires a complex system of conjecture about manifestation and magnitude of the associated local induced ﬁts as well as
the adaptation of the receptor-binding pocket to the individual ligand topology [43,46]. 4D-QSAR technology is still
plagued by the challenge of unknown manifestations and magnitude of the induced ﬁt and the ligand-induced adaptation of
the binding site to the topology of the small molecule. In the absence of the true biological receptor, these quantities cannot
unambiguously be determined.
Some of these challenges are addressed with 5D-QSAR tools. 5D-QSAR results in a model population with higher
predictive power for high-afﬁnity compounds and desirable effect in drug design applications [43]. 5D-QSAR performs
better for high-afﬁnity ligands (IC50 < 108), including all true predictions [43,46]. This allows for the simulation of
induced ﬁt. 5D-QSAR attempts to diminish the bias associated with the choice of the bioactive conformation, ligand
substituent alignment, and the induced-ﬁt model. This can be done using the Quasar software, which also allows for
H-bond ﬂip-ﬂop and accounts for solvation phenomena [47]. 6D-QSAR is basically an improvement of 5D-QSAR with
representation of different solvation scenarios [44,48].

3.1.5.4 Molecular docking
Molecular docking is a structure-based drug design (SBDD) tool that has been in use since the 1980s. The aim is to predict
ligandereceptor interaction at the atomic level, thus helping to elucidate fundamental biochemical binding parameters [49].
Several docking tools are available and are classiﬁed based on the nature of the ligand and receptor.
According to the Koshland induced-ﬁt model, ﬂexibility is an essential parameter in proteineligand interactions. The
more recent docking tools are based on this approach, though older ones designed based on the rigidity described by the
Fischer Lock and Key model are still in use. The docking methods are classiﬁed as (1) rigid liganderigid receptor docking,
(2) ﬂexible liganderigid receptor docking, and (3) ﬂexible ligandeﬂexible receptor docking. The basic steps are prediction
of the ligand pose and estimation of binding afﬁnity. Docking accuracy is higher if the receptor is already deﬁned.
Sampling algorithms for ligands in docking studies are numerous, and each is designed to help obtain the required
information from the proteineligand binding. Matching algorithms (MA) screen several ligands based on complementarity
of their shapes with the active site. Sampling based on incremental construction (IC) requires the separation of the receptor
into fragments at its rotatable bonds. The anchor is ﬁrst docked before the remaining fragments are added. The stochastic
sampling methods have the de novo ligand design and modiﬁcation features. A typical example is the multiple copy
simultaneous search (MCSS) algorithm.
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All docking algorithms use scoring functions in association with a method of search [50]. The aim of scoring is to
obtain ligands with accurate poses and good binding afﬁnity and separate them from incorrect binding ligands that do not
have the desired activity. Scoring functions estimate binding afﬁnity from the relative distances between interacting atoms
in the ligand and the protein [51]. Main approaches estimating docking score of ligands include the following [51,52]:
1. Force ﬁeldebased approach: The binding energy is calculated from the sum of the nonbonded interactions. The
distance between the interacting atoms is used as a control factor.
2. Empirical approach: Scoring is based on sum of binding energy deﬁned by factors such as hydrogen bond, ionic interaction, hydrophobic effect, and binding entropy.
3. Knowledge-based approach: This approach is based on the statistical analysis of the interatomic contact frequencies
and distances between protein and ligand in the crystal structure of the complex. An advantage of this approach is
computational simplicity.

3.1.6 Bioinformatics and genomics
The increased understanding of information handling in organisms driven by advances in computational biology approaches is of great beneﬁt to the CADD process. The deployment of advanced techniques in the rapidly evolving ﬁeld of
genomics is also a boost to this process. These methodologies potentially generate vital data that are very useful in the
identiﬁcation of metabolic pathways with the controlling genes inﬂuenced by phytochemical-derived drug molecules for
the beneﬁt of the society.

3.1.6.1 Bioinformaticsdoverview
Advances in technologies in biological sample handling involving macromolecules such as DNA, RNA, and proteins
continue to generate huge biological information or data [53,54]. Genome studies or genomics for instance is an area that is
generating large amount of biological data in the form of DNA sequences due to the development of various sequencing
technologies [55,56]. A major challenge arising there from is analysis, storage, accessibility, and manipulation of the arrays
of accumulating data. Electronic databases of interconnected biological information and computational methods emerged
for the management of the data. This birthed the interdisciplinary ﬁeld of bioinformatics deﬁned as the application of
computational techniques in understanding and organizing of the information associated with biological macromolecules
[54]. This broad ﬁeld uses computational tools and databases to generate biological knowledge and provide understanding
of biological processes and mechanisms [55].

3.1.6.2 Bioinformatics tools
Several software technologies have been developed for dealing with the huge biological data handled in bioinformatics
[57]. These data stored in databases are held in various searchable and viewable repositories that can be accessed via the
Internet using search engines [57,58]. Public repositories are developed and maintained by some government agencies and
international organizations such as the National Center for Biotechnology Information (NCBI) and the European Bioinformatics Institute (EBI) [56,57]. Some examples of large-scale public repositories are GenBank, Protein Data Bank,
SwissProt, ArrayExpress, and KEGG [15,56]. Medicinal plant resources such as ChEMBL, Binding DB, Drug Bank,
Pubchem, ebDB, etc., are also available [14].
Commonly used database searching tools in evaluating similarities between biological sequences are basic local
alignment search tool such as (BLAST) and fast alignment (FASTA) [59]. Other homology and similarity tools include
ClustalW, RASMOL, and SWISS-PdbViewer.
Protein structure prediction tools have also been developed with application in the analysis of protein target structure in
drug discovery process. Some of them are PSA [60], APSSP2 [61], OXbench [62], GeNMR, GammaPred, and COPIA
[63].
There are also microarray analysis tools such as CIMminer, SpliceMiner, MatchMiner, GoMiner, and High-Throughput
GoMiner. Similarly, distinct set of tools have been designed for RNA applications such as small nucleolar RNAs [64,65],
sRNAtoolbox [66], MirAlign, XRNA, and CARNA [67].

3.1.6.3 Writing language for software packages
Dominant languages in bioinformatics today are python, R, C, Cþþ, Java, and Perl with JavaScript to aid browser
visualization and SQL in databases. Scripting languages are an important tool in present-day applied computing research.
Scripting languages are easy to understand with strong string processing ability, ﬂexible syntax, and are object-oriented in
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nature. They are easy to handle, have inbuilt functionality, are extensible, have rich sets of libraries, and quite a few allow
support for concurrent programming [68]. These are important in computational biology to handle the large array of
biological data extracted using mathematical/computational modeling techniques [69].
Python, Haskell, Lua, Perl, Scala, PHP, JavaScript, Erlang, R, and Ruby are 10 common scripting languages applied for
writing or developing software packages in bioinformatics today. Commonly used scripting languages among the 10 listed
include Python, Perl, and R. Previously, C þþ and Java were used to program bioinformatics tools. Quite some useful
bioinformatics tools have been built using the Java, Perl, and Python programming languages [70]. Several bioinformaticsrelated tools have been written and developed by combining diverse programming languages [71]; the Bioconductor (a
bioinformatics and computational biology software project) was developed using R programming language and environment [72]; other bioinformatics tools such as FASTA and BioJava were partly developed using XML and Java [73];
high-level programming language such as Cþþ was used to develop libcov (a bioinformatics tool for manipulating
protein structures) [74]; MACBenAbim, a bioinformatics and computational biology application, was developed using
JavaScript and HTML 5 [75]; BengaSavex, a computational biology extraction tool for identical DNA sequences, was
developed using Cþþ programming language [76]; 13CFLUX2, a high-performance bioinformatics software suite,
was developed using Cþþ, Java, and python add-ons [77]. Currently, some of the latest bioinformatics tools are now being
developed using popular scripting languages such as Perl, Python, and JavaScript. PROVA is an example of a Java-based
bioinformatics tool developed using JavaScript programming language [78]; Easyﬁg is a python-based application used to
analyze genetic loci in bioinformatics; SurreyFBA is a Cþþ-based bioinformatics application developed for use by scientists; FASIMU is also another bioinformatics application that was developed using some programming languages such
as Java and Cþþ. These tools span various application areas of bioinformatics. Researchers in this ﬁeld can also explore
functional scripting languages such as Haskell, Lua, Scala, and Erlang, as they also hold great promise because they have
been previously used to develop useful applications in bioinformatics.

3.1.7 Implications of the human genome project on in silico drug discovery
In addition to its application in molecular biology, genomics, and other biomedical research areas, bioinformatics is also
applied in CADD to gain insights into binding of ligands and targets, the three-dimensional structure of proteins, and
design of novel drug molecules with high afﬁnity and speciﬁcity [14].
The full sequence data of the human genome provided in 2003 are beneﬁtting detailed understanding of the genome
and human diseases [55]. The disease-associated genes can be converted to validated drug targets [79,80]. Although this
has not produced high level of translatable results, the human genome remains a deﬁnitive resource that is actively being
exploited for the identiﬁcation of drug targets [80].

3.1.8 Current in silico analyses possible
A number of in silico tools are currently available that have transformed drug discovery and design process. A directory of
possible in silico analyses including docking, screening, chemical structure representation, molecular modeling, target
prediction, ligand design, QSAR, and ADME-Tox are available online (directory of CADD tools). The existing database of
useful bioinformatics information available today continues to expand the scope and relevance of in silico analyses to
modern drug discovery process. ADME-Tox is highlighted in this text.

3.1.9 ADME-Tox
The acronym ADME-Tox represents the pharmacokinetic parameters absorption, distribution, metabolism and excretion,
and toxicity. These are essential parameters if the drug lead will reach the target site and be bioavailable to stimulate
biological action. Signiﬁcant progress has been made in high-throughput screening for these properties in drug discovery
and development. Using in silico techniques, ADME-Tox prediction is currently possible, facilitating suitable selection of
drug leads [81]. Several ADME-Tox software types available today are presented in Table 3.1. More information on this
and other tools used in computational phytochemistry was described by Vallinayagam et al. [82].

3.1.10 Future possibilities
Current scientiﬁc and technological advancement has revolutionized the conventional drug discovery process to the extent
that some previously approved drugs have been withdrawn from circulation owing to a number of factors. This increased
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TABLE 3.1 Some ADME-Tox software types and their distributors.
Software

Distributor

QikProp

Schrodinger

VolSurf

Tripos

GastroPlus

Simulation Plus, Inc.

MedChem Studio

Simulation Plus, Inc

ADMET Predictor

Simulation Plus, Inc

DDDPlus

Simulations Plus, Inc

MedChem Designer

Simulations Plus, Inc

IMPACT-F

PharmaInformatic, Germany

MolScore-Drugs

PharmaInformatic, Germany

ADMET Modeler

Simulations Plus, Inc

ACD/ADME Suite

ACD/Labs

FAF-Drugs2

University of Paris Diderot

Discovery Studio ADMET Software

Accelrys

PK-Sim

Bayer technology Services

SimCYP

SimCYP

KnowItAlldADME/Tox Edition

Bio-Rad Laboratories

MetaDrug

Thomson ReutersLC

understanding has also made drug approval more tedious, coupled with the duration and cost implication of such
endeavors.
The way forward is the application of computer-based analysis in the drug discovery process. Over the last three
decades, pharmaceutical industries have continually become more involved in the development of computer applications
that are useful in drug discovery and design. The in silico approach has the advantage of reducing the duration, cost
implication involved in drug development, and reduced failure rate of a drug lead during preclinical and clinical trials.
The uniqueness of individuals to disease processes and responses to treatment has always called the attention of researchers and the pharmaceutical industry to precision medicine, tailored to meet individual needs. This is the future of
therapeutics and CADD is fundamental to achieving this feat.

References
[1] Target discovery and validation reviews and protocols, in: M. Sioud (Ed.), Emerging Strategies for Targets and Biomarker Discovery, vol. 1,
Humana Press, New Jersey, 2007.
[2] T. Takenaka, Classical vs reverse pharmacology in drug discovery, BJU Int. 88 (88) (2001) 7e10.
[3] L. Xiangming, C. Su, S. Zhou, W. Lisi, G. Ming, The development and application of methodology of reverse pharmacology illustrated with the
research on analgesic effect of resina, Draconis 3 (3) (2014). https://doi.org/10.4172/2167-1206.1000157.
[4] D.S. Fabricant, N.R. Farnsworth, The value of plants used in traditional medicine for drug discovery, Environ. Health Perspect. 109 (2001) 69e75.
https://doi.org/10.1289/ehp.01109s169.
[5] Artemisinin. https://pubchem.ncbi.nlm.nih.gov/compound/artemisinin#section¼Top.
[6] Pilocarpine. https://pubchem.ncbi.nlm.nih.gov/compound/pilocarpine#section¼Top.
[7] Quinine. https://pubchem.ncbi.nlm.nih.gov/compound/quinine#section¼Top.
[8] Aspirin. https://pubchem.ncbi.nlm.nih.gov/compound/aspirin#section¼Top.
[9] G. Sliwoski, S. Kothiwale, J. Meiler, E.W. Lowe, Computational methods in drug discovery, Pharmacol. Rev. 66 (2014) 334e395.
[10] J. Jaeger, Macromolecular structure by x-ray crystallography, Nat. Encycl. Life Sci. (2004) 1e8, https://doi.org/10.1038/npg.els.0002723.
[11] M. Ladd, R. Palmer (Eds.), Structural Determination of X-Ray Crystallography, Analysis by X-Rays and Neutrons, ﬁfth ed., Springer, New York,
2013.

Advances in computer-aided drug discovery Chapter | 3

35

[12] V. Mlynarik, Analytical biochemistry, Anal. Biochem. J. 529 (2017) 4e9. https://doi.org/10.1016/j.ab.2016.05.006.
[13] S.B. Nabuurs, C.A.E.M. Spronk, G.W. Vuister, G. Vriend, Traditional Biomolecular Structure Determination by NMR Spectroscopy Allows for
Major Errors, 2006. https://doi.org/10.1371/journal.pcbi.0020009.
[14] J. Fang, C. Liu, Q. Wang, P. Lin, F. Cheng, In silico polypharmacology of natural products, Brief. Bioinf. 19 (6) (2018) 1153e1171.
[15] V. Sharma, I.N. Sarkar, Bioinformatics opportunities for identiﬁcation and study of medicinal plants, Brief. Bioinf. 14 (2) (2012) 238e250.
[16] W. Yu, A.D. MacKerell Jr., Computer-aided drug design methods, Methods Mol. Biol. 1520 (2017) 85e106, https://doi.org/10.1007/978-1-49396634-9_5.
[17] T. Katsila, G.A. Spyroulias, G.P. Patrinos, M.T. Matsoukas, Computational approaches in target identiﬁcation and drug discovery, Comput. Struct.
Biotechnol. J. 14 (2016) 177e184.
[18] W.G. Richards, Computer-aided drug design, Pure Appl. Chem. 66 (8) (1994) 1589e1598, https://doi.org/10.1351/pac199466081589.
[19] P.P. Kore, M.M. Madhavi, R.V. Antre, R.J. Oswal, S.S. Kshirsagar, Computer-aided drug design: an innovative tool for modeling, Open J. Med.
Chem. 2 (2012) 139e148. https://doi.org/10.4236/ojmc.2012.24017.
[20] G. Rimon, R.S. Sidhu, D.A. Lauver, J.Y. Lee, N.P. Sharma, C. Yuan, A. Ryan, Coxibs interfere with the action of aspirin by binding tightly to one
monomer of cyclooxygenase-1, Proc. Natl. Acad. Sci. U.S.A. 107 (1) (2009) 28e33. https://doi.org/10.1073/pnas.0909765106.
[21] R. Bumgarner, DNA microarrays: types, Applications and their future, Curr. Protoc. Mol. Biol. 6137 (2014) 1e17. https://doi.org/10.1002/
0471142727.mb2201s101.DNA.
[22] K. Bayou, Current techniques and applications of reverse genetics: an overview, Int. J. Genet. 7 (2017) 31e37.
[23] L. Cekaite, O. Haug, O. Myklebost, M. Aldrin, B. Ostenstad, Analysis of the humoral immune response to immunoselected phage-displayed
peptides by a microarray- based method, Proteomics 4 (2004) 2572e2582.
[24] X.P. Chen, G.H. Du, Target validation: a door to drug discovery, Drug Discov. Ther. 1 (1) (2007) 23e29.
[25] N. Prakash, P. Devangi, Drug discovery, J. Antivir. Antiretrovir. 2 (2010) 063e068, https://doi.org/10.4172/jaa.1000025.
[26] F.J. Borgio, RNA interference (RNAi) technology:a promising tool for medicinal plant research, J. Med. Plants 3 (2009) 1176e1183.
[27] M. Xiang, Y. Cao, W. Fan, L. Chen, Y. Mo, Computer e aided drug design: lead discovery and optimization, Comb. Chem. High Throughput
Screen. 15 (2012) 328e337.
[28] G.M. Keseru, G.M. Makara, Hit discovery and hit e to e lead approaches, Drug Discov. Today 11 (2006) 741e748.
[29] M.R. Reddy, M.D. Erion, Computer e aided drug design strategies used in the discovery of fructose 1,6-bisphosphatase inhibitors, Curr. Pharmaceut. Des. 11 (3) (2005) 283e294.
[30] F. Ooms, Molecular modeling and computer aided drug design. Examples of their application in medicinal chemistry, Curr. Med. Chem. 7 (2) (2000)
141e158.
[31] H. Patel, M.J. Bodkin, B. Chen, V.J. Gillet, Knowledge e based approach to de novo design using reaction vectors, J. Chem. Inf. Model. 49 (5)
(2009) 1163e1184.
[32] G.A. Holdgate, M. Anderson, F. Edfeldt, S. Geschwindner, Afﬁnity-based , biophysical methods to detect and analyze ligand binding to recombinant proteins: matching high information content with high throughput, J. Struct. Biol. 172 (2010) 142e157. https://doi.org/10.1016/j.jsb.2010.06.
024.
[33] D.A. Annis, E. Nickbarg, X. Yang, M.R. Ziebell, C.E. Whitehurst, Afﬁnity selection-mass spectrometry screening techniques for small molecule
drug discovery, Curr. Opin. Chem. Biol. 11 (2007) 518e526. https://doi.org/10.1016/j.cbpa.2007.07.011.
[34] J. Kahmann, D. Winkler, T. Hesterkamp, The impact of physical based methods screening and their delivery of better quality hits, Drug Discov.
Today Technol. 5 (2008) 15e22. https://doi.org/10.1016/j.ddtec.2008.12.005.
[35] Z. Yan, J. Wang, Discovery, Sci. Rep. 2 (2012) 309. https://doi.org/10.1038/srep00309.
[36] E. Gregori-puigjané, V. Setola, J. Hert, B.A. Crews, J.J. Irwin, E. Lounkine, Identifying mechanism-of-action targets for drugs and probes, Proc.
Natl. Acad. Sci. U.S.A. 109 (28) (2012) 11178e11183, https://doi.org/10.1073/pnas.1204524109.
[37] S. Zhang, Computer e aided drug discovery and development, Methods Mol. Biol. 716 (2011) 23e38, https://doi.org/10.1007/978-1-61779-0126_2.
[38] E.G. Hadaji, M. Bourass, A. Ouammou, M. Bouachrine, 3D-QSAR models to predict anti-cancer activity on a series of protein P38 MAP kinase
inhibitors, J. Taibah Univ. Sci. 11 (2017) 392e407.
[39] P. Buchwald, N. Bodor, Computer e aided drug design: the role of quantitative structure e property, structure e activity and structure e metabolism
relationships (QSPR, QSAR, QSMR), Drugs Future 27 (2002) 577e588.
[40] T. Nogrady, D.F. Weaver, Medicinal Chemistry A Molecular and Biochemical Approach, third ed., Oxford press, 2005.
[41] M.A. Lill, Multi-dimensional QSAR in drug discovery, Drug Discov. Today 12 (23e24) (2007) 1013e1017, https://doi.org/10.1016/
j.drudis.2007.08.004.
[42] K.Z. Myint, X.Q. Xie, Recent advances in fragment-based QSAR and multi-dimensional QSAR methods, Int. J. Mol. Sci. 11 (10) (2010)
3846e3866, https://doi.org/10.3390/ijms11103846.
[43] A. Vedani, M. Dobler, 5D-QSAR: the key for simulating induced ﬁt? J. Med. Chem. 45 (11) (2001) 2139e2149.
[44] A. Vedani, M. Dobler, M.A. Lill, Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen
receptor, J. Med. Chem. 48 (11) (2005) 3700e3703, https://doi.org/10.1021/jm050185q.
[45] D. Streich, M. Neuburger-Zehnder, A. Vedani, Induced ﬁtdthe key for understanding LSD activity? A 4D-QSAR study on the 5-HT2A receptor
system, Quant. Struct. Act. Relat. 19 (6) (2000) 565e573, https://doi.org/10.1002/1521-3838(200012)19:6<565::AID-QSAR565>3.0.CO;2-2.

36

PART | I Plants as natural sources of drugs

[46] M.A. Lill, M. Dobler, A. Vedani, Prediction of small-molecule binding to cytochrome P450 3A4: ﬂexible docking combined with multidimensional
QSAR, ChemMedChem 1 (1) (2006) 73e81, https://doi.org/10.1002/cmdc.200500024.
[47] S. Ducki, D. Rennison, M. Woo, A. Kendall, J.F. Chabert, A.T. McGown, N.J. Lawrence, Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity, Bioorg. Med. Chem. 17 (22) (2009) 7698e7710, https://
doi.org/10.1016/j.bmc.2009.09.039.
[48] J. Polanski, Receptor dependent multidimensional QSAR for modeling drug -receptor interactions, Curr. Med. Chem. 16 (25) (2009).
[49] B.J. McConkey, V. Sobolev, M. Edelman, The performance of current methods in ligand-protein docking, Curr. Sci. 83 (2002) 845e855.
[50] A.N. Jain, Scoring functions for protein-ligand docking, Curr. Protein Pept. Sci. 7 (2006) 407e420.
[51] X. Meng, H. Zhang, M. Mezei, C. Meng, A powerful approach for structure-based drug discovery, Curr. Comput. Aided Drug Des. 7 (2011)
146e157.
[52] D.B. Kitchen, H. Decornez, J.R. Furr, J. Bajorath, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat. Rev.
Drug Discov. 3 (11) (2004) 935e949.
[53] T. Reichhardt, It’s sink or swim as tidal wave of data approaches, Nature 399 (1999) 517e520.
[54] N.M. Luscombe, D. Greenbaum, M. Gerstein, What is bioinformatics? A proposed deﬁnition and overview of the ﬁeld, Methods Inf. Med. 40 (2001)
346e358.
[55] M.H. Hofker, J. Fu, C. Wijmenga, The genome revolution and its role in understanding complex diseases, Biochim. Biophys. Acta 1842 (2014)
1889e1895.
[56] S.Y. Rhee, J. Dickerson, D. Xu, Bioinformatics and its applications in plant biology, Annu. Rev. Plant Biol. 57 (2006) 335e360.
[57] P. Garg, P. Jaiswal, Databases and bioinformatics tools for rice research, Curr. Plant Biol. 7e8 (2016) 39e52.
[58] J. Waese, N.J. Provart, The bio-analytic resource for plant biology, in: A. van Dijk (Ed.), Humana Press, New York, 2017, p. 1533.
[59] S. McGinnis, T.L. Madden, BLAST: at the core of a powerful and diverse set of sequence analysis tools, Nucleic Acids Res. 32 (2004) 20e25.
[60] G.P.S. Raghava, A graphical web server for the analysis of protein sequences and alignment, Biotech Softw. Internet Rep. 2 (2001) 255e258.
[61] G.P.S. Raghava, Protein Secondary Structure Prediction Using Nearest Neighbor and Neural Network Approach, 2000. Available at, http://crdd.
osdd.net/raghava/apssp2/.
[62] G.P.S. Raghava, S.M.J. Searle, P.C. Audley, J.D. Barber, G.J. Barton, OXBench: A Benchmark for Evaluation of Protein Multiple Sequence
Alignment Accuracy, 2003. Available at, https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-4-47.
[63] H. Kaur, G.P.S. Raghava, A neural-network based method for prediction of gama-turns in proteins from multiple sequence alignment, Protein Sci.
12 (5) (2003) 923e929.
[64] P. Schattner, A.N. Brooks, T.M. Lowe, The tRNAscan-SE, snoscan and snoGPS Web Servers for the Detection of tRNAs and snoRNAs, Nucleic
Acids Res. 33 (2005) W686eW689, https://doi.org/10.1093/nar/gki366.
[65] X. Wang, I.M. El Naqa, Prediction of both conserved and non conserved, microRNA targets in animals, Bioinformatics 24 (2008) 325e332.
[66] A. Rueda, G. Barturen, R. Lebr, C. Gomez-Martin, A. Alganza, J.L. Oliver, M. Hackenberg, sRNA toolbox: an integrated collection of small RNA
research tools, Nucleic Acids Res. 43 (2015) 467e473.
[67] A.S. Dragos, M. Mohl, M. Mann, R. Backofen, S. Will, CARNA-alignment of RNA structure ensembles, Nucleic Acids Res. 40 (2012) 49e53.
[68] L. Prechelt, Are scripting languages any good? A validation of Perl, Python, Rexx, and Tcl against C, Cþþ and Java, Adv. Comput. 57 (2003)
205e270.
[69] M. Huerta, NIH Working Deﬁnition of Bioinformatics and Biotechnology, 2013. Available at, http://www.bisti.nih.gov/docs/CompuBioDef.pdf.
[70] H. Mangalam, The Bio-toolkits - a brief overview, Brief. Bioinf. 3 (2002) 296e302.
[71] H.M. Sauro, M. Hucka, A. Finney, C. Wellock, H. Bolouri, J. Doyle, H. Kitano, Next generation simulation tools: the Systems Biology workbench
and BioSPICE integration OMICS, J. Integr. Biol. 7 (4) (2003) 355e372.
[72] R.C. Gentleman, V.J. Carey, M.D. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Homik, T. Hothom,
W. Huber, S. Iacua, R. Irizarry, F. Leisch, C. Li, M. Maechler, A.J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tiemey, J.Y.H. Yang, J. Zhang,
Bioconductor: open software development for computational biology and bioinformatics, Genome Biol. 5 (2004) 80.
[73] T. Oinn, M. Addis, J. Ferris, D. Marvin, M. Senge, M. Greenwood, T. Carver, K. Glover, M.R. Pocock, A. Wipat, P. Li, Tavema: a tool for the
composition and enactment of bioinformatics workﬂows, Bioinformatics 20 (17) (2004) 3045e3054.
[74] D. Butt, A.J. Roger, C. Blouin, A Cþþ bioinformatics library to manipulate protein structures, sequence alignments and phylogeny, BMC Bioinf. 6
(2005) 138.
[75] O. Oluwagbemi, A. Adewumi, A. Esuruoso, A multi-platform mobile application for searching key terms in computational biology and bioinformatics, Bioinformation 8 (16) (2012) 790e791.
[76] O. Oluwagbemi, S. Imolorhe, V. Agozie, A new computational genetic sequence extraction tool for DNA repeats, Afr. J. Biotechnol. 13 (21) (2014)
2103e2112, https://doi.org/10.5897/AJB12.1903.
[77] M. Weitzel, K. Noh, T. Dalman, S. Niedenfuhr, B. Stute, W. Wiechert, High performance software suite for 13C-metabolic ﬂux analysis, Bioinformatics 29 (1) (2013) 143e145.
[78] A. Kozlenkov, M. Schroeder, Rule-based Java-scripting for a bioinformatics semantic web, Lect. Notes Comput. Sci. 2994 (2004) 17e30.
[79] C. Debouck, B. Metcalf, The impact of genomics on drug discovery, Annu. Rev. Pharmacol. Toxicol. 40 (2000) 193e208.

Advances in computer-aided drug discovery Chapter | 3

37

[80] N.M. Penrod, R. Cowper-Sal_Lari, J.H. Moore, Systems genetics for drug target discovery, Trends Pharmacol. Sci. 32 (10) (2011) 623e630.
[81] S. Alqahtani, In silico ADME-Tox modeling: progress and prospects, Expert Opin. Drug Metabol. Toxicol. 13 (2017) 1147e1158, https://doi.org/
10.1080/17425255.2017.1389897.
[82] S. Vallinayagam, K. Rajendran, V. Sekar, Computational phytochemistry in drug discovery: databases and tools, in: Egbuna, et al. (Eds.),
Phytochemistry, Volume 1: Fundamentals, Modern Techniques, and Applications, Apple Academic Press, New York, 2018, pp. 497e511.

This page intentionally left blank

Chapter 4

FDA drug candidacy acceptance criteria
and steps: problems and way forward
Shahira M. Ezzat1, 2, Mahitab H. El Bishbishy2, Angelo Mark P. Walag3 and Andrew G. Mtewa4, 5
1

Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 2Department of Pharmacognosy, Faculty of Pharmacy,

October University for Modern Sciences and Arts (MSA), 6th October, Egypt; 3Department of Science Education, University of Science and
Technology of Southern Philippines, Cagayan de Oro City, Philippines; 4Chemistry Department, Institute of Technology, Malawi University of
Science and Technology, Limbe, Malawi; 5Department of Pharmacology and Therapeutics, School of Medicine, Mbarara University of Science and
Technology, Mbarara, Uganda

Chapter outline
4.1. Introduction
4.1.1. Drug approval framework
4.1.1.1. The clinical trials
4.1.2. FDA acceptance of foreign clinical studies not
conducted under an IND
4.1.2.1. Acceptance of foreign clinical studies
4.1.3. Regulatory approaches on botanical drug
development (NDAs)
4.1.3.1. Challenges in developing global
botanical drugs
4.1.3.2. Development of novel botanical
drugs using traditional medicinal
plant sources
4.1.3.3. Description and documentation of
products

39
40
41
42
43
43
43

44

4.1.3.4.
4.1.3.5.
4.1.3.6.
4.1.3.7.
4.1.3.8.
4.1.3.9.
4.1.3.10.
4.1.3.11.
4.1.3.12.

Quality control
Botanical raw materials
Safety tests on animals
Placebo
Labeling
Nonclinical safety assessment
Clinical pharmacology
Clinical evidence of efficacy and safety
Evidence to ensure therapeutic
consistency
4.1.4. Postmarketing considerations
4.1.5. FDA relationship with the industry: the FDA’s
influence on marketability of drug products
References

44
45
45
46
46
46
47
47
48
49
60
60

44

4.1 Introduction
This chapter aims at designating the criteria and procedures required for botanical drug development programs and
providing a schematic structure for dealings between the qualifying entity (Center for Drug Evaluation and Research
(CDER)) and the proposing entity (the submitter) to qualify for Food and Drug Administration (FDA) drug candidacy
acceptance. It also aims at pointing out the data to be submitted to support the qualiﬁcation and the steps for CDER’s
formal review of the data.
Recently, botanicals that can ameliorate critical and/or life-threatening diseases have gained the attention of many
pharmaceutical companies and research organizations such as the United States National Institutes of Health (NIH).
Although botanicals were used since antiquity, there is no convincing solid evidence concerning their clinical safety and
efﬁcacy [1].
Firstly, the term “botanicals” refers to products including plant materials, algae, macroscopic fungi, and their combinations. However, it excludes products containing animals or animal parts and/or minerals, except when these are
incorporated in a traditional botanical preparation at low concentrations. It also excludes genetically modiﬁed species and
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fermentation products intended to produce a single molecular entity, as well as highly puriﬁed substances derived from a
naturally occurring source or chemically modiﬁed. The FDA deﬁned the botanical drug as a botanical product prepared
from a botanical drug substance and intended for use as a drug [2]. A conventional FDA-approved drug has a deﬁnite
single well-characterized active ingredient. On the other hand, botanical drugs occur as extracts that are composed of
multiple chemical constituents.
Accordingly, botanical products could be categorized into four categories: food (e.g., dietary supplements), drugs
(including biological drugs), medical devices, or cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act) [3].
Any entity proposing to market a new botanical drug in the United States must submit a New Drug Application (NDA)
and obtain Agency approval before marketing the new drug product for the proposed use. FDA may approve a drug
product containing such a drug substance for OTC sale pursuant to a submitted application. Consequently, the marketing
approval for either prescription or OTC use of a botanical drug could be granted [3].
The consistency along the marketed drug product batches is a major challenge in botanical drugs because of their
heterogeneity and uncertainty about its active constituents which could affect their therapeutic effects. Basically,
therapeutic consistency can be supported by a “totality of the evidence” approach, comprising the following considerations:
raw material control (such as agricultural and collection procedures), quality control (including spectroscopic and/or
chromatographic methods), and manufacturing control (e.g., process validation), in addition to biological assays to reﬂect the
mechanism of action of the drug [3].
In 2004, FDA published a guidance on botanical drug products to explain the cases of a botanical drug to be marketed
under an over-the-counter drug monograph, or if FDA regulations require approval for marketing of NDA, and the
Investigational New Drug Applications (INDs) for botanical products currently lawfully marketed as foods in the United
States [4]. Furthermore, the FDA also published the Manual of Policies and Procedures (MAPP): Review of Botanical
Drug Products, which describes the review process in CDER for INDs and NDAs for botanical drug products [5].
FDA treats botanical and puriﬁed chemical drugs the same, where the INDs for botanical drug products should include
protocols, chemistry, manufacturing, and control (CMC), pharmacological and toxicology information, and previous
human experience with the product as indicated in FDA guidance [6].

4.1.1 Drug approval framework
The development of a new drug usually goes through a deﬁnite pathway. First the drug should prove to be effective in the
preclinical tests which involve both in vitro and in vivo testing and drug prototype design. In this case, this drug becomes
ready for clinical study, but before any human testing, the drug developer must involve the FDA. The process begins when
the drug manufacturer ﬁlls an investigational new drug (IND) application with the FDA agency. Federal law requires that a
drug be the subject of an approved marketing application for it to be legally shipped across state lines. An approved IND
application provides the developer with a technical exemption to this federal regulation so that clinical investigators can
distribute a drug to different study centers across the United States [7].
All drugs should undergo review by a committee, or “new drug division,” which is specializing in the class of drug
in question according to the drug use. Before the submission of a formal IND application, the FDA encourages the
Preinvestigational New Drug Application Consultation ﬁrst [8] because this early collaboration before IND applications
can guard against problems such as suggestions, mandatory changes, or clinical holds on the application; thus it deserves
the time and effort.
In addition to the preinvestigational consultation, a number of guidance documents are provided by FDA, which have
the required materials for the IND application [9], as well as information and contact numbers for submitting an EIND
application. Three basic categories of information should be supplied by each investigator [10]:
a. Data of preclinical and toxicological animal studies and any previous human experience with the drug.
b. Manufacturing data, which includes the composition, manufacturer, stability, and controls.
c. Protocols of the clinical trials, information about the investigators conﬁrming their qualiﬁcation to perform the trial, and
their commitments to obtain consent from patients, obtain institutional review board (IRB) approval, and adhere to any
regulations regarding INDs.
The investigational new drugs are either "commercial" or "research" and the investigational new drug (IND) applications are of three types [7]:
i. Investigator IND: An investigator IND is submitted by an investigator as a representative of an institution, for
example, a pharmaceutical company. The investigator is responsible for initiation and conduction of the investigation
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and control of the dispensing and administration of the drug. The clinical trials (Phase I testing) should begin at least
30 days after submitting an IND application in case that FDA does not object within that time [11]. FDA may respond
to the IND application by suggestions or mandatory changes that are required for the study. The FDA review
committees usually involve number of clinicians and researchers who necessarily have experience with drugs of a
similar class, and thus their suggestions should be taken seriously. Moreover, a collaborative relationship between
the investigator and the FDA reviewers is essential for the approval process to avoid issues down the road. Although
the FDA must respond within 30 days, but failure to make the required mandatory changes will result in a “clinical
hold” [11], preventing the study from legally proceeding until the FDA is assured of the safety of the study. In some
cases, a clinical hold may result in a delay in the study of a year or more [12].
ii. Emergency use investigational new drug (EIND): In case of emergency situation in which there is no enough time
for a standard IND process or IRB approval of an experimental drug, an emergency use investigational new drug
EIND is submitted to FDA [13]. EIND is also submitted to approve the use of the drug in a patient or patients
who do not meet study criteria or if no approved study protocol exists. EINDs are submitted through direct contact
with the concerning division of the FDA that has special contact numbers and an emergency contact number for night
and weekend contacts [13]. In emergency cases, the FDA will often authorize the use of the agent in advance of a full
IND, which must then be completed in a timely manner.
iii. Treatment IND: Treatment IND applications, which are also called “expanded use INDs,” are used for approval of an
experimental drug which shows initial efﬁciency in clinical studies before completion of the studies and before
ﬁnal FDA approval [14]. Treatment IND regulations have been introduced in 1987, during the development of the
active drug azidothymidine [15]. Additional accelerated approval measures were instituted by the Food and Drug
Administration Modernization Act of 1997 [16], which allows the FDA to “fast track” deﬁnite drugs that must be
essential for treatment of a life-threatening or serious condition; and it must have the potential to address an unmet
medical need [17]. Treatment IND requirements for a drug are ﬁrst, the drug should be intended for treatment of a
serious or immediately life-threatening disease; this disease has no alternative treatment; the drug is already under
investigation or trials are complete; and the drug sponsor is actively pursuing approval. Prospective IRB review
and informed consent are mandatory. The process and timelines for treatment IND applications follow a similar
pathway to those of regular INDs, but requirements for clinical evidence differ.

4.1.1.1 The clinical trials
Clinical trials establish the safety, efﬁcacy, and effectiveness of new drugs and are divided into Phase 0, I, II, and III trials.
Postapproval surveillance trials are generally termed Phase IV trials. The FDA encourages investigators and sponsors to
communicate directly with the appropriate FDA review section during each phase of testing.
Phase 0 clinical trials: Phase 0 clinical trials also known as “exploratory” trials were ﬁrst allowed in 2006 as a
means of facilitating the drug approval or elimination process [18]. Phase 0 clinical trials represent the earliest, ﬁrst-inman use of a proposed drug therapy [19]; they require submission of an exploratory IND followed by a full IND. They
are carried out on a very small sample which consists of 10e15 patients, with doses lower than 1% of the clinically
effective dose with number of doses and dosing duration of less than 1 week [20e22]. A Phase 0 trial investigates the
ability of the drug to act on its expected target and exert a clinical effect. It also shows the pharmacokinetic and
pharmacodynamics properties of the drug. Phase 0 trials can also be conducted while awaiting FDA review of a standard
IND application, thus providing valuable information regarding human effects while avoiding delays in the full FDA
approval process [21].
Phase I clinical trials: Exploratory INDs progress to “full” Phase I clinical trials if their results are positive. Phase I
trial aims to prove initial safety, determine safe dosing ranges, and identify common side effects and the toxicity proﬁle of
the drug. The sample size is small (20e80 subjects) [23], who are generally healthy. Single dose of drug is used, which is
not higher than one-tenth the highest dose associated with no adverse effects in the most sensitive animal safety studies
[22]. Single and multiple ascending-dose trials (Phase Ia and Ib trials, respectively) follow the single-dose trials. In Phase
Ia (single ascending-dose trials), a small group of three subjects are with a single higher dose. If no side effects are
obtained, another group receives a higher dose, and the process is repeated till either precalculated pharmacokinetic safety
levels are reached or until undesirable effects appear. If an unaccepted side effect is obtained at the chosen dose, three other
subjects should be tested at the same dose to conﬁrm. When unaccepted side effects appear, the drug is determined to have
reached its maximum tolerated dose. In Phase Ib (multiple ascending-dose studies), the pharmacokinetics and pharmacodynamics of multiple doses of the drug is studied. Groups of patients receive multiple low doses of the drug, and
biological samples are collected and analyzed. The dose is then escalated in further groups to a predetermined level.
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Phase II clinical trials: Phase II clinical trials aim to investigate the efﬁcacy of the drug while continuing to establish
its safety. The investigator ﬁrst submits the safety information regarding the drug to the FDA, together with any new data
that have been gained in Phase I testing. The submission includes any changes in drug manufacture or preparation
anticipated for Phase II studies. Phase II clinical trials depend on larger sample size (100e300 human subjects), so that
less-common side effects can be seen, and the trials involve patients with the disorder which is the target of the drug [23].
Tests are often conducted in comparison with placebo. Escalating dosing may be incorporated, exploring the therapeutic
range of the drug.
Phase III and IV clinical trials: Before this phase, the investigator must also submit updated information to the FDA
regarding continuing safety for subjects, incorporating any safety and toxicity information gained in Phase II testing. Phase
III trials are the ﬁnal conﬁrmation of safety and efﬁcacy and are carried out in large sample of 1000e3000 subjects. The
trials evaluate effectiveness, monitor side effects, and compare the drug with commonly used alternative treatments. After
the completion of Phase III clinical trials, the investigator can ﬁll an NDA with the Center for Drug Evaluation and
Research (CDER) of the FDA, which has a request by the investigator to manufacture and sell the drug [24].
The NDA should have all information on the drug including manufacturing process and facilities, quality control, and
assurance; a complete product description (chemical formula, speciﬁcations, pharmacodynamics, and pharmacokinetics);
indications; labeling; and proposed risk evaluation and mitigation processes if applicable [25,26]. The FDA has 60 days to
determine if they will ﬁle the application once it is received [27].
FDA reviewers will evaluate clinical data, analyze drug samples, inspect the production facilities, and check proposed
labeling. The Federal Food, Drug, and Cosmetics Act requires that there be “substantial evidence” of drug safety and
efﬁcacy [28].
Approval may include speciﬁc conditions, such as requirements for post-approval (Phase IV) clinical studies, distribution restrictions, changes to labeling, or other requirements. FDA review occurs within 180 days of receipt of a complete
application [24]. An accelerated process is available for generic drugs, products that provide “meaningful therapeutic beneﬁt”
over existing drugs, those that concern serious or life-threatening conditions, or those that address a previously unmet medical
need. If the application is found to have deﬁciencies, the clock stops on review while the manufacturer is given an
opportunity to respond to the deﬁciencies or withdraw the application. If approval of the NDA is denied, the FDA sends a
complete response letter describing speciﬁc deﬁciencies and recommending ways for the applicant to make the application
viable. Unsuccessful applicants may request a hearing. On review and approval of the NDA, the manufacturer is free to
manufacture and market the drug. The FDA drug approval process is summarized in Fig. 4.1.

4.1.2 FDA acceptance of foreign clinical studies not conducted under an IND
To acquire the FDA approval to market a new drug in the United States, a drug sponsor “Sponsor” must submit a
marketing application including an NDA and other application materials. This NDA must provide solid basis that the drug
is safe and efﬁcient for its prescribed use, as demonstrated from applicable and adequate evaluations according to the
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FIGURE 4.1 FDA Drug approval process.
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criteria established in section 505(d) of the FD&C Act [29,30]. Clinical studies provide a substantial proof of drug’s safety
and efﬁciency; they are usually conducted using either a “blind” or “double-blind” design. These clinical studies should be
monitored by an Institutional Review Board (IRB) and sometimes a Data Monitoring Committee (DMC) [31,32], where an
IRB is supposed to inspect the study protocols before its start, monitor the progress of the study, keep its records, and
assure clinical testing meets ethical standards; however, DMC monitors the data during the study progress to ensure that
the drug is not so dangerous, then this clinical trial needs to be terminated, or in contrast, that the drug is not so effective
that it would be unethical to keep the treatment from any participant taking an inadequate dose. To minimize these chances
of clinical studies termination, a preclinical protocol should be established, which involves only animal subjects and
computer modeling [33], after which, if the drug was found promising, the sponsor submits an IND with the FDA so as to
continue with clinical trials. If the FDA ﬁnds the IND effective, the sponsor may begin the ﬁrst phase of clinical testing.
In light of the FDA drug marketing approval process, it is a major burden placed on sponsors because of the substantial
lag between the initial drug investments and its enter to the market, a long process that could take 10e15 years which
threatens the pharmaceutical companies’ viability [34,35]. Hence, many pharmaceutical companies switch to foreign
clinical trials (FCTs) which are clinical studies that are conducted outside of the United States to supplement or comprise
their NDA and IND as an alternative solution to decrease the lag period between the initial investments and drug sales [36].
This trend was preferred as it has reduced costs compared with domestic trials and also it is easier in subject recruitment
and less ofﬁcial regulations from non-US governments [37], in addition to other factors such as funding from a foreign
government or organization to conduct a study in their region; a foreign country’s regulatory requirement that research on a
drug be conducted on their population before being locally marketed [38] or even geographic speciﬁc diseases [39]. On the
other hand, this trend is believed to stimulate questions concerning data validity, unethical conduct, and compliance with
international humanitarian standards especially if those FCTs were performed in less developed countries.

4.1.2.1 Acceptance of foreign clinical studies
As a matter of fact, the FDA has never prohibited FCTs from being submitted as part of a marketing application;
nevertheless, the FDA has historically been suspicious of FCTs before the Kefauver Harris Amendments in 1962;
therefore, the sponsors were not used to submit FCT data [40].
The FDA gradually came to accept FCTs as equivalent to their domestic complements and even began to ofﬁcially
permit the submission of an FCT that was not conducted under an IND to support a Sponsor’s marketing application during
the 1970s [41].
According to 21 CFR 312.120(c) (1), FDA will accept a foreign clinical study not conducted under an IND only if the
study conforms to either the ethical principles set out in 21 CFR 312.120(c) (4), (the Declaration of Helsinki, 1989
version), or with the laws and regulations of the country in which the study was performed, whichever provides greater
protection of the human subjects [42]. Finally, in 2008, FDA issued a ﬁnal rule entitled “Human Subject Protection;
Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application” as a modiﬁcation to 21 CFR
312.120. This ﬁnal rule and its preamble are available at http://www.regulations.gov/#!Document Detail; D¼FDA-2004N-0061-0002;old Link ¼ false.

4.1.3 Regulatory approaches on botanical drug development (NDAs)
It is glaring that the global market of botanical drugs is expanding, as it includes medical supplies, functional foods for
health, or extracts composed of single-element constituents, etc. The size of the global market is estimated to be one trillion
dollars and is rising by 8%e10% annually. About half of the medical supplies currently on sale are botanical drugs, from
natural products [43].
The FDA took the initiative in the botanical drug market by establishing a guideline for botanical drugs (Botanical Drug
Guidance) in 2004. Hence, 868 semisynthetic compounds derived from natural sources were approved by the FDA since
1982, and 20 new anticancer agents that originated also from natural agents were developed until 2002.

4.1.3.1 Challenges in developing global botanical drugs
Although the global market of botanical drugs is expanding continuously, there are several challenges that face the
development of botanical drugs worldwide, the major of which is the FDA approval. Although there are numerous
attempts, with over 500 pre-IND meetings and IND applications, these attempts fail to reach the ﬁnal NDA stage [43].
This may be attributed to

44

PART | I Plants as natural sources of drugs

i. Insufﬁcient evidence for efﬁcacy:
The FDA necessitates “adequate and well-controlled” multicenter clinical studies on any new drug candidate to prove
and document its safety and efﬁcacy. This ensures the maximum level of inspection before approval. However, the
studies should have a speciﬁed target population, proper experimental controls, appropriate outcome measures, independent monitoring, and accurate analysis. Therefore, the lack of statistically signiﬁcant evidence of drugs efﬁcacies of
clinical relevance is the most common reason that the drug candidate fails to reach the NDA stage.
ii. Unrealistic goals and expectations:
Drug sponsors, especially with insufﬁcient experience, usually set unrealistic goals, which hinder the drug approval
process.
a. The initial stages of IND development is relatively less strict, which gives the sponsors the deceiving impression
that botanical drugs are less rigorously evaluated by the FDA compared with conventional synthetic drugs.
b. The absence of internationally standardized regulatory requirements for botanicals.
c. Many non-US botanical drug sponsors who ﬁeld a drug development operation in the United States are not aware
of the practical differences in regulations between the United States and a foreign market.
iii. Insufﬁcient funding:
During the IND stage, some botanical drugs encounter the partial or complete loss of the project funding, which depends on the progress of the project. These funding cuts may be due to the general economic conditions; suspicion of
funders; deﬁciency of patents; and/or insufﬁcient project planning.

4.1.3.2 Development of novel botanical drugs using traditional medicinal plant sources
Synthetic drugs that provide the single-drug “magic bullet” strategy are actually insufﬁcient for the treatment of chronic
disorders because of their multifactorial pathogenesis. However, botanical drugs are well-known for their complex
compositions, which make them a better option for the “multitarget/multicomponent” approach for treatment of these
chronic disorders. The term “reverse pharmacology” refers to the strategies of developing novel botanical drugs through
reverse engineering of traditional herbal medicine; it involves the study of active metabolites based on traditional herbal
medicine and formulations, in addition to the subsequent development of drug candidates or formulations for preclinical
and clinical research. Reverse pharmacology represents the ultimate strategy for developing chronic disorders treatments,
where the traditional herbs that are proved safe and efﬁcient are used and therefore reduce the cost and duration of the
initial stages of synthetic drug development [44,45].

4.1.3.3 Description and documentation of products
Botanical products are described at different levels, including details they had in their natural botanical form before any
modiﬁcations and/or alterations and after a modiﬁcation has been made to improve drug likeness. This section discusses
fundamental description details of products before any alterations have been made on the biological nature of a plant or any
product coming from the natural botanicals. It is important to note that some natural drugs may be processed for application
as an IND right in their natural botanical form.
In phases I and II studies, the FDA may require some basic information that describes the drug and its products. Much of
the product’s CMC, including toxicological data at this stage, is not mandatory. However, for these phases, these data and
toxicological data from animals may be minimal or not necessary if the drugs have a very good bunch of data on safe
historical use by humans [46]. If they may not be required in these phases, the data should still be collected during this period
as it is a basic requirement to be submitted before the beginning of phase III studies. Phase III is an almost sudden turn to
strict controls where even prior historical use by humans does not give any guarantees of safety in regard to the FDA. For
botanical drugs, there is one beneﬁt with combination drugs which get a waiver in terms of assessments for individual
components of drugs which is a due requirement for drugs with a ﬁxed combination or known single component drugs [47].

4.1.3.4 Quality control
Quality standards that the FDA follows are strict and stringent to ensure the safety of consumers thereof. However, some
researchers have been arguing for a substantial lowering of such standards on natural botanical drugs suggesting that by
doing so, industries will be encouraged and promoted in robust exploration of herbal medicines and increase the rate of
availing effective herbal medicines to patients [47]. In more recent years, the debate about stringent controls of the FDA
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has always been there, weighing safety versus speed and rate of approvals. Most researchers are of the view that safety
issues for botanical natural product drugs could not be serious as they are generally considered safe to use [48]. The FDA
later came up with draft guidelines for botanical drug products in response to industries’ complaints, suggestions, and
debates to make the playing ﬁeld more conducive. More researchers and industry captains kept contributing to the
guidelines with time. For the FDA, safety issues have always remained a priority even for herbal products. Carefully
drafted quality assurance and control principles guide the process of vetting the safety of each product by ensuring that
each step of handling and decision-making is transparent and well-monitored. This section discusses how quality is
controlled for botanical NDAs.
4.1.3.4.1 Quality control systems
Quality control system in the FDA approval application processes follows a particular framework, though not in the same
exact order as described here. One most common approach that the FDA uses is quality control by CMCs. CMCs are
categorized into three for convenience of understanding. The earlier ones are the pre-CMCs, which require in-depth understanding of the biology of plant species, good agricultural and sample collection practices (GACP), and formulation
preparation processes. The second one is the conventional CMCs, which essentially checks the chemistry of the drug raw
materials, the drug itself, and any products from the drugs. This is the stage where analytical equipment and techniques are
employed to understand any possible interactions of molecules, functional groups present, and other druglike properties of
the chemical makeup of the drugs. Lastly, there comes the post-CMC phase where bioassays are conducted and advanced
clinical data are generated using various models and techniques to determine ranges of dose responses of the drugs [46,49].
4.1.3.4.2 Record and document control
Quality of drug products is assured evident from how records and documents for each step of studies are managed and
controlled. Records that are required for botanical drug INDs are always well-prepared, monitored, and controlled. These
are the ones that help in describing compliance to required standards of the CMCs and toxicological analyses of the drugs.
These records include the following items.

4.1.3.5 Botanical raw materials
The applicant is required to provide all appropriate botanic names of all raw materials including all their known synonyms
and family names as much as possible [49]. The name of the botanist who initially identiﬁed the plant species is also
required to be presented. Synonyms are important in helping to link up recent research data on the plant(s) regardless of
whatever names used during the research. On the same naming, local names of the plant species in all areas where they are
known to have medicinal uses are also required to be included along. The botanical raw materials are also required to be
described in their physical appearance, detailing if they have and how leaves, roots, bark, rhizomes, ﬂowers, and any other
part(s) can be visually identiﬁed [46].
At an early stage, only data for raw materials are required. Robust chemical analyses to determine full drug characterization at microscopic level may not be available yet. For early phase trials, general chemical groups may be enough to
be reported as substances contained in the drug(s) [46]. For example, one would have preliminary idea that the most active
group of compounds in a particular drug is alkaloids; these data need to be reported with all available quantiﬁcations.
Sometimes, one would be in a position to know speciﬁc active compounds tested on the bench or implied from previous
research literature; these data are also important to be included. At later stages (Phase III and above), speciﬁc elucidated
molecules and their characterizations are imperative to be mentioned as they include pointers to potential “druglike”
properties that will deﬁne drug adsorption, distribution, metabolism, excretion, and toxicology (ADME-Tox) should they
proceed to drug development stages [50].

4.1.3.6 Safety tests on animals
All prior animal test data are required to be available in all details including test animal models used, test protocols,
protocol standardization if available, results, limitations to the protocols, and laboratories used. Where there were conﬂicting or outstanding results, they also need to be highlighted in detail in case they may be pointing at something signiﬁcant. At earlier stages, general safety tests on animals may be reported, but ﬁner details are required to be available
before the beginning of phase III trials [51].
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4.1.3.7 Placebo
Where a placebo is required in a protocol, as it is necessary particularly at advanced phase clinical trial levels, it
becomes complicated for botanical drugs whose composition is in such a way that there is no any other botanical that
can be effectively used to blind study participants. Variations between the test drug and the available placebo items
could be taste, odor, and texture, which may be very difﬁcult to modify for natural products, despite perhaps both the
drug and blinding botanical having the same color [46,52]. In such cases, the masking botanical should not have
known pharmacological characteristics; otherwise, clinical data interpretation would be too complicated and easily
misleading. Case-by-case management and decisions on placebo for various botanical drugs can be undertaken,
provided the team of investigators is convinced enough of achieving an effective blinding effect without compromising
the study.

4.1.3.8 Labeling
Labeling is one of the most important stages of quality assurance. It helps in ensuring the quality of the raw materials,
drugs, and/or their products both backward, though traceability procedures, and forward through product record controls.
With labels, one can easily trace back the origin of the material and link all dots to do with previous environmental
contamination issues possibly that happened in an area where the species was harvested [53].
Apart from the descriptions stated above, botanical drugs, raw materials, and their products need to have other information that will help people know all important details about them [51]. These include authenticity certiﬁcations, status
of plant species endangerment, if under protected and banned species or not, if endemic to a particular region, if grown
under GMO status, harvester, dates, harvesting location, transportation used, postharvest treatment and storage, and any
other such details. If industrially packed, all information including address of the facility and regulatory laws encompassing
the same also need to be included. Any other declarations should be included, for example, if known allergens are involved
at any stage.

4.1.3.9 Nonclinical safety assessment
Safety assessments at the nonclinical stage require a critical look at the interactions between drug components and
laboratory test animals way before exposing the dug to humans. Below are the critical areas that take up most of the
qualiﬁcation studies at this stage [51].
4.1.3.9.1 Pharmacokinetic studies
Pharmacokinetic studies are imperative as they assist in making sense of clinical trial observations for a test drug. These
studies also include toxicokinetic studies. They speciﬁcally look at the movement and interaction (ADME-Tox) of the drug
within and across systems, organs, and cells of different environmental conditions to which the drug molecules respond
(behave) varyingly [50]. Where there is a chance that an active drug molecule is known, chemical structural properties need
to be exhaustedly studied as much as possible using the most precise methods, equipment, and tools available [46,50].
All parameters of ADME need to be assessed for all possible sets of pH and lipophilicity. If at an advanced stage,
doseeresponse tests are critical for various groups of people, which can be categorized according to age, sex, pregnancy
gestation stage, race, and possibly vulnerabilities (e.g., people with immunodeﬁciency, hepatic challenges, and renal
conditions). These tests help in determining a broad range of possible outcomes, whether desirable or not for relevant
research, ethical, and economic decisions.
4.1.3.9.2 General toxicity studies
Toxicity studies that go all around and inside the animal body on the bench are the ones that characterize the category
commonly called general toxicity studies. One of the most important features of these studies is repeated dosing, which
ensures recording consistent response that the animal has to drug exposure. For phase III studies, botanical drugs and
conventional medicines are treated strictly in the same exact way including exposure doses. Much as it could be possible,
the maximum dose tested at this stage should produce some sort of toxicity that can be measured to help understand what
levels should not be for human exposure [46,47]. Generally, later stage (from phase III) studies that seek speciﬁc biomarkers for toxicology are not different for botanical drugs from nonbotanicals.
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4.1.3.9.3 Reproductive toxicology
Reproductive toxicology studies for late phases should be conducted on animals in accordance with standard methods
despite any mention of historical use. Historical human use data are usually too complicated and unreliable as a measure of
toxicology on the reproductive system.
4.1.3.9.4 Genotoxicity studies
Genetic toxicity should be carefully and thoroughly studied before reaching phase III of trials as detailed in the International Council of Harmonization (ICH) guidelines S2 R1 [54]. All data handling and interpretation are the same for
botanical and nonbotanical drugs [52].
4.1.3.9.5 Carcinogenicity studies
Carcinogenicity studies are tedious, long, and require close attention. As such, they need to be planned far in advance to
avoid reaching and IND approval application stage without data at hand. What becomes more complex in this regard is that
even the protocol needs to be submitted to the FDA for assessment before embarking on the tests. The goodness with early
protocol reviews is that close attention helps easy determination of possible maximum doses for the tests which saves time
and other resources [46].
Safety assessment on drug products is expected to have been conducted by the time an application for approval reviews
is being ﬁled for INDs. At this stage, all data on animal safety studies about the product need to be readily available and
documented together with the application.

4.1.3.10 Clinical pharmacology
Biological drugs are complex in that they usually contain several compounds, all with their own activities on various
systems or biological targets. Many times, the actual active ingredient is not known, making it hard to identify which
activities are emanating from what molecules. However, this becomes simpler when an active compound is particularly
known. Pharmacodynamic and pharmacokinetic information of molecules in drugs, whether active against the intended
biological target or not, is important in the designing and interpretation of clinical studies. Approved protocols are required
before any work is began [51]. Clinical pharmacological studies are a must-do and should bring forward all issues that
could inﬂuence the acceptability or rejection of the drug. These may include residual drug in blood after some time
intervals, variations in regions and climates in relation to dose response after exposure, and interpretations of any variations
there could be.

4.1.3.11 Clinical evidence of efficacy and safety
The clinical research activities have been globally increasing and approval of new drugs will rely on both foreign and local
clinical trials. Before a new prescription drug can be made available in the United States, the FDA must review an
extensive collection of evidence of both the drug’s safety and efﬁcacy in clinical trials as required by law [55,56].
Similarly, drugs from botanical sources meant to be marketed in the United States are required to meet the same standards
on safety and efﬁcacy imposed to those other nonbotanical drugs. Safety of drugs provides the highest tolerable dose or
optimal dose required to achieve the desired clinical beneﬁt and potential adverse effects to be experienced in that exposure
range [57]. Efﬁcacy of drugs, on the other hand, refers to the ﬁndings in an adequate and well-controlled clinical trial or the
intent of conducting such a trial [55]. Adequate and well-controlled investigations should possess these essential elements,
as stipulated in Section 314.126 of Title 21 of the Code of Federal Regulations (CFR).
1. The objectives of the study and the summary of methods of analysis for the trials must be clearly stated.
2. The research design must allow comparison of with a control group to permit quantitative assessment of the drug’s
effect.
3. The protocols employed in the study design must be clearly and precisely deﬁned including the study duration, sample
size, and whether the treatment is parallel or sequential.
The effectiveness of drugs describes the clinical beneﬁts obtained in the “real-world” situation [57]. Studies that present
evidences to support effectiveness of drugs must adhere to the essential elements of an adequate and well-controlled
investigation. To establish substantial evidence of effectiveness of drugs, the US Department of Health and Human
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Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation
and Research (1998) developed a guide on the quantity of evidences and particular circumstances [58]. The effectiveness
of drugs can be addressed in three circumstances. The ﬁrst is that the effectiveness of a new use can be extrapolated entirely
from existing studies on efﬁcacy. A single adequate and well-controlled study of a speciﬁc new use can also establish
effectiveness of drugs when it is supported by information on other related adequate and well-controlled studies. These
other related studies can be studies in other phases of disease, a study on a closely related disease, of different dosage
forms, or of different endpoints. Lastly, the effectiveness of drugs can be established by a single multicenter study even
without supporting data from other adequate and well-controlled studies. Although clinical trials done abroad and
especially in developing countries can beneﬁt sponsors, critics have raised concerns about the extent to which the clinical
results on efﬁcacy and safety can be generalizable to the US population [58]. In response to this issue, the FDA requires the
sponsor to clearly state how the data FCTs are applicable to both US population and medical practice as stipulated in
Section 314.106 of Title 21 CFR.
The evaluation of safety and efﬁcacy of drugs is conducted by sponsors in three phases of clinical trials [57,59]. In the
ﬁrst phase, the safety of the drug or botanical product and right dosage is assessed in small groups of healthy volunteers.
The efﬁcacy of drugs or botanical products is evaluated in the second phase within patients with the condition sought to be
treated. In the third phase of the evaluation, both safety and efﬁcacy of a product are determined within a larger population
as stipulated in Section 312.21 of Title 21 CFR. Only a handful of unpatented botanical products reach the third phase level
of research because of complexity and extremely high cost [60]. The approval of FDA to market a new drug is largely
based on pivotal trials results sponsors submit as part of the marketing applications. The pivotal trials are generally those in
the third phase that supports both the safety and efﬁcacy of the drug or botanical product.

4.1.3.12 Evidence to ensure therapeutic consistency
Manufacturers of botanical drug products constantly face the challenge in ensuring that different batches marketed are
consistent in their therapeutic effects with those batches utilized in the third phase of clinical studies [61]. Because of the
variations and heterogeneous nature of botanical drug products, the use of chemical testing may be insufﬁcient basis for
quality control and thus for ensuring therapeutic consistency. As stipulated in the Guidelines for Industry on Botanical
Drug Development of the FDA, the quality control of botanical drugs should take into consideration three aspects:
1. Botanical raw material control.
2. Quality control by chemical tests and manufacturing control.
3. Clinical data and biological assay.
These three aspects of quality control must be viewed collectively and that sponsors should provide an integrated
assessment of these three aspects to substantiate that the commercially available botanical drug batches possess the same
therapeutic effect to that of those observed in clinical trials.
Various quality information from clinical studies conducted during drug development must be collected and these
should be meticulously summarized and presented in the NDA including an integrated evaluation [61]. The various
information required are (1) raw material control, (2) quality control by chemical tests and manufacturing control (CMC),
and (3) biological assay and clinical data. The botanical raw material control should begin with the raw materials utilized
and should be clearly described in the NDA. Speciﬁc and meticulous descriptions of the plant material used should include
information on the authenticity of morphological, macroscopic, and microscopic analyses. Agricultural practices,
geographic location of plant source, and the collection and processing methods should also be clearly described in the
NDA. Moreover, the cultivar of the citation of the plant should also be included if known [60]. The applicant is also
required to establish the Guidelines on Good Agricultural Practice (GACP), as instituted by World Health Organization
(2003) [62] or other regulatory bodies on botanical medicines, and outline the procedures utilized for each of the botanical
raw material used on submission of NDA. For plant products with cases of complicated taxonomy, DNA ﬁngerprinting can
be used to resolve disputes when issues on these materials exist. Moreover, DNA ﬁngerprinting may provide more plantspeciﬁc characteristics that can be used to identify plant sources especially if multiple related plant species have been used.
Other than important information on the botanical raw material, methods are employed to minimize contamination,
variation, or deterioration of raw materials because any changes in the protocol utilized could change the chemical proﬁle
of the drug substance [61]. Quality control by CMC includes important steps to ensure correct and complete characterization of all chemical constituents in botanical drugs, although inherent difﬁculties are present especially in the stage of
controlling of the raw materials and characterization of relative potency and in the results of bioactivity assays. Unlike
synthetically produced drugs, botanical products are mixtures of uncharacterized components [63]. Applicants are tasked to
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evaluate and develop state of the art and current emerging analytical methods and technologies to provide acceptable
identiﬁcation and quantiﬁcation of active or chemical components of the botanical drug product [61]. If complete
characterization is not possible and the active components are not known, applicants are required to select and present a
characteristic proﬁle of the chemical components for identity testing. In addition, botanical drugs with unknown
constituents may best be approached by analyzing the chemical constituent with a sizable percentage or chemical
ﬁngerprinting analyses of the total ingredients [63]. Moreover, the multiple analytical methods employed for characterizing
the active or chemical constituents should also be fully and exhaustively described in the NDA. Furthermore, all tests
performed to qualitatively and quantitatively characterize the active or chemical components should be included in the
application. Part of the application of the NDA requires information on all the sites used for the manufacturing of the
botanical drug substance including those that will be distributed commercially. It is also strongly discouraged that changes
in the sites of manufacturing of drug substances happen especially during the late phase of clinical developments. All of the
manufacturing processes of botanical drugs should be ﬁnalized and other in-process controls and chemical testing should
be clearly established [61].
Information on correlational studies on pharmacological activity and clinical effect may be required to ensure that any
variation in the raw materials and drug substance will not affect the therapeutic consistency of botanical drugs. The information required may include biological assay and clinical data [61]. Various regulations and issues on the researches
made on herbal medicines are also thoroughly reviewed by Tang et al. [64].

4.1.4 Postmarketing considerations
Medical doctors and insurance companies need to balance the effectiveness of new drugs against existing therapeutics to
decide about treatment and formularies [65]. Although clinical trials provide important data on drug’s safety and efﬁcacy,
complete information on the drug’s safety and efﬁcacy at the time of approval is impossible to determine. The use of any
drug products comes with the possibility of unintended consequences which may be beneﬁcial or harmful. Approval of
new drugs from the FDA does not assure the possibility of rare but serious or common but delayed adverse effects [66].
Brewer and Colditz [66] also suggested several postmarketing methods to identify and conﬁrm adverse drug reactions.
Moreover, many drugs pose adverse reactions and are detected only after a drug has been approved by the FDA and is in
use [67].
The effectiveness of drugs can be questioned because of the nature of botanical drugs having active components
varying from batch to batch [60]. Because of this, the stability of raw botanical drugs should be emphasized particularly in
having secure source of raw materials and in the consistency of manufacturing process as to provide a reliable botanical
drug. Changes made after approval, like in changes in agricultural sites, collection, and processing practices and methods,
should be valuated carefully to assess if drug products produced after such proposed changes possess the same therapeutic
and pharmacological effects before changes were made [61]. The US FDA ofﬁcials also conduct routine inspections of
manufacturing sites across the United States and abroad (if drugs were manufactured overseas), which can be announced or
unannounced [68]. Moreover, a much truer picture of the product’s safety actually evolves over a few months and even
years making up its life span in the market. In botanical drugs, the effects of changes are not easily evident and thus
additional studies are required to be conducted. The amount of data studies should produce will be determined by the FDA
on a case-to-cases basis.
Advertisements and promotional labeling are also regulated by the FDA. Moreover, drug developers are prohibited
from advertising unapproved uses of their product [68]. In addition, all advertisements cannot be false or misleading, such
as product claims or reminder ads, and must contain only truthful information about the effectiveness, side effects, and
prescription of drugs advertised.
As part of the postmarketing considerations, the US FDA (2018a) requires applicants and drug developers to ﬁle
supplemental application documents if there are any signiﬁcant changes from the original application [68]. These changes
can include formulation, labeling, or dosage strength and must be approved by the FDA prior changes can be made.
Moreover, if drug developers would want to develop an approved drug for new use, dosage strength, new form or different
form, or conduct clinical postmarket studies, they are required to do IND application [68].
The FDA also has several programs that allow consumers, health professionals, and manufacturers to report issues and
problems associated with approved drugs sold in the market [68]. MedWatch is platform where consumers, health professionals, and other concerned person can report problems associated with medical products such as drugs and devices
and at the same time learn about new safety information [69]. Medical Product Safety Network (MedSun), launched in
2002, is another platform also hosted by the FDA to monitor the safety and effectiveness of medical devices [70].
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Several activities are also conducted by the FDA to address postmarket drug safety and effectiveness, especially in the
aspects of production, distribution, and use. These activities are ensuring product integrity, labeling, reporting, surveillance, drug studies, risk management, information dissemination, off-label use, and direct-to-consumer advertising, which
are well described in a congressional report [71]. A list of drugs pulled from the market and reasons for withdrawal is
shown in Table 4.1 [72e75].

TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.
Withdrawal
year

Drug

2013

Ketoconazole

2010

Sitaxentan

2007e08

Lumiracoxib (Prexige)

2006

Ximelagatran (Exanta)

2006

Alatrofloxacin

2005

Pemoline (Cylert)

Branded version withdrawn by originator in several
countries in 2003, and in the US and Canada in 2004.
Generic versions available.

2004

Nefazodone

2003

Benzbromarone

Risk of liver failure

2001

Trovafloxacin (Trovan)

Risk of hepatotoxicity; superseded by pioglitazone and
rosiglitazone

2000

Troglitazone (Rezulin)

1999

Medifoxamine

1998

Bromfenac

1998

Tolcapone (Tasmar)

1998

Ebrotidine

1997

Tolrestat (Alredase)

1997

Tilbroquinol

1997

Febarbamate

1996

Coumarin

1995

Alpidem (Ananxyl)

1994

Droxicam

1993

Moxisylyte

1993

Bendazac

1992

Benzarone

1992

Pyrrolizidine

1991

Fipexide

1991

Cinchophen

1990

Dilevalol

Remarks
Hepatic toxicity

Serious side effects, mainly liver damage. Progressively
withdrawn around the world.

Rare but serious hepatotoxicity not approved in the
US, withdrawn in France in 1994 and the rest of the
market in 1995
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Risk of hepatitis

Withdrawal
year

Drug

1990

Beclobrate

1989

Exifone

1987

Clometacin

1987

Cyclofenil

1985

Suloctidil

1984

Vitamin E

1983

Isaxonine phosphate

1982

Clomacran

1982

Ticrynafen

1977

Erythromycin estolate

1975

Mebanazine

1974

Nialamide

1974

Isocarboxazid

1972

Oxyphenisatine

1971

Triacetyldiphenolisatin

1970

Fenclozic acid

1970

Sulfathiazole

1970

Oxyphenisatin acetate

1969

Pipamazine

1968

Ibufenac

1966

Phenoxypropazine

1965

Xenazoic acid

1964

Benziodarone

Uncertain

Etifoxine

Respiratory toxicity
2014

Ribavirin

High levels could slow or stop breathing, high risk of
accidental overdose when administered with alcohol

2005

Hydromorphone extended-release (Palladone)

Risk of fatal bronchospasm

2001

Rapacuronium (Raplon)

1991

Buprenorphine

1989

Proglumide

1985

Aprobarbital

1984

Hexobarbital

1984

Vinbarbital

2011

Celecoxib

2011

Dolasetron

Cardiovascular toxicity

Increased risk of heart attacks and stroke

2011

Indoramin

2010

Propoxyphene (Darvocet/Darvon)
Continued
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Withdrawal
year

Drug

Increased risk of heart attacks and death.
This drug continues to be available in the U.S.

2010

Rosiglitazone (Avandia)

Increased risks of veno-occlusive disease and based on
results of a clinical trial in which it showed no benefit
in acute myeloid leukemia (AML)

2010

Gemtuzumab ozogamicin (Mylotarg)

2010

Sibutramine (Reductil/Meridia)

2009

Orciprenaline

2009

Benfluorex

2007

Clobutinol

Imbalance of cardiovascular ischemic events,
including heart attack and stroke. It was available
through a restricted access program until April 2008.

2007

Tegaserod (Zelnorm)

Risk of heart valve damage, voluntarily withdrawn in
the U.S., still available elsewhere.

2007

Pergolide (Permax)

2006

Gatifloxacin

2006

Torcetrapib

2006

Veralipride

2005

Bicalutamide

Risk of stroke, withdrawn in Canada (Health Canada
press release). The ban was later lifted because the
death rate among those taking Adderall XR was
determined to be no greater than those not taking
Adderall

2005

Mixed amphetamine salts (Adderall XR)

Concerns about heart attack and stroke.

2005

Valdecoxib (Bextra)

2005

Thioridazine (Melleril)

2004

Dofetilide

2004

Rofecoxib (Vioxx)

2004

Ephedra

2003

Alphacetylmethadol

2001

Sparfloxacin

Remarks

Risk of myocardial infarction.

2001

Droperidol

Risk of cardiac arrhythmias.

2000s

Cisapride (Propulsid)

Risk of stroke in women under 50 years of age. When
taken at high doses (75 mg twice daily) for weight loss

2000

Phenylpropanolamine (Propagest, Dexatrim)

2000

Budipine

2000

Amfepramone Hydrochloride

Arrhythmias because of interactions with other drugs

1999

Astemizole (Hismanal)

Prolonged QT interval

1999

Grepafloxacin (Raxar)

1998

Sertindole

1998

Terfenadine (Seldane, Triludan)

1997

Dexfenfluramine/Fenfluramine

Risk of cardiac arrhythmias; superseded by
fexofenadine the FDA pulled Seldane from the market
because Allegra and Allegra D were produced by the
same company and were deemed safer by the FDA.

FDA drug candidacy acceptance criteria and steps: problems and way forward Chapter | 4

53

TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks
Heart valve disorder popular combination of
fenfluramine and phentermine. Phentermine remains
on the market, while dexfenfluramine and fenfluramine e later withdrawn

Withdrawal
year

Drug

1997

Fen-phen

1996

Nifedipine

1995

Naftidrofuryl Oxalate

1991

Encainide

1991

Terodiline (Micturin)

1990

Fenoterol

1989

Prenylamine

1987

Tranylcypromine

1986

Hydrochlorthiazide

1985

Domperidone

1983

Dimethylamylamine

1973

Adenosine Phosphate

1973

Adenosine Phosphate

1969

Cloforex

1969

Chlorphentermine

1964

Dithiazanine iodide

1999

Aristolochic acid

1993

Thiobutabarbital

1986

Bucetin

1986

Suprofen

1986

Suprifen

Risk of lactic acidosis

1978

Phenformin

Risk of lactic acidosis

1978

Buformin

1970

Aminopyrine

1963

Bunamiodyl

Uncertain

Cephaloridine

2000

Alosetron (Lotronex)

1990

Loperamide

1999

Levamisole

1993

Remoxipride

1992

Temafloxacin

1990

Metipranolol

Prolonged QT interval

Renal toxicity

Gastrointestinal toxicity
Fatal complications of constipation. Reintroduced
2002 on a restricted basis.

Hematological toxicity
Levamisole is still used to treat animals with worm
infestations in the US.

Allergic reactions and cases of hemolytic anemia,
leading to three patient deaths

Continued
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Risk of hemolytic anemia

Withdrawal
year

Drug

1989

Tryptophan

1989

Doxycycline

1988

Cianidanol

1988

Sulfametoxydiazine

1988

Mianserin

1987

Vincamine

1987

Cinepazide

1986

Nomifensine (Merital)

1985

Phenylbutazone

1985

Indalpine

1984

Althesin

1984

Glafenine

1984

Oxyphenbutazone

1982

Aminophenazone cyclamate

1980

Ethyl nitrite

1976

Azaribine

1975

Clozapine

1974

Dipyrone

1971

Acetanilide

1961

Sorivudine

1958

Thenalidine

2011

Pioglitazone

1991

Noscapine

1986

Canrenone

1983

Dibenzepin Hydrochloride

1980

Lynestrenol

1979

Methapyrilene

1977

Hexestrol

1977

Dihydroxymethylfuratrizine

1977

Piperazine

1977

Urethane

1976

Oxeladin

1976

Chloroform

1970

Chlormadinone

1969

Anagestone acetate

1969

Megestrol acetate

1965

Pronetalol

1964

Chlornaphazine

Carcinogenicity
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Withdrawal
year

Drug

1963

Danthron

Uncertain

Flumequine

Risk of progressive Multifocal Leukoencephalopathy
(PML).

2009

Efalizumab (Raptiva)

Risk of progressive Multifocal Leukoencephalopathy
(PML).Voluntarily withdrawn from U.S. market,
returned to market July 2006.

2005

Natalizumab (Tysabri)

1998

Metrizamide

1996

Minaprine

1994

Felbamate

1994

Omeprazole

1994

Bromocriptine Mesylate

1994

Gentamicin

1989

Neomycin Sulfate

1988

Nikethamide

1987

Muzolimine

1986

Bupropion

1984

Oxolamine Citrate

1982

Pentylenetetrazol

1976

Pifoxime

1972

Diamthazole

1972

Hexachlorophene

1970

Mepazine Hydrochloride

1970

Clioquinol

1970

Dihydrostreptomycin

Uncertain

Iodamide

Uncertain

Carmofur

1957

Diiododiethyltin

2001

Cerivastatin (Baycol, Lipobay)

1995

Ciprofibrate

1990

Dinoprostone

1983

Zimelidine

1975

Methiodal Sodium

1990s

Etretinate

1990

Acitretin

Neurological toxicity

Muscular toxicity
Risk of rhabdomyolysis (breakdown of muscle fibers
that results in myoglobin being released into the
bloodstream)

Risk of Guillain-Barré syndrome withdrawn by the
FDA before being released in the US market

Teratogenicity/Reproductive toxicity/Birth defects
Risk of birth defects; narrow therapeutic index

Continued
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Returned to market for use in leprosy and multiple
myeloma under FDA orphan drug rules

Withdrawal
year

Drug

1988

Isotretinoin

1983

Doxylamine

1979

Sparteine Sulfate

1970s

Diethylstilbestrol

1950s 1960s

Thalidomide

Uncertain

Fominoben

Uncertain

Flubendazole

2013

Tetrazepam

Dermatological toxicity

Rare but serious cases of toxic epidermal necrolysis

1998

Proxibarbal

1996

Chlormezanone (Trancopal)

1991

Terconazole

1987

Floctafenine

1984

Fenclofenac

1984

Feprazone

1984

Sulfamethoxypyridazine

1983

Isoxicam

1983

Zomepirac

1983

Propanidid

1977

Alclofenac

1975

Practolol

1967

Bithionol

1966

Sulfadimethoxine

1964

Butamben

1985

Canthaxanthin

1977

Polydexide sulfate

1965

Methopholine

1962

Triparanol

Uncertain

Benzydamine Hydrochloride

2012

Clorazepate

2010

Bufexamac

2007

Carisoprodol

2004

Ethinylestradiol

2000

Amineptine (Survector)

1999

Dicyclomine

1996

Flunitrazepam

Opthalmic toxicity

Multiple toxicities

Hepatotoxicity, dermatological side effects and abuse
potential.
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Withdrawal
year
1993

Zipeprol

Renal and hematological toxicities

1993

Ketorolac

1990

Secobarbital

1990

Boric acid

Hepatic and gastrointestinal toxicities

1990

Pirprofen

Dermatological, hematological, hepatic toxicities

1988

Sulfacarbamide

1987

Iophendylate

Drug

1986

Difemerine

1986

Acetylsalicylic Acid

1985

Pentobarbital

1985

Phenobarbital

1985

Perhexiline

1984

Camazepam

Carcinogenicity, gastrointestinal toxicity

1984

Indoprofen

Hematological and hepatic toxicities

1984

Nitrefazole

Risk of cancer and kidney disease

1983

Phenacetin

1983

Indomethacin

1982

Timonacic

1982

Methandrostenolone

Hepatic and renal toxicity

1982

Benoxaprofen

Severe liver and kidney damage

1982

Tienilic acid

1980

Cyclobarbital

1980

Amobarbital

1979

Pyrovalerone

1979

Phenolphthalein

1975

Pyrithyldione

1973

Methamphetamine Hydrochloride

Dermatological and opthalmic toxicities

1970

Amoproxan

Respiratory and cardiovascular toxicities

1967

Aminorex Fumarate

1966

Aminoglutethimide

Risk of severe depression and suicide

2008

Rimonabant (Accomplia)

Overdose dangers

2004

Co-proxamol (Distalgesic)

Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group.
Withdrawn in Sweden and Norway, this drug continues to be available in most of the world including
the U.S., but under strict controls.

1999

Temazepam (Restoril, Euhypnos, Normison, Remestan,
Tenox, Norkotral)

Risk of psychiatric adverse drug reactions withdrawn
in the United Kingdom, while this drug continues to
be available in the U.S.

1991

Triazolam

Hepatic and neurological toxicities

Hepatic and neurological toxicities

Carcinogenicity and dermatological toxicity

Abuse/Overdose/Psychiatric

Continued
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Withdrawal
year

Drug

Risk of addiction and overdose. Methaqualone was
originally tested in India as a malaria treatment (it was
ineffective).

1984

Methaqualone

It became widely used recreationally

19501960s

Lysergic acid diethylamide (LSD)

Increased risk of complications or death. Permanently
withdrawn in 2008 except for research use

2007

Aprotinin (Trasylol)

Dangerous interactions with other drugs

1998

Mibefradil (Posicor)

Increased risk of hospitalization or death

1993

Flosequinan (Manoplax)

Lack of efficacy. Withdrawn by Lily worldwide,
following the results of the PROWESS-SHOCK study

2011

Drotrecoginalfa (Xigris)

Poor sales caused by national restrictions on
prescribing, doubts over long term safety and high
cost.

2007

Inhaled insulin (Exubera)

2014

Telaprevir

2004

Bezitramide

1991

Oxomemazine

1986

Furazolidone

1986

Amygdalin

1984

Antrafenine

1984

Sulfamethizole

1984

Heptabarbital

1977

Acetylfuratrizine

1977

Nitrovin

Undeclared Sildenafil and Tadalafil

2018

7K and Poseidon 4500
Dietary Supplements

Elevated level of impurities

2018

Piperacillin and Tazobactam for Injection

Presence of glass particulates

2018

Piperacillin and Tazobactam for injection, USP
3.375 gss/vial

Presence of visible particulate matter

2018

Ampicillin and Sulbactam for Injection USP,
3 g/Single-Dose vial

Unapproved new drug (presence of Tadalafil)

2018

Rhino 69 extreme 50,000

Potential for contamination with yeast, mold, and
bacteria

2018

Pasta De Lassar
Andromaco Skin protectant

Detection of a trace amount of Unexpected Impurity,
N-nitrosodimethylamine (NDMA)

2018

Valsartan Tablets, 40 mg, 80 mg, 160 mg, and 320 mg;
and Valsartan-Hydrochlorothiazide
Tablets, 80mg/12.5 mg,
160mg/12.5 mg, 160mg/25 mg,
320mg/12.5 mg, and 320mg/25 mg

Potential Salmonella contamination

2018

Kratom powder Capsule

Mislabeling

2018

Neostigmine Methylsulfate 5 mL
Syringes

Remarks

Death/Dangerous Complications

Miscellaneous

Unknown

Recall
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TABLE 4.1 List of drugs pulled from the market by the FDA and reason for its withdrawal.dcont’d
Remarks

Withdrawal
year

Causes Infusion reactions

2018

Daptomycin for Injection 500 mg, lyophilized powder
for solution, single dose Vial

Potential presence of particulate matter

2018

Naloxone Hydrochloride
Injection, USP, 0.4 mg/mL, 1 ml_in 2.5 ml_ in the
CarpujectÔ
Single-use cartridge Syringe system

Potential for small glass particles

2018

Fluticasone propionate Nasal Spray

Out of order packaging

2018

Tavtulla Birth control capsules

Products may be contaminated with bacteria

2018

X-Jow. Acne Shave
Pain Gel, Moisturizer, Shave Cream

Lack of adequate manufacturing controls

2018

MBI distributing. Inc.
Various Homeopathic products

Labeling error

2018

Alka-Seltzer plus

Units may be empty or cracked at the bottom of the
glass vial

2018

Hydromorphone HCL
Injection, USP

Out of specification Impurity results

2018

Methylprednisolone Sodium Succinate for Injection, USP
40 mg, 125 mg, and 1g

Cracked glass at the rim surface of the vials

2018

Labetalol Hydrochloride
Injection, USP

Product mix-up

2018

Acyclovir Tablet, USP, 400 mg, 50 ct Unit dose

Potential microbial contamination which compromises
sterility

2018

Gericare Sterile eye Irrigation solution

Due to potential serious side effects

2018

Limbrel, Limbrel 250, Limbrel 500

Drug

Mislabeling

2018

Senna Laxative

Presence of particulate matter

2018

Nexterone 150mg/100 mL injection

Presence of particulate matter

2018

Levofloxacin in 5% Dextrose Injection 250mg/50 mL

Lack of sterility assurance

2018

PharMEDium Services LLC various compounded drug
products intended to be sterile

Due to mislabeling

2018

Clopidogrel Tablets USP,
75 mg

Presence of glass particles

2018

AuroMedics pharma LLC
Ampicillin and Sulbactam for Injection USP

Particulate contamination (mold)

2017

AuroMedics pharma LLC
Linezolid Injection

Contains glass particles

2017

Pantoprazole Sodium for Injection 40 mg per vial

Lack of sterility assurance

2017

Pharmacist Choice
Alcohol prep pads

Microbial contamination (Scopulariopsis brevicaulis)

2017

RiometÒ (Metformin
Hydrochloride Oral
Solution), 500 mg/5 mL

Sub potent and Super potent Tablets

2017

Diphenoxylate hydrochloride and atropine sulfate tablets, USP

Presence of particulate matter

2017

Amiodarone HCI
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4.1.5 FDA relationship with the industry: the FDA’s influence on marketability of drug products
The FDA as a regulatory agency possesses a critical impact on the degree of marketability and competition among
pharmaceutical companies [75]. This competition among pharmaceutical companies results in lower prices of drugs and
consequently leads to encouraging drug developers to innovation, thus considered beneﬁcial to both consumers and to the
innovative atmosphere. The competitive atmosphere is unintentionally hindered by inadequate incentives for innovation
and the existing structures and regulations of the FDA. These impositions of the FDA in hindering market competition are
systematically reviewed by Brill and were categorized by (1) long delay in elaborating the pathway for biosimilars to enter
US market, (2) prioritizing allocation and availability of resource on approval of new drugs than promoting competition
within a given drug class, and (3) ﬂooding of backlog applications of generic drugs.
Biologics are one of the most expensive drugs that are derived from living cells and account for a growing share of drug
spending in the United States totaling to $92 billion in 2013 [76]. Biosimilar, on the other hand, is a lower-priced,
competing, and highly similar copy of a brand biologic expected to yield cost savings for consumers and patients [75].
Biosimilars are even projected to be priced 40% lower than the biologic prices [77]. As biosimilar is only considered as
“highly similar” to its reference product rather than identical, the competition between a biologic and biosimilar is expected
to be different than that of the competition between generic and branded drugs. The FDA released a draft guidance on
evaluating studies used to show analytical similarity of biosimilar and the reference biologic last September 2017, it was
withdrawn recently because of the fact that the biosimilars did not foster competition as hoped by the FDA and the issues
on lot-to-lot variability, as reported in a statement made by the FDA Commissioner [78]. These issues on biosimilars
prevent generation of savings from competition. Furthermore, the regulations imposed by FDA on biosimilar naming could
limit marketability and thus result to reduction of development of biosimilar products [75].
Competition of drugs in the market can come in two different ways: (1) generic drugs competing with branded drugs
and (2) branded drugs competing with another branded drug with the same drug class [75]. The FDA’s focus of its
resources on approvals of new drugs mean that fewer resources will be allocated to enhancing activities that leads to
competition between drugs of the same class. This means that drugs that offer the same beneﬁts comparable to existing
drugs will not be eligible for expedited approval [75]. This system of FDA limits competition and allows the ﬁrst branded
drug in a given class access to and beneﬁt from limited or no competition market. Meanwhile, in terms of competition
between branded drugs and generic drugs, the enactment of Hatch-Waxman Act allowed an abbreviated pathway for
generic drugs which led to robust competition of generic drug industry in the United States, offering considerable beneﬁts
to consumers and patients [75].
The success of generics in promoting competition among drugs and in achieving savings on health care has been
belittled by the fact that generic drugs are not given the same attention by the FDA compared with innovative products.
The approval abbreviated new drug application (ANDA) takes an average of more than three times longer compared to the
approval of NDA and takes six times longer compared to a priority NDA [79]. The backlog of ANDAs at the FDA has
been steadily growing for the last decade with 150% increase from 2001 to 2005 [80]. It was only in 2012 that the Generic
Drug User Fee Amendments was enacted to address this issue where drug manufacturers pay a fee to help cover the cost of
reviewing applications, although the enactment of this act, the FDA does not anticipate to reduce the time to review ANDA
until FY 2017 [81].
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5.1 Introduction
Cardiovascular disease (CVD) is a group of diseases that involve the heart or blood vessels. CVD includes coronary artery
diseases (CADs) that are recognized as heart including angina attack and myocardial infarction. CVD is responsible for about
31.5% of all global deaths. About 92 million US adults suffer from CVD; this is expected to rise higher per the adult
population by 2030 owing to augmentation in obesity and diabetes disorders, and consequently, healthcare services are
overwhelmed with a huge load [1]. According to the World Health Organization (WHO), 2016 [2], more than 18 million
individuals lose their life annually from CVD and 1.1 billion adults recorded increased blood pressure. Many of these people
have been exposed to unhealthy lifestyle, tobacco habits, eating foods with high salt, and deﬁciency in physical practice.
CVD is usually accompanied by atherosclerosis and an increased risk of blood clots. Other organs, heart, kidneys, brain,
and eyes, might also be damaged in response to arteries injury. Therefore, CVD is regarded as a complex disease that results
from the consequence of multiple pathogenic factors, which reﬂects the different interactions of many interconnected genes
and their relevant products [3]. Chronic proatherogenic inﬂammation is one of the main causes of CVDs and its supplementary severe complications. Endoplasmic reticulum (ER) is an important organelle for folding, releasing, and synthesizing
secretory and transmembrane proteins. Any pathological stimuli such as hypoxia, ischemia, inﬂammation, and oxidative
stress can change the homeostatic function of ER, and this results in the aggregation of unfolded proteins, a phenomena
denoted as ER stress. This unfolded protein response, UPR (a complex signaling network), is triggered by ER stress. Massive
investigations revealed that ER stress is one of the crucial phases in the progress of various CVDs such as heart failure,
ischemic heart disease, and atherosclerosis. Many pharmacological therapeutics are available for treating CVDs; however, the
present drugs cause many adverse effects such as renal failure, rhabdomyolysis, and hemorrhagic with prolonged use. Natural
products have always been regarded as a valuable source for the discovery of new drugs [4].
Drugs or those obtained from animals, plants, or microorganisms have a great role in human healthcare. They have
recorded massive diversities chemically and pharmacologically. The drugs approved by the FDA constitute more than 50%
natural products or derivatives [5].
Nutraceuticals, a part of their nutritional importance and health beneﬁts, represent promising means in the protection
against CVD or as added values to current treatments. The most potential nutraceuticals are polyphenols including ﬂavonoids and their derivatives, as well as polyunsaturated fatty acids (PUFA). Because nutraceuticals come from food
sources, there are no restrictions regarding tolerability and safety that often accompanies pharmaceuticals especially those
recommended for a long term to control risk factors of CVD. Additionally, nutraceuticals usually have pleiotropic actions
exhibiting inhibition of the multiple proatherogenic changes; hence they are chosen as potential agents in combination with
conventional drugs or even recommended for other lifestyle changes [6]. Nutraceuticals would be of priority for persons
who are either at the marginal risk factors of CVD or are intolerant to the conventional drugs (e.g., statins). Moreover,
nutraceuticals may be of low cost for controlling dyslipidemia and other CVD risk factors for patients on statins therapy as
regard to its potential, however, considered of high cost alternatives that are in progress [6].
Several reports have dealt nutraceuticals and natural products for their potential in in controlling CVD, many of these
reports were supported by clinical trials. It was reported that omega-3 PUFAs have anti-inﬂammatory activity and exert
their effects through several mechanisms; disruption of lipid bundles, altering cell membrane phospholipid composition,
modulation of activation of key transcription factors and signaling pathways, besides, and their capability to bind to G
protein coupled receptor (GPR) 120 [7]. The interest in using polyphenols to decrease the risk of CVD has aroused due to
their well-established anti-oxidant and anti-inﬂammatory [8]. The cardiovascular prophylactic action of polyphenols found
in olives and grapes were reported [6,9].
Clinical trials was carried out for population with whom are obese at high risk of CVD. Results revealed that, taking
814 mg/day of ﬂavanols for about four 4 weeks led to the improvement in 30 overweight volunteers by vasodilation,
though no variation in high density and low density lipoproteins (HDL-c and LDL-C) were recorded between ﬂavanols
group and the control group. Furthermore, a trial including 57 End stage renal disease acquires CVD (ESRD) patients, risk
because of the impairment of their vascular function [10].
An improved vascular function was shown which was monitored after 1 month by the increased ﬂow-mediated
dilation (FMD), and hypotension after a dietary supplement rich cocoa ﬂavanol [11]. Allicin, the main active constituent in garlic, as a potent anti-oxidant attenuated atherosclerosis, also inhibited the uptake of LDL and avoided the
deterioration by macrophages [12]. Berberine which is a plant alkaloid, reduced the size of the plaque vulnerability,
inﬂammation as well as oxidative stress apoE(/) mice (murine models for atherosclerosis are apolipoprotein E (ApoE)
knockout) [13,14].
A higher intake of lycopene, a carotenoid present in the red fruits as well as tomatoes, reduces the CVD risk via
decreasing LDL-C, pro-inﬂammatory cytokines and blood pressure, and enhanced FMD. The effect of important secondary
metabolites such as: berberine, mangiferin, resveratrol, quercetin, stilbenes, saponins and other phytochemicals on
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improving ER stress through multiple signaling pathways accompanied by ROS production, inﬂammation and apoptosis
were reviewed [15]. Therefore, natural products ranking in contemporary medicine is now well recognized and continues
to be of interests as a source of novel lead compounds. Moreover, by applying molecular docking which is an effective
approach to identify compounds that could conform to the site of interest of the target proteins. Thus, the potency of the
compound is estimated by researchers and hence clinical application are achieved based on these biological discoveries.
Accordingly, using the virtual screening based on natural product database could also be an encouraging approach for drug
discovery, especially for complex diseases such as CVD [16].

5.2 Natural products targeting autophagy and cardiovascular disorders
Autophagy is a degradation process through which macromolecules, misfolded proteins and organelles are degraded by
lysosomes, and recycled [17]. Autophagy is essential for cellular homeostasis, especially for cardiac muscle cells (cardiomyocytes) [18]. Recent studies showed that dysregulation of autophagy in cardiomyocytes leads to severe heart diseases
including hypertrophy and failure [19e22]. In this respect, targeting autophagy by natural products is considered an
essential therapeutic strategy for prophylactic and cure of CVDs [19].

5.2.1 Physiology of autophagy
As a complex life-long sustaining multi-process, autophagy starts with autophagosome formation from sequestrated
misfolded proteins and damaged organelles in double-membrane vesicles that fuse with lysosomes to form autophagolysosomes [23]. Autophagy is activated during various stress conditions including hypoxia, energy restriction, nutrient
deprivation and excessive ROS. Three distinct types of autophagy exists; macroautophagy, microautophagy, and
chaperone-mediated autophagy [19].
In macroautophagy, soluble cytoplasmic materials and organelles are transferred to phagophores. Elongation of
phagophores results in formation of double membrane vesicles called autophagosomes. Autophaogosomes fuses with
lysosomes form autolysosomes and degradation of their contents [20]. The direct uptake of cellular constituents that by
lysosomes through invagination is called microautophagy. In chaperone-mediated autophagy, the heat shock protein
complex (HSPC) binds to the KFERQ (Lys-Phe-Glu-Arg-Gln) motif of the substrate protein and target its lysosomal
degradation via AMP-2A receptor [19,23,24]. Autophagy is regulated by several factors including AuTophaGy related 1
(Atg1) kinase, Protein kinase B (Akt)/mammalian target of rapamycin (mTOR), mAtg9 signaling pathways, class III
phosphatidylinositol-3-kinase (PI3K)/vacuolar protein sorting 34 (Vps34) complex.
Homeostasis of cardiomyocytes is achieved via autophagy. Disturbance of cardiomyocytes-speciﬁc autophagy lead to
cardiac problems including chronic ischemia and cardiomyopathy-associated heart failure [19e22]. Low level of
cardiomyocytes-speciﬁc autophagy has protective roles, while, excessive autophagy has deleterious effects such as
arrhythmia, ischemia/and heart failure [19,23,24].

5.2.2 Natural compounds with autophagy-modulating activities
Natural products such as curcumin, berberine and resveratrol can induce autophagy via canonical (Beclin-1-dependent) and
non-canonical (Beclin-1-independent) pathways. The autophagy-modulating activities of these compounds make them
essential targets and very good candidates for plant-derived remedies (Fig. 5.1).

5.2.2.1 Curcumin
Curcumin is a diarylheptanoid compound isolated from turmeric (Curcuma longa, F. Zingiberaceae). Curcumin possesses
autophagy-inducing effects through suppression of PtdIns3K-AKT/mTOR, Beclin-1, Bcl-2, c-Jun N-terminal kinase

FIGURE 5.1 Chemical structures of some natural compounds with autophagy-modulating activities.
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(JNK), Bcl-2-associated X protein (Bax), BCL2 Interacting Protein 3 (BNIP3), SIRT1 [sirtuin (silent mating type information regulation two homolog) 1 (S. cerevisiae)], and Forkhead box protein O1 (FOXO1) and activation of Adenosine
Monophosphate-Activated Protein Kinase (AMPK) and phosphatidylinositol 3 (PI3) kinase, are the reported effects of
curcumin on the cardiovascular system [25].

5.2.2.2 Berberine
Berberine is a quaternary ammonium salt from isoquinoline alkaloids isolated from many plants including Berberis
(Berberis vulgaris, F. Berberidaceae). It has been reported to have strong anti-hypercholesterolemic, anti-microbial and
antinociceptive activities. Berberine has autophagy-mediated cardiac protection by suppressing Beclin-1, p38- MAPK,
SIRT1, mTOR, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) and LC3-II [26].

5.2.2.3 Resveratrol
Resveratrol (3,5,4-trihydroxystilbene) is a polyphenolic compound isolated from the skin of grapes (e.g., Vitis vinifera, F.
Vitaceae), blueberries (Vaccinium corymbosum, F. Ericaceae), raspberries (Rubus idaeus, F. Rosaceae), mulberries (Morus
rubra, F. Moraceae). Resveratrol has been reported to have strong antioxidant, neuroprotective, and anticancer activities.
Intriguingly, resveratrol have potent cardioprotective effects such as anti-hyperlipidemic, antihypertens, antihypertrophic,
and anti-arrhythmic activities. Resveratrol induces autophagy through activation of 50 adenosine monophosphate-activated
protein kinase (AMPK) and silent mating type information regulation two homolog1 (SIRT1), LC3-II, Akt-Bcl-2, P38mitogen-activated protein kinase (MAPK), endothelial nitric oxide synthase (eNOS), gamma-aminobutyric acid
receptor-associated protein (GABARAP) and suppression of mammalian target of rapamycin (mTOR) and ribosomal
protein S6 kinase beta-1 (p70S6K) [27].

5.3 Natural products targeting endoplasmic reticulum (ER) and
cardiovascular diseases
As mentioned earlier, endoplasmic reticulum (ER) is the main organelle in which synthesis, folding, and processing of
several proteins and lipids are achieved [4]. Unfavorable cellular conditions such as oxidative stress, hypoxia and
inﬂammation lead to disruption of ER homeostasis. Such disruption lead to accumulation of unfolded and misfolded
proteins, a condition referred to as ER stress [4]. ER stresses have deleterious roles in the progression and development of
various CVDs including atherosclerosis, heart failure and ischemic heart disease [28]. The effective reduction of ER stress
by natural products is considered one of the most innovative approaches against CVDs.

5.3.1 Physiology of ER stress
Several pathophysiological cellular stimuli can induce ER stress that results in triggering a complex signaling network
known as unfolded protein response (UPR) [29]. Three UPR pathways are distinct and mediated by Activating Transcription Factor 6 (ATF6), PKR-like ER kinase (PERK), and Inositol Requiring 1 (IRE1). Among the pathophysiological
cellular stimuli can induce ER stress; nutrient deprivation, infections, hypoxia and perturbed Ca2þ or redox homeostasis
[28,29]. ER stress has a positive effect as a defensive mechanism against the deleterious stimuli, however, prolonged ER
stress can lead to ER stress-induced apoptosis that plays crucial roles in the progression and development of many CVDs
via excessive ROS production.
ER stress activates ROS production via stimulation of protein kinase JNK, activation of NADPH oxidase 2 (NOX2)
and Nox4, increasing the leakage of Ca2þ from ER lumen to the cytosol or via inducing protein folding and refolding in the
ER lumen. The above aforementioned stimuli are the major sources for ROS in the cardiovascular system and are
considered a hallmark for CVDs [4]. Additionally, ER stress-associated inﬂammation plays fundamental roles in the
progression of many CVDs such as cardiomyopathy, cardiac hypertrophy, ischemic heart diseases, and heart failure.

5.3.2 Natural compounds with ER stress-reducing activities
Natural products such as phenolics and alkaloids can reduce ER stress via several pathways. The ER-related biological
activities of these compounds make them essential targets and very good candidates for plant-derived cardioprotective
remedies (Fig. 5.2).
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FIGURE 5.2 Chemical structures of some natural compounds targeting ER stress-mediated effects.

5.3.2.1 Paeonol
Paeonol, a phenolic component of Traditional Chinese medicine (TCM) remedies, can be isolated from peonies such as
Paeonia suffruticosa, Arisaema erubescens and Dioscorea japonica. Paeonol has been reported to signiﬁcantly inhibit ER
stress-induced ROS production by reducing NOX2 [30].

5.3.2.2 Mangiferin
Mangiferin, a polyphenolic xanthonoid, was ﬁrst obtained from Magnifera indica leaves and barks. It could also be
isolated from the peels and kernels of mango, Bombax ceiba leaves, Iris unguicularis and Anemarrhena asphodeloides
rhizomes. Mangiferin was reported to have a potent ER anti-oxidative stress activity through downregulation of IRE1a
phosphorylation and inhibition of ROS production [31].

5.3.2.3 Anisodamine
Anisodamine, a tropane alkaloid known as 7b-hydroxyhyoscyamine, isolated from Hyoscyamus niger L. (F. Solanaceae),
has anticholinergic and a1 adrenergic receptor antagonist. Anisodamine has been found to protect against cardiac arrest by
inhibiting ER stress proteins such as glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), and
cleaved caspase 3. This inhibition can signiﬁcantly reduce cardiomyocytes cellular death [32].

5.3.2.4 Baicalin
Baicalin is a ﬂavone glycoside found mainly in the genus Scutellaria, especially Scutellaria baicalensis and Scutellaria
lateriﬂora. Previous reports showed that sulforaphane inhibits ER stress by downregulation of ER stress-dependent
apoptotic protein CHOP and thus inﬂuencing the CHOP/eNOS/NO pathway [33]. This ﬂavone can also protect the
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heart, cerebral vessels and neurons through its free radical scavenging activity especially against the oxygen-derived
free radicals [34]. Pretreatment with 10 mM baicalein signiﬁcantly protects against ischemia/reperfusion (I/R) injury
and doxorubicin-induced cardiomyocyte apoptosis through mediating the opening of mitochondrial ATP-sensitive
potassium channel (KATP) and anion channels [35]. Baicalein also inhibits 12/15 lipoxygenase activity; activates
Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2/AKT); and inhibits p38 mitogen-activated protein
kinase (MAPK), JNK1/2 and nuclear factor kappa (NF-kB/p65) thus reduces myocardial ischaemia/reperfusion (I/R)
injury [36].

5.3.2.5 Berberine
Previous reports has shown that berberine inhibits myocardial ischemia/reperfusion (MI/R)-induced ER stress. It can
signiﬁcantly reduce PKR-like ER kinase (PERK) and a subunit of eukaryotic initiation factor 2 (eIF2a) phosphorylation in
the heart tissues [37]. Moreover, it has potent ER-speciﬁc ROS scavenging activity [4].
It was reported to be effective against heart failure, hypertension and stroke. In case of hypertension and cardiovascular
disorders, the activation of NADPH oxidase, increased expression of Endothelin-1(ET-1) and uncoupling of endothelial
nitric oxide synthase (eNOS) can cause Endothelial dysfunction detected by the appearance of circulating endothelial
microparticles (EMPs) produced from damaged endothelial cells [38].
Berberine has been reported to suppress the over expression of NADPH oxidase 2 and 4 (NOX2 and 4), and
decrease ROS production of endothelial cells. Berberine appears to protect endothelial cells against EMPs as it
causes reduction of EMPs with subsequent down regulation of NADPH oxidase expression, especially NOX4 in
human umbilical vein endothelial cells (HUVECs). Berberine could protect HUVECs against injury caused by
elevated EMPs through reduction of NOX4-derived ROS which have an important role in oxidative stress induced by
EMPs [39]. Berberine also can affect NOX via Adenosine Monophosphate-activated Protein Kinase (AMPK) [40]. In
the presence of berberine, AMPK may also suppress production of ROS through down regulation of NOX4
expression and inhibition of its activity [41]. Moreover, the vasodilation effect of berberine is mediated by eNOS via
activation of the AMPK cascade. AMPK can phosphorylate eNOS at Ser1177, Ser633 and Thr495 [42]. Hence, the
action of berberine in cardiovascular cells can be summarized to be NADPH oxidase (NOX4) inhibitor and AMPK
stimulant.

5.3.2.6 Quercetin
Quercetin is a natural ﬂavonoid found in most vegetables and fruits. Quercetin has been reported to reduce ER stress by
restoring the normal levels of the antioxidant enzymes, superoxide dismutase 1 (SOD1) and catalase (CAT) [43].

5.3.2.7 Notoginsenoside R1
Notoginsenoside R1 is a dammarane-derived ginsenoside isolated from Panax notoginseng. Notoginsenoside R1 has a
cardio-protective effects by scavenging free radicals and protecting against ischemia/reperfusion (I/R)-induced cellular
damage [44].

5.3.2.8 Pterostilbene
Pterostilbene is a resveratrol-related phytoalexin with stilbenoid nucleus. It has been found in blueberries, almonds, and
grape leaves. Pterostilbene has a potent activity against ER stress-mediated inﬂammation by inhibiting ER-related proteins,
including IRE1, GRP78 and Eukaryotic Initiation Factor 2 (eIF2a) [45].

5.3.2.9 Sulforaphane
Sulforaphane is an isothiocyanate organosulfur compounds found in cruciferous vegetables such as cabbages, Brussels
sprouts and broccoli. Previous reports showed that sulforaphane inhibits ER stress by suppression of ER stress-dependent
apoptotic proteins such as caspase-12, CHOP and GRP78 [46].

5.3.2.10 Resveratrol
Next to its autophagy-modulating activity, resveratrol was reported to suppress ER stress by downregulation of ER stressdependent apoptotic proteins such as CHOP, as GRP78 and GRP94 [47].
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5.4 Atherosclerosis and chronic inflammation
Atherosclerosis, a chronic vascular disease, is implicated in the progressive occlusion of blood vessels. This process
originates early in life, during postnatal development and maturation. It is suggested that there is a combination of
numerous genetic, environmental, and behavioral factors, that lead to vessel occlusion and consequently to the progress of
acute coronary syndromes with myocardial infarction and sudden death. The incidence of CAD in adults is 6.4%.
Although, there is a marked decrease in the mortality rate, due to new therapeutic strategies, CAD was responsible for one
in six deaths in the USA in 2010 [48]. Inﬂammation has been associated with atherosclerosis since the nineteenth century.
Despite the involvement of inﬂammation in the development of atherosclerosis and acute coronary syndromes (ACS), the
only drugs with potential anti-inﬂammatory effects used in coronary disease are statins and aspirin. See Chapter 21 for
comprehensive details on anti-inﬂammatory drugs.
Recently, chronic inﬂammation has drawn attention as a crucial factor in the development of several chronic diseases
including CVD, with a great impact on the population. Based on of several recent researches, it has been obvious
that inﬂammation is an important mechanism when describing the life cycle of atherosclerosis. Although the normal
inﬂammatory reaction is critical in immune responses as a guard mechanism against infections, or repairing tissue
damage; but persistent inﬂammation leads to the initiation, progression, and degenerative features of chronic diseases
e.g., atherosclerosis or the vasculopathy of autoimmune disorders like rheumatoid arthritis [9].
Several adverse vascular disorders, including CAD, stroke and peripheral artery disease result from atherosclerosis
[49]. Therefore, atherosclerosis could be deﬁned as a chronic inﬂammatory disease that takes place within the arterial wall,
in response to endogenously modiﬁed structures; oxidized lipoproteins (oxidized low-density lipoprotein [oxLDL]), which
stimulate both the innate and adaptive immune responses [50]. These modiﬁed low-density lipoprotein (LDL) attract
macrophages, monocytes, smooth muscle cells, and T lymphocytes, mainly due to its lysophosphatidylcholine content. The
engaged LDL could also be liable to arterial wall SMases, which generate choline phosphate and ceramides. Ceramides can
induce NF-kB and stimulate apoptosis or mitogenesis. Modiﬁed LDL will be removed by macrophages with the help of
scavenger receptors and gets foamy [51].
Acute myocardial infarction is a complication of atherosclerosis manifested by erosion and rupture of coronary artery
leading to its occlusion by a thrombus. The consequence of the disruption in the blood supply aggravates death of cardiac
myocytes in the ischemic heart which initiates an acute inﬂammatory response, contributing to cardiac restoration through
the effect on extracellular matrix degradation or deposition along with the clearance of dead cardiomyocytes. Accordingly,
an acute inﬂammatory response is vital in resolving and the repair of tissue damage, rather than persistence of inﬂammation, which can lead to damage and loss of organ function. Therefore, anti-inﬂammatory strategies may have detrimental
effects in case of acute myocardial infarction in atherosclerotic patients. The only drugs suggested with antieinﬂammatory,
so far, used in ischemic heart disease are aspirin and statins, however their side effects are well known. The need for safe
drugs having anti-inﬂammatory effect with minor toxicity is crucial. The search for alternative pharmaceutical agents and
their identiﬁcation for the treatment of CVD has been relatively unsatisfactory due to failure at the clinical level.
Nutraceuticals, products from food sources with health beneﬁts in addition to their nutritional value, denote promising
agents in the prevention of CVD or as an add-on therapy with current treatments [6]. Some immunomodulatory or
immunosuppressive promising therapies, have a potential cardio-protective anti-inﬂammatory effects. The blockage of
other potential targets, such as the interleukin-6 (IL-6) receptor, CC2 chemokine receptor and CD20, could have an impact
to ameliorate this disorder [52].

5.4.1 Anti-inflammatory agents for treatment of atherosclerosis
Atherosclerosis, a consequence beneath CVD, is considered a chronic inﬂammation disorder that leads to atherosclerotic
lesions, which may erode or rupture leading to other clinical ailments such as angina, myocardial infarction, or cerebrovascular attack. Diets rich in bioactive compounds that maintain cardiovascular health are of priority. As this chronic
inﬂammation is the major factor in growth and progression of CVD, natural compounds with recognized anti-inﬂammatory
activities such as polyphenolics and polyunsaturated fatty acids have now drawn attention [53,54].

5.4.1.1 Polyphenols
Polyphenols, found in plants and plant products, exert important biological functions like, free radical scavenging, antioxidant and anti-inﬂammatory effects. Polyphenols (PPs) are recognized in pharmacology due to multiplicity in their
structures. They possess several beneﬁcial effects in the prevention and treatment of CVDs. Their role in opposing acute
and chronic inﬂammation is crucial.
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When the vessels are inﬂamed, macrophages adhere to the vascular injury sites, they move along the vascular endothelium, and are activated by surface-bound chemokines. The macrophages stick ﬁrmly to the vascular endothelium then
are transferred through the monolayer of endothelial cells (ECs) through certain inﬂammatory molecules: the intercellular
adhesion molecule-1 (ICAM-1), endothelial vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant
protein-1 (MCP-1) [55]. Phenolic compounds exert anti-inﬂammatory activities by changing the enrollment of inﬂammatory cells by decreasing production of soluble pro-inﬂammatory molecules such as TNF-a, IL-6 and C-reactive protein.
Moreover, they inhibit formation of adhesion molecules; VCAM-1 and (ICAM-1) to the endothelium, therefore defeating
cellular passage of monocytes into the sub-endothelial space [53]. Polyphenols initiate their anti-inﬂammatory action by
moderating transcriptional networks and/or signaling ﬂows that control gene expression, resulting in the inhibition of
inﬂammatory intermediaries.
(i) Resveratrol: Resveratrol exerts multi protective properties on the vascular and cardiac function via manipulating the
activity or the expression of several molecular targets. The anti-inﬂammatory properties of resveratrol are mainly manifested through the SIRT1-mediated down-regulation of NFkB, a key inﬂammatory transcription factor.
SIRT1 (sirtuin 1) inactivates the functional activity of a catalytic subunit in NF-kB-p65 at lysine 310 by deacetylation. SIRT1 also inhibits NF-kB expression through epigenetic deacetylation of histone H3 at lysine 9 (H3K9ac) and
consequently disorders this epigenetic mark [56]. Moreover, SIRT1 activation decreases the adhesion of NFkB-p65 to
DNA and weakens cardiac hypertrophy and oxidative stress through decreasing the transcription of NADPH oxidase
enzyme subunit. Inhibition of NF-kB prompted by resveratrol also led to decrease of endothelial expression of other
adhesion molecules such as VCAM-1 and intercellular adhesion molecule (ICAM)-1, and monocyte chemoattractant
protein 1 (MCP-1) [56]. Resveratrol hinders the angiotensin II-induced adhesion of leukocytes by reducing cellular
binding of the molecule expression and reducing serum monocyte chemoattractant protein-1 (MCP-1) and macrophage
inﬂammatory protein 1a (MIP-1a). Likewise, it decreases the release of pro-inﬂammatory cytokine (IL-6 and TNFa)
through reversing of the NF-kB pathway besides promoting adiponectin expression and its discharge from human
adipose tissue [53].
Resveratrol can also prevent atherosclerosis via NO dependent in the following manner: Initially, resveratrol prevents
superoxide production from NADPH oxidase enzyme and mitochondria. Secondly, resveratrol improves the expression of
many antioxidant enzymes like SOD isoforms, glutathione peroxidase 1 (GPx1), CAT and HO-1 [57]. Likewise,
resveratrol is thought to reverse eNOS uncoupling in hypercholesterolaemic ApoE-knockout (KO) mice by inhibiting
tetrahydrobiopterin (BH4) oxidation and stimulating BH4 biogenesis through upregulation of guanosine triphosphate
(GTP) cyclohydrolase I (GPTCH1).
Moreover, resveratrol can stimulate NO production by augmenting eNOS expression and activity as mentioned above.
Resveratrol platelet reduces platelet adhesion, activation and aggregation in an NO-dependent mode and subsequently
prevent thrombogenesis. Hence, resveratrol is regarded as a potent anti-atherosclerotic and anti-thrombotic agent.
Furthermore, resveratrol was shown to be a potent inhibitor of both nuclear factor kappa B (NF-kB) activation and NF-kB
dependent gene expression by the inhibition of kappa B (IkB) kinase inhibitor activity [58]. Furthermore, the results of
in silico docking showed that resveratrol produces stable complexes with platelet COX-1. Subsequent in vitro experiments
conﬁrmed the inhibitory action of resveratrol on COX-1; alters COX metabolite production to adjust platelet activation;
and hinders the arachidonate-dependent synthesis of inﬂammatory agents such as thromboxane B2, hydroxyheptadecatrienoate and 12-hydroxyeicosatetraenoate [59].
In conclusion, resveratrol exerts its anti atherogenesis activity by hindering proinﬂammatory activation of endothelial
cells accompanied by excessive adhesion molecules output and chemoattractant that stimulate monocytes detected in early
stages of vascular inﬂammation.
(ii) Quercetin: Quercetin exhibits its anti-inﬂammatory activity in a way similar to resveratrol, it targets signaling pathways related to the NF-kB pathway, thereby decreasing mRNA and protein levels of TNFa, IL-6, MIP1a and Pselectin [60]. On atherosclerosis and other cardiovascular risk markers such as human C-reactive protein (CRP) using
transgenic humanized models of CVD was further discussed and supported [61]. The authors revealed that, quercetin
decreased the cytokine-induced cell-surface expression of VCAM-1 and E-selectin in cultured human endothelial cells.
Quercetin also degraded the transcriptional activity of NF-kB in human liver cells. Furthermore, quercetin reduced the
gene expression of speciﬁc factors implicated in local vascular inﬂammation including IL-1R, Ccl8, IKK, and STAT3
(Signal transducer and activator of transcription 3). They concluded that the anti-inﬂammatory effect of quercetin may
be involved in the attenuation of atherosclerosis. Additional in vitro study showed that quercetin (125 mM) moderately
suppressed leptin-induced TNF-a secretion as well as signiﬁcantly inhibited leptin-induced NF-kB expression in
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HUVECs [62]. Quercetin also shows a marked reduction in the transcriptional action of NF-kB in human liver cells.
Quercetin at plasma concentration level I12.9  1.3 mM, in human CRP transgenic mice, quenched IL1binduced CRP
appearance, as regards to sodium salicylate effect (reference drug) [63]. The exposure of HUVECs (Human umbilical
vein endothelial cells) to leptin up-regulated Ob-Ra expression and raised levels of ERK1/2 phosphorylation and NFkB activation, and increased TNF-a secretion, results revealed that quercetin suppressed the aforementioned effects,
except TNF-alpha which was moderately suppressed [62].
Olive oils and nuts-rich in polyphenols, known as Mediterranean diet (MedDiet), alters adhesion molecules and proinﬂammatory cytokines in more than 772 subjects on a 3-month long dietary interference, aside from the PREDIMED trial
(Prevention with Mediterranean Diet). The groups received two Mediterranean dietary interventions on cardiovascular
endpoints through the daily consumption of Mediterranean nutrients enriched with extra-virgin olive oil (1L per week per
family). Mediterranean intake are enhanced with nuts (30 g/week/individual). Treatment with olive oil that is rich in
polyphenols decreased the circulating CRP levels, whereas both MedDiet treatments (virgin olive oil and nuts) reduced IL6, ICAM-1, and VCAM-1. In an alternative PREDIMED survey for 112 case, IL-6, ICAM-1, CD49d, and CD40 were
reduced following 3 months of both the MedDiet supplements as regards to the reduced fat diet, whereas VCAM-1 and
CRP levels were lowered by the virgin olive oil management only.
Moreover, virgin olive oil lowered plasma CRP and IL-6 concentrations and downregulated expression of VCAM-1,
ICAM-1 and E-selectin in the endothelium, which was correlated to the phenolic extract from olive oil. In conclusion, the
phenolic extract of the olive oil rich in oleuropein aglycone, interrupts TNFa signaling, hence, decreases the inﬁnite inﬂammatory process in the wall vessels that eventually leads to plaque formation [53]. Olive oil is unique, it contains
ﬂavones, lignans, phenolic acids such as hydroxybenzoic and hydroxycinnamic acids. It also contains other phenols such
as tyrosol and hydroxytyrosol. Besides, it contains tocopherol and monounsaturated fatty acids [64]. Hence, the activity of
olive oil in reducing inﬂammation might not be attributed only to the PPS but also to other constituents. Moreover, varieties exists that makes virgin olive oils different from reﬁned olive oil.
Alternative mechanisms for the biological activity of polyphenols, or their metabolites were also suggested, these
mechanisms can be activated by physiologically relevant concentrations [65]. On treating endothelial cells with gallic acid
(10e100 mM), a marked reduction in the secretion of the adhesion molecules [ICAM-1 and VCAM-1] and of the chemokine CCL2 was observed [66]. Malvidin (an anthocyanin) at a dose of 50 mM, hindered lipopolysaccharides-induced
MAPK signaling in RAW 264.7 macrophages, with concurrent improvement of MAPK phosphatase-1 (MKP-1 is a
protein that down-regulates the activity of all three branches of MAPKs) [67]. Similarly, the suppression of phosphorylation of JNK1/2, ERK1/2 and p38 kinases-three branches of MAPKs-was recorded when pretreated with delphinidin at a
dose level (100 mM). Furthermore, delphinidin (50e200 mM) reduced the oxidized low density lipoprotein-induced
expression of adhesion molecules: ICAM-1 and P-selectin, in a human endothelial hybrid cell line, besides lowering
adhesion of monocytes to endothelial cells via reducing intracellular ROS, p38MAPK expression, inhibitor of k-B a (IkBa) degradation and NF-kB transcription activity [68]. Nevertheless, delphinidin-3-sambubioside (hibiscus anthocyanin) at
a dose (50e200 mM), moderately inhibited the ERK1/2 phosphorylation exhibiting weak effect on the phosphorylation of
JNK1/2 and p38 in LPS-induced RAW264.7 [69].
Epicatechin in doses of 5, 25 and 50 mM signiﬁcantly inhibited the formation of pro-inﬂammatory mediators including
nitric oxide and prostaglandin E2, in addition to the synthesis of pro-inﬂammatory cytokines comprising tumor necrosis
factor (TNF)-alpha and interleukin (IL)-6 in LPS-induced Raw 264.7 macrophages. These ﬁndings suggested that epicatechin can inhibit inﬂammatory response and could be added as a therapeutic alternative for the management of chronic
inﬂammatory related diseases [9].
Many anti-inﬂammatory therapies were also reported which are used at various phases of atherosclerosis to minimize
the hazards of CVDs. Flavonoids exhibited a more satisfactory results for controlling atherosclerosis. Flavonoids are
reputed for their anti-inﬂammatory activity, through the control the process of proinﬂammatory gene expression which
leads to reduction of inﬂammation [70].

5.4.1.2 Polyunsaturated fatty acid
Omega-3 Eicosapentaenoic acid and docosahexaenoic acid are an n-3 fatty acids present in oily ﬁsh and other oil supplements, including Chia seeds, walnuts, ﬂaxseeds, Brussel sprouts, algal oil, and hemp seeds. These fatty acids can
moderately inhibit some inﬂammation as leukocyte chemotaxis, leucocyte-endothelial adhesive interactions, adhesion
molecule expression and, release of eicosanoids such as prostaglandins and leukotrienes from the u-6 fatty acid arachidonic acid, and inﬂammatory cytokines and T cell reactivity.
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The suggested mechanisms explaining how u-3 fatty acids reduces inﬂammation includes, changing cell membrane
phospholipid fatty acid composition, disruption of lipid mass (cholesterol-rich areas), inhibition of the pro-inﬂammatory
transcription factor nuclear factor kappa B activity, hence, decreasing manifestation of inﬂammatory genes, activation
of the anti-inﬂammatory transcription factor NR1C3.
Flaxseed was recommended as an alternative to marine products. Flaxseed is ranked as one of the richest sources of the
plant-based u-3 fatty acid, a-linolenic acid (ALA) [71]. Consumption of a-linolenic acid rich diet is recommended to
induce positive inﬂuence on CVD. This is attributed to clinical trial results, epidemiological surveys and experimental
applications and hence ﬂaxseed has been promoted to combat CVD. The clinical trial was performed by giving men and
women with hypercholesterolemia, an a-linolenic acid erich diet (6.5% of energy/day from ALA), this was followed by a
decrease in CRP levels in blood samples to 75%. The authors concluded that the vascular inﬂammation inhibition might
lead in a decrease in CVD risk.
Omega-3 PUFAs; eicosapentaenoic acid and docosahexaenoic acid decreased blood pressure and reduce the markers
indicating renal inﬂammation via their epoxide metabolites. This was achieved by supplementing mice with an omega-3
rich diet for 3 weeks in a murine model of angiotensin-II dependent hypertension. Moreover, a combination of soluble
epoxide hydrolysate (sEH) inhibitor and the u-3 rich diet was studied. Results shows that the omega-3 polyunsaturated
fatty acids epoxides had an impact in reducing systolic blood pressure and diminishing inﬂammation by reducing prostaglandins and MCP-1 and by up-regulating ACE-2 in angiotensin-II dependent hypertension [72].
The inﬂuence of omega-3 polyunsaturated fatty acids (PUFAs) as a food supplement on vascular function was evaluated on inﬂammatory and ﬁbrinolytic process in subjects with metabolic syndrome [73]. This was achieved by oral
treatment 2 g/day of omega-3 PUFAs in 29 (15 male & 14 female) subjects (mean age 44  12 years) with metabolic
syndrome tested in day 0: baseline, day 28 and day 84, applying a randomized, placebo-controlled, double-blind, crossover design. Polyunsaturated fatty acids oral intake, in the above mentioned dose, showed a marked improvement from the
ﬁrst day (0) to the day 28 and day 84 in the endothelial function and arterial stiffness. Moreover, there was a decrease in IL6 with an increase in the plasminogen activator inhibitor-1 (PAI-1). Therefore, omega-3 PUFAs enhanced endothelial
function and arterial stiffness with a corresponding anti-inﬂammatory action.
Other in vitro study [74], investigated the effects of u 3 and u 6 PUFAs on adiponectin and leptin secretion, where
the adipocytes were incubated for 24 h with EPA, DHA, or arachidonic acid combined with DHA at different concentrations. Results proved that Omega-3 PUFAs; EPA and DHA increased adiponectin secretion after 24 h of incubation,
however there was not any signiﬁcant effect on leptin secretion. Furthermore, a combination between DHA/arachidonic
acid signiﬁcantly upregulated adiponectin secretion. On the other hand, docosahexaenoic acid (DHA) only or in a mixture
with arachidonic acid exerted a potent anti-inﬂammatory effect in physiological conditions revealed by a decrease of tumor
necrosis factor-a (TNF-a) levels. Leptin - a 16 kDa protein produced by adipocytes taking part in the food intake control,
weight and energy homeostasis-is directly related to obesity that eventually leads to atherosclerosis, myocardial infarction
and stroke. Therefore, high concentrations of circulating leptin are associated with CVDs. The secretion of high concentration of leptin could be correlated with PUFA ratios of u  6/u  3 of 5/1 and 1/1. Results shows that, the best
dietary ratios of u  6/u  3 PUFA of 1/1 and 5/1 reduced the expression levels of lipid metabolism related genes and
also signiﬁcantly suppressed the expression of the inﬂammatory cytokines IL-1, TNF-a and IL-6. These results indicated
that the optimal u  6/u  3 PUFA ratios of 1/1 and 5/1 exerted more beneﬁcial effects on lipid metabolism and inﬂammatory system than other ratios [75].
In a recent review [54], the polyunsaturated fatty acids; eicosapentaenoic acid and docosahexaenoic acid (omega 3),
and arachidonic acid (omega 6) were investigated for their anti-inﬂammatory properties. The levels of some inﬂammation
biomarkers; Leptin, adiponectin and resistin -a group of hormones related to the development of CVDs were revised in
relation to omega-3 & omega-6 PUFAs. The authors concluded that, Omega-3 PUFAs decreased inﬂammatory mediators’
synthesis, and hence, they signiﬁcantly reduced CVD risk factors. However, omega-6 PUFA effect was not clear whether
they act as pro- or anti-inﬂammatory.

5.4.1.3 Alkaloids
It was reported that some anti-inﬂammatory compounds of natural origin can be used for treatment of atherosclerosis and
classiﬁed them as non-speciﬁc anti-inﬂammatory drugs [76]. The non-speciﬁc anti-inﬂammatory drugs of natural origin
described was colchicine (anti-gout natural alkaloid present in Colchicum automnale seeds). It was found to reduce Creactive protein (CRP) levels in patients whose CADs are stable. The authors concluded that, colchicine therapy at
dose 0.5e1.0 mg daily revealed promising results for treatment of cardiovascular conditions, especially acute myocardial
infarction, however more clinical studies are required to support its risk/beneﬁt ratio for treatment of cardiovascular
disorders.
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5.5 Selected classes of natural products used in the prevention of hypertension and
ischaemic heart diseases by various mechanisms
Polyphenols, the main constituents of many plants, have been extensively studied for their chemical and pharmacological
properties. Polyphenols have been reported to possess various bioactivities such as free radical scavenging and antiinﬂammatory effects, in addition to regulating the intracellular free calcium levels. Many researches have proven that
polyphenols are effective particularly in treating ischemic heart diseases [77].
Moreover, some compounds such as the alkaloid berberine, essential oil such as thymoquinone, catechin, triterpene as
celastrol, together with many phenolics such as apocynin, resveratrol, curcumin, hesperidine and glucohesperidine, and
quercetin were reported to control hypertension through inhibition of NADPH oxidase (NOX inhibitors), the enzyme that
augments blood pressure in the presence of other prohypertensive factors such as angiotensin II [78].
In addition, other classes of natural compounds such as carotenoids (a-carotene, b-carotene and lycopene) and xanthophylls (oxygen containing derivatives of carotenes) e.g., zeaxanthin, lutein, astaxanthin and b-cryptoxanthin which are
mainly plant coloring agents are reported to possess a potential health promoting effects. These compounds have proven to
exhibit a cardioprotective properties [79].

5.5.1 Phenolic acids and polyphenols
5.5.1.1 Ferulic acid
Ferulic acid (50 mg/kg/day) could reduce systolic blood pressure, left ventricular diastolic stiffness, attenuated inﬂammatory cell inﬁltration in spontaneously hypertensive rats [80]. Moreover, oral administration of its derivative, veratric acid
(40 mg/kg) for 30 days signiﬁcantly attenuated the systolic and diastolic blood pressure and lipid peroxidation products in
atherogenic diet fed-rats [81]. The structure of ferulic acid and other important molecules were presented in Fig. 5.3.

5.5.1.2 Caffeic acid
A hydroxycinnamic acid which was detected in many herbs, was reported to possess a cardioprotective effect for cardiac
cells against isoproterenol-induced apoptosis [82].

5.4.1.3 a-Mangostins
a-Mangostins is a polyphenolic xanthonoid isolated from various parts of the mangosteen tree. It improves both ultrastructural and functional abnormalities in the mitochondria induced by isoproterenol, through its free radical scavenging
activity and NO pathway activation [83].

5.5.1.4 Salvianolic acid A
Salvianolic acid which is known as Danshen has been ﬁrst isolated from Salvia miltiorrhiza [84]. It was ﬁrst reported to
cardio-protective activity against ischaemia/reperfusion (I/R) induced damage both in vitro and in vivo either by oral or
intravenous routes in normal and diabetic animal models [85].
Salvianolic acid A (2.5e10 mg/kg, i.v.) was also reported to signiﬁcantly decrease weight of thrombus in arteriovenous
shunt murine model. This effect might be attributed to its anti-platelet activity and modulatory activity on haemorheology
without effecting the coagulation system [86] and also to the inhibition of phosphoinositide 3-kinase [87]. Recently,
salvianolic acid A was reported to down-regulate the very low-density lipoprotein (VLDL) receptor expression, so can
attenuate hypoxia-induced endothelial endoplasmic reticulum stress and apoptosis [88]. It was also shown to inhibit
platelet-derived growth factor (PDGF)-BB-induced proliferation and migration of vascular smooth muscle cells, thus
indicating the anti-atherogenic effects of salvianolic acid A [89].

5.5.1.5 Salvianolic acid B
Salvianolic acid B increases the NO plasma levels through the nitrate reductase pathway, as observed in a rabbit heart
ischaemia/reperfusion (I/R) model [90]. Salvianolic acid B (40 mg/kg) could attenuate myocardial ischaemic injury in C57
mice and eNOS/ mice by producing NO via eNOS phosphorylation, L-arginine uptake and cationic amino acid
transporters expression [91].
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FIGURE 5.3 Chemical structures of phenolic acid and polyphenols for treating ischaemic heart diseases.

5.5.1.6 Magnolol
The phenolic magnolol, was found to possess a cardio-protective effect on I/R-induced injury models. It showed the in vivo
anti-apoptotic effect via the extracellular signal-regulated kinase 1/2 pathways in a rat I/R injury model [92].

5.5.2 Flavonoids and tannins
Most ﬂavonoids (Fig. 5.4) cause over expression of eNOS at both mRNA and protein levels. This effect is mediated by
deacetylase sirtuin 1 (SIRT1) and by hyperpolarization-dependent Ca2þ entry [93]. Furthermore, some ﬂavonoids are
potent inhibitors of phosphodiesterase (PDE), which may be responsible for their vasodilator responses [94]. Flavonoids
can also exert antiplatelet aggregation action through several molecular mechanisms: oxidative stress alleviation, superoxide protein scavenging, tyrosine phosphorylation, calcium mobilization and NO pathway [95]. Flavonoids such as rutin,
apigenin, myricetin, isoﬂavones, the phyto-oestrogen genistein and others have antioxidant effect which directly contributes to their anti-apoptotic effect on cardiomyocytes [96].

5.5.2.1 Quercetin
Quercetin exerts endothelium-dependent vasodilator effects through an increase in the bioavailability of NO via four
reported mechanisms. Under conditions of enzymatically or chemically increased O2 and NO metabolism, it is usually
accelerated, thus ﬂavonoid such as quercetin, luteolin, procyanidin, genistein, daidzein, biochanin A and ginkgo ﬂavone
aglycone can directly scavenge free oxygen radicals and thus protect NO in cell-free systems or in endothelial cells (ECs).
The detailed mechanisms of above mentioned examples are shown in (Table 5.1) [154]. Quercetin and other ﬂavonoids
such as monoacetyl-vitexin rhamnoside can inhibit xanthine oxidase and nicotinamide adenine dinucleotide phosphate
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FIGURE 5.4 Chemical structures of ﬂavonoids for treating ischaemic heart diseases.

(NADPH) oxidase, thus reducing the enzymatic sources of oxygen (Table 5.1) [155]. In the third mechanism, quercetin can
prevent oxidation of tetrahydrobiopterin (BH4) and uncoupling of eNOS [156]. Under normal conditions, in a dose- and
time-dependent manner, quercetin raises the eNOS activity through the increase in intracellular Ca2þ concentrations,
thus increasing NO production in ECs [157]. In addition, quercetin is known to induce hyperpolarization-mediated
endothelium-dependent relaxation and vasodilatation [157].
Studies of human umbilical vein endothelial cells (HUVECs) showed that quercetin aglycone at a concentration of
10 mM causing reduction in the Endothelin-1 (ET-1) expression, which may also increase bioavailability of nitric oxide
while, its metabolites were inactive [158]. In human aortic ECs, quercetin at concentrations of 5 and 10 mM and its
metabolites; 30 -O-methyl-quercetin and quercetin-3-Oglucuronide had protective effects via activating adenosine
monophosphate-activated protein kinase (AMPK) and inducing eNOS activity. These compounds caused an increase in
S-nitrosothiol and nitrite concentrations [159]. Treating mouse aortic rings (C57BL) with quercetin (5 and 10 mM) or its
metabolites prevented endothelium dysfunction [159].
Quercetin also improves cardiac performance and prevents the apoptosis of cardiac cell, through different mechanism:
JNK and c-fos cascade inhibition [160]; the up-regulation of phase 2 enzyme expression; and the regulation of ERK1/2,
JNK, p38 and Akt phosphorylation and interleukin (IL)-b [96]. Other mechanism for quercetin are presented in Table 5.1.

5.5.2.2 Catechin
Considerable evidence have shown that daily consumption of tea can protect against the risk of CVD, such as high blood
pressure through antioxidant effect, angiotensin converting enzyme (ACE) inhibition and endothelial dysfunction
improvement [161]. The effects of tea are related to its high polyphenols content especially catechins [162].
Catechin is a ﬂavan-3-ol, a type of natural antioxidant phenol, which can present free or combined with gallic acid in
the form of epigallocatechin gallate (EGCG), epicatechingallate (ECG) and epigallocatechin (EGC) or as its isomer epicatechin (EC) [163]. The content of catechins in the different types of tea ranges from 40 to 200 mg/g [164].
Catechins also can stabilize NO with EC being the most effective. It has been observed that 10 mg/mL of epicatechin
caused phosphorylation of nitric oxide synthase serine residues 633 and 1177 and the dephosphorylation of threonine
residues 495. This action increased the release of NO through strengthen the activity of eNOS [165]. Although catechin has

Quercetin

Chemical
class
Flavonol

The effect and its mechanism

References

Quercetin-supplemented diets in rats ([1.5 g Q/kg chow] for 7 days) had Attenuated carotid hypertrophy
and relatively lowered the arterial blood pressure.

Collins et al. [97]

Endothelium-independent vasorelaxation of the coronary vessels in animal models

Rendig et al. [98]

Reduces thickening of the medial wall of the aorta and normalized cardiac translocation this supports a
significant anti-hypertensive and antihypertrophic role of quercetin in animal models without any effects
on echocardiography

Danzi et al. [99]

Inhibition of angiotensin-converting
Enzyme activity in rats

Häckl et al. [100]; Sánchez
et al. [101]

Quercetin (5 mg/kg p.o or 10 mg/kg p.o.) for 5 several weeks in Wistar-Kyoto mice reduced the mean arterial
pressure (12%) and heart rate (in STR) after 13 weeks of treatment.
Quercetin considerably restricted the growth of Nɷ-Nitro-L-arginine methyl ester hydrochloride (L-NAME)
induced high blood pressure.
Quercetin showed full protection against all effects caused by L-NAME such as (1) enhancing of the remaining
ventricular and kidney weight indices; (2) proteinuria (3) renal histological lesions, such as hyaline arteriopathy and thickening of the vascular wall with regular lack of the lumen;
(4) improved endothelium dependent contraction; (5) increased thromboxane vascular B2 (TXB2) synthesis;
(6) reduced plasma concentrations of nitrates plus nitrates (nox); (7) increased plasma
And hepatic malondialdehyde (MDA) concentrations; and (8) reduced glutathione peroxidase activity.

Sánchez et al. [101]

Quercetin and its methylated metabolite (isorhamnetin) prevents endothelium dysfunction induced by
angii through inhibition of p47phoxover expression

Sánchez et al. [102]

L-type Ca2þ channel activation as cardioprotective

Saponara et al. [103];

Protects against myocardial
Ischemia-reperfusion harm (MIRI) in rabbits through restricted myocardial ischemia-reperfusion-induced
NOX2 and inos mrna and protein expression, and also restricted enos mrna and protein expression.

Wan et al. [104]

The actions of extracellular signal-regulated kinase (ERK1/2), p38 MAP kinase, Akt and GSK-3b were
attenuated by quercetin therapy.

Ahmed et al. [105]

Anti-aggregation effects through inhibitory effects on protein kinase C (PKC)-dependent NADPH oxidase
activation in platelets, reduced Fyn kinase activity as well as Syk and phospholipase C activation

Pignatelli et al. [106];
Wright et al. [107]

Oral supplements with quercetin (50 mg/kg bw/day) for 4 weeks in Cd intoxicated rats can reduce the
plasma levels of total cholesterol, the activity of hydroxyl-3-methylglutaryl-coenzyme A reductase
(HMG-coa reductase), triglycerides (tgs), thiobarbituric acid reactive substances (TBARS), lipid hydroperoxides (LOOH), low density lipoprotein cholesterol (LDLC), phospholipids (PL), very low density lipoprotein cholesterol (VLDL-C), free fatty acids (FFA) and raised the action of LCAT and the plasma levels of
HDL-C.

Prabu et al. [108]

10 mg/kg quercetin defends from the development of experimental autoimmune myocarditis (EAM) to
dilated cardiomyopathy (DCM) in rats through the modulation of MAPK signaling cascade

Milenkovic et al. [109]

PART | II Bio-functional leads for drug development

Compound

80

TABLE 5.1 The pharmacological effects and mechanism of action of selected classes of natural products on hypertension and ischaemic heart
diseases.

Kleemann [61]

Quercetin 3-O-b-Dglucuronide is one of the significant quercetin metabolites in human plasma, attenuated angiotensin II-induced vascular smooth muscle cell (VSMC) hypertrophy through its inhibitory effect
on JNK and the AP-1 signaling pathway

Ishizawa et al. [110]

Quercetin considerably ameliorated myocardial oxidative damage and immunity function impairment
caused by isoproterenol

Liu et al. [111]

Repairing the affected aortic endothelium-dependent vasodilatation and decreasing mesenteric contractile
reaction to phenylephrine, systolic hypertension, pulse amount, and center and renal hypertrophy. Attenuation of general NADPH oxidase-driven O2 production

Galindo et al. [112]

Quercetin prevents heart hypertrophy
By preventing activator protein 1 (c-fos, c-jun proteins) and initiating PPAR-g signaling pathways

Yan et al. [113]

Pentamethoxy
quercetin

Flavonol

It has safety results on heart hypertrophy through up-regulating the mrna and proteins stages of peroxisome proliferator-activated receptor alpha (PPAR a) and PPAR b engaged in the Procedure of inflammation response and cardiac fibrosis.

He et al. [114]

Luteolin

Flavone

Could reduce the myocardial infarct size, strengthen contractile function and attenuate cardiomyocyte
apoptosis in both normal and diabetic rats with I/R injury. The anti-apoptotic effect mediated by luteolin is
associated with the regulation of the PI3K/Akt, ERK/PP1a/phospholamban (PLB)/sarco/endoplasmic reticulum Ca2þ- ATPase (SERCA2a) and Janus kinase (JNK) signaling pathways, the upregulation of the antiapoptotic proteins fibroblast growth factor receptor 2 (FGFR2) and leukemia inhibitory factor (LIF), increases
in Bad phosphorylation and a decreased Bax-to-Bcl-2 ratio

Sun et al. [115]

Hesperidin (HES)
and Glucosylhesperidin
(G-HES)

Flavanone

Antihypertension

Schluesener [116]

Altering capillary fragility

Garg et al. [117]

HES (50 mg/kg) and a single oral administration of G-HES (10e50 mg/kg) for 1 day. A significant antihypertensive effect was observed in spontaneously hypertensive animals

Yamamoto et al. [118]

HES and G-HES suppress the mRNA
Expression of NADPH oxidase subunits such as p47phox(a cytoplasmic subunit of NADPH oxidase),
NOX2 and p22phox (the membrane bound heterodimer)

Yamamoto et al. [119,120]

The free radical production of oxygen (O2 $ -) from the NADPH oxidase increases in oxidative stress conditions such as hypertension in shrs, that makes a feed-forward
Mechanism and promote further activation of NADPH oxidase.

Li et al. [121]; Touyz [122]

G-HES reduced hypertension and improved endothelial dysfunction in SHR via suppression of NADPH
oxidase expression and enhanced NO bioavailability

Yamamoto et al. [120]

Antihypertensive effects of dietary HES and G-HES may be related to a reduction of NADPH oxidase
gene expression leading to a decrease of ROS production, an enhancement of NO bioavailability and a
decrease of TXA2S expression.

Yamamoto et al. [120]

Isoflavones

They are considered as phyto-oestrogens and have been reported to relax pre-contracted coronary artery
rings and mesenteric arterial rings of rabbit in a concentration dependent manner. Like oestrogens,
phyto-oestrogens decrease aortic stiffness and relax arteries by significantly restoring the NO levels.

Figtree et al. [123]; Van der
Schouw et al. [124]

Monoacetylvitexin
rhamnoside

Flavone-Cglycoside

A known inhibitor of PDE, was found to improve myocardial perfusion in the isolated heart model.

Schussler et al. [125]

Continued

81

Genistein and
daidzein
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In cultured human endothelial cells, quercetin secured against H2O2-induced fat peroxidation and
decreased the cytokineinduced
Cell-surface appearance of VCAM-1 and E-selectin.

Chemical
class

Procyanidins
Resveratrol

Stilbene

The effect and its mechanism

References

Stimulate the formation of a platelet aggregation inhibitor prostacyclin I2 (PGI2) that inhibit the formation
of the vasoconstrictors leukotrienes which stimulate inflammation.

Manna et al. [126]

Resveratrol exerts cardioprotective effects by activating adenosine receptors (ADRs) A1 and A3, regulating the downstream PI3K/Akt and cAMP response element-binding protein (CREB) pathway and controlling the expression and phosphorylation level of Bcl-2. The activation of guanine nucleotide-binding
protein-coupled receptors, such as adenosine receptor (ADR) and opioid receptor (OPR), is known to
repair I/R-induced damage in the heart.

Das et al. [127]

Increases NO bioavailability, inhibits NADPH oxidases in vessels, and blocks ROS production by inhibiting NOX4 expression.
Reduce NOX4 expression NOX4 is the predominant NOX isoform in endothelial cells, especially in
HUVEC and is an important source of ROS production

Schilder et al. [128]

Resveratrol decreased BP in fructose-induced hypertensive rats via activating of AMPK which checks the
Rac1-induced elevation in the activity of the p22phoxsubunit and enhanced the ERK1/2-RSK-nnos
pathway activity. This signaling leads to phosphorylation of ser 1416 in nnos and finally NO release and
reduction of BP

Cheng et al. [129]

Resveratrol induces a dose-dependent induction of heme oxygenase-1 (HO-1) protein expression. Which
has a protective effect against CVDs such as hypertension.
The antihypertensive effect of HO-1 is mediated by carbon monoxide (CO). CO causes the release of
NO, decreases sympathetic outflow and raises sodium secretion via the kidneys.
Angii induces NADPH oxidase activity via enhancement of the p22phoxsubunit

Spanier et al. [130]

It functions via specific signaling pathways to reduce I/R-induced cardiomyocyte apoptosis. For example,
resveratrol protects cardiomyocytes against anoxia/reoxygenation injury via the Toll-like receptor 4
(TLR4)/NF-kB signaling pathway. This indicates that the anti-apoptotic effect of resveratrol is associated
with its anti-inflammatory effect

Zhang et al. [131]

In pigs with metabolic syndrome fed a high-cholesterol diet, resveratrol treatment lead to increased phosphorylation of mammalian target of rapamycin (p-mTOR) and decreased levels of p70 S6 kinase (P70S6K),
lysosome-associated membrane protein (LAMP)-2 and autophagy-related gene 12e5 conjugates. These results suggested that resveratrol regulates autophagy signaling in chronic myocardial ischaemia

Sabe et al. [132]

Piceatannol

Stilbenoid

It was reported to restore the eNOS regulator dimethylarginine dimethylaminohydrolase, eNOS expression and activity in endothelial cells under high-glucose oxidative stress

Frombaum et al. [93]

Apocynin

Methoxysubstituted
catechol

Non-specific NOX inhibitor though deceleration of O2 $ - via preventing the transfer of p47phox and
p67phox into the membrane with subsequent activation of NOX so it can be used for controlling hypertension and other CVDs

Stolk et al. [133]; Hartog
et al. [134]

Reduced blood pressure in a variety of mouse models including hypertensive Ang II-infused mice, hypertensive 2 Kidney-1Clip rats, fructose-induced hypertension rat and DOCA-salt treated rats through a
decrease of ROS generation

Costa et al. [135]; Unger
and Patil [136]; Virdis et al.
[137]

Increases NO concentration via enhancement of eNOS expression.

Perassa et al. [138];
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Curcuminoid

Phenolic
(diaryl
heptanoid)

Reduces cardiac preload in rabbits with pressure overload and ameliorate left ventricular function by inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial TNF-a and MMP-2 expression

Yao et al. [139]

Induces isolated porcine coronary arteries relaxation through the action of NO, cGMP and adrenergic b
ereceptor

Xu et al. [140]

Lycopene treatment (10 mg/kg/day for 14 days) reduced the Ang II induced increase in systolic hypertensive in Wistar rats.
Prevented the increase in left ventricular weight induced by Ang II infusion at 0.3 mg/kg/day for 14 days
Reduced collagen deposition, and the consequent fibrotic area, in the heart of Ang II-infused rats.
Prevented cardiomyocyte hypertrophy.
Attenuated the increase in MDA content in Ang II-infused rats and reversed the deleterious effect of
angiotensin on SOD and GSH-PX activity.
Lycopene also ameliorated SNP-sensitivity in animals exposed to Ang II infusion.

Ferreira-Santos et al. [141]

Astaxanthin

Carotenoid

At 5 and 50 mg/kg for 5 weeks
Caused a reduction of systolic (by 6% and 4%, respectively) and diastolic blood pressure (by 10% for
both applied doses) in hypertensive rats induced relaxation of blood vessels, both endotheliumdependent (ED) and endothelium-independent (EID).

Hussein et al. [142,143]

Astaxanthin at 5 mg/kg/day for 7 weeks enhanced the vasodilation response induced by sodium nitroprusside
(SNP). In contrast, no such action was observed for the application of acetylcholine (ACh).

Hussein et al. [144]

It also caused a reduction of left ventricular hypertrophy (LVH). Improved the endothelial function by
decreasing oxidative stress and increasing nitric oxide bioavailability

Monroy-Ruiz et al. [145]

Astaxanthin may protect the heart of rats against cardiotoxicity induced by isoproterenol. A daily intake of
astaxanthin at 50 and 100 mg/kg body mass for 58 days reduced lipid and protein damage in heart cells by
reducing the level of plasma lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB). Moreover, the
level of malondialdehyde was also reduced. At the same time an increase was recorded for the catalase,
superoxide dismutase, glutathione and glutathione peroxidase activity in blood plasma and cardiac tissue.

Hussein [146]

Lutein exhibits antioxidant and anti-inflammatory action in the aorta tissue of the examined Guinea pigs.
The level of oxLDL decreased both in the blood and in the aorta. Decrease the interleukins levels: IL-1b, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-10 and IL-11 and the other cytokines: Interferon-g (IFN g) and tumor necrosis factor a
(TNFa). In contrast, no differences were observed in LDL cholesterol and triglycerides plasma concentrations.

Kim et al. [147]; Kim et al.
[148]

Lutein intake at 2 mg/day caused a reduction of L-nitroarganine methyl ester induced arterial pressure in
rats. Systolic and diastolic blood pressure were also decreased.
Lutein caused a reduction of heart and kidney L-NAME-induced hypertroph. Moreover, increased glutathione and nitric oxide concentrations were also recorded, at the simultaneous decrease of plasma
malondialdehyde level, thus confirming
Antioxidant properties of lutein

Sung et al. [149]

Zeaxanthin showed inhibitory effect on hemoglobin 2,20-azobis(2-amidino propane) dichloride (AAPH)induced oxidation

Chisté et al. [150]

Incubation of human aortic endothelial cells (HAEC) with lutein, reported a statistically significantly
decreased expression of VCAM-1 (by 28%) and ICAM (by 14%)

Martin et al. [151]

A selective inhibitor of NOX isoforms as it inhibits NOX1 and NOX2 with IC50s of 410 and 590 nM, whereas
it inhibits NOX4 and NOX5 with IC50s of 2.7 and 3.13 mM, with subsequent inhibition of ROS production.

Jaquet et al. [152]

Down regulated the expression of NOX2 which was enhanced by Ang II and is an important source of
ROS production.
Effectively attenuated AngII through activation of the Nrf2/ERK1/2/NOX2 pathway.

Li et al. [153]

Lutein and
zeaxanthin

Celastrol

Xanthophyll
compound

Pentacyclic
triterpenoid
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a strong effect in treating hypertension and other cardiovascular disorders, it suffers from poor bioavailability when
administered orally. This bioavailability subject-dependent and varies according to the physiological conditions [166,167].
Therefore, catechin can suppress NADPH oxidase activity and inhibit ROS production through its antioxidant activity. It
also improves the endothelial dysfunction through eNOS stimulation in addition to increasing the release of NO and the
decreasing the Angiotensin-II (Ang-II) [168].

5.5.2.3 Epigallocatechin gallate (EGCG)
Catechin is usually present as the water-soluble polyphenol epigallocatechin gallate (EGCG) in tea and has a potent
antioxidant properties. EGCG can reduce the levels of ROS and activate eNOS, and increases endothelium derived NO
levels through a phosphoinositide 3-kinase-dependent pathway (PI3) in spontaneously hypertensive rats thus enhances
coronary ﬂow [169].
EGCG (1e50 mM) was reported to exert endothelium-dependent vasodilation by activating eNOS in rat aortic rings
through phosphatidylinositol 3-kinase-, protein kinase A (PKA)- and a serine/threonine-protein kinase dependent (Aktdependent) pathways [170]. EGCG also decreases the levels of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) thus preserve the NO bioavailability [170]. Recently it was indicated that the activity of EGCG is due to
its metabolites which also has angiotensin-converting enzyme inhibition activity [171]. Hydrolysable tannins, another
group of phenolics that are found in many plants, have anti-ischaemic activity and endothelium-dependent vasorelaxing
activities at concentrations of 150e500 mg/mL when tested on the isolated rabbit hearts and thoracic aortae. They act
through the activation of cyclooxygenase (COX) pathway, inhibition of tumor necrosis factor alpha (TNF-a), activation of
eNOS and scavenging of free radicals and reactive oxygen species (ROS) [172]. Epigallocatechin gallate (EGCG) has a
cardioprotective activity through adenosine receptor (ADR) activation, especially A (1) and A(2B) adenosine receptors
(ADRs), but not opioid receptor (OPR) in a Langendorff-perfused rat heart I/R model [173]. EGCG also had anti-apoptotic
effect on cardiomyocytes which is thought to be associated with a telomere-dependent apoptotic pathway [174]. EGCG can
inhibit oxidative stress in hypertension induced cardiac hypertrophy [175]. The concentration of EGCG is higher in green
tea thus green tea exerts stronger ACE inhibiting effect [176]. A daily dose of EGCG (30 mg/kg for 12 weeks) or (200 mg/
kg for 3 weeks) could down-regulate the expression of p47phox and p22phox thus inhibiting ROS production in cardiac
endothelial cells which lead to lowering blood pressure. In addition, EGCG may reduce the blood pressure through ACE
inhibition and/or up-regulation of heme oxygenase (HO-1) expression [177].

5.5.3 Stilbenes
Stilbenes comprises of a subset of plant secondary metabolites derived from the phenylpropanoid pathway. They include
Resveratrol, Piceatannol, Pinosylvin, Astringin etc.

5.5.3.1 Resveratrol
Resveratrol (3,5,40 -Trihydroxy-trans-stilbene) can increase the bioavailable NO level in spontaneously hypertensive rats
via preventing NO and eNOS uncoupling. Resveratrol increases the eNOS activity by four mechanisms:
Firstly, by increasing the levels of eNOS messenger RNA (mRNA) and stabilizing the mRNA in ECs [178]. Secondly, it
enhances the eNOS activity by increasing its phosphorylation ratio at the serine 1177 residue to intensify the interaction between
estrogen receptor a (ERa) and Src-caveolin-1 at a concentration of 50 nM in vivo [179]. Thirdly, by decreasing the intracellular
levels of the endogenous eNOS inhibitor asymmetric dimethylarginine (ADMA) from 0.1 to 10 mM [93]. Lastly, the eNOS
activity is enhanced by inducing the deacetylase sirtuin 1- mediated deacetylation of lysines 496 and 506 in the calmodulin
binding domain of eNOS [180]. Other mechanism for the cardioprotective action of resveratrol are presented in Table 5.1.

5.5.3.2 Piceatannol
Frombaum et al. [93] also showed that the resveratrol analogue, piceatannol (4-[(E)-2-(3,5-dihydroxyphenyl) ethenyl]
benzene-1,2-diol), was found to be more effective than resveratrol under high-glucose oxidative stress in restoring the
expression and activity of the eNOS regulator dimethylarginine dimethylaminohydrolase in ECs (Table 5.1) [93].

5.5.4 Carotenoids
This class of compounds usually prevent oxidative changes in the plasma lipoprotein structure. They contribute in the rebuilding
of the walls of blood vessel through stimulation of leukocyte adhesion and platelet aggregation and up-regulation of growth
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FIGURE 5.5 Chemical structures of carotenoids for treating ischaemic heart diseases.

factor expression. Carotenoids also prevents the oxidized LDL formation, which is the initial cause for atherosclerosis [79].
Carotenoids include lycopene, astaxanthin, b-carotene (Fig. 5.5). The detailed actions of carotenoids are shown in Table 5.1.

5.5.4.1 Lycopenes
Lycopene is one of the most important carotenoids. It is a natural pigment found in many fruits and vegetables include
tomatoes and tomato products. It was reported that lycopene at a concentration of 2e12 mmol/L exerts inhibiting action on
blood platelet aggregation induced by collagen, arachidonic acid and adenosine diphosphate, its effect was comparable
with that of aspirin [181]. Lycopene could also inhibit smooth muscle cells SMC proliferation by its action on the transcription factor activating cell proliferation (Platelet-Derived Growth Factor -PDGF) [182].

5.5.4.2 Astaxanthin
It is called the king of carotenoids, belongs to the group of xanthophylls. Astaxanthin are mainly present in algae and yeast
[183,184]. It was reported that Astaxanthin reduce the expression for mRNA lectin-like oxidized low density lipoprotein
receptor 1 (LOX-1), causing vascular endothelium dysfunction with formation of atheroma. While, it increases the mRNA
expression of endothelial nitric oxide synthase (eNOS) producing nitric oxide dilating blood vessels [185].

5.5.4.3 b-Carotene
One of the most common carotenoids in nature. It is yellowish-orange pigment detected in carrot, pumpkin, red peppers,
sweet potatoes, apricots, peaches, mango, spinach, kale and watermelon [184]. It was found that 9-cis b-carotene
administered to mice (LDLRe/e) inhibited the development of atherosclerosis by increased elimination of cholesterol
from macrophages (RAW264.7) [186].

5.5.5 Volatile oils
5.5.5.1 Thymoquinone
Thymoquinone and dithymoquinone are the major constituents of the essential oil from the seeds of Nigella sativa L. The
have superoxide dismutase (SOD) like activity and act as free radical scavengers [187]. A recent study was designed to
examine the effects of TQ on ACE, heme oxygenase-1 (HO-1) and NADPH oxidase in nitro-Larginine methyl ester (LNAME) treated rats. L-NAME increased ACE activity which stimulated the conversion of Angiotensin I to angiotensin II
the direct vasoconstrictor that increases blood pressure [188]. Angiotensin II also increases superoxide anion production
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via membrane NADPH oxidase activation especially NOX4, leading to vascular injury [189]. Hence, overexpression of the
HO-1 gene reduces angiotensin II which thus protects against vascular injuries. Thymoquinone at oral doses of
0.5e1.0 mg/kg/day prevented L-NAME induced hypertension and renal damage through reduction of NOX4 and activation of HO-1 leading to diminution of Ang II [190].

5.6 Natural products in preclinical/clinical studies
In this section we will have a quick glance on natural products for which efﬁcacy and safety have already been proven and
which are in clinical trials.

5.6.1 Quercetin
A double-blind was performed on quercetin diet over a certain period [191], in which the serum fatty acid levels and its
relation to cardiac diseases were evaluated [192]. This study was performed on healthy males and females having
cholesterol levels of 4.0e7.2 mmol/L with no history of any heart diseases. The subjects were administered quercetincontaining capsules containing 1.0 g quercetin/day or rice ﬂour placebo for 28 days. The results showed that quercetin
has no effect on the risk factors for CVDs such as platelet thromboxane B2 production, resting heart rate, aggregation of
platelets and blood pressure. It also had no effect on the levels of serum cholesterol or triglyceride.
Another study used a placebo-controlled double blind study tested the efﬁcacy of 730 mg quercetin/day for 28 day
which showed a reduction in systolic and diastolic by seven and 5  2 mm Hg, respectively as well as the mean arterial
pressures (5  2 mm Hg) in case of level 1 hypertensive patients. However, quercetin had no effect on oxidant stress in
the plasma and urine [193].
CADs originate mainly as a result of inﬂammation. Dendritic tissues (DCs) are part of the body defense mechanisms.
The effectiveness of quercetin on DC was tested on eight healthier male volunteers using 500 mg twice daily for 4 weeks.
The study showed that quercetin decreased DC bond by 42% and appearance of CD11a by 21% [194].
In a double-blind placebo controlled cross-over design, quercetin or placebo was applied to normotensive ﬁve males
and level 1 hypertensive 12 males. In level 1 hypertensive individuals, quercetin reduced the mean BP to (103  7 mmHg)
while that of placebo was 108  7 mmHg. Quercetin reduced BP by a mechanism that didn’t involve changes in ACE (ET1), or nitric oxide supplements bioavailability and without impacting general reactivity [195].
Zahedi et al. [196] performed a double-blind randomized clinical test on 72 females with type 2 diabetes taken a
500 mg capsule daily for 10 weeks and assigned to quercetin and placebo groups. Quercetin consumption reduced systolic
hypertension considerably (8.8  9.3) and high-density lipoprotein cholesterol levels (HDL-C) was signiﬁcantly reduced
in both categories while changes in complete cholesterol levels, low-density lipoprotein cholesterol levels (LDLC), triglycerides (TG) and rate of TG/HDL-C and LDL-C/HDL-C were not important between and within categories. Quercetin
supplements considerably decreased the serum concentration of tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6).

5.6.2 Lycopene
In a randomized clinical trial designed to study the effect of lycopene supplements on cardiovascular risk factors level in
healthy subjects. Lycopene at a dose of 10 mg/day for 12 weeks had no effect plasma lipids. Similarly, lycopene had no
effect on no apolipoprotein A-I and apolipoprotein B-100 levels. A non-signiﬁcant reduction of systolic and diastolic blood
pressure by 3.2 and 0.3 mmHg, respectively [197].
Eight-week lycopene intake at a dose of 15 mg/day caused increase the serum superoxide dismutase activity. Men who
received lycopene showed lower levels of C-reactive protein, vascular cell adhesion molecule 1 (VCAM-1) and intercellular cell adhesion molecule (ICAM), which high levels correlate with the incidence of cardiovascular risk factors
[147,148,198].

5.6.3 Lutein and zeaxanthin
Patients at an early stage of atherosclerosis showed lower blood lutein levels relative to the healthy participants. It was
reported that plasma lutein concentration was inversely correlated with the carotid intimamedia thickness (CIMT).
Zeaxanthin level was also inversely proportional to the rigidity of the right common carotid artery and pulse wave velocity
(PWV), i.e., cardiovascular risk assessment markers [199].
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In random, double-blind, placebo control trials performed on Chinese volunteers IMT was signiﬁcantly reduced when
lutein concentration increases. This effect was stronger on using lutein mixed with lycopene supplements [200]. Two pilot
studies were conducted in which healthy participants received 15 mg daily dose of lutein ans zeaxanthin in the form of
dried, powdered spinach or 10 mg lutein and 5 mg zeaxanthin as a dietary supplement for 8 weeks. C-reactive protein and
isoprostanes concentrations showed no change. Similarly, lutein and zeaxanthin had no effect on the endothelial activation
markers levels: ICAM-1 and VCAM-1 [201]. Another study conducted on the atherosclerotic patients, it was found that
when the serum lutein concentration increases, the concentration of IL-6 decreases. Moreover, zeaxanthin concentration
was inversely correlated to the concentration of VCAM-1 level [202]. On the other hand, consumption of diet rich in lutein
and zeaxanthin had no effect on the risk of acute myocardial infarction [203], the risk of cerebral stroke in smokers [204],
cardiovascular risk in women [205] and the incidence of atherosclerosis [206].
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6.1 Introduction
Mankind has hypothesized the therapeutic importance of plants since the early ages. Plants have been used in the treatment
of various afﬂictions in the Sumerian and the Akkadian civilizations and have been integrated in ancient traditional
medicines in Chinese, Ayurvedic and Egyptian practices [1]. In Ancient Greece, Hippocrates described approximately 400
different plant species with medicinal purposes. Today, we know that the plant kingdom comprises approximately 250,000
species, yet only 10% have had their therapeutic promises explored [2].

6.1.1 Properties and mechanism of action of phytochemicals
Phytochemicals may exert their effects via various mechanisms. Several preclinical and clinical studies have hypothesized
that these heterogeneous bioactive compounds possess antioxidant, antimicrobial and anticancer properties [3e6].

6.1.1.1 Antioxidant activity
Antioxidants are free radical scavengers which neutralize reactive oxygen species (ROS) produced during aerobic cellular
metabolism: superoxide (O2), hydrogen peroxide (H2O2) and peroxynitrite (OONO). Also, antioxidants exert protective
effects on cells against the deleterious effects of ROS on cell membranes, mitochondria, DNA, lipids or proteins [7].
Natural antioxidants are important elements in health maintenance and prevention of atherosclerosis, aging,
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neurodegenerative diseases, carcinogenesis, hematological disorders or chronic inﬂammation [8e10]. Endogenous
antioxidants (catalase, superoxide dismutase, peroxidase and glutathione) exert their activity by scavenging oxygen free
radicals and thereby are important in preventing oxidative stress. Exogenous antioxidants (vitamin C, vitamin E,
ﬂavonoids, carotenoids and plant-derived products), however, are useful to counterbalance a deﬁcient total antioxidant
capacity [11]. Fruits, vegetables and grains contain numerous free radicals scavenging molecules including polyphenols,
ﬂavonoids, vitamins, that have a signiﬁcant antioxidant activity [12].
The aerobic metabolism of cells leads to the production of reactive oxygen species: superoxide (O
2 ), peroxynitrite
(OONO) and hydrogen peroxide (H2O2). Low concentrations of ROS are involved in normal (non-malignant) cells in
several physiological processes: cell signaling, enzyme activation, gene expression, apoptosis, antimicrobial defense and
phagocytosis. However, overproduction of ROS can induce damage to all cellular components, including nucleic acids,
proteins, lipids and carbohydrates. Antioxidants are able to neutralize ROS, acting as free radical scavengers. Antioxidants
can prevent cell damage induced by ROS and inﬂammation, and have antineoplastic properties. Endogenous antioxidants
(catalase, superoxide dismutase and glutathione peroxidase) enable ROS neutralization. Exogenous antioxidants are
present in the normal diet of man in fruit, vegetables, grains etc.

6.1.1.2 Antimicrobial activity
Plant parts and plant components can exert either bacteriostatic or bactericidal activity on microorganisms [13].
Plant extracts and essential oils induce disturbances of the cytoplasmic membrane, active transport, electron ﬂow or
coagulation of cell contents [14]. Some phytochemicals have been employed in the management of various respiratory,
urinary, skin and gastrointestinal infections [15,16]. Some examples are lemon balm (Melissa ofﬁcinalis), garlic
(Allium sativum) or tee tree (Melaleuca alternifolia), which have shown antimicrobial properties against a broad spectrum
of pathogens. Other natural compounds have been used in the management of urinary tract infections: cranberry juice
(Vaccinium macrocarpon) or bearberry juice (Arctostaphylos uva-ursi) [17]. The high number of opportunistic infections
that complicate the management of AIDS or of patients undergoing immunosuppressive chemotherapy and the numerous
multidrug resistant pathogenic bacterial strains that have emerged in the recent years have revived the interest for plants
with antimicrobial properties [18].

6.1.1.3 Anticancer activity
Phytochemicals may either be used as chemotherapeutic or chemopreventive agents in cancer, including hematological
malignancies. These constituents are able to affect cell proliferation, cell cycle regulation and participate in multiple
signaling pathways involved in carcinogenesis: interfering with the phosphoinositide 3-kinase (PI3K), MAPK/ERK
(also known as the Ras-Raf-MEK-ERK pathway), matrix metalloproteinase (MMP), toll-like receptors (TLR) signaling
pathways, suppressing the oncogenic AKT signaling and interfering with cell cycle progression [19e21]. Phytochemicals
may also activate DNA repair mechanism (p21, p27, p51 or p53 genes and their protein products), Bax, Bid, Bak proteins,
stimulating the formation of protective enzymes such as caspase-3, 7, 8, 9, 10, 12, inducing antioxidant molecules and
enzymes such as GSH, GST and GPx [2]. Phytochemicals exert their chemopreventive effects by blocking key events of
tumor initiation (promotion of DNA repair, ROS neutralization or scavenging, disposal of transformed cells via
immunosurveillance), promotion (anti-inﬂammatory and anti-hormonal effects, inhibition of cell proliferation, immune
targeting of transformed cells) and inhibiting or retarding tumor progression via promotion of cell differentiation,
inhibition of cell proliferation and angiogenesis and induction of apoptosis [22,23].

6.1.2 Plant-derived compounds for hematological malignancy treatments
Phytochemicals are employed in hematological malignancies such as acute and chronic leukemia, Hodgkin’s and
non-Hodgkin’s lymphoma, multiple myeloma, Waldenström’s macroglobulinemia and also in non-malignant hematological disorders such as autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura. Phytochemicals seems
to have a wide range of cellular effects, may prevent carcinogens from reaching target-sites and support detoxiﬁcation of
ROS, enhance innate immune surveillance and improve the elimination of transformed cells, activate intrinsic DNA repair
mechanisms and may inﬂuence tumor suppressors and inhibit cellular proliferation pathways [24e26].
Some phytochemicals used in medicine are alkaloids, ﬂavonoids, polyphenols, isothiocyanates glycosides, terpenes,
taxanes, antraquinones, vitamins, minerals and essential oils. The most frequent plant-derived natural products employed
as anticancer agents in hematological malignancies are: vinca alkaloids, anthracyclines and anthracenediones,
podophyllotoxin derivatives, isothiocyanates, polyphenols, ﬂavonoids and other antioxidants.
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FIGURE 6.1 Vinca alkaloids: Vincristine and vinblastine.

6.1.2.1 Vinca alkaloids
Vincristine and vinblastine (Fig. 6.1) are vinca alkaloids isolated from Vinca Rosea that are widely used as chemotherapeutic agents. Administered as sulfate salts to enhance solubility and increase stability, these drugs are employed in a
variety of hematologic disorders, malignant or non-malignant, and in numerous solid tumors. Semisynthetic derivatives,
such as vindesine, vinorelbine and vinﬂunine, are currently used in clinical practice [2,27,28].
Chemical structure: Vinca alkaloids contain both an indole nucleus (catharanthine portion) and a dihydroindole
nucleus (vindoline portion) connected by a carbon-carbon ring with variable substituents attached to the rings.
Mechanism of action: Vinca alkaloids family members exert their cytotoxic activity primarily by binding to tubulin,
disrupting the mitotic spindle apparatus and inhibiting further polymerization or extension of microtubules [29,30].
The ﬁnal effect of this metaphase arrest is the death of the cell through activation of apoptotic pathways [31,32]. Changes
in microtubule length are inhibited if vinca alkaloids are used at low concentrations. High concentrations, however,
are responsible for the inhibition of the formation of tubulin polymers. Other cellular effects of vinca alkaloids include
inhibition of amino acid metabolism, calmodulin-dependent Ca2þ ATP-ase activity and nucleic acid synthesis [31].
Clinical use. Standard dose. Route of administration. Pharmacokinetics: Vinca alkaloids are employed in hematological disorders, malignant or non-malignant, and in solid tumors. Vinca alkaloids are used by direct intravenous injection
as rapid bolus because they are extreme vesicants. Depending on the product used, doses may be different. These drugs
bind in a strong fashion to plasma proteins (albumin, lipoproteins and a1-acid glycoprotein) and bind rapidly to platelets
and lymphocytes after intravenous infusion. The distribution of the drug into platelets and lymphocytes is 3 h for
vincristine, 1 h for vinblastine and 0.5 h for vinorelbine [33]. Vinca alkaloids penetrate poorly in the central nervous
system, although they are are highly lipophilic. Their extensive binding to lymphocytes, platelets and proteins prevents
blood brain barrier penetration. The cytochrome P-450 (CYP3A) is an important element in the metabolism of vinca
alkaloids which takes place in the liver [34,35].
The vinca alkaloids, vincristine and vinblastine are administered in a variety of hematologic malignancies
(e.g., leukemia, lymphoma, multiple myeloma), non-hematological disorders (e.g., autoimmune hemolytic anemia,
idiopathic thrombocytopenic purpura) and in other neoplasia: breast carcinoma, ovarian carcinoma, testicular cancer,
non-small cell lung cancer, hepatoblastoma, rhabdomyosarcoma, neuroblastoma, Wilms tumor or Ewing sarcoma.
6.1.2.1.1 Vincristine
Vincristine is a ﬁrst-line chemotherapeutic agent in acute lymphoblastic leukemia, in association with Doxorubicin,
L-Asparaginase, Prednisone and Methotrexate, or Daunorubicin, Vincristine, Cyclophosphamide, Prednisone, or hyper
CVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone). It is also used to treat Hodgkin’s lymphoma as
part of BEACOPP (Doxorubicin, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Procarbazine, Prednisone),
VCAEP (Vincristine, CCNU, Adriamycin, Etoposide, Prednisone) or non-Hodgkin’s lymphoma as part of the CHOP
chemotherapy regimen (Cyclophosphamide, Hydroxyrubicin ¼ Adriamycin, Oncovin ¼ Vincristine, Prednisone), Re
CHOP (Rituximab þ CHOP), CVP (Cyclophosphamide, Oncovin ¼ Vincristine, Prednisone, ReCOP (Rituximab,
Cyclophosphamide, Oncovin ¼ Vincristine, Prednisone), CEOP (Cyclophosphamide, Etoposide, Oncovin ¼ Vincristine,
Prednisone), R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Oncovin ¼ Vincristine, Prednisone), hyper-CVAD
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(Cycle A: Cyclophosphamide, Methotrexate, Doxorubicin, Vincristine, Dexamethasone, Cytarabine); Cycle B: Methotrexate, Leucovorin, Cytarabine), EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin), VCAEP
(Vincristine, CCNU, Adriamycin, Etoposide, Prednisone) or CODOX-M (Cyclophosphamide, Doxorubicin, Vincristine,
Methotrexate, Leucovorin). It is also used as part of COP, ReCOP, mini-CHOP and R-mini-CHOP regimens in chronic
lymphocytic leukemia treatment [36e40]. In combination with dexamethasone and doxorubicin, vincristine is employed in
multiple myeloma treatment (bolus or daily infusion). It is also prescribed in pediatric oncology. Pediatric malignancies
have a higher level of sensitivity to vincristine and therapeutic doses in children are well tolerated [41,42]. The standard
dose of vincristine is 1e1.4 mg/m2 every 3 weeks (intravenous in bolus). In higher doses, it has shown a signiﬁcant
neurotoxic effect. Signiﬁcant interpatient variability has been reported: in some cases, higher doses were not associated
with a higher toxicity [43,44]. Vincristine may be given to pediatric patients weighing less than 10 kg (body surface
area <1 m2) at 0.05e0.065 mg/kg weekly. When the child’s weight is > 10 kg (body surface area 1 m2), a bolus
injection dose of 1.5e2.0 mg/m2 may be given weekly. Vincristine is employed also as second line therapy in autoimmune
hemolytic anemia (slow perfusion, 1 mg/week, four to six doses, if splenectomy fails) or in idiopathic thrombocytopenic
purpura, (slow perfusion, 1 mg/week, four to six doses of vincristine or slow perfusion, 3e6 h, 5e10 mg/week, three to six
doses of vinblastine, if there are contraindications to splenectomy). Vincristine metabolism occurs in the liver, under the
action of cytochrome P-450 IIIA. It is eliminated in bile/feces and has a terminal half-life (t1/2) of 95 h (range 19e155 h)
[45,46].
Since vincristine can bind tightly to the microtubules found in peripheral nerves that play key roles in axoplasmic
transport, the principal toxicity of this drug is peripheral or autonomic neuropathy. Vinca alkaloid-induced neurotoxicity
results in peripheral polyneuropathy. The polyneuropathy is symmetric and affects autonomic, sensory and motor ﬁbers
[47]. The ﬁrst signs of neurotoxicity are loss of Achilles tendon reﬂex (which is asymptomatic), paresthesia in the hands
and feet, neuritic pain, muscle pain, weakness, ataxia and paralysis. Deﬁcits are symmetrical and can last for weeks or
months even after the therapy has been discontinued. Cranial nerves are rarely affected, yet their involvement results in
diplopia, hoarseness and facial palsies. Autonomic neuropathy is common and can result in constipation, bloating,
abdominal pain, paralytic ileus, and atonic urinary bladder, characterized by dysuria, polyuria and urinary retention.
Cardiovascular autonomic neurotoxicity may also occur and can possess the following characteristics: hypertension,
hypotension, cardiac ischemia or massive myocardial infarction, especially when vinca alkaloids, cisplatin and bleomycin are associated [48]. Supportive care with folinic acid, glutamic acid and dose adjustments are the primary
treatment employed to reduce neurotoxicity. Dietary bulk agents, stool softeners and laxatives are used to prevent severe
constipation. Myelosuppression is another side effect of vincristine, especially neutropenia, as an effect of prolonged
treatment, high-dose treatment or patients with a certain predisposition due to comorbidities (e.g., patients with hepatic
dysfunction, the elderly). Inappropriate antidiuretic hormone secretion, alopecia, anaphylaxis, nausea and diarrhea are
other side effects. Elimination of vincristin is hepatobiliary. Thus, dose reductions are necessary based on bilirubin
levels: 50% if total plasma bilirubin levels ¼ 1.5e3.0 mg/dL and 75% if total serum bilirubin >3.0 mg/dL.
Dose reduction is not indicated in renal dysfunctions [49]. Vincristine is a strong vesicant, therefore intramuscular,
subcutaneous or intraperitoneal administration is forbidden. Accidental intrathecal injection induces severe and rapid
death. It is recommended to be administered as a bolus for minimize risk of extravasation. Side effects at site of injection
include erythema, pain and venous phlebitis. Treatment should be stopped in patients in which the suspicion of
extravasation exists, and any residual drug should be aspirated if possible. Corticosteroid administration is necessary to
limit damage upon tissues. Debridement should be initiated as early as possible. Dosage modiﬁcations or increasing
doses intervals may be justiﬁed.
6.1.2.1.2 Vinblastine
Vinblastine is a ﬁrst-line chemotherapeutic agent used to treat Hodgkin’s lymphoma. It is included in the ABVD regimen
(Doxorubicin, Bleomycin, Dacarbazine, Vinblastine). The initial recommended dose is 2.5 mg/m2 in children and 3.7 mg/
m2 in adults, six to eight every week, intravenously. The dose is increased if hematological tolerance allows it.
Myelosupression is reached even when maximum recommended doses are not administered (12.5 mg/m2 in children,
18.5 mg/m2 in adults). Leukopenia limits the administration to once weekly. Liver dysfunction requires dose reduction.
Vinblastine may be used also as second line therapy when contraindications to splenectomy exist in idiopathic thrombocytopenic purpura (slow perfusion, 3e6 h, 5e10 mg/week, three to six doses). Vinblastine is metabolized in the liver
under the action of cytochrome P-450 IIIA, elimination is via bile/feces and the terminal half-life (t1/2) is 25 h (range
7e47 h) [50]. The main toxic effects are myelosuppression, alopecia, dyspnea, severe bronchospasm, constipation and
hypertension.
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6.1.2.1.3 Semysynthetic derivatives of vinca alkaloids
As mentioned earlier, some semysynthetic derivatives of vinca alkaloids are vindesine, vinorelbine and vinﬂunine
(Fig. 6.2).
1. Vindesine: This is used in combination with other agents, such as Cytarabine, Etoposide or Dexamethasone in the
treatment of acute lymphoblastic leukemia. It is most commonly administered in 2e4 mg/m2 intravenous bolus, weekly
and twice weekly. An increased dose can be administered safely without major toxicities for 1e2 days [51]. A dose
reduction is warranted if the patient has hepatic dysfunction. Vindesine is metabolized by the hepatic cytochrome
P-450 IIIA, eliminated in bile/feces and its terminal half-life (t1/2) is 24 h (range 12e42 h). Neutropenia is its main
toxicity.
2. Vinorelbine: This is employed in the treatment of Hodgkin’s lymphoma as part of IGEV regimens (Ifosfamide,
Gemcitabine, Etoposide, Vinorelbine) or GVD (Gemcitabine, Vinorelbine, liposomal Doxorubicin). The standard
dose is 15e30 mg/m2 every 1e2 weeks, intravenous or oral administration. Alternatively, vinorelbine may be given
as slow bolus injection followed by ﬂushing with 0.9% sodium chloride or short infusion over 20 min. It appears
that shorter infusions are associated with a decrease in local venous toxicity. A dose reduction is necessary in hepatic
dysfunctions, including a 50% reduction in patients with total serum bilirubin of 1.5e3.0 mg/dL and a 75% reduction
in patients with total serum bilirubin >3.0 mg/dL. Dose reduction in kidney failure is not recommended. Vinorelbine is
the only vinca alkaloid which can be administered orally, with maximal drug concentrations achieved in 1e2 h with an
absolute bioavailability of approximately 27% (range: 10%e60%) when given in soft gelatin capsules [52]. Vinorelbine is metabolized by the hepatic cytochrome P-450 IIIA, eliminated in bile/feces, and its terminal half-life (t1/2) is
33 h (range 14e44 h). Its principal toxicity is neutropenia, followed by peripheral neuropathy, alopecia and nausea.
3. Vinﬂunine: This is currently being employed in metastatic or advanced urothelial cancer if platin-based treatment
regimens have failed to provide satisfying results [53]. It is also investigated as anticancer agent in metastatic breast
cancer and NSCLC [27,28].
Mechanisms of Resistance: The most common mechanism of resistance to vinca alkaloids is changes in efﬂux by
members of the ATP-binding cassette (ABC) transporter family, such as the permeability glycoprotein (P-gp)/MDR1
encoded gene product (ABC subfamily B1, ABCB1) and the multidrug resistance protein MRP [54]. MDR1 is a 170-kD
P-gp transmembrane pump that regulates efﬂux of large amphipathic, hydrophobic substances in an energy dependent
manner and drug resistance is proportional to the amount of channel present in the cell membrane. MRP is a 190-kD
transmembrane protein with a 15% homology to MDR1 [31]. Resistance to vinca alkaloids develops rapidly and
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commonly due to decreased drug accumulation and retention within target tumor cells. MDR1 and MRP resistance is
reversible after treatment with calcium channel blockers, detergents, progesterone or estrogenic antagonists, antibiotics,
antihypertensives, antimalarials, antiarrhythmic drugs and immune suppressors, agents which bind directly to the channel
and inhibit efﬂux, thereby increasing intracellular concentrations of chemotherapeutic agents. Other mechanisms of
resistance are changes in tubulin expression or tubulin binding, changes in heat shock response or alterations in apoptotic
signaling allowing cells to escape apoptosis and overexpression of anti-apoptotic genes such as Bcl-2 and Bcl-XL [55,56].
Drug Interactions: Drugs such as quinine, cyclosporine and nifedipine which utilize the same elimination pathway liver cytochrome P450 3A (CYP3A) metabolism - have been reported to inhibit vinca alkaloid metabolism in vitro [34].
Drugs which actively inhibit CYP3A, such as erythromycin and itraconazole, can lead to severe toxicity. Also, the use of
vinca alkaloids in combination with mitomycin C induces pulmonary toxicity, acute bronchospasm or subacute reversible
cough and dyspnea 1 hour after treatment. Association with etoposide increases vincristine toxicity. Phenytoin and
phenobarbital may increase vinca alkaloid metabolism and decrease their efﬁcacy. Combination of vinblastine
and erythromycin or cyclosporine leads to greater toxicity [57,58].

6.1.2.2 Cephalotaxus alkaloids
Harringtonine and isoharringtonine cephalotaxus alkaloids (Fig. 6.3) are anticancer agents isolated from Cephalotaxus
harringtonia and used in the treatment of chronic myelogenous leukemia, acute myelogenous leukemia and myelodysplastic syndromes. These drugs inhibit protein synthesis and target the molecular events in protein synthesis in A-549 lung
cancer and HeLa, SGC-7901 gastric cancer cell lines [59,60].

6.1.2.3 Anthracyclines and anthracenediones
Major natural bioactive in this class that has anticancer activities were discussed below (Fig. 6.4).
Daunorubicin, an anthracycline antibiotic, is the ﬁrst natural product isolated from the actinobacteria Streptomyces
peucetius in 1963. Idarubicin, epirubicin and several liposomal formulations were synthesized later. Doxorubicin is the
most widely used anthracycline. Anthracenediones are a class of compounds related to anthracyclines with antileukemic
properties. The most active compound of this class is mitoxantrone which has a reduced risk of cardiotoxicity.
Chemical structure: Anthracyclines are composed of an anthraquinone (a planar polyaromatic ring system with a
quinine moiety) linked to an amino sugar. The central anthraquinone is an intense chromophore that absorbs light at
254 nm in UV and at 480 nm in the visible spectrum and gives the compounds their characteristic orange-red color and
intense ﬂuorescence. The compounds lose their ﬂuorescence when intercalated in the DNA [61]. Many structural variations
to the basic anthracycline structure exist: idarubicin does not have a methyl ester at carbon four of the central chromophore,
doxorubicin and epirubicin have a hydroxyl moiety at carbon 14, while daunorubicin and idarubicin are missing this
hydroxyl group. Epirubicin has the opposite stereochemical conﬁguration at carbon four on the amino sugar from
doxorubicin and idarubicin.
The chemical structure of anthracyclines consists of a lipophilic anthraquinone core to which an amino sugar is
attached, enhancing the compound’s solubility in water. Idarubicin is the most lipophilic molecule, whereas doxorubicin is
the least lipophilic. They are marketed as hydrochloric acid salts since this formulation is soluble in both water and polar
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organic solvents. Mitoxantrone consists of a central dihydroxyanthraquinone chromophore to which two symmetrical
aminoalkyl chains are attached [61].
Mechanism of action: Anthracyclines act through several mechanisms, three of which are of major importance:
inhibition of the nuclear enzyme DNA topoisomerase II by intercalating between the DNA bases and stabilizing the DNAtopoisomerase II cleavage complex, generation of reactive oxygen species and stimulation of apoptosis. Anthracyclines
have an inhibitory effect on nucleic acid synthesis, interact with topoisomerase II (a nuclear enzyme that is responsible for
the tertiary structure of DNA) and/or generate free oxygen radicals that can cause widespread damage to cellular
components. The reduction of doxorubicin to the semi-quinone and the subsequent oxidation back to doxorubicin creates
the superoxide anion. In turn, the superoxide anion can react with hydrogen peroxide to create free oxygen radicals which
can subsequently induce formation of the hydroxyl radical (in the presence of metal ions such as the iron found in
myoglobin) that can have broad destructive cellular effects on DNA, lipids and proteins [62,63]. Anthracycline exposure
causes changes in cardiac biochemistry such as alterations in calcium handling characterized by inhibition of calcium
sequestration in the sarcoplasmic reticulum secondary to drug-induced free radical damage [64]. Anthracyclines inhibit
glutathione peroxidase and thus the cardiac tissue’s ability to detoxify free radicals is reduced. The lower levels of catalase
in the heart versus other tissues also contribute to the damage caused by free radicals [65].
Clinical use. Standard dose. Route of administration. Pharmacokinetics: Anthracyclines are widely used in the
treatment of hematological malignancies or solid tumors and are usually administered intravenously. Idarubicin is the only
anthracycline that is given orally. Doses and administration regimens vary from one disease to another. These drugs bind to
DNA and proteins. Doxorubicin and daunorubicin appear to cross the plasma cell membranes through free diffusion of the
non-ionized drug. The clinically signiﬁcant toxicities include myelosuppression, alopecia and mucositis, but the most
signiﬁcant and dangerous toxicity of these drugs is their cumulative cardiotoxicity which is correlated to peak drug levels.
6.1.2.3.1 Doxorubicin
Doxorubicin is widely used in the treatment of: hematological malignancies (e.g., leukemia, Hodgkin’s and non-Hodgkin’s
lymphoma, multiple myeloma), solid tumors in adults (breast, ovary, bladder, stomach, thyroid, lung or soft-tissue cancers,
osteosarcoma) and numerous pediatric solid tumors. Doxorubicin is a front-line therapy in the treatment of acute
lymphoblastic leukemia, in association with Vincristine, L-Asparaginase, Prednisone and Methotrexate, or hyper- CVAD.
It is also used as a treatment of Hodgkin’s lymphoma as part of ABVD, BEACOPP or VCAEP and in the treatment of nonHodgkin’s lymphoma as part of the following chemotherapy regimens: CHOP, ReCHOP, hyper-CVAD, EPOCH,
VCAEP or CODOX-M [36]. Doxorubicin is also used in the treatment of multiple myeloma in combination with
vincristine and dexamethasone [41]. In monotherapy, the standard dose is 35e70 mg/m2 at 3 weeks in adults and 30 mg/
m2/day 3 days consecutively, repeated at 4 weeks in children. Maximal cumulative dose is 550 mg/m2. If combined
with other myelosuppressive chemotherapeutic agents, the dose is 25e50 mg/m2 at 3e4 weeks and if combined with
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non-myelosuppressive chemotherapeutic agents, the dose is 60e75 mg/m2. A reduced dose is needed in patients with liver
failure. Dose adjustments should be considered in patients with renal dysfunction (creatinine clearance < 60 mL/h) [66].
Patients with liver dysfunction and signiﬁcantly increased bilirubin should beneﬁt from a 50% or 25% dose reduction.
The route of administration is generally intravenous, but also intraperitoneal and intra-arterial. Metabolization to
13-dihydro derivatives is low and elimination is hepatic and 10% renal. Its terminal half-life (t1/2) is 20e30 h and the main
toxicities are cardiomyopathy, neutropenia, mucositis, chemobrain and alopecia. Drug-induced cardiotoxicity seems to be
blocked by an iron chelating agent with moderate antineoplastic activity, dexrazoxane (ICRF-187) [67,68]. Liposomal
administration of doxorubicin decreases its cardiotoxic effect [69].
6.1.2.3.2 Daunorubicin
Daunorubicin is primarily used in the treatment of acute leukemia, lymphoma and breast cancer. Liposomal formulations
of doxorubicin and daunorubicin have been utilized to treat multiple myeloma and AIDS-related Kaposi sarcoma.
The standard dose is 30e45 mg/m2/day, 3e5 days, and the route of administration is intravenous only. The drug is
metabolized to 13-dihydro derivatives in high proportions, the route of elimination is mainly hepatic and 10% renal and the
drug has a terminal half-life (t1/2) of 15e18 h. Daunorubicin’s main toxicities are neutropenia, mucositis, alopecia and
cardiomyopathy [70].
6.1.2.3.3 Epirubicin
This is less potent and is used to treat acute lymphoblastic leukemia, breast cancer, gastric cancer, small cell lung cancer,
pancreatic cancer and soft-tissue tumors. Its cardiotoxicity is less signiﬁcant. The standard dose is up to 120 mg/m2 every
3 weeks and the route of administration is intravenous only. Epirubicin is converted to 13-dihydro derivatives in a small
percent and it is eliminated by the liver and 10% by the kidneys. Its terminal half-life (t1/2) is 18e24 h and its principal
toxicities are cardiomyopathy, neutropenia, mucositis and alopecia [71].
6.1.2.3.4 Idarubicin
This is used in the treatment of adult and childhood acute myeloid leukemia in combination with cytarabine as part of the
regimens FLAG-Ida (Fludarabine, Cytarabine, Idarubicin, G-CSF) or PETHEMA (ATRA, Idarubicin, Mitoxantrone,
Purinethol, Methotrexate), ETI (Etoposide, Tioguanine, Idarubicin), as well as in the therapy of lymphoma and breast
cancer. The standard dose is 8e15 mg/m2 per day, 3e5 days IV or 30e50 mg/m2 per week. The route of administration is
intravenous or oral, its metabolization to 13-dihydro derivatives is high and its elimination is 80% in urine. Idarubicin
terminal half-life (t1/2) is 12e16 h and its principal toxicities are neutropenia, mucositis, alopecia and cardiomyopathy (less
than doxorubicin) [72].
6.1.2.3.5 The anthracenedione, mitoxantrone
The anthracenedione mitoxantrone is employed in the management of acute leukemia, lymphoma, breast cancer and
prostate cancer. Mitoxantrone is used in the salvage therapy of acute lymphoblastic leukemia, in combination with high
dose Ara-C. In acute myeloblastic leukemia, it is a part of Ara-C and Mitoxantrone, or Mitoxantrone and Etoposide, or
MEC protocols (Mitoxantrone, Cytarabine, Etoposide). Mitoxantrone is especially successful in the therapy of P388
leukemia in which its beneﬁt is a 500% increase in life span and a signiﬁcant number of cured cases [61]. In the therapy of
non-Hodgkin’s lymphoma, it is employed in ReCNOP (Rituximab, Cyclophosphamide, Mitoxantrone, Vincristine,
Prednisone) or FND (Fludarabine, Mitoxantrone, Dexamethasone) regimens. The low toxicity of mitoxantrone enables its
employment in elderly patients, especially in palliative care in combination therapy for hematological malignancies.
The standard dose is 12e14 mg/m2 every 3 weeks or 12 mg/m2 every 3 days for AML. Mitoxantrone is administered
intravenously and intraperitoneally, its elimination is partially hepatic and partially renal and its terminal half-life (t1/2) is
9 h. In comparison with other anthracyclines, mitoxantrone has a lower toxicity, especially in means of cardiotoxicity [73].
Mechanism of Resistance: Drug resistance to anthracyclines is induced by several mechanisms: overexpression of
multidrug resistance transporters, alterations of topoisomerase II and changes in apoptotic signaling. Overexpression of
multidrug resistance transporters is a common mechanism of resistance to chemotherapeutic agents in hematological
malignancies. Multidrug resistance is mediated by members of the ATP-binding cassette (ABC) transporters such as MDR
(multidrug resistance protein, also known as P-glycoprotein) and MRP (MDR-related proteins) which are responsible for
the efﬂux of large compounds from cells in an ATP dependent manner [74,75]. MDR mediates the cross-resistance
phenotype which exists between anthracyclines, vinca alkaloids, epipodophyllotoxins and taxanes [61]. Increased
expression of MDR involves several mechanisms such as gene ampliﬁcation, mutations allowing for increased MDR
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transcription and increased RNA expression. It was observed that a high expression of MDR in acute leukemia is
associated with unfavorable prognosis and that patients who fail primary anthracycline therapy for leukemia and
lymphoma have post-treatment up-regulation of MDR expression [75,76]. MRP mediates anthracycline resistance via
intracellular sequestration of anthracycline after glutathione conjugation, preventing its interaction with nuclear DNA [77].
It seems that MDR and MRP function jointly in producing resistance in acute leukemia [78,79]. Another mechanism for
anthracycline resistance involves alterations in topoisomerase II activity via down-regulation of mRNA expression of
topoisomerase II and point mutations in topoisomerase II which either decrease the binding afﬁnity of anthracyclines
or prevent stabilization of the topoisomerase II e DNA cleavage complex. Another mechanism of resistance to
anthracyclines might be explained by the involvement of oxidative stress in hematological malignancies [80]. Anthracycline resistance may occur also via overexpression of bcl-2 and mutations in p53, events which alter apoptotic signaling
[81,82]. Drug resistance to anthracenediones (mitoxantrone) involves the same pathways as resistance to vinca alkaloids
and anthracyclines: MDR, MRP, and BCRP drug efﬂux channels, mutations in topoisomerase II activity etc [79,83].
Drug interactions: Anthracyclines interact with a few drugs. Co-administration of doxorubicin and etoposide has been
shown to decrease doxorubicin clearance and association with daunorubicin and heparin can increase daunorubicin
clearance [84]. Doxorubicin, daunorubicin, and mitoxantrone can cause radiosensitization of normal tissues, so the dose of
doxorubicin must be reduced by 50% in case of mediastinal radiotherapy for Hodgkin’s lymphoma. Mitoxantrone acts
synergistically with cytosine arabinoside, therefore they are frequently used in combination to treat acute myeloblastic
leukemia. Co-administration of doxorubicin or epirubicin with the cardioprotective dexrazoxane (ICRF-187) does not
seem to alter their pharmacokinetics [61]. Cyclosporine A, verapamil and quinine reversed MDR associated resistance in
leukemia and lymphoma and decreases clearance of anthracycline. Cyclosporine A co-administered with daunorubicin as
part of a standard daunorubicin and cytosine arabinoside regimen signiﬁcantly improved overall survival and relapse rates
in patients with acute myeloblastic leukemia [85].

6.1.2.4 Podophyllotoxin derivatives
Podophyllotoxin derivatives (etoposide and teniposide (Fig. 6.5)) are toxic natural products that have been manufactured
into anticancer drugs. The major active substance in podophyllin is a resin extracted from the dried roots and rhizomes of
the North American plant Podophyllum peltatum (May apple) and of the related Indian species Podophyllum emodi.
Podophyllotoxin itself is a potent antimitotic agent, however too toxic to be useful in the treatment of human cancers.
Podophyllotoxin derivatives have been isolated from natural sources or prepared by partial synthesis. Two cyclic acetals of
4-demethylepipodophyllotoxin b-D-glucopyranoside known as etoposide (VP16e213) and teniposide (VM26) are used in
acute leukemia, Hodgkin’s and non-Hodgkin’s lymphoma and in solid cancer, such as small cell lung cancer, testicular
cancer, hepatocellular carcinoma, neuroblastoma and AIDS e related Kaposi sarcoma [86].
Chemical structure: Etoposide is a cyclic acetal prepared from 4-demethylepipodophyllotoxin b-D-glucopyranoside
and acetaldehyde (as its dimethyl acetal), while teniposide is the cyclic acetal prepared by 2-thiophenecarboxaldehyde
replacement of acetaldehyde. The two drugs are insoluble in water, but soluble in organic solvents.
Mechanism of action: Etoposide and teniposide are phase-speciﬁc cytotoxic drugs acting in the late S and early G2
phases of the cell cycle. They seem to cause breaks in DNA via an interaction with DNA topoisomerase II or by the
formation of free radicals, stabilize the cleavable complex and induces apoptosis [87].
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Clinical use. Standard dose. Route of administration. Pharmacokinetics: Both etoposide and teniposide are used
in Hodgkin’s lymphoma as part of BEACOPP regimen, ICE (Ifosfamide, Mesna, Carboplatin, Etoposide), VCAEP,
BEAM (Carmustine, Etoposide, Cytosine-Arabinoside, Melfalan), PEP-C (Prednisone, Etoposide, Procarbazine,
Cyclophosphamide), non-Hodgkin’s lymphoma as part of R-CEOP (Rituximab, Cyclophosphamide, Etoposide,
Vincristine, Prednisone), ESHAP (Etoposide, Metilprednisolone, ARA-C, Cisplatin), ICE (Ifosfamide, Carboplatin,
Etoposide), CALGB 9251 (Cycle 1: Cyclophosphamide, Prednisone; Cycle 2,4,6: Ifosfamide, Mesna, Methotrexate,
Leucovorin, Vincristine, Cytarabine, Etoposide, Dexamethasone; Cycle 3,5,7: Cyclophosphamide, Methotrexate,
Leucovorin, Vincristine, Doxorubicin, Dexamethasone, with MTX, ARA-C, Hydrocortisone intrathecalecycle 2e7),
EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin), R-IVAC (Ifosfamide, Etoposide,
Cytarabine  Rituximab), VCAEP (Vincristine, CCNU, Adriblastin, Etoposide, Prednisone), PEP-C (Prednisone,
Etoposide, Procarbazine, Cyclophosphamide). Etoposide is administered also in adult acute myelogenous leukemia with
a good response rate for patients with myelomonocytic and monocytic leukemia. Etoposide is useful in pediatric acute
monocytic leukemia. The teniposide þ cytarabine combination is employed in pediatric refractory acute lymphoblastic
leukemia.
The standard dose of etoposide is 300e600 mg/m2 divided over three or 5 days and repeated every 3e4 weeks,
intravenous. Etoposide is also available for oral administration. The bioavailability of oral etoposide is about 50% but the
dose increase-absorption relationship is not linear. There is a considerable interpatient variability in the pharmacokinetics
of oral etoposide. For teniposide, the schedule for adults is similar, but at a lower dose of 300 mg/m2, intravenous.
For children, teniposide in monotherapy is commonly used in a dose of 150e200 mg/m2 weekly or 100 mg/m2 twice
weekly. The peak plasma concentrations of the drug and the area under the concentration versus time curve are linearly
related to the intravenous dose of both drugs. Considerable interpatient variability of pharmacokinetic parameters exists
following intravenous administration. There is no evidence of accumulation of etoposide and teniposide after multiple
consecutive doses by intravenous or oral routes. The limiting toxicities are myelosuppression, gastrointestinal disturbances
and alopecia. Excretion of both drugs is primarily in urine. Fecal excretion is variable [86].

6.1.2.5 Isothiocyanates
Isothiocyanates are a heterogeneous family of molecules with a common structural feature: with the eN]C]S group
(Fig. 6.6) These compounds are electrophilic and biologically active. Some vegetables contain precursors of
isothiocyanates: allyl isothiocyanate (sinigrin), benzyl isothiocyanate (glucotropaeolin), phenethyl isothiocyanate
(gluconasturtiin) and sulforaphane (glucoraphanin). Broccoli and Brussels sprouts are rich in sinigrin and glucoraphanin,
cabbage is rich in glucotropaeolin and glucoraphanin and watercress contains gluconasturtiin (phenethyl isothiocyanate).
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Isothiocyanates are involved in the regulation of the clonal expansion of leukemic cells, partaking in events such as
progression of the cell cycle, programmed cell death and induction of differentiation.
In the U937 cell line, sulphoraphane at 4 mM concentration inhibited cellular growth by 85% [88]. Studies on human
leukemia cellular models have also shown that 12 mmol/day of phenylhexyl isothiocyanate signiﬁcantly reduced tumor
formation in HL-60 cells xenografted immunodeﬁcient mice, without toxic effects on normal cells [83]. Incubation of
leukemic cells in the presence of sulphoraphane combined with arsenic trioxide strongly enhanced apoptosis induced by
arsenic trioxide via ROS-mediated mechanisms [89]. Zhang et al. observed that isothiocyanates decrease the pool of GSH,
enhance ROS levels and induce selective damage on chronic myeloid leukemia imatinib-resistant cells. Isothiocyanates are
included in the therapy of human T-leukemia and different solid cancers, such as colorectal cancer, cervical cancer, lung
cancer, prostate cancer since they arrest the cell cycle in the G2/M phases, down-regulate activated signaling cascades,
increase intracellular ROS levels, modulate epigenetic changes, inhibit proliferation, progression and invasion, without
producing toxicity [90]. Ruciferous vegetable consumption was inversely associated with the risk of bladder cancer in men
[91,92]. Sulphoraphane has antineoplastic properties in cervical cancer cells via induction of G2/M arrest, down-regulation
of cyclin B1 and up-regulation of GADD45b proteins [93].

6.1.2.6 Polyphenols
Some important polyphenols widely reported to possess anticancer properties were described below (Fig. 6.7).
6.1.2.6.1 Curcumin
Curcumin or turmeric is a polyphenol (bis-a,b-unsaturated b-diketone) derived from the rhizome of Curcuma longa,
traditionally used in Ayurvedic practice. Its employment in therapy was justiﬁed by curcumin’s promising effects:
antioxidant, hypoglycemic, anti-inﬂammatory, antineoplastic, thrombosuppressive, antibacterial, antiarthritic and
hepatoprotective. In in vitro models, curcumin inhibited cell growth in different cellular models by arresting the cell cycle
and leading to apoptosis via modulation of several distinct cancer targets: cyclooxygenase-2 (COX-2), cyclin D1, nuclear
factor kappa B (NF-kB), STAT-3 and tumor necrosis factor alpha (TNF-a) [94,95]. Curcumin acts on multiple targets:
transcription factors, growth factors and their receptors, cellular signaling molecules, genes regulating cell proliferation and
apoptosis, adhesion molecules and regulators of angiogenesis [96]. Several studies have been reported the antiproliferative
mechanism of curcumin in leukemia, lymphoma or multiple myeloma (MM) [97,98]. Curcumin blocks the constitutively
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active IKK and inhibits NF-kB activation, leading to the suppression of proliferation and induction of apoptosis in four
different MM cell lines (U266, RPMI 8226, MM.1, and MM.1R), and subsequently reduces the expression of several gene
products regulated by NF-kB, such as IkB, Bcl- 2, Bcl-XL, IL-6, and cyclin D1 [98,99]. In other MM cell lines, curcumin
inhibited IL-6-induced STAT3 phosphorylation and consequent STAT3 nuclear translocation, suppressing MM proliferation [98,99]. In other MM cell lines, curcumin suppressed MM proliferation: it disrupted phosphorylation of STAT3,
event which was induced by IL-6, and prevented translocation of STAT3 into the cell nucleus [98,99]. Curcumin also
potentiated the activity of two drugs employed in the treatment of MM, bortezomib and thalidomide [100]. Curcumin
suppressed the activation of NF-kB, COX-2 and STAT3 in MM patients [101]. It was observed that, in many cases,
curcumin kills tumor cells without damaging normal cells. It is highly probable that low concentrations of curcumin induce
antioxidant effects while higher concentrations increase the cellular levels of ROS [102,103].
Curcumin has an anti-carcinogenic effects on pancreatic cancer where it suppresses proliferation and induces apoptosis
via down-regulation of constitutively active NF-kB and IkB kinase, and inhibits cell growth by down-regulation of COX-2,
EGFR and ERK1/2 [104,105]. In human glioblastoma, curcumin inhibited cell growth by interaction with cellular and
nuclear factors and gene expression up-regulation (p16, p21, p53, BAX protein, EIK-1, Erk enzyme and caspases 3, 8, 9)
and decreasing the level of Bcl-2, mTOR, p65, protein kinase B (Akt), retinoblastoma protein (pRB), NF-kB, and cyclin
D1 proteins [106].
6.1.2.6.2 Genistein (40 ,5,7-trihydroxyisoflavone)
Genistein is the predominant isoﬂavone in the plant family Leguminosae (soybeans, lentils, beans, chickpeas). It is helpful
in preventing and treating breast and prostate cancers. Genistein may have anticancer properties by inhibiting the activity of
EGF-R PTK, HER-2, NF-kB and topoisomerase II, up-regulating expression of pro-apoptotic proteins (Bax and p21) and
antioxidant enzyme expression such as glutathione peroxidase. On the other hand, similarly to quercetin, it triggers
pathways under the control of MAPK, AKT and NF-kB [107,108]. It was shown that soy-derived isoﬂavones signiﬁcantly
inhibit growth of T-ALL (T-cell Acute Lymphoblastic Leukemia)-derived cell lines and their inﬁltration into various
organs in immunodeﬁcient murine models [109]. Uckun et al. [110] studied the effect of genistein in non-Hodgkin’s
lymphoma and ALL. When the B43 monoclonal antibody was conjugated with genistein, the drug þ polyphenol
combination targeted speciﬁcally leukemic cells of B-lineage since these malignant cells express CD19. Genistein
anti-cancer properties are also studied in breast cancer, prostate cancer, melanoma, kidney and pancreatic cancers.
6.1.2.6.3 Gingerol
Gingerol is the major phenolic constituent of the rhizome of Zingiber ofﬁcinale which induced apoptosis in leukemia cells
by mitochondrial pathway and cell cycle arrest. It also induced apoptosis in breast cancer, colon, pancreas and ovarian
cancers through iNOS and TNF-alpha expression down-regulation via suppression of NF-kB nuclear translocation and
IkBa phosphorylation [111].
6.1.2.6.4 Tea polyphenols
Camellia sinensisia contains very important class of polyphenols referred to as catechin polyphenols, such as
epigallocatechin-3-gallate (EGCG) and epicatechin-3-gallate (ECG), alkaloids, minerals and volatile organic
compounds. EGCG and ECG have an important antioxidant activity and prevent speciﬁc ROS-induced DNA damage
and tumor mutagenesis of normal cells, inducing apoptosis, inhibiting angiogenesis, enhancing the immune system’s
activity and activating enzymes involved in cellular detoxiﬁcation via the glutathione S-transferase and quinone
reductase pathways [112]. Also, EGCG has effects on intracellular signaling and seems to generate ROS [113]. Green tea
polyphenols interact with bortezomib, a proteasome inhibitor employed in the therapy of multiple myeloma. Thus,
patients receiving bortezomib should abstain from consuming green tea and derived products [114]. Another study
revealed that administration of EGCG in polyphenon E formulation in chronic lymphocytic leukemia beneﬁted patients
diagnosed with this disorder because it reduced lymphocyte numbers and the size of lymph nodes [115]. The
antineoplastic potential of tea polyphenols has also been explored in lung, liver, kidney, brain, stomach, bladder, colon,
cervical and ovarian cancer [116e120].
6.1.2.6.5 Resveratrol
This is a polyphenol identiﬁed in mulberries, peanuts, grapes, bilberries, blueberries and red wine. It has anticancer
properties by up-regulating p53 and Bcl-2 associated X proteins and down-regulating MMPs, NFkB, AP-1, Bcl-2, cyclins,
cyclin dependent kinases, cytokines, and COX-2 proteins inhibit angiogenesis, suppressing VEGF protein action by
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reducing MAP kinase phosphorylation, in breast, colorectal, liver, pancreatic, prostate and lung cancer [121,122].
Resveratrol induces apoptosis by triggering both extrinsic death receptor-mediated pathways and intrinsic mitochondrial
pathways. It has been reported that it suppresses expression of anti-apoptotic proteins, such as survivin and Bcl-XL, by
inhibition the ERK1/2 pathway, and Mcl-1 in non-Hodgkin’s lymphoma and multiple myeloma cell lines [123].
Resveratrol has also cardiovascular protective effects, inhibits platelet aggregation, prevents LDL oxidation and is
vasorelaxant [124]. Resveratrol showed potential anti-ageing properties by activating sirtuin (SIRT1), a deacetylase
enzyme that regulates the activity of several transcriptional factors and enzymes responsive to aging [125].
6.1.2.6.6 Flavonoids
Flavonoids are natural compounds found in tea, fruit, vegetables, grains and soybeans. Flavonoids are important elements
in the management of several malignancies (breast, lung, stomach, colorectal cancer etc) and act by inhibiting the DNA
topoisomerase I and cyclooxygenase [126e128]. Flavopiridol, a plant derived semisynthetic ﬂavone that inhibits cyclindependent kinases, has proven anticancer activity in cancers of the esophagus and stomach [129]. Some notable ﬂavonoids
were presented in Fig. 6.8.

6.1.2.7 Other bioactive compounds with antioxidant and corresponding anticancer activities
Some bioactive compounds with antioxidant properties and a corresponding anticancer activities were enumerated
(Fig. 6.9).
6.1.2.7.1 Lycopene
In gastric and pancreatic malignancies, lycopene was shown to down-regulate Bcl-2 and Erk proteins, emerging as an
important natural product that can target and interact with the PI3K/Akt signaling pathway [135]. It also affects cell
proliferation, progression, invasion and metastasis by interacting with cellular signaling pathways, such as NF-kB and JNK
in colorectal cancer [136,137]. It is able to efﬁciently quench singlet oxygen, scavenge free radicals and up-regulate the
ARE (antioxidant response element)-dependent transcription of antioxidant enzymes under the control of Nrf2 transcription factor [138].
a) Chrysin is a 5,7-dihydroxyﬂavone found in propolis, honey, blue passion ﬂower and chamomile that exhibits antineoplastic effects on different cancer cell lines. This ﬂavone induces cell cycle arrest at G2/M phase, resulting in DNA
cleavage and apoptosis, increases ROS production and lipid peroxidation, suppresses the S6, AKT, PI3K, P90RSK
and P70S6K, proteins, stimulates MAPK, ERK1/2 and P38 proteins in prostate cancer cells and also induces apoptosis
in SW480 colorectal cancer [130,131].
b) Oroxylin A is a potential ﬂavone isolated from Scutellariae radix which down-regulates the expression of COX-2 and
iNOS genes, blocks NF-kB, inhibits the activation of LPS-induced NF-kB by blocking IkB degradation and increases
ROS generation. It is employed in the treatment of colorectal cancer [132].
c) Chalcone is an anticancer ﬂavonoid found in fruit and vegetables, which activates caspases 8, 9 and 12, up-regulates
the pro-apoptotic proteins expression (Bid, Bax and Bak proteins) and decreases anti-apoptotic Bcl-2 gene expression.
It has therapeutic promises in the therapy of colon, lung, breast, liver and prostate cancer [133].
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6.1.2.7.2 Andrographolide
Andrographolide is a diterpene lactone with many biological effects: antioxidant, anti-inﬂammatory, antibacterial,
immunomodulatory, cytotoxic, neuroprotective and hepatoprotective. It can also exert its effect on the cardiovascular
system, enhancing cardioprotection and lowering lipid values. Its source is a plant called Andrographis paniculata.
It exhibits cytotoxic/antineoplastic effects on a myriad of cellular models via apoptosis, necrosis, oxidative stress,
anti-angiogenic activity, autophagy etc. It has also anti-inﬂammatory properties and can modulate the immune system.
Andrographolide can arrest the cell cycle and inhibit the adhesion of cells, as well as proliferation, migration and invasion
of malignant cells. The properties of andrographolide have been used successfully in melanoma, prostate cancer, colorectal
cancer and oral squamous carcinoma. In multiple myeloma cells, andrographolide was proven to inhibit the proliferation of
myeloma cells [139].
6.1.2.7.3 Triterpenoid acids
These are phytomolecules with anticancer properties against leukemia, pancreatic and breast cancer. Betulinic acid,
isolated from Ziziphus mauritiana, Ziziphusrugosa, Ziziphus oenoplia and Betula Sp. (Betulaceae), has cytotoxic effects in
various malignancies [140].
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6.1.2.7.4 Capsaicin
Capsaicin is a natural phytochemical isolated from red pepper with anticancer, antimutagenic, antimetastatic,
antiangiogenic and chemopreventive effects in leukemia, liver, lung, pancreatic, prostatic, skin, bladder, colon, and
endothelial cells. Capsaicin induces apoptosis in breast cancer via ROS and Rac1 signaling pathways [141e143].
6.1.2.7.5 Cyanidin
Cyanidin is an organic substance that has antioxidant effects, acting as free radical scavenger. It is obtained by isolation
from several vegetables (red cabbage, red onion) or fruit (red berries, blackberry, cranberry, raspberry, grapes, plums,
apples). Its antineoplastic potential has been reported in several neoplasia of the prostate (induction of programmed cell
death), colon (COX-2 expression blockade), stomach (blocks the expressions of MMP-9, Jun N-terminal kinases,
Erk enzymes), lung and bladder (blocks the expression of MMP-9) [127].
6.1.2.7.6 Antioxidant vitamins and minerals
Antioxidant vitamins and minerals are capable of preventing cellular damage induced by ROS [144]. Vitamin E is an
antioxidant consisting of both tocotrienols and tocopherols found in sunﬂower oil, germ oil, safﬂower oils and wheat.
Its pro-apoptotic and anti-proliferative effects make vitamin E a promising antineoplastic agent [145]. Vitamin A interacts
with the immune system, potentiating the activity of T-helper lymphocytes without interacting with the activity of
T-suppressor lymphocytes [146]. Vitamin C has a stimulating effect on neutrophils, chemotaxis and on the immune
system. However, several trials that investigated the effect of beta-carotene and/or alpha-tocopherol or of a combination of
antioxidants and minerals (vitamin C, vitamin E, beta-carotene, selenium, zinc) reported no global effect on various
cancers (lymphoma, leukemia, lung, bladder, pancreas or colorectal cancer) [147e149].
Vitamin D is an antioxidant which contributes to the normal calcium metabolism and inhibits iron-dependent
liposomal lipid peroxidation [150]. It may be used in the prevention of several chronic disorders such as diabetes,
cardiovascular diseases and chronic kidney disease, since it regulates oxidative stress levels by inducing the expression of
several molecules involved in the antioxidant defense system (glutathione, glutathione peroxidase and superoxide
dismutase) and suppresses the expression of NADPH oxidase [151]. The properties of vitamin D are, however,
controversial, especially with regards to its inﬂuence on biomarkers of oxidative stress [152].

6.1.2.8 Mushroom proteins
Mushroom proteins with anticancer properties such as lectins, bolesatine, hemolysins, phallolysin, nebrodeolysin, laccases,
calcaelin and ribonucleases have been isolated from different species of mushrooms (Ganoderma carpense, Pleurotus
ostreatus, Pleurotus eryngii, Pleurotus nebrodensis, Amanita phalloides). In breast and lung cancer, polysaccharopeptide
signiﬁcantly interacted with key cells of the immune system (CD4þ/CD8þ/CD14þ/CD16, T-lymphocytes and
B-lymphocytes) and induced apoptosis and cell cycle arrest in malignant cells [153,154] (Fig. 6.10).

FIGURE 6.10 Crystal structure of the common edible mushroom (Agaricus bisporus) lectin. Reproduced from: Protein Data Bank; Deposited by
M.E. Carrizo, S. Capaldi, M. Perduca, F.J. Irazoqui, G.A. Nores, H.L. Monaco, The antineoplastic lectin of the common edible mushroom (Agaricus bisporus)
has two binding sites, each speciﬁc for a different conﬁguration at a single epimeric hydroxyl, J. Biol. Chem. 280 (2005) 10614e10623.
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6.1.3 Conclusion
However, the association of phytochemicals and classical chemotherapeutic agents remains controversial. The protective
effects of antioxidants might also be exploited by malignant cells to prevent the pro-oxidant properties of cytostatic drugs
and reduce ROS levels. Therefore, in this way, cancerous cells might escape the destructive effects of chemotherapy.
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7.1 Introduction
Cancer treatment is a highly expensive and complex procedure. The major challenges with the treatment of cancer are
chemoresistance and severe side effects of standard chemotherapeutic drugs [1,2]. Therefore, from last few decades, researchers started to evaluate the effect of two or more anticancer drugs at their lower doses for designing the combinatorial
therapeutic approaches for the cancer treatment. The main objective behind these combinatorial studies was to minimize
the side effects of the anticancer drugs and to enhance the antitumor efﬁcacy at lower doses.
Recently, phytochemicals have emerged as one of the essential components of combinatorial therapy and widely
accepted as a potent adjunct therapeutic drug because of their antitumor enhancing and chemosensitizing ability [3e5]. In
recent years, combinatorial therapies have gained a considerable attention in the ﬁeld of cancer research. Although the
antitumor potential of various phytochemicals is well-documented, the major problem with the phytochemicals is that most
of them are unable to show their antitumor activity at lower doses because of their rapid metabolism or low bioavailability
[6]. In recent years, several clinical trials of various combinations of phytochemicals and standard therapeutic drugs have
also been conducted to evaluate the adjunct therapeutic values of phytochemicals for designing the novel combinatorial
therapeutic protocols for the treatment of cancer patients. Interestingly, various studies showed the chemosensitizing and
antitumor potentiating actions of phytochemicals in cancer patients [7,8]. Therefore, phytochemicals have emerged as one of
the key components of combinatorial therapy. Some phytochemicals discussed in the next section were presented in Fig. 7.1.

7.1.1 Curcumin as an adjunct therapeutic agent
Curcumin (diferuloylmethane) is a bioactive dietary polyphenol isolated from curcuma longa, a traditional medicinal plant
of India and South Asia. A range of pharmacological values such as anti-infectious, antioxidant, anti-inﬂammatory, antidiabetic, and antiallergic have been observed for curcumin [9e13]. A potent antineoplastic nature of curcumin has also been
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FIGURE 7.1 Chemical structures of curcumin, resveratrol, epigallocatechin-3-gallate (EGCG), and nimbolide.

observed against the cancers of various origin, including bone cancer, cervical cancer, breast cancer, bladder cancer, colon
cancer, gastric cancer, liver cancer, lung cancer, esophageal cancer, ovarian cancer, pancreatic cancer, head and neck
cancer, prostate cancer, and skin cancer [14]. Moreover, evidences from several studies also suggest a powerful
chemosensitizing potential of curcumin. Anuchapreeda et al. ﬁrst reported the chemosensitizing activity of curcumin against
the multidrug-resistant human cervical carcinoma cells (KBeV1) for vinblastine [15]. Later on, the chemosensitizing action
of curcumin was also observed in various other cancers such as breast cancer, bone cancer, brain cancer, bladder cancer,
esophageal cancer, colon cancer, cervical cancer, gastric cancer, head and neck cancer, liver cancer, pancreatic cancer,
ovarian cancer, lung cancer, prostate cancer, and skin cancer [14]. Moreover, curcumin also effectively chemosensitizes
various hematological malignancies such as lymphoma, multiple myeloma, and leukemia [16e19]. The combinatorial
investigation on tamoxifen and curcumin in case of tamoxifen-resistant breast cancer cell lines, namely MCF-7/LCC2 and
MCF-7/LCC9, showed that curcumin sensitizes resistant breast cancer cell lines for tamoxifen by downregulating the
NF-kB and Akt/mTOR pathways [3]. Furthermore, Guo et al. used polycurcumin as a nanocarrier for chemotherapeutic
drugs to promote the codelivery and corelease of standard chemotherapeutic drugs along with chemosensitizer in the tumor
cells to maximize the combinatorial effect of chemotherapeutic drug and chemosensitizer [20]. In this study, they found that
targeted delivery of doxorubicin through polycurcumin nanocarrier signiﬁcantly enhanced the cytotoxic efﬁcacy of
doxorubicin against multidrug-resistant MCF-7/ADR breast cancer cells because of corelease of curcumin and doxorubicin
in the tumor cells at the same time. Again, they revealed that suppressed p-glycoprotein expression and ATP activity were
responsible for the chemosensitizing potential of curcumin [20]. Moreover, curcumin is also observed in sensitizing the
glioblastoma to temozolomide and human lung cancer cells to carboplatin [21,22]. The chemosensitizing action of
curcumin is also reported against colon cancer for silymarin [23]. This study showed that treatment of colon cancer cells
with curcumin and silymarin synergistically augmented the apoptosis through signiﬁcantly enhancing caspase-3/7 activity
in colon cancer cells as compared with untreated and silymarin-treated cells [23]. Apart from the chemosensitizing action,
curcumin has also been observed in boosting up the antitumor activity of standard anticancer drugs. A study on oral
adenosquamous carcinoma and head and neck squamous cell carcinoma indicated that the cotreatment of curcumin along
with cisplatin signiﬁcantly suppressed the tumor growth than the either one used alone [24]. In addition, few studies have
also reported differential antitumor activity of curcumin and anticancer drugs in different combinations. In liver cancer,
curcumin along with cisplatin synergistically killed the cancerous cells, whereas in combination with doxorubicin it showed
only additive effect possibly because of altered expression of Bcl-xl, c-myc, XIAP, c-IAP-2, and NAIP genes [25].
Several clinical trials have also been conducted to validate the adjunct therapeutic potential of curcumin in
combinatorial therapy. In a study, James et al. showed that cotreatment of curcumin along with 5-ﬂuorouracil (5FU) and
oxaliplatin to patient-derived colorectal liver metastases cancer stem cell models (CRLM CSC models) signiﬁcantly
inhibited the number of cancer stem cell phenotypes [26]. However, they further suggested that doses of curcumin up to
2 gms daily is safe and well-tolerable when administered together with 5FU and oxaliplatin to patients with CRLM [25].
Moreover, a clinical trial by Mahammedi et al. showed the tolerability and acceptability of curcumin dose at which it
shows its maximum response in combinatorial treatment along with docetaxel and prednisone [7]. In addition, a dose of
curcumin (8 g/day) at which it shows maximum tolerability was determined in combinational therapy along with
docetaxel in patients with advanced and metastatic breast cancer [27]. In an investigation, Epelbaum et al. tried to
determine the effective dose of curcumin in combinatorial treatment with gemcitabine to patients with advanced
pancreatic cancer, and interestingly they found that the higher dose of curcumin can be reduced during the combinatorial
therapy to minimize the side effects [28].
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7.1.1.1 Mechanisms behind the adjunct therapeutic potential of curcumin
Various in vitro and in vivo studies suggest that curcumin mediates its chemosensitizing potential via altering the function
of NF-kB, a crucial transcription factor having a role in the regulation of proliferation, survival, and apoptosis [14].
Interestingly, curcumin is identiﬁed as a potent NF-kB blocker. A study on chronic myeloid leukemia cells (KBM-5)
showed that curcumin suppresses the activation of NF-kB in TNF-aedependent manner [29]. Additionally, curcumin also
modulates the expression of various others molecules such as STAT3, ERK, EGFR, TGF-b, PI3K/Akt, JNK, p38, MAPK,
Wnt, Nrf2, IGF-1R, c-src, IFN-a, EROD, FA/BRCA, ERCC1, FANCD2, HSP27, HSP70, GSK3, ATM, chk2, H2AXA,
DDR, ATF4, TRIB3, and miR34a along with some cancer stem cellespeciﬁc markers such as CD133, CD44, CD166, and
ALDH [14]. Curcumin has also been reported in directly targeting the drug transporter proteins. Several reports indicate
that multidrug resistance protein such as multidrug resistanceeassociated protein (MRP1) and p-glycoprotein (MDR1)
play a key role in providing the chemoresistant nature of cancerous cell via exporting anticancer drugs outside of the cell
[30]. Also, curcumin has been reported in the suppression of p-glycoprotein expression at transcriptional and translational
level in multidrug resistant (MDR) cervical carcinoma cells [31]. Likewise, the chemosensitizing action of curcumin has
also been observed because of inhibition of p-glycoprotein in other MDR-associated cancer cells, namely human MDR
gastric cancer, human MDR colon cancer, and mouse MDR leukemia cancer [31]. Moreover, curcumin also abrogates the
expression of multidrug-resistance protein 1 (MRP1). A study on human cervix cancer cell line (SiHa) indicates that
curcumin downregulated the expression of MRP1 in curcumin-treated SiHa cells and sensitizes cancerous cell toward the
cisplatin [32]. A combinational investigation of curcumin and doxorubicin on breast cancer cell line (MCF-7) showed an
elevated cytotoxicity in synergistic manner via retarding the activity of human epidermal growth factor and activation of
NF-kB [33]. Moreover, curcumin also enhanced the antitumor potential of docetaxel against the anaplastic thyroid cancer
by suppressing the docetaxel-mediated COX-2 expression and p65 activation [34]. In addition, cotreatment of gastric
cancer cells with 5FU and cisplatin in association with curcumin showed synergistic effect on the antitumor activity of 5FU
and cisplatin via inducing apoptotic pathway [35].
Therefore, we can conclude that curcumin could be a potent phytochemical which can be used as an effective adjunct
therapeutic drug in combinatorial therapy to overcome the chemoresistant property of cancerous cells.

7.1.2 Role of resveratrol in combinatorial cancer therapy
Resveratrol (3,5,40 -trihydroxystilbene) is a phytochemical, mainly found in spermatophytes such as grapes, berries,
blueberries, and pines. It is synthesized by these plants during different stressful conditions such as UV light, climate
change, and pathogen attack. Resveratrol controls various pathological conditions through its antimicrobial, chemopreventive, anti-inﬂammatory, and antioxidant properties [36e38]. Furthermore, extensive research on the resveratrol
revealed its potent role in several diseases such as heart disease, neurological disorders, metabolic disorders, and
degenerative conditions [4]. In addition, several reports have shown the antitumor potential of resveratrol against different
cancers such as prostate cancer, skin cancer, breast cancer, bladder cancer, and lung cancer through altering various cellular
processes including proliferation and apoptosis via modulating PI3K/Akt and MAPKs signaling pathways [4,38].
Resveratrol also helps in the reactivation of suppressed immune cells including those having a crucial role in the antitumor
response such as natural killer cells and T cells [39,40].
Most of the malignant tumors are highly aggressive and show unresponsiveness towards several standard chemotherapeutic drugs. Emerging evidence has shown that resveratrol not only shows the anticancer properties but also reverses
the drug resistance in a variety of tumor cells by sensitizing them to conventional chemotherapeutic agents [41]. However,
one of the major drawbacks of resveratrol is its inability to kill cancer cells at the lower concentrations because of its rapid
metabolism into glucuronide and sulfate metabolites [6,42]. Therefore, the use of resveratrol in combinatorial therapy is
highly encouraged. Hence, in recent years, various studies are conducted to validate the adjunct therapeutic potential of
resveratrol to design the combinatorial therapeutic strategies for the treatment of cancer.

7.1.2.1 Molecular mechanisms associated with adjunct therapeutic activity of resveratrol
A large number of studies have been done to evaluate the chemopreventive and chemotherapeutic potential of resveratrol
against cancer. Moreover, various studies have also shown the ability of resveratrol in enhancing the therapeutic efﬁcacy of
standard anticancer drugs in combinatorial cancer therapy. Hu et al. showed the synergistic effect of cisplatin and
resveratrol cotreatment on lung cancer cell [43]. They showed that cisplatin and resveratrol cotreatment synergistically
augmented the tumor cell death by inducing the apoptosis via modulating autophagy in A549 cells. Several studies have
reported that alterations in PI3K/Akt/mTOR, mitogen-activated protein kinases (MAPKs), and apoptotic pathways are
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majorly responsible for the cisplatin resistance in tumor cells [44e47]. Interestingly, resveratrol has been observed in the
inhibition of PI3K/Akt/mTOR signaling pathway through blocking the phosphorylation of Akt, a key regulatory pathway
for survival, progression, and chemoresistance [48,49]. In an investigation, Kala et al. reported the role of resveratrol in
enhancing the antitumor activity of pterostilbene against triple-negative breast cancer cells through inducing the apoptosis
as compared with resveratrol or pterostilbene alone. They found an indispensable role of suppressed expression of SIRT1,
an enzyme of class III histone deacetylase involved in the modiﬁcation of histones and nonhistone proteins through
deacetylation [50]. SIRT1 regulates cell growth, apoptosis, stress response, adaptation to calorie restriction, metabolism,
cellular senescence, and tumorigenesis via the process of deacetylation [51]. Another study by Kala et al. also demonstrated that cotreatment of resveratrol and pterostilbene to ER-negative (estrogen receptor-a) breast cancer cells reactivated
ERa expression via modulation of histone acetylation [52]. Estrogen receptor-a (ERa)-negative breast cancer cells do not
respond to conventional hormone-directed therapies such as tamoxifen; therefore, the reactivation of ERa by combinatorial
treatment may help in chemosensitizing the ERa-negative breast cancer cells toward tamoxifen. Similarly, a study by
Majumdar et al. showed the beneﬁcial impact of combinatorial treatment of resveratrol along with another popular
phytochemical curcumin [53]. In this investigation, they observed a synergistic effect of resveratrol and curcumin treatment
on the inhibition of tumor survival due to high rate of apoptosis of colon cancer cells than resveratrol or curcumin
alone [53]. The degree of synergism was greater with concentrations of curcumin and resveratrol below 20 mM.
Curcumin and resveratrol cotreatment also inhibited the constitutive activation of EGFRs and IGF-1R. Furthermore,
co-administration of curcumin and resveratrol also synergistically inhibited the tumor growth in in vivo mice model as
compared with curcumin or resveratrol alone. The group also showed that combination of curcumin and resveratrol
treatment signiﬁcantly decreased the DNA binding afﬁnity of NF-kB as compare with either curcumin or resveratrol [53].
Additionally, in recent years, several combinatorial studies are conducted against various cancers such as colorectal cancer,
prostate cancer, and breast cancer [54e56]. Furthermore, Lee et al. showed that cotreatment of resveratrol and cisplatin
synergistically affected the chemoresistance nature of malignant mesothelioma cells through inducing apoptosis and cell
cycle arrest via increasing the expression of p53, bax/Bcl-2 ratio, and ROS generation [57].
In addition, few clinical trials have also validated the antitumor potential of resveratrol. Most of the trials have been
conducted to show its bioavailability, pharmacokinetics, and efﬁcacy. However, no clinical trials have been conducted to
evaluate the adjunct therapeutic potential of resveratrol in combination therapy [8,58e61]. But in vitro and in vivo studies
provide strong evidences to conduct clinical trials on resveratrol in combination with standard chemotherapeutic drugs.

7.1.3 Adjunct therapeutic potential of nimbolide
Nimbolide is a phytochemical isolated from leaves and ﬂower of plant Azadirachta indica commonly known as neem. It
has shown various effective medicinal values including antibacterial, antimalarial, antifeedant, antioxidant, and antiinﬂammatory [62,63]. Moreover, antineoplastic action of nimbolide has also been observed against various cancers,
including human hepatocarcinoma, colon cancer, breast cancer, neuroblastoma, osteosarcoma, and choriocarcinoma cells
[64e67]. Another study suggests a vital role of nimbolide-induced cell cycle arrest and apoptosis in the inhibition of tumor
survival [68]. In addition, reports also suggest the adjunct therapeutic potential of nimbolide. A study on leukemia cell line
KBM-5 showed a signiﬁcant role of nimbolide in enhancing the antitumor activity of 5FU and thalidomide [69].
However, till date, no clinical trials have been undertaken to evaluate the efﬁcacy, bioavailability, and toxicities of
nimbolide either in alone or in combination with other standard chemotherapeutic drugs.

7.1.3.1 Molecular crosstalk in nimbolide-mediated combinatorial cancer treatment
Like curcumin, nimbolide is also a potent phytochemical which inhibits NF-kB [69,70]. NF-kB plays a central role in
supporting the crucial phenomenons, including proliferation, survival, angiogenesis, and chemoresistivity to cancerous
cells [14]. NF-kBemediated chemoresistance is achieved by alteration in the tumor microenvironment and induction of
antiapoptotic proteins [71]. A study on colon cancer suggested that nimbolide abrogates the activity of NF-kB via
interfering the translocation of p50/p65 in nucleus and its binding to the DNA [68]. Moreover, nimbolide also inhibits the
activity of NF-kB by inactivating IkB kinase, an enzyme involved in the activation of NF-kB by removing the NF-kB
inhibitory factor, IkB [72,73]. Additionally, a study showed an elevated level of PTEN and reduced level of HIF-1a in
nimbolide-treated cancer cells [74]. Several reports suggest an indispensable role of PI3K/Akt/mTOR pathway in
providing the chemoresistant property of neoplastic cells via elevating the level of p-glycoprotein [75]. More so, an
upregulated expression of HIF-1a is observed in various cancers, which has been observed in promoting the activation of
the PI3K/Akt/mTOR and suppression of PTEN expression [76e78]. Therefore, nimbolide-mediated chemosensitization
might be dependent on modulated expressions of HIF-1a and PTEN.
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7.1.4 Epigallocatechin-3-gallate in combinatorial cancer therapy
The crucial bioactive constituents of green tea leaves are catechins, polyphenolic ﬂavonoid-type compounds, which
constitute 25%e35% of their dry weight. Epigallocatechin-3-gallate (EGCG) is a type of catechin isolated from green tea
leaves. Various researches have established the anticancer, anti-inﬂammatory, antidiabetic, and antiobesity effects of EGCG
[79,80]. EGCG has also showed beneﬁcial effects on diseases such as Alzheimer’s disease and Parkinson’s disease [81,82].
Like other phytochemicals, EGCG has also been tested as adjunct therapeutic drug against various cancers and showed
chemosensitizing potential and antitumor potentiating activity for various anticancer drugs such as cisplatin, docetaxel,
doxorubicin, and gemcitabine [83e85]. However, till date, no clinical trials have been conducted to evaluate the adjunct
therapeutic potential of EGCG in combination of standard anticancer drugs. However, reports suggest that few clinical
trials are conducted to measure the effectiveness, feasibility, and safety of EGCG [86,87].

7.1.4.1 Mechanisms behind the adjunct therapeutic potential of EGCG
Various studies have demonstrated that the adjunct therapeutic potential of EGCG is because of its ability to modulate
apoptosis and angiogenesis [88].
Evasion of apoptosis is one of the key hallmarks of cancer cells. It has been observed in several studies that EGCG
induces the apoptotic potential of standard anticancer drugs via modulating the apoptotic and antiapoptotic proteins. In
breast cancer, combination of EGCG and 5FU resulted into increased expression of proapoptotic protein Bax, cleaved
caspase-3, cleaved caspase-9, and cleaved poly (ADP-ribose) polymerase (PARP) with decreased expression of
antiapoptotic protein Bcl-2 [5]. In prostate cancer, combinatorial treatment of EGCG with taxane (i.e., paclitaxel and
docetaxel) induced the expression of apoptotic genes such as p53, p73, p21, and caspase-3. The increased expression of
these genes enhances the tumor cell killing ability of taxane via augmenting the apoptosis of tumor cells [84]. Moreover,
EGCG has also been reported in enhancing the therapeutic potential of various other anticancer drugs such as gemcitabine,
mitomycin C, 5FU, vorinostat, and JAK3 inhibitor CP690550 (tasocitinib) via inducing the apoptotic pathways in
cholangiocarcinoma, melanoma, and pancreatic cancer cells [89e92].
Additionally, various studies also showed the tumor growth inhibitory potential of EGCG in combinatorial treatment
via suppressing the process of angiogenesis. In gastric cancer, EGCG has reported in the suppression of angiogenesis via
potentiating the antiangiogenic effect of capecitabine and docetaxel [88]. In this study, authors observed a declined level of
vascular endothelial growth factor (VEGF) after cotreatment of EGCG with capecitabine and docetaxel [85,88].
In cholangiocarcinoma, EGCG also showed the antiangiogenic activity via downregulating the expression of VEGF, and
therefore, cotreatment of EGCG and vorinostat synergistically inhibited the angiogenic potential of tumor cells [89].
Furthermore, combined treatment of EGCG with vincristine also showed similar effect in multidrug-resistant oral
squamous cell carcinoma model [93].

7.1.5 Role of genistein in combinatorial treatment to cancer and associated mechanisms
Genistein is isoﬂavone, a class of ﬂavonoid abundantly found in soya products, and shows a potent anticancer activity
against various cancers. Scientiﬁc reports suggest that genistein inhibits tumor growth via modulating the expression of cell
cycle and apoptosis regulatory molecules [94]. Moreover, it has been observed that genistein also inhibits NF-kB and Akt
signaling pathways, which play a key role in providing the metastatic and proliferative nature to cancer cells [95,96].
Recently, genistein has also been identiﬁed as an adjunct therapeutic drug in combinatorial cancer therapy. Supportive
evidence from various studies have shown the antitumor potentiating activity of genistein via augmenting the apoptotic cell
death caused by cisplatin, doxorubicin, erlotinib, gemcitabine, docetaxel, and CHOP in a synergistic manner on cancers of
prostate, breast, pancreas lung, and lymphoma [83,94,96,97]. In a study, Banerjee and his colleagues observed that genistein
enhanced the antitumor activities of gemcitabine and docetaxel through inducing the apoptosis of tumor cells [94]. Also, the
synergistic result was also observed when genistein was used in combination with 5FU and tamoxifen [98]. A role of genisteinmodulated AMPK and COX-2 signaling pathways has been observed in inducing the apoptosis of chemoresistant cancerous
cells [99]. Similarly, cotreatment of tamoxifen and genistein also inhibited the growth of ERþ/HER2-overexpressing human
breast cancer cells [100]. Furthermore, genistein also synergistically inhibited the survival of leukemic cells (HL-60) when
cells were incubated with bleomycin [101]. Additionally, apoptotic and antiproliferative activities of cisplatin were signiﬁcantly increased when medulloblastoma cells were cotreated with genistein and cisplatin [83]. Genistein-mediated NF-kB
inhibition was also observed when combined with docetaxel, cisplatin, gemcitabine, and radiation therapy against breast,
prostate, lung, pancreatic cancer, and lymphoma [96,102e104]. The overexpression of NF-kB was reported in various cancers
subjected to chemotherapeutic drug treatment such as gemcitabine and docetaxel [105].
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Only few clinical trials of genistein are conducted to estimate its efﬁcacy and safety but still no clinical trial has been
conducted to validate the adjunct therapeutic potential of genistein in combinatorial treatment.

7.1.6 Conclusion and future prospective
Phytochemicals have emerged as one of the important components of combinatorial therapy because of their chemosensitizing potential, antitumor potentiating activity, and ability to minimize the side effects of standard chemotherapeutic
drugs. However, adjunct therapeutic potential of many phytochemicals are not yet validated on cancer patients. Therefore,
clinical trials are needed to determine the adjunct therapeutic values of phytochemicals in combinatorial therapy for
designing the novel combinatorial therapeutic strategies for the treatment of cancer patients.
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8.1 Introduction
Diabetes remains a serious public health problem afﬂicting about 422 million people worldwide with a global prevalence
rate of about 8.5% as of 2014 [1]. The International Diabetes Federation reported a consistently increasing trend in the past
17 years, ranging from 151 million patients in the year 2000 to a staggering 425 million in 2017 and a projection of 629
million sufferers by the year 2045 [2]. The economic implications of this trend are so huge that it demands immediate
concern and attention. Efforts are on the rise in the quest for new drugs to treat and control diabetes. New molecular targets
have been discovered to signiﬁcantly increase effectiveness and decrease toxicity of the drugs.
Diabetes is a complex metabolic disease characterized by abnormal glycemic control resulting from the body’s inability
to secrete or utilize insulin that may result from several biochemical processes. A typical feature of this metabolic condition
is hyperglycemia, although protein and fat metabolisms are also adversely affected. Disturbance in the metabolism of
carbohydrates, lipids, and proteins associated with long-standing hyperglycemia may result in different metabolic problems, including nonenzymatic glycation of proteins, generation of reactive oxygen species, and peroxidation of membrane
lipids, which in turn lead to macro- and microvascular disorders in different organs such as the eyes, kidneys, brain, and
heart. Complications of chronic, uncontrolled hyperglycemia include macroangiopathic alterations leading to atherosclerosis and subsequent ischemia or infarction and microangiopathic changes, which can result in nephropathy, retinopathy,
neuropathy, and dermopathy [3e6].
Diabetes mellitus is divided into two main categories: type 1 diabetes mellitus (T1DM) formerly known as insulindependent diabetes mellitus and type 2 diabetes mellitus (T2DM) previously regarded as noneinsulin-dependent diabetes mellitus. T2DM accounts for 90%e95% cases of diabetes mellitus. Its etiology is multifactorial, although genetic
predisposition is a principal factor [7].
The increase in diabetic patient population worldwide has attracted a high degree of interest from the research community in an effort to ﬁnd agents for the control and management of this challenging disease. Until now, total cure is not
yet possible, but management is geared toward good glucose control and prevention of macro- and microvascular complications in the different organs. Numerous synthetic antidiabetics have been developed for the treatment of diabetes
mellitus, but safety concerns on toxicity of long-term usage have continually favored more research on natural compounds
with antidiabetic activity [7].
Research has shown that several phytochemicals have antidiabetic activity. The World Health Organization (WHO)
recommends the evaluation of phytochemicals for the treatment of diabetes because they are effective and the reported side
effects are less compared with the synthetic ones. Over the last few decades, many phytochemicals that have shown
antidiabetic potential properties have been isolated and characterized. Major phytochemical classes reported include alkaloids, glycosides, ﬂavonoids, saponins, dietary ﬁbers, polysaccharides, glycolipids, peptidoglycans, and amino acids.
Furthermore, plants with the potentials for the treatment of diabetes can be drawn as drug candidates for isolation of new
hypoglycemic compounds [8]. Some antidiabetics currently used have been transformed from drugs obtained and used in
crude forms from plants to synthetic products with base structures derived from natural sources. Knowledge of these
natural compounds can greatly contribute to the success in diabetic management today and in the future.
In this chapter, we present the currently studied natural productederived lead compounds for diabetes management. We
also review the classes of antidiabetic drugs in the market and those in the pipeline.

8.2 Molecular targets of antidiabetic drugs
Antidiabetics aim to achieve normoglycemia, alleviate diabetic symptoms, and slow down the progression of associated
long-term complications. The management of diabetes generally falls into categories addressing the “ominous octet” that
results in hyperglycemia, namely (1) decreased insulin secretion from pancreatic b-cells, (2) increased secretion of
glucagon from pancreatic a-cells, (3) increased glucose production in the liver, (4) insulin resistance and neurotransmitter
dysfunction in the brain, (5) enhanced lipolysis, (6) increased glucose reabsorption in the kidneys, (7) reduced incretin
effect in the small intestine, and (8) impaired glucose uptake in the peripheral tissues. Current antidiabetic management
addresses one or more of these important key pathways [9]. Several molecular targets and pathways have been identiﬁed
(Table 8.1), and several more are still being studied and undergoing clinical trials. The details of the mechanism of action
of the antidiabetic drug classes are discussed in Sectiovn 8.4.

8.3 Phytochemicals in diabetes management
Metabolic changes, suppression of sensitivity, and signiﬁcant mechanism-based side effects are concerns using synthetic
antidiabetic agents. The search for effective and safe hypoglycemic agents will continue to be an important area of
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TABLE 8.1 Diabetes dysfunctions, drug classes, and their molecular targets.
Diabetes dysfunctions

Drug classes used for treatment

Molecular target

Decreased insulin secretion from
pancreatic b-cells

Sulfonylureas
Amylin analogs

GPR120, GPR1119, PTB1B, amylin

Increased secretion of glucagon from
pancreatic a-cells

Amylin analogs

GPR119, amylin

Increased glucose production in the liver

Nonsulfonylureas/biguanides

Mitochondrial respiratory chain
complex 1

Insulin resistance and neurotransmitter
dysfunction in the brain

Nonsulfonylureas/biguanides

NFKB pathway

Enhanced lipolysis

Antioxidants

NF-KB pathway, JNK/SAPK pathway,
P38 MAPK pathway

Increased glucose reabsorption in
the kidneys

SGLT2 inhibitors

SGLT2

Reduced incretin effect in the small intestine

Incretin mimetics
DPP4 inhibitors

GLP-1, DPP4

Impaired glucose uptake in the peripheral
tissues

Thiazolidinediones
Nonsulfonylureas/biguanides

PPAR-g, GLUT4, a-glucosidase, GKA

investigation. Herbal remedies are used all over the world for the management of diabetes because of factors such as cost
and safety. Most of these herbal remedies have not been fully scientiﬁcally assessed. Major concerns are possible toxicities
and drugedrug interactions.
However, some characterized phytochemicals have been reported to elicit same hypoglycemic responses as the conventional agents via similar mechanisms [7,10,11]. Many phytochemicals have the ability to regulate the expression of
drug-metabolizing enzymes and drug transporters through cascade activation of several nuclear receptors and binding to
the responsive elements within those genes [12].
The clinical and pharmacological experiments of medicinal plants have indicated antidiabetic effects, as well as
rehabilitation of b-cells of islet of Langerhans. The Kingdom Plantae has become a main target for the ﬁnding of lead
compounds [13]. Discovery of lead compounds from natural sources entails isolating the plethora of compounds from
the real extract to ﬁnd a unique compound [14]. Several neolignans and lignans act as lead compounds for the generation
of new drugs [15]. Restriction of a-glucosidase and a-amylase, improvement in mechanisms by peroxisome proliferatoractivated receptor, effect on uptake of glucose level and transporters of glucose, restriction of the activity of protein
tyrosine phosphatase 1B, and depletion of oxidative stress are some mechanisms in which the naturally formed products
are involved [16]. Various ﬂavonoids were also indicated to act on biological targets related to T2DM, such as
a-glycosidase, aldose reductase, and glucose cotransporter [17]. Table 8.2 summarizes what is known about the
antidiabetic compounds from natural products. Selected antidiabetic compounds are also discussed in the following
section.

8.3.1 Phytochemicals from Lagerstroemia speciosa
The leaves of Lagerstroemia speciosa (Lythraceae), a Southeast Asian tree more often known as banaba, contain some
bioactive contents known to exert antidiabetic and antiadipogenesis activity. Some molecules present were highlighted.
l

l

l

Tannin molecules (ellagitannin Lagerstroemin) are accountable for insulin-like glucose transport stimulatory property
of banaba extract.
Gallotannins like penta-O-galloyl-glucopyranose (PGG) arise to be stronger and more effective than ellagitannins like
Lagerstroemin in insulin receptor binding.
PGG, a gallotannin that has greater glucose transport stimulatory characteristic than Lagerstroemin, exerts antiadipogenic features to elicit the uptake of glucose in adipocytes [33].

Lead compound

Plant source

Mechanism of action

References

Acarbose

Natural microbial product derived from cultures of
Actinoplanes sp. SE50/110

Structures

Potent inhibitors of digestive enzymes,
such as a-amylase, a-glucosidase, sucrase,
and maltase

[18]

Andrographolide

Leaves of Andrographis paniculata (Burm. f.), Swertia
pseudochinensis

Increases glucose utilization to lower
plasma glucose in diabetic rats lacking
insulin

[19,20]

Allicin

Green garlic plant extract, Allium sativum L. Family
Liliaceae, Allium hirtifolium (shallot)

May act as a vasodilator by hyperpolarizing
the membrane of normal vascular smooth
muscle cells, SUR2 opener

[21e23]

Berberine

Hydrastis canadensis (goldenseal), Coptis chinensis
(Coptis or goldthread), Berberis aquifolium (Oregon
grape), Berberis vulgaris (barberry), and Berberis aristata (tree turmeric)

AMPK activator, insulin-independent hypoglycemic effect due to inhibition of mitochondrial function, stimulation of
glycolysis and activation of AMPK pathway,
may also act as an a-glucosidase inhibitor,
cholesterol-lowering, anti-arrhythmias and
nitric oxide (NO) inducing properties, regulation of glucose and lipid homeostasis,
cancer growth and inflammation

[24e26]

Catechin

Apples, blueberries, gooseberries, grape seeds, kiwi,
strawberries, green tea extract, Camellia sinensis
plant, Withania somnifera roots

Modification of oxidative stress, stimulates
the glucose uptake by accompanying the
translocation of GLUT4 in normal and insulin resistant muscle cells, stimulates the
transcriptional activation of PPAR-g, and
enhances adiponectin expression, inhibition of DPP4

[27e32]

Ellagitannin
Lagerstroemin

Lagerstroemia speciosa (Lythraceae) banaba extract

Insulin-like glucose transport

[33]

Ferulic acid

Rice bran, tomatoes, sweet corn

Scavenger of free radical (superoxide
anion) and inhibits lipid peroxidation

[34]
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L. speciosa (Lythraceae)

Insulin receptor (IR) binding

[33]

Genistein

Legumes such as soybeans

Enhances the glucose and lipid metabolism
and may reduce glucose toxicity induced
cardiac mechanical dysfunction

[35]

Kaempferol

Equisetum spp., Sophora japonica, and Ginkgo biloba,
and edible plants, including beans, broccoli, cabbage,
gooseberries, grapes, kale, strawberries, tea, and
tomatoes

Promotes glucose metabolism in skeletal
muscle, inhibits gluconeogenesis in the
liver

[36e38]

Karanjin

Pongamia pinnata fruits

Downregulate the IR cascade

[39]

Lepidine

Seeds of Lepidium sativum (garden cress)

Reduces oxidative damage and modulates
antioxidant enzymes, potentiates pancreatic secretion of insulin from the remaining
islet cells

[7,40]

Naringenin

Citrus flavonoid grapefruit, oranges, and tomato

GLUT-4
Stimulated glucose uptake, increased
AMPK phosphorylation/activation.

[41]

Penta-O-galloylglucopyranose

L. speciosa (Lythraceae)

Antiadipogenic

[33]

Pongamol

P. pinnata fruits

Downregulate the IR cascade

[39]
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Continued

Lead compound

Plant source

Mechanism of action

References

Quercetin

Onions, grapes, berries, cherries, broccoli, and citrus
fruits

Structures

Inhibits intestinal glucose absorption, with
insulin secretory and insulin-sensitizing activities, improved glucose utilization in peripheral tissues, increases the secretion of
insulin and regeneration of b-cells in the
pancreas

[42e44]

Rosmarinic acid

Herbs such as perilla, rosemary, sage, mint, basil

Inhibits sugar digestive enzymes, protective
action toward pancreatic b-cell dysfunction
glucolipotoxicity mediated oxidative stress

[45,46]

Tecomine

Tecoma stans (Bignoniaceae)

Stimulates glucose uptake in insulinsensitive and insulin-resistant murine and
human adipocytes; no significant proadipogenic or antiadipogenic side effects

[47,48]

Reduces diabetic auditory neuropathy and
platelet aggregation, affects cell regeneration, insulin secretion, activities of enzymes related to glucose metabolism,
reactive oxygen species, axonal extension,
and neuron excitability

[49,50]

Stimulates glucose-dependent insulin secretion by a direct effect on pancreatic islets,
activates IR substrate-associated phosphoinositide 3 (PI3) kinase activity in muscle
and liver, decreases plasma triglyceride
and total cholesterol levels, increases Akt
phosphorylation and reduces activation of
JNK 1/2, ERK 1/2, p38 MAPK, NFkB

[51,52]

CH3

O

N
H 3C

Trigonelline

Trigonella foenum-graecum, Allium sepapea, Coffea
sp., Pisum sativum, Glycine max, and Lycopersicon
esculentum

4-Hydroxyisoleucine

Seed of Trigonella foenum-graecum

H

CH3

OH
H 3C

CH3
NH2

H
H

OH
O
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FIGURE 8.1 Structures of karanjin and pongamol.

8.3.2 Karanjin and pongamol
Karanjin and pongamol (Fig 8.1) are derived from Pongamia pinnata fruits as lead compounds with antihyperglycemic
effects. These compounds are capable of inhibiting protein tyrosine phosphatases (PTPase) accountable for dephosphorylation of tyrosine residues, through impairing the tyrosine kinase action, a major step in signal transduction pathways.
Thus, PTPase inhibitors raise insulin sensitivity by obstructing the PTPase-mediated negative insulin signaling pathway
and may be an interesting target in T2DM and associated complications [39].

8.3.3 Acarbose
Acarbose, a pseudo-tetrasaccharide, is a natural microbial product derived from cultures of Actinoplanes strain SE 50,
which possesses nitrogen between the ﬁrst and second glucose molecule and have a structure similar to oligosaccharide.
This modiﬁcation bestows acarbose with particularly high afﬁnity for the a-glucosidase enzyme. The inability of the
digestive enzymes to hydrolyze acarbose is because of the presence of an imino bridge, which is considered to be the key
factor for its inhibitory effect [18]. Actinoplanes sp. SE50/110 is a natural producer of the a-glucosidase inhibitor (AGI)
acarbose, a bacterial secondary metabolite that is used as a drug for the treatment of T2DM [53]. Acarbose can be taken by
T1DM and T2DM in addition with insulin [54].

8.3.4 Rosmarinic acid
Rosmarinic acid (RA) is an acid ester of caffeic acid and 3(3,4-dihydroxyphenyl)lactic acid (also known as danshensu).
The presence of this phytochemical is reported in herbs of the family Lamiaceae. They include rosemary (Rosmarinus
ofﬁcinalis), lemon balm (Melissa ofﬁcinalis), oregano (Origanum vulgare), sage (Salvia ofﬁcinalis), and thyme (Thymus
sp.). These plants are remarkable for their food ﬂavoring properties and medicinal uses.
Waring [55] reported that RA has the ability of improving insulin sensitivity with some potentials to lower plasma lipid
levels. It is a bioactive phytochemical that can be originated in numerous herbs as ethnomedicines. The inhibitory activity
of RA versus sugar digestive enzymes and protective activity regarding b-cell dysfunction as well as glucolipotoxicity
mediated oxidative stress. Former studies have demonstrated the powerful role of RA for control of plasma glucose level
and upgrade insulin sensitivity in hyperglycemia [45].

8.3.5 Naringenin
The ﬂavonoid, naringenin, found in grapefruit is known to protect the cells of the body against the destructive effects of
free radicals capable of causing cancer because of its antioxidant properties. It has also been reported to possess antiatherogenic and antidiabetic properties. Structurally, naringenin is similar to resveratrol with the ability of activating SIRT1
protein deacetylase [46]. Naringenin depicts its antidiabetic effects by the inhibition of gluconeogenesis through upregulation of adenosine monophosphateeactivated protein kinase, thereby exerting metformin-like effects [34].

8.3.6 Ferulic acid
Ferulic acid (FA) (4-hydroxy-3-methoxycinnamic acid) is a derivative of curcumin [13]. FA is a phytochemical often found
in vegetables and fruits such as rice bran, tomatoes, and sweet corn. Ferulic acid is a phenolic compound and is a powerful
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membrane antioxidant which is known to beneﬁcially affect the human health. Ferulic acid is an effectual scavenger of free
radical, and it efﬁciently scavenges the superoxide anion radical with inhibition of lipid peroxidation [34].

8.4 Classes of antidiabetic drugs currently used
Antidiabetic drugs are categorized based on their mechanisms of action. Some of these classes are discussed in following
section. These are expected to be the new-generation therapy for diabetic management, including AGIs, incretin mimetics
receptor agonists, DPP4 inhibitors, and SGLT2 inhibitors. Combination therapies usually with metformin are currently
approved to manage cases in which monotherapy is ineffective [53,54]. Some recently approved antidiabetic drugs in
clinical usage are presented in Table 8.3.

8.4.1 Alpha-glucosidase inhibitors
AGIs are unique antidiabetics derived from bacteria, and their mechanism of action is independent of pancreatic activity.
a-Glucosidase is a catabolic enzyme responsible for breaking down carbohydrates to the monosaccharide unit glucose
before absorption. As impaired cellular uptake of glucose is a characteristic feature of diabetes, slowing down a-glucosidase activity is beneﬁcial. The binding of the inhibitors to the enzyme is competitive and reversible.
The resulting slow digestion of carbohydrates delays glucose release and absorption minimizing glucose concentration
surge associated with a carbohydrate meal. Inhibitors including acarbose, voglibose, and miglitol (Fig. 8.2) have been
clinically applied to inhibit a-glucosidase. They are administered orally and they considerably reduce the formation of
advanced glycation end products that are associated with T2DM [55e57].

TABLE 8.3 Recently FDA-approved antidiabetic agents.
Generic name
(brand name)

Year of
initial FDA
approval

Class

Mechanism of action

Indication

Routes of
administration

Dipeptidyl
peptidase-4
(DPP-4) inhibitor
(Gliptins)

Intensify the effect of intestinal
hormones (incretins) by blocking DPP-4, stimulate production of insulin and reduce
glucagon

Linagliptin, saxagliptin,
sitagliptin, alogliptin

T2DM

Oral

2006

GLP-1 receptor agonists

Mimic the effect of certain intestinal hormones (incretins)
involved in the control of
blood sugar

Semaglutide (OZEMPICÒ),
Liraglutide (VICTOZAÒ),
dulaglutide (TRULICITY),
lixisenatide (ADLYXIN)

T2DM

Subcutaneous

2010

SGLT-2
inhibitors

Help eliminate glucose in the
urine

Ertugliflozin
(STEGLATROÔ )
Empagliflozin (JARDIANCEÒ)

T2DM

Oral

2014

Inhaled
insulin

Stimulates cells in the liver,
skeletal muscles, and fat
tissue to absorb glucose
from the blood

AFREZZA

T1DM and
T2DM

Inhalation

2014

Antidiabetic
combinations

Inhibition of SGLT2 and DPP4

Ertugliflozin/sitagliptin
(STEGLUJANÔ )

T2DM

Oral

2017

Inhibition of SGLT2, decrease
in hepatic glucose production
and intestinal absorption,
improvement of insulin
sensitivity

Ertugliflozin/metformin
hydrochloride
(SEGLUROMETÔ )

T2DM

Oral

2017

Stimulation of glucose
uptake and suppression
of glucagon secretion

Insulin glargine/lixisenatide
(SOLIQUAÒ 100/33)

T1DM and
T2DM

Subcutaneous

2016
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FIGURE 8.2 Miglitol

8.4.2 Amylin analog
Amylin is a polypeptide cosynthesized and cosecreted with insulin by the beta cells of the pancreas [58]. A defect in
synthesis and secretion of insulin also means less amylin. Amylin aids insulin in postprandial control of blood glucose
concentration. It also suppresses glucagon secretion, increases gastric transit time, and signals satiety, thus reducing food
intake. Amylin analogues are stable synthetic compounds, administered subcutaneously before meals and with similar
physiological function to amylin. They also reduce the good feeling associated with eating, thus reducing food intake.
Some human amylin analogues have been characterized. Pramlintide, a recombinant DNA produced polypeptide, is the
only one used clinically to treat T1DM and T2DM [59].

8.4.3 Incretin mimetics
Incretins are gut hormones that are secreted from enteroendocrine cells into the blood within minutes after eating to
regulate insulin secretion in response to a meal. Currently, two types of incretins have been characterized, namely glucosedependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). Both incretins are rapidly deactivated by
dipeptidyl peptidase-4 (DPP4).
Incretin mimetics act like incretin hormones and are only used to treat T2DM. They can bind to GLP-1 receptors to
stimulate insulin release based on the concentration of the glucose supplied, suppress appetite, inhibit glucagon secretion,
and slow down the rate of gastric emptying. Their overall effect normalizes blood glucose concentration. Another
dimension to the use of incretins in diabetes management is the development of GLP-1 receptor agonists with a view to
improving insulin secretion by maintaining the insulinotropic activity of GLP-1 in T2DM.
The GLP-1 receptor agonist, exenatide, has been approved for use. It is administered as an injection subcutaneously
twice daily. The resulting increase in insulin levels lowers blood glucose especially after a meal. Hypoglycemia is unlikely
because insulin secretion is glucose-dependent [60].

8.4.4 SGLT-2 inhibitors
Also called the gliﬂozins, they are a new class of antidiabetic drugs. Members of this class include canagliﬂozin, dapagliﬂozin, and empagliﬂozin. The mechanism of action is blockage of SGLT2, thus reducing renal tubular glucose reabsorption. Patients with renal impairment may record decreased activity. SGLT-2 inhibitors promote glycosuria and can
cause polyuria, decreased circulating blood volume, hypotension, and acute kidney injury in T2DM patients [55]. Their
action is independent of the b-cell function in the pancreas. Some SGLT2 inhibitors approved for use include ertugliﬂozin
(STEGLATRO).

8.4.5 Sulfonylureas
Sulfonylureas are a group of medicines used in the management of T2DM. The mechanism of action is by stimulating
insulin release from pancreatic b-cells. Their action is dependent on the presence of functioning beta cells, thus not
effective in the management of T1DM. It speciﬁcally binds to islet cell receptor with correspondence stimulation of insulin
secretion. The reported side effects emerge from its acute ingestions that trigger hypoglycemia mainly even when glucose
level is below the normal threshold required to signal insulin secretion [55]. Examples of drugs in this class are gliclazide,
glimepiride, and glyburide

8.4.6 Thiazolidinediones
Thiazolidinediones, also called glitazones, enhance sensitivity to insulin by stimulating peroxisome proliferator-activated
receptor gamma (PPAR-g). Ingestion can cause mild hypoglycemia in a small number of patients [55].
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Their binding to PPAR-g in adipocytes fat cells promotes maturation of fat cells and deposition of fat into peripheral
tissues. This reduces circulating fat concentrations and improves insulin sensitivity in T2DM. Thiazolidinediones may be
used alone or in combination with other oral agents. Weight gain is a common side effect. Examples are pioglitazone and
rosiglitazone.

8.4.7 Dipeptidyl peptidase-4 inhibitors
DPP4 (EC 3.4.14.5.) degrades peptide hormones such as GLP-1 and glucose-dependent insulinotropic polypeptide. It is a
serine exopeptidase and it cleaves dipeptides from the N-terminus. It is abundantly expressed on the surface of most cell
types. Because its activity directly regulates the availability of the peptide hormones GLP-1 and GIP, DPP4 inhibition is a
potential therapeutic approach for T2DM either as monotherapy or in conjunction with other oral antidiabetics [61].
Examples are alogliptin, linagliptin, saxagliptin, and sitagliptin.

8.4.8 Nonsulfonylureas/biguanides
Biguanides are classed as nonsulfonylureas which act directly against insulin resistance. A notable example is metformin,
which is the only biguanide for the treatment of diabetes. It works by inhibiting the quantity of glucose produced by the
liver. Researchers have noted that metformin does not stimulate the pancreas to make or release more insulin, so it does not
cause hypoglycemia [55,62].
Some metformin brands available include GlucophageÒ, Glucophage XRÒ, RiometÒ, FortametÒ, GlumetzaÒ,
ObimetÒ, DianbenÒ, DiabexÒ, and DiaforminÒ. Its safety and efﬁcacy makes it a frontline agent in mono- or combination therapies. It is noteworthy that metformin, despite being the most administered oral antidiabetic medication, is only
effective when there is sufﬁcient insulin.

8.4.9 Antidiabetic combinations
If monotherapy fails to achieve normoglycemia, a combination therapy comprising a frontline antidiabetic and a second
agent with a different mechanism of action is initiated. Metformin is the preferred frontline oral antihyperglycemic agent.
However, if it is contraindicated based on the clinical situation of the patient, another class of antihyperglycemic agent is
used.
Six major classes of antidiabetic agents can be combined with metformin. These are sulfonylurea, thiazolidinediones,
DPP4 inhibitors, sodium-glucose cotransporter-2 inhibitors, GLP-1 receptor agonists, and insulin.
Based on weight-reducing effect, the American Association of Clinical Endocrinologists recommends the combination
in the order: SGLT2i, followed by DPP4i, TZD, AGIs, and SU among the oral hyperglycemics [53]. Some recently
approved antidiabetic combination therapies include Segluromet (ertugliﬂozin/metformin), Steglujan (ertugliﬂozin/sitagliptin), and iGlarLixi (insulin glargine/lixisenatide) (Table 8.3).

8.5 Antidiabetic drugs on clinical trial
8.5.1 Sotagliflozin (LX4211)
Sotagliﬂozin previously known as LX4211 is a nonselective SGLT-1 and SGLT-2 inhibitor or dual SGLT inhibitor.
SGLT-1 is a protein belonging to the solute carrier sodium glucose cotransporter family (SLC5) [63]. It is a high-afﬁnity
Naþ/glucose cotransporter [64] that transports glucose and galactose across the intestinal wall, the initial step in the absorption of sugars from the diet. In the kidney, SGLT-1 is located in the proximal tubule, which helps in the reabsorption of
urinary glucose from the glomerular ﬁltrate [65]. Inhibition of both SGLT-1 and SGLT-2 receptors results to decreased
glucose absorption through the intestine and increased urinary glucose excretion, which can help diabetic patients achieve
good glycemic control.
Zynquista developed by Lexicon Pharmaceuticals is the brand name of sotagliﬂozin, which will be marketed by Sanoﬁ
in combination with insulin to control hyperglycemia in adults with T1DM. In a phase 3 clinical trial, “sotagliﬂozin
combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose,
fewer episodes of severe hypoglycemia and improved patient-reported outcomes.” However, more DKA episodes were
noted compared with placebo [66]. Phase 3 clinical trials for Zynquista have recently been completed and the drug was
submitted for FDA review last May 22, 2018 as Potential Therapy for T1DM. FDA is expected to release the results of the
review by March 22, 2019 [67].
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Additionally, phase 2 clinical trial for sotagliﬂozin as potential treatment for T2DM has just been completed. The trial
showed a very promising result of good glycemic control, lowering of HbA1C, and dose-dependent increase in urinary
glucose excretion [67]. Concerns regarding diabetic patients with renal problems are a potential challenge for this type of
medication.

8.5.2 LX2761 (Lexicon Pharmaceuticals)
LX2761 is an SGLT-1 inhibitor designed to suppress SGLT-1 in the gastrointestinal tract without inhibiting SGLT-2 in the
kidney. As SGLT-1 is a high-afﬁnity Naþ/glucose cotransporter across the intestinal wall, its inhibition will decrease
intestinal absorption of glucose with minimal effect on urinary glucose excretion [64]. LX2761 is developed by Lexicon
Pharmaceuticals, which is currently in the process of conducting (recruitment stage) a phase 1 clinical trial to evaluate the
safety and tolerability of LX2761 among healthy volunteers and T2DM patients [68].
Preclinical studies showed that LX2761 delayed and reduced intestinal glucose absorption, decreased postprandial
glucose, and increased plasma levels of GLP-1, consistent with inhibition of intestinal SGLT1. In addition, LX2761 was
minimally absorbed into the systemic circulation, resulting in minimal effect on urinary glucose excretion. Lexicon has
granted Sanoﬁ certain rights to the future development and commercialization of LX2761 [3].

8.5.3 Semaglutidedoral
Semaglutide is a GLP-1 receptor agonist indicated for T2DM. GLP-1 stimulates insulin secretion while inhibiting glucagon
release only in hyperglycemic conditions. Thus, a GLP-1 receptor agonist can potentially decrease plasma glucose without
necessarily causing hypoglycemia. It also delays gastric emptying time, which in turn decreases food intake and eventually
results to weight loss [69]. A number of GLP-1 agonists such as exenatide and liraglutide have already been approved for
the treatment of T2DM. An injectable form of semaglutide (Ozempic) marketed by Novo Nordisk was also recently given
approval by the FDA (December 5, 2017) [70]. But this is the ﬁrst GLP-1 receptor agonist that can be given orally. It can
be taken orally once a day and is claimed to be as effective as the injectable semaglutide [71].
Clinical trials on the safety and efﬁcacy of oral semaglutide as treatment for T2DM patients are still being carried out.
In its phase 1 clinical trial (PIONEER 1), oral semaglutide was found effective in reducing HbA1C by as much as 1.5%
from a baseline of 8% among T2DM patients. It also showed signiﬁcant reduction in body weight [71,72]. If clinical trials
will be successful, oral semaglutide can be considered as a very highly desirable treatment option for T2DM. It will offer a
cheaper alternative to the injectable form, and the ease of administration will greatly improve patient’s compliance.

8.5.4 Glucokinase activator, HMS5552
Glucokinase (GK), also known as hexokinase IV or D, is a 50 kDa cytoplasmic enzyme that mediates phosphorylation of
glucose to glucose-6 phosphate (G-6-P) in the presence of ATP. “GK is predominantly expressed in hepatocytes and
pancreatic b-cells and plays a key role in the regulation of carbohydrate metabolism” [73].
Several GKAs have been discovered in the past years that have shown promise as potential treatment for T2DM. Good
glucose control was achieved in diabetic animal models [74]; however, clinical trials noted some adverse effects such as
hypoglycemia, hypertension [75], and increase in triglyceride levels [76].
HMS5552 is a “fourth-generation GKA, which has a structurally novel amino acid chemical scaffold” developed to
improve GK activity and insulin resistance. Animal studies have been successful and are currently undergoing phase 2
clinical trials [77].

8.5.5 Smart Insulin
Management of T1DM and some T2DM patients requires insulin injection to treat hyperglycemia. The pain of repeated
injections and the need to constantly monitor blood glucose levels because of risk of hypoglycemia constitute a major
challenge for affected patients. To address this concern, scientists have developed “smart insulin” or glucose-responsive
insulin (GRI) that releases insulin only when there is hyperglycemia [78]. A number of GRI delivery systems have
been developed and improved, which are currently undergoing preclinical trials, but one of the most promising is the
“insulin patch” with polymer-encapsulated insulin and stem cellederived pancreatic beta cells that will detect hyperglycemia and stimulate the release of insulin when needed. The patch also contains the enzyme glucose oxidase, which helps
control hyperglycemia aside from insulin. This “insulin patch” is made of microneedles that are painless. Animal studies
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have demonstrated its efﬁcacy and safety [79,80]. If successful, this smart patch will revolutionize the delivery of insulin
therapy and will surely improve the quality of life of diabetic patients.

8.6 Future directions
Diabetes mellitus is a complex metabolic disease that causes dysfunctions in the body mainly because of insulin resistance
or insulin insufﬁciency. Biguanides are the common ﬁrst-line treatment in uncomplicated hyperglycemia. When antidiabetes monotherapy fails, different drug classes are combined to manage hyperglycemia and its complications. However,
even antidiabetic combinations can lead to harmful drugedrug interactions [81]. Thus, the search for antidiabetic drugs,
alone or in combination that can control blood glucose and mitigate the effects of diabetic comorbidities, continues, with
naturally occurring phytochemicals as candidates. Phytochemicals such as alkaloids, ﬂavonoids, and phenols, in general,
possess antioxidant properties, and these can be used as adjunct to hypoglycemic drugs to relieve oxidative stress.
As new molecular level discoveries about diabetes reveal new potential targets for antidiabetic drugs, the mechanism of
action of lead compounds with hypoglycemic activity must subsequently be elucidated. Screening for hypoglycemic
activities of natural products usually happens in basic laboratories that may not be able to perform tests requiring
specialized equipment and resources. With an organized search for antidiabetics involving basic research groups and
highly equipped laboratories, as in research consortia, more leads for developing antidiabetic drugs can be tested. This
shortens the discovery phase of the drug development process, which gives hope to alleviate the global burden of diabetes
sooner.

8.7 Conclusion
There is a global epidemic of diabetes, and the number of afﬂicted persons continues to rise. There are at least seven classes
of antidiabetic drugs currently used as mono- or combination therapy to manage hyperglycemia and its complications.
Lead compounds from phytochemicals potentially increase the number of available treatments for diabetes. Forming
research consortia can potentially reduce the time for new, more effective, and safer antidiabetic drugs to be released.
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9.1 Introduction
Obesity results from an imbalance between caloric intake and expenditure. People with body mass index (BMI) between 25
and 30 kg/m2 are considered overweight (preobese), while “obesity” is deﬁned as a BMI of 30 and above [1]. BMI is
determined as the individual’s weight in kilogram (kg) divided by the height in meter squared (m2). Obesity is characterized
by the disproportionate accumulation of adipose tissue that is commonly accompanied by systemic inﬂammation [2].
The United States Centers for Disease Control and Prevention (CDC)’s National Center for Health Statistics (NCHS)
published a report showing that, since the late 1980s and early 1990s, the average American person increased their weight
by 15 pounds or more without getting any taller and that 11-year-old girls and boys are more than 7 and 13.5 pounds
heavier, respectively, compared to two decades ago [3]. In England, 68% of men and 58% of women are overweight or
obese, and the prevalence of obesity rose from 15% in 1993 to 27% in 2015 [4]. More than one in two adults and nearly
one in six children are overweight or obese in Organization for Economic Co-operation and Development (OECD)
countries in 2015, with 19.5% of the adult population obese [5]. Globally, the World Health Organization reported that
more than 2.1 billion adults were estimated to be obese or overweight in 2014, speciﬁcally, 640 million were obese, and
1.5 billion were overweight [6]. National data on obesity trends in many African countries are rare because the focus has
been on undernutrition and food security. In Africa, in 2014, the estimated number of children, who were obese or
overweight, nearly doubled since 1990, rising from 5.4 to 10.3 million [7].
Obesity is harmful to health and more caution should be given to it. Globally, obesity contributes signiﬁcantly to the
problem of chronic disease, and disability has reached epidemic proportions [8]. Obesity-linked diseases include insulin
resistance, type 2 diabetes mellitus, heart-related diseases, osteoarthritis, sleep apnea [9,10], certain cancer, gallstones, gout,
and gouty arthritis. Besides its health risks, obesity causes too many problems including difﬁculties in employment [11,12]
and elevated business expenses and rising medical costs paid by governments, corporations, and individuals. The global
health cost of overweight and obesity was equivalent to 2.8% of gross domestic product of the world or approximately
2 trillion US dollars [13].
If the cause of obesity was solely genetic, it would be difﬁcult to explain the increase in the prevalence of obesity in the
last few decades [14]. This implies that the pathogenesis of obesity is the result of an interaction between several factors
such as genetics, high fat or carbohydrate diet, frequency of eating, physical inactivity, slow metabolism, medications,
not sleeping enough, psychological factors, diseases, social determinants, infectious agents, endocrine disruptors, and
environment [15].
Obesity prevention is preferable to management, and balancing a healthy diet (energy intake) with adequate physical
activity (energy expenditure) is recommended. Weight loss program in the form of reduced calorie intake and/or exercise
might not always produce sustainable weight loss [16,17], except in combination with psychological therapies, such as
cognitive behavioral therapy (CBT). However, it is difﬁcult to deliver CBT on a mass scale, and the long-term results
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might not be encouraging [18]. Additional management and treatment options include surgery and medications. Weight
loss surgery or bariatric surgery is the last resort for people with severe obesity (BMI 40) or BMI 35 with at least one
severe obesity-related medical problem [19], whereas obesity drugs, such as orlistat, are also effective in combination with
lifestyle changes.
As obesity possesses different etiological and pathological origins, no single treatment or drug is able to effectively
control the condition [20]. Besides, existing drugs have not been able to signiﬁcantly and successfully reduce weight, thus
research on the treatment of obesity is ongoing and multifaceted. One aspect has focused on discovering extracts and/or
compounds with antiobesity properties from medicinal plants which might be readily available with less adverse effects.
However, for most of these medicinal plants, their mode of action in reducing weight is not yet known, neither the classes
of compounds nor the active ingredients responsible for the antiobesity properties of these plants have been identiﬁed.
Thus, this chapter highlights a number of antiobesity lead compounds discovered from various classes of phytochemicals
acting on identiﬁed therapeutic targets that have been evaluated through several preclinical and clinical studies in an
attempt to develop them into antiobesity drugs, although most of them are yet to make it into the commercial market.

9.1.1 Current antiobesity drugs and their mechanism of action
Current antiobesity drugs act through several potential mechanisms including increase energy expenditure, appetite
suppression, inhibition of digestive enzymes, or interference in the absorption, at the level of the intestinal tract, of fat or
sugar from food. To date, antiobesity candidates have been associated with false starts, failures in clinical development,
restrictions to medical prescription, and withdrawals due to adverse effects [21]. Current Food and Drug Administration
(FDA)eapproved antiobesity drugs with their mechanisms of action are highlighted in Table 9.1.
Antiobesity candidates or drugs are expected to control or reduce weight with minimal side effects. Orlistat, a pancreatic
lipase inhibitor, acts by blocking lipase activity in the small intestine, thereby reducing dietary fat absorption. Weight loss
using orlistat is relatively modest, but effective in lowering low-density lipoprotein cholesterol, total cholesterol, and
triglyceride levels [22]. The negative effects of orlistat are bloating, diarrhea, ﬂatulence, and abdominal pain [2,22].
Liraglutide, a glucagon-like-peptide 1 receptor (GLP-1R) agonist, was observed to produce modest weight loss
consistently when administered to individuals who were treated for diabetes [23]. However, in the treatment of obesity,
liraglutide produces weight loss of about 8 kg or more [22], although its side effects include nausea, vomiting, and
hypoglycemia [2]. A number of antiobesity candidates or drugs have been rolled back or withdrawn from the market,
including rimonabant (cannabinoid CB1 receptor antagonist/inverse agonist) and sibutramine (serotonin and noradrenaline
[NA] reuptake inhibitor), both appetite suppressants [24].
TABLE 9.1 Current FDA-approved antiobesity drugs with their mechanisms of action.
Drug

Brand

Mechanism of action

Weight
loss (kg)

Adverse effects

Reference

Orlistat

Xenical

Lipase inhibitor

5.8ee6.7

Steatorrhea, flatulence

[22]

Liraglutide

Saxenda

Glucagon-like peptide-1
receptor agonist

8.4  7.3

Diarrhea, nausea, vomiting,
hypoglycemia, constipation

[22]

Noradrenergic drug, which
functions as an appetite
suppressant

5

Dizziness, dry mouth,
insomnia, constipation, irritability, and cardiostimulatory
effects

[2]

Diethylpropion, phentermine, phendimetrazine,
and benzphetamine
Lorcaserin

Belviq

5-HT2C receptor agonist (serotonin agonist)

5.8  0.2

Nausea, dizziness, headache

[2,22]

Naltrexone/bupropion

Contrave

Opioid receptor antagonist
and reuptake inhibitor of
dopamine and noradrenaline
(NA)

9.3

Nausea, headache, dizziness,
constipation, vomiting, dry
mouth

[2,22]

Phentermine/topiramate

Qsymia

Stimulator of synaptic NA,
serotonin, and dopamine
release plus augmenting gaminobutyrate activity

8.1e10.2

Paresthesia, dry mouth,
constipation, insomnia,
dizziness

[22]
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9.1.2 Molecular target and mode of action for antiobesity phytochemical compounds
9.1.2.1 Inhibition of lipases/lipid absorption
Pancreatic lipase secreted from the pancreas is responsible for hydrolyzing dietary triglycerides into glycerol and free fatty
acids (FFAs) in the small intestine, whereas gastric lipase facilitates the hydrolysis of 10%e30% of dietary fat in the
stomach because of its activity at low pH [25]. Also, gastric lipase maintains activity in the duodenum acting in synergy
alongside pancreatic lipase [26] to enhance absorption of lipids into the bloodstream. Thus, inhibitors of lipases may
function as antiobesity agents, as the inhibition of fat/lipid absorption characterizes an efﬁcient and effective approach for
the restriction of caloric intake [27].
Orlistat is a good example of gastrointestinal and pancreatic lipase inhibitor; however, it has serious side effects, such as
irregular menstrual periods, stomach pain, steatorrhea, and headaches [2,22,28]. Researchers have demonstrated
that certain plant compounds signiﬁcantly inhibited pancreatic lipase: examples include licochalcone A, (2S)-30 ,40 ,7trihydroxyﬂavan-(4a / 8)-catechin, procyanidin B3, luteolin, escin, scabiosaponins, hookerosides, prosapogenin 1b,
and betulinic acid [29e33].

9.1.2.2 Suppression of food intake
Appetite suppressants aim to inhibit food (energy) intake, reduce hunger perception, or increase the feeling of fullness by
acting on brain mechanisms [34]. Biochemical proofs indicate that serotonin, dopamine, histamine, and activities of their
associated receptors are carefully linked to the regulation of satiety. The increased level of serotonin in the hypothalamus
reduces food intake, food-seeking behavior, and quantity consumed per meal, thereby reducing body weight [35].
Sibutramine, the ﬁrst FDA-approved drug for treating obesity via appetite suppression is a serotonin and NA reuptake
inhibitor [36], although sibutramine was withdrawn from the US market in 2010 for increased risk for stroke and
myocardial infarction. The ﬁnding that leptin elevates serotonin turnover [37] suggests that the weight-reducing effects of
leptin are partly mediated through elevated serotonin signaling.
Studies focused on discovering natural products with appetite suppression effect have identiﬁed hydroxycitric acid
(HCA) from Garcinia cambogia, to suppress appetite by inhibiting serotonin ([3H]-5-HT) [38]. Steroidal glycoside
(P57AS3) isolated from Hoodia gordonii suppressed appetite by targeting ATP content in the hypothalamus [39,40], while
epigallocatechin gallate (EGCG) inﬂuenced weight loss via appetite suppression through the modulation of leptin
concentration [41,42].

9.1.2.3 Inhibition of adipogenesis/lipogenesis
The development of obesity is characterized by biological changes in adipocyte number, size, or both. The adipocyte life
cycle involves a multifaceted sequence of alterations in gene expression resulting in lipid storage [43]. Some of these
changes are regulated by two transcription factors, CCAAT (cytosineecytosineeadenosineeadenosineethymidine)/
enhancer-binding protein (C/EBPa) and peroxisome proliferator-activated receptor (PPAR) g, which play a role in the
preadipocyte growth arrest that is essential for adipocyte differentiation [44]. As a consequence, numerous studies testing
for antiobesity phytochemical compounds have targeted the processes of adipocyte proliferation and differentiation by
using the mouse 3T3-L1 preadipocytes cell line [45,46].
Researchers have also focused on using phytochemicals to target enzymes involved in fat synthesis and oxidation
such as acyl-CoA:diacylglycerol acyltransferase (DGAT), glycerol-3-phosphate acyltransferase (GPAT), carnitine
palmitoyltransferase-1 (CPT1), fatty acid synthase (FAS), acyl-CoA synthetase (ACS), acetyl-CoA carboxylase (ACC),
and 11b-hydroxysteroid dehydrogenase-1 (HSD1). Once FFAs are inside the epithelial cell, they are carried by fatty
acidebinding proteins into the endoplasmic reticulum and donated to ACS [27]. DGAT is, therefore, a signiﬁcant enzyme
in the synthesis of triglyceride and its inhibition might represent an effective therapeutic strategy as a target. Previously,
mice that lack DGAT displayed resistance to obesity, although they demonstrated normal fat absorption suggesting the
presence of other triglyceride synthesis pathways [47].
The initial and committed step in the de novo synthesis of triglycerides is catalyzed by GPAT, particularly GPAT1, by
acylating glycerol-3-phosphate to form acylglycerol-3-phosphate. In mammalian cell lines, overexpression of GPAT1
resulted in a signiﬁcant elevation in triglyceride synthesis [48]. In contrast, GPAT1 inactivation in mice leads to a decrease
in weight gain complemented by a notable reduction in hepatic and plasma triglycerides [49]. Accordingly, as GPAT1 and
CPT1 are reciprocally regulated by AMP-activated kinase, inhibition of GPAT1 activity would change the course of fatty
acyl-CoAs in the direction of triglyceride synthesis and prevent competition for acyl-CoAs with CPT1 [50].
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FAS is expressed abundantly in lipogenic tissues such as adipose and liver and catalyzes the de novo synthesis of
saturated fatty acids using acetyl- and malonyl-CoA. This enzyme is important in maintaining energy homeostasis in
coordination with CPT and ACC by converting excess caloric intake into lipids for energy and storage by upregulating the
rate of b-oxidation. It is believed that the action of FAS inhibitors causes elevation of malonyl-CoA in the central nervous
system (CNS), which downregulates feeding, thus suppressing appetite and producing weight loss effects in animals [51].
Bioactive compounds that have inhibited adipogenesis via downregulation/inactivation of one or more nuclear receptors
(PPAR-g, C/EBPa) and/or enzymes (like FAS) include curcumin, resveratrol, luteolin, quercetin, EGCG, berberine,
capsaicin, ginsenosides, carnosic acid, corosolic acid, and HCA [52e63].
The enzyme ACC converts acetyl-CoA to malonyl-CoA, and its action regulates mitochondrial fatty acid b-oxidation
via inhibition of CPT1. ACC1 and ACC2 are isoforms and they regulate the synthesis of fat in lipogenic tissues [50].
AMP-activated protein kinase (AMPK) inhibits ACC activity by its phosphorylation, which is followed by a decrease in
malonyl-CoA levels and consequently diminished lipid synthesis and elevated fat oxidation [64]. Also, activation of
AMPK leads to decreased hepatic SREBP1 and repressed expression of downstream lipogenic genes [65]. Thus, the
inhibition of ACC enzymes with bioactive compounds offers a possible treatment route for obesity. Ternatin (Coriolus
versicolor) has been shown to inhibit adipocyte differentiation via downregulation of SREBP1, C/EBPa, FAS, and ACC2
in 3T3-L1 adipocyte and rat hepatocytes [66].
The main function of enzyme HSD1 is to reactivate glucocorticoids locally from inactive metabolites, and HSD1
expressed in adipose tissues and overexpressed in obesity [67]. The transgenic overexpression of HSD1 in fat tissue has
been shown to produce obesity, especially visceral fat, pointing to its possible role in the development of obesity and its
complications [68]. The action of berberine in reducing lipogenic transcripts, 11b-HSD1, FAS, ADD1/SREBP1c, and aP2
in mice contributes to its antiobesity activities [69].

9.1.2.4 Induction of apoptosis and lipolysis
Another potential mechanism of action for phytochemicals is elevating the rate of apoptosis during the adipocyte life cycle
[8,54] or reducing fat accumulation. Apoptosis is a type of cell death that is essential for maintaining cellular homeostasis.
It is triggered by two main signaling pathways, that is, mitochondrial and death receptor pathways [70]. In both pathways,
in a series of molecular steps, caspases are activated and then cleavage of a number of nuclear and cytoplasmic substrates
occurs ensuing in cell suicide. Compounds that stimulate adipocyte apoptosis could possibly reduce fat content in the body,
and several phytochemicals have been shown to induce apoptosis via different pathways mostly involving the activation of
AMPK and the decrease of the extracellular signaleregulating kinase (ERK) and c-Jun-N-terminal kinase pathways,
likewise the downregulation of poly(ADP-ribose) polymerase and Bcl-2 proteins and activation of caspase-3, Bax, and Bak
proteins. Phytochemicals that have been shown to have such properties in cell systems or animal models include curcumin,
resveratrol, luteolin, quercetin, capsaicin, and ajoene [52e56,59,71e73].
Lipolysis involves the hydrolysis of triglycerides to glycerol and fatty acids, and its stimulation is an important
mechanism for energy homeostasis. Lipolysis is induced by protein kinase A activation, which phosphorylates hormonesensitive lipase (HSL), or by G proteinecoupled receptors and cyclic AMP-activated ERK, which phosphorylates HSL
[74]. The cytokine tumor necrosis factor alpha (TNF-a) was reported to elevate lipolytic activity in differentiated human
preadipocytes [75] and in humans in vivo [76]. Besides inhibiting apoptosis, several phytochemicals stimulate lipolysis in
adipocytes such as a-mangostin, g-mangostin, and resveratrol [77,78] and 4-(4-hydroxyphenyl)butan-2-one by regulating
HSL in high fat diet (HFD) fed mice [79].
The targeting of lipolysis is important in screening for antiobesity agents and one option is to stimulate triglyceride
hydrolysis (lipolysis) so as to diminish stored fat, and in so doing combat obesity. Perilipin, a protein which regulate access
to the lipids that they encompass, has been shown to inﬂuence weight reduction and counteract diet-induced obesity in
animals [80] by modulating the hydrolysis of triglycerides. Also, perilipin was demonstrated to participate in the inhibition
of HSL activity, and mice deﬁcient in perilipin are lean and resistant to obesity [81]. Ginsenosides partly inhibited
adipocyte differentiation by decreasing perilipin in in vitro human primary adipocytes [60].

9.1.2.5 Stimulation of energy expenditure/thermogenesis
Pharmaceutical approaches for the management of obesity have also focused on drug development targeting
b3-adrenoceptor, by which sympathetically released NA activates fat oxidation and thermogenesis in peripheral tissues,
together with uncoupling protein 1 (UCP1) activation that facilitates thermogenesis in brown adipose tissue (BAT). Several
studies have implicated the sympathetic nervous system (SNS) in the regulation of thermogenesis via its heat-producing
neurotransmitter NA and low SNS activity that may further diminish energy expenditure which brings about susceptibility
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to fatness [82,83]. Therefore, compounds that increase thermogenesis and mimic the activity of the SNS offer therapeutic
potential in obesity treatment.
The induction of BAT generation by de novo recruitment from preadipocytes and/or conversion of white adipocytes to
BAT presents a safer antiobesity therapeutic approach [27]. PPAR-g ligands effectively induce UCP1 expression in brown
adipocytes because of the presence of a cofactor, PPAR-g co-activator-1 (PGC-1), but not in white adipocytes, and favor
mitochondria multiplication, thereby allowing PPAR-g to facilitate thermogenesis [27]. Also, stimulation of the activity of
UCP2, which is widely distributed in the body, might increase thermogenesis in humans. Natural plant compounds, such as
berberine and fucoxanthin, have been shown to stimulate thermogenesis by inducing the expression of UCP2 and UCP1,
respectively [69,84].

9.1.2.6 Inhibition of inflammation
Obesity has been linked to chronic inﬂammatory status [85] and modulating inﬂammation to avert the adverse physiological effect of obesity might be a possible mechanism of action. In most cases of human obesity, adipocyte expression of
cytokines such as TNF-a, monocyte chemoattractant protein-1 (MCP-1), and interleukin-6 (IL-6) is increased.
TNF-a is highly expressed in adipose tissue of obese animals and humans [86]. The administration of TNF-a
antibodies in rodents resulted in inhibition of inﬂammatory activity and improvement in fatty liver disease [87] and
protection against diet-induced obesity [88]. Similarly, low-dose infusion of IL-6 into the brain prevented late-onset
obesity peculiar to IL-6edeﬁcient mice [89]. However, the clinical use of antieTNF-a antibodies in the management
of metabolic diseases in human studies is inundated by a lack of efﬁcacy [90]. Although TNF-a has not proven to be a very
valid drug target for human obesity, many studies have reported the antiobesity activities of phytochemicals with TNF-a
and IL-6 as a target. The regulation of inﬂammatory factors as a target to prevent or attenuate adipogenesis/lipid
accumulation in in vitro and in vivo preclinical models has been reported for the following compounds: 6-shogaol,
curcumin, resveratrol, quercetin, capsaicin, auraptene, and dehydroabietic acid [91e98].

9.1.2.7 Modulation of hormones and endocrine functions
Adipokines play a role in the regulation of appetite and satiety (e.g., vaspin, leptin), insulin sensitivity (e.g., leptin,
adiponectin, chemerin), vascular growth and function, and lipid metabolism (e.g., CD36) [99,100], and many other
biochemical processes not mentioned. Leptin, produced in the adipose tissue, controls food intake, through its action in
cells of the hypothalamus in the CNS [101]. Leptin’s action in mammalian hypothalamus induces a decrease in food
consumption and an increase in energy expenditure and also regulates neuroendocrine function and energy metabolism
[102]. Thus, administering leptin to an obese human with genetic leptin deﬁciency decreased body weight similarly to what
happens in ob/ob mice [103].
Adiponectin acts in the brain to escalate energy expenditure and decrease weight gain [104]. The concentration of
adiponectin is decreased in obesity, and replacement of deﬁcient adiponectin has beneﬁciary effects such as increasing lipid
oxidation rates and reducing lipids levels [105]. The action of adiponectin is partly by activating the enzyme AMP kinase
[106]. Adiponectin has been shown to reduce triglycerides and FFAs in mice [107]. Thus, either recombinant adiponectin
derivatives or adiponectin mimetic compounds might be possible antiobesity agents [64]. There are several bioactive
compounds whose antiobesity activities partly involve the regulation of obesity-related hormones and they include
6-shogaol, curcumin, EGCG, capsaicin, auraptene, fucoxanthin, and g-mangostin [41,42,59,84,95,108e110].

9.1.3 Plant-derived lead compounds with antiobesity activities
9.1.3.1 Polyphenols
A number of phytochemicals in the polyphenol class have been reported to have antiobesity activities with similar and
diverging mechanism of actions (Table 9.2). The isolated compound, 4-(4-hydroxyphenyl)butan-2-one, from Rubus idaeus
(raspberry) has been shown to increase lipolysis, like resveratrol. Curcumin, resveratrol and quercetin have been shown to
inhibit adipocyte differentiation, inﬂammation, lipid accumulation and induce apoptosis. Licochalcone A, from Glycyrrhiza uralensis, inhibited pancreatic lipase, while luteolin inhibited adipogenesis and pancreatic lipase and induced
apoptosis. A combination of genistein with EGCG or capsaicin-induced apoptosis and in combination with L-carnitine
inhibited lipid accumulation. EGCG inhibited adipocyte differentiation and lipid accumulation; in addition, it enhanced
appetite suppression, thermogenesis, and fat oxidation. A ginger derivative, 6-shogaol, inhibited inﬂammation. Among the
polyphenols, curcumin, resveratrol, and quercetin are among the most widely studied; however, none of them has
undergone a clinical trial or reached Phase II with respect to their antiobesity properties.
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TABLE 9.2 Phenols and polyphenol compounds with antiobesity activities.
Bioactive compound

Plant (part)

Mode of action

Molecular targets

Experimental model

References

4-(4-Hydroxyphenyl)
butan-2-one

Rubus
idaeus
(raspberry)

Increased lipolysis

Hormone-sensitive
lipase

In vivo HFD fed mice

[79]

6-Shogaol

Ginger

Inhibition of
inflammation

þPPAR-g, adiponectin, aP2; TNF-a

3T3-L1 adipocytes

[91]

Curcumin

Curcuma
longa

Inhibition of
adipocyte
differentiation and
induction of
apoptosis

þAMPK, PPAR-g;
VEGF and
VEGFR-2, þAMPK,
GPAT1, þCPT-1,
PPAR-g, and C/EBPa

In vitro 3T3-L1 adipocyte; in vivo HFD fed
mice

[52,53]

Curcumin

C. longa

Inhibition of
inflammation

TNF-a and IL-6,
eNF-kB and JNK

In vitro 3T3-L1
adipocyte

[92]

Curcumin

C. longa

Reversal of
inflammation and
metabolic
derangements

þAdiponectin,
hepatic NF-kB

In vivo ob/ob mice
with HFD; rats fed
HFD

[108,109]

Curcuminoids

Prevent lipid
accumulation

Hepatic acyl-CoA
oxidase

In vitro rats with HFD

[111,112]

Resveratrol

Inhibition of adipogenesis and stimulation of apoptosis

PPAR-g, C/EBPa,
SREBP1c, FAS, HSL,
LPL, þSIRT3, UCP1,
and Mfn2

In vitro 3T3-L1
adipocyte

[54]

Resveratrol

Induced apoptosis

TNF-related
apoptosis-inducing
ligand (TRAIL)

In vitro human
adipocyte

[71]

Resveratrol

Inhibited preadipocyte proliferation
and
adipogenic
differentiation

Sirt1, IL-6 and IL-8

In vitro human
adipocyte

[113]

Resveratrol

Inhibition of
inflammation

IL-6, IL-8, MCP-1,
IL-1b, and PAI-1

In vitro human
adipocyte

[93]

Resveratrol

Increased lipolysis

Ex vivo isolated rat
adipocytes

[78]

Resveratrol þ quercetin

Inhibition of adipogenesis and stimulation of apoptosis

PPAR-g and C/EBPa

In vitro 3T3-L1
adipocyte

[114]

Resveratrol

Modulating the
expression of genes
involved in lipogenesis and lipolysis

FDFT1, FASN,
PPAR-g, ALDH1B1

Hypercholesterolemic
dietefed male mice

[115]

Pancreatic lipase
inhibitor

Pancreatic lipase

In vitro inhibitory
activity of pancreatic
lipase

[29]

Luteolin

Inhibition of
adipogenesis and
induction of
apoptosis

PPAR-g and C/EBPa

In vitro 3T3-L1
adipocyte

[55]

Quercetin

Inhibition of
adipogenesis and
induction of
apoptosis

þAMPK, ERK and
JNK

In vitro 3T3-L1
adipocyte

[72]

Licochalcone A

Glycyrrhiza
uralensis

Continued
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TABLE 9.2 Phenols and polyphenol compounds with antiobesity activities.dcont’d
Bioactive compound

Mode of action

Molecular targets

Experimental model

References

Quercetin

Plant (part)

Inhibition of
adipogenesis and
stimulation of
apoptosis

PARP and Bcl-2
proteins, caspase-3,
Bax, and Bak proteins

In vitro 3T3-L1
adipocyte

[56]

Quercetin

Inhibition of
inflammation

IL-6, IL-8, MCP-1,
IL-1b

In vitro human
adipocyte

[94]

Genistein, epigallocatechin gallate (EGCG),
or capsaicin

Glycine
max (soy)
isoflavone

Induction of
apoptosis

þAMPK

In vitro 3T3-L1
adipocyte

[116]

GenisteinþL-carnitine
(soy isoflavone)

Soybean

Inhibition of lipid
accumulation

þACS and CPT-1,
PPARs agonistic
activity

Mice with HFD

[73]

EGCG

Inhibition of adipocyte differentiation
and lipid
accumulation

PPAR-g and C/EBPa

In vitro 3T3-L1
adipocyte

[57]

EGCG

Appetite suppression

Leptin, insulin,
insulin-like growth
factor 1

Lean and obese
zucker rats

[41,42]

EGCG þ caffeine

Stimulation of thermogenesis, fat
oxidation, or both

Healthy male subjects

[117,118]

EGCG

Stimulation of thermogenesis, fat
oxidation, or both

Overweight men

[119]

In vitro pancreatic
lipase inhibitory
activity

[30]

(2S)-30 ,40 ,7trihydroxyflavan(4a / 8)-catechin
(procyanidin B3, luteolin, and other
catechins)

Cassia
nomame

Inhibition of pancreatic lipase

Pancreatic lipase

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.

9.1.3.2 Alkaloids
The antiobesity compounds under the alkaloid class of phytochemicals are summarized in Table 9.3. Berberine has been
shown not only to inhibit adipocyte differentiation, lipogenesis, and lipid accumulation but also to enhance thermogenesis,
whereas capsaicin, from chili pepper (capsicum), to inhibit adipogenesis and inﬂammation and induce apoptosis.

9.1.3.3 Saponins
Summarily, escin from Aesculus turbinata (seed), chikusetsusaponins (Panax japonicus), platycodin saponins and saponins from Scabiosa tschiliensis (scabiosaponins E, F, G, and I, hookerosides A and B, and prosapogenin 1b) have been
shown to inhibit pancreatic lipase, while ginsenosides from Panax ginseng inhibit adipocyte differentiation (Table 9.4).

9.1.3.4 Terpenoids
As shown in Table 9.5, terpenoids with antiobesity activities include corosolic acid, carnosic acid, and carnosol
(Rosmarinus ofﬁcinalis) whose action is to inhibit adipocyte differentiation and lipid accumulation; neoxanthin, crocin, and
crocetin repress pancreatic lipase and lipid accumulation; fucoxanthin promotes energy expenditure; licorice ﬂavonoid oil
from Glycyrrhiza glabra inhibited lipid accumulation; abietic acid, auraptene, and dehydroabietic acid inhibited
inﬂammation.
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TABLE 9.3 Alkaloid compounds with antiobesity activities.
Bioactive
compound

Plant (part)

Berberine

Berberine

Cortidis
rhizoma

Berberine

Mode of action

Molecular targets

Experimental
model

Inhibiting adipocyte
differentiation, lipogenesis,
and lipid accumulation,
enhance thermogenesis

þAMPK, FAS, ADD1/
SREBP1c, 11b-HSD1 and
aP2, þUCP2

In vivo HFD-fed rats,
db/db mice, in vitro
3T3-L1 adipocyte

[69]

Inhibition of adipocyte
differentiation and lipid
accumulation

PPAR-g/a and C/EBPa,
aP2, CD36, ACO, LPL

In vitro 3T3-L1
adipocyte

[58]

Inhibition of adipocyte
differentiation

PPAR-g, GATA-2 and
GATA-3

In vitro 3T3-L1
adipocyte

[120]

References

Capsaicin

Chili pepper
(capsicum)

Inhibition of adipogenesis
and stimulation of apoptosis

PPAR-g, C/EBPa, PARP,
Bcl-2, and
leptin, þcaspase-3, Bax,
Bak, and adiponectin

In vitro 3T3-L1
adipocyte

[59]

Capsaicin

Chili pepper
(capsicum)

Inhibition of inflammation

þPPAR-g; þadiponectin,
IL-6 and MCP-1

Obese mice adipose
tissues

[95]

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.

TABLE 9.4 Saponin compounds with antiobesity activities.
Bioactive
compound

Plant (part)

Mode of
action

Escin

Aesculus
turbinata (seed)

Ginsenosides

Panax ginseng

Ginsenosides

Molecular targets

Experimental model

References

Pancreatic lipase
inhibitor

Pancreatic lipase

In vitro pancreatic lipase
inhibitory activity

[31]

Inhibiting
adipocyte
differentiation

þAMPK, PPARg; þ PKA with
increased intracellular cAMP

In vitro 3T3-L1 adipocyte

[121,122]

Inhibiting
adipocyte
differentiation

PPAR-g, C/EBPa,
FABP4, and
perilipin

In vitro 3T3-L1 adipocyte
and human primary adipocytes, in vivo obese leptindeficient mice

[60]

Platycodin saponins

Platycodi radix

Inhibition of
pancreatic
lipase and lipid
accumulation

Pancreatic lipase

In vitro pancreatic lipase
inhibitory activity; HFDfed rats

[123e126]

Chikusetsusaponins

Panax japonicus

Inhibition of
pancreatic
lipase and lipid
accumulation

Pancreatic lipase

In vitro pancreatic lipase
inhibitory activity, in vitro
HFD ICR mice and rats

[127]

Scabiosaponins E, F,
G, I, hookerosides A,
B, and prosapogenin
1b

Scabiosa
tschiliensisGrun.

Inhibition of
pancreatic
lipase

Pancreatic lipase

In vitro pancreatic lipase
inhibitory activity

[32]

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.
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TABLE 9.5 Terpenoid compounds with antiobesity activities.
Bioactive
compound

Plant (part)

Mode of action

Molecular targets

Experimental model

References

Abietic acid

Pine rosin

Inhibition of
inflammation

þPPAR-g

Ni

[97]

Auraptene

Citrus fruit

Inhibition of
inflammation

þPPAR-g; þadiponectin,
MCP-1

3T3-L1 adipocytes

[96]

Betulinic acid

Clusia
nemorosa L.

Inhibition of fat/
lipid
accumulation

Amylase and lipase

Mice fed HFD

[33]

Carnosic acid

Rosmarinus
officinalis

Inhibition of
adipocyte
differentiation
and lipid
accumulation

PPAR-g, SREBP1, and
C/EBPa

In vitro 3T3-L1 adipocyte

[61]

Carnosic acid
and carnosol

R. officinalis

Inhibition of
adipocyte
differentiation
and lipid
accumulation

Activation are phase 2
enzymes (Gsta2, Gclc,
Abcc4, and Abcc1) and
GSH metabolism

In vitro 3T3-L1 adipocyte

[128]

Crocin and
crocetin

Gardenia
jasminoides
(fructus)

Inhibition of
pancreatic lipase
and lipid
accumulation

Pancreatic lipase

In vitro inhibitory activity
of pancreatic lipase, in vivo
high cholesterol, high fat,
or high
carbohydrate, Triton
WR-1339 induced
hyperlipidemic mice,
and rats

[129,130]

Dehydroabietic
acid

Pine rosin

Inhibition of
inflammation

þPPAR-g; þadiponectin,
TNF-a, and MCP-1

3T3-L1 adipocytes and
HepG2 hepatocytes;
obese diabetic KK-Ay mice

[97,98]

Fucoxanthin

Undaria
pinnatifida
(seaweed)

Promoting energy expenditure

þUCP1, leptin and
TNF-a mRNA

KKAy mice with soybean
oil diet

[84]

Neoxanthin

U.
pinnatifida

Inhibition of
adipocyte
differentiation
and lipid
accumulation

PPAR-g and C/EBPa

In vitro 3T3-L1 adipocyte

[131]

Corosolic acid

Eriobotrya
japonica

Inhibition of
adipocyte
differentiation
and lipid
accumulation

PPAR-g and C/EBPa

In vitro 3T3-L1 adipocyte

[62]

Licorice flavonoid oil

Glycyrrhiza
glabra L.
(root)

Inhibition of
lipid
accumulation

þPPAR-g; upregulation of
b-oxidation genes and
downregulation of fatty
acid synthesis genes

In vitro human adipocyte,
diabetic obese KK-Ay mice;
HFD obese mice

[132,133]

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.
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TABLE 9.6 Xanthone compound with antiobesity activities.
Molecular
target

Experimental
model

Inhibition of lipid
accumulation

FAS

NADPH
absorbance
assay

[134]

G. mangostana

Inhibited adipogenesis,
lipid accumulation, and
stimulated lipolysis

FAS

In vitro 3T3-L1
adipocyte

[77]

G. mangostana

Inhibition of adipogenesis and inflammation

Nrf2,
adiponectin,
NF-kB-RE/
GFP, MCP-1

In vitro 3T3-L1
adipocyte

[110]

Bioactive compound

Plant (part)

Mode of action

Garcinone E (a-mangostin,
b-mangostin, g-mangostin,
neosmitilbin,
9-hydroxycalabaxanthone,
1,3,7-trihydroxyxanthone,
2,4,6,7-tetrahydroxyxanthone,
3,4,5,30tetrahydroxybenzophenone,
2,4,6,30, 50pentahydroxybenzophenone)

Garcinia
mangostana

a-Mangostin and g-mangostin

g-Mangostin

References

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.

TABLE 9.7 Organosulfur compounds with antiobesity activities.
Bioactive
compound

Plant
(part)

Ajoene

Garlic

Inhibition of adipocyte differentiation and induction of apoptosis

Ajoene

Garlic

Induction of apoptosis

Allicin

Mode of action

Inhibition of lipid accumulation

Molecular target

þERK and JNK, translocation
of AIF, degradation of PARP-1,
fragmentation of DNA

Experimental
model

References

In vitro 3T3-L1
adipocyte

[135]

In vitro 3T3-L1
adipocyte

[73]

In vivo rats fed
fructose-enriched
diet

[136]

Key: () indicates downregulated, decreased, reduced, or inhibited; (þ) indicates upregulated, increased, elevated, or induced.

9.1.3.5 Xanthones
A couple of xanthones from Garcinia mangostana, garcinone E, a-mangostin, b-mangostin, g-mangostin, neosmitilbin, 9hydroxycalabaxanthone, 1,3,7-trihydroxyxanthone, 2,4,6,7-tetrahydroxyxanthone, 3,4,5,30-tetrahydroxybenzophenone,
and 2,4,6,30,50-pentahydroxybenzophenone have been shown to inhibit lipid accumulation (Table 9.6). Also, a-mangostin
and g-mangostin inhibited adipogenesis, lipid accumulation, and stimulated lipolysis while only g-mangostin inhibited
inﬂammation.

9.1.3.6 Organosulfur compounds
The mode of action for some organosulfur compounds with antiobesity activities includes inhibition of adipocyte differentiation and induction of apoptosis by ajoene (garlic) or inhibition of lipid accumulation by allicin (Table 9.7).
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TABLE 9.8 Other compounds with antiobesity activities.
Bioactive
compound

Plant (part)

Mode of action

b-Conglycinin,
glycinin (globulins)

Glycine max
(soybean)

Inhibition of lipid
accumulation

Tripeptide
(Ile-Gln-Asn)

Rhynchosia
volubilis
(black soybean)

Inhibition of adipogenesis

Steroidal glycoside
(P57AS3)

Hoodia gordonii

Appetite suppression
Inhibition of lipid
accumulation

Cinnamon

Molecular
target

Experimental
model

þAcyl-CoA
oxidase, FAS,
SREBP1 and 2

Normal (ICR) and
obese (KK-Ay) mice
fed HFD

[137]

In vitro 3T3-L1
adipocyte

[138]

ATP content in
the hypothalamus

Rats

[39,40]

þPPAR-g/a,
CD36, LPL, FAS,
GLUT4, ACO

DIO and db/db
mice

[139]

Zucker obese rats

[140]

Rat brain cortex
in vitro

[38]

Overweight men
and women
subjects

[141]

In vitro 3T3-L1
adipocyte

[63]

References

Hydroxycitric
acid (HCA)

Garcinia
cambogia

Appetite suppression,
inhibition of lipid
accumulation

HCA

G. cambogia

Appetite suppression

HCA

G. cambogia

HCA

G. cambogia

Inhibition of adipocyte
differentiation and lipid
accumulation

Lectins

Phaseolus vulgaris
and Robinia
pseudoacacia

Appetite suppression

HarlaneWistar rats

[142]

Secoisolariciresinol

Linum
usitatissimum
(flax seed)

Inhibition of adipocyte
differentiation and lipid
accumulation

In vitro 3T3-L1
adipocyte

[143]

Ternatin

Coriolus versicolor
(mushroom fruit
body)

Inhibition of adipocyte
differentiation

In vitro 3T3-L1
adipocyte; rat
hepatocytes

[66]

[3H]-5-HT

C/EBPa

SREBP1,
C/EBPa, FAS,
ACC2

9.1.3.7 Others
In Table 9.8, b-conglycinin and glycinin (globulins) from Glycine max inhibited lipid accumulation via acceleration of
b-oxidation and suppression of fatty acid synthesis. Also, a tripeptide (Ile-Gln-Asn) inhibited adipogenesis; steroidal
glycoside (P57AS3) from H. gordonii suppressed appetite; cinnamon inhibited lipid accumulation; HCA suppressed appetite
and inhibited lipid accumulation; lectins suppressed appetite; secoisolariciresinol inhibited adipocyte differentiation and lipid
accumulation; and ternatin inhibited adipocyte differentiation (Table 9.8).

9.1.4 Clinical trials of antiobesity lead compounds
No FDA-approved antiobesity phytochemical compounds were found for the treatment of obesity in our search. Although
there are many phytochemicals with antiobesity activities, many are yet to enter clinical trials: this may be a result of
underreporting where there are disappointing results. It is vital to note that once a new therapeutic agent has been identiﬁed
through preclinical studies, clinical trials on the candidate/agent would involve testing for safety (Phase I); efﬁcacy and
side effects (Phase II); conﬁrmation of efﬁcacy and side effects in large-scale trials (Phase III); and postmarketing
surveillance (Phase IV). The application for approval of candidate/agent from the European Medicines Agency or FDA is
made after successful Phase III completion [24].
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Although there might not be antiobesity phytochemicals currently reported to be undergoing clinical trials, a few of
them have been tested for toxicity and safety in animals and humans. For example, after oral administration of 20 mg/kg
per day of resveratrol in rats for 28 days, no toxic effects were found [144]. Also, no toxic effects were witnessed in rats
administered 300 mg/kg per day of resveratrol for 28 days [145]. Boocock et al. [146] found no toxicity when a single dose
of resveratrol up to 5 g was administered in humans. These toxicity studies on resveratrol indicate that it could
be consumed for its useful effects without any apparent toxicity.

9.1.5 Limitations, future directions, and perspectives
9.1.5.1 Limitations of the therapeutic use of lead compounds
Despite the increased number of bioactive phytochemicals that have been reported to possess antiobesity activities in
various models, translational research from rodents to humans was mostly disappointing. There are many reasons why we
are yet to have an effective drug from plant source in the market; these might include increasing demands for safety and
novelty, the high cost of drug development, and disconnection between researchers in higher educational institutions and
drug industries. In a review, Hann [147] stated that it takes an estimated $1.8 bn to get a new drug to market, of which the
costs of clinical trials have the highest cost impact of failure for a drug. Also, in a situation where only about 5% of
drugs/candidates are successful in the clinical phases [147], pharmaceutical companies are reluctant to invest money on any
pharmacologically active compound to get it through the various stages of clinical trials.

9.1.5.2 Future directions and perspectives
Pharmacological single compounds were initially successful in achieving weight loss for obese people, but they are
now often subjected to counterregulation [24]. A combination of two or more antiobesity compounds designed to
simultaneously target multiple mechanisms might result in better weight loss effect. In fact, two treatments (Contrave and
Qnexa) that were previously submitted for FDA approval were combination therapy [24]. The advantages of combination
therapy, such as phentermine and fenﬂuramine combination, include additive weight loss due to possible synergy, lower
drug doses, less adverse effects, and less potential for counterregulation [148].
Although it was difﬁcult to ﬁnd antiobesity single compounds of plant source in the clinical trials, we observed a
large number of plant extracts, fractions, and combined compounds in the early phases in a review by Hasani-Ranjbar
et al. [149]. Greenway et al. [150] reported that the administration of herbal supplement containing caffeine and ephedra
to obese and overweight persons in a randomized clinical trial (RCT) signiﬁcantly decreased fat and body weight.
Likewise, the administration of HCA and a combination of HCA, niacin-bound chromium, and Gymnema sylvestre
extract to obese persons in an RCT who were placed on weight loss program induced a decrease (5%e6%) in body
weight, BMI, and food intake [151]. Thus, combining more than one compound from single or multiple plants acting on
multiple obesity molecular targets may offer greater advantages over treatments with single compounds in both
preclinical and clinical models.
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List of Abbreviations
AD Alzheimer’s disease
PD Parkinson’s disease
HD Huntington’s disease
NDD Neurodegenerative disorders
MS Multiple sclerosis
AChE Acetylcholinesterase
CNS Central nervous system
ALS Amyotrophic lateral sclerosis
ERK Extracellular signaleregulated kinases
MAPK Mitogen-activated protein kinase
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CREB cAMP response element-binding protein
BNDF Brain-derived neurotrophic factor
Nrf2 Nuclear factor E2-related factor 2
JNK Jun amino-terminal kinases
NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells

10.1 Introduction
The nervous system is a highly complex organ system that controls and regulates all the vital functions through the
coordination of its actions and communicating or sending signals among the different parts of the body and with the
environment. This system is made up of the brain, spinal cord, sensory organ, and nerves that connect these organs with
the rest of the body. There are around 600 nervous system diseases or neurological diseases [1]. Among the most prevalent
diverse group of neurological disease are neurodegenerative disorders (NDDs).
Neurodegeneration is a slow and progressive dysfunction or deterioration of neurons either by age or environmental
factors resulting in irreversible impairment of cognitive, motor, sensory, and emotional functions. In most cases, acute
neurodegeneration is recovered in the course of time, while the chronic NDDs progress with disease state by time. Among
the chronic NDDs, Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS), etc., are the most prevalent around the globe. According to 2016 report from the Global Burden of
Diseases, investigators disclosed that neurological disorders are the largest cause of disability-adjusted life years and the
second-largest cause of global deaths [2]. From the recent estimated data, 6.8 million people die every year on account of
neurological disorders [3].

10.1.1 Neurodegenerative diseases
10.1.1.1 Alzheimer’s disease
AD is a chronic degenerative brain disease, which is the most common form of dementia. The major clinical symptoms
include depression, apathy, memory loss, and language and learning difﬁculties. It is basically an age-related neurodegeneration with the disease onset after 65 years. Biochemical pathology of AD signiﬁes formation of amyloid beta (Ab)
plaques, neuroﬁbrillary tangles, loss of synapses, neuron, hyperphosphorylation of tau, astrogliosis, and many others [4],
leading to neurodegeneration. Studies suggest that the budding of Alzheimer’s would be way back from the presence of
symptoms. The disease starts with the major symptom of dementia and then leads to other problems in thinking, walking,
etc. From 2017 report, in America, 5.5 million people have Alzheimer’s and records from ofﬁcial death certiﬁcates states
that 93,541 deaths are from AD [5]. Globally, about 46.8 million people are living with Alzheimer’s dementia [6].
Neuropathology involves the extracellular deposition of Ab and intracellular accumulation of tau protein. The pathological
lesion called senile or neuritic plaque contains Ab protein as main component, whereas the neuroﬁbrillary tangles contain
overphosphorylated tau protein. From these changes in the brain, it shrinks and neurons degenerate. Acetylcholinesterase
(AChE) also has contributed for the pathogenesis by forming a stable complex with the amyloid component and increases
the neurotoxicity. Till date, there is no perfect cure for Alzheimer’s, but they all lower the pathological symptoms. Some of
the medications attempt for the betterment of brain functions and slows down the progression of disease. Some drugs have
shown more effectiveness when treated in the early stages. Most of the current drugs have plenty of side effects.

10.1.1.2 Parkinson’s disease
PD is a neurological degenerative disorder concerned mainly with motor neurons. Here, the loss of nerve cell takes place at
speciﬁc part of the brain called the substantia nigra. These neurons are involved in the movement by the secretion of nerve
transmitter majorly dopamine. And hence in the case of Parkinson’s, these cells degeneration will impact in disturbance of
the movement leading to primary symptoms such as tremor in hands, arms, legs, jaw, and face; rigidity or stiffness of the
limbs and trunk; bradykinesia or slowness of movement; and postural instability or impaired balance and coordination [7].
Its general range is around 100e200 per 100,000 people with annual incidence of 15 per 100,000. In old age groups, the
morbidity rate of 1e2 per 1000 is noted for PD [8]. Pathological signs involve the formation of Lewy bodies composed of
aggregated a-synuclein protein within glial cytoplasmic inclusions. Multiple system atrophy is the other major a-synucleinopathy and tauopathy known [7]. Current therapy includes the supply of artiﬁcial dopamine, prominent enzyme
inhibitors, neurosurgical treatment, etc. Although with this sophisticated therapies, this could not reach the completeness in
the curation of PD. This gap has been felt and there is a necessity to ﬁnd alternative drugs for its treatments.
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10.1.1.3 Amyotrophic Lateral Sclerosis
ALS is also known as motor neuron disease and Lou Gehrig’s disease, which involves the death on neurons relating to
voluntary muscles. At the early stage, motor dysfunction will be focal, on progression it spreads to contiguous ventral
spinal or brainstem regions, and patient in the later stages may become paralyzed. Major symptoms include muscle cramps
and twitching in the arms, shoulders, and tongue, difﬁculty in walking, speaking, swallowing, and difﬁculty in holding
head up, etc. [9]. The incidence of ALS worldwide is approximately 1.9 cases per 100,000 persons annually with the onset
usually at 58e60 years and even increasing exponentially [10,11]. Disease pathology includes oval-shaped eosinophilic
intracellular inclusions in the motor neurons of the spinal cord and brainstem called Bunina bodies, loss of the giant cells
called Betz, and most importantly TDP-43 immunoreactive neuronal cytoplasmic inclusions [9]. No cure for ALS is known
till date. Some medications extend life span and some attempts to relieve symptom.

10.1.1.4 Huntington’s disease
HD is a genetic brain disorder with progressive loss of neurons. It is caused by a single defective gene on chromosome 4.
The defective gene codes for a protein called Huntington [12]. This defective protein leads to degenerative changes in brain
cells with the symptoms of uncontrolled movement of the arms, legs, head, a severe decline in thinking and reasoning
skills, and irritability, depression, and other mood changes. Most people develop the disease between the age of
30e40 years. Previously, 4e6 people in a population of 100,000 contributed for global prevalence [13]. From recent
studies (2016), the prevalence of HD suggests differences in the disease incidence between regions across the world [14].
Approximately 12 people per 100,000 in the population have a worldwide prevalence of HD. As of the etiology, the
extensive degeneration is found in the basal ganglia and the cerebral cortex. This is accompanied by reactive astrogliosis in
the neostriatum. Currently, there are no effective treatment options or effective disease-modifying therapies available for
HD.

10.1.1.5 Multiple sclerosis
MS is a chronic inﬂammatory demyelinating autoimmune disorder of the central nervous system (CNS) with unknown
etiology. Secondary level of MS pathogenesis is considered under neurodegenerative activity. Speciﬁc symptoms include
muscle weakness, double vision leading to blindness in one eye, problem with sensation, and trouble with coordination,
etc. MS occurs in several different forms as isolated attacks (relapsing forms) or building up overtime (progressive forms).
Globally, MS prevalence has increased dramatically, affecting more than 2.3 million people [15]. The disease usually
begins between the ages of 20 and 50 and is more common in women than men. The main pathological characteristics of
MS are the formation of lesions/plaques in the brain and spinal cord, inﬂammation, and destruction of myelin sheaths of
neurons. Increase in the proinﬂammatory cytokines, oligoclonal bands in the blood, and bloodebrain barrier damage [16].
There are approved, disease-modifying medications for different stages of disease, although they are effective in
controlling the disease progression and number of attacks, and no drug is formalized for cure.

10.1.2 Factors affecting neurodegeneration
There are quite a number of factors that have been implicated as possible causes of neurodegeneration. These factors can be
grouped into three: age, environmental, and genetic factors (Fig. 10.1).
(1) Age: Aging is a natural phenomenon with complex biochemical process and also a major risk factor for many prevalent
disorders mainly cardiovascular, cancer, and neurodegenerative diseases. According to the free radical theory of aging,
which explains the deterioration of immune and neuroendocrine systems leading to major neurodegenerative disease,
researchers have shown that aging at the cellular and molecular levels alter the brain proteostasis, create oxidative
stress, impair mitochondrial function and energy metabolism, and dysregulation of neuronal transmission homeostasis
[17]. In particular, there would be the formation of amyloid plaques, hyperphosphorylation of tau and a-synuclein, and
accumulation of transactive response DNA binding protein-43 (TDP-43), which leads to the neuronal and brain volume
loss and changes in the morphology of the brain [18,19]. As one ages, the brain could begin to loss its functional and
structural plasticity, contributing to many neurofunctional changes [20].
(2) Environment: Even with the advanced research techniques, many NDD etiologies is still unknown and hence in most
cases are attributed to environmental risk factors (Table 10.1). The development of behavioral and physiological
aberrations in NDDs would be inﬂuenced by exposure to various variables in the environment. These variables
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FIGURE 10.1 Overview of factors responsible for neurodegenerative disorders.

TABLE 10.1 Environmental factors contributing to neurodegenerative diseases.
Environmental
factors

Suspected
disease

Neurological mechanism

References

Pesticides

AD, PD, ALS

Oxidative stress

[21e24]

Metals

AD, ALS, HD,
PD

Generation of reactive oxygen species, DNA damage, mitochondrial
dysfunction

[25]

Smoking

AD, PD, MS, ALS

Modulates dopamine release

[26e29]

Virus

AD, PD, ALS, MS

Involves in pathophysiology of the disease

[30e35]

include metals, pesticides, pollutants, toxic food, microorganisms, virus infection, smoking, drug abuse, etc. Even with
the exposure during in utero condition of fetus, effects the neuronal development which leads to neurodegeneration in
infancy. These kinds of variations are due to gene and environment interaction, which is collectively referred to an
emerging ﬁeld called “epigenetics.” The epigenetic changes do not alter nucleotide sequence rather inﬂuence the
expression of gene by three chief mechanisms: DNA methylation, histone modiﬁcation, and micro-RNAeassociated
posttranscriptional gene silencing according to environmental signals. Epidemiological evidences in Guam, Kii, and
papua showed that the exposure to calcium and magnesium in drinking water and cycad-derived products has led to
the origination of a rare combined neurological disorder called ALS/Parkinsonismedementia complex [36e38]. In
recent years, research investigations have shown the impact and relationship between environmental factors and NDDs.
(3) Genes: Genetic changes have a small effect on development of disease. The speciﬁc variations in the genetic makeup
results in one’s genetic susceptibility from familial inheritance and effects as disease risk factor. Genetic discoveries
for NDDs have been helpful in depicting the molecular mechanism of disease. Genome-wide association studies
(GWAS), a powerful tool, have already investigated the susceptible genes associated with the numerous NDDs
(Table 10.2). Although with complex etiology of NDDs, the environmental factors affects majorly on genetic expression contributing to disease susceptibility. Recently, GWAS have also revealed the biological pathway and networks
by genetic associations [47].

10.1.3 Therapeutic strategies and drug targets for the treatment of neurodegeneration
There are a number of therapeutic strategies targeting crucial pathways or target sites that have been studied. However, the
mechanisms of actions of some of the neurodegenerative drugs have not been fully understood. This section examines
some therapeutic mechanisms of phytochemicals that have the prospects of leading researchers to the development of more
effective drugs. This attempt was in part summarized in Fig. 10.2.

10.1.3.1 Inflammatory pathway mediators
Inﬂammation is one of the potent causes for neuronal injury in NDDs. Chronic inﬂammation in the brain leads to the
neuron deterioration. Microglia, a resident brain cell, plays a vital role in causing and sustaining neuroinﬂammation by
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TABLE 10.2 Major susceptible genes of neurodegenerative disorders.
Neurodegenerative
disease

Susceptible
genes

Major responsible
protein

Alzheimer disease [39,40]

APP

Amyloid precursor protein

Early onset of Alzheimer’s, increase in Ab
production

APOE

ε4 apolipoprotein E

Loss of synaptic plasticity and increase in
neuroinflammation

PSEN1

Presenilin 1

Intraneuronal accumulation of Ab peptides
and fibrillary accumulation.

PSEN2

Presenilin 2

Neuritic plaque formation and neurofibrillary tangle
accumulation.

SOD1

Copper/zinc SOD 1

Motor neuron death and paralysis

TARDBP

TAR DNA binding protein
(TDP-43)

Protein aggregates

FUS

Fused in sarcoma

Increase in cytoplasmic localization of the protein

SNCA

a-Synuclein

Neuropsychological disturbances, altered
neurotransmitter release

PRKN

Parkinson protein 2
(parkin, E3 ubiquitin protein ligase)

Nigrostriatal dysfunction, impaired
proteasomal and lysosomal degradation;

Huntington’s
disease [12]

HTT

Huntington

Ubiquitinated aggregates of the N-terminal
fragment of mutated huntington

Multiple sclerosis [46]

HLA-DRB1

Human leukocyte antigen

Autoimmunity

IL7R

Interleukin receptor 7

Multiplication of immune cells

Amyotrophic lateral sclerosis [41,42]

Parkinson disease
[43e45]

Pathogenic relevance

FIGURE 10.2 Overview of mechanism of actions of phytochemicals against neurodegeneration.
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production of proinﬂammatory mediators resulting in neurodegeneration. These mediators include prostaglandins,
leukotrienes; inﬂammatory cytokines such as IL-1b, tumor necrosis factor alpha, IL-6, and free radicals [48]. In the process
of production of proinﬂammatory mediators, the cells execute different inﬂammatory response signal transduction
pathways including phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), mitogen-activated protein kinase (MAPK),
and mammalian target of rapamycin. These in turn activate transcription factors-nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB), hypoxia-inducible factor-1 alpha (HIF-1a), and signal transducer and activator of
transcription, which serve as key modulators in the inﬂammatory response pathway [49,50]. All these steps of the
inﬂammatory response pathway are targeted and inhibited by phytochemicals for neuroprotection.

10.1.3.2 Enzymes
In-depth research on neuropathology of neurodegenerative diseases has given knowledge on new therapeutic targets such
as speciﬁc enzymes, contributing for disease pathology. Major enzymes include kinases such as protein kinase, RNA-like
endoplasmic reticulum kinase, protein kinase CK1 and CK2, AChE, NADPH oxidase, myeloperoxidase, cyclooxygenases,
lipoxygenases, histone deacetylase, MAO-B (monoamine oxidase type B), and so on. [51,52]. The abundant natural
compounds mainly from plants source are targeted against the speciﬁc enzymes for inhibition of its action in NDD
pathogenesis.

10.1.3.3 Oxidative stress pathway mediators
Normal aerobic metabolism in the human system produces free radicals. The uncontrolled trigger for production of free
radicals leads to the oxidative stress. These radicals attack on neurons and contribute to NDD symptoms and pathology.
On a counter to this action, there is a self-scavenging system called antioxidants. For neuroprotective mechanism,
the phytochemicals can be used as good antioxidants that scavenge the reactive oxygen species (ROS) and also can
stimulate the antioxidant enzyme systems such as catalase, glutathione peroxidase, and superoxide dismutase, as well as
upregulate the transcriptional factor such as nuclear factor E2-related factor 2 (Nrf2) [53]. They also target Nrf2/ARE
antioxidant pathway.

10.1.3.4 Mitochondrial dysfunction
Brain needs more glucose for its energy and hence its metabolism in the neurons relies mainly on mitochondria. They
perform vital cellular functions including ATP production, redox potential maintenance, intracellular calcium regulation,
free radical scavenging, etc. The mitochondrial dynamics such as fusion and ﬁssion mechanism rhythm is very much
essential for the normal functioning of the neurons. Abnormal mitochondrial gene expression, its enzyme activity, its DNA
defects, and mutant mitochondrial associated proteins increase the oxidative stress [54]. So the phytochemicals are targeted
to alter mitochondrial functions and processes for prevention of neuronal death.

10.1.3.5 Neurotrophins
Neurotrophins are the proteins produced in the brain for regular development and maintenance of neurons. These even
facilitate the repair and survival of neurons. These include nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), etc. For their action, they require neurotrophic receptor mainly
p75 and tropomyosin receptor kinase (Trk) [55]. For neuroprotective mechanism, the natural compounds are targeted as
agonists for the neurotrophic receptors and also as the enhancers of neurotrophins. And some phytochemicals directly act
as neurotrophins by enhancing neuron survival.

10.1.3.6 Apoptosis
Apoptosis is a programmed cell death. In accordance with the brain physiology, apoptosis plays a major role in neuronal
development and its establishment. In disease state mainly in NDDs, either by mitochondrial pathway (intrinsic) or by
receptor-mediated pathway (extrinsic), operates for neuronal loss. Biochemically, these involves oxidative stress,
mitochondrial dysfunction and activation of caspases. In neurons, when there is imbalance between anti-apoptotic
members like B-cell lymphoma-2 (Bcl-2) or BclxL and pro-apoptotic members like Bcl-2-associated X protein (Bax)
or Bcl-associated death promoter (Bad), this leads to apoptotic neuronal loss [56]. The cascades of apoptosis are
counteracted by radical scavengers and survival signals for neuroprotective function. Hence, the natural compounds can be
targeted to these apoptotic pathways and can assist in neuroprotection.
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10.1.3.7 Excitotoxicity
Majorly, the hyperactivation of glutamate or other amino acids and their receptors in neurotransmission leads to the
excitotoxicity, further neuron damage, and degeneration activity. In normal brain homeostasis, the glutamate and other
neurotransmitters cause neuronal depolarization and excitation. In the downstream of glutamate inducing nerve
transmission, the main receptor N-methyl-D-aspartate (NMDA) is involved, leading to calcium permeability to maintain the
equilibrium. In the neurodegenerative disease mechanism, glutamatergic system and calcium imbalance cause
excitotoxicity [57]. This kind of toxicity excites cells for apoptotic cell death and creates oxidative stress. In the
neuroprotective mechanism, these receptors are targeted to stop the overexcitation. Some phytochemicals are targeted as
antagonist to reduce the excitation intern degeneration of neurons.

10.1.4 Neuroprotective plants and major functional groups of phytochemicals
Neuroprotection by deﬁnition is the conservation of structure and function of neuronal cells and brain tissue by preventing
cell death and restoring the damage. It is also a main strategy for treatment of many NDDs of CNS. There are many
neuroprotective methods that include the use of neuroprotective agents, neuroreparative strategies, reducing
neuroinﬂammation and oxidative stress, hormonal treatment (e.g., melatonin), etc. Among the neuroprotective agents,
natural products are emerging as valuable potential agents for neuroprotection, as it has negligible side effects.
Phytochemicals, which are diverse in nature, come with distinct functional groups (Fig. 10.3), which could be modiﬁed to
yield drugs that are effective yet less toxic.

FIGURE 10.3 Basic structures of major group of phytochemicals with neuroprotective action.
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10.1.4.1 Flavonoids
Flavonoids are the secondary metabolites produced in plants with signiﬁcant role on human health. They are ubiquitously
present in plant kingdom with unique biological activity. There are more than 6000 ﬂavonoids that are isolated and
characterized. The categorized subgroups are ﬂavones, ﬂavonols, anthocyanins, proanthocyanidins, ﬂavonoids, isoﬂavones, and chalcones. Flavonoids have a speciﬁc role in CNS maintaining homeostasis by effecting as antianxiety,
anticonvulsant, by modulating neuronal oxidative metabolism, and neurotransmitters. Additionally, they act on signaling
cascades, which contribute to oxidative damage such as MAPK and P13/Akt, and prevent neuronal death. Because of
unique and speciﬁc functional groups of these ﬂavonoids, it acts as a potent inhibitor for the neurodegenerative enzyme,
contributing for scavenging of ROS [58,59].

10.1.4.2 Alkaloids
Alkaloids are the type of secondary metabolites with amine group as functional group. Its large-scale production is limited
to particular plants or trees. These molecules from plant sources have both negative and positive effects on
neuronal function. Most of these are neurotoxin in nature, even though some are medicinally helpful for mankind of
being a therapeutic. Major alkaloids are antidepressants, highly potent analgesic and narcotic drugs. Speciﬁcally, they
are stimulators of nicotinic receptors and inhibit cholinesterase activity by inhibition of enzymes relating to the same
action. They even interfere with some major neuronal survival pathways by its unique mechanism of action [59,60].

10.1.4.3 Terpenes and terpenoids
Terpenes and terpenoids are the fundamental components of essential oils from the plant source having a medicinal
importance. These pharmacologically active components are being used as natural drugs. These have GABA (B) receptor
binding property while strengthening the nervous function. There are different subtypes of terpenes with varying biological
activity including antiinﬂammatory, antioxidant, and antiapoptotic activities. Just like other phytochemicals groups, they
may interfere with the pathways and promote neuronal survival from the degenerative mechanisms [59].

10.1.4.4 Polysaccharides
Polysaccharides are long-chain glycosidically linked monosaccharides. Nowadays, attention is being drawn to their signiﬁcance in medicine especially in the ﬁeld of neurobiology. Previously, these polysaccharides had its function relating to
structure and storage, but now, in neuroprotection, it is been found to exhibit some antioxidant activity by Nrf2/HO-1
pathway, interfering with NFkB, activation of neurotrophic pathway and help in neuronal survival from neurodegenerative mechanisms [61].

10.1.4.5 Fatty acids
Fatty acids are the main composition for the formation of neuronal membranes. They are valuable in membrane ﬂuidity.
The dietary supplement of fatty acids is very much essential for the normal homeostasis of the neuronal membrane
structures. Among all the fatty acids, omega-3 and omega-6 fatty acids have very signiﬁcant importance in neuroprotection [62,63]. Polyunsaturated fatty acids are very essential for restoring the aging neuronal membrane. Rather in
interfering with the pathways, these fatty acids are important in maintaining membrane biophysical property and
synaptic plasticity.

10.1.4.6 Lignin
Lignin is the second most abundant naturally available organic macromolecule of plant source. Basically, it contributes in
the maintenance of the integrity of the cell wall. In its pure form, lignin lacks medicinal value, but its derivatives in
combination with phenol moiety has been gaining importance. These derivatives are majorly showing antiapoptotic and
neuroprotective effects in recent discovery in human neuroblastoma cell line [64].
A summary of some plants with neuroprotective properties is presented in Table 10.3.
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TABLE 10.3 Plants with neuroprotective importance.
Responsible
phytochemical
group

References
[65]

Plant name

Mechanism of neuroprotection

Acorus calamus

Protection against ischemia and neuronal damage.
Increases glutathione and superoxide dismutase activity.

Phenylpropanoid

Allium sativum

Protect from neuronal death by apoptosis.

Alkaloid

[66,67]

Angelica sinensis

Helps in viability of nerve cells.

Lactone

[68]

Bacopa monnieri

Memory development, learning, suppresses
acetylcholinesterase (AChE) activity,
and neuronal oxidative stress.

Triterpenoid
Saponins

[69]

Boswellia serrata

Acts as an Nrf2/HO-1 activator.

Triterpene

[70]

C. robusta L

Adenosine receptor antagonist and hence delaying the onset of AD.

Alkaloid

[71,72]

Camellia sinensis
Kuntze

High antioxidant activity.

Flavonoid

[73]

Celastrus
paniculatus

Decreases AChE activity

Oil

[74,75]

Centella asiatica

Treatment and management of neurodisorders,
cognitive impairment, and associated oxidative damage.
Improvement in learning and memory.

Triterpenoid

[76]

Clitoria ternatea

Protection against memory disruption.

Ethanol extract

[77]

Coriandrum sativum

Improves impart in mental concentration and memory
capabilities.
Antioxidant potential.

Terpene alcohol

[78]

Crocus sativus

Suppressing the production of free radicals and increasing antioxidant
activity.

Flavonoid

[79]

Curcuma longa

Antiinflammatory effect in the PD animal models.
Protects substantia nigra neurons.
Improves striatal dopamine levels.
Reduces neuronal apoptosis.

Polyphenol

[80,81]

Enhydra fluctuans

Antidepressant.

Glycosidic
flavonoid

[82]

Ginkgo biloba

Cerebroprotective effects.

Terpene lactones

[83]

Glycyrrhiza glabra

Neuroprotective effect via modulation of multiple pathways associated with apoptosis.

Flavonoid

[84]

Glycyrrhiza
uralensis

Apoptotic neuronal cell death induced by Ab fragments.
Anxiety.

Isoliquiritigenin

[85]

Hemidesmus indicus

Inhibition of AChE, BuChE, ab-glucosidase.

Extract

[86]

Huperzia serrata

AChE inhibitor.

Sesquiterpene
alkaloid

[87]

Hypericum
perforatum

Decreases oxidative stress and strengthen the defenses with the usage
of endogenous antioxidants.

Glycosidic
flavonoid

[88]

Lycium barbarum

Protects ganglion cells against acute ocular hypertension.
Prevents cortical neurons from damage against
ischemic insults.
Neuroprotective against ischemic injury.

Polysaccharide

[89]

Nardostachys
jatamansi

Improves cognitive impairment.

Extract

[90]

Nicotiana tabaccum

Antioxidation.

Extract

[91]
Continued
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TABLE 10.3 Plants with neuroprotective importance.dcont’d
Responsible
phytochemical
group

References

Plant name

Mechanism of neuroprotection

Ocimum sanctum

Inhibited lipid peroxidation, DNA damage, reactive oxygen species
(ROS) generation, and depolarization of
mitochondrial membrane.

Extract

[92]

Panax ginseng

Antiinflammatory, antioxidant, and antiapoptotic effects.

Steroid glycosides
and
triterpene saponins

[93]

Piper methysticum

Antianxiety and sleep-inducing ability, modulation of the
g-aminobutyric acid (GABA) receptor.

Lactone

[94]

Polygala tenuifolia

Antagonistic action on neurotoxicity induced by glutamate.

Triterpenoid
saponins

[95]

Rhinacanthus
nasutus

Free radical scavenging, caspase inhibition.

Sterol

[96]

Ricinus communis

Antiapoptotic.

Fatty acid

[97]

Rubia cordifolia

Reduced the Ab-induced cognitive and memory dysfunction.

Extract

[98]

Salvia officinalis

Improvement of cognitive functions.

Extract

[99]

Terminalia chebula

Inhibiting ROS production and reducing calcium ion influx.

Extract

[100]

Uncaria tomentosa

Antioxidation.

Alkaloid

[101]

Valeriana officinalis

Protection from Ab toxicity.

Extract

[102]

Valeriana wallichii

Potential to mitigate oxidative stress and inflammatory damage.

Extract

[103]

Withania somnifera

Improvement of memory and cognition enhancement.

Steroidal lactone

[104]

10.1.5 Lead phytochemicals molecular mechanism of action in neuroprotection
Because of the tremendous advancement in research, huge numbers of phytochemicals are screened for its potency in
neuroprotection (Table 10.4). This section discusses some important phytolead compounds and the mechanisms to which
they work.

10.1.5.1 Apigenin
Apigenin is a ﬂavone present in many fruits and vegetables such as celery, parsley, grape fruit, cabbage, etc. It has shown
protection against kainite-induced excitotoxicity and Ab 25e35 induced toxicity by antioxidant mechanism [105].
Apigenin exhibits antagonistic effect on GABA and NMDA channels, proving sedative and antidepressant activity [106].
In the double-transgenic mice model, it enhanced the ERK1/2/CREB/BDNF pathway [107]. Furthermore, it attenuated the
Ab neurotoxicity mediated by copper through mitochondrial protection by activating antioxidant enzymes. It has also
reduced hyperexcitability and apoptosis of neurons. It has even showed the decrease in the number of activated microglia
and also improved spatial reference working memory promising to be a good neuroantiinﬂammatory effect [108].

10.1.5.2 Quercetin
Quercetin is a ﬂavonol present in majority of fruits and vegetables. It has shown to decrease Ab-induced cytotoxicity by
reducing the oxidation of protein and apoptosis. It also favored the increase of antioxidant enzyme systems mainly GSH in
astrocytes and neurons against oxidative stress and in turn reduced Ab and tau levels in AD model. Its treatment reversed
b-amyloidosis, decreased tauopathy, and improved cognitive function. In vitro studies for Parkinson’s, quercetin markedly
reduced the apoptosis of pheochromocytoma (PC-12) cells and hippocampal neurons. It showed increased cell viability and
inhibited ROS and MDA production in H2O2-induced toxicity in PC-12 cells. In HD model, the supplementation with
quercetin showed effectiveness in improving mitochondrial dysfunction. Even in MS alone and in combination, interferon
beta showed a potent immunomodulatory effect [109,110].
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TABLE 10.4 List of some Phytochemicals and their structural details.
Phytochemical

Structure

Details

Flavonoid

OH

Apigenin

MF: C15H10O5
MW: 270.24 g/mol

O

O

HO

OH
OH

Quercetin

MF: C15H10O7
MW: 302.238 g/mol

O
OH

HO

O
OH
OH
HO

Epigallocatechin gallate

OH

O

OH

MF: C22H18O11
MW: 458.375 g/mol

OH
O

HO

OH

O

OH
OH

Alkaloid
CH3

Galantamine

O

H3C

MF: C17H21NO3
MW: 287.359 g/mol

O

N

OH

NH2

Huperzine A

MF: C15H18N2O
MW: 242.322 g/mol

H3C
H3C
N
H

O

Continued
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TABLE 10.4 List of some Phytochemicals and their structural details.dcont’d
Phytochemical

Structure

Details

H3C

Rivastigmine

H3C

MF: C14H22N2O2
MW: 250.342 g/mol

N

O
CH3

O
N

CH3

CH3
Terpenoids
Ginkgolides

H3C

CH3
OH

MF: C20H24O9
MW: 408.403 g/mol

OH C
3
O

O
O
HO

O

O
O

H3C

10.1.5.3 Epigallocatechin gallate
Epigallocatechin gallate (EGCG) is the main ﬂavanol of green tea. It’s an excellent natural antioxidant, vastly used in
treatment of many NDDs. In AD treatment, it reduced Ab peptide secretion and regulated APP expression in hippocampal
neurons by acting as an iron chelator. It has showed a selective antiapoptotic effect by accumulating in mitochondria
against oxidative stress in neurons. It has showed neuroprotection with scavenging activity and inhibiting DNA damage in
neurons. In this act of neuroprotection, it followed P13/Akt and GSK-3 pathway with activation of protein kinase C in
oxidative stressed neuronal cells. It has involved in the activation of cell survival/cell cycle genes in neuroprotective action.
It modulated tau pathology in AD. In MPTP-induced PD model through antioxidant mechanism, EGCG protected
dopamine neurons. It also showed protection of motor neurons by regulating glutamate level and suppressed progression of
ALS. EGCG modulates Huntington’s misfolding by reducing photoreceptor degeneration, reduces toxicity, and improves
motor function in Drosophila model of Huntington’s disease. In application to neurorescue process, EGCG inhibits HSP90
and stabilizes HIF-1a pathway, which is directly linked to suppression of hydroxyl radical scavenging. It even improves
muscle metabolism in people with relapsing MS [111e115].

10.1.5.4 Huperzine A
Huperzine A is a sesquiterpene alkaloid from ﬁrmoss Huperzia serrata. It is a potent inhibitor of AChE. This compound
boosts neuronal growth by activating NGF and concerned pathways. It reduces glutamate excitotoxicity by acting as an
NMDA receptor antagonist. It shows a signiﬁcant antiinﬂammatory activity in neuroinﬂammation. In the motor
neuron-like cell line and motor neurons in spinal cord organotypic cultures in vitro model of ALS, huperzine A has shown
potential characters to be a useful drug for ALS. It has ameliorated the disease severity of mice model of MS by reducing
the accumulation of inﬂamosomes and in turn lowering the neuronal injury. It even lowers the production of
proinﬂammatory cytokines and enhances the antiinﬂammatory cytokine production. Because of its efﬁcacy in controlling
neurodegeneration, the compound is in phase III clinical trials [116,117].
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10.1.5.5 Galantamine
Galantamine is an alkaloid isolated mainly from Galanthus caucasicus and Galanthus woronowii. It is an FDA-approved
phytochemical for the treatment of Alzheimer’s disease. The main mechanism of action of galantamine is its irreversible
binding to AChE enzyme, thereby enhancing the cholinergic neurotransmission in the CNS. The same drug even in PD has
shown an impact by improving cognitive impairment [118,119].

10.1.5.6 Rivastigmine
Rivastigmine is a derivative of plant phytochemical physostigmine. As like many alkaloids, it is also a potent inhibitor of
AChE for the treatment of AD, which is now in the clinical trials. Even the drug is used for treating Parkinson’s and
ALS-associated dementia in recent years. In MS, rivastigmine is used for improving memory, cognition, and for activation
of brain subjected to cognitive fatigue [120,121].

10.1.5.7 Ginkgolides
Ginkgolides are terpenoids isolated from Ginkgo biloba. They occur naturally in different forms namely ginkgolides A, B,
C, etc. All these forms are in nature bond with the lactone moieties. They act by increasing the cholinergic transmission,
which in turn enhances the memory in AD model. While it is shown to reduce the effect of MPTP-induced nigrostriatal
dopaminergic neurotoxicity of PD mice model, it is also shown to decrease proinﬂammatory cytokine levels by the
suppression of MAPK pathway in neurons. Again, it reduces the glutamate-induced excitotoxic damage and has
antiapoptotic and antioxidant properties [122].

10.1.6 Anticipated neuroprotective phytochemicals as medicine
Drugs that appear successful from pilot studies against neurodegeneration are moved further in hierarchy before its release
to the market. This includes clinical trials for research experiments that require the insolvent of human volunteers to
evaluate the effectiveness and side effects of the drug. As these phytochemicals are edible dietary compounds, they most of
the time lack signiﬁcant side effects. Hence, many phytodrugs are now at the later phases of drug development and approvals. Presented in Table 10.5 are some of the phytocompounds in clinical trials.

TABLE 10.5 List of some potent phytochemicals in clinical trials and in markets.
Phytochemical

Market/trials

Neurodegenerative
disease target

Galantamine

Market

Alzheimer’s

ECGC

Clinical trial

Multiple sclerosis, Parkinson’s disease, Huntington disease

Kalata B1

Clinical trial

Multiple sclerosis

Andrographis paniculata
plant extract

Clinical trial

Multiple sclerosis

NCT02280876

Ginkgo biloba

Clinical trial

Multiple sclerosis

NCT00010842

Lipoic acid

Clinical trial

Multiple sclerosis, Alzheimer’s disease

NCT03161028, NCT01058941

Omega-3 fatty acids

Clinical trial

Multiple sclerosis, Alzheimer’s disease

NCT02133664, NCT01058941
NCT03150966

Nanocurcumin

Clinical trial

Multiple sclerosis

Dimethyl fumarate

Market

Multiple sclerosis

Cholecalciferol

Clinical trial

Multiple sclerosis

Polyphenon E

Market

Multiple sclerosis

American ginseng extract

Clinical trial

Multiple sclerosis

Clinical trials gov identifier:
NCT0201145, NCT00461942,
NCT01357681

NCT01198132

NCT00754832
Continued
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TABLE 10.5 List of some potent phytochemicals in clinical trials and in markets.dcont’d
Neurodegenerative
disease target

Phytochemical

Market/trials

Coenzyme Q10

Clinical trial

Apomorphine

Market

Parkinson’s disease

Ganoderma

Clinical trial

Parkinson’s disease

NCT03594656

Resveratrol

Clinical trial

Alzheimer’s diseasehuntington disease

NCT01504854, NCT02336633

Cannabidiol

Clinical trial

Parkinson’s disease

NCT03582137

Bryostatin

Clinical trial

Alzheimer’s disease

NCT02431468

Acitretin

Clinical trial

Alzheimer’s disease

NCT01078168

HF0220 (7-hydroxy
epiandrosterone)

Clinical trial

Alzheimer’s disease

NCT00357357

S-equol (4’,7-isoflavandiol)
[metabolite of the soy
isoflavone daidzein]

Clinical trial

Alzheimer’s disease

NCT03101085

Salsalate

Clinical trial

Alzheimer’s disease

NCT03277573

Parkinson’s disease,
huntington disease

Clinical trials gov identifier:
NCT01892176

Grape granules

Clinical trial

Alzheimer’s disease

NCT03221894

Triheptanoin

Clinical trial

Huntington disease

NCT02453061

PBT2 (second-generation
8-hydroxyquinoline analog)

Clinical trial

Huntington disease

NCT01590888

Biotin

Clinical trial

Amyotrophic lateral
sclerosis

NCT03427086

Colchicine

Clinical trial

Amyotrophic lateral
sclerosis

NCT03693781

Cistanche

Clinical trial

Amyotrophic lateral
sclerosis

NCT00753571

Huperzine A

Clinical trial

Alzheimer’s disease

NCT00083590

ZT-1

Clinical trial

Alzheimer’s disease

NCT00423228

Curcumin

Clinical trial

Alzheimer’s disease

NCT00164749

10.1.7 Future perspective of phytochemicals in neurodegeneration treatment and conclusion
The problem mankind has been facing from the adverse effects of neurodegenerative diseases has led man in search of
suitable drug candidates or chemical entities that are safe, affordable, and available. Within the last few decades, the use of
synthetic drugs for the treatment of various diseases has now been inundated with research outcomes indicating long-term
severe side effects. This paradigm has reawakened the desire for natural therapeutic alternatives from natural products such
as medicinal plants.
Medicinal plants over the time has proven to be an invaluable source of vital lead compounds that could serve as a
model for the development of a more potent drug that is neither cytotoxic nor genotoxic. This is one reason why there have
been rapid advances in the development of high-throughput screening techniques with the invention of sophisticated
high-breed systems to aid the characterization and elucidation of the chemical composition of plants. Also, studies through
computer-aided drug discovery techniques and the use of animal models have found some progress. However, in all,
effort should be directed to drug designing for neurodegeneration that has the permeability to cross the bloodebrain
barrier, yet safe and readily available.
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11.1 Introduction to phytochemicals: chemistry and classification
Phytochemicals have attracted wide-ranging interest in the life sciences in the last few decades. They have been described
to include a variety of plant ingredients with varying structures, and interest in them has arisen because of their reported
health-promoting effects. They have been described as potentially beneﬁcial nutrients found in plant foods, yet despite
years of research, they are still designated as nonessential because they are not imperative for sustaining life [1].
Phytochemicals are compounds produced by plants through metabolism, which may be classiﬁed as primary or
secondary metabolism. Primary metabolism directly contributes to growth, development, and reproduction of the plant and
includes the production of compounds involved in essential metabolic functions such as photosynthesis, respiration, and
protein synthesis. Primary metabolites are produced in large quantities, and their extraction is easy. The products are
chemically similar in every plant species. They include most traditionally recognized food nutrients such as carbohydrates,
proteins, lipids, and vitamins, etc., whose functions in the body were the focus of research till the 1980s and are
well-documented in the nutritional sciences.
Plants also produce compounds through secondary metabolism, which does not aid growth and development, but
usually have important ecological functions. These are specialized compounds that are required by the plant to survive in a
particular environment. They are produced in small amounts, are difﬁcult to extract, and have complex chemical structure,
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which differs from plant species to plant species. It is accepted that they are not essential to the life of the plant. According
to one estimate, there could be about 200,000 compounds produced by plants through secondary metabolism [2], although
all have not yet been characterized. They function for the beneﬁt of the plant and may help it in a variety of ways, such as
promoting growth and in the defense of the plant against pathogens, predators, and competitors. They have also been found
to function as antigrazing agents, pesticides, pigments, hormones, and allelopathic agents that can attack other plants, and
some phytochemicals have been used as poisons in traditional medicine.
Of human interest as lead compounds for the discovery of new drugs are phytochemicals in foods that are likely to have
a beneﬁcial role in health. These can be classiﬁed in several ways: on the basis of their chemical structure, botanical origin,
biosynthesis, or biological properties [3]. The presence of characteristic structural motifs or chemical functions determines
the particular class to which they belong, for example, 2-phenyl-1,4-benzopyrone for ﬂavonoids, phenolic groups in
polyphenols, phytosterols with their steroid structure hydroxylated in the 3-position of the A-ring, alkaloids containing
nitrogen atoms in complex and highly diverse structures, etc. Phytochemical classiﬁcation may also be derived from their
biosynthetic origin, such as “true alkaloids” derived from amino acids or terpenoids resulting from the condensation of a
varying number of isoprene units formed through the mevalonate pathway. As a result, most phytochemical classiﬁcation
schemes are based on chemical structure deﬁnitions.
According to one scheme [4], phytochemicals have been classiﬁed on the basis of their chemistry into ﬁve broad
categories, namely carotenoids, phenolics, alkaloids, nitrogen-containing compounds, and organosulfur compounds
(OSCs). This classiﬁcation has been used to describe some salient features of their structure and other properties and is
presented in Table 11.1.
This humongous assemblage of compounds under the umbrella of “phytochemicals” has been connected by the thread
of the history of their role in naturopathy as medicinal herbs, spices, teas, and foods, as well as antinutrients and toxins. In
India, the Indian Council of Medical Research published its ﬁrst compilation of medicinal plants in 1987 [8]. Identiﬁcation
of a variety of phytochemicals in medicinal plants became possible with the development of highly sensitive analytical
methods. The developments in chromatographic, colorimetric, spectroscopic, microbiological, and many other techniques
led to an understanding of the biological phenomenon and biochemical mechanisms. These have found widespread
applications to study foods and their effects on the body. Consequently, the last few decades have seen a mushrooming of
research on these groups of biochemicals.

11.1.1 General mechanisms of action of phytochemicals as antioxidants and
antiinflammatory compounds
The main reasons for the increased interest in phytochemicals can be traced to the discovery of the role of free radicals in a
wide range of diseases and in aging, and the role of antioxidants in regulating their levels and achieving a physiologically
desirable balance.
During the last two decades, there has been a great amount of research on the free radical generation of reactive oxygen
species (ROS) and reactive nitrogen species by the body’s endogenous systems during a variety of physiological and
pathological conditions. An abundance of free radicals in comparison with antioxidants results in oxidative stress, which
has been implicated in many disease conditions. The role of antioxidants in reversing the adverse effects of the free radicals
has been reviewed extensively [9e11]. An antioxidant may function as a radical scavenger, a hydrogen donor, an electron
donor, a peroxide decomposer, a singlet oxygen quencher, an enzyme inhibitor, a synergist, or a metal-chelating agent to
control oxidative stress. Enzymatic and nonenzymatic antioxidants exist in the intracellular and extracellular environment
to detoxify ROS [12e14].
There has been a growing awareness among consumers that phytochemical and other plant products are safer and
healthier than chemically processed products that have several side effects. Synthetic antioxidants such as butylated
hydroxytoluene and butylated hydroxyanisole have been reported to be dangerous for human health, so the search for
effective, nontoxic natural compounds with antioxidative activity has been intensive [15]. This, coupled with a large
number of scientiﬁc discoveries linking free radical biology to the antioxidant potential of an extremely large set of
phytochemicals, has led to changes in consumer preferences toward natural phytochemicals. Owing to their speciﬁc
medicinal properties, phytochemicals became highly valued in the pharmaceutical industry, and a large amount of work
was undertaken to assess the compounds responsible for the medicinal value of these plants and their physiological action
on the human body [16].
This has resulted in the development of a multibillion-dollar industry. According to one estimate, the bioactive
ingredients’ market was estimated to grow from $23.8 billion in 2013 to $33.6 billion in 2018 at a CAGR of 7.2% from
2013 to 2018 [17]. It has been pointed out that the history of scientiﬁc investigation has been inﬂuenced by medicine,

Phytochemical
category

Characteristic
chemical nature

Carotenoids

Phenolics

Alkaloids

Selected common
examples

Function for plant

Subgroups

Oxygenated hydrocarbon

Carotenoids absorb light
for photosynthesis along
with chlorophyll and
protect chlorophyll from
photooxidative damage

Carotenoids,
xanthophylls

a-Carotene, b-carotene,
b-cryptoxanthin, lutein,
zeaxanthin, lycopene

a-Carotene, b-carotene,
and b-cryptoxanthin can
be converted by the
body to retinol

Carotenoids
>750 terpenes
>15,000

Aromatic benzene ring
compounds with one or
more hydroxyl groups

Protection against stress,
help in
reproduction, and
growth of the plant

Phenolic acids:
Hydroxybenzoic
acids, hydroxycinnamic acids

Luteolin

8000

Flavonoids:
flavanols,
flavones, flavonols,
flavanones,
anthocyanidins,
isoflavones

Quercetin, catechin,
epicatechin, naringenin,
cyanidin

Interactions with biotic
and abiotic environments
are difficult to estimate
Flavonoids contribute
about two-third dietary
phenolics

Stilbenes

Resveratrol, diethylstilbestrol, fosfestrol,
dienestrol

Coumarins

Coumarin, dicoumaral,
warfarin

Tannins

Ellagic acid, gallic acid,
pyrogallic acid

Isoquinoline
alkaloids

Berberine, morphine,
montanine

Indole alkaloids

Geissospermine

Piperidine
alkaloids

Piperine

Pyridine alkaloids

Nicotine, arecoline

Methylxanthine
derivatives

Caffeine

Group of highly diverse
natural products that
contain one or more
basic nitrogen atoms in a
heterocyclic ring

Biologically significant
as active stimulators, inhibitors, and terminators
of growth, a part of an
endogenous security and
regulation mechanism

Remarks

Approximate
number of
compounds
identified

5000 [2]

2000 [2]

>4000
>21000 [2]
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TABLE 11.1 Classification and some salient features of dietary phytochemicals.

Phytochemical
category
Nitrogencontaining
compounds

Organosulfur
compounds

Characteristic
chemical nature
An organic compound
that contains nitrogen

Organic compounds that
contain sulfur

Function for plant

Subgroups

Selected common
examples

Although research in this
area is still in its infanthood, it is clear that
cyanogenesis is part of a
complex system that,
among others, gives protection against particular
groups of herbivores

Cyanogenic
glycosides

Amygdalin, linamarin,
dhurrin

Glucosinolates

Glucobrassicin, 4methylsulfinyl butyl

Isothiocyanates

Sulforaphane

Nonprotein amino
acids

5-Hydroxytryptamine
(serotonin)
L-3,4dihydroxyphenylalanine
(L-DOPA)

Allylic sulfur
compounds

Garlic (aliin, allicin,
ajoene, allyl propyl disulfide, diallyl trisulfide,
S-allyl cysteine, vinyldithiines, Sallylmercaptocystein,
and others), onion (aliin,
allicin)

Provide protection
against a wide range of
pathogens and pests

Remarks
Providing protection
against carcinogenesis,
mutagenesis, and other
forms of toxicity of electrophiles and reactive
forms of oxygen

Approximate
number of
compounds
identified
60 [2]
100 [2]

700 [2]

May induce detoxification of carcinogens, limit
production of cancerrelated hormones, block
carcinogens, and prevent
tumor growth

Glucosinolates
Isothiocyanates

Sulforaphane

Indoles

Indole-3-carbinol

From Plant secondary metabolism. Available: https://en.wikipedia.org/wiki/Plant_secondary_metabolism. Retrieved 10th December, 2018; A. Altemimi, N. Lakhssassi, A. Baharlouei, et al., Phytochemicals: Extraction, Isolation, and Identification of Bioactive Compounds from Plant Extracts, Plants 6, 42 (2017); Y.J. Zhang, R.Y. Gan, S. Li, et al., Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases, Molecules 20 (12) (2015) 21138e21156; Manfred Hesse, Alkaloids: Nature’s Curse or Blessing? Wiley-VCH, 2002, ISBN: 978-3-906390-24-6.
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public health, commerce, and politics. Hence, it would be to assess methodological and other issues that go into the
creation of drugs from phytochemicals [18].

11.1.2 Phytochemicals from food versus phytochemicals from tablets: physiological versus
pharmacological levels of intake
Flavonoids make up the largest class of phytochemicals [19,20]. So taking ﬂavonoid as an illustration, let us assess the
issue from a quantitative viewpoint and other methodological challenges.
Foods contain quantitatively more ﬂavonoids than the antioxidant vitamins, ascorbic acid, the tocopherols, and the
carotenoids [21e23]. Consequently, their dietary intakes (70, 7e10, and 2e3 mg, respectively, of ascorbic acid, the tocopherols, the carotenoids) have been found to be less than intake of total ﬂavonoids. Early studies reported ﬂavonoid
intakes to be 1 and 1.1 g/day [24]. Studies, using superior analytic methodologies, have reported that the recommended
nine daily servings of fruits and vegetables and moderate amounts of tea, coffee, wine, beer, or chocolate can provide well
over 1000 mg of total phenols per day [25], but results are inconsistent because another study reports intake of total
ﬂavonoids in the diet of US adults to be about 189.7 mg/d [26], which is still more than the intake of antioxidant vitamins.
There is considerable evidence that diets high in fruits and vegetables reduce the risk of hypertension, chronic heart
disease, stroke, cancer, and type 2 diabetes [27]. The mechanisms of action for these ﬁndings include inhibition of lipid
oxidation, lipid-lowering effects, hypoglycemic- and insulin-lowering effects, antioxidant activity, antiinﬂammatory
activity, and antiproliferative or apoptotic cell death activity [28,29].
Experimental studies are known to employ much higher concentrations of an isolated compound than is found in
natural plants. Chocolate made headlines for its beneﬁcial effects on insulin resistance, blood pressure, and cardiovascular
diseases, attributed to its constituent polyphenols, ()-epicatechin, and (þ)-catechin, and their oligomers called procyanidins, but one had to consume about 100 g of chocolate daily, providing 480 kcal, to have a measurable impact [30].
Findings of such researches lead the consumer to look for simpler ways to achieve these high doses and are led to
nondietary sources of the compound. But such supplements are not without risks. For example, it has been reported that
high unphysiological doses of b-carotene, a phytochemical, and the precursor of vitamin A increase mortality rates [31].
Others, such as some polyphenols and ﬂavonoids, may become prooxidants if ingested in high amounts, leading to harmful
effects [32].
There is a growing recent awareness that eating a diet high in fruits, vegetables, grains, legumes, and plant-based
beverages has long-term health beneﬁts, and the USDA, in 2017, has made appropriate recommendations [33]. Furthermore, according to the Micronutrient Information Center of the Linus Pauling Institute, there is no evidence that taking
supplements of nonnutrient phytochemicals such as polyphenols and carotenoids, lycopene, extracted from plants and
tomatoes, beneﬁts health in the same way as fruits and vegetables [34,35]. In fact, they are not always even approved by
regulatory agencies such as the European Food Safety Authority (EFSA) [36].
There may be many reasons for the different results obtained from studies on phytochemicals in whole foods and
those based on puriﬁed compounds. For example, phytochemicals in freshly harvested plant foods may be degraded by
processing techniques, including cooking involving thermal decomposition [37,38]. Moreover, phytochemists study
phytochemicals by ﬁrst extracting and isolating compounds from the plant of origin, followed by deﬁning their structure or
testing in laboratory model systems, such as cell cultures, in vitro experiments, or in vivo studies using laboratory animals.
Challenges in this ﬁeld include isolating speciﬁc compounds and determining their structures, which are often complex,
and identifying what speciﬁc phytochemical is primarily responsible for any given biological activity. Consequently, the
biological activities for most phytochemicals are unknown or poorly understood, in isolation or as part of foods [39].
As the plant is a complex mixture of compounds, it is reasonable to expect that the function of the phytochemical under
study may be different when in isolation from other compounds in the plant. So the potency of the active compound on its
in vivo antioxidant capacity will also depend on the extent to which the antioxidant capacity is released from the plant
product [40].

11.1.3 Models of research to test the efficacy of phytochemicals: the complex human system
The efﬁcacy of phytochemicals may be assessed on a fairly homogenous system such as cell isolates and tissue cultures or
they may be conducted on the most heterogeneous of systems, that is, the human body, which is a conglomerate of about
50 trillion cells.
Thus, experimental models may involve in vitro techniques on isolated puriﬁed compounds, performed in a controlled
environment: in cell isolates or organelle isolates, or where the cell is made to grow outside the living organism in tissue culture.
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Because test conditions may not correspond to those inside a living organism, results may not always replicate in vivo
conditions. Studies may also be conducted in situ, which is intermediate between in vivo and in vitro conditions, for example,
in a cell within the intact organ, but after the animal is sacriﬁced, or ex vivo, where experimentation is done in or on living
tissue in an artiﬁcial environment outside the organism. Experiments are also conducted on nonhuman animals such as rats,
mice, dogs, or guinea pigs, and results are applied to humans because there is a large physiological similarity between them.
Such studies enable researchers to perform experiments that are not ethical or feasible in humans. However, in all these
models, there is the element of extrapolation.
Studies involving humans are typically empirical, where research is based on evidence and not just theory. These
include limited experimental studies involving intervention and clinical assessment but are largely based on epidemiological models such as cohort, caseecontrol, and observational studies. The variables in such studies are enormous, so
ﬁndings attributed to a particular event or phenomenon may actually be caused by another reason. Varied applications of
statistics to such studies can also often yield diverse results for the same data.
Continuing with our model, phytochemical, namely the ﬂavonoids, is the group that has been most extensively studied.
By 2005, over 5000 naturally occurring ﬂavonoids from 225 commonly consumed plants had made it to the USDA
database [41]. Studies on animals [42e44], cell isolates [45,46], and in vitro models of human or animal tissues [47,48]
have demonstrated that ingestion of ﬂavonoid-rich foods raises the antioxidant levels of blood and tissues, which in turn is
responsible for their antiviral, antiallergic, antiplatelet, antiinﬂammatory, antitumor functions, and also for prevention of
cancer and cardiovascular diseases. However, epidemiologic studies exploring the role of ﬂavonoids in human health have
been inconclusive. Some studies support a protective effect of ﬂavonoid consumption in cardiovascular disease and cancer,
other studies demonstrate no effect, and a few studies suggest potential harm.
Questions have also been raised with regard to their absorption, and the emerging view is that their absorption is much
lower and their half-life much shorter than that of other dietary antioxidants such as ascorbic acid and tocopherols [49]. So
the question regarding the in vivo efﬁcacy of ﬂavonoid-rich foods for their health-promoting functions remains wide open,
even as, in addition to the natural sources, the market is replete with nutritional supplements of speciﬁc ﬂavonoids, such as
quercetin, isoﬂavones, catechins, and various other bioﬂavonoids. Because there are many biological activities attributed to
the ﬂavonoids, some of which could be beneﬁcial or detrimental depending on speciﬁc circumstances, it has been suggested that further studies in both the laboratory and with populations are required [50,51].

11.1.4 Short-term responses versus long-term responses: the role of feedback responses
Feedback responses of living systems to varying stimuli are most important for maintenance of internal constancy. If one set
of chemicals drives the system in a given direction, another set of chemicals will drive it in an opposing direction. The more
complex a system, the more intricate are the feedback mechanisms. Therefore, the conclusions are drawn from experiments
studying the impact of any compound, a phytochemical in this case, on a simple system such as a cell culture may not get
replicated in the complex system. If one or both of these opposing inﬂuences are nonlinear, equilibrium point(s) results to
which the system gravitates. Any perturbation, generally in the form of a chemical stimulus resulting from the inﬂux of any
compound such as a nutrient, nutrient supplement, drug, or even thought, can trigger a negative feedback system to reestablish the equilibrium. As ultimately the system moves to a predetermined equilibrium, there may be results of an immediate
response to an intervention, which are often not sustained in the long run, as feedback systems come into play.
As a consequence of negative feedback mechanisms, many qualitatively different stimuli oppose each other and ﬁnally,
arrive at a point close to the equilibrium point. Hormonal regulation of blood sugar, blood pressure, body temperature, and
erythropoiesis are but a few examples of well-documented negative feedback controls.
Disruption of negative feedback can lead to undesirable results. Once the principle that equilibrium is to be maintained
in the long run is acknowledged, it is logical to accept that all perturbations will eventually get attenuated; explaining why
many drugs, supplements, and nutrients produce the expected result in short-term studies, but in the long run, the efﬁcacy is
lost. Similar mechanisms can help in adaptation to distress conditions such as food restriction, protein deﬁciency, and poor
protein quality, which have been reported to attenuate as the duration of distress increases [52e55].
Hence, it is important to assess short-term versus long-term impact of phytochemicals to recommend them as therapeutic agents.

11.1.5 Need for scientific temper
From the foregoing, it emerges that there are several possible reasons why various studies on a promising phytochemical
may yield conﬂicting ﬁndings.
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In present times, science is an important component of human culture. The scientiﬁc method is expected to provide
objective, bias-free, and reliable guidance to make informed choices to live a healthier life. The explosions of research
studies that are easily accessible to scientists and others, due to the Internet, make it even more difﬁcult to make sense of
the concerned issues. The number of citations available in MEDLINE from 1964 till mid-December 2017 is over
22.6 million, and more than 11,000 were being added every week. These studies have varying methodology, are conducted
on different populations, and use differing test conditions and interventions [56]. Even highly accepted studies are refuted
by subsequent work by the same and/or other investigators so that experts are also confused by different answers to the
same question. Other reasons for complications with regard to research ﬁndings that have been extensively discussed
elsewhere include the biases introduced because of ﬁnancial and/or career interests of the researchers, the funding agencies,
and the industry [57]. Hence this calls for dealing with the issue with a scientiﬁc temper, which includes questioning,
observing physical reality, testing, hypothesizing, analyzing, and communicating. It also requires that the public is not
misled about the issues regarding the efﬁcacy of any phytochemical.

11.1.6 Phytochemicalegene interaction: individual responses
Another reason for the variable results obtained with regard to the efﬁcacy of phytochemicals deals with genetic differences
among individuals. This area of research, known as pharmacogenomics, explores the inﬂuence of genetic variation on drug
response in patients. Pharmacogenomics links genomics, transcriptomics, proteomics, and metabolomics to drug development. Genomics allows the study of the genetic abilities of an individual to metabolize drugs, including phytochemicals,
based on its entire genome. It includes the study of genomeedrug interactions in the regulation of genome structure,
expression and stability, and the role of genetic variation on individual biochemistry. Transcriptomics allows the global
study of gene expression at the RNA level, which will ultimately determine the extent of transcription of a gene. Knowing
the proteomics helps in determining whether the enzymes and other required proteins have the desired conformation to
perform the optimal catalytic function as required. Finally, it includes metabolomics, the development of which began in
1970, to investigate the ideas of Linus Pauling with a view to studying relationships between biological variability and
wide ranges of nutritional requirements.
Gene expression may be inﬂuenced by single-nucleotide polymorphisms (SNPs). Scientists use data obtained in
genomics to locate SNPs and create HapMaps, which help predict an individual’s response to a particular drug. Such data
can be used to maximize efﬁcacy and minimize adverse reactions. Such an approach to optimize drug therapy is the latest
advancement in personalized or precision medicine [58,59].
The FDA [60] recommends that health care providers use pharmacogenomic information to help decide the most
appropriate treatment for each individual, by choosing a drug that is more likely to work, avoiding drugs that might have
side effects, adjusting the dose of a drug, or determining if closer monitoring is needed. In addition, pharmacogenomics
now plays an important role in the drug development process, opening new opportunities in drug discovery. Within the
FDA’s Ofﬁce of Clinical Pharmacology is located the Genomics and Targeted Therapy Group which works to apply
pharmacogenomics and other biomarkers to drug development and clinical practice. FDA scientists work in multiple ways
to ensure that pharmacogenomic strategies are applied appropriately in all phases of drug development. Core functions
include regulatory review, research, policy development, and education and outreach.
Thus, researches in pharmacogenomics follow the systems biology approaches for dealing with holistic behavior of an
organism, which is more predictive than the reductionist approaches that are popular in the laboratory and help in the initial
discovery of a phytochemical for its promising properties as a lead compound for developing a phytochemical for drug use.
This approach accommodates the complexity of the whole human system, which will deal with the drug, from its digestion,
absorption, transportation, and metabolism until its ﬁnal excretion from the body. It also explains why every laboratory
ﬁnding does not apply to everyone in the population.

11.1.7 Panacea or a distant dream
The foregoing discussion has attempted to analyze the present status of assessment of the utility of phytochemicals for human
health from different perspectives. While there is a consensus that the inclusion of seven to nine servings of fruits and
vegetables is desirable to provide human requirements of these compounds, the utility of all isolated, puriﬁed phytochemicals
may need more in-depth analysis. It is reasonable to assume that most of them are harmless, and many are even beneﬁcial, but
assigning the sobriquet of plant-derived “supernutrients” to all phytochemicals in tablet form may not be a scientiﬁcally
desirable conclusion. A lot would depend on the mode of consumption of these compounds and their combinations with other
complementary phytochemicals. Touting all plant-derived compounds as safe and all industry manufactured ones as unsafe
may not be wise. Hence, each phytochemical has to be evaluated for it to be labeled a panacea.
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Let us now focus our attention on the relatively small organosulfur group of phytochemical compounds that provide the
body with sulfur which is essential for life, but have also been endorsed for a wide variety of health-promoting functions.

11.1.8 Introduction to organosulfur phytochemicals
OSCs are generally found in primate bodies and in the vegetative environment. OSCs can be resourced from a large
number of plant and animal resources. The common sources of sulfur in the diet include broccoli, cauliﬂower, cabbage,
garlic, onion, meat, eggs, and ﬁsh [61]. There are two principal families of vegetables that contain OSC with speciﬁc
properties. The members of family Amaryllidaceae, which include garlic, onion, shallot, leek, and chives, contain S-alk(en)
yl-L-cysteine sulfoxides, and the members of the cruciferous family, which include cabbage, cauliﬂower, Brussel sprouts,
kale, and rucola, contain S-methyl cysteine-l-sulfoxide.
OSCs can be classiﬁed based on their functional groups to which sulfur is directly attached. OSCs constitute
isothiocyanates, indoles, and allylic sulfur compounds. The plant of genus Allium includes garlic and onions which serves as
the most important source of organosulfur and contains important compounds such as cysteine sulfoxides and g-glutamylcysteine. The hydrolysis of cysteine sulfoxides accounts for the pungency in aroma and ﬂavor of garlic and onions [62].
Another important OSC compounds is methylsulfonylmethane (MSM) (also known as dimethyl sulfone, DMSO2). It is
a naturally occurring OSC which is present in small quantities in a variety of fruits and vegetables and in animals including
humans. MSM is a strong antioxidant, capable of binding and inactivating free radicals. As a major sulfur donor, MSM is
essential for the proper functioning of the body’s antioxidation system. When neutralizing free radicals, the body uses a
variety of antioxidant enzymes that contain sulfuric amino acids. These derive their structure and biological activity from
sulfur bonds (SeS). MSM provides the sulfur for the amino sulfur acids methionine, cysteine, and taurine (Fig. 11.1),
which are considered powerful antioxidants. When split off, the thiol (-SH) groups of these amino acids are capable of
neutralizing free radicals. The fourth most common sulfur-containing amino acid is homocysteine (Fig. 11.1), which is
biosynthesized from methionine. A high accumulation of homocysteine can lead to atherosclerosis because it makes a
person more prone to endothelial cell injury, although homocysteine can be recycled into methionine or converted into
cysteine with the aid of certain B-vitamins. MSM also acts as a permeability enhancer, which increases the permeability of
other compounds through plasma membrane transport. This property of MSM makes it unique in nature and may be used
by the pharmaceutical industry to treat serious health ailments [63e65].
Two classes of OSCs are derived from garlic: (1) lipid-soluble and (2) water-soluble allyl sulfur compounds.
Lipid-soluble sulfur compounds are formed from its parent sulfur compound, alliin (Fig. 11.1), which constitutes about
80% of the cysteine sulfoxides in garlic. The cysteine sulfoxides are of four types: alliin, methiin, propiin, and isoalliin.
Lipid-soluble allyl sulfur compounds such as ajoene, diallyl sulﬁde (DAS), diallyl disulﬁde (DADS), and diallyl trisulﬁde
(DATS) are released from alliin catalyzed by alliinase enzyme, which is released by either chopping or crushing garlic.
Water-soluble allyl sulfur compounds, such as S-allyl cysteine (SAC) (Fig. 11.2) and S-allylmercaptocysteine, are obtained
during long-term incubation of crushed garlic in aqueous solutions in the aging process. Onions are primarily rich in
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isoallin, while garlic is rich in alliin that is further hydrolyzed into allicin (Fig. 11.2) by a hydrolyzing enzyme. Allicin is an
unstable compound and can be readily converted to a more stable compound under different conditions. It gets converted to
dithiin when extracted with oil, ajoene when extracted with ethanol, and DADS/DATS or SAC/S-allylmercaptocysteine
when extracted with aqueous solutions [66].
OSC as nutraceuticals not only can serve as potent antioxidants by quenching free electrons but also display other
antioxidant properties, such as antiplatelet, ﬁbrinolytic, antiinﬂammatory, immunomodulatory, and antiaging actions. These
properties of OSC have crucial roles in prophylaxis and treatment of various pathological states, including cardiovascular
diseases, diabetes, neurodegenerative disorders, and cancer, including their antibacterial and antiviral activities [67].
OSCs decrease ROS levels by inhibiting ROS generating systems, primarily via nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, and consequently inhibit the degradation of antioxidant enzymes, such as glutathione
S-transferase. Moreover, OSCs can increase the bioavailability of NO by increasing eNOS expression or preventing the
formation of NO/peroxynitrite (ONOO) [65,68,69]. Other evidence suggests that OSCs can inhibit angiotensinconverting enzyme (ACE), consequently increase vasodilation and decrease peripheral resistance that leads to decrease
in systolic blood pressure, and other endothelial injuries, all events in a row are suggestive of their antihypertensive
properties. Last but not the least, OSCs have also been shown to reduce the risk of acute vascular inﬂammation and
atherosclerosis. However, the mechanism(s) of protection needs to be explored more to strongly establish the main
beneﬁcial effect stems from its antioxidant property. Speciﬁcally, the in vitro models suggest that OSCs work to inhibit
cyclooxygenase, HMG-CoA, and platelet aggregation.

11.1.8.1 Disease states for the assessment of organosulfur compound efficacy
11.1.8.1.1 Obesity
A number of OSCs are reported to have inhibitory effects on adipogenesis [70,71]. They are found to reduce lipogenesis in
3T3-L1 adipocytes. Some of these OSCs, primarily the ajoene, are capable of suppressing cell viability and are implicated
in adipogenesis. Ajoene signiﬁcantly raises apoptosis in different stages of 3T3-L1 adipocytes. Thiacremonone, another
OSC in garlic, has been reported to signiﬁcantly reduce the differentiation of 3T3-L1 preadipocytes by downregulation of
adipogenesis-related transcription factors and markers; in differentiating cells, acetyl CoA-carboxylase 1, an essential
component in fatty acid synthesis and metabolism that has been lowered through AMP-activated protein kinase [72].
11.1.8.1.2 Diabetes mellitus
Although experimental studies demonstrated a clear hypoglycemic effect of garlic, the effect of garlic on human blood
glucose is still controversial. Many studies have shown that garlic can reduce blood glucose level in diabetic animals.
Garlic in capsule form at a dose of 500 mg per day was effective in the reduction of blood glucose in streptozotocin- and
alloxan-induced diabetes mellitus in rats and mice [73,74]. A prominent study by Huang and Joeu [75] investigated the
protective effects of six OSCs namely, DAS, DADS, SAC, SEC (S-ethylcysteine), SMC (S-methylcysteine), and SPC
(S-propylcysteine) on partially oxidized and glycated low-density lipoprotein (LDL) or plasma samples. The ﬁndings were
suggestive of the protecting role of these OSCs on partially oxidized and glycated LDL or plasma against further oxidative
and glycative deterioration, which might beneﬁt patients with diabetic-related vascular diseases. However, the exact
mechanism of the compounds and their relative efﬁcacy are not fully understood.
11.1.8.1.3 Dyslipidemia and cardiovascular disease
An important ﬁnding from a number of studies demonstrates that garlic exerts lipid-lowering effect in the blood stream.
Consequently, garlic is proposed to play a potent lipid scavenging role in the blood vessels, owing to its drastic lipidlowering effects and cardiovascular protective effects. The mechanisms of lipid-lowering effects of garlic including
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OSCs have been explored in a number of studies. Sobenin [76] supplemented 4 weeks of garlic paste and witnessed
decrease in the activities of hepatic 3-hydroxyl-3-methylglutaryl-CoA reductase (HMG-CoA reductase, the key enzyme
involved in cholesterol synthesis) (79%e83%), cholesterol 7a-hydroxylase (43%e51%), and fatty acid synthetase (the
important enzyme involved in fatty acid synthesis) (17%e29%). Qureshi et al. [77] conducted two in vitro experiments
investigating the effects of garlic powder extract on the cholesterol synthesis and found inhibition in the activity of HMGCoA reductase in primary cultured hepatocytes treated with acetate. Empirical ﬁndings witnessed that all allicin-derived
compounds have similar antibiotic, antioxidant, antithrombotic and lipid-lowering properties. Undeniably, these properties are important prospects of protection against various chronic pathological conditions such as hypertension, atherosclerosis, obesity, and related diseases. Upregulation and increase in the sensitivity of platelet is highly implicated in onset
of thrombotic disease. Garlic has been found to play important role in inhibition of platelet aggregation in human. Methyl
allyl trisulﬁde (MATS) is a principal antiplatelet compound identiﬁed in garlic oil. Ajoene as a component in garlic is also
found to possess platelet inhibitor properties. The consumption of garlic oil products reported enhanced ﬁbrinolysis and
vascular dilation in both human and animal models [78].
11.1.8.1.4 Hypertension
Clinical studies examine the effects of garlic supplemented diet to elevate blood allicin levels, which can signiﬁcantly
reduce systolic blood pressure in the hypertensive patient [79]. Recent discoveries in inclusive food-based approaches and
dietary patterns for reduction in risk for cardiovascular disease [80] reviewed the metaanalysis study including 20 clinical
trials suggesting garlic to be superior to placebo in lowering BP in hypertensive patients on average by 8e9 mm Hg in
systolic BP and 6e7 mm Hg in diastolic BP, P < .0001. This reduction in BP reported in the metaanalysis is comparable to
the BP-lowering effects of common antihypertensive medications [81,82]. At the same time, as garlic supplementation
reduced BP signiﬁcantly in hypertensive patients, it did not appreciably affect patients with normal BP [83e85]. Human
studies report the effect of garlic powder as supplement added in diet because it signiﬁcantly elevates the level of
antioxidant allicin level that helps in reducing the systolic blood pressure in hypertensive patients. The majority of clinical
trials studying the effect of garlic on BP used either garlic powder or aged garlic extract. SAC was the main active
compound in aged garlic extract. Many mechanisms of action for the BP-lowering properties of OSCs in garlic have so far
been postulated. These include mediation of intracellular nitric oxide (NO) and hydrogen sulﬁde (H2S) production, as well
as blockage of angiotensin-II production, which in turn promotes vasodilation and thus reduces the BP. The strongest
evidence of and insights into the mechanisms of the BP-lowering effect of garlic supplementation involve endotheliumdependent vasodilation. Studies indicate that OSCs can inhibit ACE, which will increase vasodilation and decrease
peripheral resistance, leading to a decrease in blood pressure, and limit endothelial injury, demonstrating their antihypertensive properties.
11.1.8.1.5 Neurodegenerative diseases
Ajoene, a principal compound in oil-macerated garlic products, was investigated against ischemic damage in the gerbil
hippocampal formations. It has been known that deﬁciency of hydrogen sulﬁde could lead to various pathological conditions, including arterial and pulmonary hypertension, Alzheimer’s disease, gastric mucosal injury, and liver cirrhosis. On
the other hand, excessive production of hydrogen sulﬁde, by using inorganic hydrogen sulﬁde donors such as NaHS, may
contribute to the pathogenesis of inﬂammatory diseases, septic shock, cerebral stroke, and mental retardation in Down
syndrome. This draws attention to look for organic molecules that are capable of regulating the formation of hydrogen.
Allium grass, an important source of organic sulfur-containing compounds, has been widely studied regarding its
therapeutic applications, and it has been established that the ingredients of garlic, such as DADS, DATS, and S-ally
cysteine, act as hydrogen sulﬁde donors or mediators in pharmacological studies. In addition, S-propargyl cysteine
(ZYZ-802) and S-propyl cysteine, two synthetic cysteine analogs, have been examined and could be used to treat ischemic
heart disease, mediating the modulation of the hydrogen sulﬁde pathway [86].
1. Short-term and long-term responses of OSC: Humans studies on metabolic diseases: Long-term and short-term
responses of phytochemical OSCs on metabolic disease depend on the intake of OSCs through garlic/onion-rich
diet or via any pharmaceutical formulations. Long-term consumption of OSCs was found to have beneﬁcial effects
on various metabolic diseases including antitumor, antiatherosclerosis functions, lowering of blood lipids and blood
sugar, and antithrombotic and antihypertensive functions [87]. Long-term preventive effect of garlic OSC, allicin on
atherosclerosis, has been attributed to its capacity to reduce lipid content in the arterial membrane [88]. The shortterm effect of garlic OSCs on elevated human blood glucose was identiﬁed and is still controversial. Studies showed
that garlic can reduce blood glucose in streptozotocin and alloxan-induced diabetes mellitus in rats and mice [73].
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Short-term beneﬁts of garlic on dyslipidemia in diabetic patients have been demonstrated by Ashraf et al. [89].
OSC decreased ROS levels by inhibiting ROS generating systems, such as NADPH oxidase, or by preventing the
degradation of antioxidants enzymes, such as glutathione S-transferase. Phytochemicals in onions include OSCs
such as isoallin, cepaenes, and thiosulﬁnates. OSC in onions has received considerable attention for their long-term
healthful, functional beneﬁts [90]. The OSCs are believed to possess antiinﬂammatory, antiallergic, antimicrobial,
and antithrombotic activities by the inhibition of cyclooxygenase and lipooxygenase enzyme [91].
2. Short-term and long-term responses of OSC: Humans studies on neurodegenerative diseases
Roles of long-term and short-term responses of phytochemical OSCs in neurodegenerative disease have been studied
extensively. Garlic powders are generally considered as beneﬁcial to human health and may also promise neuroprotective
function. Recent studies have demonstrated a beneﬁcial effect of OSCs including their antioxidative and neuroprotective
properties in neurological disorders. The active ingredient, SAC, was assessed in various models of neurodegenerative
diseases including stroke, ischemia, Alzheimer’s, and Parkinson’s disease. Therefore, OSCs can also be successfully
implemented to control inﬂammation-related neurodegenerative diseases, which include Alzheimer’s disease, stroke,
and Parkinson’s disease [92,93]. Recent studies show the short-term response of garlic OSC on the proliferation of neural
progenitor cells (NPCs) and hippocampal neurogenesis. The herbal OSC, extracted DADS, signiﬁcantly suppressed the
proliferation of NPCs, whereas other OSC-extracted components had no effect on neurodegenerative disorders. In adults,
hippocampal neurogenesis can be regulated by various signals that modulate the effects of neurotransmitters, growth factors, and neurotrophic factors and by various environmental stimuli [94]. Interestingly, it was reported that herbal supplementation such as OSC can positively and negatively modulate hippocampal neurogenesis even in adulthood [95].
Several reports have been issued on the neuroprotective effects of garlic or aged garlic extract (AGE) in Alzheimer’s disease and cerebral ischemia, and on apoptotic cell death [96]. Long-term goals of OSC in neurodegenerative disorders still
need to be addressed against longitudinal cohort, as some preliminary studies hold the positive sign of OSC in several
neurodegenerative disorders and their role in neuroprotection [97].

11.1.8.2 Potential risks with high dose consumptions of organosulfur compound
From the foregoing, there appears to be a large body of research which suggests that phytochemical OSCs have several
beneﬁcial functions in the prevention of various metabolic and neurodegenerative diseases. There has been a general
conception that therapeutic compounds from herbal origin have no adverse effects or with least side effects. Although
OSCs are often promoted as natural components and therefore harmless, they are not completely devoid of adverse effects.
One of the signiﬁcant studies addressed this question and reported how prolonged or excessive herbal supplement of OSCs
can adversely affect the metabolic pathways [98]. In general, high garlic intake can cause allergies, and the allergens have
been well identiﬁed as DADS (which is considered to be the primary allergen), allyl propyl sulﬁde, and allicin [99e101].
Some signiﬁcant studies have also emphasized the adverse effect of garlic and OSCs on respiratory function (i.e., asthma,
cough, and rhinitis). Other clinical studies have reported that garlic may cause mild gastrointestinal troubles following
administration in therapeutic doses. In due course of the observational study, the side effects occurring in a total of 1997
patients on treatment with 900 mg daily garlic powder per coated tablet (three tablets/day) included gastrointestinal
complaints (incidence of adverse effects: 6% nausea, less than 0.8% bloating) [102e104]. Prolonged low to moderate
therapeutic doses of OSCs appear to be generally safe. However, clinical trials, case reports, and case series signify the
possibilities of OSCs’ adverse effects in disturbed metabolism and inﬂammation. Answers to questions regarding the
frequency of adverse effects and whether they vary by administering different preparations have not been explored.
Consequently, studies are required for recommended dosing system for OSCs in humans. The question also needs to
address whether the need for OSC is different in healthy and diseased conditions.

11.1.8.3 The requirement for balanced viewpoints
Garlic, onion, and several other OSC-containing vegetables have been widely recognized for their nutraceutical functions
and are extensively consumed across the globe. Conventional wisdom, mostly based on observation, propagated by
folklore and handed down generations has highlighted the beneﬁts of these vegetables, even as some cultures and religious
groups have rejected them, ostensibly for their strong ﬂavors.
As described in the previous sections, researches have highlighted their medicinal properties, based on evidence that
they can serve as nutraceutical agents and as direct antioxidant trapping electrons, which can also have nonantioxidant
effects, such as antiplatelet, ﬁbrinolytic, antiinﬂammatory, immunomodulatory, and antiaging actions. These properties of
OSCs are useful in the prophylaxis and treatment of various pathological states, such as cardiovascular diseases, cancer,
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neurodegenerative disorders, and diabetes because they have been found to have antibacterial, antiviral, and other
medicinal activities. Theories have emerged that explain these properties of OSC by their correction of redox-sensing and
redox-signaling properties. Yet, there are reports that caution against their use in large quantities, highlighting the need for
a balanced approach.

11.1.9 Role of scientists and responsible media
It is not unusual to ﬁnd blazing headlines reporting the magical properties of some phytochemical compounds as panacea
for a wide range of disorders. Such news often occupies substantial space in print and electronic media. Sometimes these
recommendations are based on in vitro models or limited data, but there is no reason for a lay person to doubt the
recommendations or verify the claims.
Sometimes such recommendations are conﬂicting so that many compounds are declared beneﬁcial on one day and
detrimental to health the next. To inculcate rationality with regard to any foods or puriﬁed phytochemicals and to ensure
that the average consumer is not disillusioned by the scientiﬁc method, it is desirable to present the public with balanced
viewpoints. It is important that reports of scientiﬁc research are conveyed to the consumers in a reasonably accurate manner
so that the discerning consumer does not end up being confused.
It is important that the consumer is guided to be able to make informed choices with regard to healthy food and
desirable food habits. Media should desist from giving the misleading impression that everyone who eats a particular food
or follows a particular practice will beneﬁt from it. It is therefore suggested that media should report scientiﬁc ﬁndings to
the consumer only when reasonable consensus has been reached on a particular issue. In the absence of such a consensus,
the reports should include full details of the study design and ﬁndings in a language that is comprehensible to the typical
educated consumer yet does not give misleading impressions. For example, they should give the sample size and the extent
of the effect observed, how many among the experimental group(s) exhibited a response in a direction opposite to the
group average, and how many among the control group showed the response even without the intervention. The consumer
should also be made aware of the limitations of the scientiﬁc methodology. The tendency to reduce a study to a simple
statement expressing that “x” phytochemical causes “y” effect needs to be avoided, both by scientists and media.
The common man should be encouraged to take his own decisions regarding whether to try out a particular food for a
particular condition. The media should facilitate such decision-making, by improving its information content, and seek to
educate the consumer to take informed decisions, rather than make categorical headlines about foods as if they apply to all
individuals in a society. For example, instead of saying “Eat garlic for lowering blood cholesterol, media should be
encouraged to say that of ‘n’ persons who ate ‘m’ grams of garlic everyday, ‘x’ persons showed a ‘y-z’ percent reduction in
blood cholesterol”.
Headlines based on laboratory ﬁndings based on in vitro or animal studies can be even more damaging. For example, if
a puriﬁed compound from a plant, say a grass, shows a health beneﬁt on rats but makes media headlines that everyone who
consumes this grass will beneﬁt from it, the result can sometimes even be harmful.
Hence, it is in public interest that there are guidelines for media to refrain from making potentially irresponsible
headlines.

11.1.10 Conclusions
From the foregoing, there is little doubt that phytochemicals are an important class of molecules that have been the focus of
investigation for their health beneﬁts. Researches conﬁrm that consuming foods rich in phytochemicals provide health
beneﬁts. It is also true that a vast range of medicinal plants around the globe has not yet been investigated to ascertain the
claims made in traditional folklore about their usefulness in treating diseases. According to some estimates, there are over
25,000 phytochemicals, which include 5000 naturally occurring ﬂavonoids of which only a few have been explored.
Therefore, it is desirable that future research is focused on medicinal plants.
At the same time, science and scientists need to admit that not enough information exists to make speciﬁc recommendations for phytochemical intake. While there is a never-before quantum of information available at the click of a button,
uncertainties and methodological limitations are inherent in the scientiﬁc method. Hence researches and researchers, despite
conﬂicting observations or because of them, must promote understanding of the complex phytochemicalephysiological
interactions. This will add to safe drug development for wide applications in disease amelioration and the promotion of good
health. Although "natural" products of phytochemical origin are generally considered safe, in complicated medical
conditions, their ingestion can make the difference between life and death.
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Therefore, it is necessary to caution the media from creating euphoria over viewpoints that may not extend to in vivo
functionality based on superﬁcial reports of research ﬁndings. Education in the modern world must endeavor to make
people understand the strengths and limitations of the scientiﬁc method in general and phytochemical research in particular.
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TGF-b1 Transforming growth factor-b1
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HCV Hepatitis C virus
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MCD Methionine/choline deﬁcient
MYD88 Myeloid differentiation primary response 88
HIF-1a Hypoxia-inducible transcription factor-1a
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CTGF Connective tissue growth factor
HMGB1 High-mobility group box 1
TLR Toll-like receptor
SA-B Salvianolic acid B
HBV Hepatitis B virus

12.1 Introduction
The liver is one of the largest organs responsible for various metabolic functions. The liver is susceptible to several forms
of tissue injury because of its unique metabolic function it undertakes [1]. When the liver is exposed to hepatotoxins,
hepatotoxic drugs, alcohol, and hepatitis viral infections, makes it highly susceptible to injuries [2]. The acute liver injury is
often reversible, whereas the chronic liver injury is responsible for various pathological manifestations such as hepatic
inﬂammation, ﬁbrosis, cirrhosis and associated portal hypertension, and hepatocellular carcinoma (HCC).

12.1.1 Chronic liver diseases
Chronic liver injury leads to a sustained scarring response which progressively disrupts the liver architecture and functions
through the accumulation of extracellular matrix (ECM) in perisinusoidal space or space of Disse that eventually causes
liver failure [3]. Among chronic liver diseases (CLDs), ﬁbrosis is regarded as a common pathway that represents a
convergent point from many etiologies, most prominently viral hepatitis, nonalcoholic steatohepatitis (NASH), and alcohol
[4]. Hepatic ﬁbrosis accounts for 45% of all deaths in industrialized nations, making this unmet need in clinical medicine
[5]. Liver ﬁbrosis is a highly orchestrated process characterized by the net accumulation of ECM resulting from the woundhealing response to chronic liver injury of any etiology [6]. Hepatic stellate cells (HSCs) are nonparenchymal and resident
perisinusoidal cells in the liver, commonly implicated in the progression of hepatic ﬁbrosis. In normal liver, HSCs
contribute to development and regeneration, regulation of ECM synthesis and degradation, retinoid metabolism, sinusoidal
endothelial cellemediated vasoregulation, secretion of a variety of growth factors and cytokines, immune regulation, lipid
metabolism, and detoxiﬁcation, etc. [7]. Following chronic liver injury, HSCs undergo phenotypic transition and acquire
myoﬁbroblast-like phenotypes that subsequently secrete various proﬁbrogenic cytokines responsible for the synthesis of
the enormous amount of ECM in diseased liver (Fig. 12.1) [8]. If left untreated, ﬁbrosis progresses into cirrhosis and
subsequently HCC. Cirrhosis is one of the common sequels of persistence hepatic ﬁbrosis and is responsible for signiﬁcant
morbidity and mortality of patients with CLDs [9].

Normal hepatocytes
Healthy liver
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FIGURE 12.1 Progression of CLDs. aHSC, activated stellate cells; qHSC, quiescent hepatic stellate cells; CLD, chronic liver diseases, KC, Kupffer
cells; SEC, sinusoidal endothelial cells.
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12.1.2 Origin of problem
Currently, 844 million people are affected with various forms of CLDs, with a mortality rate of two million per year
[10,11]. Globally, 400 million people are suffering from chronic hepatitis B virus (HBV) infections and up to 2 billion
people are with the evidence of exposure [12]. Furthermore, approximately 3% of the world population is suffering from
hepatitis C virus (HCV) infections and 170 million people are infected by HCV [13]. Obesity has become a global public
health problem with the increasing incidence of NASH [14]. Alcohol causes of liver diseaseeassociated mortality
worldwide result in steatosis, alcoholic steatohepatitis, ﬁbrosis, and cirrhosis [1]. According to a recent World Health
Organization report, 3.3 million deaths (6% of all global deaths) are associated with alcohol use [15]. Thus, CLDs
represent a major, neglected global health burden, and presently, there are no approved drugs available to treat CLDs
especially for ﬁbrosis [9]. Therefore, effective antiﬁbrotic drugs are warranted for the treatment of CLDs. In search of new
antiﬁbrotic drugs, several drugs are being developed to treat a different form of CLDs.

12.1.3 Complementary alternative medicines in liver diseases
Complementary and alternative medicine (CAM), as deﬁned by the National Center for Complementary and Alternative
Medicine (NCCAM), is a diverse group of medical and health-care systems, practices, and products that may not yet
be incorporated into conventional medicine [16]. The CAM-based treatments or therapies are organized into several
categories employing natural products including herbs, vitamins, minerals, Ayurveda, traditional medicines, homeopathy,
etc. Nowadays, interest toward the alternative medicines increased among patients [17]. For instance, it has been estimated
that 80 million, 2.3 billion, and 1 billion US$ annual expenditure have been spent on traditional medicines in Australia,
United Kingdom, and Canada, respectively [18]. Interestingly, more than 80% of the present-day anticancer, cardiovascular,
antimicrobial, and immunosuppressive drugs are derived naturally, especially from plant origin [18,19].

12.1.4 Herbal medicine in the treatment of liver diseases
Herbal medicines are traditionally used for the treatment of various liver ailments since time immemorial. Medicinal
plantsebased preparations are very common in Indian and Chinese traditional medicinal systems and are frequently used
for various liver-related problems [20,21]. For instance, in Indian traditional medicines systems such as Siddha and
Ayurveda, Phyllanthus extract use has been reported for various liver-related ailments especially against jaundice since
time immemorial [20,21]. In North East Asia, especially Chinese herbal medicinal system is well-known traditional
medicines for liver diseases. The traditional Chinese medicines have great potential in the treatment of hepatitis [22].
Herbal plants such as Glycyrrhiza glabra, Salvia miltiorrhiza (Danshen), Phyllanthus amarus, Phyllanthus niruri, and
Phyllanthus urinaria have been considered as antiviral (against HBV and HCV) herbs, and oxymatrine extracted from
Sophora ﬂavescentis and S. subprostratae has the efﬁcacy against HBV infections. In Western region, Silybum marianum
extract has been widely used against several hepatic and bile-related complications [20,23]. At present, several phytoconstituents isolated from the above plants are being tested against various liver disease models in experimental settings and
some of them reached clinical trials.

12.1.5 Phytochemicals in liver diseases
Plants have several secondary metabolites and chemically they are phenolic and ﬂavonoid compounds. Active compounds
from herbal medicines have been shown on the molecular basis for pharmaceutical effects against liver diseases [20]. The
plant-derived compounds such as curcumin, silymarin (SIL), silibinin (SBN), quercetin, resveratrol, salvianolic acids,
berberine, glycyrrhizin, and phyllanthin are extensively reported for their beneﬁcial effect against CLDs. Therefore, this
chapter further reviews the beneﬁcial effects of these compounds against various forms of CLDs.

12.1.5.1 Silymarin and silibinin
SIL, a standardized extract, is derived from the seeds of the medicinal plant Silybum marianum (milk thistle) [24]. This
plant contains ﬂavonolignans (Fig. 12.2) such as SBN, silydianin, silandrin, and silychristine and a ﬂavonoid taxifolin [25].
SIL is a well-known hepatoprotective agent and it usually contains a mixture of 50%e60% of SBN and its diastereoisomers,
i.e., SBN A, B and isosilybin A, B [24,26,27]. Kren and Walterova [28] stated that, although numerous pieces of knowledge
of many medicinal plants have been forgotten in the Dark Ages and later reinvented, the use of milk thistle has been
systematically mentioned in all important medicinal herbaria, e.g., by abbess Hildegarda von Bingen (1098e1179),
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FIGURE 12.2 Some ﬂavonolignans active constituents of silymarin extract from Silybum marianum (milk thistle).

Hyeronymus Bock (1593), Jacobus Theodorus (1664), Mattioli (1626), Valentini (1719), Von Haller (1755), and many
others until the present time.
In European countries, SIL is widely used as a hepatoprotective agent against various hepatobiliary problems such as
hepatitis, jaundice, cholestasis, gallstones, and cirrhosis [29,30]. The German Commission E recommends SIL as a
hepatoprotective agent for liver cirrhosis and supportive therapy for chronic inﬂammatory conditions of the liver [31].
Several pharmacological and therapeutic studies have shown that SBN and SIL are not toxic even at high doses, welltolerated, and free of adverse effects. For instance, a previous study demonstrated that intravenous administration of
very high doses of SBN, i.e., 5e20 mg/kg/d for 14 days was free of toxic effects [32], and hence, it is considered as safe for
human use. Numerous scientiﬁc papers have been published on SBN and SIL, in which they reported to act as antioxidants,
chemopreventives, and anticancer agents, and especially as hepatoprotectants. Experimental and clinical evidence has
shown that SIL and SBN are effective in preventing oxidative stresseinduced hepatotoxicity. It is an established fact that
CLDs are commonly preceded by the oxidative stress with upregulation of reactive intermediates and downregulation of
intracellular enzymic and nonenzymic antioxidants [1]. The hepatoprotective and antioxidant activities of SIL and SBN are
achieved by their ability to inhibit the free radicals generation during the biotransformation of various hepatotoxins such as
ethanol, carbon tetrachloride (CCl4), acetaminophen, thioacetamide (TAA), N-nitrosodimethylamine (DMN), etc., in the
liver [20,33]. SIL and SBN are powerful antioxidants as a consequence of their polyphenolic structure [34], and they
upregulate the intracellular antioxidant defense via activation of superoxide dismutase (SOD) and reduced glutathione
(GSH) content in oxidative stress condition in the liver [35,36]. SIL and SBN recover the immune system, protect blood
vessels, and stabilize the membranes via inhibition of lipid peroxidation in patients with alcoholic cirrhosis [37]. SBN has
been accepted as a potent scavenger of most free radicals [23,38]. These phytochemicals mitigate ﬁbrosis via modulation of
the inﬂammatory cascade, oxidative stress, and ECM synthesis by upregulation of intracellular antioxidants and promotion
of ﬁbrosis resolution by degradation of ECM [20,39].
It is well-known that the antioxidant and antiinﬂammatory effect of these compounds is attributed to the reduction of
hepatitis-related CLD through inﬂammatory and immune modulation [39]. Various in vitro studies have well-documented
the antiﬁbrotic efﬁcacy of SIL and SBN against CLDs [4,40]. These phytochemicals inhibits HSCs activation and their
proliferation and induces apoptosis and cell cycle arrest in vitro [4,20,41,42]. Clinically, SIL administration for 6 months in
72 patients with nonalcoholic fatty liver disease (NAFLD) on a controlled diet led to signiﬁcant reduction of the
inﬂammation and marker enzymes of hepatotoxicity such as alanine and aspartate aminotransferase (ALT and AST) and
g-glutamyl transpeptidase (g-GT) [43]. Studies from Aller and coworkers suggested the combination of SIL and vitamin E
for NAFLD particularly when other drugs are not indicated or have failed. This combination is reported to improve the
liver functions and induce weight loss in NAFLD patients [44,45]. Recently, high-dose of SIL was considered as a good
choice for the improvement of liver biochemical proﬁle and quality of life in chronic HCVeinfected cirrhotic patients
[46,47]. Currently, SIL and SBN are mainly used for Amanita phalloides intoxication, where it inhibits the pharmacokinetics
proﬁle of a-amanitin, i.e., enterohepatic cycle, and prevents the binding of phalloidin and a-amanitin on hepatocyte
membrane [48].
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Ample research evidence shows that milk thistle components has (1) the ability to regulate the membrane permeability,
thereby preventing the entry of toxin into hepatocytes, (2) the ability to stabilize the hepatocytes cell membrane, (3) the
ability to control nuclear expression by means of a steroid-like effect (attributed to a structural similarity of SIL to steroid
hormones) followed by tissue regeneration, (4) the potential to scavenge/nullify free radicals generation during the
biotransformation of various hepatotoxins, (5) the inherent ability to upregulate the intracellular enzymic and nonenzymic
ﬁrst-line antioxidants such as SOD, CAT GSH, etc., toward the suppression of free radicals, (6) the antiinﬂammatory effect
results in attenuation of liver inﬂammation and proinﬂammatory cytokines, possibly as a result of regeneration, (7) the
ability to inhibit the phenotypical transition of qHSCs into aHSCs, which are responsible for the enhanced ECM synthesis
and hepatic ﬁbrosis, and (8) the ability to increase ribosomal protein synthesis by means of stimulating RNA polymerase I.
It can be concluded that SIL and SBN offer a hepatoprotective effect by means of any of the above mechanism involved in
CLD. However, other vital phytolead compounds reportedly used for the treatment of various liver ailments were presented
in Fig. 12.3 and discussed in the next section.
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12.1.5.2 Curcumin
Curcumin is widely used spice and isolated from the rhizome of Curcuma longa (turmeric). It has been used for centuries
in Asia for culinary purpose and as a treatment for inﬂammation, wounds and gastrointestinal, pulmonary, and liver
disorders [49]. The phytochemicals such as curcumin, turmerone, methylcurcumin, demethoxy and bisdemethoxycurcumin, and sodium curcuminate are present in turmeric. Among them curcumin is one of the most active and widely
used agents for its beneﬁcial effects against various diseases [50]. The antioxidant, antiinﬂammatory, and antiﬁbrotic
effects of curcumin have been clearly demonstrated in previous studies [51,52].
In in vivo scenario, curcumin is able to modulate the immune system and attenuate the intrahepatic inﬁltration of
Gr1hi, Ly6Chi monocytes in CCl4-induced ﬁbrotic liver via monocyte chemoattractant protein-1 inhibition [51,53]. HSCs are
highly responsive to hedgehog (Hh) signaling during their transdifferentiation into myoﬁbroblast. Curcumin treatments
downregulated the Hh signalingerelated hepatic ﬁbrosis in rats [54]. Curcumin supplementation mitigates Western diet and
CCl4-induced NASH and ﬁbrosis development in rats. There was a signiﬁcant reduction in steatosis, hepatic inﬂammation,
and ﬁbrosis reported after curcumin supplementation [55]. Interestingly, bisdemethoxycurcumin in combination with SIL
reported to having a synergistic effect on lipolysis against methionine/choline deﬁcient (MCD) diet-induced NAFLD [56].
Accumulating evidence suggests that activation of cannabinoid receptors 1 (CBR1) plays signiﬁcant role in the hepatic
ﬁbrogenesis. In a CCl4-induced ﬁbrosis model, curcumin administration found to have antagonistic effect against CBR1 and
thus contributed the antiﬁbrotic effect [57]. Curcumin has the potential to mitigate the bile duct ligated (BDL) and
CCl4-induced hepatic cirrhosis by downregulating the ﬁbrogenic cytokine transforming growth factor beta 1 (TGF-b1)
expression in rats [52]. Curcumin has been found to alleviate the sinusoidal angiogenesis in ﬁbrotic condition by HSCs
through peroxisome proliferator-activated receptor (PPAR-g) activation [58].
Curcumin has been demonstrated for senescence-inducing potentials and clearance of aHSC from the injured liver by
upregulation of natural killer celleactivating ligand major histocompatibility complex class I chain-related genes A and
UL16-binding protein 2 [59]. Curcumin treatment decreases Hh signaling and downregulates HSCs activation [54]. In
view of the pharmacokinetic properties, curcumin has poor stability, water solubility, intestinal absorption, and has rapid
biotransformation through reduction and conjugation reactions, which limit its bioavailability and hepatoprotective action
[60]. Therefore, to improve the suboptimal bioavailability, curcumin in the form of nanoformulation used previously and
reported with promising results. For instance, NanoCurc, a nanoformulation of curcumin administration contributed to the
sustained release of intrahepatic curcumin level in both hepatocytes and nonparenchymal cells and this preparation
signiﬁcantly reduced the proﬁbrogenic cytokines and ﬁbrosis, and in vitro, NanoCurcÔ also induced signiﬁcant HSCs
apoptosis [61].

12.1.5.3 Green tea extracts and its phytochemicals
Green tea is one of the popular drinks that is produced from the plant leaves of Camellia sinensis [62]. Green tea and its
phytochemicals have been widely promoted and marketed for weight loss and various other beneﬁcial effects. Green tea
extract (GTE) containing phytochemicals such as (þ)-catechin, ()-epicatechin, (þ)-gallocatechin, ()-epigallocatechin,
()-epicatechin gallate, and ()-epigallocatechin gallate (EGCG) are well-studied against various forms of liver injuries
[62,63]. Green tea intake has been reported to reduce the risk of liver disease across Asian, American, and European races
[64]. The GTE has been demonstrated to have excellent antioxidant activities through downregulation of lipid peroxidation
with concomitant upregulation of various intracellular antioxidants and modulation of collagen expression that contributes
antiﬁbrotic activities against various hepatotoxin-induced ﬁbrosis in rats [65e67]. In in vitro studies, GTE reduced proliferation and activation of HSCs and downregulated the collagen expression, thereby ameliorating the ﬁbrogenic potential
of HSCs [67].
()-Epigallocatechin-3-gallate is one of the most abundant polyphenols in green tea, upregulates miR-221, and caused
osteopontin degradation that results in the reduction of osteopontin-dependent hepatic ﬁbrosis in vitro and in vivo against
TAA-induced hepatic ﬁbrosis [68]. In BDL rats, EGCG treatment signiﬁcantly ameliorates hepatic inﬂammation, necrosis,
and ﬁbrosis via downregulation of tumor necrosis factor-a (TNF-a), interleukin-1b, TGF-b1, matrix metalloproteinases-9
(MMP-9), a-smooth muscle actin (a-SMA), and collagen a1. Similar results have also been obtained in vitro studies using
a hepatic ﬁbrogenic cell line, i.e., LX-2 [69]. Interestingly, EGCG has also been found to inhibit the HBV infection in
human liver chimeric mice and it inhibits HCV attachment to the host cell and viral entry makes less susceptible to hepatitis
infections [70,71]. These studies show that green tea phytochemicals may decrease the risk of HBV- and HCV-related liver
ﬁbrosis. NAFLD is an orchestrated and progressive liver disorder related to obesity, diabetes, and insulin resistance [72]. In
clinical subjects, fat reduction and body weight loss have been reported after GTE (270e1200 mg/day) consumption [73].
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Green tea contains a variety of polyphenols such as catechins reported to have antioxidant, antiinﬂammatory, thermogenic,
and hypolipidemic properties. Therefore, in NAFLD condition, green tea consumption has been suggested to mitigate the
progression of the disease [72]. In an NAFLD model, EGCG reduces the oxidative stress, proinﬂammatory, and ﬁbrogenic
cytokines via modulation of TGF/SMAD signaling, nuclear factor-kB (NF-kB) pathways [74]. As an adjuvant, EGCG in
combination with atorvastatin downregulates liver ﬁbrosiserelated gene expressions in an NAFLD model [75]. Catechin
administration signiﬁcantly lowers serum transaminases levels; oxidative stress and ﬁbrosis-associated parameters such as
4-hydroxynonenal, TGF-b1, tissue inhibitors of metalloproteinases-1 (TIMP-1), and a-SMA in BDL induced cholestatic
rats. Catechin has antiﬁbrotic properties by amelioration of oxidative stress and controlling the transcription factors
expression involved in HSCs activation [76]. These studies have undoubtedly reported the hepatoprotective effect of
GTE and its phytoconstituents. However, hepatic dysfunction such as acute liver failure has also been reported after
consumption of green tea [77].

12.1.5.4 Resveratrol
Resveratrol (3,40 ,5-trihydroxy-trans-stilbene, RVT), a polyphenol, was found in the skin of red grapes, peanuts, and berries
and was ﬁrst isolated from the Veratrum album in 1940 and later isolated from Polygonum cuspidatum (Japanese knotweed) in 1963 [78]. Resveratrol supplementation mitigates the oxidative stress and ﬁbrosis in DMN-induced ﬁbrosis
model. The antiﬁbrotic action of RVT was attributed through the restoration of antioxidant enzymes and downregulation of
ﬁbrosis markers [79]. RVT is lipophilic compound and readily crosses the cell membrane, and in the cytosol, it binds to
various intracellular compounds and scavenges the free radical generated because of oxidative stress. RVT administration
not only downregulated the markers associated with ﬁbrosis but also reduced the portal pressure and improved the
endothelial functions [80]. Furthermore, RVT administration reduces the incidence of portal vein thrombosis after
splenectomy in a rat ﬁbrosis model [81]. These studies show that RVT can also be used as an agent to counteract the
cirrhosis-associated complications such as portal hypertension.
In a recent proteomic study, RVT supplementation is reported to restore hepatic architecture and promote the collagen
degradation against DMN-induced hepatic ﬁbrosis in rats [82]. In a previous study, RVT was shown to reduce ﬁbrosis via
its interaction with protein kinase C and a-fetoprotein enhancer region in ﬁbrotic rat liver [83]. RVT mitigates the alcoholic
fatty liver diseases by inducing autophagy in mice fed with standard ethanol Lieber-DeCarli liquid diet [84]. Accumulating
evidence indicates that Notch signaling is essential for ﬁbrosis, and increased expression of Notch proteins in ﬁbrotic areas
mediates signaling associated with liver ﬁbrosis through activation of HSCs [85,86]. In the CCl4 model, RVT prevented
liver ﬁbrosis by alleviating lipid peroxidation and Notch signaling [86].
Resveratrol mitigates hepatic steatosis and inﬂammation in MCD-induced NASH model by regulating autophagy. In
the MCD diet model, RVT administration downregulated serum transaminases, lipid peroxidation, triglycerides, TNF-a,
interleukins (IL-1b, IL-6), and mRNA expressions of TNF-a, IL-1b, and IL-6 [87]. In a murine model of NAFLD, RVT
supplementation alleviates the insulin resistance, glucose tolerance to oxidative stress, and inﬂammation and at molecular
level it inhibits the NF-kB activation through the restoration of inhibitor IkBa [88]. Clinically, a randomized,
double-blinded, controlled clinical trial involving 50 NAFLD patients supplemented with 500-mg of RVT capsule for
12 weeks showed a signiﬁcant reduction in ALT, proinﬂammatory cytokines, NF-kB activity, serum cytokeratin-18, and
hepatic steatosis grade [89]. These studies show that RVT could be a promising drug candidate for oxidative stress and
inﬂammation associated with NASH.

12.1.5.5 Glycyrrhizic acid
Glycyrrhizic acid (GA) or glycyrrhizin, isolated from Glycyrrhiza glabra (roots), is traditionally used to treat a variety of
diseases in China. It has been found to have numerous liver-related health beneﬁts, such as antiinﬂammatory, antiviral, and
hepatoprotective activities [90]. In vivo studies, GA administration results in signiﬁcant downregulation of apoptosis
markers, a-SMA, connective tissue growth factor, MMP-2 and -9, and a-SMA, collagen I and III mRNA expressions in
CCl4 intoxicated ﬁbrotic liver. Histologically, GA treatments signiﬁcantly improve the pathological changes associated
with hepatic ﬁbrosis [90]. During chronic hepatic inﬂammation, CD4þ T cells and other immune cells produce several
cytokines and they are said to indirectly modulate the behavior of qHSCs [91]. Therefore, immunomodulatory effects of
GA on CD4þ T cell responses during liver ﬁbrogenesis have been studied previously. GA administration dramatically
enhances the antiﬁbrotic cytokine interferon-g and IL-10 and mitigates the ﬁbrosis progression through regulation of
CD4þ T cell response in c-Jun N-terminal kinases, extracellular signaleregulated kinases, and PI3K/AKT-dependent
pathways [92].
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In an MCD diet-induced NASH model, GA administration ameliorated the hepatic steatosis, oxidative stress,
inﬂammation, and ﬁbrosis and partially decreased serum bile acid accumulation in mice and restored inﬂammationmediated hepatic farnesoid X receptor inhibition [93]. These results show that GA can restore the bile acid homeostasis
and inhibit the inﬂammation-mediated NASH. In a standard ﬁbrosis rat model, 18a-glycyrrhizin (18-GL) suppresses the
HSCs activation and induces apoptosis by blocking the translocation of NF-kB into the nucleus and clears MFBs from the
injured liver and thereby slow down the ﬁbrosis progression [94]. A similar study from the same group has also been
reported the interference of 18-GL into TGF/SMAD signaling pathway. There was a signiﬁcant downregulation of TGF/
SMAD gene expressions and phosphorylated SMADs (2 and 3) and SMADs (2 and 3) protein expressions reported after
18a-GL treatment in ﬁbrotic rat liver [95].

12.1.5.6 Quercetin
Quercetin (QUE), a plant-derived ﬂavonoid, is used as a nutritional supplement for its antiinﬂammatory, antioxidative, and
antiﬁbrotic properties [20]. In CCl4 intoxicated ﬁbrosis model, QUE modulates the proinﬂammatory cytokines activity and
HSCs activation markers, such as TNF-a, IL-6, IL-1b, cyclooxygenase-2, TGF-b, a-SMA, collagen 1 and 2, TIMP-1,
MMP-1, and desmin. The antiﬁbrotic mechanism of QUE is associated with regulation of NF-lB/IlBa, p38,
MAPK, and antiinammatory signaling pathways [96]. Quercetin has also been shown to inhibit the macrophages
activation and M1 polarization and decrease the mRNA expression of M1 macrophage (with decreased Notch1 expression)
and inﬂammatory markers such as TNF-a, IL-1b, IL-6, and nitric oxide synthase 2. This study indicates the antiinﬂammatory and macrophages inﬁltration inhibitory role of QUE in CCl4-induced ﬁbrosis [97]. Quercetin ameliorated
hepatic ﬁbrosis by attenuating HSCs activation and reducing autophagy through regulation of TGF-b1/SMADs and PI3K/
Akt pathways [98]. Quercetin also inhibits the activation of HSCs and reduces ﬁbrosis via downregulation of high-mobility
group box 1, toll-like receptor 2 and 4 gene, and protein expressions [99].

12.1.5.7 Berberine
Berberine (BBR) extracted from Coptis chinensis (roots, rhizomes, and stems) and from several other Chinese herbal plants,
chemically, is an isoquinoline alkaloid [100]. In vivo BBR has signiﬁcantly downregulated the lipogenic regulators such as
sterol regulatory element-binding protein 1, carbohydrate-responsive element-binding protein, and CCAAT-enhancerbinding proteins-b mRNA expressions in db/db mice, and BBR prevents the progression from hepatic steatosis to steatohepatitis and ﬁbrosis by reducing endoplasmic reticulum (ER) stress. Furthermore, BBR treatment causes signiﬁcant
downregulation of tunicamycin-induced fatty inﬁltration and ER stress in hepatocytes in vitro [101]. In clinical studies, six
randomized controlled trials involving 501 NAFLD patients, BBR administration (1e1.5 gm/day) causes downregulation of
TG, insulin resistance, serum transaminases, and degree of hepatic steatosis [102].
The effect of BBR has been tested against TAA-induced ﬁbrosis model, in which it signiﬁcantly improved inﬂammation and ﬁbrosis resolution and induces apoptosis [100]. The activation 5’ AMP-activated protein kinase (AMPK) has
been implicated in BBR mechanism of action against hepatic ﬁbrosis. In the CCl4 model, BBR administration has been
shown to cause AMPK activation and reduction in TNF-a and TGF-b1 expressions [103,104]. In BDL ﬁbrosis model,
BBR inhibits proﬁbrogenic factors such as a-SMA, collagen1, and 4A3 expressions and at the same time, it did not alter
the TGF-b/SMAD signal transduction. In higher doses, BBR has been shown to reduce ﬁbrosis through induction of
apoptosis via the intrinsic mitochondrial pathway. While in low doses, it causes AMPK activationemediated antiﬁbrotic
effect [105].

12.1.5.8 Miscellaneous
S. miltiorrhiza (Danshen in Chinese) is traditionally used in Chinese herbal medicine for the treatment of hepatobiliary
ailments. Presence of water-soluble phenolic acid called salvianolic acids A and B (SA-A and B) in this plant responsible
for various health beneﬁts [106]. In high-fat diet-fed and streptozotocin-induced diabetic rat model, SA prevents the
ﬁbrosis progression. Oral administration of SA at 0.3 mg/kg twice a day for 16 weeks signiﬁcantly alleviates the hyperlipidemia and reduces hepatic triglyceride (TG) levels. SA treatment also inhibited the a-SMA and TGF-b1 expression in
diabetic rats [107]. In vitro studies, SA-A and B potentially inhibited the PDGF-induced proliferation of HSC-T6, a rat
HSC line. SA-A inhibits 70-kDa ribosomal S6 kinase and SA-B mitigates oxidative stress markers and PDGF-induced
c-jun-N-terminal kinase, p38, and PKC-d phosphorylations, and these markers were said to play a signiﬁcant role in the
HSCs proliferation during the ﬁbrosis progression [108]. Presence of phyllanthin is associated with the hepatoprotective
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effects of P. amarus. TGF-b1 receptor kinase or activin receptor-like kinase (ALK5) is responsible for hepatic ﬁbrosis by
increasing the transcription of downstream entities such as collagen via SMAD 2 and 3. Phyllanthin has the ability to inhibit
the TGF-b1, ALK5 receptor, and its downstream target such as SMAD 2 and 3 [109]. Phyllanthin treatment suppresses the
CCl4-induced inﬂammation and ﬁbrosis via downregulation of NF-kB, TNF-a, and TGF-b1, ﬁbronectin, and collagen
expressions, respectively [110]. Furthermore, coffee consumption was associated with improved serum markers of liver
damage. Low doses of caffeine (5 and 10 mg/kg) were shown to improve liver architecture and oxidative stress injury [111].
In a cross-sectional study, involving 910 and 113 patients with chronic HCV infection, consumption of caffeine was
associated with lower liver ﬁbrosis [112,113]. Some of the hepatoprotective effects of phytochemicals have been presented in
Table 12.1.

TABLE 12.1 Promising hepatoprotective effect of plant phytochemicals.
Phytochemicals

Source

Hepatoprotective effects

References

Silymarin
silibinin

Silybum
marianum

In vitro: Inhibits HSCs activation, migration, and
proliferation and induces apoptosis
In vivo: Mitigates oxidative stress and reduces the activation of
HSCs, Kupffer cells, and fibrosis-associated markers such as
a-SMA and TGF-b1
Clinical: High dose SIL (1050 mg/day) improves quality of life
in chronic HCV cirrhotic patients. SBN inhibits HCV entry into
hepatocytes

[4,42,47,114,115]

Curcumin

Curcuma longa

In vitro: Protects HSCs activation and migration through
inhibition of CXCL12/CXCR4 biological axis, promotes
apoptosis of aHSCs via inhibition of MYD88, protects the
hepatocytes from lipoapoptosis and mitochondrial dysfunction
In vivo: Attenuates oxidative stresseinduced hepatic fibrosis,
inhibits HSCs activation via suppression of succinate-associated
HIF-1a induction, inhibition of CXCL12/CXCR4 biological axis
Clinical: At 400 mg/kg, it has promising effect on
morphological characteristics of liver in patients with
metabolic syndrome, at 1 000 mg/day in two divided doses for
8 weeks improves fatty liver and transaminase levels in NAFLD
subjects.

[116e121]

Green tea
phytochemicals

Camellia sinensis

In vitro: EGCG inhibits PI3K/Akt/SMAD pathway in
TGF-b1-stimulated LX-2 cells, potently inhibits HCV entry into
hepatoma cell lines and hepatocytes
In vivo: EGCG downregulates the collagen, TNF-a, IL-1b,
TGF-b1, MMP-9, a-SMA expressions, and NF-kB pathway;
catechin suppresses TGF-b1 and collagen expressions
Clinical: Green tea consumption for 12 weeks improves liver
function and fat infiltration in the liver of NAFLD patients

[69,71,75,122,123]

Resveratrol

Veratrum album,
Polygonum
cuspidatum, skin
of red grapes,
peanuts, and
berries

In vitro: Blocks the HSCs activation via modulating NF-kB
activation and PI3K/Akt phosphorylation, induces
antiproliferative effect and cell cycle arrest
In vivo: Attenuates oxidative stress and decreases the collagen
and a-SMA expressions and modulates of
a-fetoprotein and normalization of protein kinase C
responses, improves fibrosis-mediated intrahepatic
endothelial dysfunction and portal hypertension
Clinical: Improves inflammation in NAFLD patients,
regulates lipid metabolism in patients with NAFLD,
metaanalysis of placebo-controlled clinical trials shows
negligible effects of RVT in NAFLD patients

[78e80,83,124e128]

Continued
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TABLE 12.1 Promising hepatoprotective effect of plant phytochemicals.dcont’d
Phytochemicals

Source

Hepatoprotective effects

References

Glycyrrhizic
acid and
18a-glycyrrhizin

Glycyrrhiza
glabra

In vitro: Induces HSCs apoptosis and suppresses its
activation via interaction with NF-kB pathway
In vivo: Inhibits apoptosis and reduces fibrosis markers such as
collagens 1 and 3, MMP-2 and -9, a-SMA, CTGF in fibrotic
liver, reduces portal hypertension in isolated perfused rat livers
with chronic hepatitis, interacts with TGF-b1/SMAD signaling,
mitigates fibrosis via CD4(þ) T cell regulation
Clinical: Prevents HCV progression in interferon-resistant
patients with HCV-related cirrhosis, intravenous injection of
glycyrrhizin (stronger neo-minophagen C) at 100 mL/day for
8 weeks improved liver histology in patients with chronic
hepatitis

[90,92,94,95,129e131]

Quercetin

Fruits, vegetables,
black and green
tea, red wine

In vitro: Triggers cell cycle arrest, mitochondrial apoptosis in
HSCs via endoplasmic reticulum stress, inhibits HSCs
activation and decreases HMGB1, toll TLR 2 and TLR4
protein and gene expressions
In vivo: Inhibits HSCs activation and fibrosis progression,
reduces autophagy through TGF-b1/SMADS and PI3K/Akt
signaling, protects liver from oxidative stress and
inflammation via blocking NF-kB activation and
downregulation of IL-1
Clinical: Exhibits potential antiviral efficacy in patients with
HCV

[98,99,132e134]

Berberine

Berberis vulgaris,
Berberis aristata

In vitro: Inhibits HSCs proliferation mediated fibrosis
In vivo: Inhibits AKT signaling and induces apoptosis via
intrinsic pathway and decreases the fibrosis markers
expression, ameliorates autophagic flux inhibition in liver via
regulation of cholesterol metabolism
Clinical: Decreases circulating ceramide and
ceramide-1-phosphate and improves fatty liver in patients with
NAFLD, ameliorates NAFLD via regulation of hepatic lipid
metabolism

[100,135e138]

Phyllanthin
Caffeine
Salvianolic acids

Phyllanthus
amarus
Coffea arabica
and Coffea
canephora
Salvia miltiorrhiza

In vitro: SA-B inhibits HSCs activation via TGF-b1/SMAD
signaling; caffeine induces HSCs apoptosis and inhibits HSCs
adhesion and activation
In vivo: Phyllanthin ameliorates liver fibrosis by
downregulation of TNF-a/NF-kB, and TGF-b1 signaling
pathways; SA-B modulates profibrogenic TGF-b1/SMAD
signaling and reduces cirrhosis associated portal
hypertension; caffeine protects alcohol-induced liver fibrosis
Clinical: Coffee caffeine consumption reduced the fibrosis risk
among NASH patients, caffeine intake lowered the risk of
NAFLD; SA-B resolves the fibrosis in HBV infected
patients; Phyllanthus amarus inhibits HBV replication and
improves liver of HBV-infected patients

[109,110,139e146]

12.1.6 Herbal medicines in clinical trials for CLDs
Undoubtedly, phytochemicals possess promising health beneﬁts against various forms of CLDs by virtue of their antioxidants, antiinﬂammatory, and antiﬁbrotic properties (Fig. 12.4). Several phytochemicals have reached clinical trials to
test their effect on patients with various forms of liver disease. For instance, in a recent open-label, randomized clinical trial
involving 400 participants with compensated liver cirrhosis, SIL along with other antioxidants improved liver stiffness,
portal hypertension, and quality of life (ClinicalTrials.gov Identiﬁer: NCT03659058). In a randomized clinical trial, SBN
along with vitamin E underwent phase 3 trial against liver ﬁbrosis (NCT01935817). In phase 2 and 3 clinical trials,
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FIGURE 12.4 Antiﬁbrotic effect of phytochemicals. aHSC, activated stellate cells; qHSC, quiescent hepatic stellate cells; ECM, extracellular matrix;
MMP, matrix metalloproteinases; PDGF, platelet-derived growth factor; TGF-b1, transforming growth factor b1; TIMP, tissue inhibitor metalloproteinases.

curcumin supplements have been tried against NAFLD patients with type 2 diabetes (NCT02908152). Resveratrol has
undergone phase 2 and 3 clinical trials against NAFLD patients (NCT02030977). A phase 1 trial is currently ongoing with
green tea catechin extract for the prevention of liver cirrhosis (NCT03278925). GA has been used in clinical trial along
with antiviral drugs for chronic HCVeassociated ﬁbrosis (NCT00686881) (source: NIH, Clinicaltrials.gov).

12.1.6.1 Limitations of herbal medicines use in CLDs
A number of phytochemicals show promising beneﬁcial effects, for instance, SIL for A. phalloides poisoning, P. amarus
and its derived phytochemicals for chronic HBV and jaundice, glycyrrhizin to treat HCV, etc. Most of the herbal drugs
have poor water solubility, intestinal absorption, and bioavailability, and these properties hinder their biological activity
and limit the efﬁcacy. In addition to therapeutic properties, several case studies related to liver injures are accumulating
after the intake of herbal products, including those advertised for liver diseases, and this could be because of the lack of
awareness among patients. For instance, according to NIH website, more than 100 green tea related over-the-counter herbal
preparation are available; however, none of them indicated as a speciﬁc medicine and FDA has not regulated the safety and
efﬁcacy of such preparations (NIH, 2018) [146]. Furthermore, herbal medicineeinduced liver disease could be due to lack of
(1) awareness among general public, (2) standardization of herbal medicines and their identiﬁcation of active ingredients,
(3) toxicological evaluation in experimental studies, and (4) quality of clinical trial and rigorously designed, larger,
randomized, double-blind, placebo-controlled trials. Therefore, more basic and clinical studies on these phytochemicals are
warranted on pharmacokinetic and pharmacodynamic levels. In spite of these limitations, a number of phytocompounds show
promising effects, and they currently are used to improve disease state and quality of life.

12.1.7 Conclusion
Undoubtedly, plant-derived phytochemicals are excellent source for the new drug entity. Phytochemicals, such as SIL,
SBN, curcumin, etc., were prescribed for CLD in human to improve the quality of life. Most of the phytochemicals
reviewed here possess free radical scavenging, antioxidant, and anti-inﬂammatory activities. Mechanistically, these phytochemicals interact with free radicals, proinﬂammatory, and ﬁbrogenic markers, and various other molecular mechanisms are
responsible for the progression of CLD.
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13.1 Introduction
Plethora of chemical compounds that may have therapeutic effect on the biological system are extra-nutritional. This
implies that most of the chemical compounds, which may exert therapeutic effect on the body are not synthesized by the
body, hence the need to derive them from plants and some certain foods. Since they are hardly synthesized in the body
unlike primary metabolites (protein, carbohydrates, nucleic acids and lipids), they are called secondary metabolites.
The term bioactive compound is usually associated with positive effects of secondary metabolites on an organism.
They are found in small amounts in plants and certain foods like fruits, vegetables, nuts, oil and whole grains. Their
positive effects in the body promote good health. They are being studied in the prevention of skin diseases, cancer, heart
diseases and others. Some of these promising compounds are lycopene, resveratrol, lignin, tannins, indoles, ﬂavonoids
etc. They have been reported to possess pharmacological activity likely to be therapeutically useful when administered
but may still have sub-optional structure that requires modiﬁcation to ﬁt better to the targets to exhibit the desired effect.
A bioactive lead compound may become a target in drug discovery or a leading compound in the synthesis of drug if a
part of its molecular structure capable of pharmacological interaction with its receptor to produce positive effect can be
elucidated [1].
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13.1.1 Type of skin diseases
There are different kinds of skin diseases. To better understand them, they are being grouped according to their causative
agents. Basically, there are seven types of skin diseases; (i). Eczema (ii). Fungal/yeast (iii). Bacterial (iv). Viral (v). Parasite
(vi). Autoimmune (vii). Miscellaneous skin disease.

13.1.1.1 Eczema skin diseases
The term eczema and dermatitis are often used to describe the same condition. Eczema is a non-infectious inﬂammation of
the skin. It may be acute or sub-acute. There are many different types of eczema, the most common ones includes.
Atopic eczema: This is a multifactorial skin disease seen in patients with atopic constitution. This means that they have
a genetic pre-disposition for hypersensitivity reactions, such as asthma and hay fever. This skin disease affects children and
adults and appears in elbow and knee folds, on wrist and ankles and on the face and neck. In a long term infection,
licheniﬁcation is common.
Pityriasis alba: This type of eczema occurs predominantly in the infants, children and adolescents. Multiple hypopigmented, vaguely bordered, very ﬁnely scaling patches are found on the face and trunk and sometime the extremities.
Lichen simplex: This occurs as a well circumscribed patch of licheniﬁed skin which is very itchy. Licheniﬁcation
means thickening of the skin with exaggerated skin lines and this is usually caused by continuous scratching, rubbing with
stone or stick and the likes. Patches are commonly seen in the neck, genital area and on the lower legs.

13.1.1.2 Fungal/yeast skin infection or diseases
The fungal/yeast infection may occur at any age. The most common fungal infection is ‘athlete’s foot ‘infection of the
interdigital spaces of the toes. They include;
Mycids: A hypevergic reaction for the fungus may occur in the course of fungal infection. These are usually itchy
eruptions of small blisters at a site distant from the fungal infection, often the hands and ﬁngers.
Tineacorporis: This fungal infection of the skin, is most common on the exposed surfaces of the body, namely the face, arms
and shoulders. Tinea or ringworm presents in typical round lesions, which show scaling at the periphery or in concentric rings.
Tineacapitis: Scalp ringworm is very common in children. The fungus can grow into hair follicle which may not be
removed by topical treatment only. Lymph nodes in the neck swell and the patient may have a fever and headache.
Mycetoma: This is a chronic localized infection which can be caused by various species of fungi (Eumycetoma) and
bacteria, actinomycetes and nocardia (actinomycetoma). Thesemicrobes live in the soil and enter the skin usually after a
penetrating injury.

13.1.1.3 Bacteria skin diseases
Impetigo: This skin disease is caused by staphylococci and/or streptococci. It is associated with blisters which become
oozing erosions with yellow crusts as its spreads. Impetigo is contagious and may even spread with the shared use of
Vaseline, which makes it worse.
Folliculitis: This is an inﬂammation of hair follicles, usually caused by infection with bacteria, speciﬁcally staphylococci. Common localizations are face, the trunk and the buttock but anus skin area with hairs may be infected.
Erythrasma: This is caused by Corynebacterium minutissimum. It presents as dry, smooth to slightly creased or scaly
clearly demarcated reddish-brown plaques, in the groins, armpits or under the breast.
Leprosy: This is an infectious disease caused by mycobacterium leprae. An airborne infection which affects skin and
nerves. Leprosy often presents with hypo pigmented or slightly erythematous patches on the skin with loss of sensation and
enlarge nerves.
Buruliulcer: Buruli ulcer is caused by mycobacterium ulcerans. It is the third most common mycobacterium disease
after tuberculosis and leprosy in non HIV-infected patients.

13.1.1.4 Viral skin diseases
HIV related skin infection: HIV related skin diseases occur throughout the cause of HIV infection in 90% of the infected
persons. During sero conversion, an exanthema may occur together with fever and constitutional symptoms. Herpes zoster
is an early clinical sign, which in young age group is much related to HIV infection.Severe and chronic seborrhoic eczema
and other manifestations of HIV infection aremalluscumcontagiosum, papular pruritic eruption, severe herpes simplex or
human papilloma infection, severe bacteria mycobacterium and fungal infection and Kaposi sarcoma.
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Chicken pox: Chicken pox or varicella is a primary infection with the varicella zoster virus. It is common, very
contagious infection in children. Scratching is the main cause of bacteria super infection and may cause scaring. Crusts fall
off in 1e3 weeks.
Herpes zoster: Herpes zoster or strangles is the recrudescence of a latent varicella-zoster infection in the person’s immune
host. After a short period of itch, tenderness or pain along one or occasional several dermatomes on one side of the body
papules and plaques appear which quickly change into blisters. Most often thoracic and cervical dermatomes are affected. If
the ophthalmic branch of the trigeminal nerve is involved a keratoconjunctivities may develop or result to blindness.
Herpes simplex (lips and genital): The common presentation of herpes simplex virus infection are the ‘cold sores’ or
‘fever blisters’ on the lip (herpes labialis) and the genital herpes infection.

13.1.1.5 Parasitic infections
Creeping eruption: The larvae of hook worms of cats and dogs usually cause this disease. They enter the skin accidently
and migrate through the skin leaving a very itchy, winding red trail of inﬂamed skin behind them.
Scabies: This is caused by mite sarcoptes scabies which lives and move in the skin producing burrows (s-shaped ridge),
small blisters and papules.
Leishmaniasis: An infection caused by leishmanic parasite, after the bite of an infected sand ﬂy. After an incubation
period of 2 weeks to 4 months, an erythematous or skin colored nodule appears.
Lymphatic ﬁlariasis: Elephantiasis in the tropics may have a number of causes ranging from bacteria or fungal
lymphangitis and adenitis disease. A common cause of elephantiasis species of bacteria (e.g., Onchocerca volvulus,
Loa loa, Mansonella streptocerca) transmitted by mosquitoes. It causes oedema of extremities or genitals.

13.1.1.6 Auto-immune skin disease
Alopecia areata: This occurs in adults and children and generally presents as one or more round or oval bald patches on
the scalp or beard area.
Chronic bullous dermatosis of childhood: This is a chronic blistering disease which occurs in children. It usually
starts before the age of 5years. Small and large blisters appear predominantly on the lower trunk, genital area and thigh.

13.1.1.7 Miscellaneous skin disease
Acne vulgaris: A common disease of puberty and it usually regresses in early adulthood. Sometime it persists up to age 30
or lifelong. Sebum production is the most important factor in acne.
Albinism: This is a disorder of melanocytes in which melanin (pigment) are not synthesized. This result in absence
pigmentation of the skin, hair, and eyes, combined with photophobic and nystagmus from birth. The skin is white, the hair
white or yellow and the iris light blue. Since the patient lacks UV absorbing melanin, after a short term exposure to UV
light or rays, the skin gradually age and actinic keratoses occur with a tendency toward malignant transformation [2].

13.1.2 Potential druggable targets
Druggable targets involves proteins, peptides and nucleic acids interactions that can be regulated, ampliﬁed by a drug with
a small molecular weight chemical compound (smol) or a biologic (Biol), such as an antibody or a recombinant protein [1].
The term druggability is used in drug discovery to describe a biological target such as proteins that is known to or is
predicted to bind with high afﬁnity to drug. Smol and Biol are important therapeutic options for treatment of cutaneous
disease. The major advances in understanding the pathophysiology of diverse dermatologic conditions with new molecules
binding to speciﬁc extracellular or cell surface targets are being developed; monoclonal antibodies already in use and under
investigation are targeted for psoriasis, atopic dermatitis, myeloma hidraderitis suppurativa (HS) and pemphigus vulgaris.

13.1.2.1 Pathogenic mechanisms of certain skin diseases
Psoriasis: The prevalence of psoriasis is around 2.5%. Traditional oral systemic treatments include acitretin, cyclosporine
and methotrexate [1]. The discoveries of key cells and mediators in psoriasis such as mAbs have become important
targeted treatment options for moderate to severe plague psoriasis. Classically, tumor necrosis factor a (TNF-a) was
considered the main cytokine protein in patients with psoriasis nonetheless, the IL-23/IL-17A axis has recently been
recognized as playing an important role in plaque psoriasis. This led to the development of novel drugs, such as the human
mAb targeting IL-12/23 ustekinumaband the K-17A inhibitors.
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Atopic dermatitis: It is a common chronic inﬂammatory pruritic skin disease. From a pathophysiologic point of view,
atopic epidermal could include genetic dysfunction or the epidermal barrier, for which emollients, topical corticosteroids,
and calcineurin inhibitor are still a cornerstone of treatment.
A more recent study demonstrated T2H-driven inﬂammation in patients, including the implication of IL-4 and IL-13.
This ﬁnding promoted the investigation of target treatments in patients with atopical dermatitis, which has led to
development of dupilumab and anti-IL-4 receptor and antibody inhibiting IL-4 and IL-13 signaling.
Melanoma: The worldwide incidence of melanoma is increasing, and so the mortality that comes with it. Between
1999 and 2011, no new medication had received FDA approval for advanced melanoma. The survival rate has not
substantially improved with dacarbazine and IL-2 which are the two FDA approved drugs in 1975 and 1998
respectively.
A new pathway for therapy began when prolonged survival was reported with targeted therapies blocking the
mitogen-activated protein kinase pathway (the RAS-RAF-MEK-ERK signaling pathway, which normal function is to
regulate cell proliferation, growth and migration) and immunotherapy with checkpoint inhibitors. In zolo, a phase 3 study
showed improved survival with ilpilimumad, a fully human mAb (IgGI) that blocks cytotoxic T lymphocyte-associated
antigen 4 (CTLA-40), thus limiting T-cell cultivation and promoting antitumor immunity. A braf kinase inhibitor, also
showed a survival beneﬁt for the treatment of metastatic melanoma with the BRAFV600E mutation. Dabrafenib targeting
BRAF and MEK respectively, were FDA approved in 2013.
New class of mAbs targeting the programmed cell death 1 (PD-1) monitoring inhibitor has been in the market since
2014. Although the role of CTLA-4 is limited to T-cell activation, PD-I inactivate T-cells reacting the tumor and is
therefore a checkpoint in the immune system. The anti-PD-I antibodies nivolumab and pembrolizumab showed a response
rate of 30%e40%, with the majority experiencing long-standing responses.
Hidradenitus suppurativa (HS): HS is a chronic, inﬂammatory and possibly debilitating recurrent disease of the hair
follicles. It presents clinically with nodules, abscesses, sinus track formation and scarring. Commonly, it affects the
intertriginous areas of the skin, such as the axillae (the most common sited), inquinal, gluteal, and sub mammary areas.
Many cytokines (proteins) implicated in HS are still under investigation, but TNF-a, IL-13, IL-17 and IL-23 have been
identiﬁed as causing the inﬂammation.
Pemphigus Vulgaris: This is a group of rare autoimmune bullous diseases that can be fatal. The main condition in the
category is pemphigus vulgaris, which is characterized by blisters and erosions of the mucous membrane and frequently of
the skin, which is mediated by autoantibodies against Desmoglein 3 (Dsg 3) and to a lesser extent Desmoglein 1 (Dsg 1).
Rifuximabhas revolutionized the treatment of pemphigus vulgaris, providing a target anti-B cell therapy. It depletes B-cells
while maintaining the terminally differentiated plasma cells, as well as stem cells.

13.1.2.2 Promising druggable targets of skin diseases
BRAF Kinase: A serine/threonine kinase protein that is part of mitogen-activated protein kinase signaling pathway.
Mutated BRAF protein (oncogenes) has increased kinase activity, which is known to be a cause of melanoma.
Calcineurin: Calcium and calmudulin-dependent serine/threonine protein phosphates that activates T-cells and can be
blocked by inhibitors. Calcineurin activates cytoplasmic nuclear factor of activated T-cells (NFATc), a transcription factor,
through dephosphorylation. Activated NFATc up-regulates IL-2 expression, stimulating growth and differentiation of the
T-cell response.
CD20: An activated glycosylated phosphoprotein expressed on the surfaces of all B-cells that plays a role in the
development and differentiation of B-cells into plasma cells.
CD22: Is a transmembrane protein that preferentially bind to a-2,6 linked sialic acid and mediated B-cell-B-cell
interactions. CD22 is known to be regulatory molecule that functions as an inhibitory receptor for B-cell receptor
signaling that prevents over activation of the immune system and development of autoimmune diseases.
Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4): A receptor that functions as an inhibitory signal that down
regulates immune responses. CTLA4 is constitutively expressed in regulatory T-cells but is only up regulated in
conventional T-cells after activation.
Desmoglein1 and 3 (Dsg1 and Dsg 3): Calcium-binding transmembrane glycoproteins of desmosomes in vertebrate
epithelial cells and members of the cadherin cell adhesion molecule superfamily. Furthermore, Dsg1 and Dsg three protein
has been identiﬁed as auto antigens of the autoimmune skin-blistering disease pemphigus vulgaris.
IL-1a: A cytokine of the IL-1 family responsible for the regulation of inﬂammation, as well as the promotion of fever
and sepsis. IL-1a is involved in TNF-a activation.
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TABLE 13.1 Drug targets classes addressed by smol, biol and their mode of action.
Drug

Target class

Mode of action

Small molecular weight
chemical compounds(smol)

Enzymes
Receptors

Inhibitors, activators
Agonists, antagonist, modulators
allosteric activators

Transcription factors

Inhibitors, activators

Ion channels

Inhibitors, openers

Transport proteins

Inhibitors

Protein-protein interface

Inhibitors of protein-protein interface

Nucleic acid

Alkylation, intercalation

Extracellular proteins

Antibiotics

Trans membrane receptors,
extracellular proteins

Recombinant proteins

Cell surface receptors

Antibody-drug conjugates (ADC2)

Substrates and metabolites

Enzymatic cleavages

Biologic (biol)

IL-17A: A proinﬂammatory cytokine that regulates nuclear factor Kb and mitogen-activated proteinkinase expression.
IL-17A has been shown to stimulate IL-6 and COX-2 (PTGS 2/COX-2) expression, as well as nitric oxide production.
IL-23: A cytokine secreted by activated dendritic cells and activated macrophages, IL-23 functions in both innate and
adaptive immunity to regulate TH 17 function in proliferation. In addition, IL-23 induces CD8þ memory T-cells to
proliferate and produce IL-17. AS such IL-23 is a key in controlling inﬂammation in peripheral tissues.
Mitogen-Activated Protein Kinase (RAS-RAF-MER-ERK): These cascade is key signaling pathways involved in
the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of RAS-RAF-MEK-ERK has
been shown to cause cancer and other human diseases, which have led to the development of pharmacologic inhibitors.
Programmed Cell Death (PD-1): Are cell-surface receptors that play an important role in down regulating the immune
system and suppressing inﬂammatory T-cell activation. PD-1 is an immune checkpoint that serves a dual role of promoting
apoptosis in antigen-speciﬁc T-cells while as the same time reducing apoptosis in regulatory T-cells.
TNF-a: It is secreted primarily by macrophages; this cytokines primary role is immune cell regulation [1].
The bases of classiﬁcation of potential targets were described by smol, biol and their mode of action and presented in
Table 13.1 [1].

13.1.3 Phytocompounds for the treatment of skin diseases
In this section, some selected phytochemicals with the potentials of serving as a lead compound have been presented. They
include kojic acids, resveratrol, green tea polyphenols, isorhamnetin and kaempferide (Fig. 13.1).

13.1.3.1 Kojicacid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one)
A bioactive lead compound such as kojic acid can be extracted from leaves of common bearberry and are often used in skin
care products as a lightning agent. It has been shown to be safe and effective for topical use [3]. Recently, bibenzyl
analogues are reported to have potent anti-tyrosinase activity with almost 20-fold stronger than kojic acid. Kojic acid, a
well-known tyrosinase inhibitor is used as the positive control in literature for comparing the inhibitory strength of new
inhibitors [4e6]. The fashion industry regard kojic acid as one of the best natural based lotions as far as skin lightning
agents is concerned. It is the lead compound found to prevent photodamage and wrinkling of the skin in the hairless mouse.
It is a good chelator of transition metal ions and a good scavenger of free radicals. Therefore, it is an effective agent for
photoprotection [7]. Current evidence suggest that it induces skin depigmentation via suppression of free tyrosinase,
mainly due to chelation of its copper at the active site of the enzyme. It is responsible for therapy and often affecting
women, especially those living in areas of intense UV radiation in treatment of melisma [8e10].
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FIGURE 13.1

Structure of some common bioactive lead compounds and their sources.

13.1.3.2 Resveratrol
Understanding the pathophysiology of Acne, the ideal drug should be capable of reducing the inﬂammatory response. As a
result, resveratrol is emerging as a new approach in treating acnes, as it possesses anti-proliferative and anti-inﬂammatory
properties. Resveratrol is a natural phytoalexin which is produced by certain spermatophytes, such as grapes. A single blind
vehicle-control pilot study was carried out in which resveratrol (trans-isomer) was formulated into a gel with a
carboxymethyl cellulose base. This formation was applied on the right side of the face of volunteers with inﬂammatory
acne vulgaris for 60days and compared to the left side of the face where the control was applied. All the volunteers had a
profound reduction in pustular lesions and inﬂammation with an overall noticeable clinical improvement on the side treated
with resveratrol. The resveratrol etreated side of the face also showed a signiﬁcant decrease of macrocomedones and
microcomedones when compared to the control side. Though it was observed that, resveratrol inhibited the keratinocyte
hyper proliferation process.
Resveratrol was found to be bacteriostatic at lower concentrations (50 mg/L and 100 mg/L) and bactericidal at the
highest concentration (200 mg/L). The inhibiting effect of resveratrol compared well with the activity of frequently used
acne treatments-benzoyl peroxide and erythromycin [11].

13.1.3.3 Green tea polyphenols
Polyphenols are naturally occurring chemicals derive from plants, fruits, nuts and vegetables [12]. It is known
that UV-radiation induces oxidative stress, DNA damage and affects immune system. It has been observed that,
()-Epigallocatechin-3-gallate (EGCG) as a bioactive lead compound in green tea polyphenols (GTPP) signiﬁcantly
inhibits acute or chronic UV irradiation-induced protein oxidation in the skin of mice. This suggests that GTPP may be
able to reduce photo damage in the skin and prevent premature aging. Other studies showed that pretreatment of mouse
skin with EGCG inhibited UV-induced inﬁltration of leukocytes, speciﬁcally CD11bþ cells in the skin, which mediates
UV-induced immunosuppression. These inﬁltrating leukocytes can be a potential source of hydrogen peroxide (H2O2) and
nitrogen oxide (NO) which play important roles in initiating and promoting tumor cells. Less damage to the epidermal
structure of the mouse skin was also observed with the topical application of EGCG before being exposed to UV light. The
data collected from the study indicated the potent preventive effects of topical EGCG in mice against UV radiation-induced
inﬁltration of leukocytes, suggesting that GTPP may have preventive effects against the development of skin cancer in
humans. EGCG effectively inhibited human melanoma cell culture growth by decreasing IL-1b secretion and NF-kB
activity.
EGCG attenuates UV induced IL-6 secretion, apoptosis and NF-kB activation in keratinocytes. It also has differentiating effects on keratinocytes via activation of the nPKC, RAS, MEKKI, MEKB, and the p388-ERK1/2 signaling
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cascade, which leads to increased P-1 and C/EBP transcription factor expression and transcriptional activity. A randomly
assigned split body (face) trial was conducted by Yoon et al. (2013) to examine the effectiveness of 1% EGCG and 5%
EGCG topical compared to vehicle containing 3% ethanol in decreasing acne lesion count. Overall study showed that 1%
and 5% EGCG were both effective in improving acne vulgaris without major side effects [13].

13.1.3.4 Isorhamnetin and kaempferide
Based on the research work carried out by Wang et al. [14], the pharmacological mechanisms of Vernonia anthelmintica
(L) in the treatment of vitiligo (a long-term skin disease characterized by loss of pigment in the skin) revealed the potential
lead compounds from Vernonia anthelmintica. The result identiﬁed top ﬁve active compounds with relative higher
bioavailability that interacted with 23 therapeutic targets in Vernonia anthelmintica (L) using admet SAR and SDTNB1
methods. Among these ﬁve (5) compounds, Isorhamnetin and Kaempferide, which are methyl-ﬂavonoids performedbetter
in order of their signiﬁcance. Both signiﬁcantly increased the expression of melanin-biosynthetic gene (MCIR, MITF,
TYR, TYRPI and BCT), and the tyosinase activity in BI6F10 cells. Isorhamnetin and kaempferide signiﬁcantly increase
the expression of melanin-biosynthetic genes (MCIR, MITF, TYR, TYRPI and BCT) the protein level of MITF and the
tyrosinase activity [14].
Some bioactive compounds have been studied for the treatment of skin disease; 5-O-demethyl-nobiletin, sylimarin,
5-hydroxy-3,6,7,8,30 ,40 -heamethoxyﬂavone and black tea the aﬂavin derivatives are active or leading in acute skin inﬂammatory models, white ginkgetin, a biﬂavone, is leading or active in chronic skin inﬂammation. Similarly, eupatilin and
jaceosidin diminish the response of skin cells to IgE-antigen complex [1].

13.1.4 FDA approved drugs for dermatological disorders
Drugs for dermatological disorders are generally known as topical glucocorticosteroids: These are the most widely
prescribed drugs for skin diseases. They bind to cytoplasmic receptors that transport the drugs to the nucleus, where the
complex binds to particular regions of DNA known as the glucocorticoid response elements (GRE) and alter the gene
expression. Their exact mechanism of action is not clear however they are known to inhibit the expression of cytokines and
adhesion molecules and to antagonize the activity of transcription factors, such as NF-KB, NF-AT and AP-I. They are
useful in inﬂammatory dermatoses and psoriases, pemphigus vulgaris, bullus pemphigoid and lupus erythematosus. These
drugs are:
Acitretin: This cocorticosteroid promotes normalization of dysregulated keratinocyte proliferative activity in the
epidermis and is anti-inﬂammatory. In the USA, this drug has been approved for topical treatment of psoriasis and facial
acne. It is contraindicated in women who are pregnant.
Bexarotene: This drug exerts antiproliferative effects on some tumor lines of hematopoietic and squamous cell origin.
Topical bexarotene are approved for early stage (patch and plaque) cutaneous T-cell lymphoma that is refractory to at least
one therapy. Local irritation, such as burning, pruritus and irritant contact dermatitis is common contraindication following
application.
Alitretinoin: It is approved for the topical treatment of cutaneous lesion of kaposi’s sarcoma. Contraindication upon
application is irritation, but this does not necessitate discontinuation of the drug.
Photodynamic therapy: porphyrins are potent photosensitizing intermediates in heme synthesis and are thought to
accumulate in malignant cells. This modality has been shown to be effective in treating basal cell and squamous cell skin
cancers. Such drugs include:
Aminolevulinic acid: The drug is indicated for the treatment of non-hyperkeratotic actinic keratosis of the face and
scalp.
Dapsone: This drug is important in anti-inﬂammatory properties in many non-infectious skin diseases. It is approved
for the treatment of dermatitis herpetiformis.
Systemic antibiotics: Antibiotics are used in dermatology for both infectious and noninfectious skin eruptions. Such
includes:
Itraconazole: This drug is highly lipophilic and concentrates in skin. It is approved for both cutaneous deep fungal
infections and dermatophyte nail diseases.
Terbinaﬁne: It is a highly lipophilic and concentrates in stratum corneum and nail plate. It is very effective for many
dermatophyte infections, especially those of the nails.
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Crisaborole: It is a topical PDE-4 inhibitor. As a small molecule, it has good skin penetration and the boron-based
architecture contributes to its molecular stabilization. Serious side effects of crisaborole include hypersensitivity
reactions such as pain, burning or stinging. Thus, it should not be used for patients who have had hypersensitivity.
Dupihumab (IL-4/13): It is a novel subcutaneously administered therapy for atopic dermatitis that targets the IL-4
receptor alpha subunit, which is shared between both IL-4 and IL-13 receptors. It side effects include hypersensitivity
to conjunctivitis, keratitis, eye pruritus, oral herpes, blepharitis and dry eye. It should not be given to hypersensitive
patients.
Ilumya (tildrakizumad-asmn): It is an interleukin-23 antagonist. It is speciﬁcally indicated for the treatment of adults
with moderate to severe plague psoriasis. Adverse effects associated with Ilumya include upper respiratory infection,
injection site reaction and diarrhea. Asthmatic patient should not be given the drug.
Baxdela (delaﬂoxacin): It is used in treatment of acute bacterial skin and skin structure infection caused by
gram-positive organism (Staphylococcus aureus) and by gram-negative organism (Escharichia coli). Patients with known
history of myasthenia gravis should not use it.
Fluoroquinlones: These are associated with disabling and potentially irreversible adverse reaction that have occurred
together with tendinitis and tending rupture, peripheral neuropathy, central nervous system effects. Fluoroquinolones
should not be used by patients with these experiences.

13.1.4.1 Drugs used for disorders of pigmentation
Hydroquilone: This interferes with the production of the pigment melanin by epidermal melanocytes through at least two
mechanisms: it competitively inhibit tyrosinase, one of the principal enzymes that converts tyrosine to melanin and it
selectively damages melanocytes and melanosomes.
Monobenzone: This drug inhibits melanin production and destroys melanocytes.

13.1.4.2 Antihistamines drugs
These drugs are available with and without prescription for the treatment of mast cell-mediated diseases such as acute and
chronic urticaria, angioedema, and cutaneous mastocytosis.
Doxepin: The tricyclic tertiary amine doxepin; a potent H1 and H2- receptor antagonist is indicated for the short-term
relief of pruritus associated with topical eczematous dermatitis. The most common contraindication is drowsiness.
Keratolytics drugs: These drugs are used to treat hyperkeratosis i.e., thickening of the stratum corneum. Examples of
agents involved in these drugs are salicylic acid, urea, lactic acid and colloidal or precipitated sulfur.

13.1.4.3 Anti-skin disease drugs in clinical trials
Ixekizumad: This drug is in phase three trials involving patients with psoriasis. It was effective through 60 weeks of
treatment. The efﬁcacy and safety of Ixekizumad beyond 60 weeks of treatment is yet to be known [15]. As with any
treatment, the beneﬁts need to be weighed against the risks of adverse events.

13.1.5 Multi-drug therapy for anti-leprosy resistance drugs
Leprosy control depends solely on case detection and treatment with multi-drug therapy (MDT). The strategy is based on
the principles that identiﬁes and treat chronic infectious disease with combination of effective antibiotics that limits the
emergence and spread of new or existing antibiotic resistant pathogens. According to the world health organization
(WHO), MDT formulated for leprosy has been effective at reducing both the prevalence and incidence of leprosy globally.
The WHO study group on chemotherapy of leprosy for control program recommended the introduction of MDTin 1982 in
response to the serious threat to leprosy control posed by the world spread emergence of Dapsone resistance. Concerns are
raised about the development of drug resistance to rifampicin, as it is the most important component of the MDT regimen
[16].

13.1.5.1 Multi-drug therapy
The drugs used in WHO-MDT are a combination of rifampicin, clofazimine and dapsonefor MB leprosy patients and
rifampicin and dapsone for PB leprosy patients. Among these drugs, rifampicin is the most important anti-leprosy drug and
therefore, is included in the treatment of both types of leprosy.
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MDT for leprosy has been very practical and successful for both MB and PB leprosy and the overall prevalence rates of
leprosy in the world have fallen drastically. However, noncompliance is a primary reason that drug-resistant strains
develop and relapses with resistant strains, which pose potential problem to MDT in the control of leprosy. A new drug
have been shown to be active against M. leprae, new combination have been tried in attempts to shorten the duration of
therapy and to improve the therapeutic efﬁcacy. For example in 1998, a single dose of a combination of rifampicin
(600 mg), oﬂoxacin (400 mg) and minocycline (100 mg) (ROM) was evaluated for treating single lesion, PB leprosy.

13.1.5.2 Anti-leprosy resistant drugs
Dapsone: The ﬁrst effective treatment for leprosy was promin (diamino-azobenzene-40 - sulfonamide) introduced in 1941
and given intravenously. Six years later, more effective oral sulphonedapsone (diamino-diphonylsulphone), replaced
promin and is still fundamental part of MDT for leprosy. Sulphone drug target the dihydropteroate synthase (DHPS), a key
enzyme in the folate biosynthesis pathway in bacteria including M. leprae, by acting as a competitive inhibitor of
p-aminobenzoic acid (PABA). Missense mutation within codon 53 and 55 of the drug resistance determining region
(DRDR) of the folpl gene, encoding the DHPS of M. leprae, has been observed in dapsone-reistant strains. In addition, the
majority of the patient’s biopsies were conﬁrmed to harbor M. leprae with a moderate to high levels of dapsone resistance
as demonstrated by the mouse footpad (MFP) drug susceptibility assay.
Rifampicin: Rifampicin C3 {[(4-methyl-1-piperazinyl)-Imino]-methyl] rifampicin} is the key bacterial component of
all recommended MDT regimens. Rifampicin resistance in M. leprae correlates with missense mutation within the
rpoBRRDR. Substitutions within codon ser456 have been shown to be most frequent mutations associated with the
development of the rifampicin-resistant phenotype in M. leprae.
Clofazimine: Clofazimine [3-(p-chloroaniline)-10-(p-chlorophenyl)-2, 10]-dihydro-2-(isopropylimino)-phenazine] is a
lipophilic riminophenazine antibiotic that possess antimycobacterial activities. Clofazimine binds preferentially to
mycobacterial DNA. Binding of the drug to DNA appears to occur principally at base sequences containing guanine, which
may explain Clofazimine’s preference for the GþC- rich genomes of accumulation over human DNA. The accumulation of
lysophospholipids appears to mediate the activity of Clofazimine in some gram-positive bacteria. However, it is not clear
whether this mechanism of action is operational in M. leprae. Since Clofazimine may act via different mechanisms, and it
is not difﬁcult to understand why only a few cases of Clofazimine-resistant leprosy have been reported [16].

13.1.6 Outlook of topical drugs development for dermatological disorders
According to Eric and Mary-Margaret [17], on drugs used in dermatological disorders, they considered the skin structure to
be made up of two compartments, the epidermis; a stratiﬁed squamous epithelium and the underlying dermis; a richly
vascularized tissue embedded in a connective tissue matrix.
The epidermis consists of multiple layers of keratinocytes, which differentiate into the outermost layer, the structure
corneum. This layer contains the hydrophilic structural protein keratin surrounded by hydrophobic intercellular lipids, a
better barrier to many topically applied agents.
The distinguishing factor of keratinocytes in the basal layer from proliferative cells to highly differentiated non-divided
cells in the stratum corneum, are ﬁrmly regulated by a variety of intrinsic, and extrinsic factors, including cytokines and
calcium. The epidermis also contains melanocytes, which synthesize the photoprotective pigment melanin and langerhans
cells, the dendritic antigen-preventing cells that compose the farthest outpost of the body’s immune system.
The dermis on the other hand is a base for the epidermis and contains ﬁbroblasts that elaborate proteins, such as
collagen and elastin, which are crucial for the skin’s structural integrity.
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14.1 Introduction
Loss of hair or alopecia is a major dermatological issue throughout the world. Alopecia is a common term which covers
several types of hair loss, which is usually treatable [1]. Androgenic alopecia [2], telogen efﬂuvium [3], anagen
efﬂuvium [4], alopecia areata [5], alopecia totalis [6], alopecia universalis [7], and scarring alopecia [8] are the
classiﬁcation of alopecia, depending on the reason for hair loss. Each alopecia type is unique and is caused by several
factors. Androgenic alopecia and alopecia areata are the most relevant hair loss types. The former is hereditary and
known as pattern baldness [9], while the latter is a patchy hair loss type, where the immune system of the patient’s body
damages hair follicles [10]. Similar to alopecia areata, alopecia totalis is termed as the comprehensive scalp hair loss and
complete loss of body hair, including nose hairs and eyelashes because of the damage caused by immune system is
termed as alopecia universalis [11]. Telogen and anagen efﬂuvium are the terms associated with hair shedding in women
after giving birth and chemotherapy, respectively. Generally, these are short-term hair loss complications and hair
growth will resume in both cases [12,13]. Scarring alopecia is a rare hair loss type, where the hair follicles are replaced
by scar tissues which inhibit hair growth, and the causative factor of this hair loss type is still unclear [14]. It is
noteworthy that most of these hair loss types are because of damages caused by immune system, and these ﬂuctuations in
the immune system are mainly because of the side effects of conventional chemical-based drugs and chemotherapy that
are used for the treatment of other diseases [15,16]. Furthermore, the chemical-based drugs for hair loss treatment, such
as minoxidil, also lead to various other side effects, including contact dermatitis, seborrheic dermatitis, scaling, and scalp
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pruritus [17]. Thus, natural, plant-based formulations are utilized for alopecia treatment as an alternative to chemical
drugs, since ancient times.
Plant-based drug formulations are synthesized via herbal and plant extracts, which contains secondary metabolites
called phytochemicals [18]. Flavonoids, terpenoids, xanthophyll, carotenoids, and phenols are the common phytochemicals that are present in all the plants. Phytochemicals are extracted and isolated by methods such as steam,
hydro-distillation, pressurized solvent-free, vacuum micro-assisted, microwave hydro-distillation, hydro-diffusion gravity,
supercritical ﬂuid extraction, and ultrasound extraction [19]. These phytochemicals are used in the traditional medicine for
curing hair loss problems [20]. Recently, the advancements in the phytochemical research and their extraction methods
have led to the availability of numerous plant-based drug formulations for the alopecia treatments [21]. Thus, the aim of
this chapter is to clarify the difference between conventional and phytochemical-based drugs for the treatment of common
alopecia types. In addition, the molecular mechanism of phytochemicals in alopecia treatment and the future of plant-based
formulations for the treatment of hair fall were also discussed.

14.1.1 Conventional treatment of alopecia
The conventional methods for the treatment of alopecia date back to several centuries. Plant or herbal extract mixed with
oil or formulated into a gel that are instructed to be applied in the place of hair fall is the basic treatment method used by
ancient humans for alopecia. Later, the formulations were improved with the advancements in science and pharmaceutical
product production. Currently, the alopecia treatment methods are classiﬁed into three types such as nondrug, synthetic
drug, and natural drugebased therapies as shown in Fig. 14.1.

14.1.1.1 Nondrug therapies
The common nondrug therapies that are employed by dermatologists and cosmetologists to treat alopecia include hair
transplantation, laser therapy, platelet-rich plasma therapy, and microneedling (MN). Apart from the above widely
accepted nondrug therapies, novel techniques such as follicular neogenesis, phototherapy, inductive cell therapy, and stem
cell therapy are emerging and are in clinical trials.

FIGURE 14.1 Classiﬁcation of alopecia treatments.
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14.1.1.1.1 Hair transplantation
Hair transplantation or surgical hair restoration is the most efﬁcacious nondrug-related solution for men with androgenic
alopecia [22]. The hair transplantation technology is promoted by the principle of donor dominance as proposed by
Norman Orentreich [23]. In this method, hair follicles that are conﬁned to androgen-insensitive areas have the potential to
withhold their properties, even when grafted into androgen-sensitive bald scalp areas [24]. In hair transplantation, hair
follicles from the occipital scalp region are removed and reimplanted into the areas of frontal scalp and bald vertex.
The prerequisites for hair transplantation are hair loss stabilization with medications and a large population of donor hair in
the occipital scalp region [25]. The contemporary hair transplantation technique called follicular unit hair transplant (FUT)
helps to transplant hairs in their naturally occurring follicular units [26]. In FUT method, the donor’s hair is harvested by
two diverse routes: strip harvesting and the follicular unit extraction (FUE) method. In the strip harvesting method, a scalp
strip from the occipital region is removed under local anesthesia and the wound is sutured back. The strip is then detached
into units of follicles, which was later implanted into the area of bald scalp. In FUE harvesting method, individual hair
follicles are detached from the donor occipital site under local anesthesia and then transplanted into the bald sites.
Immediately after transplantation, the hair follicles enter a temporary postoperative telogen resting phase, which inhibits
further hair growth until 3 months or less. Transplantation results are evident after 6e8 months of the procedure,
and successful transplantation helps to refashion patient’s face and renew their morale [25,27]. The adverse circumstance
of hair transplantation is that strip harvesting method leaves a long linear scar in the donor site, while FUE method leaves
only tiny, nonvisible scars and both the methods lead to reduced hair density in the donor region as no regrowth of hair will
occur, once the hair follicle is extracted [27,28]. The major obstacles faced in the pre- or posthair transplantation are pain,
infection, and failure of the transplanted graft follicles to sprout [24,25]. Also, patients with alopecia areata are infrequently
considered as hair transplantation candidates, which is another drawback of this technique [22].
14.1.1.1.2 Laser therapy
Low-level laser therapy (LLLT) or photobiomodulation is a popular drugless therapy that is used by dermatologists for
treating hair loss throughout the world [29]. The concept of laser therapy for hair fall treatment originated in 1967 after the
invention of commercial laser. Endre Mester observed that the treatment of hair fall with 694 nm wavelength of laser
accelerates hair growth in shaved mice, which lead to the discovery of laser biostimulation [30]. Incidence of this strange
paradoxical hypertrichosis or hair induction in the neighboring areas after undergoing laser epilation of unwanted hair in a
large population lead to LLLT development during the treatment of hair loss [31e35]. The promising feature of LLLT is
the efﬁciency of this method to treat alopecia areata, androgenic alopecia, and chemotherapy-induced alopecia in both male
and females with equal chances of success, and they are comparatively cheaper than other methods [36]. The precise
mechanism of LLLT in promoting hair growth is still unknown. It was proposed that the laser therapy activates the reentry
of anagen in hair follicles present in telogen phase, lengthen their time interval, escalate hair growth rate in anagen phase,
and avert the catagen phase entry. Adverse effects of LLLT include acne, headache, pruritus, scalp tenderness,
warm sensation, dry skin, and redness at the laser therapy site [37].
14.1.1.1.3 Microneedling
MN or collagen induction therapy is a recent modality for alopecia therapy in the dermatology ﬁeld, which involves
repetitive skin puncturing with pasteurized tiny microneedles [38]. The principle of MN is the physical trauma induced by
puncturing the skin with needles to stimulate dermis regeneration [39]. The modern-day dermarollers (microneedles) that
are being used to treat multiple cosmetic problems are developed based on MN technique. Although MN therapy was
initially introduced to treat scars, investigative case studies advocated that MN can also be useful as an adjuvant hair
growth treatment method for alopecia, especially alopecia areata and androgenic alopecia [38]. Combinatorial therapy of
dermaroller with minoxidil and corticosteroids for alopecia areata and androgenic alopecia, respectively, showed increased
hair growth in several case studies [40e42]. It is hypothesized that MN creates microchannels that permit effective drug
delivery in the transdermal region of hair follicle via stratum corneum in the skin [43]. The major disadvantage of this
technique is the painful experience patients endure and it is endurable for small patchy lesions in alopecia areata, whereas
the pain is unbearable for alopecia universalis or totalis patients [11].
14.1.1.1.4 Platelet-rich plasma
A unique autologous blood preparation method called platelet-rich plasma (PRP) was also utilized for hair loss treatments,
in which platelets in autologous blood are concentrated with growth factors by several processes in laboratory [44,45].
Initially, PRP therapy was predominantly used in musculoskeletal treatments to treat damaged ligaments, tendons, and
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accelerated healing of sports injuries [46]. Later, the method was introduced into the cosmetic dermatology ﬁeld to treat
burn scars, acne scars, and postsurgical scars as PRP induces human ﬁbroblast proliferation and stimulates type I collagen
synthesis [47]. After subsequent research, PRP technique gained importance in alopecia treatment and is evaluated for
alopecia areata and androgenic alopecia treatment [48,49]. Numerous studies revealed that the PRP therapy increases hair
growth, even as an isolated therapy, and offers an effective treatment option in combination with other treatment options
[45,50]. However, this technique is still in the infant stages of research and the clinical evidence for PRP technique is
fragile. Thus, the PRP method is considered as a promising treatment only for patients with thin hair [45].
14.1.1.1.5 Other emerging nondrug therapies
The hair follicle transplantation technique is gaining escalating interest in the last decades with the introduction of robotic
systems to harvest hair follicles. Follicular neogenesis is an extent of such advancement, wherein the hair follicles are
isolated from the donor sites of the patient undergoing hair transplantation that are expanded via cell culture method and
injected back into the patient’s bald sites [51]. Likewise, phototherapy is a light-based modality that utilizes ultraviolet
(UV) light to treat various skin diseases. Different wavelength phototherapies such as excimer laser, broad and narrowband
UV-B, excimer lamp, and psoralen UV-A and UV-A1 are in use for hair loss therapeutic purposes. The modulatory effect
of UV on the cutaneous immune system makes it a potential option for enhanced alopecia areata treatment. However,
excimer laser is the most investigated device for alopecia areata treatment, which has displayed positive results as of now
and further clinical trials are warranted for its safety levels [52,53]. Furthermore, stem cell therapies are also being
considered for alopecia treatment; however, the techniques have not been entirely explored [36].

14.1.1.2 Drug-based therapies
The current approved drug-mediated therapies for hair loss treatments are the solution of topical minoxidil, oral ﬁnasteride,
and dutasteride tablets. No speciﬁc drugs are approved by medical agencies to treat alopecia areata, totalis, and universalis
types; however, the Food and Drug Administration (FDA) of United States approved drugs for other autoimmune diseases
such as corticosteroids and are prescribed off-label by healthcare providers to treat alopecia of autoimmune disorder origin.
14.1.1.2.1 Minoxidil
Minoxidil is an effective vasodilator, potassium channel opener, and an FDA-approved synthetic drug that was effectively
used in 1980s to treat androgenic areata. It is serendipitous, as it was originally developed as an antihypertensive drug,
which produces hypertrichosis as side effects during systemic administration. This drug in the formulation of 2% and 5%
solution, and 5% foam was approved by FDA in 1988, 1991, and 2016, respectively, and was beneﬁcial in the male pattern
baldness treatment [24,25,54]. Minoxidil induces hair growth by activating the ATP-sensitive potassium channel [55,56],
lengthens the anagen phase, reverts vellus hair to terminal hair through the upregulation of vascular endothelial growth
factor (VEGF) [57] and ﬁbroblast growth factor-7 (FGF-7) [58e60], and sometimes by activating the pathway of b-catenin
in the cells of dermal papilla (DP) [61]. However, minoxidil is only 30%e35% impressive among patients and the
medication regimen must be continued for lifetime [62]. It is noteworthy that the 5% solution of minoxidil is highly
efﬁcient than 2% solution and 5% foam in terms of better hair growth result among patients [24]. Minoxidil is also used to
treat alopecia areata and universalis by certain dermatologist, though this drug is not approved to treat such conditions
[63,64]. Minoxidil solutions also have side effects such as irritation in scalp, redness, dryness, scaling, itchiness, pruritis,
contact dermatitis, hypertrichosis in face, and an interim increase of hair fall [60,65]. The reported adverse events of
long-term minoxidil application in men are erectile dysfunction, dizziness, depression, decreased libido, chorioretinopathy,
contact dermatitis, headache, hypoesthesia, and anxiety [66].
14.1.1.2.2 Finasteride
Finasteride is a synthetic azasteroid and a precise 5a-reductase (5a-R) type II (SRD5A2) inhibitor, which was approved by
the FDA in 1997 for treating androgenic alopecia in men [67]. It is an androgenic drug that irreversibly binds with 5a-R
type II enzyme and inhibits testosterone (T) to 5a-dihydrotestosterone (5a-DHT) conversion. Oral ingestion of ﬁnasteride
(1 mg) everyday reduces serum 5a-DHT and scalp 5a-DHT concentration by 64.1% and 71.4%, respectively [68].
Furthermore, medication regime at this rate led to 30% of improvement in vertex area than frontal or centroparietal regions
[65]. However, ﬁnasteride is only 48% efﬁcient toward hair loss patients [69]. The reported adverse events in men for
long-term ﬁnasteride usage are erectile dysfunction, sexual dysfunction, depression, anxiety, cognitive disorder, fatigue,
decreased or loss of libido, decreased semen volume, ejaculation disorder, dizziness, and headache [66].
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14.1.1.2.3 Dutasteride
Dutasteride is another compound with 4-azasteroid, which is a synthetic, selective, and competitive 5a-R type I and II
isoenzymes inhibitor [70]. Dutasteride was originally used for treating benign prostatic hyperplasia, and it is almost three
times highly efﬁcient in inhibiting type II 5a-R and 100 times highly effective as type I 5a-R inhibitor compared with
ﬁnasteride. Moreover, it reduces the level of dihydrotestosterone (DHT) in serum and scalp and increases secretion of
testosterone [71]. It has been approved by Pharmaceuticals and Medical Devices Agency (PMDA), Japan, and also in
countries such as Korea and Mexico, for treating androgenic alopecia [71e73]. Comparative studies showed that
_dutasteride was highly efﬁcacious compared with ﬁnasteride in promoting new hair growth and reversing miniaturization
process. Additionally, the disadvantages of dutasteride are comparable and analogous to ﬁnasteride [71,74,75]. Dutasteride
versus placebo-controlled studies have reported the adverse effects of this drug such as decreased libido (mild to moderate),
sexual dysfunction, erectile dysfunction, and ejaculation disorder [72,73,76].
14.1.1.2.4 Corticosteroids
Topical corticosteroids remain as the foremost drug of choice to treat alopecia areata or universalis, as they are commonly
used to treat other skin inﬂammatory disorders [36]. Drugs such as clobetasol propionate and hydrocortisone are the
common corticosteroids prescribed by dermatologist to treat alopecia areata, totalis, and universalis [64,77]. Most
physicians prescribe topical application of corticosteroids, but oral corticosteroids are also prescribed in few cases [64].
These drugs are not accepted as a cure for hair fall problems because of the frequent occurrence of spontaneous remissions
in several cases [36]. The reported side effects of these steroid therapies include hyperglycemia, acne, osteoporosis,
osteonecrosis in the femoral head, cataracts, dysmenorrhea, obesity, and Cushing syndrome [78e80].
14.1.1.2.5 Topical immunotherapy
Topical immunotherapy is widely preferred for the treatment of extensive chronic alopecia areata in adults. This treatment
involves the application of chemicals such as diphencyprone and dinitrochlorobenzene in the skin to irritate it, leading to an
allergic reaction that promotes hair growth. The hair growth promotional behavior of mechanistic immunotherapy has not
yet been identiﬁed. Topical immunotherapy can manifest a few drawbacks such as fever, persistent dermatitis, blistering,
lymphadenopathy with pain in cervices, arthralgia, generalized eczema, yellowish discoloration of gray hair, and contact
leukoderma [63].
14.1.1.2.6 Investigational drug-based therapies
Drugs such as anthralin, cyclosporine, sulfasalazine, adalimumab, and methotrexate are used to treat alopecia areata and
universalis off-label and they are in investigative clinical trials for approval [36,63]. Likewise, pinacidil, tretinoin,
bicalutamide, ﬂutamide, ﬂuridil, spironolactone, bimatoprost, and SGF57 growth factors are in clinical trials for androgenic
alopecia treatment [36]. Although modern synthetic drugs have been scientiﬁcally proven for their hair growth promotion
effects, most of the drugs lead to serendipity and are not designed as rational drug for alopecia. Also, treatments with these
synthetic drugs are uncertain as they lead to side effects and occasionally lack of efﬁcacy. Lack of efﬁciency in the
synthetic drugs, especially their potential sex-related side effects, drives people toward natural herbal remedies for alopecia
treatment.

14.1.1.3 Drugs from natural products
Drugs from natural products have been widely used for treating alopecia by several civilizations, since ancient times.
Folk and traditional medical systems of different ethnic groups such as Ayurveda, Unani, Chinese, Siddha, and Islamic
medicinal systems throughout the world use herbal drugs to promote hair growth, and most of them are documented for
their enhanced activity in promoting hair growth. In addition, several homemade remedies inﬂuenced by traditional
knowledge are also practiced by people to treat alopecia [81e83]. The plant-based drug derivatives provide nutritional
support to the hair follicles, improve scalp blood circulation, and modulate the speciﬁc pathways that are responsible for
the destruction of hair follicle to be beneﬁcial in alopecia treatment.
14.1.1.3.1 Herbal therapy for alopecia
There are numerous herbs that are suggested to be useful for alopecia treatment by various ancient medicinal systems,
based on the herbs that are available in their region, geography, climate, and the health condition of people. The herbs
mentioned in the Ayurvedic literature of India such as Charak Samhita and Sharangdhar Samhita Grantha to treat alopecia
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and baldness are Wedelia chinensis (Osbeck), Eclipta alba, Tridax (Bhringraj), Ocimum sanctum L (Tulsi), Glycyrrhiza
glabra L (Mulethi), Nerium oleander L (Kaner), Trachelospermum lucidum (Dudhi), Solanum nigrum L (Makoy), Cedrus
Deodara Roxb. and Polyalthia longifolia Sonn. (Devdaru), Terminalia chebula Retz. (Harad), Terminalia bellirica Gaertn
(Bahede), Rubia cordifolia L (Manjistha-Indian Madder), Symplocos racemosa Roxb. (Lodh), Semecarpus anacardium
L.F. (Bhilawa), Jasminum ofﬁcinale L. (Mallika), Psoralea corylifolia L (Babchi), Calacanthus grandiﬂorus Mill
(Sahchar), Gmelina arborea Roxb (Kumbher), Terminalia arjuna Roxb (Arjuna), Trichosanthus species (Patol), Solanum
xanthocarpum (Kateri), and Ribes rubrum L (Dakh) [84].
Likewise, several medicinal plants were also reported in Thai traditional medicinal system to treat hair loss such as
Acacia concinna Wall, Alpinia galanga Wild, Averrhoa carambola L, Carthamus tinctorius L, Cassia siamea Lam, Citrus
hystrix DC, Clitoria ternatea L, Cymbopogon citratus Stap, Ipomoea aquatica Forssk, Lawsonia inermis L, Phyllanthus
emblica L, Rhinacanthus nasutus Kuntze, Sapindus rarak DC, Tinospora rumphii Boerl, Trichosanthes cucumerina L, and
Zingiber ofﬁcinale Roscoe [85]. Furthermore, the Chinese traditional medicine system uses herbs such as Ginseng Radix,
Ligustri Fructus, Astragali Radix, Rehmannia glutinosa, Angelicae Sinensis Radix, and Eclipta prostrata Linn [86]. In
spite of these wide varieties of herbs that are used for alopecia treatment, lack of documentation is a major drawback to
utilize them as medicine for alopecia treatment. However, some of these herbs have been documented herbal remedies and
their method of application to treat alopecia [87] is displayed in Table 14.1.

14.1.2 Signaling pathways targeted by herbs to promote hair growth
In general, signaling mechanisms involving VEGF, IGF-1 (insulin-like growth factor-1), FGF-2 (ﬁbroblast growth
factor-2), EGF (epidermal growth factor), eNOS (endothelial nitric oxide synthase), PGE (prostaglandin E), PGF
(prostaglandin F), and signal pathway of Wnt/b-catenin that promotes growth of hair and pathways involving 5a-R (5
alpha-reductases), TGF-b (transforming growth factor-beta), FGF-5 (ﬁbroblast growth factor-5), and PGD2
(prostaglandin D2) inhibit hair growth. Furthermore, the active phytochemicals that are present in herbs with hair growth
promoting properties to modulate the above-mentioned signaling pathways are shown in Fig. 14.2 [88].

14.1.2.1 Action through IGF-1
IGF-1 controls proliferation and migration of cells during development of hair follicles. It is a hair growth cycle controller
as the IGF-1 production in the DP activates the hair root cells and promotes anagen phase, while its antiapoptotic function
delays onset of the catagen and telogen hair cycle phase [89]. It is postulated that DHTeandrogen receptor interaction and
subsequent signaling pathway lead to a decrease in IGF-1 production by inhibiting sensory neuron stimulation
in androgenic alopecia pathology because DHT administration blocks the production of IGF-1 in mice that results in
decreased growth of hairs [90]. The herbs and their extracts that are reported to possess the potential of promoting
increased growth of hairs by elevating the production of IGF-1 are mentioned in Table 14.2.

TABLE 14.1 Herbal preparations and the method of application for hair loss treatment.
Herbs

Mode of application

Ginkgo biloba

The extracted drug is coconut oil mixed and massaged on the scalp.

Phyllanthus emblica

Indian gooseberry oil extracted by boiling dry fruit pieces with coconut oil is to be applied on scalp.

Allium cepa L.

Onion juices have to be rubbed on the bald patches in morning and evening followed by rubbing with
honey afterward.

Rosmarinus officinalis and
Lavandula
angustifolia Miller

These oils prepared from the two herbs are to be massaged onto the scalp for minimum 2 min daily for
at least 7 months.

Juglans regia L.

Walnut oil prepared from the nuts has to be applied on the scalp.

Glycyrrhiza glabra L.

Liquorice paste synthesized by grinding a pinch of saffron in milk which is applied in the bald patches
at night.
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Different signaling pathways targeted by herbs and their active phytochemicals for hair growth.

14.1.2.2 Action through vascular endothelial growth factor
VEGF is an angiogenesis marker that plays a signiﬁcant role in the growth of hairs by enabling constant nutrient
supplement to hair follicle and increases hair follicle diameter [122,123]. Its expression decreases in human alopecia hair
follicles and are increased via introduction minoxidil. This reaction demonstrates that upregulation of VEGF expression in
hair papillae is necessary for proper hair growth [123]. The medicinal herbs and their extracts, which are reported to
augment VEGF growth factor production and promote hair growth, are listed in Table 14.2.

14.1.2.3 Action through epidermal growth factor
EGF is secreted in the outer hair follicle root sheath and acts as a biological hair cycle switch to promote cell propagation
and formation of hair follicles by inducing anagen phase. EGF expression is turned on in the anagen phase and its
expression prevents the hair follicle entry into catagen phase, while the hair follicles move into the catagen phase,
when EGF is turned off [124]. The plants and their extracts that promote EGF production are reported in Table 14.2.

14.1.2.4 Action through endothelial nitric oxide synthase
Nitric oxide (NO) is a relaxing factor derived from endothelium and it is involved in maintaining the homeostasis of skin.
As it is a potential cellular toxin, it also mediates the inﬂammatory reactions in the immune system [125]. It is strongly
suspected that NO is responsible for the inﬂammatory reactions that occur in androgenic alopecia [126,127] and alopecia
areata [128,129]. Similarly, the melanocytes in the active anagen hair bulbs are negative for NO synthases (NOS), while
the melanocytes in the apoptosis-driven hair follicles express NOS [130]. Certain herbs and herbal extracts promote hair
growth, through their antiinﬂammatory processes, by suppressing NOS and NO and are mentioned in Table 14.2.

14.1.2.5 Action through fibroblast growth factor
The ﬁbroblast growth factor (FGF) family regulates hair follicle development, as they control the differentiation and
proliferation of epidermal and mesenchymal cells [131,132]. FGF-7 or keratinocyte growth factor (KGF) signals a pathway
to instruct the proliferation of hair germ cells and initiates the cycle of new hair formation by interacting with the Wnt
signaling pathway in the hair cycle process [132e134]. Meanwhile, FGF-5 is a catagen inducer and its expression drives
the hair follicle out of anagen [135]. The medicinal herbs and their active phytochemicals that stimulate KGF secretion and
inhibiting FGF-5 activity are given in Table 14.2.

14.1.2.6 Action through wnt/b-catenin pathway
Signal pathway of Wnt/b-catenin performs a crucial role in the development of hair follicle and the regulation of hair
growth cycle, whereas aberration in this signaling mechanism affects hair growth immensely [134]. In androgenic alopecia,
the androgenic DHT modulates this pathway and secretes certain factors such as protein-1 related to Dickkopf (DKK-1),
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TABLE 14.2 Signaling pathways targeted by herbs and their phytochemicals to treat alopecia.
Signaling
pathway
targeted

Action on signaling
pathway

Observed effect on hair
growth

Essential oils from Mentha
piperita

IGF-1

Elevated expression of IGF-1

Induces anagen stage in hair
growth in C57BL6/N mice

[91]

Alium tuberosum Rottler ex
Spreng extract

IGF-1

Increased IGF-1 expression

Number of hair follicles
increased in C57BL6/N mice

[92]

Platycarya strobilacea extract

IGF-1, FGF,
TGF-b1

Improved expression of KGF,
IGF-1 and decrement in the
expression of TGF-b1

Promotes hair growth in male
mice (C57BL/6)

[93]

Rubus idaeus (raspberry ketone)

IGF-1

Increased IGF-1 production
through sensory neuron
activation

Encourages growth of hair in
alopecia associated with both
mice and human beings

[94]

Fujiflavone P40 (a soybean product
with isoflavone); Capsaicin (active
ingredient in chilli peppers)

IGF-1

Amplified secretion of IGF-I
plasma

Helps growth of hairs in
alopecia cases of mice and
humans

[95]

SM-215 herbal extract
(15% concentration of extracts
from Stemona japonica, Psoralea
corylifolia, Liriope platyphylla,
Scrophularia buergeriana,
Anemarrhena asphodeloides,
Rubus coreanus, Thuja orientalis,
Loranthus parasiticus and
Schizandra chinensis)

IGF-1

Increased expression of IGF-1

Increment in growth of mice
hair by stimulating hair
follicles by elevating the
sebaceous gland distribution
and hair follicles capillaries.

[96]

Asiasari radix

VEGF

Induces the expression of
VEGF in human DPCs

Potent hair growth stimulation
in C57BL/6 and C3H mice

[97]

Carthamus tinctorius floret
ethanolic extract

VEGF, FGF

Increased expression of VEGF
and KGF and reduced expression of TGF-b1

Amplifies the cultured hair
follicle length and stimulates
growth of hairs in mice

[98]

Chamaecyparis obtuse essential
oils

VEGF,
FGF

Induces secretion of VEGF and
KGF without upregulation of
TGFb1

Promotes hair growth in mice
model

[99]

Extracts of Lycopersicon
esculentum with isolated solution
of lycopene

IGF-1, FGF,
VEGF

Increased mRNA expression of
VEGF, KGF and IGF-1

Amplifies growth of hairs in
mice (C57BL/6)

[100]

Rice bran oil

IGF-1, FGF,
VEGF,
TGF-b1

Increased mRNA expression of
VEGF, KGF, and IGF-1;
suppressed TGF-b1 expression

Helps growth of hair in mice
model (C57BL/6)

[101]

Korean herbal mixture named
yonnyuniksoogobon-dan
made up of 11 herbs
(Polygoni Multiflori Radix, Lycii
Fructus, Lycii Radicis Cortex,
Rehmanniae Radix Preparat,
Poria, Asparagi Radix,
Rehmanniae Radix,
Liriopis Tuber and Acori
Graminei Rhizoma)

EGF, VEGF,
eNOS,
TGF-b1

VEFG and EGF upregulated
expression, TGF-b1
downregulation and eNOS
expression on hair roots

Promotes development of hairs
in mice model (C57BL/6)

[102]

Korean polyherbal mixture

EGF,
VEGF

Increased EGF and VEGF
expression

Hair regrowth in C3H/HeJ
mice

[103]

Ishige sinicola extract

Wnt/b-catenin; 5a-R

Increased secretion of Cyclin
E, phospho-GSK3b, CDK2
b-catenin; downregulation of
p27kip1; 5a-reductase activity
inhibition

Amplified proliferation of cells
in vibrissa cell culture of
dermal papilla

[104]

Herb/herbal mixture/
phytochemicals

Reference
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TABLE 14.2 Signaling pathways targeted by herbs and their phytochemicals to treat alopecia.dcont’d
Signaling
pathway
targeted

Action on signaling
pathway

Observed effect on hair
growth

Aconiti Ciliare Tuber extract

Wnt/
b-catenin

Increased b-catenin protein
expression

Stimulated the anagen hair
development induction in
mice model (C57BL/6)

[105]

Acanthopanax koreanum leaves
extract

Wnt/
b-catenin

Elevates nuclear b-catenin
secretion with CDK2, cyclin E,
cyclin D1 upregulation, and
p27kip1 downregulation.

Promotes the proliferation of
immortalized vibrissa dermal
papilla cells

[106]

Thuja orientalis hot water extract

Wnt/
b-catenin

Early b-catenin induction and
hair follicles expressing Shh
proteins.

Induces telogen in anagen
phase of mouse model
(C57BL/6 N)

[107]

Malva verticillata seed extract

Wnt/
b-catenin

Increased Wnt reporter
activity; increased b-catenin
levels

Stimulates the proliferation of
DPCs in a dose-dependent
manner

[108]

Polygonum multiflorum

Wnt/
b-catenin

Earlier Shh proteins and
b-catenin induction

Amplifies growth of hair by
inducing telogen in anagen
phase of mouse model
(C57BL6/N)

[109]

Cuscuta reflexa petroleum ether
extract

5a-R

Inhibition of 5a reductase

Promotes hair growth in
alopecia induced albino mice
by testosterone

[110]

Panax ginseng & Panax japonicus
rhizome extracts

5a-R

Inhibition of 5aR in the model
representing androgenetic
alopecia

Suppresses after-shaving
regrowth of hair in C57BL/6
mice treated with testosterone

[111]

Rosmarinus officinalis leaf extract

DHT and
AR

Stops dihydrotestosterone
binding with receptors of
androgen

Enhances regrowth of hair in
testosterone treated C57BL/
6NCrSlc mice

[112]

Thujae occidentalis semen extract

5a-R

Inhibits type 2 5a-reductase
activity

Inhibitory against alopecia in
B6CBAF1/j hybrid mouse

[113]

Scutellaria baicalensis extract

DHT and
AR

Inhibits dihydrotestosterone
binding with receptors of
androgen

Improved, in vitro human
dermal papilla cell
proliferation

[114]

Glycyrrhiza glabra petroleum
ether root extract

Not
reported

Not reported

Shows growth of hair, longer
than minoxidil-treated female
Wistar rats

[115]

Eclipta alba petroleum ether
extract

TGF-b1

Downregulation of TGF-b1
expression

Increases the number of
follicular keratinocytes in nude
mice

[116]

Schisandra nigra 85% ethanol
extract

TGF-b2

Decrease in TGF-b2
expression

Significant increase in the
length of hair fibers of vibrissa
follicles

[117]

Undariopsis peterseniana

Wnt/b-catenin and
ERK
pathways

Elevates ERK phosphorylation
and Wnt/b-catenin signal
levels of proteins such as
b-catenin and kinase-3b
synthase of glycogen (GSK-3b)

Decrement in the activity of
5a-reductase and upsurge of
dermal papilla cell
proliferation

[118]

Perilla frutescens (n-butanol
soluble fraction)

Not
reported

Not reported

Shows activity of
antiandrogenic property in
testosterone-sensitive male
C57Bl/6NCrSlc mice

[119]

Cacumen platycladi

5a-R

Suppresses the expression of
5aR

Promotes growth of hairs in
androgen-sensitive mouse
model

[83]

Herb/herbal mixture/
phytochemicals

Reference

Continued
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TABLE 14.2 Signaling pathways targeted by herbs and their phytochemicals to treat alopecia.dcont’d
Herb/herbal mixture/
phytochemicals

Signaling
pathway
targeted

Action on signaling
pathway

Observed effect on hair
growth

Avicennia marina

5a-R

5a-R1 inhibitory activity

Production of 5a-DHT in
human dermal papilla cell
assay

[120]

Phyllanthus niruri
(petroleum ether extract)

5a-R

5a-R2 inhibitory activity

Promotes hair regrowth in
male albino swiss rats

[121]

Carthamus tinctorius

5a-R

5a-R inhibitory activity

Potential hair growth promoter
in C57BL/6 mice

[85]

Reference

TGF-b1, interleukin-6 (IL-6), and PGD2, which drives the hair follicle into the catagen phase [136]. It is evident from these
studies that the stabilization of b-catenin by targeting the Wnt inhibitors leads to hair growth [137]. The herbs and herbal
extracts that possess the ability of curing hair loss by promoting Wnt/b-catenin signaling are mentioned in Table 14.2.

14.1.3 Potential phytochemicals in alopecia treatment
Despite the fact that many medicinal herbs and their solvent extracts have been studied for antialopecia and hair growth
promoting activities, in-depth analytical studies have not been conducted to identify individual active constituents that
contributes for their antialopecia activity. However, few studies with the help of recent scientiﬁc advancements have
reported the effect of individual phytochemicals against alopecia. The various phytochemicals with properties that promote
hair growth are classiﬁed based on their chemical groups in this section.

14.1.3.1 Polyphenols
Polyphenols belong to the class of semiewater-soluble phytochemicals that are ubiquitously found among plants with
various pharmacological properties [138,139]. In recent years, several novel treatments for dermatological conditions have
been developed from polyphenols as they have demonstrated antiinﬂammatory and antioxidative activity in numerous
studies [139]. Surprisingly, most of the individual phytochemicals with antialopecia properties such as forsythiaside-A
[140], rosmarinic acid [119]; lignans such as ()-cubebin, ()-3,4-dimethoxy-3,4-desmethylenedioxycubebin [141],
acetosyringone [142]; phenols such as acankoreoside J [106], octaphlorethol A [104]; ﬂavonoids such as proanthocyanidins, procyanidin B2, B-3, and B-2 [143e146], isoﬂavone [147], formononetin [148], quercetin [149], and baicalin [114]
are reported to possess enhanced hair growth promoting activities.

14.1.3.2 Alkaloids
Alkaloids are the largest group of phytochemicals present in plant that represent a diverse group of chemical entities with
nitrogen atoms at any position of the molecule, excluding the nitrogen in an amide or peptide bond [150]. Piperine from
Piper nigrum fruit [141], capsaicin from Capsicum annum [95], and norgalanthamine from Crinum asiaticum [151] are the
three signiﬁcant alkaloids that are reported to have antialopecia activity.

14.1.3.3 Saponin
Saponins are amphiphilic compounds usually found as glycosides of steroids or polycyclic triterpenes in plants and have
enhanced bioactivity [152]. The bioactive saponin compounds present in the ginseng medicinal herb (Panax ginseng) are
used to treat hair fall in Korean traditional medicinal systems are called as ginsenosides [153,154]. Studies in animal
models and human hair DP cells have revealed that ginsenosides arrest hair fall and promote hair growth by targeting 5a-R,
arresting apoptosis process, and modulating the Wnt pathway, which leads to improved hair proliferation [153]. Another
study demonstrates that ginsenosides performed similar actions of minoxidil in promoting hair growth, which shows that
ginsenosides are useful as an effective treatment for alopecia [155]. In addition, Pueraria thomsonii extracts with
kaikasaponin III, soyasaponin I [156], senegose A, senegin II, senegin III, and senegasaponin b from Polygala senega have
enhanced hair growth promoting activity [157].
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14.1.3.4 Terpenoids
Terpenoids are derived from ﬁve carbon isoprene units and are a large group of organic metabolites that are produced by
plants and microbes. The terpenoid compounds such as nardin, jatamansic acid from Nardostachys jatamansi DC, and
3,4-dihydroxybenzaldehyde from Polyporus umbellatus have demonstrated elevated hair growth promotional activity
in vivo [158,159]. 12-Methoxycarnosic acid is a type of diterpene from Rosmarinus ofﬁcinalis, which was reported to have
DHT-AR binding inhibiting properties in an in vitro study. This DHT-AR binding reaction in DP cell happens in the
upstream of the androgenic alopecia pathogenesis and so this phytochemical is considered as a potential drug for alopecia
[112,136]. Apo-90 -fucoxanthinone is a norisoprenoid from Sargassum muticum, which increases VEGF-R2 level and Wnt/
b-catenin signaling proteins which eventually increases the DP cell proliferation, and is considered as potential drugs for
androgenic alopecia treatment [160].

14.1.3.5 Other phytochemicals
Other phytochemicals that have been recently reported with potential hair growth promoting activity are myristoleic acid
from Malva verticillata seed [108], steroids namely 24S-polyporusterone A, polyporusterone B extracted from Polyporus
umbellatus [142] and raspberry ketone obtained from Rubus idaeus [94]. A list of phytochemicals with hair growth
promoting activity that are used in alopecia treatment is presented in Table 14.3. Such phytochemicals are less toxic toward
other cells and do not cause side effects because of their high biocompatibility, bioavailability, and bioactivity. However,
drawbacks such as amount of time involved in the extraction procedure, nonpredictability of exact phytochemical quantity
present in each plant, and water solubility are the challenges to be addressed before using them for large-scale alopecia
treatment in future.

14.1.4 Future perspective
The future of phytochemicals for alopecia treatment depends on ﬁnding the correct formulation that helps in reducing hair
fall and increasing hair growth. Researchers are slowly identifying several phytochemicals from various plants that stops
hair fall and elevates hair growth. The mechanism of action reveals that the collective effect of phytochemicals helps in
alopecia treatment compared with individual phytocompounds. Thus, the combination of several phytochemicals that helps
in alopecia treatment and formulating them to increase hair growth will be beneﬁcial for alopecia treatment in future [164].
The emergence of nanotechnology has been a major advantage in reducing the drawbacks related to the formulation of
phytochemicals. Nanoparticles that are synthesized using phytochemicals as reducing agents lead to phytochemical-capped
nanoparticles, which is the new ﬁeld of research for the treatment of alopecia [165]. Additionally, nanoformulation of
phytochemicals with polymers is widely used in recent times to deliver them in the targeted site to enhance their bioactivity
and bioavailability. Liposomes, dendrimers, micelles, and nanocomposites are nanoformulations that are extensively under
research for acting as a nanocarrier and delivery agents of phytochemicals for enhancing alopecia treatment [166].
In future, it is possible to use molecular nanorobots with virus as phytochemical carriers [167] and multicompartment
nanosized dendrimers [19] for real-time diagnosis and treatment of alopecia.

14.1.5 Conclusion
This chapter is an overview of the conventional methods that are used for distinct alopecia treatments and the ability of
herbal products to replace the conventional treatments. It can be concluded that chemical-based drugs used for the
treatment of alopecia are highly toxic toward patients and they exhibit severe side effects, which is a drawback in its use.
On the other hand, herbal drugs that have been used to treat alopecia since ancient times and yielded good results, however,
lack clarity in mechanism and documentation, and this has been their major hindrance in competing with conventional
drug-based treatments. Thus, recent research in alopecia focuses on identifying signal pathways that are targeted by
phytochemicals to enhance hair growth and reduce hair fall. Numerous phytochemicals have been identiﬁed to possess
greater potential to be useful as an antialopecia drug to replace conventional chemical-based drugs. Therefore, it is believed
that phytochemical formulation in future will help in the treatment of several alopecia types and help people with baldness
to boost their appearance and conﬁdence.

TABLE 14.3 Phytochemicals with hair growth promoting activity.
Biological
source

Mechanism

Effect on
hair growth

Phytoconstituents

Category

Reference

Forsythiaside-A

Polyphenol

Forsythia
suspensa

Apoptosis was
prevented by
Forsythiaside-A
via mechanism
analogous to
finasteride

The comparative
in vitro study of finasteride
and forsythiaside-A
revealed that treatment
with forsythiaside-A leads
to 30% of DHT-induced
apoptosis inhibition in
human hair dermal papilla
cell (HHDPCs) and human
keratinocytes (HaCaTs)

[140]

Rosmarinic acid

Polyphenol

Perilla
frutescens

-Not reported-

The activity antiandrogenic agent in vivo
after hair growth assay
utilization in male C57Bl/
6NCrSlc mice that are
sensitive to testosterone

[119]

()-Cubebin, ()-3,
4-dimethoxy-3,4desmethylenedioxycubebin

Lignan

Piper nigrum
leaf

5a-R inhibitory
activity

Significant activity of
anti-androgenic agent in
in vivo assay showing
regrowth of hair in
C57Black/6CrSlc strain
mice

[141]

Acetosyringone

Lignan

Polyporus
umbellatus

-Not studied-

Promotes hair regrowth in
C3H/He mice

[142]

Acankoreoside J

Phenol

Acanthopanax
koreanum

Increase of nuclear
b-catenin with
cyclin D1, cyclin E
and CDK2,
upregulation and
p27kip1
downregulation

The hair-fiber lengths of
the rat vibrissa follicles
increased significantly on
treatment

[106]

Octaphlorethol A

Phenol

Ishige
sinicola

Activation of b-catenin pathway, and
the 5a-reductase
inhibition

Increases cell proliferation
in vibrissa dermal papilla
cell culture

[104]

Proanthocyanidins
(epicatechin and catechin)

Flavonoids

Vitus vinifera
L. (grape
seed)

-Not studied-

Conversion activity of hair
cycle from the phase of
anagen to telogen in C3H
mice

[143]

Procyanidin B-3

Flavonoids

Hordeum
vulgare L
(barley)

The effect of
growth-inhibition
by TGF-b1 in hair
epithelial cell
culture is
neutralized

Promotion of hair growth
in epithelial cells in vitro

[145]

Procyanidin B-2

Flavonoids

Malus
domestica
Borkh (apple)

Downregulation of
protein kinase C
isozymes

Promotes in vitro hair
growth in epithelial cell

[144]

Procyanidin B2

Flavonoids

Malus pumila
Miller cv.
Annurca

Not reported

Increases hair growth,
density and keratin content
in human

[161]

Quercetin

Flavonoids

Most
vegetables
and fruits

Suppressed the
expression of heat
shock protein 70
which is an
inflammatory
response mediator

Prohibited the initiation of
alopecia areata in C3H/
HeJ mouse model

[149]
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TABLE 14.3 Phytochemicals with hair growth promoting activity.dcont’d
Biological
source

Mechanism

Effect on
hair growth

Flavones

Various
legumes
plants

Increase in the
production of IGF-I
hair follicles

Accelerated growth of hair
in mice as well as in
humans with alopecia

[95,147]

Formononetin

Isoflavones

Red clover
plants

Inhibiting apoptosis
by Fas/Fas
L-induced caspase
activation

Hair regrowth effect in
C57BL/6 mice

[148]

Baicalin

Flavone
glycoside

Scutellaria
baicalensis

Inhibits the
dihydrotestosterone
binding with the
receptors of
androgen

Enhances human dermal
papilla cell
proliferation in vitro

[114]

Piperine

Alkaloid

Piper nigrum
fruit

5a-R inhibitory
activity

-No data-

[141]

Capsaicin

Alkaloid

Capsicum
annum

Increased
production of IGF-I
in the follicles hair

Accelerated growth
of hair in alopecia mice
and humans

[95]

Norgalanthamine

Alkaloid

Crinum asiaticum Linn.

Not reported

Amplifies the length of
hair-fiber in follicles of
vibrissa and dermal
papilla cell proliferation

[151]

Ginsenoside Ro;
ginsenoside Rg3

Saponin

Panax
ginseng and
Panax
japonicus

Inhibitory activity
against 5aR in the
androgenetic
alopecia model

Suppresses the
after-shaving regrowth of
hair in C57BL/6 mice
treated with
testosterone

[111]

Ginsenoside F2

Saponin

Panax
ginseng L

High b-catenin
expression and
Lef-1secretion
(Wnt pathway)

Promoted hair growth in
C57BL/6 mice

[162]

Soyasaponin I,
kaikasaponin III

Saponin

Pueraria
thomsonii
(Benth.)
Maesen

Inhibitory activity
against testosterone
5a-R

Activity of anti-androgenic
in male C57Black/6NCrSlc
strain mice
that are
sensitive to
testosterone

[156]

Senegose A, senegin II,
senegin III, senegasaponin
b

Saponin

Polygara
senega

Not reported

Promotes hair regrowth in
C3H/He mice

[157]

Nardin, jatamansic acid

Terpenoids

Nardostachys
jatamansi DC

Not reported

Promotes growth of hair in
female Wistar rats

[158]

3,4Dihydroxybenzaldehyde

Terpenoids

Polyporus
umbellatus

Not reported

Promotes hair regrowth in
C3H/He mice

[159]

12-Methoxycarnosic acid

Diterpene

Rosmarinus
officinalis

Suppresses
dihydrotestosterone
binding with
receptors of
androgen

Inhibits proliferation of
LNCaP cells that are
dependent on androgen as
64.5% at 5 mg/mL and
66.7% at 5 mM

[112]

Apo-90 -fucoxanthinone

Norisoprenoids

Sargassum
muticum

Increases the level
of VEGF-R2 and
Wnt/b-catenin
signaling proteins

Increases the proliferation
of dermal papilla cells

[160]

Phytoconstituents

Category

Isoflavone

Reference

Continued
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TABLE 14.3 Phytochemicals with hair growth promoting activity.dcont’d
Phytoconstituents

Category

Biological
source

Myristoleic acid
(omega-5 fatty acid)

Monosaturated
fatty acid

Malva verticillata seed

Increases Wnt
reporter activity;
increases b-catenin
levels and increases
the level of
transcription in
HGF, KGF, IGF-1,
and VEGF

Increased proliferation of
human dermal papilla
cells

[108]

24S-polyporusterone A,
polyporusterone B

Steroids

Polyporus
umbellatus

Not reported

Promotes hair regrowth in
C3H/He mice

[142]

Methyl vanillate

Mmethoxybenzoic
acid

Not reported

Increase in
WNT10B mRNA
expression levels

Increases hair count and
hair mass index in females
with androgenic alopecia

[163]

0.01% Raspberry ketone

Ketone

Rubus idaeus

Increased
production of IGF-1
through sensory
neuron activation

Amplifies growth of hair in
humans and mice with
alopecia

[94]

Mechanism

Effect on
hair growth

Reference
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15.1 Introduction
A huge number of pathogens, especially the viruses have the capacity to adjust themselves according to the new trends of
human society. The population explosion, globalization, and sex revolution have collectively caused an increase in the
incidence and prevalence of viral diseases. By the year 2020, it is projected that viral diseases will become the deadliest of
all the pandemics in human history. Therefore, virus poses a continuous threat to human health and the global economy.
Viruses have efﬁcient means to survive and broadcast in a number of varieties of hosts such as birds, insects, ﬁsh, humans,
and other mammals and various cell types with respect to their host distribution, genomic organization, and clinical
presentations. Virus may possess DNA or RNA as genome and may follow diverse routes for replication, transcription, and
translation processes. Clinically, they may present themselves as self-resolving, localized infections or may attain several
forms to affect the whole body. Although belonging to various classes, viruses follow similar general pathway for causing
pathogenesis in the host. Repetitive replication of viruses results in the appearance of clinical features. Although there has
been an increase in the number of approved antiviral agents, yet these drugs cover a very narrow range of viruses.
Moreover, an increased incidence of resistance to these antivirals further decreases their therapeutic potential [1,2].
Plants form a fundamental part of many medicinal systems under practice today. Around 50% of prescribed drugs are
either produced from plants or are derivatives of plant products [3]. Plants represent a large, untapped, potential source of
antiviral agents. Although there has been relatively few studies seeking antiviral agents from plants, those studies have
revealed an unexpectedly frequent occurrence of antiviral activity in plants. A large number of compounds of varied
chemical structures isolated from medicinal plants have been shown to possess antiviral activity. Thus, this chapter made
an attempt to explore various antiviral compounds from plants for the development of antiviral drugs.
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15.1.1 Data mining of antiviral phytocompounds
The antiviral phytocompounds were manually mined from publicly available phytochemical databases (Dr. Duke’s
phytochemistry and ethnobotanical database; www.ars-grin.gov/duke).

15.1.1.1 Collection and mining of literature for bioactive antiviral agents
The literature related to antiviral activities of phytochemicals were collected from publicly available online sources. The
full texts of peer-reviewed scientiﬁc publications in a variety of journals were manually mined from online sources such as
Google scholar (http://scholar.google.co.in/) and pubmed (http://www.ncbi.nlm.nih.gov/pubmed). From each publication,
target virus, details of the compounds, plant source of the compounds, and the assays performed were briefed and
illustrated in Tables 15.1e15.6.
TABLE 15.1 Anti-herpes compounds and their plant sources.
Compound name

Nature of compound

Plant species

Family

References

Ursolic acid

Triterpenoid

Balanocarpus heimii

Dipterocarpaceae

Swallow et al. [4]

Caffeine

Alkaloid

Theobroma caco

Malvaceae

Yamazaki and tagaya [5]

B-D-glucopyranoside

Steroidal glycoside

Gypsophila capillaries

Caryophyllaceae

Elgamal et al. [6]

Allicin

Sulfur

Allium sativum

Amaryllidaceae

Weber et al. [7]

Chelidonine

Alkaloid

Chelidonium majus

Papaveraceae

Manske and Brossi [8]

Emetine

Alkaloid

Cephaelis ipecacuanha

Rubiaceae

Hanish et al. [9]

b-Pelatin

Organic heterotetracyclic
compound

Podophyllum peltatum

Berberidaceae

Bedows and Hatfield [10]

a-Pelatin

Organic heterotetracyclic
compound

Podophyllum peltatum

Berberidaceae

Bedows and Hatfield [10]

Podophyllotoxin acetate

Alkaloid

Juniperus Sabina

Cupressaceae

Feliciano et al. [28]

TABLE 15.2 Anti-influenza compounds and their plant sources.
Compound name

Nature of compound

Plant species

Family

References

Canavanin

Protein amino acid

Canavalia ensiformis

Leguminosae

Pilcher et al. [11]

Gymmnemic acid

Triterpenoid glycosides

Gymnema sylvestre

Asclepiadaceae

Rao et al. [12]

Beta aescin

Triterpenoid

Aesculus hippocastanum

Hippocastanaceae

Hiller [13]

D-glucosamine

Amino sugar

Dahlia sp., Glycine max (L.),
Phaseolus aureus

Leguminosae

Kaluza et al. [14]

TABLE 15.3 Anti-measles compounds and their plant sources.
Compound name

Nature of compound

Plant species

Family

References

b-Pelatin

Organic heterotetracyclic
compound

Podophyllum peltatum

Berberidaceae

Bedows and Hatfield [10]

a-Pelatin

Organic heterotetracyclic
compound

Podophyllum peltatum

Berberidaceae

Bedows and Hatfield [10]

Podophyllotoxin

Alkaloid

Glycine max

Leguminaceae

McKee et al. [15]

D-glucosamine

Amino sugar

Dahlia sp., Phaseolus aureus

Leguminosae

Kaluza et al. [14]
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TABLE 15.4 Anti-polio compounds and their plant sources.
Compound name

Nature of compound

Plant species

Family

References

Caffeine

Alkaloid

Theobroma cacao
Coffee sp.

Malvaceae, Rubiaceae

Yamazaki and tagaya [5]

Digitoxin

Phytosteroid

Digitalis purpurea

Scrophulariaceae

Koch and Gyorgy [16]

Chlorogenic acid

Polyphenol

Coffea arabica

Rubiaceae

Molgaard and Ravn [17]

TABLE 15.5 Anti-HIV compounds and their plant sources.
Compound name

Nature of compound

Plant species

Family

References

Carnosolic acid

Diterpene

Rosmarinus officinalis

Lamiaceae

Paris [18]

Betulinic acid

Triterpenoid

Syzygium claviflorum

Myraceae

Fujioka et al. [19]

Betulinic acid

Triterpenoid

S. claviflorum

Myraceae

Kashiwada et al. [20]

Oleanolic acid

Triterpenoid

Prosopis glandulosa

Leguminosae

Kashiwada et al. [20]

Alphitolic acid

Triterpenoid

Rosa woodsii

Rosaceae

Ma et al. [21]

Oleanolic acid

Triterpenoid

Xanthoceras sorbifolia

Sapindaceae

Ma et al. [21]

Berberine

Alkaloid

Berberis vulgaris

Berberidaceae

Manske and Brossi [22]

Fagaronine

Alkaloid

Plumeria rubra

Apocynaceae

Tan et al. [23]

TABLE 15.6 Anti-viral compounds and their plant sources.
Compound
name

Nature of
compound

Plant species

Family

Virus name

References

Allicin

Sulfur

Allium sativum

Amaryllidaceae

Vesicular stomatitis
virus

Weber et al. [7]

Caffeine

Alkaloid

Theobroma cacao

Sterculiaceae

Coxsackie virus

Yamazaki and tagaya [5]

Cyanidol

Flavonoid

Silybum
marianum

Asteraceae

Hepatitis

Swallow et al. [4]

Allicin

Sulfur

A. sativum

Amaryllidaceae

Vaccinia virus

Weber et al. [7]

Ouabain

Cardioactive
glycoside

Acokanthera
ouabaio

Apocynaceae

Newcastle disease

Becher [24]

Morin

Flavonoid

Chlorophora
tinctoria

Moraceae

Pseudorabies virus

Beladi et al. [25]

Fagaronine

Alkaloid

Fagara
zanthoxyloides

Rutaceae

Retrovirus

Manske and Brossi [26]

15.1.2 Herpes simplex virus
Herpes simplex virus causes herpes which is an infection around the mouth, external genitalia, anal region, and mucosal
surfaces of the body. Many more phytochemicals and phytosources are available for the treatment of herpes. In this review,
11 phytochemical compounds from different plant extracts were reported as antiherpes leads. They are ursolic acid,
caffeine, B-D-glucopyranoside, acemannan, allaicin, camptothecin, chelidonine, emetine, b-pelatin, a-pelatin, and
podophyllotoxin acetate (Table 15.1).
Scientists reported that ursolic acid of Balanocarpus heimii [4], caffeine from Theobroma caco [5], B-D-glucopyranoside of Gypsophila capillaries [6], allicin of Allium sativum [7], camptothecin of Ophiorrhiza mungos [27], chelidonine
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of Chelidonium majus [8], emetine from Cephaelis ipecacuanha [9], b-pelatin and a-pelatin from Podophyllum peltatum
[10] and podophyllotoxin acetate of Juniperus Sabina [28] have efﬁcient antiviral activity against herpes virus. It is
understood that most of the antiherpes compounds belongs to the family Rubiaceae and Berberidaceae, and majorly of
alkaloid groups.

15.1.3 Influenza virus
This inﬂuenza virus causes a severe infectious disease, inﬂuenza (ﬂu). Flu is an acute viral infection of lower and upper
respiratory passages, causing fever, severe aching and catarrh, and often occurring in epidemics. Antiﬂu ayurvedic and
herbal medicines have played a signiﬁcant role in ﬁghting the virus pandemic. A recent in vitro study has shown that
Plumbago indica L. and A. sativum extracts can inhibit inﬂuenza A (H1N1) pdm09 virus by inhibiting viral nucleoprotein
synthesis and polymerase activity [29]. Earlier, several researchers reported anti-inﬂuenza activity phytochemicals
(Table 15.2), such as Canavanin, Gymmnemic acid, Beta Aescin and D-glucosamine, which are isolated from Canavalia
ensiformis, Gymnema sylvestre, Aesculus hippocastanum and Glycine max, respectively [11e14]. The glucosamine
isolated from some other plants viz., Dahlis sp. (Compositae), and Phaseolus aureus Roxb. (Leguminosae) also showed
inhibitory activity against inﬂuenza virus [14]. It is understood that most of the antiinﬂuenza compounds belongs to
triterpenoid group and leguminaceae family. The next chapter (Chapter 16) expanded further on the role of Shikimic acid
as intermediary model for the production of drugs effective against inﬂuenza virus.

15.1.4 Measles virus
Rubella or measles virus cause a highly contagious disease, measles. It is a childhood infectious disease of the respiratory
system. World Health Organization reported that measles remains an important cause of death among young children
globally, despite the availability of a safe and effective vaccine. However, traditionally, people are using plant based
medicine for the treatment of measles. Scientists have also studied antimeasles activity of some phytochemicals i.e.,
b-pelatin and a-pelatin from Podophyllum peltatum, podophyllotoxin from Glycine max and D-glucosamine isolated from
Dahlis sp. and P. aureus (Table 15.3). They reported that these phytochemicals have moderate to high antimeasles activity.
a- and b-pelatin isolated from P. peltatum showed good antiviral activity [10]. The podophyllotoxin isolated from
P. peltatum was found to be the most active component in inhibiting the replication of measles [15]. D-glucosamine
isolated from Dahlis sp. (Compositae), Glycine max (L.) and P. aureus exhibited potent antiviral activity [14]. From these
studies, it is clear that majority of antimeasles compounds belongs to the family Berberidaceae, and organic hetero
tetracyclic group.

15.1.5 Poliovirus
Poliovirus is an etiologic agent of the paralytic disease known as poliomyelitis. It is an acute communicable disease of
childhood. There are no recognized treatment, either during the illness or after paralysis. However, traditionally, people use
some plants and their parts for the treatment of polio. Kudi and Myint [30] reported the antipoliovirus activity of medicinal
plants which includes; Bauhinia thonningii, Cassia goratensis, Anacardium occidentale, Butyrospermum parkii, and
Boswelia dalzielii. Later, Ogbole et al. [31] studied antipolio activities of medicinal plants selected from Nigerian ethnomedicine. Out of the 14 plant extracts evaluated for antipoliovirus activity, Senna siamea (Lamk.) and Zephyranthes
candida demonstrated signiﬁcant in vitro activity with IC50 of 0.0019 and 0.121 mg/mL, respectively. Before the 90s, some
researcher reported the antipolio activity of caffeine, digitoxin, and chlorogenic acids. Caffeine isolated from Theobroma
cacao L. and Coffea sp. suppressed the growth of poliovirus [5]. Digitoxin isolated from Digitalis purpurea L. exhibited
inhibition of poliovirus replication [16]. Chlorogenic acid isolated from Coffea arabica showed an effective antipolio
activity against polio viruses [17]. Most of the antipolio compounds belong to the family Malvaceae, Scrophulariaceae, and
Rubiaceae, and basically of the group alkaloid, polyphenol and phytosterol (Table 15.4).

15.1.6 Human Immunodeficiency Virus
Human Immunodeﬁciency Virus (HIV) is a virus that targets and alters the immune system, increasing the risk and impact
of other opportunistic infections and diseases. Without treatment, the infection might progress to an advanced disease stage
called Acquired Immune Deﬁciency Syndrome (AIDS). The use of traditional medicine and Natural Health Products is
widespread among those living with HIV infection [32]. Many patients take a broad range of natural health products
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(NHPs) in addition to their conventional therapeutic products [33,34]. Previously, some authors reported that anti-HIV
activity of phytocompounds which includes carnosolic acid, betulinic acid, oleanolic acid, alphitolic acid, berberine,
and fagaronine. Carnosolic acid isolated from Rosmarinus ofﬁcinalis had a potent activity against HIV [18]. Betulinic acid
isolated from the leaves of Syzygium claviﬂorum inhibits HIV replication in H9 lymphocyte cells [19]. Kashiwada et al.
[20] reported that betulinic acid isolated from Syzygium claviﬂorum inhibited HIV-1 replication in acutely infected H9
cells. The HIV inhibitory effects of oleanolic acid isolate from Prosopis glandulosa were reported by Kashiwada et al.
[20]. They stated that the compound severely inhibited HIV-1 replication in acutely infected H9 cells. Alphitolic acid
isolated from Rosa woodsii inhibited the growth of HIV and Oleanolic acid isolated from a methanolic extract of the wood
of Xanthoceras sorbifolia also inhibit the viral replication [21]. The alkaloid Berberine of Berberis vulgaris was found to
be a strong inhibitor against HIV-1 [22]. A fraction of Plumeria rubra L viz., Fagaronine showed high inhibitory activity
of HIV-1 [23]. This study revealed that most of the anti-HIV compounds belong to the plant family Myraceae and
consisted of the Triterpenoid group (Table 15.5).

15.1.7 Other viral diseases
Wide varieties of compounds have been tested against different common virus which causes dreadful diseases (Table 15.6).
The compounds allicin isolated from A. sativa showed signiﬁcant effects on vesicular stomatitis virus [7]. Caffeine isolated
from T. cacao suppressed the grown of Coxsackie-virus [5]. Cyanidol isolated from Silybum marianum has been used in
the treatment of acute viral hepatitis [4]. Allicin isolated from A. sativa showed potent viricidal activity against vaccinia
virus [7]. Becher [24] reported that Ouabain isolated from Acokanthera ouabaio is active against Newcastle disease virus.
The ﬂavone isolated from Chlorophora tinctoria L. shows activity against pseudorabies virus [25]. Fagaronine isolated
from Fagara zanthoxyloides inhibited viral reverse transcriptase activity on retrovirus Lam [26].

15.1.8 Conclusion
From this review, it is concluded that plants belonging to the family Berberidaceae has more antiviral compounds.
Moreover, the phytochemicals of alkaloid group had more potent antiviral activity. The present results suggest further
investigation about the characterization of active compound and their speciﬁc mechanism against respective virus. Further,
it is possible that the elucidation of the active constituents in these plants may provide useful leads in the development of
antiviral therapeutics.
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16.1 Introduction
Viruses are small infectious organism or obligate intracellular parasite found in virtually all ecosystem, numbering in
millions. Within the last 30 years, the etiological mechanisms of some notorious viruses affecting humans have been
described. Viruses are enclosed by structural coded protein coat along with either a DNA or RNA genome. The genetic
material (DNA or RNA) of viruses contain information needed to replicate or to make number of copies of the virus.
Viruses are considered as genetic mobile elements of mainly cellular origin, identiﬁed by an extended coevolution of host
and virus. Specialized host cells providing complex biosynthetic and metabolic machinery of prokaryotic and eukaryotic
organisms help in the propagation of viruses and a whole virus particle is known as virion.
Viral infections have the ability to spread from man to man or from other sources to man either by indirect or direct
contact, particularly by means of excretal matter, contaminated articles, throat and nose secretions, and very common is
droplet infection. An insect vector also spreads infections, e.g., transmission of dengue fever is by mosquito Aedes aegypti.
A number of viral diseases are transmitted through milk and water, e.g., infectious hepatitis and poliomyelitis. Sometimes
viruses change the function of the cell without destroying the host cell. Viruses might remain dormant for a period of time
before multiplying again.
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The genetic material of viruses controls the cells by forcing it to replicate. Generally, infected cells dies as it cannot
perform the normal function and after cell death it releases a new virus which continues to infect other cells. A number of
viruses alter the cellular functions instead of killing the cells and these infected cells multiply abnormally by losing the
control over normal cell division and turning into cancerous cells. A virus proliferates and infects cells causing viral
infection.
For some viral infections, lifelong immunity is conferred after one attack of the disease such as small pox, measles, and
mumps, whereas in case of common cold, short-duration immunity is produced after an attack. In viral diseases, the mode
of artiﬁcial immunization is similar to those of bacterial infections, for passive immunization dead or live vaccines are used
to bring about active immunity.
Diagnostically, prospective and laboratory-based surveillance is of principal signiﬁcance for the management and early
detection of emerging or reemerging infectious diseases. Within the past years, many techniques have been developed for
diagnosing viral infections and these procedures include (1) the detection of viral antigen in the lesions through ﬂuorescent
antibody techniques, (2) microscopic examination of the lesions, (3) performing serological tests during the course of
infection, (4) skin tests, and (5) techniques for identiﬁcation and isolation of virus.

16.1.1 Description of the various classes of viruses
Viruses that are pathogenic to human are broadly classiﬁed according to the different regions of the body mostly affected
and clinical nature of the infection or disease produced (Table 16.1). A simple classiﬁcation system of viruses is the
following:
l
l

l

l
l

l

l

Neurotropic viruses: These are viruses that affect the central nervous system, e.g., viruses of rabies and poliomyelitis.
Dermotropic viruses: This class of viruses produces generalized infection by inducing characteristic lesions on the skin,
e.g., viruses of measles, small pox, and chicken pox.
Pneumotropic viruses: These are viruses that produce characteristic symptoms of the respiratory tract, e.g., viruses of
inﬂuenza and common cold.
Hepatotropic viruses: This group of viruses infects the liver, e.g., viruses of infectious hepatitis.
Sialadenitis or salivary gland infection: These are viruses that affect salivary gland or duct, resulting in viral infection
such as mumps and ﬂu.
Ocular viral infection: These are viruses that affect the eyes, e.g., viruses of trachoma and epidemic
keratoconjunctivitis.
Viruses producing generalized infections: These include viruses of dengue fever and yellow fever.

16.2 Influenza and its various forms
Inﬂuenza is a contagious respiratory infection caused by an inﬂuenza virus, commonly known as the ﬂu. The most
common symptoms is high fever, coughing, sneezing, runny nose, headache, sore throat, muscle aches (myalgias), and a
general feeling of illness (malaise). In early stage of infection, the symptoms of ﬂu are similar to those of the common cold
and commonly confused with common cold; however, it is a much more severe disease. In more serious conditions,
inﬂuenza leads to pneumonia, which could be fatal, signiﬁcantly in young children and the elderly. However, nausea and
vomiting can be produced, especially in children, and mistaken by gastroenteritis or “stomach ﬂu” Typically, inﬂuenza is
spread by the air because of coughs or sneezes and through infected birds because of their droppings. In addition, it can
also be transmitted by direct contact with virus-contaminated surfaces and body ﬂuids such as saliva, nasal secretions,
feces, and blood.

16.2.1 Epidemiology
Each year, 10%e20% of the world’s population is affected by seasonal epidemic inﬂuenza. Seasonal inﬂuenza epidemics
occur every year both in the Northern and the Southern hemispheres, mainly in the winter; however, in tropical countries,
inﬂuenza can occur throughout the year. According to the World Health Organization, the annual pandemic leads to about
3e5 million cases of serious illness and about 250,000e500,000 deaths. About 20% of unvaccinated children are infected
each year. Death occurs mostly in the young, the old, and those with other health problems. Antigenic shifts lead the
emergence of a new and very different inﬂuenza virus that may cause an inﬂuenza pandemic. Pandemics are less frequent
and result in larger outbreaks. In the 20th century, three inﬂuenza epidemics occurred: Spanish inﬂuenza in 1918
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TABLE 16.1 Classification of viruses with notable examples.
Virus group

Illness (major signs)

Incubation

Duration

Remarks

Respiratory viral infections
Rhinovirus

Common cold, sneezing, coughing,
sore throat, and mild headache

12e72 h

2 weeks

As soon as immune cells invades the
local area it becomes inflamed

Seasonal influenza

Acute respiratory infection, flu,
severe fatigue, and body aches

1e3 days

5e7 days

Antigenic makeup of virus gets
significantly changed

Respiratory
syncytial virus
(RSV)

Airway and lung infection, cough,
and sneezes

2e8 days

1 days

RSV is a single-stranded enveloped
RNA paramyxovirus

Molluscum
contagiosum virus
(MCV)

Flesh-colored bumps

2e7 weeks

1 week to
6 months

MCV only replicates in human
keratinocytes

Varicella-zoster
virus (VZV)

Cold sores and genital herpes

14e16 days

10e21 days

It is a DNA virus of herpes virus
group

Herpes simplex
virus-1 (HSV-1)

Chickenpox, fatigue, itchiness,
oozing blisters, and high fever

2e12 days

10 days

Transmission of HSV-1 virus is
mainly through oral-to-oral contact
causing oral herpes or cold sores

Viral skin infections

Foodborne viral infections
Hepatitis A

Affects the liver, nausea, vomiting,
diarrhea, and yellow skin

14e28 days

15e50 days

Transmission of virus is through
fecal-oral route

Norovirus

Gastroenteritis, vomiting, and
diarrhea

12e42 h

24e60 h

It is a small virus containing RNA
surrounded by protein coat

Rotavirus

Stomach flu, dry mouth, and throat

2 days

2e8 days

It is a nonenveloped, double-shelled
wheel-like appearance viruses

Human
immunodeficiency
virus (HIV)

Attack T cells of immune system,
rapid weight loss, night sweats,
tiredness

1e4 weeks

9 months to
20 years or
longer

Leading to acquired immune
deficiency syndrome (AIDS)

Human
papillomavirus
(HPV)

Increases risk of cervical cancer,
genital warts, or precancerous
lesions

2e3 months

2 years

It is a DNA virus from the papillomavirus family

Hepatitis B

Inflammation of liver, vomiting,
diarrhea, jaundice, abdominal pain

75 days

30
e180 days

Transmission of virus is through
exposure to infectious blood or body
fluids

Genital herpes or
herpes simplex
virus (HSV)

Cold sores, myalgia, headache,
malaise, urethral, and vaginal
discharge

3e7 days

1 day to
3 weeks

HSV-1 and HSV-2 are implicated in
orofacial and genital primary
infections

Viral meningitis

Inflammation in the lining of spinal
cord and brain, headache, stiff
neck, and fever

3e7 days

10 days

The most common cause of viral
meningitis is echovirus or coxsackie
groups of enteroviruses

EpsteineBarr virus
(EBV)

Swollen lymph nodes, fatigue, fever,
and enlarged spleen

1e2 months

4e6 weeks

EBV is a human herpes virus causing
acute infectious mononucleosis and
related to autoimmune disease and
cancer

West Nile virus

Encephalitis or inflammation of
surrounding tissues spinal cord and
brain (meningitis)

2e6 days

2e14 days

Transmission is mainly through
infected mosquitoes

Sexually transmitted

Other viral infections
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(w50 million deaths), Asian inﬂuenza in 1957 (2 million deaths), and Hong Kong inﬂuenza in 1968 (1 million deaths). In
June 2009, the World Health Organization announced an outbreak of a new type of inﬂuenza A/H1N1 to be a pandemic. It
was found to affect other animals also, such as pigs, horses, and birds.

16.2.2 Types of influenza viruses
On the basis of surface antigens, there are four genera of this family: types A, B, C, and thogotovirus. Inﬂuenza A and B
are the predominant pathogen in seasonal inﬂuenza, while inﬂuenza virus A is most severe than inﬂuenza virus B and may
cause severe inﬂuenza. Inﬂuenza type C infections are generally responsible for mild respiratory illness and could not
cause epidemics. Inﬂuenza D viruses mainly affect cattle and are not found to infest on humans or cause illness in them.

16.2.2.1 Type A influenza
Type A inﬂuenza is the most dangerous and known to cause outbreaks and diseases. Wild birds represent the natural hosts
for these viruses, while these viruses can infect animals, birds, pigs, and horses. Inﬂuenza A viruses are subdivided into a
number of subtypes based on the composition of the hemagglutinin (HA) and neuraminidase (NA) proteins. There are 18
different hemagglutinin subtypes and 11 different neuraminidase subtypes (H1 through H18 and N1 through N11,
respectively) exist so far. Type A ﬂu virus is continuously changing and generally causes the large ﬂu pandemics; however,
inﬂuenza B viruses are not responsible for pandemics. Mutation in inﬂuenza viruses resulted in a number of different
inﬂuenza subtypes and strains; it is more common in inﬂuenza A virus. Speciﬁc varieties of the virus are generally named
according to the host of origin, geographical location, strain number, and year of isolation.

16.2.2.2 Influenza B
Inﬂuenza B infections occur only in humans and are not divided into subtypes, but can be further broken down into
lineages and strains. Currently circulating inﬂuenza B viruses belong to one of two lineages: B/Yamagata and B/Victoria.

16.2.2.3 Influenza type C
Inﬂuenza type C infections cause a mild respiratory illness (comparable to other common respiratory viruses) and nearly all
adults have been infected with inﬂuenza C virus. However, it is milder and rare than either type A or B and does not cause
epidemics. The structures of inﬂuenza C viruses are different in comparison to inﬂuenza A and B. The genera C virion has
hexagonal structures on the surface and forms stretched cord-like structures. Inﬂuenza C viruses have seven RNA segments, while inﬂuenza A and B contain eight RNA segments.

16.2.3 FDA-approved drugs for influenza
Inﬂuenza is a serious infectious disease, which is very dangerous and deadly speciﬁcally in young one, elderly, and weak
immunity patients. After the invention of modernized vaccinations, the mortality rate due to ﬂu virus has been considerably
decreased, but there are chances of recurrent infestation. Vaccination, accompanying the emergence of new antiinﬂuenza
agents, is necessary to ﬁght against seasonal and pervasive inﬂuenza strains. Nowadays, most importance is given to the
designing of inhibition agents of inﬂuenza neuraminidase, which has proved itself as an appropriate medicine for the
prophylaxis and inﬂuenza infections therapy. Till now only four medicines have been accepted by the Food and Drug
Administration (FDA) to cure inﬂuenza ailment, of which two of these drugs have grown resistance for inﬂuenza A strains
and hence are not in the application. Therefore, there are a numerous chances in this area for further development of
antiviral therapy. The two recent drug mechanisms for inhibition of the inﬂuenza virus are the M2 proton channel, which
involves the procedure of liberating virus particles from an infected host cell, and the neuraminidase (NA) enzyme, which
works on the basis of viral recognition and entry into a host cell. Currently, neuraminidase inhibitors are the most
frequently used FDA-approved treatments for the inﬂuenza virus, which is applied effectively as they have not developed
any resistance yet within the virus. Oseltamivir and zanamivir are the drugs that function by affecting the activity of
neuraminidase (NA) protein of the virus. The neuraminidase enzyme operates on the basis of cleaving the host cell sialic
acid residues with viral hemagglutinin, in turn releasing the new viruses to carry forward and infect other healthy cells. The
viral neuraminidase catalytic site is highly speciﬁc for all inﬂuenza A and B viruses. Both the drugs oseltamivir and
zanamivir serve as stable transformation state counterparts of the sialosyl cation. It is a very unstable transformation state
complex in the enzymatic procedure of viral sialidase. The neuraminidase inhibitor drugs 1 and 2 are similar enough in
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structure to the sialosyl cation transition state complex. It allows them to attach tightly to the sialic acid active site and
obstruct viral budding. However, constant development of drug-resistant inﬂuenza strain enhances the need of continuous
researches on innovative technologies for the production of new drugs with improved antiviral mechanism, more safety,
and enhanced tolerability.

16.2.3.1 Influenza virus inhibitors
Eight drugs have been accepted to cure inﬂuenza virus infections on April 2016. These drugs could be classiﬁed as
neuraminidase inhibitors, e.g., oseltamivir, zanamivir, peramivir, and laninamivir octanoate, matrix 2 inhibitors,
e.g., rimantadine and amantadine, and polymerase inhibitors such as favipiravir and ribavirin.
16.2.3.1.1 Rimantadine and amantadine
Amantadine (1-adamantanamine) approved in 1966 was the ﬁrst antiviral compound for the treatment of widely distributed
inﬂuenza A virus infections. This compound has the ability to block the transfer of H ions with the help of M2 (matrix 2)
protein medium into the inner portion of viral particles and hence prevents the disassembling of inﬂuenza virus molecule
inside the endosomes. Amantadine and rimantadine were approved for adult patients, but they were not able to prevent,
treat, or reduce the severity of inﬂuenza A virus infestation in children and older ones. The prevalent resistance also leads
to abandon amantadine in the medication of inﬂuenza infections. However, the interest is growing for the application of
amantadine in the evidential therapy of Parkinson disease and levodopa-induced dyskinesia, although more clinical
researches are necessary to explore its new application.
16.2.3.1.2 Zanamivir, oseltamivir, peramivir, and laninamivir octanoate
Zanamivir is a distinct and potent inhibitor of neuraminidases protein of inﬂuenza A and B virus. It prevents the inﬂuenza
infections by affecting release of virus. Zanamivir applied by inhalation was also accompanied with oseltamivir, ingested
by the oral route. According to many researches, oral oseltamivir and inhaled zanamivir have proved to be a net beneﬁt by
controlling death rate and the severity of inﬂuenza symptoms and complications. Two more neuraminidase inhibitors were
introduced for the therapy of inﬂuenza infections after the success of zanamivir and oseltamivir. First was peramivir, which
could be administered as an intravenous injection, and the other was laninamivir octanoate, which was found to be
effective if administered in an inhalation. Notably, peramivir has been found to have clinical potency equal to that of
oseltamivir for curing the severe seasonal inﬂuenza, and the efﬁcacy of laninamivir octanoate has been found for the
treatment of seasonal inﬂuenza, as well as oseltamivir-resistant virus, in adults. Both peramivir and laninamivir are
effectively used as a one-dose therapy for inﬂuenza A and B viruses, but their applications are bounded in very few
countries only.
16.2.3.1.3 Ribavirin
Ribavirin also known as Virazole (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) has been reported as the ﬁrst synthetic
nucleoside analogue, which is active toward a broad spectrum of RNA viruses (RSV, HCV, and inﬂuenza virus). It was
found to be the broadest spectrum antiviral agent ever reported for a synthetic material which did not induce interferon. The
chief mechanism of its drug action includes the inhibition of inosine-5-monophosphate (IMP) dehydrogenase, which helps
in conversion of IMP to xanthosine monophosphate and thus responsible for the production of GTP. Ribavirin inhibits the
IMP dehydrogenase and hence possesses immunosuppressive activity, which leads to the remarkable success of ribavirin,
for the therapy of HCV infestation accompanied with peginterferon alfa-2a. The patients of HCV infection undergoing
therapy of telaprevir, peginterferon alfa-2a, and ribavirin are found to have an outstanding level of response against the
virus. Ribavirin effectively hinders the RNA polymerase of inﬂuenza virus in the triphosphate form. Apart from this,
ribavirin could also be used in the treatment of “Lassa fever” (hemorrhagic fever virus infection), but ribavirin has yet not
got the formal license for this medication. The effect of ribavirin on RNA viruses has also been found to have potential
effects against many other infectious diseases such as dengue virus, norovirus, Hendra and Nipah viruses, and Marburg
virus. However, more clinical evidence is still necessary to prove these new applications.
16.2.3.1.4 Favipiravir
Favipiravir (T-705), having chemical structure as 6-ﬂuoro-3-hydroxy-2-pyrazine carboxamide, has been chieﬂy introduced
for therapy of inﬂuenza virus infections. Favipiravir was invented and approved in Japan and could be effectively used for
the treatment of inﬂuenza A, B, and C virus infections. Importantly, favipiravir triphosphate is a broad-spectrum antiviral
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agent and shows inhibitory activities against the RNA polymerases present in inﬂuenza A viruses. Highly pathogenic
H5N1 viruses and many other positive- and negative-sense RNA viruses also belong to the group of inﬂuenza A virus and
hence favipiravir is active against them. Recently, favipiravir was found effective to cure patients infected because of Ebola
virus (EBOV). It also inhibits the growth of human norovirus and human arena viruses (Machupo, Junin, and Pichinde
viruses), but these new applications need further extensive researches and clinical trials.

16.2.4 Plant-derived phytochemicals with antiviral effects
Plants are the foundational element of many medicinal structures under application today. About 50% of the drugs prescribed are either directly extracted from plants or are derivatives of products resulted from plants [1]. Antivirals extracted
from natural origin have found to possess pharmacological and pharmaceutical properties. Using different medicinal plants
in combination therapy has been proved to be effective against a numerous viruses such as HSV and inﬂuenza viruses
[2,3]. Many plant extracts are observed to have broad spectrum of antiviral activity. For example, Ocimum basilicum and
Agrimonia pilosa are potent against a wide range of RNA and DNA viruses [4e6]. Many phytochemicals may also have
dose-dependent viral inhibition [7,8]. Moreover, they are resolving an important issue of drug resistance generated because
of synthetic drugs [9], e.g., a plant-derived product. Polycitone A is functional against the resistant strains of HIV [10].
Plant-derived products are also inexpensive and could be easily accessible in different parts of the world. Natural products
are even found to be less toxic, cheaper, and impart no side effects in comparison with the synthetic drugs. Apart from this,
they have proved their wide therapeutic beneﬁts for different types of conditions. Plant-derived ingredients have shown
different kind of mechanisms against the activities of viruses:

16.2.4.1 Immunomodulators
The enhancement of defensive immune reaction is one of the most important mechanisms of antiviral treatment. Many of
the recently registered products are working on the immunity boosting procedures toward viral infections. Interleukins,
colony-stimulating factors, and interferons are the most well-known immunostimulants. Interferons, which are the
derivable polypeptides and glycoproteins, act as catalyst to enhance the growth of certain peculiar enzymes that control
viral reconstruction in the cell [11,12]. Interleukins are the factors that increase the activation, development, distinction,
progression, and guidance of immune cells, which can be able to nullify the virus [13]. Similarly, colony-stimulating
factors regulate the proliferation and distinction of progenitor cells in the white blood cells lineage [14]. However,
many of the drugs, such as ribavirin, also affect positively the immune responses [15]. Many of natural materials have been
researched for their immunomodulatory activities. Carbohydrates, stilbenoids, alkaloids, polyphenols, lectins, and peptides
from plant sources are the chief categories of drugs that could be used as immunomodulators.

16.2.4.2 Virus attachment and entry inhibitors
Another most important target for the antiviral therapy is the adjunction of virus to the host cell and its entrance. The entry of
the virus occurs into the cell by interacting either by a single cell surface receptor or by certain coreceptors. After that, the
viral envelop gets fused with host cell membrane, and as it intrudes into the cell, the virus is dismantled to release its genome.
Many of the approved drugs affect this procedure of viral infection, e.g., tromantadine for the treatment of HSV infections
changes the glycoproteins present on the surface of the host cells and stops the adhesion, intrusion, and uncoating of the virus.
Studies on different plant-derived materials have shown the similar mechanisms for preventing viral growth, e.g., plant lectins
extracted from genera Hippeastrum and Galanthus have shown the inhibition activity against the HIV-speciﬁc glycoproteins,
thus resulting in inhibiting the entrance of virus into the cell. Other categories of plant materials, which includes, galactose,
glucose, and N-acetylgalactosamine, have been found to contain antiviral action against severe acute respiratory syndrome
corona virus (SARS-coV) and the feline infectious peritonitis virus. These factors also inhibit the viral adhesion to the host
cell. Many of natural agents also work against inﬂuenza virus receptor attaching and merging protein, i.e., hemagglutinin. In
many studies, retardation of virus dismantling and emergence of genetic matter into the cell has been done by the extracts
derived from various seaweeds. Heparin sulfate molecules extracted from carrageenans, seaweed, also have shown to employ
antiviral activity toward dengue virus by arresting the uncoating of virus in host cells.

16.2.4.3 Modifiers of viral genome and protein processing
Viral arrangement and mutation processes are the next important mechanism for an antiviral policy. The genome could be
managed earlier, and it can utilize the cellular machinery to its beneﬁt (RNA viruses) or it could directly integrate to the
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host genome (DNA viruses). Reverse transcription, integration, replication, transcription, and translation are the potential
steps of this procedure. Coumarins also known as the calanolides are extracted chieﬂy from Calophyllum lanigerum and
belong to eminent category of plant-derived antivirals. They have been found to irreversibly bind to the active site of the
reverse transcriptase enzyme. Large quantity of calanolides could be extracted from the latex of relevant species of the
plant. Calanolide are also chosen for phase II clinical studies for antiretroviral treatment and has shown a synergistic effect
with currently approved drugs.

16.2.4.4 Virus assembly and release inhibitors
These medicines hinder the transcription of newly amalgamated viral proteins into virions and their liberation out of the
cell. Neuraminidase inhibitors work by hampering the inﬂuenza virus liberation out of the infected cells, hence resulting in
safeguarding cell-to-cell transmission. Zanamivir and oseltamivir are the two most important parts of the approved drugs of
this group. Up till now, more than 30 various types of protease inhibitors are extracted from plants possessing potential
antiviral activities. Compounds of different botanical and chemical sources have been studied for this purpose. Extracts
from Zingiber zerumbet, Orostachys japonicus, Boesenbergia pandurata, Alpinia galanga, Coccinia grandis, Cassia
garretiana, and Eclipta prostrata have proved their antiviral potential exploiting their protease inhibiting property.
Bevirimat extract obtained from a Chinese herb, Syzygium claviﬂorum, has been found to have “maturation inhibition”
capability [16]. Same as the protease inhibitors, this compound possesses the ability of suppressing the cleavage of Gag
polyprotein of HIV. Hence, both the structural and enzymatic proteins are not formed. Another Chinese preparation,
Ching-fang-pai-tu-san consumed as a traditional herbal decoction, contains quercetin, isoquercetin, and chaihu. These
compounds stop inﬂuenza virus replication by interrupting the intracellular protein processing, transportation, and budding
properties [17].

16.2.5 Shikimic acid and its mode of action on influenza virus
Shikimic acid having a chemical formula 3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid is an organic compound found
naturally and is an important link in the pathway for the development of aromatic amino acids, lignin, and various alkaloids
present in plants and microorganisms.
Shikimic acid is a primary progenitor of the pharmaceutical manufacturing as antiinﬂuenza drug oseltamivir. Oseltamivir is marketed under the brand name Tamiﬂu. It is a potential antiviral medicine used to cure and prevent inﬂuenza A
and inﬂuenza B infections. The mode of application is by mouth, either in the form of pill or liquid.
Oseltamivir was the ﬁrst neuraminidase inhibitor available orally. It was approved for medical use and now found in the
complementary list of World Health Organization’s List of Essential Medicines, indicating a lower costebeneﬁt ratio. Its
generic version was approved in the United States in 2016.
Oseltamivir is a compound acting as neuraminidase inhibitor, which is a potential inhibitor of inﬂuenza’s neuraminidase enzyme. Neuraminidase inhibitors (NAIs) deﬁne a class of drugs that stop and block the activity of neuraminidase
enzyme and hence they are generally utilized as antiviral medicines. They inhibit the action of viral neuraminidases present
in inﬂuenza viruses and prevent their reproduction through budding in the host cells. This enzyme is responsible for
cleaving the sialic acid, which is present in glycoproteins on the surface of human cells, which in turn helps new virions to
come out from the cell. Oseltamivir inhibits the function of neuraminidase protein and prevents new viral particles from
being released, so that the virus cannot leave the cell to infect other cells. Eventually, the virus dies.

16.2.5.1 Plant sources of shikimic acid
The isolation of shikimic acid from the fruit of Illicium religiosum was primarily reported by Ekmann in 1885 [18]. The
name shikimic acid was derived after the oriental plant shikimi-no-ki in Japanese. Shikimic acid is now available in more
quantities through the extraction from the fruit Illicium verum (Chinese star anise). It was recently reported that Liquidambar styraciﬂua, more commonly known as the sweetgum tree, could be a renewable source of shikimic acid. In fact, it
was shown that the sweetgum tree can yield shikimic acid in amounts comparable with that of I. verum, through the seeds
of its annual fruit. Other plants to which shikimic acid have been isolated from were presented in Table 16.2.

16.2.5.2 Biosynthesis of shikimic acid in plants
Shikimic acid, obtained from star anise present in its anionic form shikimate, is a cyclohexanecarboxylic acid, a cyclohexene, and a cyclitol. The shikimic acid is formed through the following biosynthesis pathway as described in Fig.16.1.
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TABLE 16.2 Plant sources of shikimic acid.
Plant source

Organ or part of plant

References

Iris pseudacorus

Rhizome

Henshaw et al. [19]

Picea pungens

All branches

Neish [20]

Picea glauca

All branches

Neish [20]

Eucalyptus sieberiana

Cambium

Hillis [21]

Eucalyptus regnans

Cambium

Hillis [21]

Ginkgo biloba

Inner bark, leaves

Hasegawa and Tateoka [22]

Pinus thunbergii

Leaves

Hasegawa and Tateoka [22]

Liquidambar styraciflua

Seeds

Enrich et al. [23]

Pinus densiflora

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Pinus thunbergii

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Illicium anisatum

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Magnolia grandiflora

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Houttuynia cordata

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Saxifraga stolonifera

Roots, seeds, bark, leaves

Hasegawa et al. [24]

Terminalia arjuna

Fruits

Bharathi et al. [25]

Pistacia lentiscus

Whole plant

Bharathi et al. [25]

Ribes aureum

Whole plant

Bharathi et al. [25]

Symphytum officinale

Leaf

Bharathi et al. [25]

Actaea pachypoda

Whole plant

Bharathi et al. [25]

Alangium salvifolium

Root

Bharathi et al. [25]

Veratrum viride

Leaf

Bharathi et al. [25]

Dipsacus laciniatus

Leaf

Bharathi et al. [25]

Agastache urticifolia

Whole plant

Bharathi et al. [25]

Inula helenium

Leaf

Bharathi et al. [25]

Hypericum spp.

Whole plant

Bharathi et al. [25]

Commelina benghalensis

Stem

Bharathi et al. [25]

Gymnema sylvestris

Leaf

Bharathi et al. [25]

Terminalia chebula

Fruits

Bharathi et al. [25]

Illicium floridanum

Leaf

Bharathi et al. [25]

Illicium diffengri

Fruits

Bharathi et al. [25]

Illicium henryi

Fruits

Bharathi et al. [25]

Illicium verum

Fruits

Bharathi et al. [25]

Illicium lanceolatum

Fruits

Bharathi et al. [25]

Illicium pachyphyllum

Fruits

Bharathi et al. [25]

Illicium anisatum

Fruits

Bharathi et al. [25]

Illicium religiosum

Fruits

Bharathi et al. [25]

Hemidesmus indicus

Root

Bharathi et al. [25]

Cistus incanus

Whole plant

Bharathi et al. [25]

Sida acuta

Whole plant

Bharathi et al. [25]

Celastrus paniculatus

Leaf

Bharathi et al. [25]

Glycosmis muricata

Root

Bharathi et al. [25]
Continued
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TABLE 16.2 Plant sources of shikimic acid.dcont’d
Plant source

Organ or part of plant

References

Tanacetum parthenium

Leaf and blossom

Bharathi et al. [25]

Triticum aestivum

Leaf

Bharathi et al. [25]

Hypericum dolabriforme

Whole plant

Bharathi et al. [25]

Dipsacus pilosus

Leaf

Bharathi et al. [25]

Triadenum walteri

Whole plant

Bharathi et al. [25]

Hypericum frondosum

Whole plant

Bharathi et al. [25]

Terminalia pallid

Leaf

Bharathi et al. [25]

Hemidesmus indicus

Whole plant

Bharathi et al. [25]

Chelidonium majus

Whole aboveground part with blossoms

Bochkov et al. [26]

Ribes aureum

Blossoms and young sprouts

Bochkov et al. [26]

Pteridium aquilinum

Aboveground part before expansion

Bochkov et al. [26]

Populus nigra

Leaves

Bochkov et al. [26]

Acer negundo

Seeds

Bochkov et al. [26]

Pinus sylvestris

Summer, winter needles

Bochkov et al. [26]
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FIGURE 16.1 The shikimic acid biosynthesis pathway.

Phosphoenolpyruvate reacts with erythrose 4-phosphate to yield 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP),
in the presence of catalyst, i.e., enzyme DAHP synthase. DAHP then changes to 3-dehydroquinate (DHQ), in the presence
of enzyme DHQ synthase.
DHQ is dehydrated to 3-dehydroshikimic acid by the enzyme 3-dehydroquinate dehydratase in the next biosynthetic
step, which transformed into shikimic acid in the reduction reaction catalyzed by the shikimate dehydrogenase.
Nicotinamide adenine dinucleotide phosphate (NADPH) contributes as a cofactor in this reduction reaction.
Shikimic acid, a natural compound, has key role as an intermediary substance in the manufacturing of amino acids.
Therefore, this derivative is wide spread in various plants and has potential biological properties. Apart from this, shikimic
acid has pharmacological relevance because it also acts as an intermediate in the manufacturing of many drugs and the
mostly related to antiviral agent called oseltamivir (Tamiﬂu).

16.2.5.3 Other methods for the synthesis of shikimic acid
16.2.5.3.1 Chemical synthesis
The most common method for synthesis of racemic SA was obtained by Diels Alder reaction with (1E, 3E)-1,4-diacetoxy1,3-butadiene, and in this method acrylic acid was used as starting material for the SA synthesis with 15% yield [27,28].
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Other studies have also reported that SA was synthesized from ()-quinic acid obtained from cinchona bark [29]. Grewe
and Hinrichs [30] also reported a synthesis of SA, but achieved only 11% overall yield. Koreeda and Ciufolini [31]
achieved a higher yield (29% overall yield). Among all the highest yields, up to 55% was found in synthesis by Fleming
oxidation.
16.2.5.3.2 Microbial synthesis
The SA ﬁrst isolated of microbial source was from Escherichia coli by Millcan [32]. It was also reported that bacillus
species increases the yield of SA by initiating the activity of shikimate dehydrogenase and shikimate kinase enzyme. Other
strains of E. coli such as E. coli SP1.1/pKD12.112 yields 20.2 g/L culture while W3110.shik 1 yields a signiﬁcant amount
of SA through the increase of the activity of kinase II enzyme for the synthesis of SA.
16.2.5.3.3 Enzymatic approach
Adachi et al. [33] have introduced a novel method for the enzymatic synthesis of shikimic acid from quinic acid with the
help of dried cells or the membrane portion of gluconobacter oxydans IFO 3244. The enzymes obtained quinate dehydrogenase and 3-dehydroquinate dehydratase and were utilized to transform quinic acid into 3-dehydroshikimate.
Dehydroshikimate was then treated with NADPH-dependent D-glucose dehydrogenase and shikimate dehydrogenase for
obtaining shikimic acid. This technique is suitable for laboratory recovery of shikimic acid only but not from the
perspective of industrial production.

16.2.5.4 Usefulness of shikimic acid pathway
The shikimic acid pathway is a biosynthetic pathway which is absent in mammals. It involves the metabolism of carbohydrates and allows the biosynthesis of aromatic amino acids and aromatic compounds such as naphthoquinones,
ubiquinones, and folates. The shikimate pathway is a part of the metabolism occurred only in plants and microorganisms
such as microbial eukaryotes, bacteria, and parasites. The sequence of seven-step shikimate pathway consists of transforming phosphoenolpyruvate and erythrose-4-phosphate starting with the condensation of them. Their condensation and
cyclization lead to the synthesis of chorismic acid. Active forms of these with coenzyme A (CoA) can lead to the formation
of phenolic compounds, which in turn by b-oxidation changes to acids of the benzoic acid series (gallic, protocatechuic, etc.).
Gallic acid in combination with simple sugars transforms to the tannin compounds such as gallic and ellagic tannins and, after
the addition of a molecule of phosphoenolpyruvate and additional intermediate stages, leads to the formation of aromatic
amino acids tyrosine and phenylalanine amino acids. The pathway includes various enzymes such as 2-keto3-deoxy-Darabinoheptulosonate-7-phosphate synthase, 3-enoylpyruvylshikimate-5-phosphate synthase, shikimate dehydrogenase,
shikimate kinase, 5-dehydroquinate dehydratase, and chorismate synthase. Shikimic acid is the intermediate product of
this biological pathway by shikimate dehydrogenase, which facilitates the reversible transformation by reduction of
3-dehydroshikimate into shikimate. The shikimic acid pathway provides a new methodology for developing new herbicides
and herbicide-resistant crops. It also provides the opportunity for engineering new antibiotic and antiparasitic drugs by
interrupting the action of its enzymes. Hence, various important researches are being carried out to explore this pathway.

16.2.5.5 Shikimic acid isolation from plant raw materials
The Illicium genus is the basic source of shikimic acid, and the acid was discovered in 1885 from its fruits. The techniques
are constantly improving for isolation of shikimic acid from these plants’ fruits. Adams et al. [34] extracted shikimic acid
of 98% purity and >5% yield based on a dried fruit weight obtained with the help of Soxhlet extractor in 24 h extraction
and subsequent puriﬁcation by a Solka-Floc anion exchange resin from 900 g of Illicium anisatum seeds. Adams’s method
was modiﬁed and simpliﬁed by Payne and Edmonds [35] and improved the yield of shikimic acid up to 7% on a dry basis.
In their method, about 25 g of I. anisatum seeds were ground to dust and were extracted in a Soxhlet extractor with 95%
ethanol as a solvent for approximately 2 h. The extract was then treated with water and few drops of formaldehyde solution
to obtain an orange clear solution which was passed through an anion exchange column (Amberlite IRA-400, acetate form,
dry weight 25 g). Shikimic acid was than eluted with acetic acid and the yellow eluent was collected, which was again
heated with methanol, activated carbon and recrystallized with toluene to yield a brilliant white, crystalline substance. The
modiﬁed Adams’s and Payne’s methods are being exploited in China for the industrial production of shikimic acid from
Illicium genus plants.
Weinstein et al. [36] have ﬁrstly isolated high purity C14-labeled shikimic acid from Ginkgo biloba L. and conducted
experiments for studying the metabolism in plants, especially for studying the shikimate pathway. For this purpose, the
plant was kept for metabolism in an atmosphere of radioactive carbon dioxide for several days. Extraction of the plant
material was done with ethanol and water, and the impurities of the extract were removed by passing it through a Dowex
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50-X4 (Hþ form) column. The column of Dowex 1-X8 (acetate form) was used to pass the eluate. The excellent separation
of shikimic and quinic acids was achieved by gradual elution with an aqueous acetic acid, and sufﬁciently pure compounds
were found after the ﬁnal passage through the Dowex 1-X8 column. 2.12 g of shikimic acid and 0.593 g of quinic acid
were yielded by 287 g of fresh leaves. G. biloba L. is known to yield shikimic acid no less than 4% based on wet leaves.
During chromatographic puriﬁcation, high loss of shikimic acid occurs and hence the above technique gave an extremely
low yield (below 20%). A modiﬁed technique was employed by Underhill et al. [37] in which Ginkgo and rose shoots were
grown with each other in a radioactive atmosphere, which yielded higher content of shikimic acid (2.5% on a dry basis of
Ginkgo leaves) than in case of using Ginkgo only. These techniques are important from the perspective of research but
could not be used to the industrial-level production of shikimic acid as they are multistage process and results in high
product loss.
An efﬁcient method for isolating shikimic acid from leaves of plants of the Liquidambar genus was developed by Li
et al. [38]. In the process, fruit coatings and leaves of the Liquidambar genus trees were dried at 65 C and milled, which
was further soaked in deionized water for 4 h subsequently three times. The extracts were then passed through Amberlite
IRA-400 (acetate form), and shikimic acid was eluted with 25% acetic acid, concentrated, and then crystallized from the
mixed ethyl acetate and methanol. The shikimic acid was obtained of 98% purity and 70% yield depending on the original
content of shikimic acid in the Liquidambar fruits leaves, which is approximately 3%e8% on a dry basis, depending on a
species. The above-described method is being actively exploited in the Chinese industry for the production of shikimic acid
from the Liquidambar genus plants.

16.2.5.6 Mechanism of action of oseltamivir
As discussed above, oseltamivir commercialized under the trade name Tamiﬂu is an antiviral drug, which is being synthesized from shikimic acid. The oseltamivir help to lower down the rate of spread of inﬂuenza (ﬂu) virus among cells in
the body by interrupting the removal of the virus from its host cell. The drug is ingested orally in capsules or in the form of
suspension. Both inﬂuenza A virus and inﬂuenza B virus may be treated by it.
After ingestion of oseltamivir, ﬁrstly it acts like an inactive chemical or prodrug which changes into its active state by
metabolic process inside the liver, where because of hydroxylation, it changes to active metabolitedthe free carboxylate of
oseltamivir (GS4071). It was the ﬁrstly used orally active neuraminidase inhibitor, which serves as a competitive inhibitor
for the action of the viral neuraminidase (NA) enzyme on sialic acid, present on glycoproteins found on the surface of
normal host cells. By hindering the activity of the enzyme, oseltamivir stops new viral particles from being formed by
infected cells. Oseltamivir is indicated for the treatment and prevention of infections due to inﬂuenza A and B viruses. In
gastrointestinal tract, there is approximately 80% bioavailability of oseltamivir phosphate, which made it readily absorbed
in the cells. Consequently, the oseltamivir is well distributed after ingestion as pill to the nasal mucosa, the tracheal lining,
and the tissues of the middle ear. The elimination of oseltamivir carboxylate from the body follows the route for its
elimination by glomerular ﬁltration and then renal tubular excretion without undergoing further metabolism process. The
estimated average half-life of elimination in adults ranges from 6 to 10 h. Inﬂuenza A and B are the two most important
viruses responsible for the yearly ﬂu seasons in human beings. They are named on the basis of major types of antigenic
proteins present on the viral coating. These antigenic proteins are hemagglutinin (HA) and neuraminidase (NA), out of
which the NA is a primary target of oseltamivir and zanamivir.

16.2.6 Conclusion
Despite the rapid growth of pharmaceutical and biotechnological approaches, the development of effective antiviral
therapy is still a challenge. Inﬂuenza has created a global menace for the society as it has yet not developed the appropriate
technology to manage the epidemic from resistant strains. Apart from the emergence of drug resistance, development of
mutant strains of the virus, introduction of a more virulent strain, expensive available drugs, time lapse in vaccine
manufacture, and mass mortality cause difﬁcult problems. In this scenario, counterpart and alternate medicine offers huge
possibilities to help patients. Herbs possess a wide array of biological actions and could be efﬁciently exploited for
managing pandemic ﬂu. Nutritional and botanical properties together are responsible for providing potent tools for controlling different types of viral infections. The accessibility of a wide array of herbs and constituents with potentially active
phytochemicals, to increase the effect as antiinﬂuenza agents, could have an important role in the ongoing research toward
the novel H1N1 infection. Shikimic acid is also found as potential antiviral source as it could be used as a precursor for
industrial production of the antiviral oseltamivir or Tamiﬂu, a potent viral neuraminidase inhibitor. Rigorous researches for
optimization of shikimic acid production and its utilization can bring a revolutionary change in antiviral therapy.
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17.1 Introduction
The Earth is home to an estimated 10 million species, of which a large chunk belongs to marine environment. Marine
environment occupies a large section on the surface of earth which provides umpteen kinds of habitats that support marine
life, which primarily depend on the salt present in marine water. Marine environment is a home to a very wide diversity of
ﬂora and fauna, which includes an array of genetically diverse coastline and under seawater plant species, animal species
and microbial species, their habitats, ecosystems, and supporting ecological processes. Marine habitats spread as coastline
or coastal habitats and as open sea habitats. Coastal habitats occupy merely 7% of the total ocean area, yet most marine life
exists in this zone. Open sea habitats extend into the deep ocean, beyond the continental shelf. Marine sea columns have
been classiﬁed into pelagic and demersal zones, away from ocean bottom while close to the open surface and those near the
bottom or on the bottom of the ocean, respectively. Demersal habitats are stationary, compared with pelagic habitats as
they depend on the ocean currents and tend to be transient and ephemeral. Marine habitats are shaped by the species that
inhabit them such as kelp, mangroves, and sea grasses, which are the base of ecosystems formed for other life.
Lot of natural medicinal therapy research today is directed toward marine products, derived from marine species, which
have proved to be a potent source of structurally widely diverse and yet highly bioactive antimicrobial secondary
metabolites. Particularly important are ﬂavones and ﬂavonols, terpenoids, alkaloids, peptides, carbohydrates, fatty acids,
polyketides, polysaccharides, phenolic compounds, and steroids. These are housed in the varied species of phylum
Porifera, algae including diatoms, Chlorophyta, Euglenophyta, Dinoﬂagellata, Chrysophyta, cyanobacteria, Rhodophyta,
and Phaeophyta, bacteria, fungi, and weeds, which have been exploited by mankind for their inherent indigenous
biological antimicrobial compounds, produced under the extreme stressful underwater conditions of temperature,
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atmospheric pressure, light, and nutrition. The present study aims at presenting a brief review of these bioactive marine
compounds possessing antimicrobial potency [1].
Some of these marine species live in a stressful habitat, under cold, lightless, and high-pressure conditions.
These factors have resulted in the development of unique metabolisms, which provide the opportunity to produce
metabolites that differ from the terrestrial ones, offering a wonderful resource for discovery of new compounds with
interesting biological activities, including antimicrobial and antiviral properties [2].
Signiﬁcant oceanic resources, such as marine ﬂora constituting halophytes, cyanobacteria, actinobacteria, bacteria,
microalgae, fungi, seaweeds, and mangroves, make up more than 90% of oceanic biomass. Taxonomically diverse, largely
productive, biologically active, and chemically unique, they are a storehouse of antimicrobial and prohuman health
promoting drugs. Marine ﬂora is rich in medicinally potent chemicals such as sulfated polysaccharides and polyphenols,
which possess antioxidant, immunostimulatory, and antitumour pharmacological activities. They probably control
carcinogenesis by inducing apoptosis, activating macrophages and preventing oxidative damage of DNA. They may prove
as cheaper, safer, and potent medicinal remedies to challenge the dreadful human disease [3].

17.1.1 Bioactive compounds in marine plants with various molecular targets in bacteria
17.1.1.1 Flavonoids (Bioflavonoids)
Flavones and ﬂavonols (ﬂavusdLatin for yellow) are present in plant and fungi as secondary metabolites and are naturally
yellow in color. Chemical structure has a 15-carbon skeleton, with two phenyl rings (A and B) and one heterocyclic ring
(C); abbreviated as C6eC3eC6. They are anthoxanthins (ﬂavones and ﬂavonols), ketone-containing polyhydroxy
polyphenol compounds. More than 5000 natural ﬂavonoids are studied from ﬂora and fauna, classiﬁed according to their
chemical structure. Flavonoids have been shown to have a wide range of biological and pharmacological activities such as
antibacterial [4], antiviral, antifungal [5], antimicrobial, antidiarrheal activities [6], antiinﬂammatory [7], and antioxidant
[8]. Flavonoids show antibacterial potency, synergism with antibiotics along with suppression of virulence factors in
bacteria [9].

17.1.1.2 Terpenoids/Isoprenoids/modified terpenes
Terpenoids are organic chemicals derived from terpenes, which can also be termed as modiﬁed terpenes, in which either
methyl groups are removed or transferred or oxygen atoms are added. Simple terpenoids and unusual terpenoids are found
in ample amount in ﬂora growing in marine environment. Isopentenyl pyrophosphate and dimethylallyl pyrophosphate
condense to produce geranyl pyrophosphate, which is a precursor to all terpenes and terpenoids.
Cytochrome P450s modify the structure of terpenes and this property is found to be due to enzymes terpenoid synthase
encoded by genes of 17 plant species genomes [10]. Sesterterpenoids, sesquiterpenoids, and meroterpenoids found to be
antimicrobial and antiviral are more commonly found in marine environments. Marine sesterterpenoids exhibiting
prominent antimicrobial and antiviral bioactivities occur in marine sponges [11]. Seven different types of sesterterpenes
sulfates were isolated from tropical sponge belonging to Dysidea sp., of which most were found strong isocitrate lyase
inhibitors showing potent antibacterial effect against Bacillus subtilis and Proteus vulgaris [12]. Hyrtiosal is a bioactive
sesterterpenoid isolated from Hyrtios erectus, which is a marine sponge inhibiting HIV integrase (IN), which binds to viral
DNA at a new binding site for inhibitor, observed to bind to HIV N-terminal domain at Ser17, Trp19, and Lys34, having
potential application in anti-HIV research [13]. Terpenes possess 1,4-benzoquinone supposed to be responsible for
antimicrobial and antiviral properties. Puupehanol, a novel sesquiterpene-dihydroquinone derivative, and chloropuupehenone and puupehenone are responsible for antifungal activity in marine sponge Hyrtios sp. extract [14].
Puupehenone proved most inhibitory against Candida krusei and Cryptococcus neoformans. Nakijiquinones G-I from
Okinawan marine sponges, belonging to family Spongilidae, were found to be a sesquiterpenoid quinone with antimicrobial potency [15]. Novel sesquiterpenoid hydroquinones from Dysidea arenaria, a marine sponge, were found
moderately inhibitory for enzyme HIV reverse transcriptase (RT) [16]. Peyssonoic acids A and B, novel sesquiterpene
hydroquinones, with a novel carbon skeleton, isolated from crustose marine red alga Peyssonnelia sp [17] were found
inhibitory for bacterial pathogen Pseudoalteromonas bacteriolytica in marine algae and Lindra thalassiae, a fungal
pathogen of marine algae.
Sesquiterpenoid hydroquinones such as tiomanene and acetylmajapolene A and B isolated from Malaysian Laurencia sp.
showed antimicrobial activity probably because of incorporation of halogens occasionally [18]. 10-Hydroxykahukuene B,
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a brominated metabolite, isolated from the red marine alga Laurencia mariannensis [19] was found antimicrobial.
Meroterpenoids isolated from marine sponges were found to have antimicrobial activities. They include the following:
a) Fascioquinols series AeF are bioactive antimicrobial meroterpenes isolated from Southern Australian marine sponge
Fasciospongia sp. found in deepwater [20]. Fascioquinol A produces acid-mediated hydrolysis/cyclization products
fascioquinols B, C, and D. Fascioquinol A and B exhibited antibacterial potency against Gram-positive organisms,
especially Staphylococcus aureus and Bacillus subtilis.
b) Meroterpenes, alisiaquinones A-C, and alisiaquinol isolated from deepwater sponge New Caledonian [21] showed
activity against two enzymesdplasmodium kinase Pfnek-1 and protein farnesyltransferase, signiﬁcant in control of
malaria. They were active against chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum strains.
Marine algae Brazilian brown algae Dictyota pfafﬁ and Dictyota menstrualis showed the presence of diterpenes
8,10,18-trihydroxy-2,6-dolabelladiene and (6R)-6-hydroxydichotoma-4,14-diene-1,17-dial , which are found to have
antiviral potency. Diterpenes 8,10,18-trihydroxy-2,6-dolabelladiene and (6R)-6-hydroxydichotoma-4,14-diene-1,17dial inhibited replication of Herpes Simplex type-1 (HSV-1) in Vero cells. Marine Brazilian brown algae Dictyota pfafﬁ
and Dictyota menstrualis possessed dolabellane diterpene dolabelladienetriol, which is a noncompetitive inhibitor of
enzyme HIV RT [22]. Marine brown alga Sargassum macrocarpum methanol extract showed the presence of diterpene
sargafuran, which proved bactericidal against Propionibacterium acnes. Marine antibacterial diterpenes, dehydroxychlorofusarielin B, a polyoxygenated decalin derivative from Aspergillus sp., exhibited antieS. aureus and methicillinand multidrug-resistant S. aureus activities [23].

17.1.1.3 Alkaloids
Alkaloids are a vast group of heterogenous natural nitrogenous metabolites, thickly interwoven with human affairs.
Morphine takes the credit of being the ﬁrst alkaloid, isolated from opium poppy Papaver somniferum, in 1804, by Friedrich
Sertürner, a German chemist [24]. Alkaloids are bitter, natural, organic compounds with basic structure containing nitrogen
atoms along with carbon, hydrogen, oxygen, sulfur, sometimes chlorine, bromine, and phosphorus. Alkaloids may include
weakly acidic [25] or neutral [26] or few synthetic compounds, similar in structures [27]. Alkaloids are produced by proand eukaryotes and are known to have antimalarial-like quinine and antibacterial-like chelerythrine [28] activities.
Marine macroalgae are rich sources of alkaloids, though few marine alkaloids of algal origin like those using
phenylethylamine as precursors have been extracted from plants of terrestrial origin. Halogenated alkaloids from green
algae (marine speciﬁc) and indole derivatives from red algae are speciﬁc. Algae of marine origin possess 44 types of
alkaloids, 41 indole, 1 naphthyridine, and 1 phenylethylamine derivatives. Halogenated ones possess 25 bromine, 7
chlorine, and 5 sulfur components [29].
Marine fauna is a rich source of alkaloids, rather unique chemicals that inhibits enzyme enoyl-ACP reductase, a
clinically relevant enzyme target from the type II fatty acid pathway of several pathogenic microorganisms. Several
compounds related to bromopyrrole alkaloids have also been isolated from marine bacteria. A strain of marine Streptomyces is known to have A and B marinopyrroles, which are axially chiral and densely halogenated metabolites possessing
an uncommon bispyrrole structure [30], signiﬁcant because of their potent antibiotic properties against MRSA or
methicillin-resistant S. aureus. A, B, C.
Marine sponges are very potent reservoirs of antimicrobially active natural sources of nitrogen-containing heterocyclic
alkaloids like 1H-benzo [de] [1,6]-naphthyridine. Bromotyrosine alkaloids ceratinadins from Okinawan marine sponge
belonging to Pseudoceratina sp., show N-imidazolyl-quinolinone moiety and antifungal potency [31]. A and B pseudoceratins, two bicyclic bromotyrosine-derived metabolites from Pseudoceratina purpurea [32], showed signiﬁcant anti
Candida albicans fungal activity. Two pyrroloiminoquinone alkaloids of class discorhabdin from sponge Sceptrella sp.
from Gageodo, Korea [33] showed antibacterial potency, especially against enzyme sortase A, with a key role in anchoring
of cell wall protein responsible for S. aureus virulence. 19-oxofasciospongine A and fasciospongine C (sulfated
sesterterpene alkaloids) and 25-hydroxyhalisulfate 9 (sesterterpene sulfate), found recently and known sesterterpenes
sulfates halisulphates 7 and 9, have been extracted from marine sponge Fasciospongia sp. organic extract [34], showed
strong inhibitory hyphae - formation efﬁciency against Streptomyces 85E. Chinese marine sponge Iotrochota baculifera
showed the presence of sulfated alkaloids baculiferins A-O and O-sulfated pyrrole alkaloids [35]. Of these, Baculiferins C,
E e H, KeN efﬁciently inhibited HIV IIIB, by binding to targets viral infectivity factor (Vif), cellular deoxycytidine
deaminase APOBEC3G and recombinant gp41, a trans-membrane protein. Caribbean sponge Monanchora unguifera
shows the presence of guanidine alkaloids which are polycyclic with signiﬁcant antimicrobial and antiviral properties [36]
and batzelladine alkaloids like batzelladines K, L, M, N; 16 b-hydroxycrambescidin 359, ptilomycalin A, batzelladine C,
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crambescidine 800, and dehydrobatzelladine C with signiﬁcant inhibitory activities against HIV and opportunistic
pathogens of Acquired Immuno Deﬁciency Syndrome (AIDS). Merobatzelladines A, B isolated from this marine sponge is
antibacterial [37]. Marine sponge Aaptos aaptos possesses alkaloid 4-methylaaptamine which shows inhibition against
HSV-1 replication and antiherpetic activity [38]. Four aaptamines from A. aaptos show inhibitory activity against enzyme
sortase A which is involved in S. aureus virulence and anchoring of cell wall protein [39]. Topsentin and hamacanthin are
antimicrobial bisindole alkaloids isolated from marine sponge Spongosorites sp [40]. Dysideanins A and B from marine
sponge Dysidea sp. are found to have antimicrobial potency [41]. 5-hydroxyindole-type alkaloids from Hyrtios sp.
Sponges from tropical regions exhibited inhibitory potency against isocitrate lyase in C. albicans [42]. A family of
alkaloids isonitrile-containing indole alkaloids, such as hapalindoles, have fused pentacyclic and hexacyclic carbon
skeletons from cyanobacteria, are contemplated for use in pharmaceuticals. Fischambiguines A and B, ambiguine P,
ambiguine Q nitrite, ambiguine G nitrite were isolated and identiﬁed from Fischerella ambigua [43]. Fischambiguine B
showed antieMycobacterium tuberculosis activity. Diketopiperazine alkaloids are marine antimicrobial alkaloids. A
marine halotolerant fungal strain - Alternaria raphani from sea salt ﬁelds showed the presence of cerebrosides,
alternarosides A, B, C, and diketopiperazine alkaloid, alternarosin A [44], which show weak antibacterial activity against
Escherichia coli, Bacillus subtilis and C. albicans. Caboxamycin produced by deep-sea Streptomyces sp. NTK937 showed
inhibitory activity against Gram-positive bacteria [45].

17.1.1.4 Peptides
Marine antimicrobial peptides are present in all living species and build up their defense mechanisms. They probably act as
humoral natural humoral defense in invertebrates, also termed as “natural antibiotics” [46]. Cyclodepsipeptides are marine
peptides found in sponges exhibiting antiviral and antimicrobial potencies [47]. Cyclic peptides family includes unique
N-terminal polyketide-derived molecules and diverse types of unusual amino acid residues.
Cyclic depsipeptides Papuamides from marine sponges have shown in vitro cytoprotective activity for HIV, preventing
entry of the virus. Antiviral cyclic depsipeptides - mirabamides A, B, C, D are isolated from sponge Siliquariaspongia
mirabilis [48], probably preventing HIV fusion. Mirabamides are composed of 4-chloromoproline in 1, 2, 3 positions,
b-methoxytyrosine 40 -O-a-L-rhamnopyranoside (unusual glycosylated amino acid) in 1, 2, 4 positions and rare N-terminal
aliphatic hydroxy acid. Mirabamide A, C, D is found to inhibit HIV acting at entry stage of HIV. Mirabamides A, B, C
inhibit Bacillus subtilis and C. albicans. Alternaramide, a cyclic depsipeptide from the marine fungus Alternaria sp.
SF-5016 [49] exhibited weak anti S. aureus and anti Bacillus subtilis activity. Homophymine A, a cyclodepsipeptide from
marine sponge Homophymia sp [50]. showed anti - HIV cytoprotective potency. Homophymime A is composed of 11
amino acids, an amide-linked-3-hydroxy-2, 4, 6-trimethyloctanoic acid molecules; four Dextro, two Levo, one N-methyl
amino acids and four unusual amino acid residues. Callyaerins A, B, C, D, E, F and H are antiviral and antimicrobial
peptides from marine sponge Callyspongia aerizusa [51]. Theonellamides are bicyclic peptides from marine sponges
which show antifungal activities [52]. Aminolipopeptides, Trichoderins A, A1 and B, are marine antimicrobial peptides
from sponge - derived fungus of Trichoderma sp. They show antimycobacterial activity versus dormant and active marine
bacilli [53], especially against Mycobacterium tuberculosis, M. Smegmatis and M. bovis. Anthranilic acid and
dehydroamino acid units, sclerotides A and B, components of cyclic hexapeptides obtained from marine halotolerant
Aspergillus sclerotiorum PT06-1 [54] exhibited antibacterial and antifungal activities. Aspergillus sclerotiorum PT06-1
was found to contain cyclic tripeptides scleraotiotides A-K of aspochracin nature [55]. Sclerotiotides A, B, F, I showed
antifungal activity for C. albicans. Maribasins A and B cyclic lipopeptides, from marine Bacillus marinus B-9987 showed
broad-spectrum activity against phytopathogens [56]. Two antifungal lipopeptides on eof which is the rare 6-Abu fengycin
lipopeptides from marine Bacillus amyloliquefaciens SH-B10 [57] showed remarkable inhibitory potency against ﬁve
phyto-fungal pathogens, suggesting bio-control and sustainable agricultural practicese. Tauramamide, lipopeptide from
marine bacteria Brevibacillus laterosporus PNG276 [58] along with ethyl ester 3, showed selective inhibitory activity
against pathogenic species of Enterococcus. Thiopeptides and depsipeptides are marine bacterial antimicrobial peptides
found in Nocardiopsis sp. TP-1161 [59], possessing a unique aminoacetone group. Unnarmicine A and C, marine
depsipeptides from Photobacterium MBIC06485 [60] selectively killed two Pseudovibrio species, commonly existing in
marine environment. Hybrid forms of marine peptide polyketide-nonribosomal antimicrobial agents from Myxobacteria
have been isolated. One example is halophilic myxobacterium Paraliomyxa miuraensis, producing miuraenamides A and
B which are hybrid cyclic polyketide-peptide antimicrobial agents [61]. Two rare hybrid polyketide-nonribosomal linear
peptide antibiotics, Ariakemicins A and B found in marine gliding bacterium Rapidithrix species [62], are found to be
composed of two U-amino-(U-3)-methyl carboxylic acids with diene or triene units, threonine and d-isovanilloylbutyric
acidand inhibited particularly Gram-positive bacterial growth. Nonribosomal peptides from marine Brazilian
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cyanobacterial isolates are antimicrobial [63], while from Brevibacillus laterosporus Lh-1 exhibit antimicrobial activity for
fungi and Gram-positive and Gram-negative bacteria [64].

17.1.1.5 Carbohydrates
Carbohydrates are biomolecules present in abundance, in the form of cellulose and chitin, glycogen and starch acting as
great energy sources and cellular recognition molecules, at cell surface [65]. They are structurally complex with dynamic
properties, structural ﬂuctuations, large diversity of units due to umpteen enantiomers, various glycosidic bonds and
modiﬁcations after polymerization. The diverse classes of carbohydrate classes consist of negatively charged neutral and
neutral saccharides of different lengths [66]. Marine carbohydrate compounds are chemically diverse with glycosidic
domains and exhibit various biological properties and functions which may help in their implementation in bioactive
products. Many are the known applications of substances obtained from marine species. Their activities include antioxidant, antiinﬂammatory, anticoagulant, antitumor, and antimicrobial potencies. This may utilize them for their nutritional
and therapeutic potential, though they are the most poorly explored but promising molecules. Many of them are being
clinically tried out for possible potential for antiviral therapies [67]. Their biological roles include signiﬁcant pharmacological potencies like antiinﬂammatory [68], antiviral [69], cellular interactions [70], and pathogen recognition [71].
17.1.1.5.1 Neutral and acidic polysaccharides
a) Laminaran: Laminarans are marine glycans, brown algal polysaccharides existing in chains made up of 3-linked b-Dglucose (Glc) residues with less than 10% of single b-D-Glc residues branches attached to C-6 of backbone Glc residues
[72], Type G with chains terminated by D-Glc residues, and Type M - with chains ending with D-mannitol (Man)
residues [73].
They show antiinﬂammatory activity [74]. Laminaran enhances release of few inﬂammation mediators, thus being
immunostimulatory and antiinﬂammatory [75]. Laminaran, a marine glycan inhibits both Gram-positive and
Gram-negative marine bacteria such as Vibrio parahaemolyticus, Listeria monocytogenes, and Salmonella typhimurium.
It prevents HIV virulence by decreasing its adsorption in human lymphocytes, reducing the efﬁciency of HIV enzyme
reverse transcriptase, thus preventing HIV replication and multiplication [76].
b) Alginic acid: It is a marine polysaccharide extracted from brown algae, with a broad spectrum of medicinal, food,
biotechnological, and industrial applications [77].
Brown algae Sargassum wightii species show alginic acid with antioxidant and antiinﬂammatory activities, reducing
many cyclooxygenase, lipoxygenase, and myeloperoxidase enzyme activities, C-reactive protein levels, rheumatoid factor
and ceruloplasmin along with lipid peroxidation reduction and enhanced enzyme activity [78]. The antioxidant activity of
alginic acid is because of its metal chelating capacity, scavenging of free radicals, reducing tissue ferric ions and enhancing
antimicrobial potency [79]. It controls Listeria monocytogenes growth, responsible for serious food infections [80].
17.1.1.5.2 Sulfated polysaccarides
a) Fucoidan: Fucoidan is found in Brown algae. It has a complex structure, with a backbone of alternating a-L-Fuc
residues with 3 - and 4 - glycosidic linkages or 3-linked a-L-fucose (Fuc), which case can be replaced by acetyl groups
or sulfate groups or Fuc or glycosyl unit side chains [81], with monosaccharides like Glc, Galactose (Gal), Xylose,
Mannose [82].
Biological activities of Fucoidan are because of its polysaccharide nature, consisting of 3-linked a-L-Fuc units [83].
Fuc units in Fucoidan backbone can occur in a-1, 2 linkage, in addition to a-1, 3, a-1, 4 bonds [84]. Fucoidan has a wide
spectrum of applications with reference to its biomedical features [85]. Fucoidan shows antiinﬂammatory effects, selection
inhibition, complement inhibition and enzyme inhibitory activities because of its pleiotropic properties [86]. Three brown
algae Sargassum polycystum, Sargassum mcclurei, Turbinara ornate Fucoidan has shown anti-HIV potency, probably due
to blocking of ﬁrst HIV entry steps in target cells [87]. Alga Padina tetrastromatica synthesizes silver nanoparticles
(AgNPs) with the help of fucoidan as a coating material [88], which probably increases activity against antibiotic resistant
bacterial strains. Antibiotics along with fucoidan in nanoparticles show synergistic effect.
b) Carrageenan/Agaran: Carrageenans are extracted from red seaweeds. They are sulfated galactans, made up of linear
chains of alternating A units and B units (4-linked a-D-Gal or a-D-3, 6-anhydrogalactose (AnGal) and 3-linked b-DGal), forming repeating disaccharide building units [89].
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Commercially used carrageenans are kappa (k), iota (i) and lambda (l), alias carrageenan 4-sulfate (DA-G4S),
carrageenan 2,4-disulfate (DA2S-G4S) and carrageenan 2,6,2-trisulfate (D2S,6S-G2S), respectively (IUPAC) and
carrageenans ѵ and m which ar biological precursors of i- and k-carrageenans [90] (Campo et al.), which show emulsifying,
gelling, thickening, stabilizing characteristics which offer protective effects for food [91], pharmaceutical and cosmetic
products [92]. Oligosaccharides derived from Carrageenan show scavenging activity for hydroxyl radicals, DPPH radicals
and reducing power [93]. l and i carrageenans show strong inhibitory action against Dengue virus type 2 and 3 (DENV-2
and DENV-3) [94]. l-Carrageenan reduces the infectivity of Bovine Herpes virus type 1 and Suid Herpes virus type 1
((BoHV-1 and SuHV-1) viruses. i-carrageenan inhibits Inﬂuenza A (H1N1) virus infection [95]. l-carrageenan
oligosaccharide (P32) particularly inhibits early post-adsorption replication of RABV strains, viral internalization and
fusion mediated by glycoproteins. P32 from l-carrageenan is a possible agent for developing anti-RABV drugs [96].
c) Sulfated Polymannuronate: SPM or Sulfated polymannuronate or sulfated polymannuroguluronate from brown algae
is a sulfated polysaccharide composed of 4-linked b-D-ManA, molecular weight 10,000 D with sulfation at C-2 or C-3,
another form propylene glycol mannuronate sulfate being used for medical purpose. SPM takes credit of being ﬁrst
marine sulfated polysaccharide exhibiting anti-HIV property. Oligosaccharides derived from SPM interact with
gp120, targeting HIV [97]. SPM is known to bind speciﬁcally at CD4 on lymphocytes.
d) Glycosaminoglycans: GAGs or Glycosaminoglycans are heterogeneous linear sulfated glycans with repeating building
units of disaccharides UroA - uronic acid (glucuronic acid (GlcA) or iduronic acid (IdoA)) or Gal and hexosamine
(glucosamine or N-acetylgalactosamine or its substituted sulfated derivatives [98].
GAGs in animals include Heparin, heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), keratan
sulfate (KS) and hyaluronan (HA), with varying sulfation patterns and alternating monosaccharides. Even same class of
GAG of marine or terrestrial origin, has structural difference [99] because of sequence domains or occurrence in
extracellular matrix or on surface of cells, giving them diverse medicinal and biological and functions.
e) Fucosylated Chondroitin Sulfate: FCS or Fucosylated Chondroitin Sulfate, a marine GAG, in sea cucumber
(Echinodermata, Holothuroidea), is made up of CS backbone with branches made of a-L-Fuc units attached to C-3
of GlcA residues, lateral units showing different sulfation patterns [99].
It is found to be antiinﬂammatory [100] and that from Thelenota ananas, sea cucumber inhibits replication of many
strains of HIV, strongly binding recombinant HIV-1 gp120 protein, while not inhibiting reverse transcriptase [101].
FCS displays antiviral action against HIV [102].
17.1.1.5.3 N-acetylated sugars
Chitin and Chitosan: Chitin is present in organism’s exoskeletons like crustaceans and insects. It is biopolymer and found
abundance in marine environment, structurally made up of GlcNAc, GlcN units linked by b-1, 4 glycosidic bonds. GlcNAc
is strongly N-acetylated due to the presence of more than 70% of total monosaccharides, decreasing its water solubility.
Chitin has 4-linked N-acetyl Glucosamine (GlcNAc 2-acetamido-2-deoxy-D-b-glucose) units and partly glucosamine,
GlcN (2-amino-2-deoxy-b-D-glucose) units. In case of less than 50% GlcNAc content or DA - degree of N-acetylation, the
polymer is called Chitosan. Chitosan, a cationic polysaccharide, is made up of repeating units with chitin glycosidic
linkages, but less than 50% levels of GlcNAc. Their interactions and hydrophobicity depends on number and positions of
acetyl groups [103]. Due to non-toxicity, it can be biomedically applied for special functions like antipathogenic activity
[104], decided by its molecular weight, extent of deacetylation and substitution, pH, length of substituents and their
positions in GlcN units [103].
ChNP or Chitosan nanoparticles exhibit antifungal activity [105]. ChNP inhibits Pseudomonas aeruginosa, S. aureus,
E. coli, Klebsiella pneumonia, clinically important pathogens and antibioﬁlm potency [106].
17.1.1.5.4 Triterpene Glycosides
Triterpene Glycosides are amphiphilic with a sugar molecule (mono- or oligosaccharide) linked to a functional group
(terpene or ﬂavonoid or other natural molecules) with a glycosidic bond [68]. They are highly diverse in nature.
Marine Glycosides have been observed in starﬁsh [107], sea cucumber [108], algae [109], sponge [110] and corals
[111].
Melophlus sponge shows the presence of a tetramic acid glycoside - Aurantoside K with wide spectrum antifungal
action against C. albicans strains, yeast Cryptococcus neoformans, Aspergillus niger, Penicillium sp., Rhizopus sporangia
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and Sordaria sp [112]. Variegatusides - Triterpene glycosides from Holothuriida, Stichopus variegatus sea cucumber
shows antifungal activity [113].
17.1.1.5.5 Glycoproteins
Glycoproteins are a big class of biomolecules, present in cell membranes. Glycoprotein glycoconjugates have a protein
backbone to which different monosaccharides are covalently attached. Glycoproteins contain N- linked sugar chains
(GlcNAc group at reducing end attached to amide group of asparagine residue of polypeptide backbone) and O-linked
sugar chains (GalNAc at reducing nd, attached to hydroxyl group of Serine (Ser) or Threonine (Thr) groups of polypeptide
backbone) [114].
Glycoproteins act as receptors capturing ligands into cells like transport proteins responsible for ingestion of nutrients,
structures mediating molecular recognition, molecular signaling and cellular interactions [99].
Mannose-speciﬁc Lectin from Green alga Halimeda renschii showed strong activity against inﬂuenza virus due to high
afﬁnity binding to hemagglutinins on envelopes of viruses [115].
17.1.1.5.6 Glycolipids
Glycolipids, amphipathic in nature, are a diverse and large lipid group, containing a hydrophilic portion with carbohydrate
units, from which its preﬁx “glyco” is derived. The lipid portion is the hydrophobic tail, with aliphatic chains of fatty acids
[116]. Glycosphingolipids are a class of glycolipids, which constitute cell membranes in marine or terrestrial organisms
[117]. Their action is because of variations in sugar chains, based on which they are classiﬁed as cerebrosides, ceramide
oligohexosides, globosides and gangliosides.
Marine algae show three types of glycolipids; MGDG e Mono Galactosyl Di Glyceride, DGDG e Di Galactosyl Di
Glyceride and SQDG e Sulfono Quinovosyl Dipalmitoyl Glyceride, found in chloroplasts of algae. MGDG, DGDG are
abundant in thylakoid membrane playing a signiﬁcant role in photosynthesis [118]. SGDGs from Sargassum vulgare
brown alga showed antiviral activity against HSV1 and V2 (Herpes Simplex Virus 1 and 2) viruses [119].
17.1.1.5.7 Iminosugar
These are natural aza or imino monosaccharides in which nitrogen replaces oxygen in ring structure. Nojirimycin,
a 5-amino-5-deoxyglucose antibiotic, was ﬁrst to be isolated and characterized in 1960. Later, more than 25 analogues of
nojirimycin were studied in plant and microbes [120].
Iminosugars show nematicidal [121], antiviral [122], and insecticidal [123] activities because of their glycosidase
potency, interfering with processing of glycoprotein. 1-Deoxynojirimycin iminosugar with Glc inhibits synthesis of
infective viruses such as dengue (DENV), hepatitis B, hepatitis C, HIV, and inﬂuenza A viruses because of virus release
inhibition due to inhibition of endoplasmic reticulum a-glycosidases [124]. Batzellasides A, B, and C are extracted from
Batzella sp. sea sponge, consisting of an iminosugar nucleus with a long chain of alkyl substituent. Batzellasides differ in
the lengths of alkyl chains. Batzellasides A, B, and C show inhibition of Staphylococcus epidermidis [120].

17.1.1.6 Fatty acids
Marine fatty acids in marine organisms possess biological properties such as antiviral and antimicrobial potencies.
Paragrantia cf. waguensis, a calcareous sponge, possesses acetylenic fatty acid [125], exhibiting antimicrobial activity
against E. coli and S. aureus. Brominated unsaturated fatty acids from marine sponge showed antimicrobial fatty acids
[126]. Motualevic acids A, B, C, D, E, and F from marine sponge Siliquariaspongia sp. have shown inhibitory potency
toward S. aureus and MRSA [127]. Marine algae diatom Phaeodactylum tricornutum has shown antibacterial activity,
which was due to unique (6Z, 9Z, 12Z)-hexadecatrienoic acid, a polyunsaturated fatty acid, and (9Z)-hexadecenoic acid,
a monounsaturated fatty acid [128], both of which are inhibitory toward Gram-positive bacteria and marine pathogen
Gram-negative Listonella anguillarum (9Z)-hexadecenoic acid kills bacteria at great speed, showing potent activity against
multidrug-resistant strains of S. aureus. P. tricornutum produces eicosapentaenoic acid, an antibacterial fatty acid
inhibitory toward a range of Gram-positive and Gram-negative bacteria, as well as multidrug-resistant S. aureus [129].
Asperamides A and B, a sphingolipid and their corresponding glycosphingolipid possessing a 9-methyl-C20-sphingosine
moiety, from A. niger EN-13, an endophytic fungus from marine brown alga Colpomenia sinuosa [130], showed inhibitory
action against C. albicans. Marine fungi are of great importance as potential sources of agricultural pesticide leads such as
unsaturated fatty acid glycerol esters, asperxanthone and asperbiphenyl, extracted from marine fungus Aspergillus sp.
MF-93 [131], active against tobacco mosaic virus.
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17.1.1.7 Polyketides
Polyketides can be deﬁned as natural secondary metabolites used in human therapy as antibiotics and antifungal agents.
Classical examples are nystatin, amphotericin, and rapamycin antibiotics. Polyketides such as polycyclic ether macrolides
and open-chain polyketides are produced and stored by marine sponges and show strong antiviral and antimicrobial
activities.
Marine sponges of the Xestospongia species show the presence of various polyketides of halenaquinone type, such as
orholquinone 8 and xestosaprol C methylacetal 7 [132]. Orholquinone 8 exhibited inhibition of enzymes farnesyl
transferase from yeast, human and P. falciparum. Marine macrolide, neopeltolide, from a deepwater sponge species of
Neopeltidae [133] showed antifungal activity for C. albicans. Marine 7-O-methylkoninginin D and trichodermaketones A,
B, C, D are antifungal polyketides from fungus Trichoderma koningii, exhibiting synergistic antifungal potency against C.
albicans [134]. Curvularin and a,b-dehydrocurvularin are marine polyketides from fungus Eupenicillium sp. in association
with sponge Axinella sp. [135]. Marine macrolides, (þ) brefeldin A, (þ) brefeldin C, and 7-oxobrefeldin A from
Penicillium sp. PSU-F44 [136] exhibited antimicrobial potency for Microsporum gypseum and MRSA.
Marine fungal Nigrospora sp. PSV-F18 and PSU-F5 showed the presence of nigrosporapyrones A, B, C, and D and
nigrospoxydons A, B, and C, which are antimicrobial macrolides [137].

17.1.1.8 Polysaccharides
Polysaccharides are structurally very diverse biological macromolecules because of presence of various sugars and their
derivatives such as uronic acid. In nature, each sugar is linked covalently to another sugar at different sites in the sugar ring.
Marine plants, animals, organisms, bacteria, and fungi are a source of a large diverse variety of polysaccharides [138],
some of which exhibit antiviral and antimicrobial actions.
Edible Nostoc ﬂagelliforme, a species of blue-green alga, shows nostoﬂan, an acidic polysaccharide which shows
antiviral activity (anti-HSV-1) [139], inhibiting virus binding. Lectin is a marine polysaccharide from Oscillatoria agardhii
NIES-204, a ﬁlamentous cyanobacterium inhibiting HIV replication in MT-4 cells [140]. Chitinase is a marine antifungal
polysaccharide from marine South China sea sponge inhibiting Streptomyces sp. DA11. Craniella australiensis exhibited
antifungal defense activity for C. albicans and A. niger [141], which may be because of its microbial symbiont exhibiting
chitinase activity bringing about chitin degradation.

17.1.1.9 Phenolic compounds
The vastest group of secondary metabolites in plants is the group of phenols. It is naturally spread wide and present in
natural compounds with aromatic moieties. They have a wide range of structures from simple one aromatic ring structure to
extremely complex polymeric compounds. Commonly, in marine regions, phenolic compounds with halogens as moieties
occur in high frequency. Marine sponges exhibit phenolic compounds, which are studied commonly for antimicrobial
activity.
Sponge Dysidea granulosa showed presence of 2-(20 ,40 -dibromophenoxy)-4,6-dibromophenol exhibiting wide
spectrum and strong antibacterial activity potency especially toward MRSA and sensitive S. aureus, vancomycin-resistant
and -sensitive Bacillus and Enterococci species [142].
Presence of bromines and phenolic hydroxyl groups at C-2 and C-5 is essential for antimicrobial activity. Bromophenol
compounds are present in marine red algae and bacteria show antimicrobial activity. Crude extracts from marine algae
Odonthalia corymbifera exhibited antimicrobial activity [143]. Natural bromophenol compound 2, 20 , 3, 3’-tetrabromo-4,
40 , 5, 50 -tetrahydroxydiphenylmethane was most active against Trichophyton mentagrophytes, Trichophyton rubrum,
Aspergillus fumigates, and C. albicans. Marine Pseudoalteromonas extract of CMMED 290 species, 4, 40 , 6-tribromo-2, 2’biphenol exhibited signiﬁcant antimicrobial action against MRSA [144]. Marine bacterium Pseudoalteromonas phenolica
O-BC30T produces 2, 20 , 3-tribromobiphenyl-4, 40 -dicarboxylic acid [145], exhibits antieMRSA, Bacillus subtilis,
Enterococcus serolicida, but not for Gram-positive bacteria or fungi. Other antimicrobial bromophenyl compounds have
also been isolated from the marine bacterium Pseudoalteromonas haloplanktis INH strain [146].
Anthraquinones, coumarins, and ﬂavonoids from marine extracts show antimicrobial action. Aspergillus versicolor
derived from Petrosia species marine sponge shows ﬁve bioactive anthraquinones which exhibited antimicrobial activity
for Gram-positive bacteria [147]. Marine-derived 05F16 Aspergillus sp. possesses hexahydroanthrones, tetrahydrobostrycin, and 1-deoxytetrahydrobostrycin [148] showing antibacterial potency for E. coli and S. aureus. Anthraquinone
monodictyoquinone A (1,8-dihydroxy-2-methoxy-6-methylanthraquinone) is antimicrobial found in sea urchin fungus
Monodictys sp. [149]. Anthraquinone monodictyoquinone A was found in marine ALAA 2000 Nocardia sp., from marine
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red alga Laurencia spectabilis and exhibited antimicrobial action toward Gram-positive, Gram-negative bacteria, and
fungi. 7-Methylcoumarin and ﬂavonoids, rhamnazin, and cirsimaritin are antimicrobial phenolic compounds from marine
Streptomyces [150]. Derivatives of chroman-ammoniﬁcins A and B, from marine bacterium Thermovibrio ammoniﬁcans
present in hydrothermal vent are found to be antimicrobial [151].
Edible seaweed Ecklonia cava shows antimicrobial phlorotannins [152]. Marine fungus Zygosporium sp. KNC52
showed the presence of sulfoalkyl resorcinol with multidrug-resistant bacteria antimicrobial potency [153].

17.1.1.10 Steroids
Steroids are natural products which are glycosides in nature and marine or terrestrial in origin. Many glycosides exhibit
various biological activities including antimicrobial.
Marine steroidal glycosides show their presence in microalgae and invertebrates such as echinoderms, soft corals, and
sponges [154]. Euryspongia, a marine sponge from Palau, showed two new steroidal sulfates Eurysterols A and B [155]
with antifungal potency activity against wild-type and amphotericin B-resistant C. albicans strains. Geodisterol-3-O-sulﬁte
and 29-demethylgeodisterol-3-O-sulﬁte, two novel sulfated sterols, exhibited reversal of ﬂuconazole resistance [156].
Marine endophytic fungus Colletotrichum sp. containing ring B aromatic steroids exhibited showed antimicrobial activity
against the fungus Microbotryum violaceum, E. coli, and Bacillus megaterium [157].

17.1.2 Antimicrobial drugs of marine origin under clinical trials
There are various marine originating chemical antimicrobial lead compounds which can be further explored for human
health issues. There are currently over 3000 new substances identiﬁed from marine organisms in the past three decades,
giving researchers a large pool of novel molecules from which to ﬁnd new compounds to develop [158].
They have to be clinically tried out before being implemented for general prescriptions. This requires ample amounts of
compounds under trial to be isolated and extracted in pure forms from the source. Obtaining them from invertebrates in
sufﬁcient amounts can prove difﬁcult. There are various such compounds that are presently under clinical trials. Aqua
culture is an alternative but may not be viable in all cases. Microorganisms may be used as sustainable sources for
production of required compounds for production of intermediates in the ﬁrst step of semisynthesis which can later produce
ﬁnal compound of interest.

17.1.2.1 Antibacterial compounds under clinical trials
In the era of rapid emergence of antibiotic-resistant bacteria, marine sponge extracts have shown the best antimicrobial
potency against terrestrial bacteria [159]. When 101 arctic sponges were antimicrobially screened against opportunistic
infections causing bacteria, approximately 10% of them showed signiﬁcant results, values of IC50 ranging from 0.2 mg/mL
to 5 mg/mL [160]. About 800 compounds with antibiotic properties have been isolated and identiﬁed from marine sponges
[161]. Of 31 sponges checked, 18 showed strong antimicrobial potency against Gram-positive and Gram-negative bacteria
and are being screened for a range of therapeutically signiﬁcant substances [162]. Presently, various such antibacterial
compounds are under trials, at various stages.
Examples of antibacterial compounds under clinical trials include the following:
l

l

l
l

l

Cribrostatin 6 is an alkaloid from Cribrochalina sp. being tried out against antibiotic-resistant strain of Streptococcus
pneumonia [163].
Isojaspic acid, cacospongin D, and jaspaquinol are meroditerpenes from Cacospongia sp. tried out against
S. epidermidis showing an MIC of 20 mg/mL [164].
Isoaaptamine is an alkaloid from A. aaptos inhibitory for S. aureus exhibiting an MIC of 3.7 mg/mL [39].
Microcionin-1 is a terpenoid from Fasciospongia sp. inhibitory toward Micrococcus luteus showing an MIC of 6 mg/
mL [165].
Pseudopterosins from soft corals are diterpene glycoside with eicosanoid metabolism under Phase II trial for wound
healing.

17.1.2.2 Antiviral compounds under clinical trials
No cure has yet been available for adenovirus serotype 5 (AdV-5) associated with respiratory infections [166] or
rotaviruses associated with severe gastroenteritis of animals and humans or diarrhea in immunocompromised patients,
which may prove fatal [167]. About 40 antiviral substances from marine species have been reported, half of which have
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shown prospects in treatment of HIV infection. On this background, marine sponges, sources of novel antivirals,
may prove to be good therapeutic agents [168]. Avarol inhibits HIV infection progression and increases humoral immune
response. Avarol in 0.3, 0.9 mM concentration inhibited 50%, 80% of viruses, respectively, released by infected cells [169].
Avarol derivatives, 60 -hydroxyavarol and 30 -hydroxyavarone, strongly inhibit HIV reverse transcriptase in HIV.
Avarol converts viral genomic RNA to proviral DNA and integrates it in host chromosomal DNA [170]. Various antiviral
marine metabolites are currently under clinical trial.
Examples of antiviral compounds under clinical trials are the following:
l
l
l
l

l

l
l

l
l
l

l

4-Methylaaptamine is an alkaloid from A. aaptos inhibitory toward HSV-1 [38].
Papuamides AeD are cyclic depsipeptides from Theonella sp. acting against HIV-1 [171].
Ara-A is a nucleoside from Cryptotethya crypta inhibitory toward HSV-1, HSV-2, and VZV [172].
Avarol is a sesquiterpene hydroquinone from Dysidea avara acting against HIV-1, UAG suppressor glutamine tRNA
inhibitor [169].
Haplosamates A and B are sulfated steroids from Xestospongia sp. alias Haplosclerida, antiviral (inhibitor of enzyme
HIV-1 integrase) in action [173].
Dragmacidin F is an alkaloid from Halicortex sp. acting against HIV-1 [174].
Hamigeran B, a phenolic macrolide from Hamigera tarangaensis has antiviraleantiherpes and antipolio virus potency
[175].
Mycalamides AeB are nucleosides from Mycale sp. with anti-A59 coronavirus (HSV-1) action [176].
Mirabamides A, C, and D are peptides from S. mirabilis with antiviral (HIV-1) potency [48].
FDA-approved vidarabine (Ara-A), Vira-AÒ, is a nucleoside Ara-A from marine sponge C. crypta and is an arabinosyl
nucleoside, inhibiting synthesis of viral DNA [177].
Azidothymidine (zidovudine), Ara-A, acyclovir, Ara-Cemodiﬁed semisynthetic arabinosyl nucleosides in use against
viruses [178].

17.1.2.3 Antifungal compounds under clinical trials
Invasive mycoses, an increasing resistant fungal infection in patients of AIDS, on immunodepressants, with blood cancers,
undergoing transplants [179], have proved fatal. Candida, Aspergillus, Cryptococcus, and other opportunistic fungi are
common culprits. Sponges belonging to Jaspis sp. have given Jaspamide cyclodepsipeptide, a 19-unit macrocyclic
depsipeptide, exhibiting in vitro antifungal potency against C. albicans [180].
Examples of antifungal compounds under clinical trials are the following:
l
l

l

l

l

l

l

Jaspamide, a macrocyclic depsipeptide from Jaspis sp., has shown an MIC against C. albicans of 25 mg/mL [180].
Eurysterols AeB are sterols from Euryspongia sp. inhibiting Amphotericin B-resistant C. albicans, with an MIC of
62.5 mg/mL and 15.6 mg/mL [155].
Naamine D, an imidazole alkaloid, from Leucetta cf. chagosensis, bioactive against C. neoformans, with an MIC of
6.25 mg/mL [181].
Mirabilin B is a tricyclic guanidine alkaloid, from M. unguifera, acting against C. neoformans, with an MIC of 7.0 mg/
mL [36].
Hamacanthin A is an indole alkaloid, from Spongosorities sp., active against C. albicans, with an MIC of 6.25 mg/mL
[182].
Macanthins AeB are indole alkaloids, from Spongosorities sp., active against C. albicans and C. neoformans, with
MIC of 1.6 mg/mL and 6.2 mg/mL, respectively [182].
Agelasines and agelasimines are purine derivatives, from Agelas sp., bioactive against C. krusei, and MIC of 15.6 mg/
mL [183].

17.1.2.4 Antimalarial compounds under clinical trials
Plasmodium vivax, the predominant malarial parasite, has caused havoc by spreading malaria in vast areas of Asia and
America, while showing accelerating antibiotic resistance. A need for new antimalarial compounds led to antimicrobial
agents from marine sponges. Cymbastela hooperi has exhibited antimalarial potency against P. falciparum through
isonitriles, terpenoid isocyanates, and isothiocyanates [184]. Diacarnus megaspinorhabdosa, a marine sponge exhibited
antimalarial potency toward chloroquine-resistant and -sensitive P. falciparum through epidioxy-substituted
norsesterterpenes and norditerpene endoperoxides [185].
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Examples of antimalarial compounds under clinical trials are the following:
l

l

l

l

l

l

l

l

Monamphilectine A, an antimalarial b-lactam obtained from Hymeniacidon sp., acting against chloroquine-resistant P.
falciparum W2, with an MIC of 0.6 mM [186].
Manzamine A is an alkaloid obtained from Haliclona sp./Haplosclerida and C. hooperi/Halichondrida, Diacarnus
levii/Poecilosclerida, Toxoplasma gondii, Plasmodium berghei, P. falciparum, acting against chloroquine-resistant
P. falciparum W2 with an MIC of 4.5 ng/mL [185]).
Kalihinol A, an isonitrile-containing kalihinane diterpenoid, from Acanthella sp./Halichondrida, with an MIC of
0.0005 mg/mL, against P. falciparum D6 clone [187].
Diisocyanoadociane, a tetracyclic diterpene, from C. hooperi, acting against P. falciparum, with an MIC of 0.005 mg/
mL for D6 clone [188].
Halichondramide is a macrolide, from P. falciparum, with an MIC of 0.002 mg/mL, against P. falciparum D6 clone
[184].
Sigmosceptrellin B is a norsesterterpene acid, from Diacarnus erythraeanus, T. gondii, active against P. falciparum
D10, with an MIC of 1200 ng/mL [184].
(E)-Oroidin is an alkaloid, from Agelas oroides, bioactive against P. falciparum, with an MIC of 0.30 mg/mL for D6
clone [189].
Plakortin and dihydroplakortin are cycloperoxidases, from Plakortis simplex, acting against P. falciparum, D10 at
1263-1117 nM [190].

Manzamines are efﬁcient antimalarials from a variety of sponges [191] and have exhibited inhibitory activity against
P. falciparum (D6 clone), MIC 0.0045 mg/mL [191], by increasing host immunity [187].

17.1.3 Future outlook and conclusion
Natural products have always played a signiﬁcant role in drug discovery for treating human diseases. Drugs developed
from marine sources have ignited a hope to offer novel mechanisms to ﬁght some of the most debilitating diseases such as
HIV, osteoporosis, Alzheimer’s, and cancer. Although costs required for developing drugs from marine sources have been
exorbitant, development of new technology and better understanding of marine species and associated ecosystem has
helped us in developing research in the area of drug development. Bright future awaits pharmaceutical industry for
developing new drugs from antimicrobial lead compounds obtained from marine sources. The progress is slow, but surely
drug manufacturing units have started showing interest in implementing natural marine sources for drug developing. A
future trend is developing in research today, positively toward use of marine natural resources. There are ample of marine
lead compounds, more than imagined [192].
Metabolites derived from marine species such as sponges span wide with respect to their chemical components such as
alkaloids, peptides, terpenoids, polyketides, and others, with a variety of antimicrobial and other properties [187].
When these compounds are prepared for the market, they need to have a known chemistry, enhanced bioavailability,
and minimized side effects. Manzamines are metabolites from marine sponges that can be potentially used as drugs against
tuberculosis [193], HIV [169], malaria [184], and others. Ara-A, ara-C, and acyclovir are a few products originating from
marine sponges in clinical use [169].
It has been observed that medicines derived from various metabolites and derivatives from marine species such as
sponges possess their efﬁciencies as medicines, based on their doses, qualitative, and quantitative effects of inhibition and
their other effects. Besides, they are present in the marine species in very low quantities, which presents difﬁculties in their
being reproduced in ample amounts in the market. Avarol, obtained from sponge D. avara sponge, is an efﬁcient drug for
treatment of HIV [169], which could not be available for studies further than preclinical ones because of its low availability
for assessment [194]. Another advantage of marine species metabolites is that their carbon skeletons can be used as carriers
or vehicles for generating efﬁcient derivatives. Mankind now faces a challenge of preparing the miracle drugs in large
quantities, transforming bioactive metabolites to medicines by selecting proper marine species, isolating the correct
metabolite, with its precise action and its target point toward a disease.
Although marine environment has umpteen numbers of species which are natural resources for antimicrobial
compounds, very few of these secondary metabolites have reached the stage of being approved as drugs, while some
metabolites and their derivatives are still under clinical trials or preclinical trials at various stages.
These trials require a large amount of these metabolites, which has lead to novel ideas like chemically modifying
marine natural products or MNPs to transform them into "druglike" products, farming organisms in natural environment,
and culturing organisms artiﬁcially [195]. Preclinical trials need very systematic, detailed pharmacokinetic investigation to
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tailor MNPs, a challenging task. Antimicrobial efﬁciency of marine metabolites has shown a promising future for
development as human therapeutic agents. A revolution has been set up because of the technique of genome mining
for natural product discovery. Technology is being targeted optimally for drug research, its approvals and its launches, for
the betterment of human life. This chapter has attempted to give a sketch of antimicrobial lead compounds from marine
species, a step forward toward the development of medicinal and biological agents from marine natural sources. This may
be an endeavor toward exploring an untrodden path in drug discovery, from marine environment, for the global health
beneﬁts of mankind.

References
[1] M.J. Abad, L.M. Bedoya, P. Bermejo, Marine compounds and their antimicrobial activities, @formatex 2011, Science against microbial pathogens:
Communicating Current Research and Technological Advances (2011) 1293e1306.
[2] H. Rahman, B. Austin, W.J. Mitchell, P.C. Morris, A.J. Jamieson, D.R. Adams, A.M. Spragg, M. Schweizer, Novel anti-infective compounds from
marine bacteria, Mar. Drugs 8 (2010) 498e518.
[3] N.S. Boopathy, K. Kandasamy, Anticancer drugs from marine ﬂora: an overview, J. Oncol. 162 (2010) 1687e8450.
[4] T.P. Cushnie, A.J. Lamb, Recent advances in understanding the antibacterial properties of ﬂavonoids, Int. J. Antimicrob. Agents 38 (2) (2011)
99e107.
[5] M. Friedman, Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea ﬂavonoids and teas, Mol. Nutr. Food Res. 51 (1) (2007)
116e134.
[6] M. Schuier, H. Sies, B. Illek, H. Fischer, Cocoa-related ﬂavonoids inhibit CFTR-mediated chloride transport across T84 human colon epithelia,
J. Nutr. 135 (10) (2005) 2320e2325.
[7] Y. Yamamoto, R.B. Gaynor, Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inﬂammation and cancer, J. Clin.
Investig. 107 (2) (2001) 135e142.
[8] L.H. Cazarolli, L. Zanatta, E.H. Alberton, M.S. Figueiredo, P. Folador, R.G. Damazio, M.G. Pizzolatti, F.R. Silva, Flavonoids: prospective drug
candidates, Mini Rev. Med. Chem. 8 (13) (2008) 1429e1440.
[9] P.W. Taylor, J.M. Hamilton-Miller, P.D. Stapleton, Antimicrobial properties of green tea catechins, Food Sci. Technol. Bull. 2 (7) (2005) 71e81.
[10] A.M. Boutanaev, T. Moses, J. Zi, D.R. Nelson, S.T. Mugford, R.J. Peters, A. Osbourn, Investigation of terpene diversiﬁcation across multiple
sequenced plant genomes, Proc. Natl. Acad. Sci. Unit. States Am. 112 (1) (2015).
[11] S.S. Ebada, W. Lin, P. Proksch, Bioactive sesterterpenes and triterpenes from marine sponges: occurrence and pharmacological signiﬁcance, Mar.
Drugs 8 (2010) 313e346.
[12] D. Lee, J. Shin, K.M. Yoon, T.I. Kim, S.H. Lee, H.S. Lee, K.B. Oh, Inhibition of Candida albicans isocitrate lyase activity by sesterterpene sulfates
from the tropical sponge Dysidea, Bioorg. Med. Chem. Lett 18 (2008) 5377e5380.
[13] Y. Qiu, Z. Dengx, Y. Peiz, H. Fuy, J. Liy, P. Prokschk, W. Lin, Sesterterpenoids from the marine sponge Hyrtios erectus, J. Nat. Prod. 67 (5) (2004)
921e924.
[14] W.H. Xu, Y. Ding, M.R. Jacob, A.K. Agarwal, A.M. Clark, D. Ferreira, Z.S. Liang, L.X.C. Puupehanol, A sesquiterpenehydroquinone derivative
from the marine sponge Hyrtios sp, Bioorg. Med. Chem. Lett 19 (2009) 6140e6143.
[15] Y. Takahashi, T. Kubota, J. Ito, J. Kobayashi, Jane, G.-I. Nakijiquinones, New sesquiterpenoid quinones from marine sponge, Bioorg. Med. Chem.
16 (16) (2008) 7561e7564.
[16] Y. Qiu, X.M. Wang, A new sesquiterpenoid hydroquinone from the marine sponge Dysidea arenaria, Molecules 13 (2008) 1275e1281.
[17] A.L. Lane, L. Mulac, E.J. Drenkarrd, T.L. Shearer, S. Engel, S. Fredericq, C.R. Fairchild, J. Prudhomme, K. Le Roch, M.E. Hay, W. Aalbersberg,
J. Kubanek, Ecological leads for natural product discovery: novel sesquiterpene hydroquinones from the red macroalga Peysonnelia sp, Tetrahedron 66 (2010) 455e461.
[18] C.S. Vairappan, M. Suzuki, T. Ishii, T. Okino, T. Abe, M. Masuda, Antibacterial activity of halogenated sesquiterpenes from Malasyan Laurencia
sp. phytochemistry 69 (2008) 2490e2494.
[19] N.Y. Ji, X.M. Li, K. Li, L.P. Ding, J.B. Gloer, B.G. Wang, Diterpenes, sesquiterpenes and a C15-acetogenin from the marine red alga Laurencia
mariannensis, J. Nat. Prod. 70 (2007) 1901e1905.
[20] H. Zhang, Z. Khalil, R.J. Capon, A.-F. Fascioquinols, Bioactive meroterpenes from a deep-water Southern Australian marine sponge,
Fasciospongia sp. ChemInform 67 (14) (2011) 2591e2595.
[21] D. Desoubzdanne, L. Marcourt, R. Raux, S. Chevalley, D. Dorin, C. Doerig, A. Valentin, F. Ausseil, C. Debitus, Alisiaquinones and alisiaquinol,
dual inhibitors of Plasmodium falciparum enzyme targets from a New Caledonian deep water sponge, J. Nat. Prod. 71 (2008) 1189e1192.
[22] C.C. Cirne-Santos, T.M. Souza, V.L. Teixeira, C.F. Fontes, M.A. Rebello, L.R. Castello-Branco, C.M. Abreu, A. Tanuri, I.C. Frugulhetti,
D.C. Bou-Habib, The dolabellane diterpene dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme,
Antivir. Res. 77 (2008) 64e71.
[23] H.P. Nguyen, D. Zhang, V. Lee, J.S. Kang, H.D. Choi, B.W. Son, Dehydrochlorofusarielin B, an antibacterial polyoxigenated decalin derivative
from the marine-derived fungus Aspergillus sp, J. Nat. Prod. 70 (2007) 1188e1190.
[24] Luch Andreas Molecular, Clinical and Environmental Toxicology, Springer, 2009, p. 20.
[25] R.H.F. Manske, The Alkaloids. Chemistry and Physiology, Volume VIII., Academic Press, New York, 1965, p. 673.

Antimicrobial lead compounds from marine plants Chapter | 17

269

[26] A.D. McNaught, A. Wilkinson, Iupac. Compendium of chemical terminology, in: (The "Gold Book"). Compiled by. Blackwell Scientiﬁc
Publications, Oxford (1997) Goldbook Lewis RA, Lewis’ Dictionary of Toxicology, second ed., CRC Press, 1998, p. 51.
[27] R.A. Lewis, Lewis’ Dictionary of Toxicology, CRC Press, 1998, p. 51.
[28] T.P. Cushnie, B. Cushnie, A.J. Lamb, Alkaloids: an overview of their antibacterial, antibiotic-enhancing and antivirulence activities, Int. J.
Antimicrob. Agents 44 (5) (2014) 377e386.
[29] K.C. Guven, C. Burak, C. Ekrem, E. Huseyin, K. Ferda, Alkaloids of marine macroalgae, in: EditionBook: Natural Products. Phytochemistry,
Botany and Metabolism of Alkaloids, Phenolics and Terpenes, 1st, Publisher: Springer Verlag, 2013. Chapter: 2.
[30] C.C. Hughes, A. Prieto-Davo, P.R. Jensen, W. Fenical, The marinopyrroles, antibiotics of an unprecedented structure class from a marine
Streptomyces sp, Org. Lett. 10 (2008) 629e631.
[31] Y. Kon, T. Kuboto, A. Shibazaki, T. Gonoi, J. Kobayashi, Ceratinadins A-C, new bromotyrosine alkaloids from a Okinawan marine sponge
Pseudoceratina sp, Bioorg. Med. Chem. Lett 20 (2010) 4569e4572.
[32] J.H. Jang, R.W. Van Soest, N. Fusetani, S. Matsunaga, Pseudoceratins A and B, antifungal bicyclic bromotyrosine-derived metabolites from the
marine sponge Pseudoceratina purpurea, J. Org. Chem. 72 (2007-a) 1211e1217.
[33] J.E. Jeon, Z. Na, M. Jung, H.S. Lee, C.J. Sim, K. Nahm, K.B. Oh, J. Shin, Discorhabdins from the Korean marine sponge Sceptrella sp, J. Nat.
Prod. 73 (2010) 258e262.
[34] G. Yao, T.P. Kondratyuk, G.T. Tan, J.M. Pezzuto, L.C. Chang, Bioactive sulfated sesterterpene-alkaloids and sesterterpene sulfates from the
marine sponge Fasciospongia sp, J. Nat. Prod. 72 (2009) 319e323.
[35] G. Fan, Z. Li, S. Shen, Y. Zeng, Y. Yang, M. Xu, T. Bruhn, H. Bruhn, J. Morschhäuser, G. Bringmann, W. Lin, Baculiferins A-O, O-sulfated
pyrrole alakaloids with anti-HIV-1 activity from the Chinese marine sponge Iotrochota baculifera, Bioorg. Med. Chem. 18 (2010) 5466e5474,
1304.
[36] H.M. Hua, J. Peng, D.C. Dunbar, R.F. Schinazi, A.G. de Castro, C. Cuevas, L.F. Garcia-Fernández, M. Kelly, M.T. Hamann, Batzelladine
alkaloids from the Caribbean sponge Monanchora unguifera and the signiﬁcant activities against HIV-1 and AIDS opportunistics infections
pathogens, Tetrahedron 63 (2007) 11179e11188.
[37] S. Takishima, A. Ishiyama, M. Iwatsuki, K. Otoguro, H. Yamada, S. Omura, H. Kobayashi, R.W. Van Soest, S. Matsunaga, Merobatzelladines
A and B, anti-infective tricyclic guanidines from a marine sponge Monanchora sp, Org. Lett. 11 (2009) 2655e2658.
[38] T.M. Souza, J.L. Abrantes, R. Epifanio, C.F. Leite Fontes, I.C. Frugulhetti, The alkaloid 4-methylaaptamine isolated from the sponge Aaptos
aaptos impairs herpes simplex virus type 1 penetration and immediate-early protein synthesis, Planta Med. 73 (2007) 200e205.
[39] K.H. Jang, S.C. Chung, J. Shin, S.H. Lee, T.I. Kim, H.S. Lee, K.B. Oh, Aaptamines as sortase A inhibitors from the tropical sponge Aaptos aaptos,
Bioorg. Med. Chem. Lett 17 (2007-b) 5366e5369.
[40] B. Bao, Q. Sun, X. Yao, J. Hong, C.O. Lee, H.Y. Cho, J.H. Jung, Bisindole alkaloids of the topsentin and hamacanthin classes from a marine
sponge Spongosorites sp, J. Nat. Prod. 70 (2007) 2e8.
[41] S. Ren, W. Ma, T. Xu, X. Lin, H. Yin, B. Yang, X.F. Zhou, X.W. Yang, L. Long, K.J. Lee, Q. Gao, Y. Liu, Two novel alkaloids from the South
China Sea marine sponge Dysidea sp, J. Antibiot. 63 (2010) 699e701.
[42] H.S. Lee, K.M. Yoon, Y.R. Han, R.J. Lee, S.C. Chung, T.I. Kim, S.H. Lee, J. Shin, K.B. Oh, 5-hydroxyindole-type alkaloids as Candida albicans
isocitrate lyase inhibitors, from the tropical sponge Hyrtios, Bioorg. Med. Chem. Lett 19 (2009) 1051e1053.
[43] S. Mo, A. Krunic, B.D. Santarsiero, S.G. Franzblau, J. Orjala, Hapalindole-related alkaloids from the cultured cyanobacterium Fischerella
ambigua, Phytochemistry 71 (2010) 2116e2123. Wang W, Wang Y, Tao H, Peng X, Liu P, Zhu W., Cerebrosides of the halotolerant fungus
Alternaria raphani isolated from a sea salt ﬁeld. J. Nat. Prod.; (2009) 72:1695-1698.
[44] W. Wang, Y. Wang, H. Tao, X. Peng, P. Liu, W. Zhu, Cerebrosides of the halotolerant fungus Alternaria raphani isolated from a sea salt ﬁeld,
J. Nat. Prod. 72 (2009) 1695e1698.
[45] C. Hohmann, K. Schneider, C. Bruntner, E. Irran, G. Nicholson, A.T. Bull, A.L. Jones, R. Brown, J.E. Stach, M. Goodfellow, W. Bell, M. Kramer,
J.F. Imhoff, R.D. Süssmuth, H.P. Fiedler, Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces
sp. NTK937, J. Antibiot. 62 (2009) 99e104.
[46] A. Otero-González, B. Simas, M. García-Villamarin, C. López-Abarrategui, D. Amaro, S. Campos, O. Luiz, Antimicrobial peptides from marine
invertebrates as a new frontier for microbial infection control, FASEB J. 24 (2010) 1320e1334.
[47] G.S. Andavan, R. Lemmens-Gruber, Cyclodepsipeptides from marine sponges: natural agents for drug research, Mar. Drugs 8 (2010)
810e834.
[48] A. Plaza, E. Gustchina, H.L. Baker, M. Kelly, C.A. Bewley, Mirabamides A-D, depsipeptides from the sponge Siliquariaspongia mirabilis that
inhibit HIV-1 fusion, J. Nat. Prod. 70 (2007) 1753e1760.
[49] M.Y. Kim, J.H. Sohn, J.S. Ahn, H. Oh, Alternaramide, a cyclic depsipeptide from the marine-derived fungus Alternaria sp., SF5016, J. Nat. Prod.
72 (2009) 2065e2068.
[50] A. Zampella, V. Sepe, P. Luciano, F. Bellotta, M.C. Monti, M.V. D’Auria, T. Jepsen, S. Petek, M.T. Adeline, O. Laprevote, A.M. Aubertin,
C. Debitus, C. Poupat, A. Ahond, Homophymine A, an anti-HIV cyclodepsipeptide from the sponge Homophymia sp, J. Org. Chem. 73 (2008)
5319e5327.
[51] S.R. Ibrahim, C.C. Min, F. Teuscher, R. Ebel, C. Kakoschke, W. Lin, V. Wray, R. Edrada-Ebel, P. Proksch, Callyaerins A-F and H, new cytotoxic
cyclic peptides from the Indionesian marine sponge Callyspongia aerizusa, Bioorg. Med. Chem. 18 (2010) 4947e4956.
[52] S. Nishimura, Y. Arita, M. Honda, K. Iwamoto, A. Matsuyama, A. Shirai, H. Kawasaki, H. Kabega, T. Kobayashi, S. Matsunaga, M. Yoshida,
Marine antifungal theonellamides target 3b-hydroxysterol to activate Rho1 signalling, Nat. Chem. Biol. 6 (2010) 519e526.

270 PART | II Bio-functional leads for drug development

[53] P. Pruksakorn, M. Arai, N. Kotoku, C. Vilcheze, A.D. Baughn, P. Moodley, W.R.J. Jacobs, M. Kobayashi, Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp. are active against dormant mycobacteria, Bioorg. Med. Chem. Lett. 2010 20 (2008)
3658e3663.
[54] J. Zheng, H. Zhu, K. Hong, Y. Wang, P. Liu, X. Wang, X. Peng, W. Zhu, Novel cyclic hexapeptides from marine-derived fungus Aspergillus
sclerotiorum PT06-1, Org. Lett. 11 (2009) 5262e5265.
[55] J. Zheng, Z. Xu, Y. Wang, K. Hong, P. Liu, W. Zhu, Cyclic tripeptides from the halotolerant fungus Aspergillus sclerotiorum PT06-1, J. Nat. Prod.
73 (6) (2010) 1133e1137.
[56] D.J. Zhang, R.F. Liu, Y.G. Li, L.M. Tao, L. Tian, Two new antifungal cyclic lipopeptides from Bacillus marinus B-9987, Chem. Pharm. Bull.
(Tokyo) 58 (12) (2010) 1630e1634.
[57] L. Chen, N. Wang, X. Wang, J. Hu, S. Wang, Characterization of two anti-fungal lipopeptides produced by Bacillus amyloliquefaciens SH-B10,
Bioresour. Technol. 101 (2010) 8822e8827.
[58] K. Desjardine, A. Pereira, H. Wright, T. Matainahu, M. Kelly, R.J. Andersen, Tauramamide, a lipopeptide antibiotic produced in culture by
Brevibacillus laterosporus isolated from a marine habitat: structure elucidation and synthesis, J. Nat. Prod. 70 (2007) 1850e1853.
[59] K. Engelhardt, K.F. Degnes, M. Kemmler, H. Bredholt, E. Fjaervik, G. Klinkenberg, H. Sletta, T.E. Ellingsen, S.B. Zotcheu, Production of a new
thiopeptide antibiotic, TP-1161, by a marine Nocardiopsis species, Appl. Environ. Microbiol. 76 (2010) 4966e4976.
[60] N. Oku, K. Kawabata, K. Adachi, A. Katsuta, Y. Shizura, Unnarmicine A and C, new antibacterial depsipeptides produced by marine bacterium
Photobacterium sp. MBIC06485, J. Antibiot. 61 (2008) 11e17.
[61] M. Ojika, Y. Inukai, Y. Kita, M. Hirato, T. Iizuka, R. Fudov, Miuraenamides: antimicrobial cyclic depsipeptides isolated from a rare and slightly
halophilic myxobacterium, Chem. Asian J. 3 (2008) 126e133.
[62] N. Oku, K. Adachi, S. Matsuda, H. Kasai, A. Takatsaki, Y. Shizuri, Ariakemicins A and B, novel polyketide-peptide antibiotics from a marine
gliding bacterium of the genus Rapidithrix, Org. Lett. 10 (2008) 2481e2484.
[63] M.E. Silva-Stenico, C. Souza, A. Sturion, T. Keiko, A. Etchegaray, S. Possedente, L.A. Beraldo, M. Fatima, Non-ribosomal peptides produced by
Brazilian cyanobacterial isolates with antimicrobial activity, Microbiol. Res. 166 (2011) 161e175.
[64] Z.Z. Ren, Y. Zheng, M. Sun, J.Z. Liu, Y.J. Wang, Puriﬁcation and properties of an antimicrobial substance from marine Brevibacillus laterosporus
Lh-1, Weishengwu Xuebao 47 (2007) 997e1001.
[65] B. Ernst, J.L. Magnani, From carbohydrate leads to glycomimetic drugs, Nat. Rev. Drug Discov. 8 (2009) 661e677.
[66] V.H. Pomin, Marine medicinal glycomics, Front. Cell. Infect. Microbiol. 4 (2014) 1e13.
[67] T.S. Vo, D.H. Ngo, Q.V. Ta, S.K. Kim, Marine organisms as a therapeutic source against herpes simplex virus infection, Eur. J. Pharm. Sci. 44
(2011) 11e20.
[68] H.K. Kang, C.H. Seo, Y. Park, The effects of marine carbohydrates and glycosylated compounds on human health, Int. J. Mol. Sci. 16 (2015)
6018e6056.
[69] K.I.P.J. Hidari, N. Takahashi, M. Arihara, M. Nagaoka, K. Morita, T. Suzuki, Structure and anti-dengue virus activity of sulfated polysaccharide
from a marine alga, Biochem. Biophys. Res. Commun. 376 (2008) 91e95.
[70] P.C.N. Chiu, H.Y. Tsang, H. Koistinen, M. Seppala, K.F. Lee, W.S.B. Yeung, The contribution of D-mannose, L-fucose, N-acetylglucosamine,
and selectin residues on the binding of glycodenlin isoforms to human spermatozoa, Biol. Reprod. 70 (2004) 1710e1719.
[71] J. Alpuchea, A. Pereyrab, C. Agundis, C. Rosasa, C. Pascuala, M.C. Slomiannyc, L. Vázquez, E. Zentenob, Puriﬁcation and characterization of a
lectin from the white shrimp Litopenaeus setiferus (Crustacea decapoda) hemolymph, Biochim. Biophys. Acta 1724 (2005) 86e93.
[72] K.K.A. Sanjeewa, J.S. Lee, W.S. Kim, Y.J. Jeon, The potential of brown-algae polysaccharides for the development of anticancer agents: an update
on anticancer effects reported for fucoidan and laminaran, Carbohydr. Polym. 177 (2017) 451e459.
[73] L.E. Rioux, S.L. Turgeon, M. Beaulieu, Structural characterization of laminaran and galactofucan extracted from the brown seaweed Saccharina
longicruris, Phytochemistry 71 (2010) 1586e1595.
[74] S.U. Kadam, B.K. Tiwari, C.P. O’Donnell, Extraction, structure and biofunctional activities of laminarin from brown algae, Int. J. Food Sci.
Technol. 50 (2015) 24e31.
[75] S.H. Lee, C.I. Ko, G. Ahn, S. You, J.S. Kim, M.S. Heu, J. Kim, Y. Jee, Y.J. Jeon, Molecular characteristics and anti-inﬂammatory activity of the
fucoidan extracted from Ecklonia cava, Carbohydr. Polym. 20 (2012) 599e606.
[76] A. Ahmadi, S. Zorofchian, S.Z. Moghadamtousi, S. Abubakar, K. Zandi, Antiviral potential of algae polysaccharides isolated from marine sources:
a review, BioMed Res. Int. (2015) 1e10.
[77] K.I. Draget, S.T. Moe, G. Skjak-Braek, O. Smidsrod, Alginates, in: A.M. Stephen, G.O. Phillips, P.A. Williams (Eds.), Food Polysaccharides and
Their Applications, second ed., Taylor and Francis Group Press, Boca Raton, FL, USA, 2006.
[78] C.H. Sarithakumari, G.L. Renju, G.M. Kurup, Anti-inﬂammatory and antioxidant potential of alginic acid isolated from the marine algae,
Sargassum wightii on adjuvant-induced arthritic rats, Inﬂammopharmacology 21 (2013) 261e268.
[79] Y. Endo, T. Aota, T. Tsukui, Antioxidant activity of alginic acid in minced pork meat, Food Sci. Technol. Res. 21 (2015) 875e878.
[80] H. Neetoo, M. Ye, H. Chen, Bioactive alginate coatings to control Listeria monocytogenes on cold-smoked salmon slices and ﬁllets, Int. J. Food
Microbiol. 136 (2010) 326e331.
[81] P. Karunanithi, M.R. Murali, S. Samuel, H.R.B. Raghavendran, A.A. Abbas, T. Kamarul, Three dimensional alginate-fucoidan composite hydrogel
augments the chondrogenic differentiation of mesenchymal stromal cells, Carbohydr. Polym. 147 (2016) 294e303.
[82] M.T. Alea, A.S. Meyer, Fucoidans from brown seaweeds: an update on structures, extraction techniques and use of enzymes as tools for structural
elucidation, RSC Adv. 3 (2013) 8131e8141.

Antimicrobial lead compounds from marine plants Chapter | 17

271

[83] M.S. Patankar, S. Oehninger, T. Barnett, R.L. Williams, G.F. Clark, A revised structure for fucoidan may explain some of its biological activities,
J. Biol. Chem. 268 (1993) 21770e21776.
[84] A.D. Holtkamp, S. Kelly, R. Ulber, S. Lang, Fucoidans and fucoidanasesdfocus on techniques for molecular structure elucidation and modiﬁcation of marine polysaccharides, Appl. Microbiol. Biotechnol. 82 (2009) 1e11.
[85] J.H. Fitton, D.N. Stringer, S.S. Karpiniec, Therapies from fucoidan: an update, Mar. Drugs 13 (2015) 5920e5946.
[86] J.H. Fitton, Therapies from fucoidan; Multifunctional marine polymers, Mar. Drugs 9 (2011) 1731e1760.
[87] T.T. Thuy, B.M. Ly, T.T. Van, N.V. Quang, H.C. Tu, Y. Zheng, C. Seguin-Devaux, B. Mi, U. Ai, Anti-HIV activity of fucoidans from three brown
seaweed species, Carbohydr. Polym. 115 (2015) 122e128.
[88] S. Rajeshkumar, Phytochemical constituents of fucoidan (Padina tetrastromatica) and its assisted AgNPs for enhanced antibacterial activity, IET
Nanobiotechnol. 3 (2017) 292e299.
[89] V.H. Pomin, Structural and functional insights into sulfated galactans: a systematic review, Glycoconj. J. 1 (2010) 1e12.
[90] V.L. Campo, D.F. Kawano, D.B. Silva Jr., I. Carvalho, Carrageenans: biological properties, chemical modiﬁcations and structural analysisda
review, Carbohydr. Polym. 77 (2009) 167e180.
[91] M.J. Cash, New iota carrageenan allows gelatin replacement, simpliﬁed manufacturing, and new textures for confectionary applications, in:
Proceedings of the Abstract of IFT Annual Meeting, Dallas, TX, USA, 2000, pp. 10e14.
[92] Y. Sun, B. Yang, Y. Wu, Y. Liu, X. Gu, H. Zhang, C. Wang, H. Cao, L. Huang, Z. Wang, Structural characterization and antioxidant activities of
k-carrageenan oligosaccharides degraded by different methods, Food Chem. 178 (2015) 311e318.
[93] V. Lucille Abad, L.S. Relleve, C.D.T. Racadio, C.T. Aranilla, A.M. De la Rosa, Antioxidant activity potential of gamma irradiated carrageenan,
Appl. Radiat. Isot. 79 (2013) 73e79.
[94] L.B. Talarico, E.B. Damonte, Interference in dengue virus adsorption and uncoating by carrageenans, Virology 363 (2007) 473e485.
[95] A. Leibbrandt, C. Meier, M. König-Schuster, R. Weinmüllner, D. Kalthoff, B. Pﬂugfelder, P. Graf, B. Frank-Gehrke, M. Beer, T. Fazekas, et al.,
Iota-carrageenan is a potent inhibitor of inﬂuenza a virus infection, PLoS One 5 (2010).
[96] Z. Luo, D. Tian, M. Zhou, W. Xiao, Y. Zhang, M. Li, B. Sui, W. Wang, H. Guan, H. Chen, et al., l-carrageenan P32 is a potent inhibitor of rabies
virus infection, PLoS One (2015) 10.
[97] H. Liu, M. Geng, X. Xin, F. Li, Z. Zhang, J. Li, J. Ding, Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated
polymannuronate (SPMG)-derived oligosaccharides, with gp 120 and their anti-HIV activities, Glycobiology (2005) 501e510.
[98] V.H. Pomin, B. Mulloy, Glycosaminoglycans and proteoglycans, Pharmaceuticals 11 (2018) 27.
[99] A.A. Vasconcelos, V.H. Pomin, The sea as a rich source of structurally unique glycosaminoglycans and mimetics, Microorganisms 5 (2017) 51.
[100] C.G. Panagos, D.S. Thomson, C. Moss, A.D. Hughes, M.S. Kelly, Y. Liu, W. Chai, R. Venkatasamy, D. Spina, C.P. Page, et al., Fucosylated
chondroitin sulfates from the body wall of the sea cucumber Holothuria forskali: conformation, selectin binding, and biological activity, J. Biol.
Chem. 289 (2014) 28284e28298.
[101] N. Huang, M.Y. Wu, C.B. Zheng, L. Zhu, J.H. Zhao, Y.T. Zheng, The depolymerized fucosylated chondroitin sulfate from sea cucumber potently
inhibits HIV replication via interfering with virus entry, Carbohydr. Res. 380 (2013) 64e69.
[102] H. Hoshino, M. Heiwamachi, Anti-Hiv Drug, 1991. European Patent EP 0410002A1.
[103] J. Kumirska, M. Czerwicka, Z. Kaczynski, A. Bychowska, K. Brzozowski, J. Thöming, P. Stepnowski, Application of spectroscopic methods for
structural analysis of chitin and chitosan, Mar. Drugs 8 (2010) 1567e1636.
[104] H. Liu, W. Tian, B. Li, G. Wu, M. Ibrahim, Z. Tao, Y. Wang, G. Xie, H. Li, G. Sun, Antifungal effect and mechanism of chitosan against the rice
sheath blight pathogen, Rhizoctonia solani. Biotechnol. Lett. 34 (2012) 2291e2298.
[105] K. Divya, V. Smitha, M.S. Jisha, Antifungal, antioxidant and cytotoxic activities of chitosan nanoparticles and its use as an edible coating on
vegetables, Int. J. Biol. Macromol. 114 (2018) 572e577.
[106] K. Divya, S. Vijayan, T.K. George, M. Jisha, Antimicrobial properties of chitosan nanoparticles: mode of action and factors affecting activity,
Fibers Polym. 18 (2017) 221e230.
[107] O.S. Malyarenko, S.A. Dyshlovoy, A.A. Kicha, N.V. Ivanchina, T.V. Malyarenko, B. Carsten, V.A. Gunhild, V.A. Stonik, S.P. Ermakova, The
inhibitory activity of luzonicosides from the starﬁsh Echinaster luzonicus against human melanoma cells, Mar. Drugs 15 (2017) 227.
[108] D.L. Aminin, E.S. Menchinskaya, E.A. Pisliagin, A.S. Silchenko, S.A. Avilov, V.I. Kalinin, Anticancer activity of sea cucumber triterpene
glycosides, Mar. Drugs 13 (2015) 1202e1223.
[109] M.M. Garcia, M.J.E.C. van der Maarel, Floridoside production by the red microalga Galdieria sulphuraria under different conditions of growth and
osmotic stress, Amb. Express 6 (2016).
[110] V.I. Kalinin, N.V. Ivanchina, V.B. Krasokhin, T.N. Makarieva, V.A. Stonik, Glycosides from marine sponges (porifera, demospongiae): structures,
taxonomical distribution, biological activities and biological roles, Mar. Drugs 10 (2012) 1671e1710.
[111] C.Y. Liu, T.L. Hwang, M.-R. Lin, Y.H. Chen, Y.C. Chang, L.S. Fang, W.H. Wang, Y.C. Wu, P.J. Sung, A. Carijoside, A bioactive sterol glycoside
from an octocoral Carijoa sp. (Clavulariidae), Mar. Drugs 8 (2010) 2014e2020.
[112] R. Kumar, R. Subramani, K.D. Feussner, W. Aalbersberg, K. Aurantoside, A new antifungal tetramic acid glycoside from a Fijian marine sponge of
the genus Melophlus, Mar. Drugs 10 (2012) 200e208.
[113] X.H. Wang, Z.R. Zou, Y.H. Yi, H. Han, L. Li, M.X. Pan, Variegatusides: new non-sulphated triterpene glycosides from the sea cucumber Stichopus variegatessemper, Mar. Drugs (4) (2014) 2004e2018.
[114] Glycoproteins, in: R.K. Murray, D.K. Granner, P.A. Mayes, V.W. Rodwell (Eds.), Harper’s Illustrated Biochemistry, 26th ed, McGraw-Hill
Companies, New York, NY, USA, 2003.

272 PART | II Bio-functional leads for drug development

[115] J. Mu, M. Hirayama, Y. Sato, K. Morimoto, K. Hori, A novel high-mannose speciﬁc lectin from the green alga Halimeda renschii exhibits a potent
anti-inﬂuenza virus activity through high-afﬁnity binding to the viral hemagglutinin, Mar. Drugs 15 (2017) 255.
[116] W.M.N. Ratnayake, C. Galli, Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper,
Ann. Nutr. Metab. 55 (2009) 8e43.
[117] H. Che, L. Du, P. Cong, S. Tao, N. Ding, F. Wu, C. Xue, J. Xu, Y. Wang, Cerebrosides from sea cucumber protect against oxidative stress in
SAMP8 mice and PC12 cells, J. Med. Food 20 (2017) 392e402.
[118] B. Kalisch, P. Dörmann, G. Hölzl, DGDG and glycolipids in plants and algae, Subcell. Biochem. 86 (2016) 51e83.
[119] W. Zhu, L.C. Chiu, V.E. Ooi, P.K. Chan, P.O. Ang Jr., Antiviral property and mechanisms of a sulphated polysaccharide from the brown alga
Sargassum patens against Herpes simplex virus type 1, Phytomedicine 13 (9e10) (2006) 695e701.
[120] N.L. Segraves, P.A. Crews, Madagascar sponge Batzella sp. as a source of alkylated iminosugars, J. Nat. Prod. 68 (2005) 118e121.
[121] A.N.E. Birch, W.M. Robertson, I.E. Geoghegan, W.J. McGavin, T.J.W. Alphey, M.S. Phillips, L.E. Fellows, A.A. Watson, M.S.J. Simmonds,
E.A. Porter, Dmdpda plant-derived sugar analogue with systemic activity against plant parasitic nematodes, Nematologica 39 (1993) 521e535.
[122] J. Chang, L. Wang, D. Ma, X. Qu, H. Guo, X. Xu, P.M. Mason, N. Bourne, R. Moriarty, B. Gu, et al., Novel imino sugar derivatives demonstrate
potent antiviral activity against ﬂaviviruses, Antimicrob. Agents Chemother. 53 (2009) 1501e1508.
[123] F. Jüttner, H.P. Wessel, Isolation of di (hydroxymethyl) dihydroxypyrrolidine from the cyanobacterial genus Cylindrospermum that effectively
inhibits digestive glucosidases of aquatic insects and crustacean grazers, J. Phycol. 39 (2003) 26e32.
[124] A.C. Sayce, D.S. Alonzi, S.S. Killingbeck, B.E. Tyrrell, M.L. Hill, A.T. Caputo, R. Iwaki, K. Kinami, D. Ide, J.L. Kiappes, Iminosugars inhibit
dengue virus production via inhibition of ER alpha-glucosidases-not glycolipid processing enzymes, PLoS Neglected Trop. Dis. (2016) 10.
[125] M.D. Tianero, N. Hanif, N.J. De Woogd, R.W. Van Soest, J. Tanaka, New antimicrobial fatty acids from the calcareous sponge Paragrantia cf,
Waguensis. Chem. Biodivers. 6 (2009) 1374e1377.
[126] M. Taniguchi, Y. Uchio, K. Yasumoto, T. Kusumi, T. Ooi, Brominated unsaturated fatty acids from marine sponge collected in Papua New Guinea,
Chem. Pharm. Bull. 56 (2008) 378e382.
[127] J.L. Keffer, A. Plaza, C.A. Bewley, Motualevic acids A-F, antimicrobial acids from the sponge Siliquariaspongia, Org. Lett. 11 (2009)
1087e1090.
[128] A.P. Desbois, T. Lebl, L. Yan, V.J. Smith, Isolation and structural characterization of two antibacterial free fatty acids from the marine diatom
Phaeodactylum tricornutun, Appl. Microbiol. Biotechnol. 81 (2008) 755e764.
[129] A.P. Desbois, A. Meams-Spragg, V.J. Smith, A fatty acid from the diatom Phaeodactylum tricornutum is antibacterial against diverse bacteria
including multi-resistant Staphylococcus aureus (MRSA), Mar. Biotechnol. 11 (2009) 45e52.
[130] Y. Zhang, S. Wang, X.M. Li, C.M. Cui, C. Feng, B.G. Wang, New sphingolipids with a previously unreported 9-methyl-C20-sphingosine moiety
from a marine algous endophytic fungus Aspergillus Niger EN-13, Lipids 42 (8) (2007) 759e764.
[131] Z.J. Wu, M.A. Ouyang, Q.W. Tan, New asperxanthone and asperbiphenyl from the marine fungus Aspergillus sp, Pest.Manag. 65 (2009) 60e65.
[132] A. Longeon, B.R. Copp, M. Rove, J. Dubois, A. Valentin, S. Petek, C. Debitus, M.L. Bourguet-Kondracki, New bioactive halenaquinone derivatives from South Paciﬁc marine sponges of the genus Xestospongia, Bioorg. Med. Chem. 18 (2010) 6006e6011.
[133] A.E. Wright, J.C. Boterho, E. Guzmán, D. Harmody, P. Linley, P.J. McCarthy, T.P. Pitts, S.A. Pomponi, J.K. Reed, Neopeltolide, a macrolide from
a lithistid sponge of the family Neopeltidae, J. Nat. Prod. 70 (2007) 412e416.
[134] F. Song, H. Dai, Y. Tong, B. Ren, C. Chen, N. Sun, X. Liu, J. Bian, M. Liu, H. Gao, H. Liu, X. Chen, L. Zhang, Trichodermaketones A-D and 7-Omethilkoninginin D from the marine fungus Trichoderma koningii, J. Nat. Prod. 73 (2010) 806e810.
[135] L.W. Xie, Y.C. Ouyang, K. Zon, G.H. Wang, M.J. Chen, H.M. Sun, S.K. Dai, X. Li, Isolation and difference in antiStaphylococcus aureus
bioactivity of curvularin derivates from fungus Eupenicillum sp, Appl. Biochem. Biotechnol. 159 (2009) 284e293.
[136] K. Trisuwan, V. Rukachaisirikul, Y. Sukpondma, S. Phongaichit, S. Preedanon, J. Sakayaroj, Lactone derivatives from the marine-derived fungus
Penicillium sp, PSU-F44. Chem. Pharm. Bull. 57 (2009 a) 1100e1102.
[137] K. Trisuwan, V. Rukachaisirikul, Y. Sukpondma, S. Preesanon, S. Phongpaichit, J. Sakayaroj, Pyrone derivatives from the marine-derived fungus
Nigrospora sp, PSU-F18. Phytochemistry 70 (2009 b) 554e557.
[138] N. Ruocco, S. Costantini, S. Guariniello, M. Costantini, Polysaccharides from the marine environment with pharmacological, Cosmeceutical and
Nutraceutical Potential , Molecules 21 (2016) 551.
[139] K. Kanekiyo, K. Hayashi, H. Takenaka, J.B. Lee, T. Hayashi, Anti-herpes simplex virus target of an acidic polysaccharide, nostoﬂan, from the
edible blue-green alga Nostoc ﬂagelliforme, Biol. Pharm. Bull. 30 (2007) 1573e1575.
[140] Y. Sato, S. Okuyama, K. Hori, Primary structure and carbohydrate binding speciﬁcity of a potent anti-HIV lectin isolated from the ﬁlamentous
cyanobacterium Oscillatoria agardhii, J. Biol. Chem. 282 (2007) 11021e11029.
[141] Y. Han, B. Yang, F. Zhang, X. Miao, Z. Li, Characterization of antifungal chitinase from marine Streptomyces sp. associated with South China sea
sponge Craniella australiensis, Mar. Biotechnol. 11 (2009) 132e140.
[142] D.M. Shridhar, G.B. Mahajan, V.P. Kamat, C.G. Naik, R.R. Parab, N.R. Thakur, P.D. Mishra, Antibacterial activity of 2-(2’, 4’- dibromophenoxy)4,6-dibromophenol from Dysidea granulosa, Mar. Drugs 7 (2009) 464e471.
[143] K.B. Oh, J.H. Lee, S.C. Chung, J. Shin, H.J. Shin, H.K. Kim, H.S. Lee, Antimicrobial activities of the bromophenols from the red alga Odonthalia
corymbifera and some synthetic derivatives, Bioorg. Med. Chem. Lett 18 (2008) 104e108.
[144] D. Feher, R. Barlow, J. McAtee, T.K. Hemscheidt, Highly brominated antimicrobial metabolites from a marine Pseudoalteromonas sp, J. Nat.
Prod. 73 (2010) 1963e1966.

Antimicrobial lead compounds from marine plants Chapter | 17

273

[145] A. Isnansetyo, Y. Kamei, Anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of MC21-B, an antibacterial compound produced by
the marine bacterium Pseudoalteromonas phenolica O-BC30T, Int. J. Antimicrob. Agents 34 (2009) 131e135.
[146] G. Hayashida-Soiza, A. Uchida, N. Mori, Y. Kuwahara, Y. Ishida, Puriﬁcation and characterization of antibacterial substances produced by a
marine bacterium Pseudoalteromonas haloplanktis strain, J. Appl. Microbiol. 105 (2008) 1672e1677.
[147] Y.M.1 Lee, M.J. Kim, H. Li, P. Zhang, B. Bao, K.J. Lee, J.H. Jung, Marine-derived Aspergillus species as a source of bioactive secondary
metabolites, Mar. Biotechnol. 15 (5) (2013) 499e519.
[148] J. Xu, T. Nakazawa, K. Ukai, H. Kobayashi, R.E.P. Mangindan, D.S. Wewenkang, H. Rotinsulu, M. Namikoshi, Tetrahydrobostrycin and
1-deoxytetrahydrobostrycin, two new hexahydroanthrone derivatives, from a marine-derived fungus Aspergillus sp, J. Antibiot. 61 (7) (2008)
415e419.
[149] A.A. El Beih, T. Kawabata, K. Koimaru, T. Ohta, S. Tsukamoto, Monodictyoquinone A: a new antimicrobial anthraquinone from a sea
urchin-derived fungus Monodictys sp, Chem. Pharm. Bull. 55 (2007) 1097e1098.
[150] M.M. El Gendy, U.W. Hawas, M. Jaspars, Novel bioactive metabolites from a marine derived bacterium Nocardia sp. ALAA2000, J. Antiobiot. 61
(2008) 379e386.
[151] E.H. Andrianasol, L. Haramaty, R. Rosario-Passapera, K. Bidle, E. White, C. Vetrioni, P. Falkowski, R. Lutz, Ammoniﬁcins A and B,
hydroxyethyleneamine chroman derivatives from a cultured marine hydrothermal vent bacterium Thermovibrio ammoniﬁcans, J. Nat. Prod. 72
(2009) 1216e1219.
[152] I. Wijesekara, D.Y. Yoon, S.K. Kim, Phlorotannins from Ecklonia cava (Phaephyceae): biological activities and potential health beneﬁts,
Biofactors 36 (2010) 408e414.
[153] K. Kanoh, K. Adachi, S. Matsuda, Y. Shizuri, K. Yasumoto, T. Kusumi, K. Okumura, T. Kirikae, New sulfoalkylresorcinol from marine-derived
fungus Zygosporium sp. KNC52, J. Antibiot. 61 (2008) 192e194.
[154] N.V. Ivanchina, A.A. Kicha, V.A. Stonik, Steroid glycosides from marine organisms, Steroids 76 (2011) 425e454.
[155] C. Boonlarppradab, D.J. Faulkner, Eurysterols A and B, cytotoxic and antifungal steroidal sulfates from a marine sponge of the genus Euryspongia,
J. Nat. Prod. 70 (2007) 846e848.
[156] J.A. Digirolamo, X.C. Li, M.R. Jacob, A.M. Clark, D. Ferreira, Reversal of ﬂuconazole resistance by sulphated sterols from the marine sponge
Topsentia sp, J. Nat. Prod. 72 (2009) 1524e1528.
[157] W. Zhang, S. Draeger, B. Schulz, K. Krohn, Ring B aromatic steroids from an endophytic fungus Colletotrichum sp, Nat. Prod. Commun. 4 (2009)
1449e1454.
[158] V. Subramanian, Coastal Environments: Focus on Asian Coastal Regions, Springer Science & Business Media, 2012, p. 226, p. 226.
[159] P. Amade, C. Charroin, C. Baby, J. Vacelot, Antimicrobial activities of marine sponges from the Mediterranean Sea, Mar. Biol. 24 (1987).

[160] T. Turk, J. Ambrozic Avgustin, U. Batista, G. Strugar, R. Kosmina, S. Civovi
c, D. Janussen, S. Kauferstein, D. Mebs, K. Sepcic, Biological
activities of ethanolic extracts from deep-sea antarctic marine sponges, Mar. Drugs 11 (2013) 1126e1139.
[161] Y.R. Torres, R.G. Berlink, G.G. Nascimento, S.C. Fortier, C. Pessoa, M.O. de Moraes, Antibacterial activity against resistant bacteria and
cytotoxicity of four alkaloid toxins isolated from the marine sponge Arenosclera brasiliensis, Toxicon 40 (2002) 885e891.
[162] R.M. Moura, A.F. Queiroz, J.M. Fook, A.S. Dias, N.K. Monteiro, J.K. Ribeiro, G.E. Moura, L.L. Macedo, E.A. Santos, M.P. Sales, CvL, a lectin
from the marine sponge Cliona varians: isolation, characterization and its effects on pathogenic bacteria and Leishmania promastigotes, Comp.
Biochem. Physiol., Part A Mol Integr Physiol. 145 (2006) 517e523.
[163] R.K. Pettit, B.R. Fakoury, J.C. Knight, C.A. Weber, G.R. Pettit, G.D. Cage, S. Pon, Antibacterial activity of the marine sponge constituent
cribrostatin 6, J. Med. Microbiol. 53 (2004) 61e65.
[164] B.K. Rubio, R.W. van Soest, P. Crews, Extending the record of meroditerpenes from Cacospongia marine sponges, J. Nat. Prod. 70 (2007)
628e631.
[165] H. Gaspar, S. Santos, M. Carbone, A.S. Rodrigues, A.I. Rodrigues, M.J. Uriz, S.M. Savluchinske Feio, D. Melck, M. Humanes, M. Gavagnin,
Isomeric furanosesquiterpenes from the Portuguese marine sponge Fasciospongia sp, J. Nat. Prod. 71 (2008) 2049e2052.
[166] D.L. Wiedbrauk, S.L.G. Johnston, Manual of Clinical Virology, Raven Press, New York, 1992.
[167] D.E. White, F.J. Fenner, Medical Virology, Academic Press, San Diego, 1986.
[168] J. Yasuhara-Bell, Y. Lu, Marine compounds and their antiviral activities, Antivir. Res. 86 (2010) 231e240.
[169] W.G. Muller, C. Sobel, B. Diehl-Seifert, A. Maidhof, H.C. Schroder, Inﬂuence of the antileukemic and anti-human immunodeﬁciency virus agent
avarol on selected immune responses in vitro and in vivo, Biochem. Pharmacol. 36 (1987) 1489e1494.
[170] S. Loya, A. Hizi, The inhibition of human immunodeﬁciency virus type 1 reverse transcriptase by avarol and avarone derivatives, FEBS Lett. 269
(1990) 131e134.
[171] P.W. Ford, K.R. Gustafson, T.C. McKee, N. Shigematsu, L.K. Maurizi, L.K. Pannell, D.E. Williams, E.D. De Silva, P. Lassota, T.M. Alien,
R. Van Soest, R.J. Andersen, M.R. Boyd, Papuamides AeD, HIV-inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and
Theonella swinhoei collected in Papua New Guinea, J. Am. Chem. Soc. 121 (1999) 5899e5909.
[172] D.J. Faulkner, Marine natural products, Nat. Prod. Rep. 19 (2002) 1e48.
[173] A. Qureshi, D.J. Faulkner, Haplosamates A and B: new steroidal sulfamate esters from two haplosclerid sponges, Tetrahedron 55 (1999)
8323e8330.
[174] A. Cutignano, G. Bifulco, I. Bruno, A. Casapullo, L. Gomez-Paloma, R. Riccio, F. Dragmacidin, A new antiviral bromoindole alkaloid from the
mediterranean sponge Halicortex sp, Tetrahedron 56 (2000) 3743e3748.

274 PART | II Bio-functional leads for drug development

[175] K.D. Wellington, R.C. Cambie, P.S. Rutledge, P.R. Bergquist, Chemistry of sponges. 19. Novel bioactive metabolites from hamigeratarangaensis,
J. Nat. Prod. 63 (2000) 79e85.
[176] N.B. Perry, J.W. Blunt, M.H.G. Munro, A.M. Thompson, Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and
solution conformations of mycalamides A and B, J. Org. Chem. 55 (1990) 223e227.
[177] W. Bergmann, A.N. Swift, Contributions to the study of marine products. XXX. Component acids of lipids sponges. I, J. Org. Chem. 16 (1951)
1206e1221.
[178] S. Sagar, M. Kaur, K.P. Minneman, Antiviral lead compounds from marine sponges, Mar. Drugs 8 (2010) 2619e2638.
[179] J.C. García-Ruiz, E. Amutio, J. Pontón, Invasive fungal infection in immunocompromised patients, Rev. Iberoam. De. Micol. 21 (2004) 55e62.
[180] T.M. Zabriskie, J.A. Klocke, C.M. Ireland, A.H. Marcus, T.F. Molinski, D.J. Faulkner, C. Xu, J.C. Clardy, Jaspamide, a modiﬁed peptide from a
Jaspis sponge, with insecticidal and antifungal activity, J. Am. Chem. Soc. 108 (1986) 3123e3124.
[181] D.C. Dunbar, J.M. Rimoldi, A.M. Clark, M. Kelly, M.T. Hamann, Anti-cryptococcal and nitric oxide synthase inhibitory imidazole alkaloids from
the calcareous sponge Leucetta cf chagosensis, Tetrahedron 56 (2000) 8795e8798.
[182] K.B. Oh, W. Mar, S. Kim, J.Y. Kim, T.H. Lee, J.G. Kim, D. Shin, C.J. Sim, J. Shin, Antimicrobial activity and cytotoxicity of bis (indole) alkaloids
from the sponge Spongosorites sp, Biol. Pharm. Bull. 29 (2006) 570e573.
[183] A. Vik, E. Hedner, C. Charnock, L.W. Tangen, O. Samuelsen, R. Larsson, L. Bohlin, L.L. Gundersen, Antimicrobial and cytotoxic activity of
agelasine and agelasimine analogs, Bioorg. Med. Chem. 15 (2007) 4016e4037.
[184] G.M. Konig, A.D. Wright, C.K. Angerhofer, Novel potent antimalarial diterpene isocyanates, isothiocyanates, and isonitriles from the tropical
marine sponge Cymbastela hooperi, J. Org. Chem. 61 (1996) 3259e3267.
[185] M. Ambrosio, A. Guerriero, E. Deharo, C. Debitus, V. Munoz, F. Pietra, New types of potentially antimalarial agents: epidioxy-substituted
norditerpene and norsesterpenes from the marine sponge Diacarnuslevii, Helv. Chim. Acta 81 (1998) 1285e1292.
[186] E. Avilés, A.D. Rodríguez, A. Monamphilectine, A potent antimalarial b-lactam from marine sponge Hymeniacidon sp: isolation, structure,
semisynthesis, and bioactivity, Org. Lett. 12 (2010) 5290e5293.
[187] K.K. Ang, M.J. Holmes, U.A. Kara, Immunemediated parasite clearance in mice infected with Plasmodium berghei following treatment with
manzamine A, Parasitol. Res. 87 (2001) 715e721.
[188] H. Miyaoka, M. Shimomura, H. Kimura, Y. Yamada, H.S. Kim, Y. Wataya, Antimalarial activity of kalahinol A and new relative diterpenoids
from the Okinawan sponge, Acanthella sp, Tetrahedron 54 (1998) 13467e13474.
[189] M. Yousaf, K.A. El Sayed, K.V. Rao, C.W. Lim, J.F. Hu, M. Kelly, S.G. Franzblau, F. Zhang, O. Peraud, R.T. Hill, M.T. Hamann, 12,34Oxamanzamines, novel biocatalytic and natural products from rnanzamine producing Indo-Paciﬁc sponges, Tetrahedron 58 (2002) 7397e7402.
[190] D. Tasdemir, B. Topaloglu, R. Perozzo, R. Brun, R. O’Neill, N.M. Carballeira, X. Zhang, P.J. Tonge, A. Linden, P. Rüedi, Marine natural products
from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and
Escherichia coli, Bioorg. Med. Chem. 15 (2007) 6834e6845.
[191] R. Sakai, T. Higa, C.W. Jefford, G. Bernardinelli, A. Manzamin, A novel antitumor alkaloid from a sponge, J. Am. Chem. Soc. 108 (1986)
6404e6405.
[192] M.L. Bourguet-Kondracki, J.M. Kornprobst, Marine pharmacology: potentialities in the treatment of infectious diseases, osteoporosis and
alzheimer’s disease, Adv. Biochem. Eng. Biotechnol. 97 (2005) 105e131.
[193] G. Schwartsmann, Marine organisms and other novel natural sources of new cancer drugs, Ann. Oncol. 11 (2000) 235e243.
[194] W.E. Müller, H.C. Schröder, M. Wiens, S. Perovic-Ottstadt, R. Batel, I.M. Müller, Traditional and modern biomedical prospecting: Part II-the
beneﬁts, Evid Based Complement Alternat Med 1 (2004) 133e144.
[195] A. Choudhary, L.M. Naughton, I. Montánchez, D.W. Alan, I.D. Dobson, K.R. Dilip, Review current Status and future prospects of marine natural
products (MNPs) as antimicrobials, Mar. Drugs 15 (272) (2017) 1e42.

Chapter 18

Antibacterial lead compounds and their
targets for drug development
Ashutosh Gupta and Abhay K. Pandey
Department of Biochemistry, University of Allahabad, Allahabad, India

Chapter outline
18.1. Introduction
275
18.1.1. Characterization of good antibiotic
276
18.1.2. Criteria for choosing and validating a suitable
antibiotic target
276
18.1.3. Targets of major antibacterial drugs
277
18.1.4. Protein synthesis
277
18.1.4.1. DNA replication and repair
277
18.1.4.2. Aminoacyl t-RNA synthetases
278
18.1.4.3. Biosynthesis of cell wall
278
18.1.5. Potential targets (new possible antibacterial
targets)
278
18.1.5.1. Two-component signal transduction
systems
278
18.1.5.2. FtsAeFtsZ interaction
279
18.1.5.3. Chorismate biosynthesis
279
18.1.5.4. Isoprenoid biosynthesis
279
18.1.5.5. Fatty acid biosynthesis
280
18.1.6. Major groups of natural antimicrobial compounds 280
18.1.6.1. Phenolic compounds
280
18.1.6.2. Quinones
280
18.1.6.3. Stilbenoids
281

18.1.6.4. Flavonoids
18.1.6.5. Tannins
18.1.6.6. Coumarins
18.1.6.7. Terpenoids and essential oils
18.1.6.8. Alkaloids
18.1.6.9. Lectins and polypeptides
18.1.6.10. Other compounds
18.1.7. Recent FDA-approved antibacterial drugs
18.1.7.1. Bezlotoxumab
18.1.7.2. Ozenoxacin
18.1.7.3. Ceftazidime/avibactam
18.1.7.4. Vabomere
18.1.7.5. Ceftaroline
18.1.7.6. Ceftobiprole
18.1.7.7. Doripenem
18.1.7.8. Telithromycin
18.1.8. Antibacterial drugs on clinical trial
18.1.9. Future perspectives and conclusion
Acknowledgment
References

281
281
282
282
282
283
283
283
283
283
284
285
285
285
285
286
286
286
287
287

18.1 Introduction
Since antiquity, natural bioactive compounds have been a major source of drugs and protect against countless health
challenges affecting mankind. Herbs, microbes, and marine organisms produce wide variety of bioactive compounds,
which are beneﬁcial in drug preparation, lead structure, or raw materials as well [1]. The previously documented records on
Greek, Chinese, Roman, Egyptian, and Indian traditional medicine systems have described the plentiful aspects of
therapeutic plants and advice for use in the management of various abnormalities. Even in developing countries,
plant-based medicinal formulation are been passed verbally from generation to generation. It has been observed that nearly
14%e28% species of higher plants are used as medicine, while the remaining 72% are found to be suitable after following
up on ethnomedicinal use of their bioactive compounds. There are plentiful examples of natural antiinfective drugs [2].
Isoquinoline, heterocyclic aromatic alkaloidal drug isolated from Cephaelis ipecacuanha and other associated species,
has been used as amoebicidal agent along with hepatic abscesses treatment caused by Entamoeba histolytica infections.
Quinine occurs naturally in the bark of cinchona tree. Besides its sustained effectiveness in the management of malarial
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infection, it can also be used in nocturnal leg cramps medication. Presently, the commonly recommended drugs are quinine
analogs such as chloroquine.
It is validated that plant and their derivatives are present in or act as a suitable model for 50% Western drugs [3].
Various established drugs used in the current medicinal system were primarily used in crude form in traditional
therapeutic practices or for various other purposes that supported effectively beneﬁcial biological activity. The usual
beneﬁt of using plant-derived drugs is that they are comparatively safer than synthetic substitutes, providing thoughtful
medicinal advantages and more reasonable treatment. There are usually two major routes of drug discovery: the ﬁrst one
refers to the formation of completely new chemicals and analyzing them for a particular pharmacological interest.
The other method is to recognize the biological or chemical source and examine it for direct or indirect involvement in
the formation of new drug. The 19th century was stated as the golden era for the development of synthetic drugs.
A number of people became attentive toward synthetic drugs because of their rapid action and cost-effective bulk
production by industries. In the 1970s, around 75% of all standard medicines are either derived synthetically or as the
product of fermentation. Lastly, the enhanced number of occurrences of microbial resistance toward synthetic
formulations and microbe-derived antibiotics has turned the attention of scientists toward the traditional medicines,
especially herbal drugs or drugs of plant origin [4].

18.1.1 Characterization of good antibiotic
The antibiotic class that has been most successful in terms of medical utility is the b-lactam class followed by
ﬂuoroquinolones and the macrolides, with rifampicins, aminoglycosides, and tetracyclines, secure minor but an imperious
positions. Nearly all are derived naturally (even though their marketed forms are usually semisynthetic or fully synthetic),
but the ﬂuoroquinolones are synthetically prepared compound. Fluoroquinolones and b-lactams (bactericidal) are
pathologically the most potent drugs and are commercially available. Meanwhile, rest are the temporarily bactericidal
(aminoglycosides and rifampicins) or bacteriostatic (macrolides and tetracyclines). Their key targets are enzymes, which
are connected with essential cellular utilities, viz. dynamics of nucleic acid supercoiling in replication and transcription
(ﬂuoroquinolones), peptidoglycan synthesis (b-lactams), DNA to RNA transcription (rifampicin), and mRNA translation
for protein formation (macrolides, aminoglycosides, and tetracyclines). Besides this, each antibiotic class prevents one
major cellular activity; some drugs possess multiple molecular targets such as ﬂuoroquinolones interact with DNA
topoisomerase IV and DNA gyrase (two separate type II topoisomerases). From the above details, two major features arise.
Firstly, the antibiotics discontinue major metabolic pathways in bacteria. Secondly, the antibiotics are those molecules
which can be modiﬁed accordingly for more effective antibacterial properties and to gain good pharmacodynamic/pharmacokinetic attributes with least acceptable toxicity against a living being cells.

18.1.2 Criteria for choosing and validating a suitable antibiotic target
An enzyme should be a best suitable target for drug, as they played a major role in various biochemical processes or
pathways within bacterial cells. Several complementary methodologies have been used to identify genes coding for
important target functions in related pathogenic species. Genetics is the initial step to understand the necessity of particular
genes, commonly by inadvertent transposon mutagenesis or by constructing systematic knockouts for gene by gene.
Information of complementing gene essentiality is a useful tool for analysis of pathogen genome sequence to collect a list
of genes that are conserved between major pathogens. These targeted genes should be absent or expressively modiﬁed in
the human genome. The purpose is to identify novel and vital targets existing in most curious pathogens, whose prevention
will not cause any collateral harm to the human host. Additionally, there are numerous limitations and critical points to
investigate before restricting the search for ideal drug hits.
For instance, aminoglycosides, macrolides, and tetracyclines directly interact with the ribosome to avert synthesis of
protein. Although the resistance to these antibiotics, at the level of structural modiﬁcations in the ribosome, does not
suggest resistance against either of the others, it may be because of the different molecular targets. Indeed, various other
antibiotics also damage the ribosomal machinery at structurally different targets. The purpose is that when preparing a data
of active target sites, one should not remove those targets for which effective antibiotics already developed because there
may be some separate methods of preventing the functional entity. Hence, the major features which researchers want to
identify in a novel antibiotic target interaction are that it must prevent the bacterial growth, should be accessible in a bulk
amount of key bacterial pathogens, and should not be altered by previously using resistance mechanisms. The preconception to evade mammalian cell targets also comes with an important attention. Ribosome occurs in all cell types and its
large subunit is extremely conserved at both the organizational and operational levels. In authenticity, the ribosomal
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molecular machine is one of the key target sites that we know for natural antibiotics. Another effective target site selection
is the chance that resistance due to a target modiﬁcation should come with a noteworthy ﬁtness cost, but this is presently
challenging to forecast in advance.

18.1.3 Targets of major antibacterial drugs
To reveal the mechanism of antibiotics action and why they become less effective, there is a need to discuss the main
classes of target sites. There are commonly three identiﬁed targets for the major antibacterial drugs, namely bacterial
protein synthesis, cell wall biosynthesis, and DNA replication and repair.

18.1.4 Protein synthesis
The prokaryotic ribosomal RNA and associated protein machinery are much enough distinct from the analogous eukaryotic
machinery as there are various protein synthesis inhibitors, targeting separate steps in ribosome action along with desire
antibacterial activity. These encompass essential antibiotics like macrolides of the class erythromycin [5], the aminoglycosides [6] (streptomycin was an initial member of this class which was later displaced by synthetic alternative
kanamycin), and tetracyclines [7] (an aromatic polyketide biosynthetic pathways products) (Fig. 18.1). There are a number
of steps involved in protein assembly, viz. initiation, elongation, and termination by the ribosomal machinery that could be
prohibited by these drug and various other protein synthesis inhibitors. This diversity suggests that protein synthesis will
provide a multidimensional target for new antibiotics [8].

18.1.4.1 DNA replication and repair
The ﬂuoroquinolones (e.g., ciproﬂoxacin) (Fig. 18.2) are synthetic antibiotic that prevents bacterial proliferation by
preventing DNA gyrase activity [9]. This enzyme requires for an unwinding of DNA double-strand coiling that introduced
after each round of DNA replication. DNA topoisomerases are categorized into type I or II classes on the bases of their
mode of action. Bacterial DNA gyrases come under the type II topoisomerases and the transient break of both DNA strands
comprises the alterable attachment on the sliced DNA at the 50 ends to tyrosyl residues on each of the two GyrA subunits
[10]. Ciproﬂoxacin, a quinolone antibiotic, is a potent suppressor of DNA gyrase and proceed by creating a complex
structure with the enzyme and cleaved DNA that is covalently joined to the GyrA subunits. Type-II topoisomerase also acts
as an active target and perhaps the major one in Staphylococcus aureus infections [11]. In each of the three main targets,
namely cell wall synthesis, DNA replication, and protein biosynthesis, the antibiotics use differs biochemically between
prokaryotic and eukaryotic machinery to act speciﬁcally. New classes of antibiotic drug that may work on surplus and new
targets will have to show equivalent medicinal indices and efﬁciency to toxicity ratio to achieve regulatory and extensive
approval.
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FIGURE 18.1 Antibiotics comprises a vast range of natural product structures, demonstrated by tetracyclines, erythromycin (class of macrolides),
kanamycin (aminoglycosides), and linezolid (oxazolidinone). These drugs act on the 23S rRNA and related proteins in the peptidyl transferase center of
the ribosome to block steps in the elongation of the protein chain.
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FIGURE 18.2 The ﬂuoroquinolones, denoted by ciproﬂoxacin, destroy microbes by preventing DNA gyrase and the associated topoisomerase IV in the
midcatalytic cycle, by trapping a double-cleaved DNA intermediate.

18.1.4.2 Aminoacyl t-RNA synthetases
Just before the joining of polypeptides, amino acids make the association with particular t-RNA molecules. Nearly in all
organisms, each amino acid is transformed by a particular aminoacyl tRNA synthetase (E) to an aminoacyl adenylateenzyme complex (E-AA-AMP), which then make binding with an amino acidespeciﬁc t-RNA to generate an
aminoacyl t-RNA (AA-tRNA) molecule. AA-tRNA molecules are then arranged in a linear manner by forming a complex
with ribosome-bounded mRNA. Authentication of the aminoacyl tRNA synthetases as effective drug targets has been
supported by the discovery and advancement of mupirocin (pseudomonic acid), a suppressor of bacterial isoleucyl tRNA
synthetase (IRS) [12]. Several other AA-tRNA synthetases are crucial for microbial growth and feasibility and other
inhibitors of synthetase with antimicrobial action have been reported. Furthermore, most of them are deﬁcient in
prokaryotic speciﬁcity or having the least antibacterial property. This possibly reﬂects insufﬁcient uptake into bacteria,
which has resulted in chemical derivatization programmes to seek analogs with improved antibacterial potency.
Indolmycin was identiﬁed in 1960, which is now gaining attention as an effective antibacterial candidate [12,13]. As the
crystal forms of different AA-tRNA synthetases have now been understood, there are new prospects for structure-based
design of inhibitors against this enzymes family.

18.1.4.3 Biosynthesis of cell wall
The strength of bacterial cell wall is connected with the peptidoglycan, a web-like network of glycan and peptide strands
that can be interconnected covalently. The larger fragment of neighboring peptide strands is linked with amide bond and
the reaction is mediated by transpeptidases. Transglycosylases lengthen the sugar chains by adding new peptidoglycan
units from N-acetylglucosamine-b-1,4-N-acetylmuramyl-pentapeptide-pyrophosphoryl-undecaprenol (lipid II).
Bifunctional enzymes cover both the transpeptidase and transglycosylase domains that are the target sites for bacterial
assassination by b-lactam bearing cephalosporins and penicillins, which acylate transpeptidases active sites (also termed as
penicillin-binding proteins or PBPs) [14] and act as pseudo-substrates. The opened ring, penicilloylated transpeptidases,
gradually deacylated and thus occupied the active sites of enzyme, averting general peptide chains cross-linking with the
peptidoglycan layer and exit it instinctively weak and vulnerable to damage on alteration in osmotic pressure. Besides
cephalosporin and penicillin, the vancomycin family of glycopeptide antibiotics also targets the peptidoglycan layer.
Instead of targeting the enzymes functioning as cross-linking of peptide, vancomycin bind with peptide substrate [15] and
by doing so inhibit it from reacting with either transglycosylases or transpeptidases. The ﬁnal result is the same as
incapable in the formation of peptidoglycan cross-links, which leads to a fragile cell wall that predisposes the treated
bacteria to lysis. The cup-shaped structure of vancomycin antibiotic form ﬁve hydrogen bonds with D-Ala-D-Ala dipeptide
terminus of each uncross-linked peptidoglycan pentapeptide side chain, which is responsible for the high afﬁnity of
antibiotic for its target, both in lipid-II intermediate and in partially cross-linked walls. As vancomycin and b-lactams work
on contiguous manner as substrate and enzyme, they show interaction when used in combination.

18.1.5 Potential targets (new possible antibacterial targets)
18.1.5.1 Two-component signal transduction systems
Two-component signal transduction (TCST) system is ubiquitous in prokaryotes and naturally contains a histidine kinase
linked with membrane and a response regulator present in the cytoplasm. Microbes use this system to observe the changes
in the surrounding environment and acclimatize accordingly, and thus they can survive. Various TCST systems had been
recognized till the beginning of genomic era in which some had been worked in pathogenesis, and their efﬁcacy as novel
antibacterial targets was recommended. However, little information was known related to the number of different systems
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that occurred in a particular pathogen. Genomic sequencing disclosed the complete set of TCST systems in diverse
microbial species such as Helicobacter pylori, Haemophilus inﬂuenzae, Streptococcus pneumoniae, and S. aureus.
Detailed computational evaluation of these systems suggested that homology occurs between the TCST systems within
the same microbes and from microbes to microbes and that no human homologous exists. Additionally, the requirement of
the complete set of TCST systems in S. aureus and S. pneumoniae has been shown that several systems are needed for the
handling of infections [16,17]. Therefore, the search of a wide spectrum and the speciﬁc inhibitor of TCST systems would
compromise the microbe’s capability to acclimatize and survive in any type of surrounding atmosphere, thus forming a
striking antibacterial strategy. Till now, no targeted inhibitors of TCST systems have been prepared, but the future
accomplishment of this area is based on the design of physiologically relevant, high output relative to input assays for the
major systems. Genomics has emphasized TCST systems as a valid approach for novel antibiotic discovery.

18.1.5.2 FtsAeFtsZ interaction
Cell division is crucial and a critical process for the survival of microbes, yet it is perhaps one of the least fully disclosed
process. Cell division includes a protein to protein communication network that is essential for the development of
septum. FtsZ played a key role in this network as it forms a ring-shaped structure at the mid of the cell by the process
of polymerization, after that it added other proteins to the polymer to trigger the downstream actions in the cell division.
A number of evidence indicated that protein to protein interactions are crucial for cell feasibility and hence suitable
candidate as antibacterial targets, and FtsAeFtsZ protein interaction is one of them. In the last few years, extensive
efforts in this area had focused on the proteins associated with cell division in Escherichia coli. Study of the FtsA and
FtsZ proteins from diverse bacterial genomes has suggested that these are ubiquitously distributed and conserved
proteins, which are still studied to evaluate these proteins in Gram-positive pathogens. Arrangement of FtsZ sequences in
different pathogenic species indicates a conserved motif toward C-terminus end of protein, which might actively
participate in interacting with other proteins used in cell division. Site-directed mutagenesis of this section in S. aureus,
FtsZ recognized as a single important residue for interaction with FtsA in S. aureus [18]. This study revealed that the
interaction between FtsA and FtsZ might be relatively small and hence, the formation of small molecule antagonists may
be worthwhile during antibacterial approach. There are several other vital interactions necessary for cell division that
provides importance to the investigation, and the task will be to design an efﬁcient high-output screening procedure for
such types of interactions.

18.1.5.3 Chorismate biosynthesis
Chorismate biosynthetic pathway is necessary for the formation of p-aminobenzoic acid ubiquinone, aromatic amino acids,
enterochelin, and vitamin K. Mammals do not hold such type of pathway, and therefore, it is a selectively preferable
antibacterial target. It is well-known that bacteria cannot utilize the end product of this pathway from the host and that
product is crucial for bacteria to grow in vivo and sustain an infection. The necessity of the pathway has been described
predominantly in Gram-negative microbes, through which deletion or mutation in one of the genes responsible for
biosynthesis, such as 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, has been revealed to give rise to extremely
virulence-attenuated strains in vivo. Furthermore, earlier to the misuse of bacterial genomics, the vast mainstream of work
on the biosynthetic enzymes and investigational antimicrobial targeted at this pathway focused on E. coli. Still,
investigation of S. pneumoniae and S. aureus genomes has demonstrated the occurrence and maintenance of the genes
involves in chorismate biosynthetic in major Gram-positive pathogens. This has assisted in the identiﬁcation and speciﬁcity
testing of such type enzymes in Gram-positive pathogens. For instance, the deletion of the aroA gene, which codes for
EPSP synthase causes the strain to be entirely weakened for pathogenicity in two separate animal models with no
retrievable bacteria. S. pneumoniae EPSP synthase has been broadly categorized [19] and a vast output screening layout
has been designed. If the data obtained from this enzyme are illustrative of the other enzymes in the Gram-positive
pathway, then biosynthesis of chorismate delivers an additional source of wide spectrum antibacterial targets.

18.1.5.4 Isoprenoid biosynthesis
There are fundamentally two types of pathways through which biosynthesis of isopentenyl diphosphate (IPP) have been
deﬁned: the traditional ‘mevalonate’ pathway and the more recently recognized ‘nonmevalonate’ pathway, which does not
synthesize IPP with the help of mevalonate. The relative genomic investigation has recognized the whole set of mevalonate
pathway enzymes in Enterococci, Streptococci, and Staphylococci. The Gram-positive cocci forms of these genes are
extremely different from the mammalian equivalent, delivering rationale for the prospective selectivity of this target area.
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Additionally, genetic interruption investigations have shown that ﬁve of the six genes codes for the pathway are important
for the in vitro development of S. pneumoniae. Subsequently, this study has established a complete vital selective pathway
appropriate for antibacterial targets [20,21].

18.1.5.5 Fatty acid biosynthesis
In higher eukaryotic organisms, the biosynthesis of fatty acid is governed by a single polypeptide chain, while in case of
microorganisms, the pathway is mediated by various distinct enzymes. This difference in fatty acid biosynthesis makes
microbial pathway a selectively potential antimicrobial target. Before genomic analysis, much of the work related to this
pathway and the constituent enzymes was studied on E. coli [22]. Furthermore, extensive work in E. coli had revealed that
triclosan, diazaborine, thiolactomycin, and cerulenin destroy microbes via inactivation of few or more of the enzymes in
this pathway. This provides some earlier indication of the potential targets of this area for recognizing antibacterial agents.
Prior information to completely sequenced and proper assembled microbial genomes has permitted the characterization of
the constituent enzymes in a diversity of essential clinical pathogens, which delivers a clear investigation of the effective
spectrum of a speciﬁc enzyme [23]. For instance, FabK would be a suitable target for streptococcus, while the existence
of FabH in all the key RTI and Gram-positive pathogens makes this target suitable for broad-spectrum usefulness.
The efﬁcacy of the enzymes used in the biosynthesis of fatty acid as novel antibacterial targets has lately been validated
with FabI. High-throughput selection of this enzyme has provided two unique antibacterial targets. Both of these targets
prevented E. coli and S. aureus FabI enzymes. Advanced analysis of the imidazole leads to 16-fold enhancement in
antibacterial action and a ﬁve-time improvement in efﬁcacy against the enzymes [24]. Furthermore, strains with adjustable
expression levels of FabI have been used to track and validate that the mechanism of antibacterial action of these
compounds is required via prevention of FabI. These leads suggested the prospectivity of screening Fab enzymes to
discover new antibiotics for the future.

18.1.6 Major groups of natural antimicrobial compounds
18.1.6.1 Phenolic compounds
Phenolic compounds are the simplest known bioactive phytochemicals that consist of a benzene ring with single hydroxyl
group. Caffeic and cinnamic acids are key representatives of an inclusive collection of phenylpropane-derived compounds
that are in the maximum oxidation state, well-established to possess antimicrobial activities [25]. Both pyrogallol and
catechol are hydroxylated phenolic compounds supposed to be toxic against microbial agents. Augmented hydroxylation
of the phenolic group has been suggested to outcome in ampliﬁed toxicity toward microorganisms. The numbers and the
site(s) of hydroxyl (OH) groups on the phenolic group are assumed to be associated through their relative toxicity toward
microorganisms, with proof that high hydroxylation results in enhanced toxicity [26]. Consequently, in some cases, it has
been observed that highly oxidized phenolic compounds can act as an inhibitor [27]. Phenolics are thought to prevent
microbial enzymes maybe by reacting with sulfhydryl groups (the oxidized phenols) or by nonspeciﬁc associations with
the proteins [28]. Phenolic compounds having a side chain of three carbons at a lower oxidation level and comprising no
oxygen are categorized as essential oils and frequently mentioned as antimicrobial as well. Eugenol is a well-classiﬁed
compound isolated from clove oil (Fig. 18.3A). Eugenol is supposed to be a good bacteriostatic against both bacteria
and fungi [29,30].

18.1.6.2 Quinones
Cell wall polypeptides, adhesin molecules present in the cell surface, and membrane-bound enzymes are possible targets
for the quinones (Fig. 18.3C). It forms an irreversible complex with nucleophilic amino acids present in proteins [31],
therefore leading to protein denaturation and loss of its activity. Anthraquinones, one of the leading class of quinones, have
been revealed to possess antibacterial potential in Bacillus subtilis by inhibiting the synthesis nucleic acid [32,33]. Kazmi
and coworkers (1994) deﬁned anthraquinone as a compound isolated from Cassia italica, which possess bacteriostatic
activity against Pseudomonas aeruginosa, Bacillus anthracis, and Corynebacterium pseudodiphthericum, and bactericidal
activity against Pseudomonas pseudomallei. Hypericin, an anthraquinone derivative isolated from Hypericum perforatum,
has gained much attention because of antidepressant property [34], while Duke in 1985 described that it had antimicrobial
activity.
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FIGURE 18.3 Structure of antimicrobial compounds from plants. (A) phenol, (B) ﬂavonoid, (C) quinone, (D) stilbenoid, (E) alkaloid, (F) coumarin,
(G) terpenoid, (H) tannin.

18.1.6.3 Stilbenoids
Stilbenoids (Fig. 18.3D) are a separate class of phenolic compounds consisting C6eC2eC6 unit in their basic structures
and are further subclassiﬁed into stilbenes, phenanthrenes, bibenzyls, oligostilbenes, and bisbibenzyls. Phenanthrenes are
isolated biosynthetically from the stilbenes and bibenzyls. Stilbenes commonly occur as glycosides or aglycones, while
sometimes as polymers [35]. Various families of the higher plant are supposed to synthesize stilbenes. Bibenzyls and their
derivatives are rarely found in higher plants but present in some families, viz. Dioscoreaceae, Orchidaceae, and
Combretaceae, which are frequently present alongside the corresponding stilbene or phenanthrene derivates. Several
stilbenoids are explored for their antibacterial and antifungal attributes [36]. Eloff and coworkers (2005) have suggested
that Combretum woodii leaves contain rich amount of bibenzyl, combretastatin B5 compounds which possess good
antimicrobial activity [37].

18.1.6.4 Flavonoids
Flavonoids (Fig. 18.3B) are manufactured by herbs in response to microbial attack [38]. It has been observed that
ﬂavonoids possess antimicrobial activity against an extensive range of microorganisms during in vitro analysis, while some
are showing signiﬁcant activity against methicillin-resistant Staphylococcus aureus (MRSA) [39]. Their antimicrobial
potential has been recognized by the capability to form a complex with soluble proteins, extracellular components, and the
bacterial cell wall. Lipophilic ﬂavonoids may also be responsible for microbial membranes destruction [40]. There are
contradictory outcomes on the type of molecular alteration required by the ﬂavonoid in a direction to identify antimicrobial
potential. Some researcher has suggested that hydroxyl groups lacking ﬂavonoids on their b-rings are more dynamic
against microorganisms than those who comprise hydroxyl groups and this result supports the concept that microbial target
is generally membrane-speciﬁc [41]. Several other workers have yet also revealed the reversible activity; the more
hydroxyl groups, the greater antimicrobial activity [42]. The low toxic potential of ﬂavonoids makes them ideal as
antimicrobial medicines.

18.1.6.5 Tannins
Tannins (Fig. 18.3H) have gained attention in the last few years because of their demanding ability to treat a wide range of
infections and abnormalities [43]. Tannins are again subclassiﬁed into two major classes namely proanthocyanidins
(condensed tannins) and hydrolyzable tannins. Tannins have capability to form complex with proteins by nonspeciﬁc
bonding, viz. hydrophobic and hydrogen bonding and also with the help of covalent binding [31]. The antimicrobial
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activity of tannins may therefore be associated with their potential to denature microbial enzymes, adhesins, plasma
membrane transport proteins, etc. Because of their property to bind with metals and proteins, tannins also prevent the
growth of microbes through the deprivation of metal ion and substrate [27]. Hydrolyzable and condensed tannins have
been suggested to show similar antibacterial and antifungal potency, although the hydrolyzable tannins seemed to be more
signiﬁcant against yeasts. The occurrence of a hexahydroxydiphenoyl group or its oxidatively altered entities was an
essential factor for the anticryptococcal action of the ellagitannins corilagin, phyllanthusiin, and pelargoniin B [44]. The
hydroxylation pattern of monomeric ﬂavonols b-ring in condensed tannins has been found to alter the level of growth
inhibition of S. mutans and S. sobrinus, C. botulinum, Staphylococcus sp., and P. vulgaris, and in all cases, gallocatechins
were comparatively more potent inhibitor than that of their catechin counterparts [45e47]. It has also been recommended
that lethality of tannin would be associated with molecular size, as larger molecule would more efﬁciently bind to proteins.
While, in some cases the harmfulness of tannins was observed to be not greater than that of catechins [48], although
catechins have a less signiﬁcant binding afﬁnity toward proteins. Kakiuchi and co-workers [49] revealed that incorporation
of BSA in glucosyl transferase medium before addition of gallotannins failed to eliminate the prevention of enzyme by the
tannins and they proposed that prevention of the enzyme is not essentially because of the vague binding of tannins to it.
Zhu et al. [50] in their study found that some tannins suppressed ligand binding to particular receptors.

18.1.6.6 Coumarins
Coumarins (Fig. 18.3F) are also a class of phenolic compounds formed by the association of b-pyrone rings with benzene [51].
They are accountable for the speciﬁc odor of food. In in vitro analysis, coumarin was shown to prevent Candida albicans.
Hydroxycinnamic acids, linked to coumarins, possess inhibitory action against Gram-negative bacteria [52]. Furthermore,
phytoalexins, a hydroxylated derivative of coumarin synthesized in carrots in response to fungal contamination and can be
assumed to have antifungal property [53]. The common antimicrobial property was recognized in G. odoratum extracts [29].
Recently, Smyth and co-workers [54] revealed the antimicrobial potential of various naturally or synthetically
occurring coumarins with the help of microtitre assay against both Gram-positive and Gram-negative bacteria, along
with MRSA and outcomes indicated that the coumarins were displaying good bioactivity against clinically isolated MRSA
strains.

18.1.6.7 Terpenoids and essential oils
Terpenes are a major group of compounds accountable for the fragrance of herbs and encompass the essential oil fraction.
They are produced from isoprenoid units and share fatty acid origins. They are vary from fatty acids in term of having
cyclized and branched structure. Their common chemical formula is C10H16 and present in various forms, viz.
hemiterpenes (C5), sesquiterpenes (C15), diterpenes (C20), triterpenes (C30), and tetraterpenes (C40). When terpenes contain
additional elements, mostly oxygen, then it is termed as terpenoids (Fig. 18.3G). Some common examples of terpenoids are
camphor (monoterpenes), artemisinin, and farnesol (sesquiterpenoids). Terpenes and terpenoids have been shown to
possess antibacterial activity [55,56], fungi [57e59], protozoa [60], and viruses [61,62]. In 1977, it was stated that 60% of
the essential oil derivatives analyzed to date were prevented fungal growth, while 30% inhibits bacterial growth [63].
The molecular basis of terpenes activity is not completely known but is supposed to be involved in membrane disruption
by the lipophilic compounds. Mendoza et al. [64] suggested that increasing the hydrophilicity of kaurene diterpenoids by
addition of a methyl group signiﬁcantly suppressed their antimicrobial activity. Cichewicz and Thorpe [65] revealed that
capsaicin might trigger the growth of C. albicans but that it completely inhibited various bacteria to differing extents.
Batista and co-workers [66] extracted two diterpenes that were known to be more democratic; they worked well against
S. aureus, Vibrio cholerae, P. aeruginosa, and Candida sp.

18.1.6.8 Alkaloids
Alkaloids (Fig. 18.3E) are heterocyclic nitrogen containing a group of bioactive compounds. Morphine is the ﬁrst
therapeutically used natural alkaloid, extracted in the year 1805 from a ﬂower of Papaver somniferum. Diterpenoid
alkaloids are normally isolated from plants of the family Ranunculaceae [67] and are usually observed to have
antimicrobial properties [68]. A glycoalkaloid namely solamargine, derived from Solanum khasianum berries and other
alkaloids, may be beneﬁcial in the treatment of HIV infection [69,70], intestinal disorders linked with AIDS [71].
Szlavik et al. [72] revealed that lycorine, homolycorine, and acetyllycorine hemanthamine derived from Leucojum vernum
showed high antiretroviral actions with low medicinal indices, whereas drymaritin derived from Drymaria diandra had
anti-HIV property [73].
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18.1.6.9 Lectins and polypeptides
Peptides, which possess inhibitory property against microorganisms, were ﬁrst described by Balls and co-workers [74].
Such type of peptides is positively charged and having disulﬁde linkage. Their mechanism of action may be governed with
the ion channels in the microbial plasma membrane [75,76] or by competitive inhibition of host polysaccharide receptors
by preventing microbial proteins adhesion to it [77]. Recent attentiveness has been concentrated mainly on analysis of
lectins and anti-HIV peptides, but the prevention of fungi and bacteria by these macromolecules, such as that isolated from
the herbaceous Amaranthus sp., has been properly studied [78]. Thionin peptides usually found in wheat and barley and are
made up of 47 amino acid residues, reported to be lethal to yeasts, Gram-negative and Gram-positive bacteria [79]. Fabatin,
a recently recognized peptide of 47 residues from fava beans, seems to be structurally similar to g-thionins from grains and
prevents P. aeruginosa, E. coli, and Enterococcus hirae [76]. The bigger lectin molecules which comprise
mannose-speciﬁc lectins are found in variety of plants [80], MAP30 from jacalin [81], and bitter melon [82] and are shown
antiproliferative property in HIV and cytomegalovirus. It is possibly by inhibiting viral interaction with important
components of the host cell.

18.1.6.10 Other compounds
Various phytoconstituents not described above have been shown to possess antimicrobial activity. There are a number of
antimicrobial studies related to isothiocyanates [83,84], polyamines (in particular spermidine) [85], glucosides [86,87],
and thiosulﬁnates [88]. Estevez-Braun et al. [89] identiﬁed a polyacetylene compound (C17) from Bupleurum salicifolium,
a plant native to the Canary Islands. The compound 8S-heptadeca-2(Z), 9(Z)-diene-4,6-diyne-1,8-diol was an inhibitor of
B. subtilis and S. aureus but not to yeasts or Gram-negative bacteria. Flavonoids and acetylene compounds of plant origin
have been used in Brazilian traditional system of medicine for treatment of hepatic abnormalities, and malaria fever has
also been related to antimalarial activity [90]. Much has been reported about the antimicrobial potential of cranberry juice.
In view of history, females have been told to drink the juice for prevention and moreover to cure urinary tract infections.
In the early 1990s, researchers found that the monosaccharide fructose occurs in blueberry and cranberry juices strongly
suppressed the adsorption of pathogenic E. coli to epithelial cells of the urinary tract, performing as an analog of mannose.
Clinical analysis has disclosed the protective potential of cranberry juice. Fructose occur in numerous fruits, but researchers
still seek a new bioactive compound from cranberry juice which enhances the antimicrobial activity [91,92]. Table 18.1
summarizes the major class of phytochemicals, their sources, and possible antimicrobial mechanism.

18.1.7 Recent FDA-approved antibacterial drugs
18.1.7.1 Bezlotoxumab
Bezlotoxumab (trade name Zinplava) is a completely humanized monoclonal IgG1 antibody function against Clostridium
difﬁcile toxin-B [115]. Bezlotoxumab applies its activity by hindering the binding of toxin B with colonic cells and
simultaneously inhibiting the growth of C. difﬁcile infection [116]. In in vitro analysis, bezlotoxumab by deactivating the
toxin B diminishes proinﬂammatory responses and lessens damage to epithelial tissue of colonic explants [117,118]. It has
not exerted direct antimicrobial action on C. difﬁcile; it has low immunogenicity and is usually well tolerated. Recent data
revealed that it is also economical when administered together with standard antibiotics [119]. In October 2016, FDA
approved bezlotoxumab and was obtained based on randomized, double-blind, placebo-controlled, phase III clinical trials,
Modify I and II, which involved 2655 adults treated for primary or recurrent C. difﬁcile infection. During trials,
bezlotoxumab was linked with a smaller rate of repeated infection and had safety norms nearly the same to that of placebo
[120]. An additional monoclonal antibody, actoxumab was found to act against C. difﬁcile toxin A [121]. Advanced trials
did not show any signiﬁcant assistance in adding actoxumab with bezlotoxumab. However, the rates of continued cure
were lesser compared with bezlotoxumab alone.

18.1.7.2 Ozenoxacin
Ozenoxacin approved by the FDA in December 2017 for the topical treatment of impetigo caused by S. pyogenes or
S. aureus in adult and pediatric patients older than 2 months. It possess bactericidal property against vulnerable
microorganisms by prevention of enzymes used in bacterial DNA replication, topoisomerase IV, and DNA gyrase A [122].
After topical application, the majority of ozenoxacin plasma samples were below the limit of quantiﬁcation, suggesting
no systemic absorption. Thus, the distribution, metabolism, and excretion of ozenoxacin have not been investigated
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TABLE 18.1 Major classes of natural antimicrobial compounds from plants and their mechanism of action.
Class of
phytochemicals

Bioactive
compounds

Natural
sources

Possible mechanism of action

References

Alkaloid

Berberine, Piperine

Barberry

DNA binding, inhibition CDR1, induction fungal
apoptosis, intercalate cell wall

[93,94]

Carotenoid

Lycopene

Tomato

Membrane damage, induction fungal apoptosis

[95,96]

Polyphenol

Curcumin

Culinary

ROS, inhibition of morphogenetic switch and
biofilm formation, membrane pore formation

[97,98]

Resveratrol

Grape

Fungal apoptosis

[99]

Amentoflavone

Selaginella

Induction fungal apoptosis

[100]

Isoquercitirin

Starwart

Disruption of membrane

[101]

Cathechin

Green tea

Cell wall damage

[102]

Inactive enzymes, inhibit HIV reverse transcriptase

[103,104]

Flavonoid

Flavones

Abyssinone

Lectins and
polypeptides

Mannose-specific
agglutinin, fabatin

Helichrysum
aureonitens

Block viral fusion or adsorption, form disulfide
bridge

[76,105]

Quinones

Hypericin

Hypericum
perforatum

Bind to adhesion complex in cell wall

[106,107]

Saponin

Tomatine

Tomato

Disruption of membrane, induction fungal apoptosis

[100]

Tannins

Ellagitannin

Cocoa

Binds to adhesins, binds to proteins, enzyme
inhibition, substrate deprivation, membrane
disruption, form complex with cell wall

[108e110]

Terpenoid

Carvacrol

Oregano

Biofilm inhibition, calcium stress

[111,112]

Eugenol

Clove

Perturbation of cytoplasmic permeases, inhibition of
ergosterol biosynthesis, interference with the
integrity of the cell membrane, biofilm inhibition

[112,113]

Caffeic acids

Tarragon

Biofilm inhibition

[114]

Capsaicin

Capsicum
species

Membrane disruption

[65]

in humans [123]. FDA approval was granted after a phase III randomized, double-blind, multicentre study proved the
efﬁcacy and safety of ozenoxacin in the treatment of impetigo [124]. Adverse reactions, such as rosacea or seborrheic
dermatitis, were rarely reported, but prolonged use may result in overgrowth of nonsusceptible bacteria and fungi.

18.1.7.3 Ceftazidime/avibactam
Ceftazidime/avibactam is a mixture of ceftazidime, a third-generation cephalosporin that acts as a b-lactamase inhibitor in
association with avibactam [125]. Ceftazidime averts formation of peptidoglycan by blocking penicillin-binding proteins,
ensuing cell wall variability and cell death [126]. Avibactam and ceftazidime are eliminated through the kidney as drugs
having a neutral charge. Approximately 5.7%e8.2% of avibactam and 10% of ceftazidime are bound to a protein [127].
In patients with declined renal functioning, the half-life of ceftazidime in blood is sustained and a concentration
modiﬁcation is suggested [128]. Antagonistic reactions that have been deﬁned are hypersensitivity, anaphylaxis, neural
functions (such as seizures), and C. difﬁcileemediated diarrhea, usually in patients with renal injury. Avibactam/ceftazidime is used for the management of typical intraabdominal disorder and intricate urinary tract problem produced by the
vulnerable Gram-negative microorganisms, namely P. aeruginosa, E. coli, P. mirabilis, K. oxytoca, E. cloacae, C. freundii,
and K. pneumoniae [129,130]. In serious intraabdominal problems, combination medication of avibactam/ceftazidime and
metronidazole is suggested [131]. Avibactam/ceftazidime might be appreciated for the intensive care unit (ICU) patient
while it is also used as a carbapenem-sparing antibiotic [132]. However, an analytical case series debated the rapid
occurrence of resistance in medicated patients [133,134].
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18.1.7.4 Vabomere
Vabomere is the mixture of a b-lactamase and carbapenem inhibitor, made up of meropenem, and vaborbactam permitted
in August 2017 by the FDA for the medication of critical urinary infections in the adult [135]. Vaborbactam is an inhibitor
of b-lactamase and has no antibacterial potential on its own, but it inhibits carbapenemases activity which is synthesized by
K. pneumonia and other b-lactamases, which could cause meropenem to break down, therefore leading to analyze in vitro
efﬁcacy against K. pneumoniae carbapenemase Enterobacteriaceae. Meropenem susceptible microbes comprise
Gram-negative bacteria such as P. aeruginosa, E. coli, K. pneumoniae, and E. cloacae species complex [136].
After association to penicillin-binding proteins, meropenem prevents the last step of peptidoglycan formation and hence
the synthesis of cell walls without peptidoglycan, leading to lysis of bacteria. Meropenem is 2% protein bound and a
half-life of 2.3 h, while vaborbactam is 33% protein bound and a half-life of 2.2 h. Furthermore, vaborbactam is not
absorbed completely and is excreted through the urine in the next 2 days. Nearly 30% dose of the meropenem is utilized by
b-lactam ring hydrolysis to denature form, which is passed out by the urine and between 40% and 60% amounts of
meropenem is eliminated unchanged within 2 days [137]. Because of its potential against multidrug-resistant microbes,
vaborbactam-meropenem displays promising suggestions in the treatment of ventilator-mediated pneumonia [138,139].
Any of the two constituents or other drugs in the same class is admonition in patients suffering from hypersensitivity and
the most commonly faced adversative reactions, viz. phlebitis or infusion site reactions, headache, and diarrhea [135].
Rare but severe side effects comprise hypersensitivity reactions, thrombocytopenia, seizures, C. difﬁcileemediated
diarrhea, occurrence of drug-resistant bacteria, neuromotor impairment, and excessive growth of nonvulnerable microbes
[136]. Doses should be modiﬁed and precaution must be taken by the patients with compromised renal function [140].

18.1.7.5 Ceftaroline
Ceftaroline is a new broad-spectrum antibiotic used for the treatment of penicillin- and cephalosporin-resistant
S. pneumoniae, methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. aureus, and vancomycinintermediate S. aureus [141]. It also shows activity against several Gram-negative microbes but nonfunctional against
b-lactamase synthesizing bacteria. It has been widely accepted for the medication of pneumonia. Ceftaroline was prepared
by an advance alteration in the structure of fourth-generation cephalosporin cefozopran [142]. This drug shows activity by
forming an association with penicillin-binding proteins. It also possesses much afﬁnity toward S. aureus penicillin-binding
protein-2a (PBP2a), which is responsible for methicillin resistance. Other than the blood circulation, ceftaroline fosamil
(prodrug) is quickly transformed to ceftaroline (an active form) with the help of phosphatase enzymes. It displays linear
pharmacokinetics and has a half-life (t½) of 120 min (for a single dose) to 155 min (for multiple doses) in serum. Ceftaroline
is processed by hydrolysis of its b-lactam ring, which further leads to the formation of neutral, open-ring metabolite termed
as ceftaroline M-1. It has less potential for drug interactions because of inappropriate breakdown by CYP450 enzymes
[143]. Dose regulation is mandatory in patients with renal injury as it is predominantly excreted by the kidney. The most
common adverse effects detected in clinical trials were headache, dysgeusia, vomiting, diarrhea, and nausea.

18.1.7.6 Ceftobiprole
It is a newer form of cephalosporin which has accomplished its trial in 2007 and is waiting for approval by the FDA
because of supplementary safety documents being required by the FDA. Ceftobiprole is a broad-spectrum antibiotic which
possess a wide range of activity against Enterococci, MRSA, penicillin-resistant P. aeruginosa, and S. pneumoniae [144].
It exhibits high afﬁnity for PBP2x of S. pneumoniae and PBP2a of MRSA [145]. It is given as IV infusion in 1 h every
12 h for Gram-positive infection and a 2-hr infusion of 500 mg every 8 h for Gram-negative infection. Dose adjustment is
needed in patients with renal impairment [146]. It is well-tolerated with the most usual side effects being nausea and
dysgeusia.

18.1.7.7 Doripenem
This drug is permitted for the medication of complex intraabdominal infections or urinary tract infections (UTI). It performs its function by binding with PBPs and consequently averting the cross-linking structure of the peptidoglycan.
The high binding afﬁnity of doripenem with PBP-2 and -3 may boost its potential against drug-resistant P. aeruginosa.
Therefore, it is an appropriate option to presently used antipseudomonal carbapenems (i.e., meropenem, imipenem) [147].
It demonstrates activity against Gram-positive cocci and Gram-negative bacilli such as imipenem and meropenem,
respectively [148]. Doripenem, in similarities to other carbapenems, is stable to ESBLs synthesized by E. coli and
Klebsiella species and to AmpC b-lactamases enzymes; but it is susceptible to some acquired b-lactamases such as class B

286 PART | II Bio-functional leads for drug development

metallo-b-lactamases produced by some P. aeruginosa isolates and carbapenemases produced by some Enterobacteriaceae and Acinetobacter species [149]. 500 mg in every 8 h through IV is a recommended dose of doripenem. Protein
binding is low (8.1%) and is independent of the amount of drug in the plasma. The projected excretion half-life of
doripenem is 57 min, and 75% of the drug is excreted as an uncharged molecule through the urine; recommended dosage
modiﬁes in renal damage patients [150]. The most common ADRs are nausea, phlebitis, diarrhea, and headache and rash.
Postmarketing reports have also recognized toxic epidermal necrolysis, StevenseJohnson syndrome, seizures, and
interstitial pneumonia as antagonistic drug reactions.

18.1.7.8 Telithromycin
It is the ﬁrst ketolide to enter clinical use for the treatment of CAP, chronic bronchitis, and acute sinusitis. Other ketolides
are in the phase of clinical development. It acts as an inhibitor of protein synthesis that prevents the advancement of the
growing polypeptide chain by binding to lager subunit (50S) of the microbial ribosome. It shows 10-folds more afﬁnity to
the larger subunit of ribosome in comparison with erythromycin. Furthermore, telithromycin simultaneously binds strongly
with two domains of 23-S RNA of larger subunit of the ribosome, while older macrolides bind strongly only with one
domain and loosely with the second domain. In in vitro analysis, it is found to be more effective against S. pneumonia
followed by clarithromycin and azithromycin and retains their property against macrolide-resistant strains (S. pyogenes, S.
pneumoniae) [151]. Telithromycin has marketed as a tablet form with a concentration of 400 mg for oral administration.
It is well metabolized orally with 60% bioavailability. A terminal half-life of 9.81 h is attained with a single 800 mg daily
oral dose with peak plasma concentration of 2.27 mg/L [152]. It achieves high tissue concentrations in respiratory ﬂuids
and tissues, including epithelial lining ﬂuid, alveolar macrophages, bronchial mucosa, and saliva [153]. Telithromycin is
66%e89% bound to serum protein, mainly albumin. The drug is excreted predominantly by hepatic metabolism, 50% by
CYP3A4, and 50% by CYP-independent metabolism. No dose modiﬁcation is required for patients with hepatic failure or
mild to moderate renal abnormalities.

18.1.8 Antibacterial drugs on clinical trial
No doubt herbs and their bioactive compounds have been serving for centuries to protect living beings from a wide range
of infections and illness but organized clinical trials are scarce. In some of the cases, traditional therapists together with an
expert scientist working in the area of keeping records of the efﬁcacy of the phytochemicals medication and safety
measurements; however, these are usually randomized and unplanned studies. Some of the clinical trials associated with
the use of phytochemicals in the welfare of humans are brieﬂy summarized here.
In West Africa, to reveal the efﬁcacy of toothbrushes versus chewing sticks by cross-sectional epidemiological study in
encouraging oral hygiene, a study was conducted. Research associated with this study found a lowered effectiveness in
chewing stick in comparison with toothbrush and suggested that chemicals responsible for antimicrobial activity are known
to occur in the sticks not promoted oral health beneﬁts [154]. Furthermore, mouth washes containing various antimicrobial
compounds have been examined in humans [155]. Mouthwash having phytoconstituents were not found to be as potent in
suppressing plaque or gingivitis as was chlorhexidine or Listerine. Till now, few unsystematic clinical trials of herbal
antimicrobial agents have been executed. Giron et al. [156] compared Solanum nigrescens extract with nystatin, both given
as intravaginal suppositories in female with conﬁrmed C. albicans vaginitis. The extract supposed to be as effective as
nystatin. In 1996, cranberry juice was tested against urinary tract infections in a group of aged women. The researcher did
not reveal any data related to this clinical study, whereas medicated women had fewer microbes in their urine than did the
untreated group [92]. Four different formulations of natural compounds as reported in Ayurveda were examined against a
placebo for their action against acne vulgaris. One of the formulations namely Sunder Vati produced an appreciably greater
drop in lesion count than did the other three as well as the placebo. No adverse side effects were noticed [157].
Two proprietary compounds isolated from tropical plants, provir, for the management of viral infections associated with
respiration, and virend in 1994, a topical antiherpes compound were evaluated in clinical trials [158]. Meanwhile then, the
efﬁcacy and safety of virend have been established in phase II studies [159]. More information on plants and
phytochemicals with antiviral properties can be found on chapter 15 of this book.

18.1.9 Future perspectives and conclusion
The need for effective curative therapies is constantly on the increase because of antibiotic-resistant microbial pathogens.
The continuing scarcity of strong antibiotics is neither just a biological issue (evolution in resistance) nor even a public
problem (misapplication of antibiotics and selection of resistance), although is in broader side the consequence of a
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long-term gap of investigation in research and advancement programs by most of the pharmaceutical industries. Nowadays,
there are a very small fraction of antibiotics in late phase of clinical trials, and practically all of these are belonging to
preexisting classes. The causes for this investment break in novel classes are multifaceted, but they are linked with the least
assurance on the part of the pharmaceutical companies in the comparative proﬁtability of antimicrobials as a good option
for investment. As clinical trials demonstrate the bulk of the expenditure of drug advancement, it is preferable to remove
strongly problematic molecules in the early hit-to-lead or lead-to candidate phases, rather than have an expensive failure.
The high rate of attrition in antibiotic drug development makes it essential, and hence that investment in early stage of
research and advancement is continued at a high enough level to produce a sustainable pipeline of novel ideas used into
advance stages of development and serving into clinical trials.
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19.1 Introduction
Malaria is endemic in tropical and subtropical developing countries where it is a major public health problem. Every year
there are about 300e500 million clinical cases of malaria with 1e2 million deaths, most of them found in Africa. Inadequate
administration and implementation of malaria control measures, failure of insecticides, and emergence of drug-resistant
strains of the parasites are responsible for the resurgence of malaria. It is estimated that there are about 215 million people chronically affected by malaria and 150 million new cases per year. Most hard-hit areas include Africa, India, China, and
the East Asia. Malaria is a disease caused by a closely related group of four different species of Plasmodium, viz., Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, and Plasmodium malariae. It is a very ancient disease, which has
adversely affected the progress of the nations and has been a decisive factor in many wars. Malaria has been responsible for a
high morbidity directly or indirectly. Malaria affects all age groups, but children and pregnant women are most at risk. One
out of 20 children in Africa dies because of malaria infection before the age of 5 years. Most of the severe infection occurs
between 6 months and 3 years of age. Herbal medicines are being used clinically in the treatment of various ailments [1]. The
number of pregnant women is 25 million that are at risk of P. falciparum annually. At the time of delivery, evidence of
placental infection is one out of four pregnant women. Study indicates that complication such as perinatal mortality, low birth
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weight, and severe maternal anemia can be reduced by preventing P. falciparum infection. The number of death of baby with
low birth weight because of malaria in pregnant women is estimated about 100,000 in Africa annually [2].
In this chapter, herbal medicines are documented for their efﬁcacy to treat malaria. Herbal medicines were found to
have in vivo and in vitro antimalarial activity [3]. Documentation of herbal medicines assists and enhances the understanding of efﬁcacy of these medicines on different diseases [4]. Traditional medicines are practiced worldwide for
treatment of malaria since ancient times. Herbs and plants always have been used in the treatment of different diseases such
as malaria, gastrointestinal tract (GIT), and central nervous system (CNS) diseases since long time ago. Malaria is one of
the leading infectious diseases worldwide. Traditional healers prescribe herbal medicine as a remedy against fever and
other symptoms of acute malaria. Medicinal plants have been used to treat malaria since ancient time. Herbal medicines are
important because of the emergence and spread of chloroquine resistance. Documentation of antimalarial plants can be a
springboard for new facilities-based therapies that could be available for the treatment of malaria, especially among poor
people in developing countries living in endemic areas of the tropics, mostly at risk from this devastating disease.
Allopathic medicines are effective but they exert side effects such as chloroquine (retinal damage, corneal opacities,
retinopathy, headache, nausea, vomiting, neutropenia, pruritus, lichenoid dermatitis, alopecia, cardiorespiratory arrest, and
conduction defects), primaquine (abdominal pain, leukopenia, methemoglobinemia, hemolytic anemia), amodiaquine
(headache, nausea, neutropenia, vomiting, pruritus, cardiorespiratory arrest, and conduction defects), quinine sulfate and
quinine dihydrochloride (gastric irritation, tinnitus, antibody-mediated thrombocytopenia, ventricular arrhythmias, hypotension, fever, agranulocytosis, rash, anaphylaxis, hypersensitivity reaction, visual disturbance, nausea, and headache),
pyrimethamine (convulsions, macrocytic anemia, and GI upset), meﬂoquine (skin reaction, GI disturbance, blood dyscrasias, and liver cell damage), pyrimethamine þ sulfadoxine (Fansidar) (GI upsets and skin rash), halofantrine (abdominal
pain, diarrhea, skin rash, and ventricular arrhythmias), and artemether (slight rise of SGPT and SGOT, reticulocytopenia).
Achenbach et al. [5] stated the opposite antimalarial compounds Hoslundia. Lee et al. [6] stated that Viola websteri
Hemsl. has antiplasmodial activity and can be used as an antimalarial agent. A number of studies have been carried out to
document the use of natural agents as antimalarial such as indicated that tropical Meliaceae extracts and derivatives have
antimalarial activity and can be prescribed to treat malaria [7]. Wright et al. [8] stated that cryptolepine and some other
anhydronium bases have antimalarial activity. Kalauni et al. [9] stated that cassane- and norcassane-type diterpenes from
Caesalpinia crista have antimalarial activity. Frederich et al. [10] stated that indole alkaloids have potential antimalarial
activity. Fandeur et al. [11] stated that sergeolide has in vitro and in vivo antimalarial activity. Guru et al. [12] stated the
antimalarial activity of bruceantin in vitro. Trager et al. [13] stated that quassinoids have antimalarial activity against
chloroquine-resistant P. falciparum in vitro. Vivas et al. [14] stated the antimalarial activity and drug interactions of the
new semisynthetic endoperoxide artemisone in vitro and in vivo. Artemisia annua, which is the main source of artemisinin,
is the recommended treatment for uncomplicated malaria. The mechanism of action of artemisinin is still debated. Many
reports suggest that artemisinin acts by heme-dependent activation of endoperoxide bridges within the parasite s’ food
vacuole converting artemisinin into unstable organic free radicals and or other electrophilic species, damaging the biomolecules of parasite‘’s cell leading to death. There seems to be big analysis of the information presented.
There are insights or connections between plants and compounds. The World Health Organization focuses on the use of
herbal medicine to treat malaria. WHO statement and references are helpful inclusion to ensure the review advocate of the
use of herbal remedies for malaria treatment. The purpose of this chapter is to encourage researchers to look for the
parallels between the listed plants and know antimalarial activities. This chapter might lead to new research into other
classes of antimalarial compounds. There are interesting insights to be gained from the part of the plant used for treatment.
For example, artemisinin is manufactured and stored in the trichomes. Although artemisinin is used in malaria, there is
issue of emerging resistance of P. falciparum parasite to artemisinin, which is a considerable risk with the use of herbal
remedies. Alternative compounds should be searched out from listed plants.
The material used for this chapter was taken mostly from phytomedicine textbooks and electronic journal up-to-date.
To collect publication PubMed and the Cochrane database of systematic reviews was used. Some other relevant references
were collected from personal database of articles on antimalarial activities of plants.

19.1.1 Prevalence, risk factors, and mode of transmission
Maximum prevalence is found in South Asia from July to November [15]. Malaria affects all age groups, but newborn and
infants are resistant to P. falciparum because of high levels of fetal hemoglobin in them. Malaria is uncommon in person
with sickle cell hemoglobin than in persons with normal adult hemoglobin. Men are more frequently exposed than women
because females are clothed better. In India, women cover whole body. Individuals with sickle cell trait have a milder
illness, e.g., Negroes with sickle trait are immune to falciparum infection. More prevalent is in underdeveloped countries.
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Economic depression is associated with epidemic and malaria ill-ventilated and ill-lighted houses. Nomads, laborers, and
wandering tribes import malaria parasites. Sleeping outdoors, sleepy with or without mosquito net, etc., man has no natural
immunity. Temperature between 20 and 30 C is optimum temperature for the development of the malaria parasite in
infected vector. Relative humidity of 60% is necessary for mosquitoes to live their normal span of life. Altitude mosquitoes
are not found at altitude above 2000e2500 m (6000 ft) sea level. Man-made activities such as burrow pits, excavations
during construction of barrage, railways, roads, irrigation canals, etc., contribute to the breeding of mosquitoes because of
waterlogging [16]. As mentioned earlier, malaria is transmitted by the bite of certain species of infected female Anopheles
mosquitoes. Other rare modes of transmission are blood transfusion, use of contaminated syringes or needles, and vertical
transmission (from mother to the fetus). Hepatic schizogony does not occur when malaria is transmitted through these
routes; therefore, in case of P. vivax infection, relapse will not occur [17].

19.1.2 Incubation period
The incubation period is between 7 and 12 days for P. falciparum from the introduction of sporozoites to clinical symptom,
whereas for P. vivax and Plasmodium ovale, it is between 12 and 16 days. In temperate areas, protected incubation period
for P. vivax may be 8e10 months. In case of Plasmodium ovale infection through blood transfusion, the incubation period
varies with the number of parasites transfused, which is usually short. Incubation period for Plasmodium malariae is
between 7 and 30 days. The incubation period may be prolonged if suboptimum doses of antimalarial drugs are given.
Extrinsic incubation period varies from sucking of gametes to development of sporozoites. It is between 8 and 55 days
depending on malaria parasite species and environmental conditions of humidity and temperature [18].

19.1.3 Pathogenesis
The symptoms are caused by asexual erythrocytic stage of the parasite. Symptoms appear when mature schizont-infected
erythrocytes rupture and release endogenous pyrogens and other toxins in the blood. Anemia occurs because of hemolysis,
dyserythropoiesis, iron deﬁciency, and malnutrition. Hypertrophied Kupffer cells containing malarial pigment cause
enlargement of liver. Enlargement of spleen occurs because of accumulation of large numbers of phagocytic cells, which
contain erythrocytes and malarial pigment (hemozoin). The release of large number of merozoites from tissue schizonts,
ability of merozoites to invade erythrocytes at different stages of maturation, and sequestration of parasitized erythrocytes
in small blood vessels of a variety of organs̊ including brain are possible reasons for high-density parasitemia and complications in falciparum infection [19].

19.1.4 Life cycle of malarial parasite
The bite of mosquito containing the malarial parasites introduces parasites into the blood of a healthy person. From the
blood, parasites (sporozoites) approach the liver cells. They multiply in liver cells and ﬁll them with parasites (tissue
schizonts). Hepatic cells are ruptured, and parasites (merozoites) are released into the blood circulation. Merozoites again
enter RBCs (red blood corpuscles) and multiply to ﬁll the RBCs (blood schizonts). RBCs rupture with liberation of
merozoites and toxins. The release of toxins causes shivering and fever. Merozoites thus liberated enter fresh RBCs, and
cycle is repeated again with liberation of more toxins and merozoites. Some of the parasites in the RBCs form gametocytes
(sexual forms). Gametocytes enter a mosquito when it bites the patient of malaria and multiply in the mosquito to form
merozoites, which go to salivary glands of the mosquito and enter the blood of a healthy person when the mosquito bites
him or her [20].

19.1.5 Symptoms
The indications of jungle fever rely on the types of Plasmodium and resistance of the host. An assault of jungle fever
comprises of three progressive stages. Icy stage: sudden beginning of fever and chills, which goes on for 15e60 min. Hot
stage: temperature rises up to 41oC/106oF with migraine, which goes on for 2e6 h. Sweating stage: fever descends by
lavish sweating. It is an old illness, as was depicted by Charaka and Sushrutha. As a rule, in jungle fever cases, there are
chills, thoroughness, paleness, cyanosis, sickness, retching, cerebral pain, which may proceed for 15 min to an hour and,
even, writhing in kids. The spiking fever, achieving 104oF (40oC) or high, may keep going for a few hours. Taken after by
plentiful sweating with fringe vasodilatation, the temperature drops, and the patient feels moderately well, while the fever
travels in every way. As the ailment advances, there is splenomegaly, and liver may likewise be extended and delicate;
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in the beginning time, paroxysms of fever take place after a sporadic example; however, later the paroxysms may happen
yet following 62 h in malariae contamination (quartan jungle fever). The periodicity of chills and fever in both vivax and
falciparum disease is, however, impacted by the invulnerability of the patient strain contrasts and from contamination by
more than one type of Plasmodium. Nevertheless, in vivax contamination (amiable tertian intestinal sickness), heaving
might be troublesome, and the condition tends to drop after long tranquil interims. Symptomatically, ovale disease (ovale
tertian intestinal sickness) may mimic subintense and infected appendix or rheumatic fever; however, as a rule the condition offers ascend to little side effects. Falciparum contamination (subtertian jungle fever) may take after ﬂu, yellow
fever, or may even invigorate typhoid fever and numerous different sicknesses when it includes inner organs. Serious
falciparum contamination may cause renal harm, while malariae disease is subject to create nephrosis in kids, with summed
up edema, oliguria, proteinuria, and hypoproteinemia. In falciparum contamination, the fever is sporadic and may do not
have the periodicity or may even happen each day. There might be normocytic paleness, hack, spewing, loose bowels,
jaundice, and postural hypotension. In extreme type of falciparum disease, there might be cerebral intestinal sickness,
giving high fever, disarray, incoherence, seizures, daze, trailed by trance state persevering for a couple of hours. There may
likewise be different paresis and hemiplegia. Likewise, there might be renal debilitation with low pee yield or persistent
oliguria, hemoglobinuria, aspiratory edema, hypoglycemia, hypotension, and serious frailty. In grown-ups, there might be
unconstrained seeping from the sullen, skin wounding, gastrointestinal drain, and overﬂowing from venipuncture.
Ceaseless falciparum contamination, particularly in patients treated with quinine, can offer ascent to genuine inconvenience, blackwater fever, giving intravascular discharge and hemoglobinuria, likewise. Jungle fever can create a few
inconveniences, for example, hyperpyrexia, algid intestinal sickness (looking like intense adrenal insufﬁciency), malevolent paleness, gastrointestinal confusion, break of spleen, and premature birth in pregnant ladies.
Symptoms associated with P. vivax and P. ovale: P. vivax and P. ovale present clinically as restlessness, nausea,
vomiting, headache, mild cough, and fever. Febrile convulsions may occur; liver and spleen may become palpable.
Symptoms associated with Plasmodium falciparum: P. falciparum infection causes fever, anemia, and probable heart
failure. Complications of P. falciparum also include hemoglobinuria, renal failure, metabolic disturbances, disseminated
intravascular coagulation, convulsions, coma, purpura, and retinal hemorrhage [21].
Cerebral malaria: The symptoms are that the patient becomes drowsy and passes into coma. In some cases, the patient
is in a state of semiconsciousness, responding to stimulation by questioning. In others, there may be acute mental
disturbance. Accompanying these symptoms, there is usually remittent fever and some anemia. Some may develop
hyperpyrexia [22].

19.1.6 Methods of diagnosis
Clinical diagnosis: This is the most common method for the diagnosis of malaria in endemic countries. However, this
method is unreliable because symptoms of malaria overlap with those of many other febrile illnesses such as viral fever,
viral encephalitis, and typhoid fever [23].
Laboratory diagnosis: This involves blood examination, which is examined 8 hourly for 3 days during and between
attacks. Thick and thin ﬁlms are examined. The diagnosis of malaria relies on detecting one or more of the four human
plasmodia in blood smears. Giemsa-stained thick smears offer the highest diagnostic accuracy for malarial parasites. A
semiquantitative estimate of parasitemia is best done on thin smears. Other laboratory measures are the use of ELISA,
DNA hybridization, polymerase chain reaction, DNA probe and rapid antigen detection, immunoﬂuorescent assay, and
other laboratory ﬁndings that reﬂect severity of hemolysis, which include decreased hematocrit, hemoglobin, and
haptoglobin, increased reticulocyte count, hyperbilirubinemia, and increased lactate dehydrogenase. Thrombocytopenia is
common but the incidence of leukocytosis is variable. These ﬁndings may be seen in cases that are more chronic.
Community knowledge about malaria: Thus, communities generally have excellent information about malaria and
they are well aware of sign and symptoms of malaria. Community knows that cause of malaria is mosquito and mosquito is
found in stagnant water.

19.1.7 Treatment
If the patient with malaria is not treated in time, patient with minor symptoms may progress toward severe symptoms and
death. In the recent past, artemisinin combinations have been remained in use at large scale to treat malaria. In past,
standard treatment of malaria was considered with chloroquine monotherapy [24]. A combination of resistance of Plasmodium species to antimalarial drugs such as chloroquine and the resistance of the vector mosquitoes to insecticides has
resulted in malaria emerging as the World’s most common tropical disease. Quinine has been used for many years as an
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antimalarial drug. In recent years, clinicians have continued to use quinine because the resistance of Plasmodium strain is
low when compared with other drugs. Primaquine is given to eliminate dormant stage of parasite in liver (hypnozoites) [25]
Sulfadoxine (30 mg/kg) and pyrimethamine (2.5 mg/kg) are given as single dose. Meﬂoquine is given as single dose of
15 mg/kg alone or in combination with sulfadoxine and pyrimethamine. Quinine is given at dose of 10 mg/kg three times
per day for 7 days. Halofantrine is given at dose of 8 mg/kg at 6 hourly intervals, three doses only, with fatty meals. Oral
chloroquine is still the best. Relapses occur in P. vivax and Plasmodium ovale. It is a synthetic drug. It is a 4aminoquinoline. Perhaps it acts by concentration of chloroquine in the food vacuoles of malarial parasite. Hence, it
prevents the formation of hemozoin from heme. Hemozoin acts as a food substance for the parasite. This will prevent the
food supply of the parasite and causes accumulation of free heme in the parasite to toxic level, resulting in the death of the
malarial parasite [26]. The Chinese antimalarial drug artemisinin is a sesquiterpene lactone containing an endoperoxide
moiety, which is a rare feature in natural product. Problem of low solubility in both organic and aqueous solvents has been
overcome by the development of the sodium dihydroartemisinin in hydrogen succinate monoester. Over, 2000 malarial
patients have been treated with artemisinin in China [27].

19.1.8 Medicinal plants used to treat malaria and their phytochemical constituents
The following plants have been reported to possess antimalarial activities. The phytochemical constituents of the plants
were also discussed.

19.1.8.1 Ageratum conyzoides (Asteraceae)
Part used is bark. It contains tannins, terpenoids, benzofurans, chromenes, essential oils, cumarins, alkaloids, and ﬂavonoids.
It is used in pyrexia, inﬂammation, wounds, constipation, abdominal pain, dysentery, arthritis, burns, bacterial infections, and
headache. It is antibacterial, muscle relaxant, analgesic, antiarthritis, wound healer, antiulcer, antioxidant, insecticidal, lithotriptic, laxative, carminative, stimulant, expectorant, depurative, resolvent, antiprotozoal, antiinﬂammatory, anticancer,
anticoccidial, gastroprotective, and hypoglycemic. A study was conducted to investigate the antimalarial activity of the
aqueous extract and fractions of leaves of Ageratum conyzoides in mice infected with Plasmodium berghei. In this study,
Ageratum conyzoides is found effective for malaria [28].

19.1.8.2 Bridelia ferruginea Benth (Euphorbiaceae)
Part used is bark. It contains D-glucopyranoside and biﬂavanol gallocatechin-[4-O-7]-epigallocatechin. It is used in bacterial
infection, fungal infection, and malaria. It is diuretic, antibacterial, antiulcer, xanthine oxidase inhibitor, antioxidant, antiplasmodic, and antimalarial. Kolawole and Adesoye [29] stated that Bridelia ferruginea Benth bark has antimalarial activity.
Extract of Bridelia ferruginea (100e400 mg/kg) was administered to investigate its efﬁcacy against P. bergheieinfected
mice. Extract exhibited signiﬁcant antiplasmodial activity that was comparable to chloroquine 100 mg/kg [30].

19.1.8.3 Azadirachta indica (Meliaceae)
Parts used are bark, root bark, young fruit, nut, seeds, leaves, and ﬂowers. It contains diterpenoids, margolone, nimbonolone, nimbolinin, methyl gallate, margosinone, margosinolone, nimbina sulfur, nimbidin, and oreophenol-nimbiol. It is
used to treat various ailments. It is diuretic antimalarial [31]. It is used in skin disorders and blood disorders. A study was
conducted to investigate the in vivo antiplasmodial activity of ethanolic extract of Azadirachta indica (neem) via intraperitoneal inoculation of P. berghei ANKA followed by intraperitoneal extract administration at a dose of 300, 500, and
1000 mg/kg daily for 5 days. Chloroquine and artemether (IP) were used as standard drug. There was no improvement by
use of extract. However, in chloroquine and artemether standard group, cerebral malaria symptoms were not present and no
death occurred. Edema, cerebral hemorrhage, and apoptosis in Purkinje cells were found in neem-treated mice. When
compared with control group to whom no treatment was given, there was difference in the manifestation of neurological
symptom that was more serious in untreated control group. This study showed that neem is not effective in protecting mice
against sign and symptoms of malaria but has some neurological protective efﬁcacy [32].

19.1.8.4 Ochna integerrima (Ochnaceae)
Part used is stem bark. It contains ﬂavonoids and glycosides. It is an antimalarial agent. Chikara et al. [33] stated that
bioﬂavonoids from Ochna integerrima have antimalarial activity.
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19.1.8.5 Artemisia annua L. (Compositae)
Part used are leaves. Chemical constituents are sesquiterpenes and artemisinin. It is used in malaria, cough and diarrhea
[34]. It is antimalarial and cytotoxic. A. annua contains a compound artemisinin that is prescribed to treat malaria. A study
was conducted by Mueller et al. [35] to investigate the antimalarial activity of A. annua. In this study, ﬁve patients were
selected for studies that were infected with parasitemia. There was signiﬁcant reduction in parasitemia within 2e4 days of
treatment with A. annua. In another study conducted by Mueller [35], it was reported that this plant was administered to 48
patients of parasitemia. There was 92% disappearance of parasitemia in 44 patients after 4-day treatment. In both trials,
there was signiﬁcant reduction in symptoms of malaria. In this study, author concluded that this study justiﬁes use of this
plant in malaria [35].

19.1.8.6 Artemisia nilagirica (Asteraceae)
Parts used are leaves. It contains 9-octadecenoic acid (Z)- tetradecyl ester, agaricic acid, bufa-20, 22-dienolide, 3, 14dihydroxy-(3a, 5a), 9, 10 secocholesta, 5, 7, 10 (19)-triene- 3, 2. 4, 25-triol, (3a, 5Z, 7E), Cycloheptasiloxane, tetradecamethyl, Tripalmitin, Prednisone, and Ergosta- 5, 7, 22- trien- 3-ol, acetate, (3a, 22 E) [36]. This plant also contains
ﬂavonoids, alkaloids, terpenoids, tannins, and glycosides [37]. Artemisia nilagirica leaf extracts prepared in different
solvents, viz. aqueous, methanol, ethanol, n-hexane, petroleum ether, and chloroform, were studied for efﬁcacy of its
antimalarial activity against malarial parasite P. falciparum. The study concluded that the leaf extracts of this plant possess
antiplasmodial activity and can be used as potent antimalarial drug due to the presence of bioactive phytochemicals [38].

19.1.8.7 Esenbeckia febrifuga (Rutaceae)
Parts used are stems. It contains isopimpinellin, bergaptene, limonoid, skimmiamine, kokusaginine, and ﬂindersiamine. It
is used in malaria and fever. It is antimalarial. A study conducted by Dolabela et al. [39] indicated the antiplasmodial
activity of ethanol extract. This activity was observed against P. falciparum strain W-2 and 3D7. Furthermore, its constituents were isolated and activity was checked against various strains of Plasmodium. Fluoroquinolone 5 and 6 are most
active at IC50 < 50 mg/mL. Findersiamin was less active. Rutaevine 8 and alkaloid 7 was inactive [39].

19.1.8.8 Remijia ferruginea (Rubiaceae)
Part used is bark. It is used in malaria and herpes. It is antimalarial. A study was conducted by Brandao et al. [40] indicated
that Remijia ferruginea has antimalarial activity. Another study was conducted in mice infected with P. berghei. For this
study, ethanol crude extract of plant was investigated for study. There was signiﬁcant antimalarial activity. On phytochemical analysis, there were found two alkaloids and no quinine was found [41].

19.1.8.9 Amaranthus spinosus (Amaranthaceae)
Parts used are roots and leaves. It contains beta-carotene, rutin, linoleic acid, stigmasterol, sitosterol, betanin, amaranthins,
and glycosides. It is used in abscesses, piles, and wounds. It is laxative and emollient. A study was conducted to investigate
the antimalarial activity of Amaranthus spinosus. Extract was found effective at fourth day of treatment. There was signiﬁcant suppressant effect on antimalarial assay in mice that were inoculated with RBCs parasitized with P. berghei.
Values obtained for A. spinosus were ED (50) of 789. A. spinosus showed low toxicity at 1450 mg/kg [42].

19.1.8.10 Ticodendron incognitum (Ticodendraceae)
Parts used are leaves, bark, and roots. It contains phenols, ﬂavonoids, terpenes, triterpenes, reducing compounds, anthocyanins, coumarins, tannins, and sterols. Antimalarial activity of the fractions of this plant has been evaluated against
P. berghei NK65. The study reported that bioactive metabolites present in this plant are responsible for it antiplasmodial
activity [43].

19.1.9 Promising phytochemicals for the treatment of malaria
Various phytochemicals found in plants are used for the treatment of malaria and few are described below.
The two ﬂavonoids including 8-formyl7-hydroxy-5-methoxyﬂavanone and 30-formyl-20,40-dihydroxy-60-methoxychalcone isolated from the leaves of Friesodielsia discolor (Annonaceae Family) showed antiplasmodial activity which were
reported from various studies [44].
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Miliusacunines A and B are the plant phytoconstituents obtained from leaves and twigs extract in acetonic solvent of
Miliusa cuneatas [45]. Miliusacunines A exhibited antimalarial activity by inhibiting the TM4 malarial strain (IC50
19.3 mM), whereas Miliusacunines B exhibited antimalarial activity by inhibiting the K1 malarial strain (IC50 10.8 mM).
An alkaloid 5-hydroxy-6-methoxy onychia obtained from Mitrephora diversifolia, an Australian tree plant display
antiplasmodial activity showing IC50 values of 11.4 and 9.9 mM against Dd2 and 3D7 clones of P. falciparum,
respectively [46].
Seven phytocompounds obtained from methanolic extract of leaves and stem of Rhaphidophora decursiva (Araceae
family) showed antimicrobial activity against W2 and D6 clones. Polysyphorin and rhaphidecurperoxin showed antimalarial activity against D6 and W2 strains. Other phytoconstituents exhibiting antiplasmodial activity, rhaphidecursinols A
and B, epigrandisin, grandisin, and decursivine also showed activity against P. falciparum [47].
A new steroidal glycoside identiﬁed from Gongronema nepalense (Asclepiadaceae family) called gongroneside A
through antimalarial bioassay directed separation technique. The study reported the antimalarial activity of this plant [48].
The ﬂavonoid glycosides, luteolin 7-O-glucoside and Apigenin 7-O-glucoside obtained from Achillea millefolium aerial
parts showed antimalarial activity against W2 and D10 strains [49].
Another bioactive compound, 2-isopropenyl-6-acetyl-8-methoxy-1,3 benzodioxin-4-one obtained from Carpesium
divaricatum have antimalarial activity exhibiting the inhibition of D10 strains [50].
Plants have been a valuable source of bioactive constituents for the treatment of malaria. The above discussed plants
have been found to exhibit curative potentials against malaria. Table 19.1 was presented to highlight more plants of
antimalarial importance.
TABLE 19.1 Plants proved as antimalarial agents.
Origin
of plant

Parts
used

Use in
which part
of world

Plant name

Family

Pharmacological activity

References

Alstonia boonei

Apocynaceae

Tropical
West
Africa

Stem
bark

Nigeria,
Ghana

Antimalarial, antiinflammatory

[51]

Pterocarpus
erinaceus

Fabaceae

West
Africa

Seeds

Burkina
Faso,
Belgium

Antimalarial, antiinflammatory,
analgesic

[52]

Artemisia
nilagirica

Asteraceae

Europe

Seeds

Austria,
USA, India,
Bulgaria

Antimalarial, antifungal, and
antibacterial

[53]

Croton
zambesicus

Euphorbiaceae

Nigeria

Leaf

Belgium,
Nigeria

Antimalarial, antimicrobial,
analgesic

[54]

Fagara
zanthoxyloides

Rutaceae

Uganda

Root
and
stem

California,
Uganda,
Nigeria

Antimalarial, antioxidant, and
antifungal

[55]

Andrographis
paniculata

Acanthaceae

India, Sri
Lanka

Roots

United
Kingdom,
Thailand,
Armenia

Antimalarial, immunostimulant,
anticancer

[56]

Anastatica
hierochuntica

Brassicaceae

North
Africa

Flowers

Japan,
Egypt,
Oman

Antimalarial, hepatoprotective

[57]

Funtumia
elastica

Apocynaceae

West
Africa

Bark

Ghana, USA

Antimalarial, antiinflammatory,
antimicrobial

[58]

Vernonia
amygdalina

Asteraceae

West
Africa

Leaves

Nigeria,
Uganda,
Singapore

Antimalarial, antioxidant,
hepatoprotective

[59]

Pycnanthus
angolensis

Myristicaceae

Tropical
Africa

Seeds

Nigeria,
USA,
California

Antimalarial, hypoglycemic,
antiplasmodial

[60]

Continued
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TABLE 19.1 Plants proved as antimalarial agents.dcont’d
Parts
used

Use in
which part
of world

Plant name

Family

Origin
of plant

Pharmacological activity

References

Morinda lucida

Rubiaceae

Nigeria

Leaves

Togo,
Ghana,
Japan

Antimalarial,
antispermatogenic

[61]

Bidens pilosa

Asteraceae

America

Flowers

Brazil,
Taiwan,
India

Antimalarial, antipyretic, and
anticancer

[40]

Cryptolepis
sanguinolenta

Asclepiadaceae

West
Africa

Roots

USA,
Portugal,
Ghana

Antimalarial, antimicrobial,
antidiarrheal

[62]

Tithonia
diversifolia

Asteraceae

Mexico
and Central
America

Flowers

Brazil,
Spain, USA

Antimalarial, antiplasmodial,
analgesic, and
antiinflammatory

[63]

Peschiera
fuchsiaefolia

Apocynaceae

Brazil

Bark

Italy, Brazil

Antimalarial, antiplasmodial,
antioxidant

[64]

Andira inermis

Leguminosae

Mexico

Flowers

Germany,
Brazil

Antimalarial, antiplasmodial

[65]

Harungana
madagascariensis

Hypericaceae

Tropical
Africa

Leaves

Nigeria,
France

Antimalarial, antimicrobial,
antiplasmodial

[66]

Virola
surinamensis

Myristicaceae

Brazil

Leaves

Brazil

Antimalarial, antiinflammatory,
antinociceptive

[67]

Vernonia amygdalina Del

Asteraceae

Africa

Leaves

Malaysia,
Nigeria,
Ibadan,
Uganda

Antimalarial, antioxidant, hepatoprotective, antihyperlipidemic, and anticancer

[68]

Cryptolepis
sanguinolenta

Apocynaceae

West
Africa

Root

USA,
Portugal

Antimalarial, antimicrobial,
antifertility

[69]

Cochlospermum
angolense

Cochlospermaceae

Congo

Bark

Italy, Berlin,
Congo

Antimalarial, antiviral

[70]

Abuta
grandifolia

Menispermaceae

South
America

Roots

United
Kingdom,
East Asia

Antimalarial, antiplasmodial

[71]

Picralima nitida

Apocynaceae

Africa

Seeds

Africa,
Germany,
Nigeria

Antimalarial, antidiabetic, antioxidant, and antishigellosis

[72]

Momordica
foetida

Cucurbitaceae

Tropical
Africa

Leaves

Italy,
Uganda

Antimalarial, antioxidant, and
antiulcer

[73]

Distephanus
populifolius

Asteraceae

South
West Indian
Ocean

Root

South
Africa,
Denmark,
USA

Antimalarial, antimutagenic,
antioxidant, antimicrobial

[74]

Vernonia
colorata

Asteraceae

South
Africa

Leaves

South
Africa, Italy,
Germany

Antimalarial, antiinflammatory,
antidiabetic

[75]

Carpesium
rosulatum

Asteraceae

Korea

Whole
plant

South Korea,
Europe,
China

Antimalarial, anticancer,
antiplasmodial

[76]

Selaginella
bryopteris

Selaginellaceae

India

Whole
plant

India, USA

Antimalarial, anticancer

[77]

Continued
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TABLE 19.1 Plants proved as antimalarial agents.dcont’d
Origin
of plant

Parts
used

Use in
which part
of world

Plant name

Family

Pharmacological activity

References

Cassia siamea

Fabaceae

South
Asia

Bark

Congo,
China, India

Antimalarial, antiinflammatory,
analgesic, vasodilator, antiinflammatory, antiviral, and
anxiolytic

[78]

Moronobea
coccinea

Clusiaceae

South
America

Latex

USA, France

Antimalarial and
antiplasmodial

[79]

Brucea javanica

Simaroubaceae

South
East Asia

Seeds

South Korea,
USA

Antimalarial

[80]

Diospyros montana Roxb

Ebenaceae

India

Leaves

India,
Pakistan

Antimalarial

[81]

Sapindus
emarginatus

Sapindaceae

India

Leaves

India, Japan

Antimalarial

[82]

Cassia singueana

Fabaceae

Nigeria

Root
bark

Nigeria,
Tanzania,
South Africa

Antimalarial

[83]

Artemisia
japonica

Asteraceae

Japan

Aerial
parts

Sri Lanka,
United
Kingdom

Antimalarial

[53]

Phyllanthus
niruri

Phyllanthaceae

China

Aerial
parts

India, Chile,
Nigeria

Antimalarial, hepatoprotective

[84]

Cyperus
rotundus

Cyperaceae

Africa

Tuber

India, Iran,
Republic of
Korea

Antimalarial

[85]

Morinda lucida

Rubiaceae

Senegal

Leaves

Togo, Japan,
Ghana

Antimalarial, antidiabetic,
antioxidant

[61]

19.1.10 Prevention, control and prognosis
Malaria control is as simple as prescribing 2 tablets of chloroquine a week. The following actions are necessary: The use of
mosquito nets, screening of houses and the use of repellents ward off the mosquitoes because of their odor and thus
dissuade the mosquitoes from biting. It should be noted that an ideal repellant should be nonirritant, nontoxic, stainless, and
harmless to individuals and effect should last for at least 12 h [86]. Spray killing which aims at cutting short the life span of
mosquitoes to less than 10 days so that they may not spread the disease. Space-spray insecticides kill the mosquitoes by
contact immediately and they must be applied at least twice a week. Pyrethrum is a contact poison, which paralyses the
nervous system of the insects. The use of chlorinated hydrocarbons and other synthetic insecticides prolong the residual
killing effect when sprayed on the surface on which mosquitoes rest.
The prognosis is generally good with effective treatment. About 10% of cerebral malaria patients can develop complications such as behavior disturbances, hemiplegia, blindness, ataxia, and loss of hearing [87].

19.1.11 Conclusion
This chapter presents the efﬁcacy of medicinal plants used to treat malaria. The study featured a rich diversity of antimalarial medicinal plants with equally divergent herbal remedy preparation. There is a crucial need for the development of
novel drugs to treat malaria. Biological investigations into plants used traditionally for primary health care are one evident
way in which searching for new leading compounds should concentrate. Many countries have wide experience in the use of
medicinal plants and the required knowledge spans many centuries. Researchers are working in the isolation for identiﬁcation of the active ingredients and for understanding the mechanism of inhibition. As the products of the plant are used,
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worldwide and bioactive compounds isolated from these plants can serve as biomarkers in a variety of medicinal herbs.
These formulations can meet the needs of the time against malaria. The next chapter (Chapter 20) presents an in silico
study of the effectiveness of phytoconstituents present in Bulbine frutescenes and other phytochemicals such as methylated
ﬂavonoids and sesquiterpene lactones on various protein targets against different life cycle stages of malarial parasite and
its metabolism.
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20.1 Introduction
Malaria is one of the most prevalent infectious diseases across the globe especially in Africa and South Asia. Plasmodium
falciparum is a microscopic parasite which is responsible for malaria. The disease transmits through the genus Anopheles.
The severe disease condition leads to multiple ailments such as cold, fever, and sometimes death. Necessary action should
be taken to inhibit the malaria-carrying mosquitoes to avoid their population growth in the surroundings. The house walls
should be sprayed with insecticides and antimalarial drugs with different combinations and concentrations. To control
malaria disease, many international boards have been established across the globe. The major issues related to malaria are
the development of antimalarial drugs. Since the last decades, people are focusing on natural products because of its
easier availability and cost-effectiveness. Several pharmacological and medicinal reports demonstrated the prominent
roles of phytochemicals in treating malarial diseases [1]. Because of its effective potential on malaria, they are now
being used throughout the world and in the revolutionary approach for antimalarial drug discovery. There are multiples of
natural products which are already approved by FDA and are under clinical trials. The new era of computer-aided drug
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discovery (CADD) has become so prominent in the quest to identify lead compounds against malaria. The optimization of
lead compounds and their validation requires a pharmacokinetic study with multiple parameters including absorption,
metabolism, excretion, toxicity, and distribution (ADME/T) [2].
In vitro and In vivo screening comprises the validation of the lead compounds. During clinical trials, drug passes
through the different parametric stages to get approval for treatment of disease. P. falciparum parasite spreads through
vertebrates and invertebrates in the environment. The control on the P. falciparum parasite life cycle (Fig. 20.1) can be the
best step for prevention of malarial disease in humans. To achieve this, the study of the life cycles of P. falciparum may
help in antimalarial drug discovery and malaria treatment.
Firstly, the primary host Anopheles mosquito, which carries P. falciparum parasite, bites a person and introduces the
parasite into their bloodstream as a secondary host. Then this parasite immediately modulates to haploid sporozoite and
then schizont. Schizont contains more than a 1000 haploids called merozoites. Within a week of infections, schizonts
ruptures, kills hepatocytes, and releases millions of merozoites into the bloodstream. This event is commonly known as
asexual exoerythrocytic schizogony. Later, in the liver, the dormant parasite called as hypnozoites causes a relapse of
Plasmodium vivax and Plasmodium ovale malaria in humans. Relapse characteristics comprise asymptomatic latency
remains up to months/years. Various tactics are available to treat the parasites remains in the body, but it’s critical to clear
the whole parasites from the bloodstream which sometimes results in chance mitotic division. After maturation, parasite
feeds hemoglobin present in the erythrocytes and leads to transformation into trophozoites. Early merozoites are produced
by the maturation of trophozoites into schizonts. Both schizont and erythrocytes rupture in 2e3 days, which releases
merozoites that severely invades other uninfected erythrocytes. Major symptoms in the affected person show some
paroxysm such as cold and fever. The infected erythrocytes containing merozoites release toxins into the bloodstream.
Some fractions of erythrocytes then turn to gametocytes and further into male and female haploid gametes inside the gut of
mosquito. The male mosquito fertilizes the female gametes for producing a diploid zygote. Ookinete is developed by the
meiotic division of zygote. Ookinete is a highly motile zygote with the capability to migrate and invade semipermeable
membranes of the mosquito gut wall through the process called the peritrophic matrix. The ookinete transforms into oocyte
when it is residing in between the gut wall and basal lamina. In the hemocoel cavity, the oocyte breaks and releases
sporozoites. These sporozoites migrate to the salivary glands of mosquito and pass into the bloodstream of a host whenever
it bites for a meal. Transformation of the parasite from one form to another form supports its developmental process and
spread of disease. To eradicate the malarial disease, we should try to develop different strategies for inhibiting such
function of a speciﬁc cycle in both primary and secondary host systems.

FIGURE 20.1 Life cycle of Plasmodium falciparum.
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20.1.1 Antimalarial products: A historical preview
Plants have a history of being used as a source of medicine and using as a foundation for many pharmaceuticals drugs
nowadays [3]. The medicinal uses of plants are labeled already on Assyrian clay tablets dated about 2000 B.C. and
acknowledged in the Egyptian culture, Indian Ayurveda [4], conventional Chinese medicine (TCM) [5] and numerous
European documents. Conventional medicine support drug discovery paradigm from ‘ﬁnding new-entity drugs’ to
‘combining existing agents’ [6]. Modern pharmaceutical industries producing natural and synthetic medicine and giving
better orientation in the ﬁeld of drug discovery. Several reviews on drugs have been published in between 1981 and 2006,
in which 62% of the drugs comprises small natural molecule derived from the natural product known as semi-synthetic.
These small molecule inhibitors also comprise natural product inspired pharmacophores (natural product analogs). The
output of modern antimalarial pharmaceutical research and development has inspired new interests in the discovery of
natural compounds. In the pharmaceutical industry, high-throughput screening of chemical libraries against potential
targets was emphasized and giving opportunities to identify the novel antimalarial compound.

20.1.2 Current antimalarial compounds
Quinine, a 4-methanolquinoline alkaloid isolated from the bark of Cinchona species in 1820, is the oldest and most
signiﬁcant antimalarial drugs among all the drugs being used nowadays [7]. Quinine alkaloid showed much potential
against P. falciparum. For the development of the antimalarial drug such as 4- and 8-aminoquinoline classes, it is supposed
to be the prototype and later represented by chloroquine (CQ) and primaquine, respectively. CQ was one of the effective
and affordable drugs for the treatment of malaria. Quinine, a stage-speciﬁc blood schizonticide, acts mainly on the mature
trophozoite in their life cycle. The Chinese conventional treatment of malaria comprises the utilization of Artemisia annua
and its active compound such as artemisinin [8]. Artemisinin has a greater chemotherapeutic index in comparison to
chloroquine. It also has effective potential against chloroquine-resistant strains of malaria [9]. Another Chinese conventional medicine Dichroic febrifuga has been reported for the treatment of malaria [10]. In another study, febrifugine has
been shown for the P. vivax and P. ovale malaria, but its hepatotoxicity makes it unsuitable as an antimalarial drug [11].

20.1.3 Natural antimalarial compounds and their advantage
Natural compounds are the best-known antimalarial drugs worldwide. Current investigations have been reported that
numerous extracts of many plants possess antiplasmodial activity. Cinchona species and their component alkaloid quinine are
widely well-known as an effective drug for the antimalarial activity. A well-known stereoisomer of the quinine namely
quinidine showed better potential than the quinine [12]. Identiﬁcation of the new antimalarial drugs and therapies are still a
priority for malarial therapy because of its resistance activity against the drugs. Natural products signify a source for
pharmacophores development which can accommodate excellent activity to kill the parasites. Herbal medicinal products are
frequently supposed as being safe by the patient and disease-endemic community. Furthermore, natural products possess
structural and chemical diversity which give opportunities to modify the structure according to the need as an inhibitor.

20.1.4 Computer-based drug designing and antimalarial drug discovery
Most of the antimalarial drugs are small molecules that are designed to bind, interact, and modulate the biological activity
of the receptors. Computer-Aided Drug Discovery (CADD) is being applied to recognize hits, pick leads, and optimize
drug leads by studying their physicochemical, pharmaceutical, and ADMET (absorption, distribution, metabolism,
excretion, and toxicity) properties [2]. The main goal of CADD is to amplify the set of molecules with practically active,
drug-like properties, and eliminate compounds with unsuitable properties such as inactive, reactive, toxic, and poor
ADME/T. The ADEM/T property of compounds provides few important in silico predictions of the lead compounds,
which comprises bioavailability, bloodebrain barrier crossing, and inhibition of K ion channels, etc. In silico screening
method is the principal technique for initial identiﬁcation of natural products as inhibitors of target protein and predicting
their biological binding mode. In other words, in silico modeling is utilized signiﬁcantly to reduce time and resource
supplies of chemical synthesis and biological in vitro and in vivo testing [2].

20.1.4.1 Recent targets for antimalarial drug discovery
20.1.4.1.1 Heat shock proteins (HSPs)
Heat shock proteins (HSPs) are the chaperones that direct the protein folding and makes them functional [13,14]. HSP
family comprises various numbers of proteins, but HSP90 is the best-studied chaperons. HSP90 plays an important role in
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eukaryotic growth and development. Cytosolic HSP90 forms chaperon complex with Hsp70 and Hsp60. This multichaperone complex facilitates folding and modulates functional activity of the various kinases and transcription factors
[14]. Various Hsp90 inhibitors are reported and are under clinical trials for cancer pathophysiologies [15e17]. ATPase
activity of Hsp90 required for the chaperone action onto the protein and their release from their pocket. Inhibition of
ATPase activity of Hsp90 at N-terminal prevents its function and interaction with respective protein [18]. P. falciparum
Hsp90 (PfHSP90) and eukaryotic Hsp90s possess substantial similarity at the site of ATP-binding domain [19,20].
Cytosolic P. falciparum Hsp90 expression increases because of the stress during erythrocytic life cycle and facilitates
developmental process of the parasite [19,20]. A study reported that Hsp90 acts as a drug target for Trypanosoma infections and malaria [21].
20.1.4.1.2 PfATP6
Several proteins have been demonstrated as a drug target for novel antimalarial drugs [22]. For the ﬁrst time in 1993,
ATPases encoded by P. falciparum was reported as a drug target for new antimalarial therapies [23]. Another study
demonstrated that PfATP6, a sarco/endoplasmic reticulum Ca2þ-ATPase (SERCA) homologue, was the main target
against antimalarial artemisinin drug [24].
20.1.4.1.3 OMPDC
Orotidine 50 -monophosphate decarboxylase (OMPDC) facilitates the pyrimidine nucleotides synthesis pathway, which is
essential for the malaria parasites [25]. Unlike human that have salvage pathway, malaria parasites comprise de novo
nucleotide synthesis pathway. Being as an important enzyme for the crucial step of the pyrimidine nucleotides synthesis
pathway, OMPDC has been demonstrated as a selected target for antimalarial drug discovery [26].

20.1.4.2 Recent lead group of compounds for antimalarial drug discovery
20.1.4.2.1 Bulbine frutescens
About 50 species of Bulbine are used in traditional herbal medicine system. It includes Bulbine asphodeloides, Bulbine
alooides, Bulbine narcissifolia, Bulbine natalensis, Bulbine latifolia, and Bulbine frutescens species. B. frutescens is
indigenous to South Africa and occur as a common garden plant. B. asphodeloides, B. natalensis, and B. latifolia are wildharvested and sold on markets. Bulbine comes from the Greek word bolbine, a general word for a bulbous plant, but
particularly Ornithogalum. The name is misleading, as plants do not have a bulbous base. Leaves can be used to make an
alcohol tincture. Quinones and anthraquinones are the major bioactive phytochemicals found in the B. frutescens. Isofuranonapthoquinone, chrysophanol dimethyl ether, knipholone, 1,8-dihydroxy-3-methylanthraquinone, etc., are some of
the phytochemicals found in B. frutescens plant extract. The isofuranonaphthoquinone occurs in Bulbine plant species such
as Bulbine abyssinica, Bulbine capitata, and B. frutescens. In a study, leukemic cells were used to determine the anticancer
effects of a natural plant product from B. frutescens [27].
20.1.4.2.2 Methylated flavonoids
Flavonoids are an important class of phytochemical. During their natural synthesis, the ﬂavonoid skeleton gets modiﬁed
with the help of different enzyme. This enzymatic modiﬁcation of ﬂavonoids reﬂects their variety of biological functions.
O-methylated (hesperetin, homoeriodictyol, sakuranetin, isosakuranetin, sterubin, kaempferide, annulatin, combretol,
europetin, laricitrin, 5-O-methylmyricetin, acacetin, chrysoeriol, diosmetin, biochanin A, calycosin, formononetin, and
glycitein) and C-methylated (7-O-methylapigenin, 7-O-methylnaringenin, 7-O-methyl quercetin, sinensetin, matteucinol,
hirsutidin, tricin, and zapotin) ﬂavonoids are such naturally modiﬁed ﬂavonoid having various biological activities and
have role in digestive process. Cleistocalyx operculatus (Myrtaceae), Pisonia grandis (Nyctaginaceae), and Talinum
triangulare are some plants that are known for the presence of methylated ﬂavonoids [28,29].
20.1.4.2.3 Sesquiterpene lactones
Terpenes are the important group of phytochemicals. The basic unit of terpenes consists of isoprene, which is a simple
hydrocarbon molecule. They are the most numerous and structurally diverse plant natural products [30]. The isoprene unit
assembles itself in various ways to produce a wide array of phytochemicals. Based on the unit of isoprene in the ﬁnal
phytochemical, terpenes may be monoterpene (C10), diterpenes (C20), and triterpenes (C30). A different combination of
isoprene unit constitutes a biologically potent group of phytochemicals known as sesquiterpenes. They contain three isoprene
units (C15). Sesquiterpenes are known for antimicrobial, antifungal, anticancer, and other biologically active potential.
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Sesquiterpenes, containing cyclic esters of hydroxycarboxylic acids (lactone), are known as sesquiterpene lactones. The
lactone ring contains a 1-oxacycloalkan-2-one moiety which sometime present shows unsaturation or replacement of the ring
carbon atom(s) with heteroatoms. These compounds are found in various plants and are well-known for their toxic proﬁle.
Nowadays these compounds act as potential emerging drug moiety in a dose restriction manner.

20.1.4.3 Protein preparation for antimalarial drug discovery
The crystal structure of different target proteins (such as HSP90, PFATP6, PF orotidine 50 -monophosphate decarboxylase,
and plasmepsin II) may be retrieved from Protein Data Bank. This databank comprise of three dimensional structure
information/data of proteins (https://www.rcsb.org/). Next step is the removal of heteroatoms which leaves only the residues
of the receptor. The protein is prepared using AutoDockTools (ADT) by addition polar hydrogens to the macromolecule.
This is an essential step to correct the calculation of partial charge. Finally, Gasteiger charges are calculated for each atom of
the macromolecule.

20.1.4.4 Ligand preparation for antimalarial drug discovery
Different literature database has been searched for methylated ﬂavonoids, phytochemicals present in bulbine phytochemicals, and sesquiterpene lactone. At the end of a literature survey, we found the presence of 14 ﬂavonoids, 21 bulbine
phytochemicals, and 1557 sesquiterpene lactone.
The literature based phytoconstituents will be used as ligand for molecular docking. The 3D or 2D structure of phytochemicals of targeted proteins like HSP90 (3K60), plasmepsin 2(1LF2), P. falciparum ATPase (1U5N) and Plasmodium
orotidine 50 decarboxylase (3N3M) and respective reported inhibitors of particular protein were retrieved from NCBI
PubChem in sdf format. Open Babel molecule format converter was used for conversion of 2D to 3D conformation, Marvin
Sketch software was performed for the conversion of sdf to pdb (for docking) and mol (for molecular properties prediction)
ﬁle. Ligands energy was minimized by applying mmff94 force ﬁeld and conjugate gradients optimization algorithm using
PyRx-Python prescription 0.8 [31] for 200 steps.

20.1.4.5 Molecular docking as a tool for antimalarial compound screening
Crystal structure of target HSP90 (3K60), PFATP6 (1U5N), PF orotidine 50 -monophosphate decarboxylase (3N3M) and
plasmepsin II (1LF2) were obtained from the RCSB Protein Data Bank. The preparation of target enzyme/proteins with the
help of Auto Dock Tools involved addition of hydrogen atoms to the target. It is a necessary step for the computation of
partial atomic charges. Gasteiger charges were considered for each atom present in the target in Auto Dock 4.2.

20.1.4.6 Ligandeprotein interaction of new antimalarial compounds
The ligands were docked against targeted proteins to predict the binding interaction. The result of binding interaction
is summarized in Table 20.1. The table contains residues which forms hydrogen and hydrophobic bond. It includes
binding pattern for the proteins against the ligands. The ligands such as (2S)-2-(3,4-dimethylphenyl)-5,6,7-trimethyl-3,4dihydro-2H-1-benzopyran-4-one, (2S)-2-(3,4-dimethylphenyl)-5,6,7,8 tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one,
3,3a,6-trihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-4-[(2-methyl butanol)oxy]-2-oxo 2H,3H,3aH,4H,5H,
6H,6aH,7H,8H,9bH-azuleno[4,5-b]furan-7-yl 6-methyl octanoate, (1S,2S,6R,7S,9R,10R,11S,12R,14S)-7,11-dihydroxy-9,
14-dimethyl-5-methylidene-4-oxo-3,13-dioxatetracyclo [7.5.0.0^{2,6}.0^{12,14}] tetradecane- 10-yr 2-methylprop-2-enoate
showed better binding energy between (8.5 kcal/mol to 10.7 kcal/mol) against targeted proteins such as plasmepsin 2
(1lf2), HSP90 (3k60), ATPase (1u5n), and Plasmodium omp 50 decarboxylase(3n3m) as compared to standard inhibitors.

20.1.4.7 In silico antimalarial potential of phytochemicals
Different groups of phytochemicals such as methylated ﬂavonoids, phytochemicals present in B. frutescens, and sesquiterpene lactones were used as ligands to dock against different target proteins. Binding patterns of test phytochemicals
(methylated ﬂavonoids, sesquiterpene lactones, and B. frutescens) are given in Table 20.1.

20.1.4.8 Proteineligand interaction
The binding of the modiﬁed ligand with active sites of the targeted proteins is known as proteineligand interaction. The
interaction between the protein and ligand showed the position of the orientation of a ligand when it is bound to the

Amino acids residues of different proteins involved in the hydrogen bonding and hydrophobic interaction with methylated flavonoid.
S.No

Protein
(PDB)

Ligand

Hydrogen bonding

Hydrophobic interaction

1

1u5n

(2E)-3-(3,4-dimethoxyphenyl)-1-(6-hydroxy-2,3,
4-trimethoxyphenyl)prop-2-en-1-one

Asp419, Lys418, Glu398,
Asn458, Lys749

Val372, Asn454, Ser399

2

1lf2

(2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,
4-dihydro-2H-1-benzopyran-4-one

Tyr192

Ser218, Phe120, Met15, Ile32, Phe111, Gly216, Ile123,
Ser79, Asp214, Tyr77, Asp34, Gly36, Val78, Thr217

3

3k60

(2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,
4-dihydro-2H-1-benzopyran-4-one

Asn37

Thr171, Ala38, Ala41, Asp79, Leu34, Met84, Ile173,
Phe124, Leu93, Gly123, Asn92

4

3n3m

(2S)-5,7-dihydroxy-2-(3-hydroxy-4methoxyphenyl)-3,
4-dihydro-2H-1-benzopyran-4-one

Gly293, Thr195

Gln269, Arg294, Asn104, Asn291, Asp23, Pro264,
Asp136, Phe107, Val240, Lys138, Leu191, Thr194

Amino acids residues of different proteins involved in the hydrogen bonding and hydrophobic interaction with Bulbine frutescens.
5

1u5n

[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl9,10-dioxo-9,10-dihydroanthracen-1-yl)oxy]oxan-2-yl]
methyl 3,4,5-trihydroxybenzoate

Asn59, Glu55

Asp63, Gly111, Leu104, Ala108, Asn107, Glu316,
Gly317

6

3n3m

(10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,
10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,
10-dihydroanthracen-9-one

Asp23, Asn291

Gln269, Arg294, Phe107, Asn196, Pro264, Thr195,
Lys138, Thr194, Val240, Asn104

7

3k60

(2,3,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,
10-dioxo-9,10-dihydroanthracen-1-yl)oxy]oxane-2carboxylic acid

Arg98, Phe124, Asn37,
Thr171

Asn92, Met84, Ala41, Asp79, Ile77, Ala38, Leu34,
Ile173, Leu93

8

1lf2

(10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,
10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,
10-dihydroanthracen-9-one

-

Phe120, Met15, Ala219, Phe111, Thr114, Ile32, Ser79,
Ser218, Ile290, Thr217, Val78, Gly216

Amino acids residues of different proteins involved in the hydrogen bonding and hydrophobic interaction with sesquiterpene lactones.
9

1lf2

PCID102276755

Asp214, Val78, Gly36,
Tyr192, Ser79, Ser218

Ile212, Leu292, Ser37, Tyr77, Ile300, Ala219, Ile290,
Thr217, Gly216, Phe111, Ile123, Phe120, Ile32

10

3k60

PCID102276755

Phe120, Arg98, Phe124,
Asn37

Gly121, Phe104, Val122, Thr101, Gly123, Ile12, Ile96,
Thr125, Asn92, Leu93, Thr171, Ile173, Met84

11

3n3m

PCID639694

Arg294, Asp136, Lys102

Gly293, Asn291, Asp23, Asn104, Gln269, Thr194,
Thr195, Asn196
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TABLE 20.1 Interaction pattern of different proteins and ligands.
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proteins. The surface structure of the protein and ligand were determined through the Pymol software after the modiﬁed
pdbqt ﬁles of protein and ligand were prepared. The surface structure showed the interaction between the protein and
ligands. The best binding afﬁnity of ligands showed the better interaction with targeted proteins. The binding afﬁnity was
found in the range of (6.0 kcal/mol) to (10.7 kcal/mol). The surface structure of the targeted proteins and best lead
compounds is shown in Fig. 20.2e20.4.

20.1.5 Results
20.1.5.1 Antimalarial drug target and novel lead compounds
Different proteins such as plasmepsin II (1lf2), PfATPase6 (1U5N), P. falciparum Hsp90 (3K60), and P. falciparum
orotidine 50 -monophosphate decarboxylase complex (3N3M) were used as antimalarial drug target for variety of phytochemicals such as methylated ﬂavonoids, phytochemicals present in B. frutescens plant and sesquiterpene lactones/similar
compounds.
20.1.5.1.1 Methylated compounds and target proteins
A methylated ﬂavonoid “(2E)-3-(3,4-dimethoxyphenyl)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)prop-2-en-1-one” exhibits
better 1u5n protein inhibition potential (11.9) in comparison with known standard inhibitor “artemisinin” (7.3). Four
compounds (2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one; 2-(3,4-dimethylphenyl)-3,
5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-2-(3,4-dimethylphenyl)-5,7-dimethyl-3,4-dihydro-2H-1-benzopyran4-one; and (2S)-2-(3,4-dimethylphenyl)-5,6,7-trimethyl-3,4-dihydro-2H-1-benzopyran-4-one showed about 8.5 Dock
Score against 1lf2 and 3k60 protein in comparison with standard inhibitors 9.4 (RS370) and 6.9 (tanespimycin),
respectively. Flavonoids “(2S)-2-(3,4-dimethylphenyl)-5,7-dimethyl-3,4-dihydro-2H-1-benzopyran-4-one” showed better
potential (about 8.8) against 3n3m proteins in comparison with standard inhibitors “(2R,3S,4R,5R)-5-(2,6-dioxo-2,3,6,9tetrahydro-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy phosphonic” (6.9). Residues involved and the type of
interaction formed in proteineligand (methylated ﬂavonoids) interaction is shown in Table 20.1.
20.1.5.1.2 Bulbine frutescens compounds and target proteins
B. frutescens compound “(10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6methyl-9,10-dihydroanthracen-9-one” exhibit better inhibition potential against 1lf2 and 3n3m proteins (7.9 and 9.8)
in comparison to known standard inhibitors “artemisinin”, and “(2R,3S,4R,5R)-5-(2,6-dioxo-2,3,6,9-tetrahydro-1H-purin-9-yl)-3,
4-dihydroxyoxolan-2yl]methoxy}phosphonic”. Compound “(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10dioxo-9,10-dihydroanthracen-1-yl)oxy]oxan-2-yl]methyl3,4,5-trihydroxybenzoate” and “(2,3,4S,5R,6S)-3,4,5-trihydroxy-6-[(8hydroxy-6-methyl-9,10-dioxo-9,10-dihydroanthracen-1-yl)oxy]oxane-2-carboxylic acid” showed 8.9 and 8.4 Dock
Score against 1u5n and 3k60 protein in comparison to standard inhibitors scores 9.4 (artemisinin) and 6.9 (tanespimycin),
respectively. Residues involved and the type of interaction formed in proteineligand (B. frutescens phytochemicals)
interaction is shown in Table 20.1.
20.1.5.1.3 Sesquiterpene lactones and target proteins
Two sesquiterpene lactone or similar compound “PubChem CID: 639694” and PubChem CID: 102276755 showed better
inhibitory potential against Plasmodium orotidine 50 decarboxylase and plasmepsin 2 proteins. Residues involved and the
type of interaction formed in proteineligand (sesquiterpene lactones) interaction are shown in Table 20.1.

20.1.6 Discussion
Different proteins are involved in malaria which changes the microenvironment of the parasite. These proteins play a
signiﬁcant role in homeostasis maintenance and some vital process such as proliferation, differentiation, and apoptosis in
malarial parasite. OMP decarboxylase, PfATPase6, plasmepsin 2, and HSp90 are the targeted proteins in the malarial life
cycle, which are involved in drug resistance. In this chapter, we explored potential phytoconstituents that inhibit various
proteins in malarial parasite life cycle.
Two aspartic proteases, plasmepsin 1 and plasmepsin 2, are encoded by malarial parasite. Plasmepsin 2, which helps in
hemoglobin degradation, is a novel target for an antimalarial drug. Human erythrocyte is invaded by malarial parasite in the
asexual stage of infection. When it enters in erythrocyte, parasite uses human hemoglobin as a food source and digests it
with the help of series of protease. Plasmepsin is also called as aspartic protease, which has an important role in
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FIGURE 20.2 Fig. A, C, E, G representing the surface structure of PDB 1u5n, 1lf2, 3k60 and 3n3m with methylated ﬂavonoids (2E)-3-(3,4-dimethoxyphenyl)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)
prop-2-en-1-one, (2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one, (2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one, and (2S)5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one, respectively. Fig. B, D, F, H representing the interaction pattern of PDB 1u5n, 1lf2, 3k60 and 3n3m with methylated
ﬂavonoids (2E)-3-(3,4-dimethoxyphenyl)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)prop-2-en-1-one, (2S)-2-(3,4-dimethylphenyl)-5,6,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one, (2S)-2-(3,4dimethylphenyl)-5,6,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-4-one, and (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one, respectively.
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FIGURE 20.3 Fig. A, C, E, G representing the surface structure of PDB 1u5n, 3n3m, 3k60, and 1lf2 with B. frutescens [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-9,10dihydroanthracen-1-yl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate, (10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracen9-one, (2,3,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-9,10-dihydroanthracen-1-yl)oxy]oxane-2-carboxylic acid, and (10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,10dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracen-9-one, respectively. Fig. B, D, F, H representing the interaction pattern of PDB 1u5n, 3n3m, 3k60 and 1lf2 with
B. frutescens [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-9,10-dihydroanthracen-1-yl)oxy]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate, (10R)-10-[(9R)-4,5-dihydroxy-2methyl-10-oxo-9,10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracen-9-one, (2,3,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-9,10-dihydroanthracen-1-yl)
oxy]oxane-2-carboxylic acid, and (10R)-10-[(9R)-4,5-dihydroxy-2-methyl-10-oxo-9,10-dihydroanthracen-9-yl]-1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracen-9-one, respectively.
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FIGURE 20.4 Fig. A, C, E representing the surface structure of PDB 1lf2, 3k60 and 3n3m with sesquiterpene lactones PCID102276755, PCID102276755 and PCID639694, respectively. Fig. B, D, F
representing the interaction pattern of PDB 1lf2, 3k60 and 3n3m with sesquiterpene lactones PCID102276755, PCID102276755 and 639,694, respectively.
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hemoglobin degradation, so it is a good target in antimalarial drug development. Cysteine protease and aspartic protease of
plasmepsin are considered as important antimalarial drug targets [32]. In vitro studies showed antimalarial activity of some
natural compounds such as myricetin and ﬁsetin against P. falciparum. In the present study, we found that phytochemical
sesquiterpene lactone has potential in silico inhibitory activity against plasmepsin 2 with docking score (9.4), in
comparison to standard inhibitor RS370, sesquiterpene showed 101% of binding activity.
We investigated the potential of standard inhibitors and new phytochemicals against PfATP6 protein. Artemisinin, a
potent antimalarial compound, is activated by iron and inhibits P. falciparum ATPase by inhibiting phosphorylation.
Endoperoxide bridge of artemisinin is left by intraparasitic heme, now this cleaved endoperoxide bridge transform to
carbon-centered free radical, which act as alkylating agent, and this reacts with both heme and parasite protein. Previous
studies of chloroquine and pyrimethamine/sulfadoxine (SP) were serious hindrance to the control of malaria. Artemisinin is
used at clinical levels to avoid malarial drug resistance [33]. A previous study with P. falciparum suggested that a
sarcoplasmic and endoplasmic reticulum Ca2þ ATPase (SERCA)-type protein encoded by a gene-denoted pfatp6 might be
the major chemotherapeutic target of these drugs [24]. In the present study, we found that methylated ﬂavonoids have
potential in silico inhibitory activity against PATPase6 with docking score (7.3), in comparison to standard inhibitor
artemisinin, ﬂavonoid showed 128% of binding activity.
HSP90 is involved in growth and development of malarial parasite, regulating its sexual development in human
erythrocyte, and has a crucial role in regulating ring to trophozoite stage transition in the parasite. It shows higher ATPase
activity than that of human HSP90. The previous reported HSP90 inhibitor, SNX-0723, in combination with PIK inhibitor,
synergistically reduces the liver stage parasite load [34]. An amino alcohol carbazole was identiﬁed as a pfHSP90 selective
inhibitor by virtually docking a large set of antimalarial compounds [35]. In the present study we found that ﬂavonoids
have in silico inhibitory potential against HSP90 with docking score (6.9). In comparison with standard inhibitor
tanespimycin, ﬂavonoid showed 133% of binding activity.
OMP decarboxylase enzyme exhibits rapid nucleic acid synthesis during malarial parasite intraerythrocytic growth
phase. In Plasmodium, purine and pyrimidine metabolic pathways are distinct from those of their human host. Thus,
targeting purine and pyrimidine metabolic pathways served as novel drug target in antimalarial drug discovery. The
previous report showed that TDHO, atovaquone, and pyrazafurin arrest growth of P. falciparum, and only moderate
decrease in UTP, CTP, and TTP were observed. 5-Fluoroacetates also arrest the growth of P. falciparum with major of de
novo biosynthesis inhibition of pyrimidine nucleotide [36]. In the present study, we found that phytochemical sesquiterpene lactone has potential in silico inhibitory activity against OMP decarboxylase with docking score (6.9), in
comparison with standard inhibitor XMP, phytochemicals showed 142% of binding activity.

20.2 Conclusion
Plant products are readily available because of their therapeutic. These plant products have been reported by various
traditional system of medicine for the treatment of various disorders. The present study showed that the phytoconstituents
present in B. frutescens and other phytochemicals such as methylated ﬂavonoids and sesquiterpene lactones have potential
to target various proteins involved in different life cycle stages of malarial parasite and metabolism involved. The data from
the present study also depicted the proteineligand interaction behavior of phytochemicals.
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21.1 Introduction
Inﬂammation can be described as an immunogenic response which is generated against the adverse stimuli and results in
pain and swelling. This biological phenomenon is governed by set of regulatory genes which result in the generation of
enzymatic proteins, i.e., cyclooxygenases (COX-1 and 2), along with iNOS systems. On receiving the inﬂammatory
stimulus, cells such as macrophages and monocytes get activated and release some factors such as tumor necrosis factors or
TNFs, interleukins or ILs, prostaglandins or PGEs, and histamines. All of these chemical mediators lead to the release of
inﬂammatory progenitors, which activates a series of events, which eventually leads to the activation of COX and iNOS
systems, ultimately leading to inﬂammation.
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Depending on the severity of inﬂammation, it can be divided into acute and chronic. Conditions such as arthritis,
inﬂammatory bowel diseases, rhinitis, dermatitis, folliculitis, inﬂammations of chemical, and those of microbial origins are
of main concern. To combat this condition, certain drugs are used, most of them being categorized as nonsteroidal
antiinﬂammatory drugs or NSAIDs, which include some common drugs such as aspirin, ibuprofen, and diclofenac. These
salts are approved by the Food and Drug Administration (FDA) and they regulate the COX systems, which help in
lowering down the inﬂammation. Despite having a quick and spontaneous antiinﬂammatory action, they carry certain side
effects with the possibility of damaging vital organs when used for a long time. Apart from the pharmaceutics, several plant
extracts and plant derivatives also play a key role in minimizing the inﬂammatory effects to a greater extent. These
phytoconstituents include quercetin, curcumin, capsaicin, estragole, mangiferin, tannin, catechin, caryophyllene oxide,
linolenic acid, and others, which have shown a strong antiinﬂammatory potential. This chapter attempts to provide the
basic understanding of the inﬂammatory mechanisms and the role of various bioactive lead compounds in minimizing the
inﬂammation.

21.1.1 Inflammation
Inﬂammation is a kind of response that living tissue gives to injury. It contains a well-designed cascade of ﬂuidic and
cellular changes. It causes both beneﬁcial and detrimental effects locally and systemically. In general, the simplest classiﬁcation is acute and chronic inﬂammation. Types of inﬂammatory diseases are the following:
l
l
l
l

Peracutedminutes or hours
Acuteda few hours to a few days
Subacutedthe nebulous period between acute and chronic
Chronicdweeks to months
Usually, inﬂammation progress is as given below:
Peracute/acute/subacute/chronic.

21.1.1.1 Acute inflammation
Acute inﬂammation is the early stages of inﬂammation. The injured or patient tissue color goes to red because blood ﬂow
increase and it swells because of edema ﬂuid. They have become as a result of vascular response to inﬂammation. The
main processes of the acute inﬂammation are changes in vessel caliber and consequently blood ﬂow (hemodynamics);
increased vascular permeability; and formation of the ﬂuid exudate [1].

21.1.1.2 Chronic inflammation
Chronic inﬂammation is a response to an inciting stimulus. It is different from acute inﬂammation. Chronic inﬂammation is
productive or proliferative and takes weeks to months. Cells in the chronic inﬂammatory process tend to produce substances that add new tissue, such as collagen and new blood vessels. Many of these changes also represent the repair
process and there is a blurry continuum between chronic inﬂammation and the whole repair process [2].
In general, chronic inﬂammation is characterized by inﬂammation, tissue destruction, and attempts to repair all
happening at once. Grossly, chronic inﬂammation does not have as much redness or heat as in the acute reaction.
Also, exudates are not as grossly apparent as they are in acute inﬂammation. Because of the ﬁbroplasia and neovascularization, areas affected by chronic inﬂammation tend to be slightly swollen and ﬁrm. If ﬁbrosis is extensive, the
lesions can be large and disﬁguring. Fibrosis (granulation tissue) is the best indicator that the inﬂammatory response
is chronic.

21.1.2 Effects of inflammation
Inﬂammation can have both local and systemic effects. Fever, malaise, and leukocytosis are the systemic effects of acute
inﬂammation. Leukocytosis, an abnormally high number of circulating white blood cells, is a regular point of inﬂammatory
reactions. Generally, increased neutrophils indicate a bacterial infection, whereas increased lymphocytes are most likely to
occur in viral infections. The local effects are usually clearly beneﬁcial for the destruction of invading microorganisms, but
at other times they appear to serve no obvious function or may even be harmful.
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21.1.3 Major inflammatory diseases
21.1.3.1 Alzheimer disease
Alzheimer is a biochemical and neuropathological disease of the brain. People who work on Alzheimer believe that there is
a correlation between Alzheimer and inﬂammatory pathways. Using the antiinﬂammatory drugs for long term is linked
with minimized risk to develop disease [3]. Scientists conﬁrm that there is a relationship between Alzheimer and
inﬂammatory, and there is a realization that some components of this complex molecular and cellular machinery are most
likely promoting pathological processes leading to Alzheimer, whereas other components serve to do the opposite. The
challenge will be to ﬁnd ways of ﬁne tuning inﬂammation to delay, prevent, or treat Alzheimer.

21.1.3.2 Asthma disease
Asthma is the most common disease which is triggered by environmental factors, airﬂow obstruction, bronchial hyperresponsiveness, and inﬂammation [4]. Both smooth muscle contraction and inﬂammation are the dominant specialty which
causes narrowing of the airway and obstruction.

21.1.3.3 Bowel diseases
Inﬂammatory bowel diseases are a group of inﬂammatory conditions in which the body’s own immune system attacks parts
of the digestive system. Crohn’s disease and ulcerative colitis are most known inﬂammatory bowel diseases. Both are
caused by the chronic inﬂammation of the gastrointestinal tract. Crohn’s disease frequently affects the end of the small
intestine and the beginning of the large intestine. Ulcerative colitis is characterized by inﬂammation in the large intestine
(colon) and the rectum. The inﬂammation in ulcerative colitis occurs only in the innermost layer of the intestinal lining [5].

21.1.3.4 Atopic dermatitis disease
The most known inﬂammatory disease of the skin is called atopic dermatitis. It is a disease which precedes asthma and
allergic disorders [6]. The genetic sensitivity to make IgE antibody respond to most known environmental or food protein
antigens shows that it is strongly associated with an incidence of approximately 80% in infants with atopic dermatitis.

21.1.3.5 Nephritis disease
Nephritis is a kind of disease which causes swelling or inﬂammation of the glomerulus. This inﬂammation reduces the
kidney’s ability to ﬁlter waste from the blood. Nephritis is often used as an abbreviation for glomerulonephritis [7].

21.1.3.6 Periodontal disease
There are two most known diseases about the periodontium. Gingivitis is the ﬁrst one which is outlined as an inﬂammation
of the gingiva, and the connective tissue attachment to the tooth remains at its original level [8]. The disease is limited to
the soft tissue compartment of the gingival epithelium and connective tissue. The second is periodontitis, which is an
inﬂammation of the supporting tissues of the teeth with progressive attachment loss and bone destruction.

21.1.4 Plants and leads bioactive compounds with antiinflammatory activities
The natural environment bestows the world with medicinal plants to take care of health needs. The potentials of the plant as
sources of drugs have long been recognized. Over the years, natural products from plants have indeed offered humanity
clinically useful drugs in treating inﬂammation-related diseases such as aspirin, quinine, ginseng, etc. Some of these plants
are shown in Table 21.1.
They are the symbolic antiinﬂammatory herbals in almost each family in the plant kingdom. Many of these plants have
proven oral and published evidence of their use in the treatment of inﬂammatory disorders in traditional medicine. For
some of the plants, the intrinsic antiinﬂammatory activity is inferred from other identiﬁed pharmacological activities related
to modulation of the complex inﬂammatory response [41].
Currently, there is an increasing methodical evidence for the antiinﬂammatory activity of many herbs. For some,
the antiinﬂammatory activity has been extensively studied while preliminary evidence has been established for
others. A number of antiinﬂammatory bioactive constituents have been isolated and characterized structurally and
pharmacologically.

S.
No.

Structure of the lead
bioactive compound

Methodology of analysing
the antiinflammatory effect
of the plant

Plant species

Part(s) used

Leads bioactive
compounds

1

Turmeric (Curcuma longa)
Zingiberaceae

Leaves

Curcumin

Carrageenin-induced paw
edema model

[9]

2

Chili Pepper (Capsicum species) Solanaceae

Fruits

Capsaicin

Ethanol-induced inflammation of
gastric mucosa;
Carrageenin-induced paw
edema model

[10,11]

3

Basil (Ocimum basilicum)
Lamiaceae

Leaves, flowering
tops

Estragole

Carrageenin- and dextraninduced paw edema model

[12]

4

Black cumin (Nigella sativa)
Ranunculaceae

Seeds

Thymoquinone

Induced pancreatic ductal
adenocarcinoma (PDA)

[13]

5

Devils claw (Harpagophytumprocumbens)
Pedaliaceae

Root

Harpagoside

ELISA in Lipopolysaccharide
(LPS)-stimulated monocytic
THP-1 cells

[14]

6

Black currant (Ribes nigrum)
Grossulariaceae

Leaves

Proanthocyanidins
(PACs)

Carrageenin-induced paw
edema model

[15]

7

Mangabeira (Hancornia speciosa)
Apocynaceae

Fruits

Rutin, chlorogenic acid

Xylene-induced ear edema
model;
Carrageenan-induced peritonitis
model;
Zymosan-induced air pouch
model.

[16]

Monosodium urate crystalinduced NACHT-LRR-PYDcontaining protein-3 (NALP3)
inflammasome

[17]

Rutin

8

Autumn crocus (Colchicum
autumnale) Colchicaceae

Colchicine

References
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TABLE 21.1 Plants and leads bioactive compounds with antiinflammatory activities.

9

Green tea (Camellia Sinensis)
Theaceae

Leaves

Chlorogenic acid; epigallocatechin-3-gallate

CCL 4 induction to cause liver
inflammation

[18e20]

10

Fruit varieties

Apples, grapevines,
berries, broccoli, red
onions

Quercetin

Review

[21,22]

11

Black garlic (Allium nigrum)
Amaryllidaceae

Seed

S-allylcysteine

LPS-induced inflammatory
response model

[23]

12

Cat’s Claw (Uncaria tomentosa)
Rubiaceae

Bark

Mitraphylline

LPS-induced inflammatory
response model (Elisa multiplex)

[24]

13

Citrus fruits (Orange, Lemon,
Lime)

Epicarp, mmesocarp,
and endocarp

Hesperidin

Azoxymethane (AOM)-induced
mouse colon carcinogenesis.
(listopathological analyses for
PCNA index and modulations in
expression of inflammatory
markers were used for confirming the antiinflammatory
activity)

[25]

14

(Myracrodruo urundeuva)
Anacardiaceae

Bark

Tannin and catechin

Carrageenan- and dextraninduced paw edema model in
mice

[26]

(+)-Catechin

15

Cactus (Opuntiafiscus indica)
Cactaceae

Stem

b-Sitosterol

Adjuvant-induced pouch granuloma in mice

[27]

16

Jamaican Nettletree (Trema
micrantha) Ulmaceae

Leaves

b-Sitosterol

Carrageenan-induced paw
edema model in mice

[28]
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Continued

S.
No.

Leads bioactive
compounds

Plant species

Part(s) used

17

Crateva (Crataevareligiosa)
Capparaceae

Stem bark

Lupeol and lupeol
linoleate

18

Tansy (Tanacetum vulgare)
Asteraceae

Aerial parts

Parthenolide,
methoxyflavones

Structure of the lead
bioactive compound

Methodology of analysing
the antiinflammatory effect
of the plant

References

Carrageenan-induced paw
edema model in mice

[29]

12-0-Tetradecanoylphorbol-13acetate (TPA)-induced mouse
ear edema

[30]

Lupeol

Parthenolide

19

Himalayan fir (Abies pindrow)
Pinaceae

Leaves

(þ)-Pinitol

Carrageenan-induced paw
edema model

[31]

20

Lichen (Roccella montagnei)
Roccellaceae

Whole plant

(þ)-Usnic acid

Carrageenan-induced paw
edema model and cotton pellet
einduced granuloma models in
rats

[32]

21

Neem (Azadirachta indica)
Meliaceae

Fruit skin

Azadiradione

Carrageenan-induced paw
edema model

[33]

22

Custard apple (Annona squamosa)
Annonaceae

Bark

Caryophyllene oxide

Carrageenan-induced paw
edema model

[34]
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Holy Basil (Ocimum sanctum)
Lamiaceae

Seed oil

Linolenic acid

Carrageenan-induced paw
edema model

[35]

24

Mondo grass (Ophiopogon
japonicus)
Asparagaceae

Leaves

Ruscogenin

Zymosan A-induced peritoneal
leukocyte migration in mice

[36]

25

Magnolia-vine (Schisandra
chinensis)
Schisandraceae

Fruit

Gomisin N
Gomisin J
Schisandrin C

LPS-induced inflammatory
response in murine macrophages (Raw 264.7 cells)

[37]

26

Ginseng(Panax ginseng)
Araliaceae

Leaves

Ginsenosides

Tumor necrosis factor-a-mediated inflammation

[38]

Croton oil-induced ear edema in
mice model

[39]

Carrageenan-induced paw
edema model in mice

[40]

Gomisin N

Ginsenoside Rg1

27

Pepper vine (Piper ovatum)
Piperaceae

Leaves

Piperovatine
Piperlonguminine

Piperlonguminine

28

Fagara plant (Zanthoxylum
zanthoxyloides)
Rutaceae

Roots

3,4-Dihydro-2-dimethyl2H-1-benzopyran-6butyric acid (DBA)
Fagaramide (piperonyl4-acryliciso-butylamide)
Fagaramide
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21.1.5 Mode of action of antiinflammatory drugs
The human system comprises of different types of immune systems namely cell-mediated or humoral immunity and innate
immunity. Inﬂammatory mechanism comes under the category of innate immune system [42e44]. The mechanisms
involved in the inﬂammatory pathway are governed at certain regulatory points, which involve physiological and
immunological responses [45e47] and the details of which has been elaborated in Fig. 21.1. Thus, to combat these
stimulus, it is important to understand the molecular mechanisms that underlie this phenomenon.
The inﬂammatory response of an individual is governed by the set of genes that decide the immunological fate of that
organism. These set of genes comprise genes responsible for the generation and proliferation of immunological cells,
mainly leukocytes and monocytes [48,49] and also the chemokines produced by them such as TNFs, ILs, prostaglandins,
and histamines [50]. These signals often initiate a set of reaction which provokes the inﬂammatory response leading them
to be either chronic or acute [44,46,51].
To combat these responses, several drugs of plant origin and chemically synthesized have been made, which acts on
various target molecules, thus suppressing their effect and generating an antiinﬂammatory response. Most of these have
speciﬁc targets such as the cyclooxygenase systems (COX 1 and 2), PGE-2, TNF, and ILs, as these are the main inducers
of pain and inﬂammatory responses [43]. Cyclooxygenase converts arachidonic acid to an effective vasoconstrictor
thromboxane A2 and prostacyclin. The function of thromboxane A2 is to increase platelet aggregation, while prostacyclin
acts to inhibit platelet activation and is an effective vasodilator [52].
The major approaches opted for the treatment comprise of drugs which mainly include NSAIDS, which has a strong
potency against the COX-2 system, thus reducing the level of pain and inﬂammation [43e54]. The main mechanism of
action of NSAIDs is by the inhibition of COX-1 and COX-2 [55e57]. The other antiinﬂammatory agent with its effect on
the COX-2 system includes glucocorticoids or cortisols, which despite of having side effects is effectively used as a strong

FIGURE 21.1 Mechanisms involved in inﬂammatory response.
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antiinﬂammatory agent [43,53]. Similarly, several other drugs play an important role in silencing the cytokine receptors,
thus promoting an antiinﬂammatory effect. Recent researches in the ﬁeld of drug development have categorized itself into
two parts, i.e., chemosynthesized and phytosynthesized. Although as a matter of fact, most of the chemosynthesized
compounds are actually the derivatives of phytosynthesized compounds, e.g., aspirin, whose main composition is
acetylsalicylate, is in fact a derivative of Willow Tree [58], and is a widely used antiinﬂammatory drug across the globe.

21.1.6 Mechanism of plant-derived antiinflammatory agents
Among the different biological activities of natural plant products that have been published until now, antiinﬂammation is
one of the most reported effects. Some studies have showed that the antiinﬂammatory activity of pure compounds (such as
amentoﬂavone, pseudohypericin, and hyperforin, isolated from extracts of Hypericum perforatum) extracted from the plant
materials is higher than that of the extracts [59,60]. In addition to plant extracts, essential oils are also widely used for their
antiinﬂammatory properties. Essential oils are known to possess plenty of phytoconstituents that have signiﬁcant role in
minimizing the inﬂammation rate. Major compound found in the essential oils belongs to the family of terpenoids that are
known to suppress inﬂammation by suppressing the factors responsible for swelling and redness of the injured region
[61e63]. In addition, the compounds such as () Myrtenol, which is commonly found in plants such as Tanacetum vulgare
and Aralia cachemirica, are known to have a strong effect on the reduction of IL-1b levels along with declining number of
leukocytes and reduced edema [59,64,65]. While some of the other phytoderivatives, which is found in common vegetables
such as tomato (Solanum lycopersicum), have ferulic acid, which has a strong antiinﬂammatory potential and reduces LPSinduced release of IL-1b and TNF-a expression followed by a signiﬁcant reduction in NF-kB activity [59,66]. Apart from
essential oils and plant extract derivatives, oxidative derivatives of fatty oils, such as omega-3, produce the compound
called as resolvins and are known to have a strong antiinﬂammatory activity against interleukins and prostaglandins [43,67].

21.1.7 Mechanism of chemically synthesized antiinflammatory agents
Several new chemically derived agents out of either plants or synthesized chemically to minimize the inﬂammatory process
are termed as biologicals, which has the potency for minimizing the effect of certain cytokines or the signaling pathways,
which has the ability to inﬁltrate the tissues and prevent the activation of B-lymphocytes, block the binding of
monocyteelymphocyte interacting molecules [43]. Several drugs of nonsteroidal origins, also known as NSAIDS, are
commonly used as antiinﬂammatory agents and help in the reduction of inﬂammation. Some of the commonly known
NSAIDS include drugs such as ibuprofen (such as Nurofen), naproxen (such as Naprosyn), diclofenac (such as Voltaren),
and celecoxib (such as Celebrex). These drugs are often provided in the case of musculoskeletal-related injuries. Based on
their selectivity of COX targets, these NSAIDs can be classiﬁed as nonselective traditional NSAIDs (t-NSAIDs) or COX-2
selective. These t-NSAIDs have a varied range of activity which differs among its varieties, e.g., diclofenac and ibuprofen
favor COX-2 and COX-1, respectively [68]. Based on the dosage consumption, the activity for COX suppression also
varies, e.g., celecoxib inhibits COX-2 more than COX-1, whereas meloxicam, at lower doses preferentially, inhibits the
COX-2 isoform, whereas at higher doses it affects COX-1 [68].
Despite having a diverse spectrum of molecular activity of inhibition of pain and inﬂammation receptors of NSAIDs,
they carry huge risks of disrupting the normal function of various organs. As a well-known fact, inhibition of COX systems
is necessary for the inhibition of inﬂammation, but COX systems also have several important roles, apart from being a
participant in the inﬂammatory cycle, e.g., COX-1 governs the formation of endothelial lining of the gastrointestinal tract
and thus inhibition of this system may hamper the normal functionality of this system [68,69]. Inhibition of COX-2 blocks
the synthesis of vasodilatory prostaglandins, favoring a vasoconstrictive state and may lead to severe cardiovascular
conditions including infarctions and stroke [55,57,69,70].

21.1.8 Molecular approaches to diagnose the inflammatory conditions
Recent advances in the ﬁeld of medical diagnostics have led to the accurate analysis of the pathological conditions. Few of
the most widely used molecular approaches to study the inﬂammatory conditions include the following:
a) Western blotting: Analysis of various inﬂammatory proteins and cytokines.
b) ELISA: Quantiﬁcational analysis of ILs, TNFs, and PGE.
c) Electron microscopy: Assessment of histopathology of inﬂammatory tissues at the molecular level.
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d) Ultrasound molecular imaging: This molecular technique has recently gained much importance as it has shown
inﬂammation diagnosis in preclinical, murine models of inﬂammatory bowel disease. These models, however,
presented acute inﬂammation on normal colons, as compared with the patients with acute and worsening situations
often in inﬂamed regions.
e) In vivo ﬂuorescence optical imaging technology: This technique has recently gained importance and they have been
used in the diagnosis of inﬂamed synovium resulting in severe arthritis.
Apart from the above-mentioned molecular approaches, the common processes that are routinely assessed for
diagnosing the inﬂammatory conditions involve the in vivo approaches by using certain models like rat models in which
the inﬂammatory conditions are often generated either by knocking out of genes or manually causing edema through
certain chemical methods.

21.1.9 FDA-approved antiinflammatory drugs
The antiinﬂammatory drugs can also be called NSAIDs. They are regarded as group of medicines that relieve pain and
fever and also reduce inﬂammation. These antiinﬂammatory drugs mediate by blocking a speciﬁc group of enzymes known
as cyclooxygenase (COX) enzymes. The two COX enzymes, COX-1 and COX-2, promote inﬂammatory signs such as
pain and fever. Only COX-1 helps in the production of prostaglandins, which supports platelet growth and protects the
stomach. COX-2 inhibitors are the NSAIDs that selectively blocks COX-2 enzymes and not COX-1. Obstructing this
enzyme slows down the production of prostaglandins by COX-2, which results in inﬂammatory and pain-like conditions
[71]. Because of the fact that they selectively block COX-2 enzyme instead of COX-1 enzyme, these drugs vary from other
drugs which usually block both COX-1 and COX-2 enzymes. Prostaglandins are lipid groups that are produced at the site
of tissue injury or infection involved in tackling the injury and illness; it is not secreted from a gland to be carried in the
bloodstream; neither is speciﬁc to some part of the body. They are produced through a chemical reaction at the site at their
speciﬁc site of origin and it is made in all the individual organ system. At such tissue site, they cause inﬂammation, fever,
and pain resulting in the healing process. A prostaglandin known as thromboxane participates in the formation of blood
clot to heal damages when a blood vessel is injured. At this time, it causes vasoconstriction of blood vessels and thus
prevents blood loss. However, another prostaglandin known as prostacyclin inhibits the blood clotting and lysis of any clot
that is no longer needed. Prostaglandin exerts such contraction and relaxation in the muscles of the gut and airways.
NSAIDs are available by prescription and through retail. The FDA-approved NSAIDs were presented in Fig. 21.2.

FIGURE 21.2 Some antiinﬂammatory drugs currently in clinical use.
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21.1.9.1 Aspirin
Aspirin (1) is a nonsteroidal reliever of mild to moderate pain of many causes including headaches, arthritis, menstrual
cramps, and injury among others. Aspirin also prevents blood clots (i.e., antithrombotic). FDA approved Bayer Aspirin in
June 1965 and recommends that it should be taken with food. Doses range from 50 to 600 mg daily depending on the use.
The usual doses for mild to moderate pain are 350 or 650 mg every 4 hours.
21.1.9.1.1 Drug or supplement interaction with aspirin
There is probable aspirin interaction that affects other drugs. Aspirin when taken with blood thinners or anticoagulant such
as warfarin can cause excessive blood thinning that may lead to serious bleeding because just like anticoagulant thins
blood, aspirin also thins blood.

21.1.9.2 Celecoxib (brand name celebrex)
Celecoxib (2) is used in treatment of pain, arthritis (rheumatoid, juvenile and osteoarthritis, and ankylosing spondylitis),
and menstrual cramps. One of the signiﬁcant uses of celecoxib is in the treatment of familial adenomatous polyposis (FAP).
Patient suffering from FAPs is because of the result of developing profuse number of tumors in their colons, which
invariably became malignant. The only cure of FAP is the removal of the colon. However, celecoxib is accepted as a
secondary treatment for patients with FAP (who do not have their colon removed). The FDA approved celecoxib in
December 1998. FDA recommends the least effective dose to be used for each patient such as osteoarthritis (100 mg twice
daily or 200 mg as a single dose), rheumatoid arthritis (200 mg twice daily), acute pain or menstrual cramp (400 mg as
single dose on the ﬁrst day, then 200 mg twice daily if needed), and for FAP (400 mg twice daily).
21.1.9.2.1 Drug and supplement interaction with celecoxib
a) Patients who are taking ﬂuconazole treatment with celecoxib should be initiated at lowest recommended dose because
ﬂuconazole increases the concentration of celecoxib in the liver.
b) Patients concomitantly using celecoxib with aspirin or other NSAIDs may experience increased occurrence of stomach
and intestinal ulcers; therefore it is recommended that it may be used with low-dose aspirin.
c) Celecoxib increases the concentration of lithium in the blood by 17% and may promote lithium toxicity. It is therefore
recommended that lithium therapy be closely monitored during and after therapy with celecoxib.

21.1.9.3 Diclofenac (brand names voltaren, zipor, cataflam, zorvolex)
Diclofenac (3) is used for the treatment of mild to moderate pains, fever, and inﬂammation. The FDA approved diclofenac
in July 1998. It is advised that diclofenac should be taken with food to reduce stomach upset. The FDA recommended dose
for most conditions is 100e200 mg daily. Dosing intervals are 2e4 times daily depending on the diclofenac formulation
used and the condition being treated.

21.1.9.4 Ibuprofen (brand names advil, medipren, motrin, nuprin)
Ibuprofen (4) is used for treatment of mild to moderate pain, inﬂammation, and fever. It is also used in treating menstrual
cramps and types of arthritis. Intravenous ibuprofen is used for treating patent ductus arteriosus. The FDA approved
ibuprofen in 1974. The FDA recommended dosages include minor aches, menstrual cramps, and fever (200 or 400 mg
every 6 h for adults), arthritis (300e800 mg, 3 to 4 times daily), and children of 6 monthse12 years of age are given
5e10 mg/kg of ibuprofen every 6e8 h for fever and pain treatment.
21.1.9.4.1 Drug and supplement interaction with ibuprofen
a) May increase blood levels of lithium just like celecoxib
b) Causes excessive blood thinning when taken with anticoagulant like warfarin
c) Increases the negative effect of cyclosporine or kidney function [72].

21.1.9.5 Indomethacin (Indocin)
Indomethacin (5) is NSAID for treatment of fever, pain, and inﬂammation. The FDA recommended adult dose for treating
inﬂammation or rheumatoid is 50e200 mg per day (split into two to three doses). Bursitis or tendonitis is treated with total
dose of 75 to 15 mg daily while acute gouty arthritis will be treated with 50 mg every hour for 3e5 days.
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21.1.9.5.1 Drug and supplement interaction with indomethacin
a) Colestipol (Colestid) binds with indomethacin in the intestine preventing absorption into the body, thereby decreasing
the absorption of indomethacin.
b) If aspirin is taken with indomethacin, there may be an increased risk for developing ulcers.

21.1.9.6 Naproxen
Naproxen (6) is used for treatment of mild to moderate pain, inﬂammation, and fever. It was approved by the FDA in
December 1991. The usual adult dose for pain is 250 mg every 6e8 h or 500 mg twice daily and should be given with food
to reduce upset stomach.
21.1.9.6.1 Drug and supplement interaction with naproxen
a) Naproxen may increase the blood levels of lithium just like celecoxib.
b) Taking naproxen with anticoagulant should be avoided to shun excessive blood thinning that may lead to bleeding.

21.1.9.7 Oxaprozin (brand name Daypro)
Oxaprozin (7) is used for management of mild to moderate pain, fever, and inﬂammation. It was approved by the FDA in
October 1992. The usual dose of oxaprozin is 600e1200 mg once daily taken with food.
21.1.9.7.1 Drug and supplement interaction with oxaprozin
a) Oxaprozin increases the negative effect of cyclosporine on kidney function.
b) Oxaprozin taken with aspirin may increase the risk for developing ulcer.
c) Oxaprozin may increase the blood levels of lithium just like celecoxib.

21.1.9.8 Piroxicam (brand name Feldene)
Piroxicam (8) is a group of NSAIDs that relieves mild to moderate pain of many causes such as injury, arthritis, menstrual
cramp, and other musculoskeletal conditions. The FDA approved piroxicam in 1982. The FDA recommended dose is
20 mg once daily or 10 mg twice daily and should be taken with food.
21.1.9.8.1 Drug and supplement interaction with piroxicam
a) It may increase blood levels of lithium just like celecoxib.
b) Combining piroxicam with angiotensin receptor blockers such as valsartan or angiotensin-converting enzyme inhibitors
such as enalapril and captopril in patients who are elderly and are volume depleted or with poor kidney function may
result in reduced kidney functioning including kidney failure.

21.1.9.9 Other drugs
a) Diﬂunisal (brand name Dolobid): FDA approved diﬂunisal in April 1982, but the brand has been discontinued
(no longer available in the United States).
b) Etodolac (brand name Lodine): Approved by the FDA in January 1991.
c) Ketorolac: Approved by the FDA in November 1989 and used for short-term management (up to 5 days) of moderately or severe acute pain that otherwise would require narcotics. It is not used for minor or chronic painful conditions.
d) Sulindac (brand name Clinoril): Approved by the FDA in September 1978.
e) Tolmetin: Approved by the FDA in March 1976.

21.1.10 Side effects of NSAIDs
The antiinﬂammatory drugs are associated with many side effects; however, the frequency of side effects may vary among
the drugs. The common side effects include vomiting, diarrhea, rash, dizziness, headache, nausea, drowsiness, etc., the
serious side effects are liver failure, kidney failure (primarily with chronic use), ulcers, and prolonged bleeding after injury
or surgery. However, some variation exists. Based on potency, how they are eliminated from the body, duration of action,
tendency to cause ulcers and promote bleeding, how strongly they inhibit COX-1 versus COX-2, NSAIDs can vary
from each other. Celecoxib blocks COX-2 but has little effect on COX-1 and is therefore further classiﬁed as selective
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COX-2 inhibitor. Selective COX-2 inhibitors cause less bleeding and fewer ulcers than other NSAIDs. Aspirin is the only
NSAID that inhibits the clotting of blood for a prolonged period of time (4e7 days). This makes aspirin an ideal drug for
preventing blood clots that cause heart attacks and strokes. Ketoralac (Toradol) is a very potent NSAID used for
moderately severe acute pain that usually require narcotics. It inhibits blood clotting for only a few hours. It causes ulcers
more frequently than other NSAID and therefore not used for more than 5 days. Although NSAIDs have a similar
mechanism of action, individuals who do not respond to one NSAID may respond to another.

21.1.11 Antiinflammatory drugs under clinical trial
21.1.11.1 Anabasam (formerly known as Resunab)
Corbus Pharmaceuticals reported an early stage clinical study of a potential antiinﬂammatory drug for people with cystic
ﬁbrosis (CF). The researchers believed that reducing excessive inﬂammation in people with CF will reduce lung damage
and slow down progression of the disease. According to Corbus Pharmaceuticals, the early trial study of 16 weeks
involving 85 participants demonstrated that anabasam reduced multiple markers of inﬂammation including both inﬂammatory cells and mediators (chemicals that trigger an exaggerated immune responses). The researchers maintained that the
drug did not show signs of suppressing immune response, which has been a problem with other potential CF antiinﬂammatory. In their conclusion, Corbus Pharmaceuticals said that synthetic drug “anabasam” demonstrated in a phase 2
trials is safe and well-tolerated at all doses with no serious or severe adverse effects.

21.1.11.2 ATB-346
ATB-346 is gastrointestinal safe NSAID as reported by Wallace [73]. ATB-346 is hydrogen sulﬁde (H2S) releasing derivative of naproxen. H2S is an endogenous signaling molecule that exerts powerful antiinﬂammatory and cytoprotective
effects. According to the study conducted by Wallace [73], in animal model (rats and dogs), the drug showed a profound
reduction in gastrointestinal (GI) toxicity and plasma levels remained elevated much longer after administration when
compared to equimolar doses of naproxen. The study in animal model explained further that ATB-346 suppresses COX-1
and COX-2 in vivo and in vitro with similar potency to naproxen. The study went further to explain the trial on human and
found out that ATB-346 neither produced any serious adverse events across dose ranges and treatment paradigms studied
nor were there any signiﬁcant GI, cardiovascular, renal, or hematological ﬁndings associated with administration of the
drug. In their conclusion, ATB-346 was very well-tolerated and is a high-level safety drug and support progression of
testing to a relevant patient population in phase 2 trials.
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22.1 Introduction
An important factor responsible for male infertility is abnormal sperm production or impaired function of sperm [1].
Factors such as age, smoking, high pollution levels, changes in food habit, and alcohol intake are those that negatively
affect male fertility [2]. Natural herbs from ancient times are being used for the treatment of male reproductive disorder [3].
Because of the harmful effects of modern medicine, the use of natural herbs and their by-products could be more beneﬁcial
for the management of infertility condition. Therapeutic use of natural herbs is well-known in increasing sexual desire,
body stamina, removing stress, and indirectly lowering risk to infertility [4]. There are several plants phytoconstituents
such as alkaloids, steroids, ﬂavonoids, and terpenoids that has a potential to treat male infertility [3]. Long ago, Ayurveda
developed aphrodisiac therapy called Vajikarana-chikitsa for treatment of male infertility [3]. Ayurveda also suggested that
the proper use of plant-based medicines, appropriate lifestyle, and nutritious diet improve male fertility. Ayurveda explains
three main causes for male infertility: (1) bija upa tapa (congenital abnormalities), which means defects in the gamete; (2)
shukra dosha (diseases of sperm) because of poor food habit, improper behavioral, and psychological factors; and (3)
Klaibya (loss of libido) [3]. There are several factors that cause impotency in males; however, by the use of Ayurvedic
medicines and healthy lifestyle, male infertility can be treated.
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22.1.1 Oligospermia and plant products
Out of all major defects, oligospermia is the most prevalent cause of male infertility in more than 90% of patients [5].
Oligospermia means low sperm count or insufﬁcient number of spermatozoa characterized by less than 20 million
spermatozoa per milliliter of ejaculate. Oligospermia causes abrupt imbalance of hormones such as testosterone, LH and
FSH secretion, or activation of reactive oxygen species (ROS) pathway, which cause low count of sperm [4].
Till now no drugs are available for the management of oligospermia in modern medicine. Natural herbs from ancient
times are used for treatment of male reproductive disorder. Because of the harmful effects of modern drugs, the use
of natural herbs and their by-products could be beneﬁcial for the management of infertility condition. The therapeutic use
of natural herbs is well-known for increasing sexual desire, body stamina, removing stress, and indirectly lowering risk of
infertility [6]. Several studies have reported that plant products such as alkaloid, steroids, ﬂavonoids, and terpenoids have a
potential in treating male infertility.
Ashwagandha (Withania somnifera) is an important medicinal plant used in curing number of diseases because of its
enrichment with medicinally important compounds in form of alkaloids, ergostane steroids, amino acids, and neurotransmitters [7]. Also, some studies showed that ashwagandha root extract is an effective remedy for stress and infertility
by increasing sperm count, ejaculation volume, and motility of sperm [8]. Ashwagandha also balances sexual hormone
by regulating testosterone production in oligospermic male [8]. Besides ashwagandha, there are several plants that have
efﬁcacy in treating male fertility. Chlorophytum borivilianum, Hygrophila spinosa T., Mucuna pruriens, etc., have been
reportedly used for the treatment of male infertility. C. borivilianum is one of the few plants used to cure impotency
because of its aphrodisiac action. It is also used in certain forms of sexual inadequacies such as premature ejaculation
and oligospermia [9]. H. spinosa T. seeds play vital role in curing fertility disorder by regulating spermatogenic activity
and sex hormone [10]. M. pruriens, a medicinal plant with antioxidant, antitumor, and antiinﬂammatory properties,
enhances spermatogenesis and the number of spermatozoa in oligospermia-affected person. It also increases enzymatic
alkaline phosphatase activity in epididymal and regulates hormone production such as testosterone, LH, dopamine,
adrenaline, and noradrenaline and FSH and PRL (prolactin) in infertile men [11]. This is probably because of high
content of alkaloids. The seed extract of Mimosa pudica also showed beneﬁcial effect in treating male infertility by
regulating hypothalamicepituitaryetesticular axis components and by preventing hormone imbalance [12]. Acacia
senegal is useful in diabetic-induced infertility complication by enhancing semen quality and antioxidant activity to
protect testis [13]. One study using Astragalus membranaceus found that it increases sperm motility up to 215%
in comparison to placebo control an important factor in male infertility [14]. Plantago ovata helps in reversing
oligospermia and boosts male fertility by unknown mechanism [15]. The root extract of Bombax ceiba enhanced
spermatogenesis, sexual behavior, and erectile function in oligospermia patient [16]. Eurycoma longifolia is known for
augmenting testosterone level by activating enzyme 17a-hydroxylase/17,20 lyase (CYP17) activity, which helps in
enhancing overall sexual activity by increasing sexual desire, penile tumescence, rigidity, and strength [16e18].
Although these plants mentioned above are not totally proven, they can be explored as a future medicine for the
treatment of oligospermia-affected individuals.

22.1.2 Stress, male infertility, and plant products
Male infertility is commonly known as alteration in sperm concentration and/or motility and/or morphology [19]. There are
several factor associated with male infertility including oxidative stress, ROS, inﬂammation, and environmental factors
[20]. In the following section, these factors associated with male infertility and the role of various exogenous (carnitines,
vit E, vit C, and carotenoids) and endogenous (superoxide dismutase [SOD], catalase [CAT], GPx, and peroxidins)
antioxidants were discussed.

22.1.2.1 Oxidative stress and infertility
Oxidative stress is the most common cause of idiopathic male infertility [20]. Sperm is very prone to oxidation as it
contains a large amount of unsaturated fatty acid. It increases apoptosis activity in spermatogenic cells, which leads to
infertility [20]. However, spermatozoa cannot acquire its fertilizing capacity without a small amount of ROS. Excessive
production of ROS results in cell damage, lipid peroxidation, and DNA fragmentation, which impair fertilization [21].
Moreover, sperm oxidative stress has been associated with reduced sperm motility, excessive DNA damage, reduced
acrosome reaction, and decreased implantation rates in vitro fertilization (IVF) [21]. Thus, oxidative stress is one of the
important factors responsible for male infertility.
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22.1.2.2 Reactive oxygen species and infertility
The major source of ROS in human species is leukocytes and spermatocytes. Recently, some studies showed that the
increase in ROS production is related to poor sperm quality, functional defect in spermatozoa, and motility of sperm [22].
Mitochondria provide constant supply of energy for spermatozoa motility, and its oxidoreductase and oxidase enzymes are
involved in ROS production [22]. However, dysfunctional mitochondria cause abrupt increase in ROS production in
spermatozoa with a resultant negative effect on its functions [22]. Similar observation was also found in the other studies
which showed that ROS levels in fertile men are lower than in semifertile men [20]. ROS also cause increase in leukocyte
number, which further increases ROS production and impairs fertility.

22.1.2.3 Environmental factor and infertility
In last ﬁve decades, environmental pollutants also slowly affect male fertility and cause decline in sperm count, density,
and mean seminal volume [20]. Recently, it is proposed that decrease in sperm quality is connected with the amount of
exposure to chemicals, radiation, heat, and heavy metals [20]. Some studies also showed that environmental pollutant such
as estrogen and pesticides causes DNA fragmentation during spermatogenesis. Heavy metal such as lead hampers the
sperm function, i.e., binding and fertilization of the egg [20]. Another known environmental pollutant is bisphenol-A
(BPA), which is used in food packaging and it impairs estrogenic and antiandrogenic activities. BPA also negatively
affects motility, acrosome reaction, fertilization, and embryonic development. Also, cigarette smoke adversely affects male
reproduction by impairing sperm quality morphology and motility [23]. Industrial wastes harm normal physiological
processes, alterations in the synthesis of hormones and proteins, which cause inﬂammation, oxidative stress, and male
infertility [24]. So there is a need to identify other pollutant that may negatively affect male fertility.

22.1.2.4 Inflammation and infertility
The most common host response against microbial attack or tissue injury is inﬂammation, which helps in the restoration of
tissue vasculature and functions [25]. Neutrophils and macrophages are the ﬁrst immune cells that migrate to the site of
infection and play protective role. Macrophages and other immune cells secrete various inﬂammatory molecules such as
prostaglandins PGE2, cytokines, and nitric oxide (NO), which initiate innate and adaptive immune response [25].
Inﬂammation is also associated with infertility and causes dysfunction in spermatogenesis. It also negatively affects
testosterone and luteinizing hormone production in male [26]. Some evidences showed that inﬂammation negatively affects
spermatogenic sperm maturation and epididymis function [26]. Inﬂammatory reaction reduces lipid component of the sperm
membrane and enhances rigidity of sperm ﬂagella with decrease in sperm motility, which leads to sperm agglutination and
asthenozoospermia [27]. There is need to identify inﬂammatory molecules that negatively affect male fertility.

22.1.2.5 Exogeneous antioxidants and infertility
Exogenous antioxidants are known to combat stress-mediated harmful effects on male fertility. In the following sections,
we discussed male infertility ameliorating effects of exogenous antioxidants.
22.1.2.5.1 Carnitines
Carnitines are polar compounds and semiessential vitamins that form an essential part of human metabolism. Two main
sources for carnitine are dietary products and endogenous biosynthesis in human body. In male genital organ, carnitine is
present in high concentration especially in epididymis and spermatozoa [28]. It boosts cellular process in spermatozoa
mitochondria by increasing metabolism of fatty acid, which helps in the restoration of phospholipid containing mitochondrial
membrane [20]. Carnitine also protects sperm cell membrane against ROS-induced DNA fragmentation and apoptosis and
hence positively affects spermatogenesis process [28]. Earlier studies showed that carnitine therapy improved sperm motility
and sperm count in patients, which help in successful pregnancy [28].
22.1.2.5.2 Vitamin E
Vitamin E is one of the important antioxidant molecules localized in the cell membrane. The function of vitamin E is to
inhibit lipid peroxidation and scavenge free radicals generated by oxidative enzymes during normal metabolic process [20].
Free radicals also cause peroxidation of phospholipid membrane in sperm mitochondria which negatively affects its function
[29]. However, vitamin E helps in the synthesis of scavenging antioxidant enzymes and its supplementation reduces lipid
peroxidation in seminal plasma. Thus, it improves sperm motility and increases pregnancy rate in patients [29].
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22.1.2.5.3 Vitamin C
Vitamin C (ascorbic acid) is a water-soluble antioxidant that plays key role such as cofactor in numerous hydroxylation and
amidation processes [30]. It helps in the metabolic processes of folic acid, tyrosine, and tryptophan [31]. Vitamin C also
helps normal physiological processes such as tissue growth, wound healing [30], and as scavenger of ROS [30]. Some
clinical trial showed that daily supplementation of vitamin C increases sperm count in infertile men [20]. Vitamin C acts as
protector of human spermatozoa against oxidative damage and also helps in increasing seminal plasma volume [30]. A
combined administration of vitamins C and E showed promising result in protecting spermatozoa against peroxidative
attack and DNA fragmentation [30]. Thus, both vitamins are essential for normal functioning of sperm and male fertility.
22.1.2.5.4 Carotenoids
Fruits and vegetable contain very important component known as carotenoids. They are responsible for the yellow, red,
and orange pigmentation in plants and are also involved in photosynthesis [32]. However, humans do not have the ability
to synthesize carotenoids and they solely depend on fruits and plants for their supplementation. Lycopene is one of the
most important components of carotenoid family, which act as quencher of singlet oxygen. Lycopene is also present in
testes and plays antioxidative role in spermatogenesis. Also, some studies have found that lycopene supplementation
improves sperm motility and integrity [32]. Therefore, good diet containing high amount of carotenoids helps oxidative
enzymes to counter ROS production, which affect fertility. Thus, vitamins C and E protect the sperm from DNA damage,
and carnitines energize the sperm while carotenoid protects from oxidative stress. However, all antioxidants have different
properties, which is essential for normal functioning of reproductive organ.

22.1.2.6 Endogenous antioxidants and infertility
Endogenous antioxidants are enzymatic and nonenzymatic antioxidants such as SOD, CAT, glutathione peroxidase (GPx),
and peroxidoxins (PRDXs). Endogenous antioxidants are known to combat stress-mediated harmful effects on male
fertility. In the following sections, we discussed male infertility ameliorating effects of endogenous antioxidants.
22.1.2.6.1 Superoxide dismutase
SOD or superoxide oxidoreductase is known as metalloenzymes that catalyze dismutation reaction of superoxide anions
[30]. There are two forms of SOD, which is distinguished by the metal(s) in their active centers and the organelle where
they are located [30]. The ﬁrst one contains copper and zinc (SOD-1) in the active center and localized in the cytoplasm,
while the second form contains manganese in the active (SOD-2) center and found in the mitochondria. Other forms of
SOD also exit, present in extracellular space (SOD-3) and associated with the surface polysaccharide and exist in a free
form [30]. In seminal plasma, both SOD-1 and SOD-3 play important roles and are necessary for proper sperm functioning
[30].
22.1.2.6.2 Glutathione peroxidase
GPx catalyzes reduction of hydrogen peroxide and organic peroxides including reduction of peroxides of phospholipids.
Selenium is found in the active center of GPx and exists as selenocysteine [33]. GPx is found in the matrix of mitochondrial sperm and helps in the protection of sperm DNA from oxidative stress. It is also present in the seminal plasma
and also protects it from oxidative damage [33].
22.1.2.6.3 Catalase
CAT is also an enzyme that catalyzes hydrogen peroxide into water and oxygen. It is present in different organelles such as
peroxisomes, endoplasmic reticulum, mitochondria, and the cytosol in various types of cells [30]. CAT function is to
protect cells from oxidative stress induced by nitric oxide and improving sperm cell capacitation, which helps in increasing
fertility [33].
22.1.2.6.4 Peroxidoxins
PRDXs are highly expressive acidic protein that contains one or two cysteine (cys) residues in their active site with
molecular weight of 20e31 kDa [34]. They form complex with thioredoxin reductase system and reduce both organic and
inorganic peroxynitrite and hydroperoxides [34]. PRDXs target H2O2 and act as scavenger in many cellular compartments
(cytosol, nucleus, endoplasmic reticulum, mitochondria, and plasma membrane), including in spermatozoa [34]. PRDX6,
one of the forms of PRDXs, is highly essential in human spermatozoa, which reacts with H2O2 and triggers
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sperm capacitation. Thus, PRDX6 may play a critical role in sperm activation and fertility [34]. Overall, there are different
endogenous antioxidants that are present in human spermatozoa and sperm, which plays important role in decreasing
oxidative stress and oxidative damage.

22.1.3 Nutrition and male fertility
Nowadays, one of the global concerns is infertility, affecting 60e80 million couples worldwide, and new observation
showed that male factor infertility (MFI) contributes to more than 40% cases [35]. There are several etiologies that cause
male infertility including idiopathic oligospermia (low sperm counts), complete asthenozoospermia (absence of sperm
motility), and isolated asthenozoospermia (low sperm motility) [36]. Recently, some of the ongoing studies have found that
lifestyle and nutrition play a major role in healthy reproduction [37]. Apart from lifestyle factors (such as age, smoking,
and alcohol intake), nutrition also play critical role in maintaining healthy reproductive system and its deﬁciency leads to
sperm dysfunction and male infertility [37]. Both animal and human studies showed that male obesity and high-fat diet
damage the molecular and physical structure of sperm, which cause negative effect on reproduction [37]. Recent evidences
showed that change in diet (high-fat diet) alters the testicular physiology and metabolism in rats, which impair sperm
quality [37].
Trans-fatty acid and saturated fat negatively affect the testicular lipid metabolism and further harm sperm production
[38]. In another study, some workers found that obesity negatively affects both the motility and the fertilizing ability of
sperm in male mice [38]. Also, high-fat diet increases plasma cholesterol level, which impairs spermatogenesis in
mammals [38]. In human, deﬁciency in nutrition (fruits and vegetable) and intake of high-fat diet increase oxidative stress,
which cause DNA fragmentation and male infertility. It also affects testosterone production from Leydig cells [39]. Thus, it
seems like there is correlation between dietary pattern and healthy reproduction. Therefore, in the following section, we
summarize all the data discussed by Giahi et al. [36] on nutrition and male infertility. Giahi and co-workers designed new
methodology by which they easily studied all the data available on nutrition and infertility in systemic way [36].

22.1.3.1 Nutrition, unhealthy diet, and infertility
The higher consumption of nutrient-rich food such as fruits, green vegetables, chicken, ﬁsh, whole grains, and low-fat dairy
products and less intake of meat, sweets, processed foods, and high-fat products positively affect the sperm quality and
increase reproduction rate [40]. The intake of low-fat milk increases insulin growth factor 1 and insulin level, which
enhances sperm motility. The intake of high amount of meat product negatively affects male infertility. It may be reversed
by taking good amount of antioxidants and ﬁsh products (contain long-chain fatty acid), which help in increasing sperm
quality and further boost fertility. Fruits and vegetables are rich in various antioxidants such as vitamin E, vitamin C, and
b-carotene and help in removing oxidative stress required for male fertility. It might be concluded that nutrients are
necessary for proper functioning of genital organ [40].
Furthermore, it has been reported that unhealthy diet impaired spermatogenesis. By taking high energy diet with high
caloric load increases the number and size of adipocytes in obese person, which decreases testosterone level. This is
because of the presence of enzyme aromatase cytochrome P450 in white adipose tissue, which converts androgens into
estrogen and not into testosterone [40]. Another hormone, leptin, which increases by taking unhealthy diet and high
amount of leptin, impairs spermatogenesis and cause infertility. Also, leptin negatively modulates gonadotropin hormone
production, which decreases sperm quality [38]. High-fat diet also increases ROS production, which causes DNA damage
in sperm and leads to infertility [40]. Thus, unhealthy diet slowly affects the fertility; however, there is still need for further
research.

22.1.4 Novel targets for male infertility
Long noncoding RNAs (lncRNAs) do not possess signiﬁcant protein encoding capacity [41]. Mammalian genome
intergenic region encodes thousands of lncRNAs and plays key role in important biological process [41]. At least 20,000
functional lncRNA genes are encoded by human genome, and these genes produce RNA molecules that have regulatory
function in different biological processes [41]. Dysfunction of lncRNAs causes abrupt activation/deactivation of different
pathways which lead to different disorders and diseases in human [42]. Previous studies showed that dysregulation of
speciﬁc mammalian lncRNAs causes low sperm count or infertility, and thus lncRNAs also play important role in
spermatogenesis [42]. Recent studies showed that there are several regulatory elements and regulatory noncoding RNAs
present in mammalian species and are speciﬁc to spermatocyte [42]. LncRNAs are critical for orchestrating sperm
maturation as each developmental stage was associated with different lncRNAs. It has mechanism to escape from gene
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silencing process during sperm development and involves in spermatogenesis and fertility [42]. In summary, the current
ﬁndings observed that lncRNA will provide a new biomarker for detection of infertility in near future [42].
There are several potential drug targets recently identiﬁed which belong to integrins, ﬁbronectins, epidermal growth
factor receptors (EGFRs), collagens, and tetraspanin protein families, and their dysfunction leads to defective spermeegg
interaction and infertility [43]. Spermeegg interaction is required phenomenon for fertilization event, and defect in this
process leads to failure of IVF with method for reproduction. Integrins belong to family of cell adhesion molecules, which
helps in interaction between cell extracellular and cellecell matrix during spermeegg interaction required for fertilization.
Crystal structure of integrins revealed that they are heterodimeric transmembrane proteins and consist of two subunits “a”
and “b” in mammals [44]. Both “a” and “b” subunit names are ITGB and ITGA based on Mouse Genome Database and
Human Genome Organization nomenclature [43]. Disintegrin and metalloproteinase are recently identiﬁed as integrin
ligand and collectively called as ADAM. Functional blocking of ITGB1 decreases spermeegg binding by inhibiting
ADAM2 adhesion to mouse oocytes [43].
Fibronectin is transmembrane protein which involves in cell adhesion via integrin. Arg-Gly-Asp (RGD) amino acid
sequence in ﬁbronectin is responsible for binding to integrin. Human sperm expresses ﬁbronectin on their surface
following capacitation, and it also secretes during cumulus penetration. Fibronectin is also involved in selecting damage
spermatozoa [45]; thus abrupt increase in expression deﬁnes problem in fertility [45].
Another target belongs to receptor tyrosine kinase family, i.e., EGFRs and following the activation by ligand, EGFR
autophosphorylates and induces cascade of signaling effect that is required for spermeegg interaction. EGFR is localized in
the head and midpiece of sperm. EGFR phosphorylation/activation increases during capacitation and further it opens
intracellular calcium channel which is necessary for spermeegg interaction [46]. Zona pellucida glycoprotein 3 (ZP3)
interacts with EGFR and helps in the fertilization and fertility.
One of the common proteins, which is a very important and essential structural component of organs and tissues,
comprising skin, lung, blood vessels, and bone, is collagen [44]. Collagens are member of the extracellular matrix
protein family, and their expression increases during reproduction [43]. COL1A1 is a collagen protein involved in
spermatogenesis where it facilitates the migration and detachment of germ cells. There are several drugs such as
ocriplasmin (Jetrea©), geﬁtinib (Iressa©), erlotinib hydrochloride (Tarceva©), cilengitide, cetuximab (Erbitux©), and
panitumumab (Vectibix©) that are of interest to the above-mentioned drug targets. These drugs may be beneﬁcial in near
future to increase efﬁciency of IVF in patients [43]. However, there are some drugs that are available which have
negative effects on male reproductive function, e.g., calcineurin inhibitors, cyclosporine A, and FK506 that may act as
contraceptive in future drug development [47].
Calcineurin is a Ca2þ- and calmodulin-dependent serine/threonine phosphatase that plays key role in calcium signaling
[48]. Calcineurin activates T cell and increases production of interleukin 2 (IL-2). Calcineurin inhibitors such as
cyclosporine A (CsA) and FK506 suppress this process and act as immunosuppressant in organ transplantation [48].
However, these drugs negatively affect male reproductive organ and negatively regulate spermatogenesis and epididymal
sperm maturation and sperm motility [39]. As human spermatozoa expresses calcineurin with two functional subunits
PPP3CC and PPP3R2, inhibition of sperm-speciﬁc calcineurin may lead to the development of a reversible male
contraceptive, targeting spermatozoa in the epididymis. Thus, calcineurin has important role in male fertility. Speciﬁc
inhibition of sperm calcineurin or its interaction with substrates may lead to the development of reversible and rapidly
acting male contraceptives that target spermatozoa in the epididymis but leave testicular function intact [47].

22.1.5 Natural compounds to treat male infertility
Herbal plants provide new therapeutics for the treatment of male infertility, which is affordable and easily available.
Natural compounds are component of traditional medicinal system that has potent antioxidant phytochemical activity,
which may help in improving the gonadal function. In the following section, we will discuss two important plants that have
beneﬁcial effect on male fertility, i.e., W. somnifera and Moringa oleifera.

22.1.5.1 Moringa oleifera
M. oleifera commonly known as drumstick or horseradish tree belongs to Moringaceae family with various nutritional and
medicinal properties. M. oleifera leaves are rich in vitamins, minerals, and antioxidants which play signiﬁcant role in
cellular and humoral immunity [49]. Earlier studies showed that ethanolic extract of M. oleifera leaves protects the prepubertal testicular tissue from toxic effect caused by cyclophosphamide [50]. It also increases sperm count and motility and
repairs integrity of the spermatozoa induced by cyclophosphamide [50]. M. oleifera reduces lipid peroxidation and
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increases activity of SOD and CAT antioxidant enzymes. It has the ability to scavenge free radicals, which help in
protection of various tissues and organ [50]. M. oleifera also regulates oxidative balance for the restoration of testicular
homeostasis.

22.1.5.2 Withania somnifera
W. somnifera (ashwagandha) is an Ayurvedic medicine plant, an Indian ginseng with small evergreen shrub and long
tuberous roots [51]. W. somnifera has several medicinal properties and their roots are used as an adaptogen, diuretic,
sedative, antioxidant, and aphrodisiac [51]. Other parts of the plant are also beneﬁcial in pain, as a memory enhancer,
antineoplastic agent, antimicrobial agent, and antiinﬂammatory agent [51]. It contains various compounds such as
withanolides, alkaloids, and several sito sitoindosides. In addition, W. somnifera contain several metabolites such as iron,
alanine, aspartate, fructose, lactate, glutamine, etc. W. somnifera have several pharmacological properties and its
antioxidant activity is beneﬁcial for proper functioning of spermatozoa which protects person from idiopathic male
infertility. W. somnifera also regulates sex hormone in infertile men who are under physiological stress. Thus,
W. somnifera helps in altering various factors responsible for male infertility. Ahmad and co-workers [52] reported that
root extract of W. somnifera signiﬁcantly increases sperm concentration and motility in normozoospermia, oligozoospermia, and azoospermia patient. The possible mechanism by which W. somnifera exert its effect on male fertility and
reproduction is through oxidative and nonoxidative process [53]. The oxidative mechanism increases the antioxidant
activity by proper maintains of antioxidant enzymes and the cofactors which are essential for the effective functioning of
antioxidant enzymes [53].
The nonoxidative mechanisms involve in the regulation of hypothalamicepituitaryegonadal axis and
hypothalamicepituitaryeadrenal axis for proper functioning of reproductive organ [53]. W. somnifera extract contains
compounds such as withaferin A, withanolide D, withanone (Fig. 22.1), etc., which act directly on male reproductive cells
and indirectly regulate endocrine homeostasis to improve male fertility [53]. Thus, it has potential to treat male infertility
and further research on its various component helps in combating various male infertility issues.
Table 22.1 summarizes important medicinal plants and their mode of action that boosts fertility and cures male
infertility problems.
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TABLE 22.1 Plant product in the management of male fertility and mode of action.
Plant name

Part used

Target/Mechanism

Withania somnifera

Seeds

Psychosexual condition.
Erectile dysfunction.
Improves sperm count.

Clerodendrum serratum

Root

Improves male fertility.

Asparagus racemosus

e

Acts as vitalizer and regulates hormone imbalance.

Solanum surattense

e

Cures idiopathic infertility patient.

Tribulus terrestris

Herb

Stimulates spermatogenesis and libido.

Dioscorea bulbifera

Herb

Its action is same as gokshru.

Nyctanthes arbor-tristis

Changes libido.

Semecarpus anacardium

Seeds

Helps in maturation of spermatozoa.

Elettaria cardamomum

Seeds

Activates secretions of hormone.

Plumbago zeylanica

Stimulates generative cells and regulates seminal
fluid and prostatic secretions.

French maritime bark
extract

Bark

Improves sperm quality and function.

Rubus coranus

Extract

Increases weight of the testes and enhancing
spermatogenesis, sperm count, and sperm motility.

Psidium guineense

Aqueous extract

Improves testes, epididymis, and seminal vesicles
function.

Mucuna pruriens

Alkaloid

Increases weight of testes, seminal vesicles and
prostate, testosterone levels in the blood.

Dactylorhiza hatagirea

Aqueous extract

Improves the genesis of steroidal hormones

Korean ginseng

Roots

Increases sperm count and motility and
spermatogenesis.

Hibiscus macranthus and
Basella alba

Leaves

Increases testosterone production.

Hachimijiogan (blend of
eight herbs)

Rehmannia root, Comus fruit, Dioscorea
rhizome, Alisma rhizome, hoelen, moutan
bark, cinnamon, and aconite root

Improves spermatogenesis and helps with
impotence by reducing serum prolactin levels.

Astragalus membranaceus
Serenoa serrulata

Increases sperm motility in vitro.
e

Strengthens male reproductive system and
increases the production of testosterone.

Semen cuscutae, rhizoma
curculiginis, and radix
morindae officinalis

Extract

Improves sperm motility.

Lepidium meyenii

Alcoholic extract

Increases epididymal sperm count.

Zingiber officinale and Pentadiplandra brazzeana

Aqueous extracts

Increases weight of the testis, serum testosterone
level, testicular cholesterol level, and epididymal
a-glucosidase activity.

Mondia whitei

Roots

Increases testicular weight, testosterone, and level.

Satureja khuzestanica

Essential oil

Improves potency, fecundity, fertility index, and
litter size.
Increases number of spermatogonium, spermatid
cords, Leydig cells, and spermatozoids.

Eurycoma longifolia Jack

Roots

Stimulates the biosynthesis of various androgens.
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TABLE 22.1 Plant product in the management of male fertility and mode of action.dcont’d
Plant name

Part used

Target/Mechanism

Cardiospermum
halicacabum

Leaves

Increases sperm count, motility, and serum
testosterone level.

Vitis vinifera

Seeds

Increases sperm count, viability, and sperm
motility.

Origanum majorana

Leaves and flower

Increases spermatogenic and sperm cells.

Syzygium aromaticum

Oil

Improves histologically seminiferous tubules.

Nigella sativa

Seeds

Increases the level of testosterone.

Lycium barbarum

Fruit

Reduces DNA damage.
Increases in the level of testosterone.

Tribulus terrestris

Extract

Improves semen quality.
Increases levels of testosterone, FSH, and LH.

Asteracantha longifolia

Seeds

Increases height of Sertoli cells, diameter of
seminiferous tubules, and testosterone production.

Polycarpaea corymbosa

Ethanol extract

Boosts sperm motility and density.
Reduces sperm abnormality.
Increases serum levels of testosterone and LH.

Dactylorhiza maculata

Dried root and tubers

Increases the libido, improves erection, delays
ejaculation, increases sperm count and testosterone
hormone and semen volume and spermatogenesis.

Crocus sativus L.

Stigma

Improves Rigiscan parameters (rigidity and
tumescence) and sexual functions such as erectile
function, sexual satisfaction, orgasm, sexual desire,
and overall satisfaction.

Nigella sativa

Seeds

Increases fertility, weight of reproductive organs,
numbers of mature Leydig cells, sperm motility,
and testosterone level.

Urtica dioica

Hydroalcoholic extract

Preserves seminiferous tubules activity and
seminiferous epithelial height.

Tribulus terrestris

Alcoholic extract

Increases libido and prevents reluctance, infertility,
and menopausal disorders. Testosterone levels
modulate estrogen, progesterone, and pregnenolone levels.

Artemisia annual

Essential oil

Increases the proliferation of spermatogenic cell
diameter of seminiferous tubules and number of
Leydig cells.

Apium graveolens

Seeds

Normalizes sperm count, sperm motility, and the
histopathological recovery.

Allium cepa

Promotes spermatogenesis cycle.
Decreases abnormal sperm.
Increases sperm count, motility, and serum total
testosterone.

Sesamum indicum

Seeds

Improves epididymal sperm reserved.
Increases testosterone level and decreases FSH
level.
Improves testicular parameters, fertility, sperm
count, and motility.

Cucurbita pepo L.

Seed and seed oil

Improves libido and semen quality and histology of
testis.
Continued
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TABLE 22.1 Plant product in the management of male fertility and mode of action.dcont’d
Plant name

Part used

Target/Mechanism

Lepidium meyenii

Hypocotyl

Increases spermatogenesis, sperm number and
motility, testosterone, LH, and FSH.

Petroselinum crispum

Oil

Increases the levels of glutathione reductase and
superoxide dismutase (SOD) activity.

Ginseng

Roots

Improves erectile parameters such as penile
rigidity, girth, erection duration, libido, and
patient satisfaction.
Decreases chromosomal aberrations and sperm
abnormalities.
Increases testosterone concentration sperm
numbers and motility.

Flaxseed

Oil

Increases serum LH and cauda epididymal sperm
counts.

Trigonella foenum-graecum

Seeds

Improves the histopathological defects in testis.
Suppresses the oxidative stress.

Cinnamomum

Bark

Increases the weight of testes, caudae
epididymidies, seminal vesicles, sperm count,
and motility.

Capsicum

Capsaicin

Inhibits DNA synthesis in the testes.

Rose flowers

Oil

Increases number and motility of sperm and Leydig
cell counts, seminiferous tubule diameters improves histopathological defects in testes and total
testosterone levels.

Zingiber officinale

Oil

Inhibits DNA damage by decreasing oxygen
radical.
Increases sperm counts, motility, testosterone;
stimulates spermatogenesis and testosterone level.

Allium sativum

Extract

Promotes spermatogenesis.
Increases sperm count, viability, and motility.

Daucus carota

Seeds

Antioxidants property, increases sperm number.
Increases testosterone level.
Increases spermatogenesis.

Camellia sinensis

Leaves

Increases SOD activity. Decreases lipid
peroxidation.

22.1.6 Suvarna bhasma
Ayurvedic formulation offers wide range of treatment by herbo-metalo-mineral or animals products for all health problems.
Ayurveda medicines are available in form of decoction, tablets, and powder as per patient treatment. In some special
condition of infertility, Ayurvedic formulated Suvarna Bhasma formulation (Gold Ash, SB) showed increased total sperm
count and motility in both healthy and unhealthy individuals [54]. The possible mechanism is that gold enters the seminal
plasma by treatment with SB, which improves sperm motility and quality [54]. Skandhan and co-workers [54] showed
promising results that SB in minimum dose improves sperm motility and fertility.

22.1.7 Pharmaceutical medications and male fertility
There are possibly numerous different reasons of male infertility, including hormonal, anatomical, and exposure to
exogenous substances including MFI [55]. Pharmaceutical medications and recreational drugs have some negative effects
on fertility, and nowadays, it is one of the leading causes of MFI [55]. Some medications weaken ejaculation and erectile
function and decrease libido. The association between MFI and exposure to pharmaceutical compounds has only recently
been explored, and it is topic for further research and debate [55].
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22.1.7.1 Antidepressants
Depression is a common disorder affecting approximately 16% of individuals. There are several medicines that are
available for the treatment of depression, and one of the current regimens used against depression is speciﬁcally selective
serotonin reuptake inhibitors (SSRIs) [56]. However, SSRIs have been known as a source of MFI. Some previous and
ongoing studies showed that there is association between SSRI and decreased sperm motility [57]. In vitro studies also
prove that SSRIs have a spermicidal effect. Short clinical trial also relates with in vitro data as SSRIs cause semen
abnormalities and MFI [58]. However, reported data link SSRIs to MFI, but there is need to identify possible mechanism
by which SSRIs increase infertility.

22.1.7.2 Calcium channel blockers
Calcium channel blockers (CCBs) are calcium ion antagonist. This means that they block the calcium ions movement
between ion channels and ionophores [55]. Calcium ion movement is an important phenomenon that serves as secondary
messenger. CCBs are speciﬁed therapy for a number of medical conditions, including hypertension and heart failure [55].
However, CCB drug such as nifedipine produces dose-dependent adverse reaction on sperm morphology, motility,
viability, and phospholipid composition in vitro. Additionally, some studies showed that treatment with CCB caused
structural changes in both the head and tail regions of sperm. Other studies also observed that CCB inhibits the ability of
sperm to bind to an egg by varying the lipid bilayer of the sperm plasma membrane morphology [59]. In short clinical trial,
same results were found and pregnancy rate decreases as compared with placebo control [44]. Thus, signiﬁcant data exist,
which suggest that CCBs may contribute to MFI.

22.1.7.3 Alpha-adrenergic blockers
Most commonly available medication for the treatment of lower urinary tract syndrome associated with benign prostatic
hyperplasia are a-adrenergic blockers (AABs) [55]. These drugs have a very high afﬁnity for a-adrenergic receptors
present in the smooth muscle cells of the lower urinary tract and blood vessels [60]. Nonspeciﬁcally, AABs also show high
binding afﬁnity for various other receptors including dopamine and serotonin. However, the use of AABs also has some
side effects on ejaculation. Clinical trial using tamsulosin for 5 days (an AAB) found measurable decrease in ejaculate
volume in almost 90% cases [60]. Additionally, AABs also negatively affect semen parameter, such as sperm concentration and motility. Thus, there is link between AABs and MFI.

22.1.7.4 Antiepilepsy
In large studies, it is proven that epileptic males have signiﬁcantly lower fertility rates and greater risks of hyposexuality than the
normal population. However, antiepileptic medications including carbamazepine, phenytoin, and valproate have also drugdependent side effects on sperm morphology, which reduced motility, lower sperm count, and reduced testicular volume
[55]. The possible mechanism that causes MFI is interaction between antiepileptic medication and sex hormones, which alter
some main pathways. Other studies also conﬁrmed these ﬁndings as there is decrease in sperm motility in carbamazepine-taking
patient [55]. Thus, all existing data suggested that various antiepileptic medications may contribute to MFI.

22.1.7.5 Antiretrovirals
For treatment of human immunodeﬁciency virus (HIV), antiretrovirals therapy is used, i.e., highly active antiretroviral
therapy (HAART). HAART is given to HIV patients, which helps in reduction in HIV-induced mortality. However, it has
various adverse side effects, including neuropathy and lipodystrophy and fertility on HIV patients. In vitro studies showed
that using saquinavir, commonly used in HAART regimens, decreases sperm motility and had adverse effect on mechanisms that are essential for fertilization of an oocyte such as the acrosome reaction. A clinical study further proves that
following HAART regimen, there is 60% reduction in sperm motility over a period of 48 weeks. Other researchers also
observed similar ﬁndings including reduction in ejaculation volume, increased rates of abnormal sperm morphology, and
decreased sperm motility. Thus, antiretroviral drugs also negatively affect fertility and cause MFI.
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23.1 Introduction
Flavonoids having lipophilic prenyl side chain in their skeleton are known as prenylated ﬂavonoids. Flavonoids are very
common and ubiquitous in nature compared with prenylated ﬂavonoids. Around 37 plant genera are well identiﬁed for
their occurrence in the environment, which generally includes enhanced bioactivities. Prenylation of ﬂavonoids facilitates
ﬂavonoids lipophilicity and increases the chance of interaction with the membrane and target proteins [1]. Length of prenyl
side chain decides different kinds of prenylated ﬂavonoid structures. Different isoforms of ﬂavonoids such as ﬂavones,
ﬂavonols, chalcones, and ﬂavanones have been reported with the addition of prenyl side chains and form prenylated
ﬂavonoids. Phytoalexins (also called prenylated ﬂavonoids) are reported for their excellent antipathogenic activity [2].
Prenylated ﬂavonoids also possess various biological activities such as immunomodulatory, antioxidant, anticancer,
neuroprotective, antityrosinase, antiglycosidase, and estrogenic activity [2,3]. The application of prenylated ﬂavonoids is
very restricted because of its lesser abundance in the environment. In vitro synthesis of prenylated ﬂavonoids can solve the
abundance problem and diminish the ailment characteristics. Kurarinone is a trihydroxyﬂavanone, (2s)-ﬂavanone
substituted by hydroxy group at positions 7, 20 , and 4’. Kurarinone also comprises a lavandulyl group at position 8 and a
methoxy bunch at position 5 (Fig. 23.1). It is isolated from the base of Sophora ﬂavescens. S. ﬂavescens, which belongs to
Leguminosae family, is a perpetual bush, generally developed in East Asia. The dried extracts of S. ﬂavescens have been
utilized in conventional Chinese medication to treat diarrhea, gastrointestinal hemorrhage, eczema, and skin itch. It also
showed cytotoxicity activity against human myeloid leukemia HL-60 cells.
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FIGURE 23.1 Kurarinone molecule structure.

23.1.1 Isolation
Flavonoids from S. ﬂavescens were speciﬁcally separated by mechanochemical promoted extraction technology to specify
the reaction surface procedure to set the ideal extraction parameters [4]. A technique coupling high-performance liquid
chromatography with diode-cluster distinguished and electrospray ionization mass spectrometry was set up for the separation
and characterization of ﬂavescent [5e8]. Traditionally, S. ﬂavescens is utilized to treat abscess, diarrhea, dermatitis, and skin
tingle. The different ﬂuorescence has the seven identiﬁed alkaloids such as cytisine, oxymatrine, oxysophocarpine,
sophoridine, N-methylcytisine, matrine, and sophocarpine. The total content of detected alkaloids is 1.47% in ﬂower bud,
1.34% in primary ﬂower, 1.17% in full blossomed bloom, and 1.01% in faded blossom [9]. The main three substances of
alkaloids are N-methylcytisine, oxysophocarpine, and oxymatrine, which accounts for w83% of all detected alkaloids [10].

23.1.2 Metabolism
Metabolism is an important pharmacokinetic behavior that inﬂuences the biological activity and toxicity of drugs in vivo.
Xenobiotics biotransformation is primarily catalyzed by the liver. However, kurarinone metabolism in the liver and the
function of its metabolites in kurarinone-induced cytotoxicity remains unknown. Some study revealed that kurarinone
could be extensively metabolized to glucuronidated products in human liver microsomes [11e15].

23.1.3 Apoptosis induction and anticancer activity
Apoptosis, the process of programmed cell death, is characterized by different morphological characteristics. It is an
energy-dependent biochemical mechanism. It is considered a main section of various parameter/processes such as normal
cell turnover number, embryonic development, chemical-induced cell death, and proper functioning of the immune system.
Inappropriate apoptosis induces many unsuitable conditions in human-like neurodegenerative diseases, autoimmune
disorders, and cancer. Therefore, researchers are continuously trying to focus to resolve the problems and ailments.
Analysis of cell cycle and signaling pathways demonstrate the cell cycle arrest and various gene expression patterns.
Induction of apoptosis is one of the important processes to produce its markers. Kurarinone is well-known prenylated
ﬂavonoids to induce the apoptotic pathways in cancer cells via several mechanisms and inhibition of antiapoptotic genes.
Kurarinone also arrests G2/M phase of cell cycle in human gastric adenocarcinoma and triggers mitochondrial apoptotic
pathway via ﬂuctuation in mitochondrial membrane potential, which leads to downregulation of Bcl-2 (antiapoptotic) and
upregulation of bax (apoptotic) gene [16e18]. Kurarinone treatment releases the cytochrome c from the mitochondria to
the cytosol and activates caspase 3emediated apoptosis [19]. Kurarinone also inhibits tumor cell propagation and precisely
blocks NF-kB transactivation [20e23]. Inhibition of NF-kB speciﬁcally targets IL-6, cyclin D1, and SOD2 gene via
diminution of extracellular signal-regulated protein (ERK), RSK2 pathways, S6 ribosomal protein (SRP6) inhibition, and
histone H6 S10 phosphorylation [22,24]. A transporter-related study reported that S. ﬂavescens ﬂavonoids do not affect
p-glycoprotein action [25].

23.1.4 Antidiabetic activity
Diabetes is a fast-growing long-term disease that affects millions of people all over the world. During diabetic period, body
fails to employ the glucose appropriately. This occurs because of lack of insulin hormone or because of nonfunctional
insulin, which causes nephropathy, neuropathy, and eye cataracts. It also increases the production of aldolase reductase
(AR)erelated polyol pathway, increased formation of advanced glycation end products, activation of protein kinase C,
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increased production of hexosamine pathway ﬂux, and overproduction of superoxide. Under normal conditions, cell-based
AR for galactose and glucose showed lower afﬁnity. The diabetic condition increases the rate of AR-related pathway,
which further increases the intracellular production of sorbitol and its metabolites such as fructose. Accumulation of these
metabolites has poor penetration property across the membrane and posses inefﬁcient metabolism which results in diabetic
complications originations. Kurarinone has the ability to inhibit AR enzyme and sodium glucose cotransporter (SGLT)
[26,27]. SGLT plays an imperative role in glucose reabsorption in the kidneys. SGLT1 is expressed mainly in brush border
membrane of mature erythrocytes in the small intestine where it absorbs galactose and glucose from the gut lumen. SGLT2
is expressed in the renal cortex of proximal tubule brush border membrane and is responsible for the reabsorption of
glucose from the glomerular ﬁltrate. It is investigated that kurarinone acts as an antidiabetic medicine that comprises
lavandulyl group in the ﬂavone skeleton required for the inhibition of SGLT1 [28,29]. Lavandulyl isoﬂavones also require
dehydroxy group on C-3 for the inhibition of SGLT2 transporter. Methoxy group in the ﬂavanone skeleton at C-5 position
increases the antidiabetic activity of kurarinone against type 2 diabetes. Inhibition of SGLT could decrease the glucose
reabsorption which results in urine glucose concentration increment and excretion which ultimately decreases blood
glucose level.

23.1.5 Antimalarial activity
Malaria is a life-threatening disease, ordinarily transmitted via the bites of a contaminated Anopheles mosquito. Infected
mosquito conveys the Plasmodium parasite. During mosquito biting, the parasite is discharged into the bloodstream. There
are four species of Plasmodium, which can infect the humans, namely Plasmodium ovale, Plasmodium vivax, Plasmodium
malariae, and Plasmodium falciparum. P. falciparum causes a serious type of infection and the individuals who get this
type of malaria have a sophisticated chance of death. Malaria is generally transmitted via blood or sometimes during organ
transplants, transfusion, or use of shared needles or syringe.
In 2016, 216 million instances of malaria have been reported in India. This was around an increment of 50 lakh cases
over 2015 reports. India is one of the 15 countries worldwide which has the maximum cases and deaths from malaria. The
drugs used for this disease are the chloroquine and quinine. Chloroquine hinders parasitic enzyme called heme polymerase
that renovates the poisonous heme into nontoxic hemozoin.

23.1.5.1 Chemotherapy targets
To date, there is no potent drug present for treatment of malaria. Drugs are being used in the current scenario based on the
difference in structure between host and parasitic organism. The most potent antimalarial drug known as artemisinin is also
prone to resistance to strains of Plasmodium. Artemisinin acts as an effective inhibitor of phosphatidylinositol-3-kinase
(PfPI3K).
23.1.5.1.1 Malaria parasite protease as antimalarial drug target
The hemoglobin degradation, erythrocyte invasion, and erythrocyte rupture require proteases after infection. The most
common proteases are the aspartic protease (plasmepsins) and cysteine protease (falcipins). E64, leupeptin, chymostatin,
and vinyl sulfones are reported as active protease inhibitors.
23.1.5.1.2 Apicoplast of parasite
Apicoplast is an organelle associated with regulation of fatty acid synthesis, heme synthesis, and iron-sulfur cluster
biogenesis. Fatty acid and isoprenoid precursor synthesis are the major targets for antimalarial drug development.
23.1.5.1.3 Targeting parasites mitochondrion
Compounds such as 4(1H)-pyridines, acridones, and 4(1H)-quinolones selectively target parasite mitochondrion. These
compounds inhibit mitochondrial electron transport chain and cause the breakdown of mitochondrial membrane potential.
Decoquinate is reported as a speciﬁc inhibitor of P. falciparum mitochondrial bc1 complex.
23.1.5.1.4 Plasmodium sugar transporters as drug targets
Intraerythrocytic stages of P. falciparum take host glucose for energy generation. P. falciparum hexose transporter (PfHT)
is involved in uptake of sugar from the host blood. PfHT is similar to mammalian GLUT1 transporter with exception of
carrying both D-glucose and D-fructose. Hexose O-3 derivatives also inhibit PfHT activity. A compound 3361 inhibits
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FIGURE 23.2 Structures of lavandulyl ﬂavanones (1e4).

glucose uptake by P. vivax orthologue of PfHT. Four lavandulyl ﬂavanones such as (2S)-2-methoxykurarinone (1),
sophora ﬂavanone G (2), leachianone A (3), and kurarinone (4) have been tested for in vitro antimalarial activity against
P. falciparum (Fig. 23.2). These compounds also showed moderate antimalarial activity and selective toxicity against
P. falciparum. These compounds also displayed remarkable toxicity against mouse mammalian tumor cells. Position of
methoxy groups in the ﬂavanone skeleton performs signiﬁcant role in antimalarial activity [30].

23.1.6 Antimicrobial activity
Infectious diseases caused by pathogenic bacteria have been the primary reason of death in human history. Antimicrobial
agents are those that interfere with the reproduction and growth of microorganisms such as bacteria, fungus, protozoa, or
virus. Although many antibiotics are available in the market for several diseases, it also leads to antibiotic resistance
development in many bacterial pathogens [31]. The extract made from S. ﬂavescens has shown potent bioactivity against
Streptococcus mutans (cause tooth decay diseases in the United States), vancomycin-resistant enterococci, and methicillinresistant Staphylococcus aureus. Several demonstrated that prenylated ﬂavonoids have high potential activity against
microbes and posses antiinﬂammatory activity to treat pyretic and analgesic symptoms [32e34].

23.1.7 Antioxidant activity
Oxidative stress, the inequality between antioxidants and oxidants at the cellular level, causes the loss of the integrity of
biomolecules (protein, lipid, and DNA). Overproduction of free radicals and other ROS are considered to be important
causative factors in the expansion of neurodegenerative diseases such as Alzheimer’s and in aging processes. ROS are also
accountable for low-density lipoprotein (LDL) proteins oxidation. Oxidized LDL accumulates in artery wall and promotes
atherosclerosis and endothelial cell damages. However, several synthetic antioxidants have been suggested to prevent and
treat oxidative stress diseases, but their toxicity and side effects make them inappropriate for the ailment treatment.
Therefore, researchers are paying more attention to natural antioxidants. Efforts have been made for the safe and effective
treatments of the oxidative stresserelated diseases which are induced by various factors such as irradiation, redox
decomposition by metal ions, hydroperoxides, hydrogen peroxide, thermal decomposition of free radical initiators such as
hyponitrites, peroxides, and azo compounds. Kurarinone posses as a potent natural therapeutic compound having cytotoxic
activities, radical scavenging, antiinﬂammatory, and antioxidant properties [35,36]. It is also partly responsible for
intracellular ROS inhibition and it also aids the body by improving the antioxidant capacity [37]. In a study, it has been
demonstrated that kurarinone has excellent potential to protect the LDL oxidation [38].

23.1.8 Effect on calcium and potassium channels
BKca (large conductance calcium-activated potassium channels) directs circulatory processes in both volatile and
nonsensitive cells that generally engaged with numerous cell capacities such as potential repolarization, neural edginess,
synapse discharge, hormone emission, tuning of cochlear hair cells, natural resistance and regulation of vascular tone,
aviation route, uterine, gastrointestinal and urinary bladder, and smooth muscle tissue. High conductance of BKca channels
strongly affects membrane potential. BKca channels vary from all the other potassium channels because of their high
affectability to both intracellular calcium ﬁxation and voltage.
A huge family of genes comprises the KCNA1 gene which directs instructions for construction of Kþ channels.
KCNA1 gene encoding protein has three primary basic areas with a particular capacity such as voltage-detecting area
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detects layer potential over the ﬁlm, the cytosolic space (Ca2þ particles), and pore entryway area (PGD), which closes and
opens to control the Kþ permeation. The voltage-gated areas and pore-gated spaces are considered as layer traversing
spaces that are framed by transmembrane fragment S1eS4 and S5eS6. In the S4 helix, positively charged residues act as a
voltage sensor. In BKca channels, Arg123 is engaged with voltage detecting over the layer. In BKca channel, the fragment
is required for B subunit balance and voltage sensitivity. BKca channel also performs important function in smooth muscle
relaxation.
Kurarinone continuously maintains conductance voltage of BKca channels when treated extracellularly. Kurarinone also
maintains conductance voltage of alpha subunits made of homometric BKca channels. However, sometimes kurarinone
shows less effect on alpha subunits made of homometric BKca channels. Another study reported that kurarinone has
excellent potential to deactivate the BKca channels [39].

23.1.9 Effect on cardiovascular disease
Cardiovascular diseases (CVDs) are one of the ﬁrst and major causes of death all over the world. CVD comprises number
of ailment of blood and heart vessels which includes coronary heart disease, rheumatic heart disease, heart attacks,
strokes, and atherosclerosis. These ailments originate because of deposition of lipids in cells and ﬁbrous elements in the
arteries. Triacylglycerol, synthesized by diacylglycerol acyltransferase (DGAT), catalyzes the ﬁnal committed step in the
glycerol phosphate pathway. A study reported that lavandulyl side chain of kurarinone acts as a compelling inhibitor of
DGAT activity [40]. Another study demonstrated that kurarinone has the aptitude to hinder monocytes chemoattractant
protein-1 (MCP-1), responsible for the migration of monocytes into the arterial wall and prompting the atherosclerosis
progression [41].

23.1.10 Effect on chronic inflammatory skin diseases
S. ﬂavescens are medicinal plants that have many biological functions, including antiinﬂammatory, antiarthritic, antibacterial, antitumor, neuroprotective, and antioxidant activity. A lavandulyl ﬂavonoid such as kurarinone has numerous
biological activities by inhibiting NF-kB signaling pathway. A study demonstrated that kurarinone regulates CD4þ T cell
differentiation and immune response. It ameliorates IL-23-induced psoriasis-like dermatitis and 2,4,6trinitrochlorobenzene-induced contact dermatitis such as an inﬂammatory skin disease. Antigen-presenting cells trigger
activation of T cell antigen receptor, which promotes CD4þ T cells differentiation into diverse Th cell lineages. Several
factors such as master transcription factors, cytokines, and STAT proteins have ability to inﬂuence these processes.
Kurarinone has potential to modulate the production and expression of cytokines and Th cell lineage-speciﬁc master
transcription factors [42]. Another study mentioned that GATA-binding protein 3 (Th 2 master regulator) and retinoic
aciderelated orphan receptor gT (Th17 master regulator) were additionally vulnerable to lavandulyl ﬂavonoid such as
kurarinone than the T-bet (Th1 master transcription factor). The above factors and their effects keen positive correlation at
their transcription levels and cytokine production for Th cell lineage. In addition, kurarinone has potential to increase
Foxp3 mRNA levels (Treg master transcription factor) and both mRNA and cell lineageespeciﬁc cytokines such as IL-10
and TGF-b production. The inhibitory action of kurarinone on CD4þ T cell differentiation demonstrated that it may
ameliorate several immune-related ailments. Kurarinone remarkably reduces the cytokine-mediated STAT protein
activation such as STAT1, STAT3, and STAT4-6 [43]. The JAK/STAT signaling tightly transduces the signals controlled
by cytokine. STAT proteins are imperative transcription factors in CD4þ T cell differentiation. Abnormal JAK/STAT
signaling is allied with numerous inﬂammatory diseases and cancers. Modulation of perversely triggered JAK/STAT
signaling may act as a therapeutic target for human diseases treatment, including cancers, autoimmune diseases, and
inﬂammatory diseases. In fact, numerous trivial molecules targeting JAK/STAT signaling have been established and are
being used on clinical trials for cancer, autoimmune diseases, and inﬂammatory diseases. The differentiation and function
of CD4þ T cells are regulated via a composite network of cytokines, master regulators, and STAT proteins. Regulation of
CD4þ T cell differentiation, master transcription factors expression, T cell lineage-speciﬁc cytokines production and
expression of cytokine-induced STAT proteins collectively regulates kurarinone action. Psoriasis development is allied
with STAT3 proteins, which requires for the development of Th17 cell regulated by IL-17, cytokines, IL-22, and IL-23. In
addition, inhibition of STAT3 activation through STAT3 inhibitor in vivo and in psoriasis patients exhibited effective
therapeutic activities in psoriatic lesions. The study showed that STAT3 is activated in human PBMCs (peripheral blood
mononuclear cells) isolated from psoriasis patients compared with those of healthy volunteers. Kurarinone repressed
cytokine-induced STAT3 phosphorylation in PBMCs. These results showed that STAT3 is a key factor for psoriasis
development and kurarinone as a therapeutic molecule for its treatment. Antigen presentation occurs in CD4þ cells via
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TCR (T cell receptor) signaling pathways. TCR signaling pathway regulates immune response via activation of Src family
kinases such as Lck and Fyn, protein tyrosine kinases, Ras/MAP kinases, NF-kB, and PI3K/Akt pathways. Another study
reported that kurarinone efﬁciently repressed the TCR-mediated signaling cascades. As a result, kurarinone repressed the
production and expression of proinﬂammatory mediators, whereas the production and expression of antiinﬂammatory
cytokines such as IL-10 and TGF-b were increased by kurarinone. Kurarinone modestly expanded the mRNA expression
of Foxp3 and Treg factors and ultimately regulates cytokines such as IL-10 and TGF-b. The variant initiation of CD4þ
T cells results in various human ailments including immune system disorders, inﬂammatory infections, and tumors. Th1
cells are known for organ-speciﬁc autoimmunity, Th2 cells for sensitivity and asthma, Th17 cells for fundamental immune
system sicknesses and malignant growths, and Treg cells for immunosuppressive exercises by the generation of their
particular cytokines. The inhibitory impact of kurarinone on CD4þ T cell separation recommends that this compound may
improve side effect caused by a resistant reaction especially mediated by Th2 and Th17 cells. Kurarinone additionally
hindered the cytokine-prompted expression of the STAT proteins such as STAT1, STAT3, STAT4, STAT5, and STAT6.
The JAK/STAT pathway also transduces cytokine-mediated regulation [44]. In addition to this, STAT proteins also act as
essential translation factors for the CD4þ T cell separation. The inhibitory action of kurarinone on CD4þ T cell separation
was because of the regulation of different factors, T cellemediated cytokine, and STAT protein expression.

23.1.11 Effect on liver ailments
The liver is one of the vital organs of our body as it is involved in performing the fundamental role in the regulation of
physiological activities such as biomolecule metabolism (carbohydrate and fats), bile acid secretion, vitamins storage, toxic
compounds detoxiﬁcation, and clotting factor formation. Liver utilized the aminotransferases to convert the glucose to
glycogen as an energy source for future purpose. The two main aminotransferases namely alanine aminotransferases (ALT)
and aspartate aminotransferases (AST) generally produced in the cytoplasm act as most important liver injury (hepatotoxicity) biomarkers. Yu et al. [45] demonstrated that ethanol extraction of S. ﬂavescens may induce liver toxicity and as
could elevate ALT and AST contents.

23.1.12 Effect on melanogenesis
Melanogenesis refers to melanin pigment production in melanosome by the melanin-producing specialized cells called
melanocytes. Tyrosinase enzyme is responsible for the melanin production by the oxidation of tyrosine (Tyr) amino acid.
Tyrosinase enzyme is not only responsible for the biosynthesis of melanin, but it is also responsible for the browning of
ripened fruits. Sometimes, melanin production increases abnormally, a stage called hyperpigmentation of skin which
results in darkening of the natural color of the skin. It occurs because of various factors such as radiations (UV or ionizing
radiations), over the release of a-melanin-stimulating hormone (MSH), genetic factors, birth control pills, or overuse of
fairness products. Son et al. [46] demonstrated that tyrosinase is a target enzyme in skin whitening treatment and in
hyperpigmentation diseases. In addition to this, other study demonstrated that ethanolic extract of S. ﬂavescens root acts as
a powerful inhibitor of tyrosinase enzyme, which can be utilized as a safe and natural skin whitening agent and to treat
hyperpigmentation disorders [47e49].

23.1.13 Effect on renal interstitial fibrosis
Renal interstitial ﬁbrosis comprises devastation or damage of renal tubules as well as interstitial capillaries because of the
deposition of extracellular matrix (ECM). It is not only affecting renal but also other tissues within the body such as the
lungs, brain, and heart. This process is introduced when immune cells such as macrophages releases some soluble factors
such as transforming growth factor, platelet-derived growth factor (PDGF), interleukin factor (IL-4), and connective tissue
growth factor. All these factors lead to stimulation of ECM as they initiate signal transduction pathways such as SMAD3,
which activates ﬁbroblast proliferation. These events result in loss of renal function and failure which ultimately generates
the condition of dialysis or kidney transplantation [50]. Gao et al. [51] demonstrated that kurarinone has the strong ability
to downregulate the SMAD3 expression and thus alleviate renal interstitial ﬁbrosis. In another study, kurarinone shows
strong oxidase inhibitory activity [52].

23.1.14 Neuroprotective activity
Neuroprotection is a process to protect the nerve from injury, neuronal loss, or to avoid neuronal cell death. Reactive
oxygen species or oxidative stress is one of the leading causes of the pathogenesis of neurodegenerative ailments such as
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Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and ischemia. Park et al. [53] reported that S. ﬂavescens
extracts have the potency of neuroprotection in focal cerebral ischemia in vivo. It is reported that acute ischemia is known
to induce histopathological and neuronal damage. It is also related to sodium nitroprussideeinduced apoptotic cell death
and DNA fragmentation by caspase-3 enzyme activation. Root extracts from S. ﬂavescens inhibit apoptosis by inhibiting
caspase-3 enzyme activity in a dose-dependent manner [54]. Apart from this, Yang et al., (2011) reported that kurarinone
modulates GABAA receptor [55].

23.1.15 Osteogenic effects
Osteoporosis is a disease in which bones become brittle and breakable because of low bone mass and loss of bone tissue.
This condition is also known as “silent disease” because many people do not even know that they are suffering from this
condition. Wang et al. [56] showed that kurarinone exhibits the capacity to increase the alkaline phosphatase levels (the
marker of osteogenic differentiation), which promotes the osteogenic differentiation and enhances bone mineralization.
Another study also reported that kurarinone promotes osteogenic differentiation through the ER signaling pathway.

Acknowledgments
PPK acknowledges ﬁnancial support from University Grants Commission, India in the form of CSIR-UGC Senior Research fellowship. SK
acknowledges Department of Science and Technology, India and University Grants Commission, India for providing ﬁnancial support in the
form of DST-SERB Grant [EEQ/2016/000350] and UGC-BSR Research Start-Up-Grant [No. F.30e372/2017 (BSR)] respectively.

References
[1] M.J. Xu, B. Wu, T. Ding, J.H. Chu, C.Y. Li, J. Zhang, W.Z. Ju, Simultaneous characterization of prenylated ﬂavonoids and isoﬂavonoids in
Psoralea corylifolia L. by liquid chromatography with diode-array detection and quadrupole time-of-ﬂight mass spectrometry, Rapid Commun.
Mass Spectrom. 26 (2012) 2343e2358.
[2] B. Botta, A. Vitali, P. Menendez, D. Misiti, G.D. Monache, Prenylated ﬂavonoids: pharmacology and biotechnology, Curr. Med. Chem. 12 (2005)
713e739.
[3] F. Cerqueira, A. Cordeiro-da-Silva, N. Araujo, H. Cidade, A. Kijjoa, M.S.J. Nascimento, Inhibition of lymphocyte proliferation by prenylated
ﬂavones: artelastin as a potent inhibitor, Life Sci. 73 (2003) 2321e2334.
[4] Q. Zhang, J. Yu, Y. Wang, W. Su, Selective extraction of ﬂavonoids from Sophora ﬂavescens Ait. by mechanochemistry, Molecules 21 (2016) 1e14.
[5] C. Zhang, Y. Ma, H.M. Gao, X.Q. Liu, L.M. Chen, Q.W. Zhang, A.P. Li, Non-alkaloid components from Sophora ﬂavescens, Zhongguo Zhongyao
Zazhi 38 (2013) 3520e3524.
[6] H.Y. Ma, W.S. Zhou, F.J. Chu, D. Wang, S.W. Liang, S. Li, HPLC ﬁngerprint of ﬂavonoids in Sophora ﬂavescens and determination of ﬁve
components, Zhongguo Zhongyao Zazhi 38 (2013) 2690e2695.
[7] W. Li, H. Liang, T. Yin, B. Wang, Y.Y. Zhao, Main ﬂavonoids from Sophora ﬂavescenes, Yao Xue Xue Bao 43 (2008) 833e837.
[8] L. Zhang, L. Xu, S.S. Xiao, Q.F. Liao, Q. Li, J. Liang, K.S. Bi, Characterization of ﬂavonoids in the extract of Sophora ﬂavescens Ait. by highperformance liquid chromatography coupled with diode-array detector and electrospray ionization mass spectrometry, J. Pharm. Biomed. Anal. 44
(2007) 1019e1028.
[9] H.Q. Zhang, Z.H. Zhu, D.W. Qian, Z.B. Weng, S. Guo, J.A. Duan, A.P. Li, Analysis and evaluation of alkaloids and ﬂavonoids in ﬂower of Sophora
ﬂavescens from Shanxi province, Zhongguo Zhongyao Zazhi 41 (2016) 4621e4627.
[10] M.J. Jung, S.S. Kang, H.A. Jung, G.J. Kim, J.S. Choi, Isolation of ﬂavonoids and a cerebroside from the stem bark of Albizzia julibrissin, Arch
Pharm. Res. (Seoul) 27 (2004) 593e599.
[11] X. Zhang, P. Jiang, P. Chen, N. Cheng, Metabolism of kurarinone by human liver microsomes and its effect on cytotoxicity, Pharm. Biol. 54 (2016)
619e627.
[12] W.M. Zhang, R.F. Li, J.F. Qiu, Z.Y. Zhang, H.B. Wang, L. Bian, J.H. Lei, Determination of kurarinone in rat plasma by UPLCeMS/MS,
J. Chromatogr. B 986 (2015) 31e34.
[13] Z. Yang, W. Zhang, X. Li, B. Shan, J. Liu, W. Deng, Determination of sophoraﬂavanone G and kurarinone in rat plasma by UHPLCeMS/MS and
its application to a pharmacokinetic study, J. Sep. Sci. 39 (2016) 4344e4353.
[14] C.M. He, Z.H. Cheng, D.F. Chen, Qualitative and quantitative analysis of ﬂavonoids in Sophora tonkinensis by LC/MS and HPLC, Chin. J. Nat.
Med. 11 (2013) 690e698.
[15] Y.Q. Shi, X.L. Xin, Q.P. Yuan, C.Y. Wang, B.J. Zhang, J. Hou, X.C. Ma, Microbial biotransformation of kurarinone by Cunninghamella echinulata
AS 3.3400, J. Asian Nat. Prod. Res. 14 (2012) 1002e1007.
[16] W. Zhou, A. Cao, L. Wang, D. Wu, Kurarinone synergizes TRAIL-induced apoptosis in gastric cancer cells, Cell Biochem. Biophys. 72 (2015)
241e249.
[17] C.Y. Wang, X.Y. Bai, C.H. Wang, Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development, Am. J.
Chin. Med. 42 (2014) 543e559.

354 PART | II Bio-functional leads for drug development

[18] Y.Q. Shi, X.L. Xin, H.C. Zhang, B.J. Zhang, C.Y. Wang, J. Hou, X.C. Ma, Microbial transformation of norkurarinone by cunninghamella
blakesleana AS 3.970, J. Asian Nat. Prod. Res. 14 (2012) 906e912.
[19] A. Rasul, B. Yu, L.F. Yang, M. Ali, M. Khan, T. Ma, H. Yang, Induction of mitochondria-mediated apoptosis in human gastric adenocarcinoma
SGC-7901 cells by kuraridin and Nor-kurarinone isolated from Sophora ﬂavescens, Asian Pac. J. Cancer Prev. APJCP 12 (2011) 2499e2504.
[20] T.H. Kang, S.J. Jeong, W.G. Ko, N.Y. Kim, B.H. Lee, M. Inagaki, Y.C. Kim, Cytotoxic lavandulyl ﬂavanones from Sophora ﬂavescens, J. Nat.
Prod. 63 (2000) 680e681.
[21] A. De Naeyer, W. Vanden Berghe, V. Pocock, S. Milligan, G. Haegeman, D. De Keukeleire, Estrogenic and anticarcinogenic properties of kurarinone, a lavandulyl ﬂavanone from the roots of Sophora ﬂavescens, J. Nat. Prod. 67 (2004) 1829e1832.
[22] J. Han, M. Sun, Y. Cui, T. Wang, W. Zhang, M. Guo, S. Xiong, Kushen ﬂavonoids induce apoptosis in tumor cells by inhibition of NF-kB
activation and multiple receptor tyrosine kinase activities, Phytother Res. 21 (2007) 262e268.
[23] M.Y. Sun, J. Zuo, J.F. Duan, J. Han, S.M. Fan, W. Zhang, M.H. Yao, Antitumor activities of kushen ﬂavonoids in vivo and in vitro, Zhong Xi Yi Jie
He Xue Bao 6 (2008) 51e59.
[24] W. Vanden Berghe, A. De Naeyer, N. Dijsselbloem, J.P. David, D. De Keukeleire, G. Haegeman, Attenuation of ERK/RSK2-driven NFkB gene
expression and cancer cell proliferation by kurarinone, a lavandulyl ﬂavanone isolated from Sophora ﬂavescens Ait, Roots Endocrine, Metabol
Immune Disord-Drug Targets. 11 (2011) 247e261.
[25] S.U. Choi, K.H. Kim, E.J. Choi, S.H. Park, C.O. Lee, N.P. Jung, S.Y. Ryu, P-glycoprotein (Pgp) does not affect the cytotoxicity of ﬂavonoids from
Sophora ﬂavescens, which also have no effects on Pgp action, Anticancer Res. 19 (1999) 2035e2040.
[26] H.A. Jung, N.Y. Yoon, S.S. Kang, Y.S. Kim, J.S. Choi, Inhibitory activities of prenylated ﬂavonoids from Sophora ﬂavescens against aldose
reductase and generation of advanced glycation endproducts, J. Pharm. Pharmacol. 60 (2008) 1227e1236.
[27] S. Sato, J. Takeo, C. Aoyama, H. Kawahara, Naþ-glucose cotransporter (SGLT) inhibitory ﬂavonoids from the roots of Sophora ﬂavescens, Bioorg.
Med. Chem. 15 (2007) 3445e3449.
[28] J.H. Kim, Y.B. Ryu, N.S. Kang, B.W. Lee, J.S. Heo, I.Y. Jeong, K.H. Park, Glycosidase inhibitory ﬂavonoids from Sophora ﬂavescens, Biol.
Pharm. Bull. 29 (2006) 302e305.
[29] T. Sasaki, W. Li, K. Higai, T.H. Quang, Y.H. Kim, K. Koike, Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl ﬂavonoids from roots
of Sophora ﬂavescens, Planta Med. 80 (2014) 557e560.
[30] Y.C. Kim, H.S. Kim, Y. Wataya, D.H. Sohn, T.H. Kang, M.S. Kim, H. Park, Antimalarial activity of lavandulyl ﬂavanones isolated from the roots of
Sophora ﬂavescens, Biol. Pharm. Bull. 27 (2004) 748e750.
[31] E.S. Chong, G.B. Hwang, C.W. Nho, B.M. Kwon, J.E. Lee, S. Seo, J.H. Jung, Antimicrobial durability of air ﬁlters coated with airborne Sophora
ﬂavescens nanoparticles, Sci. Total Environ. 444 (2013) 110e114.
[32] L. Chen, X. Cheng, W. Shi, Q. Lu, V.L. Go, D. Heber, L. Ma, Inhibition of growth of Streptococcus mutans, methicillin-resistant Staphylococcus
aureus, and vancomycin-resistant enterococci by kurarinone, a bioactive ﬂavonoid isolated from Sophora ﬂavescens, J. Clin. Microbial. 43 (2005)
3574e3575.
[33] R.X. Tan, J.L. Wolfender, L.X. Zhang, W.G. Ma, N. Fuzzati, A. Marston, K. Hostettmann, Acyl secoiridoids and antifungal constituents from
Gentiana macrophylla, Phytochemistry 42 (1996) 1305e1313.
[34] H.Y. Sohn, K.H. Son, C.S. Kwon, G.S. Kwon, S.S. Kang, Antimicrobial and cytotoxic activity of 18 prenylated ﬂavonoids isolated from medicinal
plants: Morus alba L., Morus mongolica Schneider, Broussnetia papyrifera (L.) Vent, Sophora ﬂavescens Ait and Echinosophora koreensis Nakai,
Phytomedicine 11 (2004) 666e672.
[35] H.A. Jung, D.M. Jeong, H.Y. Chung, H.A. Lim, J.Y. Kim, N.Y. Yoon, J.S. Choi, Re-evaluation of the antioxidant prenylated ﬂavonoids from the
roots of Sophora ﬂavescens, Biol. Pharm. Bull. 31 (2008) 908e915.
[36] X.L. Piao, X.S. Piao, S.W. Kim, J.H. Park, H.Y. Kim, S.Q. Cai, Identiﬁcation and characterization of antioxidants from Sophora ﬂavescens, Biol.
Pharm. Bull. 29 (2006) 1911e1915.
[37] J.M. Han, Y.Y. Jin, H.Y. Kim, K.H. Park, W.S. Lee, T.S. Jeong, Lavandulyl ﬂavonoids from Sophora ﬂavescens suppress lipopolysaccharideinduced activation of nuclear factor-kB and mitogen-activated protein kinases in RAW2647 cells, Biol. Pharm. Bull. 33 (2010) 1019e1023.
[38] T.S. Jeong, Y.B. Ryu, H.Y. Kim, M.J. Curtis-Long, S.J. An, J.H. Lee, K.H. Park, Low density lipoprotein (LDL)-antioxidant ﬂavonoids from roots
of Sophora ﬂavescens, Biol. Pharm. Bull. 31 (2008) 2097e2102.
[39] S. Lee, M.R. Chae, B.C. Lee, Y.C. Kim, J.S. Choi, S.W. Lee, C.S. Park, Urinary bladder-relaxant effect of kurarinone depending on potentiation of
large-conductance Ca2þ-activated Kþ channels, Mol. Pharmacol. 90 (2016) 140e150.
[40] M.Y. Chung, M.C. Rho, J.S. Ko, S.Y. Ryu, K.H. Jeune, K. Kim, Y.K. Kim, In vitro inhibition of diacylglycerol acyltransferase by prenylﬂavonoids
from Sophora ﬂavescens, Planta Med. 70 (2004) 258e260.
[41] S.W. Lee, H.S. Lee, J.Y. Nam, O.E. Kwon, J.A. Baek, J.S. Chang, Y.K. Kim, Kurarinone isolated from Sophora ﬂavescens Ait inhibited
MCP-1-induced chemotaxis, J. Ethnopharmacol. 97 (2005) 515e519.
[42] D.W. Kim, Y.S. Chi, K.H. Son, H.W. Chang, J.S. Kim, S.S. Kang, H.P. Kim, Effects of Sophoraﬂavanone G, a prenylated ﬂavonoid from Sophora
ﬂavescens, on cyclooxygenase-2 and in vivo inﬂammatory response, Arch Pharm. Res. (Seoul) 25 (2001) 329e335.
[43] B.H. Kim, K.M. Na, I. Oh, I.H. Song, Y.S. Lee, J. Shin, T.Y. Kim, Kurarinone regulates immune responses through regulation of the JAK/STAT
and TCR-mediated signaling pathways, Biochem. Pharmacol. 85 (2013) 1134e1144.
[44] Y.S. Chi, H. G Jong, K.H. Son, H.W. Chang, S.S. Kang, H.P. Kim, Effects of naturally occurring prenylated ﬂavonoids on enzymes metabolizing
arachidonic acid: cyclooxygenases and lipoxygenases, Biochem. Pharmacol. 62 (2001) 1185e1191.

Prenylated flavonoids as a promising drug discovery candidate: a pharmacological update Chapter | 23

355

[45] Q. Yu, N. Cheng, X. Ni, Identifying 2 prenylﬂavanones as potential hepatotoxic compounds in the ethanol extract of Sophora ﬂavescens, J. Food
Sci. 78 (2013) T1830eT1834.
[46] J.K. Son, J.S. Park, J.A. Kim, Y. Kim, S.R. Chung, S.H. Lee, Prenylated ﬂavonoids from the roots of Sophora ﬂavescens with tyrosinase inhibitory
activity, Planta Med. 69 (2003) 559e561.
[47] S.K. Hyun, W.H. Lee, D.M. Jeong, Y. Kim, J.S. Choi, Inhibitory effects of kurarinol, kuraridinol, and trifolirhizin from Sophora ﬂavescens on
tyrosinase and melanin synthesis, Biol. Pharm. Bull. 31 (2008) 154e158.
[48] Y.B. Ryu, I.M. Westwood, N.S. Kang, H.Y. Kim, J.H. Kim, Y.H. Moon, K.H. Park, Kurarinol, tyrosinase inhibitor isolated from the root of
Sophora ﬂavescens, Phytomedicine 15 (2008) 612e618.
[49] S.J. Kim, K.H. Son, H.W. Chang, S.S. Kang, H.P. Kim, Tyrosinase inhibitory prenylated ﬂavonoids from Sophora ﬂavescens, Biol. Pharm. Bull. 26
(2003) 1348e1350.
[50] J. Yamahara, G. Kobayashi, M. Iwamoto, T. Chisaka, H. Fujimura, Y. Takaishi, Y. Tamai, Vasodilatory active principles of Sophora ﬂavescens root,
J. Ethnopharmacol. 29 (1990) 79e85.
[51] H.Y. Gao, X.F. He, J.F. Shao, Effect of kurarinone on renal tubular epithelial cell-mesenchyma trans-differentiation in rats with renal interstitial
ﬁbrosis, Zhongguo Zhong Xi Yi Jie 27 (2007) 535e539.
[52] R. Suzuki, Y. Hasuike, M. Hirabayashi, T. Fukuda, Y. Okada, Y. Shirataki, Identiﬁcation of a xanthine oxidase-inhibitory component from Sophora
ﬂavescens using NMR-based metabolomics, Nat. Prod. Comm. 8 (2013) 1409e1412.
[53] S.J. Park, K.W. Nam, H.J. Lee, E.Y. Cho, U. Koo, W. Mar, Neuroprotective effects of an alkaloid-free ethyl acetate extract from the root of Sophora
ﬂavescens Ait. against focal cerebral ischemia in rats, Phytomedicine 16 (2009) 1042e1051.
[54] G.S. Jeong, B. Li, D.S. Lee, E. Byun, R.B. An, H.O. Pae, Y.C. Kim, Lavandulyl ﬂavanones from Sophora ﬂavescens protect mouse hippocampal
cells against glutamate-induced neurotoxicity via the induction of heme oxygenase-1, Biol. Pharm. Bull. 31 (2008) 1964e1967.
[55] X. Yang, I. Baburin, I. Plitzko, S. Hering, M. Hamburger, HPLC-based activity proﬁling for GABA A receptor modulators from the traditional
Chinese herbal drug Kushen (Sophora ﬂavescens root), Mol. Divers. 15 (2011) 361e372.
[56] X. Wang, L. Zhen, G. Zhang, M.S. Wong, L. Qin, X. Yao, Osteogenic effects of ﬂavonoid aglycones from an osteoprotective fraction of Drynaria
fortuneidan in vitro efﬁcacy study, Phytomedicine 18 (2011) 868e872.

This page intentionally left blank

Index
Note: ‘Page numbers followed by “f ” indicate ﬁgures, “t” indicates tables’.

A
Aaptos aaptos, 259e260
Acarbose, 133
Acidic polysaccharides, 261
Active neuraminidase inhibitor, 255
Acute inﬂammation, 318
Adenovirus serotype 5 (AdV-5), 265e266
ADME-Tox prediction, 33, 34t
a-Adrenergic blockers (AABs), 343
Afﬁnity proﬁling, 29
Ageratum conyzoides, 297
Agrimonia pilosa, 250
Alginic acid, 261
Alitretinoin, 217
Alkaloids, 259e260, 282
Allopathic medicines, 294
Alopecia areata, 213
Alopecia treatment
alkaloids, 230
alopecia areata, 221e222
alopecia totalis, 221e222
alopecia universalis, 221e222
anagen efﬂuvium, 221e222
androgenic alopecia, 221e222
classiﬁcation, 222f
conventional treatment, 222e226
corticosteroids, 225
dutasteride, 225
ﬁbroblast growth factor, 227
ﬁnasteride, 224
future perspective, 231
hair transplantation, 223
herbal therapy for alopecia, 225e226
IGF-1, 226
investigational drug-based therapies, 225
laser therapy, 223
microneedling, 223
minoxidil, 224
natural products, 225e226
nondrug therapies, 222e224
other emerging nondrug therapies, 224
other phytochemicals, 231
plant-based drug formulations, 222
platelet-rich plasma, 223e224
polyphenols, 230
potential phytochemicals, 230e231
saponin, 230
scarring alopecia, 221e222
signaling pathways targeted by herbs,
226e230
telogen efﬂuvium, 221e222

terpenoids, 231
topical immunotherapy, 225
vascular endothelial growth factor, 227
wnt/b-catenin pathway, 227e230
Alpha-adrenergic blockers, 343
Alternaria raphani, 259e260
Altitude, 21
Alzheimer disease, 319
Amaranthaceae, 298
Amaranthus spinosus, 298
Aminoacyl t-RNA synthetases, 278
Aminoglycosides, 276e277
Aminolevulinic acid, 217
Amylin, 135
Anabasam, 329
Anthraquinone monodictyoquinone A,
264e265
Antibacterial compounds, clinical trials, 265
Antibacterial drugs, clinical trials, 286
Antibacterial fatty acid, 263
Antibacterial lead compounds
antibacterial drugs on clinical trial, 286
characterization of good antibiotic, 276
choosing and validating suitable antibiotic
target, 276e277
FDA-approved antibacterial drugs
bezlotoxumab, 283
ceftaroline, 285
ceftazidime/avibactam, 284
ceftobiprole, 285
doripenem, 285e286
ozenoxacin, 283e284
telithromycin, 286
vabomere, 285
groups of natural antimicrobial
compounds, 283
alkaloids, 282
coumarins, 282
ﬂavonoids, 281
lectins and polypeptides, 283
phenolic compounds, 280
quinones, 280
stilbenoids, 281
tannins, 281e282
terpenoids and essential oils, 282
natural antiinfective drugs, 275e276
potential targets
chorismate biosynthesis, 279
fatty acid biosynthesis, 280
FtsAeFtsZ interaction, 279
isoprenoid biosynthesis, 279e280

two-component signal transduction
(TCST) system, 278e279
protein synthesis
aminoacyl t-RNA synthetases, 278
biosynthesis of cell wall, 278
DNA replication and repair, 277
targets of major antibacterial drugs, 277
Anticancer activity, 96, 348
Antidepressants, 343
Antidiabetic activity, 348e349
Antidiabetic combinations, 136
Antidiabetic lead compounds
classes, 134e136
amylin analog, 135
antidiabetic combinations, 136
dipeptidyl peptidase-4 inhibitors, 136
incretin mimetics, 135
miglitol, 134, 135f
nonsulfonylureas/biguanides, 136
SGLT-2 inhibitors, 135
sulfonylureas, 135
thiazolidinediones, 135e136
clinical trial
future perspectives, 138
glucokinase (GK), 137
lexicon pharmaceuticals (LX2761), 137
semaglutide, 137
smart insulin, 137e138
sotagliﬂozin, 136e137
diabetes management, 128e134
acarbose, 133
ferulic acid (FA), 133e134
Lagerstroemia speciosa, 129
naringenin, 133
protein tyrosine phosphatases
(PTPase), 133
rosmarinic acid (RA), 133
diabetes mellitus, 128
examples, 130te132t
molecular targets, 128, 129t
type 1 diabetes mellitus (T1DM), 128
type 2 diabetes mellitus (T2DM), 128
Antiepilepsy, 343
Antifungal compounds, clinical trials, 266
Anti-herpes compounds, 240t
Anti-HIV compounds, 241t
Antiinﬂammatory drugs, 317
chemically synthesized antiinﬂammatory
agents, 325
under clinical trial, 329
effects of inﬂammation, 318
FDA-approved, 326e328

357

358 Index

Antiinﬂammatory drugs (Continued )
inﬂammation, 318
major inﬂammatory diseases, 319
mode of action of antiinﬂammatory drugs,
324e325
molecular approaches to diagnose
inﬂammatory conditions, 325e326
plant-derived antiinﬂammatory agents, 325
plants and leads bioactive compounds with
antiinﬂammatory activities, 319
side effects of NSAIDs, 328e329
Antimalarial activity, 349e350
Antimalarial agents, 299te301t
Antimalarial compounds, clinical trials,
266e267
Antimalarial drugs, 305e306
antimalarial products, 307
compounds for, 308e309
computer-based drug designing and
antimalarial drug discovery, 307e311
current antimalarial compounds, 307
discovery, 307e311
natural antimalarial compounds and their
advantage, 307
quinine, 4
target, 311
Antimalarial products, 307
Anti-measles compounds, 240t
Antimicrobial activity, 96, 350
Antimicrobial drugs
marine origin
antibacterial compounds under clinical
trials, 265
antifungal compounds under clinical
trials, 266
antimalarial compounds under clinical
trials, 266e267
antiviral compounds under clinical trials,
265e266
Antimicrobial efﬁciency of marine
metabolites, 267e268
Antimicrobial lead compounds, 257
antimicrobial drugs of marine origin
antibacterial compounds under clinical
trials, 265
antifungal compounds under clinical
trials, 266
antimalarial compounds under clinical
trials, 266e267
antiviral compounds under clinical trials,
265e266
bioactive compounds in marine plants
alkaloids, 259e260
carbohydrates, 261e263
fatty acids, 263
ﬂavonoids, 258
peptides, 260e261
phenolic compounds, 264e265
polyketides, 264
polysaccharides, 264
steroids, 265
terpenoids/isoprenoids/modiﬁed terpenes,
258e259
natural medicinal therapy research, 257e258

Antiobesity
antiobesity phytochemical compounds,
146e148
adipogenesis/lipogenesis, 146e147
energy expenditure/thermogenesis,
147e148
hormones and endocrine functions, 148
inhibition of inﬂammation, 148
lipases/lipid absorption, 146
sibutramine, 146
suppression of food intake, 146
uncoupling protein 1 (UCP1), 147e148
body mass index (BMI), 144
clinical trials, 154e155
cognitive behavioral therapy (CBT),
144e145
future directions, 155
glucagon-like-peptide 1 receptor (GLP-1R)
agonist, 145
limitations, 155
Organization for Economic Co-operation
and Development (OECD), 144
perspectives, 155
plant-derived lead compounds, 148e154
alkaloids, 150, 151t
b-conglycinin and glycinin, 154
organosulfur compounds, 153, 153t
polyphenols, 148, 149te150t
saponins, 150, 151t
terpenoids, 150, 152t
xanthones, 153, 153t
Antioxidant activity, 95e96, 350
Anti-polio compounds, 241t
Antiretrovirals, 343
Anti-viral compounds, 241t
Antiviral compounds under clinical trials,
265e266
Antiviral effects
plant-derived phytochemicals with, 250
immunomodulators, 250
modiﬁers of viral genome and protein
processing, 250e251
virus assembly and release inhibitors, 251
virus attachment and entry inhibitors, 250
Antiviral phytocompounds
anti-herpes compounds, 240t
anti-HIV compounds, 241t
anti-measles compounds, 240t
anti-polio compounds, 241t
anti-viral compounds, 241t
collection and mining, 240
data mining, 240
herpes simplex virus, 241e242
human immunodeﬁciency virus (HIV), 243
inﬂuenza virus, 242
measles virus, 242
other viral diseases, 243
poliovirus, 242
Antiviral therapy, 250
Apicoplast of parasite, 349
Apoptosis induction, 348
Approval abbreviated new drug application
(ANDA), 60
Artemisia annua, 294, 307

Artemisia annua L. (Compositae), 298
Artemisia nilagirica (Asteraceae), 298
Artemisinin, 26f, 307, 349
Ashwagandha, 334
Aspergillus versicolor, 264e265
Aspirin, 26f, 327
Asteraceae, 297e298
Asthma disease, 319
Astragalus membranaceus, 334
ATB-346, 329
Atherosclerosis
acute myocardial infarction, 79e84
alkaloids, 76
anti-inﬂammatory agents, 73e76
intercellular adhesion molecule-1
(ICAM-1), 74
low-density lipoprotein (LDL), 78e79
monocyte chemoattractant protein-1
(MCP-1), 74
polyphenols, 73e75
polyunsaturated fatty acid, 75e76
quercetin, 74e75
resveratrol, 74
vascular cell adhesion molecule-1
(VCAM-1), 74
Atopic dermatitis, 214, 319
AutoDockTools (ADT), 309
Azadirachta indica, 120, 297

B
Bacillus subtilis, 258e259
Baxdela, 218
1,4-Benzoquinone, 258
Bexarotene, 217
Bezlotoxumab, 283
Bioactive compounds, 26
alkaloids, 259e260
carbohydrates
glycolipids, 263
glycoproteins, 263
iminosugar, 263
N-acetylated sugars, 262
neutral and acidic polysaccharides, 261
sulfated polysaccarides, 261e262
triterpene glycosides, 262e263
fatty acids, 263
ﬂavonoids, 258
peptides, 260e261
phenolic compounds, 264e265
polyketides, 264
polysaccharides, 264
steroids, 265
terpenoids/isoprenoids/modiﬁed terpenes,
258e259
Bioﬂavonoids, 258
Bioinformatics, 32e33
Biosynthesis of cell wall, 278
Bisphenol-A (BPA), 335
b-lactams, 276
Body mass index (BMI), 144
Bowel diseases, 319
Bridelia ferruginea, 297
Bridelia ferruginea Benth
(Euphorbiaceae), 297

Index

1-Bromomethyl-3,4,5-trimethoxybenzene
undergoes, 8
Bromotyrosine alkaloids, 259e260
Brown adipose tissue (BAT), 147e148
Bulbine frutescens, 308, 311
Bupleurum salicifolium, 283

C
Caesalpinia crista, 294
Calanolide, 250e251
Calcineurin, 214, 338
Calcium, 350e351
Calcium channel blockers (CCBs), 343
Callyspongia aerizusa, 260e261
Calophyllum lanigerum, 250e251
Cancer treatment
curcumin, 117e119
5-ﬂuorouracil (5FU), 118
mechanisms, 119
epigallocatechin-3-gallate (EGCG), 121
mechanisms, 121
vascular endothelial growth factor
(VEGF), 121
future prospective, 122
genistein, 121e122
molecular mechanisms, 119e120
nimbolide, 120
molecular crosstalk, 120
phytochemicals, 117, 118f
resveratrol, 119e120
Candida albicans, 282
Candida krusei, 258
Carbohydrates
glycolipids, 263
glycoproteins, 263
iminosugar, 263
N-acetylated sugars, 262
neutral and acidic polysaccharides, 261
sulfated polysaccarides, 261e262
triterpene glycosides, 262e263
Cardiovascular disease (CVD), 351
atherosclerosis. See Atherosclerosis
autophagy, 69e70
berberine, 70
curcumin, 69e70
natural compounds, 69e70, 69f
physiology, 69
resveratrol, 70
berberine, 68
carotenoids, 84e85
astaxanthin, 85
b-carotene, 85
lycopenes, 85
endoplasmic reticulum (ER). See
Endoplasmic reticulum (ER)
end stage renal disease acquires CVD
(ESRD), 68
ﬂavonoids, 78e84
catechin, 79e84
epigallocatechin gallate (EGCG), 84
quercetin, 78e79, 80te83t
ﬂow-mediated dilation (FMD), 68
G protein coupled receptor (GPR) 120, 68
hypertension, 77e86

ischaemic heart diseases, 77e86
nutraceuticals, 68
phenolic acids, 77e78
caffeic acid, 77
ferulic acid, 77
magnolol, 78
a-mangostins, 77
salvianolic acid A, 77
salvianolic acid B, 77
polyphenols, 77e78
preclinical/clinical studies, 86e87
lutein, 86e87
lycopene, 86
quercetin, 86
zeaxanthin, 86e87
stilbenes, 84
piceatannol, 84
resveratrol, 84
volatile oils, 85e86
thymoquinone, 85e86
Carnitines, 335
Carotenoids, 336
Carpesium divaricatum, 299
Carrageenan/Agaran, 261
Catalase, 336
Catharanthus roseus, 20
CD20, 214
CD22, 214
Ceftaroline, 285
Ceftazidime/avibactam, 284
Ceftobiprole, 285
Celecoxib, 327
Cephaelis ipecacuanha, 275e276
Cerebral malaria, 296
Chemical synthesis of shikimic acid, 253e254
Chinese antimalarial drug artemisinin,
296e297
Ching-fang-pai-tu-san, 251
Chitin, 262
Chitosan, 262
Chloroquine (CQ), 307
Chromatographic puriﬁcation, 254e255
Chronic inﬂammation, 318
Chronic inﬂammatory skin diseases,
351e352
Chronic liver diseases
complementary alternative medicines, 197
deﬁnition, 196
extracellular matrix (ECM), 196
hepatic stellate cells (HSCs), 196
hepatitis B virus (HBV), 197
herbal medicines, 197, 204e205
limitations, 205
National Center for Complementary and
Alternative Medicine (NCCAM), 197
origin of problem, 197
phytochemicals, 197e203
berberine (BBR), 202
curcumin, 200
glycyrrhizic acid (GA), 201e202
green tea extracts (GTE), 200e201
quercetin, 202
resveratrol, 201
silibinin, 197e199

359

silymarin, 197e199
S. miltiorrhiza, 202e203
progression, 196f
superoxide dismutase (SOD), 198
Ciproﬂoxacin, 277
Clofazimine, 219
Clostridium difﬁcile, 283
Coenzyme A (CoA), 254
Colpomenia sinuosa, 263
Combretastatin A-1 (CA1), 8
Combretastatin A-4 (CA4), 8
Combretum woodii, 281
Complex human system, 183e184
Compositae, 298
Computer-aided drug discovery (CADD),
27, 307
ADME-Tox prediction, 33, 34t
afﬁnity proﬁling, 29
bioactive compounds, 26
bioinformatics, 32e33
chemical structure, 26
computer-aided drug design (CADD), 27
digitoxin, 26f
1D-QSAR, 30
2D-QSAR, 30
3D-QSAR, 31
forward genetics, 28
future possibilities, 33e34
genomic techniques, 27e28
lead identiﬁcation, 28e29
lead optimization, 29
molecular docking, 31e32
multidimensional quantitative
structureeactivity relationship, 31
process, 27e29
proteomics, 28
quantitative structureeactivity relationships
(QSAR), 29e31
reverse genetics, 28
reverse pharmacology, 26e27, 27f
in silico human genome project, 33
software packages, 32e33
structural considerations, 29e32
structure-based drug design (SBDD), 27
target identiﬁcation, 27e28
target speciﬁcity, 29
target validation, 28
Computer-based drug designing, 307e311
Coumarins, 250e251, 282
Craniella australiensis, 264
Crisaborole, 218
Crohn’s disease, 319
Cryptococcus neoformans, 258
Curcumin
5-ﬂuorouracil (5FU), 118
mechanisms, 119
Cyclic depsipeptides Papuamides, 260e261
Cyclodepsipeptides, 260
Cyclooxygenase (COX) enzymes, 324, 326
Cymbastela hooperi, 266
Cytochrome P450s, 258
Cytosolic HSP90, 307e308
Cytotoxic T-Lymphocyte-associated protein
4, 214

360 Index

D
Dapsone, 217, 219
Dehydroshikimate, 254
3-Dehydroshikimic acid, 253
Demersal habitats, 257
29-Demethylgeodisterol-3-O-sulﬁte, 265
3-Deoxy-D-arabino-heptulosonate7-phosphate (DAHP), 251e253
Depsipeptides, 260e261
Dermotropic viruses, 246
Diabetes mellitus, 187
Diacarnus megaspinorhabdosa, 266
(1E, 3E)-1,4-diacetoxy-1,3-butadiene,
253e254
Diclofenac, 327
Dictyota menstrualis, 259
Dictyota pfafﬁ, 259
Digitoxin, 26f
Diisocyanoadociane, 267
Dimethylallyl pyrophosphate, 258
Dipeptidyl peptidase-4 inhibitors, 136
DNA replication and repair, 277
Doripenem, 285e286
Doxepin, 218
1D-QSAR, 30
2D-QSAR, 30
3D-QSAR, 31
Drug-resistant inﬂuenza strain, 248e249
Drymaria diandra, 282
Dupihumab, 218
Dysidea arenaria, 258
Dysidea granulosa, 264
Dyslipidemia, 187e188

E
Ebola virus (EBOV), 249e250
Ecklonia cava, 265
Endogenous antioxidants and infertility,
336e337
Endoplasmic reticulum (ER), 70e72
anisodamine, 71
baicalin, 71e72
berberine, 72
mangiferin, 71
natural compounds, 70e72, 71f
notoginsenoside R1, 72
paeonol, 71
physiology, 70
pterostilbene, 72
quercetin, 72
resveratrol, 72
Entamoeba histolytica, 275e276
Environmental factor and infertility, 335
Enzymatic synthesis, shikimic acid, 254
Ephedra sinica, 4
Epigallocatechin-3-gallate (EGCG)
vascular endothelial growth factor (VEGF),
121
Esenbeckia febrifuga (Rutaceae), 298
Euphorbiaceae, 297
European Food Safety Authority (EFSA),
183
Eurycoma longifolia, 334
Euryspongia, 265
Evasion of apoptosis, 121

Exogeneous antioxidants and infertility,
335e336
Extracellular matrix (ECM), 352
Extracellular signaleregulating kinase
(ERK), 147

F
Fabatin, 283
Fatty acids, 263
Favipiravir, 249e250
FDA-approved antibacterial drugs
bezlotoxumab, 283
ceftaroline, 285
ceftazidime/avibactam, 284
ceftobiprole, 285
doripenem, 285e286
ozenoxacin, 283e284
telithromycin, 286
vabomere, 285
FDA-approved antiinﬂammatory drugs
aspirin, 327
celecoxib, 327
diclofenac, 327
ibuprofen, 327
indomethacin, 327e328
naproxen, 328
oxaprozin, 328
piroxicam, 328
FDA-approved drugs for inﬂuenza
inﬂuenza virus inhibitors, 249
favipiravir, 249e250
ribavirin, 249
rimantadine and amantadine, 249
zanamivir, oseltamivir, peramivir, and
laninamivir octanoate, 249
plant-derived phytochemicals with antiviral
effects, 250
immunomodulators, 250
modiﬁers of viral genome and protein
processing, 250e251
virus assembly and release inhibitors, 251
virus attachment and entry inhibitors, 250
shikimic acid, 251
chemical synthesis of, 253e254
Enzymatic synthesis of, 254
isolation from plant raw materials,
254e255
mechanism of oseltamivir, 255
microbial synthesis of, 254
pathway, 254
in plants, biosynthesis of, 251e253
plant sources of, 251, 252te253t
Feline infectious peritonitis virus, 250
Ferulic acid (FA), 133e134
Fibronectin, 338
Flavonoids, 78e84, 258, 281, 283, 308
catechin, 79e84
epigallocatechin gallate (EGCG), 84
quercetin, 78e79, 80te83t
Fluoroquinlones, 218
Fluoroquinolones, 276e277, 278f
Food and Drug Administration (FDA) drug
candidacy acceptance
approval process, 42f
botanical drug development regulatory
approaches, 43e49

botanical raw materials, 45
carcinogenicity studies, 47
challenges, 43e44
clinical pharmacology, 47
Code of Federal Regulations
(CFR), 47
description and documentation of
products, 44
efﬁcacy, 47e48
general toxicity studies, 46
genotoxicity studies, 47
labeling, 46
nonclinical safety assessment, 46e47
novel botanical drugs, 44
pharmacokinetic studies, 46
placebo, 46
quality control, 44e45
quality control systems, 45
record and document control, 45
reproductive toxicology, 47
safety, 47e48
safety tests, 45
therapeutic consistency, 48e49
botanicals, 39e40
Center for Drug Evaluation and Research
(CDER), 39
chemistry, manufacturing, and control
(CMC), 40
foreign clinical studies, 42e43
acceptance of, 43
investigational new drug (IND), 40
clinical trials, 41e42
emergency use investigational new drug
(EIND), 41
investigator IND, 40e41
treatment IND applications, 41
marketability of drug products, 60
National Institutes of Health (NIH), 39
postmarketing considerations, 49e50,
50te59t
Friesodielsia discolor, 298
Fucoidan, 261
Fucosylated Chondroitin Sulfate
(FCS), 262

G
Gallic acid, 254
Gametocytes, 295
Gene to drug approach, 25
Genistein, 121e122
Geodisterol-3-O-sulﬁte, 265
Geographic variation, 21
Gingivitis, 319
Glucagon-like-peptide 1 receptor (GLP-1R)
agonist, 145
Glucokinase (GK), 137
Glutathione peroxidase, 336
Glycolipids, 263
Glycoproteins, 263
Glycosaminoglycans (GAGs), 262
Glycosphingolipids, 263
Gongronema nepalense, 299
Good antibiotics,
characterization of, 276

Index

H

I

Halichondramide, 267
Halimeda renschii, 263
Heat shock proteins (HSPs), 307e308
Hematological malignancy treatments
andrographolide, 108
anthracenediones, 100e103
anthracyclines
anthracenedione, 102e103
daunorubicin, 102
doxorubicin, 101e102
epirubicin, 102
idarubicin, 102
mitoxantrone, 102e103
anthracyclines and
anthracenediones
administration, 101
chemical structure, 100
clinical use, 101
mechanism, 101
pharmacokinetics, 101
capsaicin, 109
cephalotaxus alkaloids, 100
cyanidin, 109
isothiocyanates, 104e105, 104f
lycopene, 107
mushroom proteins, 109, 109f
podophyllotoxin derivatives,
103e104
administration, 104
chemical structure, 103, 103f
clinical use, 104
mechanism, 103
pharmacokinetics, 104
polyphenols, 105e107
curcumin, 105e106
ﬂavonoids, 107
genistein, 106
gingerol, 106
resveratrol, 106e107
tea polyphenols, 106
triterpenoid acids, 108
vinca alkaloids, 97e100, 97f
Hemozoin, 296e297
Heparin sulfate molecules, 250
Hepatotropic viruses, 246
Herbal medicinal products, 307
Herbal medicines, 294
Herpes simplex virus, 241e242
Hidradenitus suppurativa (HS), 214
Highly active antiretroviral therapy
(HAART), 343
High-throughput screening (HTS), 17
Homophymime A, 260e261
Human immunodeﬁciency virus
(HIV), 243
Hydrolyzable, 281e282
Hydroquilone, 218
5-Hydroxyindole-type alkaloids,
259e260
10-Hydroxykahukuene B, 258e259
Hypertension, 188
Hyrtios erectus, 258

Ibuprofen, 327
Illicium religiosum, 251
Illicium verum, 13
Ilumya, 218
Iminosugar, 263
Immunomodulators, 250
Incretin mimetics, 135
Incubation period, 295
Indomethacin, 327e328
Inﬂammation and infertility, 335
Inﬂuenza A viruses, 248
Inﬂuenza B, 248
Inﬂuenza B viruses, 248
Inﬂuenza D viruses, 248
Inﬂuenza type C, 248
Inﬂuenza virus, 242
Inﬂuenza virus inhibitors, 249
favipiravir, 249e250
laninamivir octanoate, 249
oseltamivir, 249
peramivir, 249
ribavirin, 249
rimantadine and amantadine, 249
zanamivir, 249
Inosine-5-monophosphate (IMP)
dehydrogenase, 249
In silico antimalarial potential of
phytochemicals, 309
In silico human genome project, 33
Interferons, 250
Interleukins, 250
Iotrochota baculifera, 259e260
Isopentenyl pyrophosphate, 258
Itraconazole, 217
Ixekizumad, 218

K
Kalihinol A, 267
Keratolytics drugs, 218
Kurarinone, 347e348, 348f, 350e351

L
Lagerstroemia speciosa, 129
Laminaran, 261
Laninamivir octanoate, 249
“Lassa fever”, 249
Laurencia mariannensis, 258e259
Lavandulyl isoﬂavones, 348e349, 350f
Lectins, 283
Leucojum vernum, 282
Lexicon pharmaceuticals (LX2761), 137
Life cycle of malarial parasite, 295
Ligand preparation for antimalarial drug
discovery, 309
Ligandeprotein interaction of new
antimalarial compounds, 309
Lindra thalassiae, 258
Lipophilic ﬂavonoids, 281
Liquidambar genus, 255
Liquidambar styraciﬂua, 251
Liver ailments, effect on, 352

361

Long noncoding RNAs (lncRNAs), 337e338
Long-term responses, 184
Lycopene, 336

M
Macrolides, 276e277
Macrophages, 335
Malaria parasite protease as antimalarial drug
target, 349
Malaria, therapeutic strategies of, 293e294
Ageratum conyzoides (Asteraceae), 297
Amaranthus spinosus (Amaranthaceae), 298
Artemisia annua L. (Compositae), 298
Artemisia nilagirica (Asteraceae), 298
Azadirachta indica (Meliaceae), 297
Bridelia ferruginea Benth
(Euphorbiaceae), 297
Esenbeckia febrifuga (Rutaceae), 298
incubation period, 295
life cycle of malarial parasite, 295
methods of diagnosis, 296
Ochna integerrima (Ochnaceae), 297
pathogenesis, 295
phytochemicals for treatment of malaria,
298e299
prevalence, risk factors, and mode of
transmission, 294e295
prevention, control and prognosis, 301
Remijia ferruginea (Rubiaceae), 298
symptoms, 295e296
Ticodendron incognitum
(Ticodendraceae), 298
treatment, 296e297
Male factor infertility (MFI), 337
Male infertility, 333
natural compounds to treat, 338e339
novel targets for, 337e338
nutrition and, 337
oligospermia and plant products, 334
pharmaceutical medications and, 342e343
stress and plant products, 334e337
suvarna bhasma, 342
Man-made activities, 294e295
Manzamine A, 267
Manzamines, 267
Marine antimicrobial peptides, 260
Marine carbohydrate compounds, 261
Marine fauna, 259
Marine ﬂora, 258
Marine fungi, 263
Marine macroalgae, 259
Marine metabolites, antimicrobial efﬁciency
of, 267e268
Marine origin
antimicrobial drugs of
antibacterial compounds under clinical
trials, 265
antifungal compounds under clinical
trials, 266
antimalarial compounds under clinical
trials, 266e267
antiviral compounds under clinical trials,
265e266

362 Index

Marine plants
bioactive compounds in
alkaloids, 259e260
carbohydrates, 261e263
fatty acids, 263
ﬂavonoids, 258
peptides, 260e261
phenolic compounds, 264e265
polyketides, 264
polysaccharides, 264
steroids, 265
terpenoids/isoprenoids/modiﬁed
terpenes, 258e259
Marine sesterterpenoids, 258
Marine sponges, 259e260
“Maturation inhibition” capability, 251
Measles virus, 242
Medicinal plants
Ammi visnaga (L.) Lam, 3e4
anticancer agents, 9te10t
antidiabetic agents, 5te7t
case studies, 8e13
Catharanthus roseus, 7e8
computer-aided drug discovery
(CADD), 3
Galega ofﬁcinalis L., 3
Papaver somniferum, 3e4
primary and secondary metabolites, 4f
Rauwolﬁa serpentina, 4
traditional medicine leads, 7f
World Health Organization (WHO), 3
Meﬂoquine, 296e297
Melanogenesis, 352
Melanoma, 214
Meliaceae, 297
Melophlus sponge, 262e263
Meroterpenes, 259
Merozoites, 295
Metabolites, 267
Methicillin-resistant Staphylococcus aureus
(MRSA), 281
Methylated compounds, 311
Methylated ﬂavonoids, 308
Methylsulfonylmethane (MSM),
186e190
Microbial synthesis of shikimic acid, 254
Microwave-assisted extractions
(MAE), 16
Miglitol, 134, 135f
Miliusa cuneatas, 299
Mitogen-activated protein kinases (MAPKs),
119e120, 215
Mitrephora diversifolia, 299
Molecular docking, 31e32
antimalarial compound screening, 309
Monamphilectine A, 267
Monanchora unguifera, 259e260
Moringa oleifera, 16, 338e339
Multidimensional quantitative
structureeactivity relationship, 31
Multidrug-resistance protein 1
(MRP1), 119
Myrtenol, 325

N
N-acetylated sugars, 262
Naproxen, 328
Naringenin, 133
“Natural antibiotics”, 260
Natural antimalarial compounds, 307
Natural antimicrobial compounds, 283
alkaloids, 282
coumarins, 282
ﬂavonoids, 281
lectins and polypeptides, 283
phenolic compounds, 280
quinones, 280
stilbenoids, 281
tannins, 281e282
terpenoids and essential oils, 282
Natural compounds, male infertility,
338e339
Natural compounds stability, 19
Natural medicinal therapy research,
257e258
Natural products, drug discovery
altitude, 21
Catharanthus roseus, 20
factors, 20e21
geographic variation, 21
high-throughput screening (HTS), 17
microwave-assisted extractions (MAE), 16
molecular size, 17, 17f
Moringa oleifera, 16
palytoxin, 18f
pharmacodynamics, 19e20
pharmacokinetics, 19e20
plant age, 20
plant material, 16e17
plant part, 20
plant samples collection, 20e21
pre- and postharvesting ingredients, 20e21
process, 15e16
rainfall, 21
seasonality, 20
soil type, 21
stability, 19
structural modiﬁcation, 21e22
supercritical ﬂuid extraction
(SFE), 16
temperature, 21
toxicity, 21
Nephritis, 319
Nephritis disease, 319
Neuraminidase (NA) enzyme, 248e249
Neuraminidase inhibitors (NAIs), 251
Neuraminidase (NA) protein, 248e249
Neurodegenerative diseases
Alzheimer’s disease, 162
Amyotrophic lateral sclerosis, 163
factors, 163e164, 164f
aging, 163
environment, 163e164
future perspective, 174
Huntington’s disease, 163
lead phytochemicals molecular mechanism,
170e173, 171te172t

apigenin, 170
epigallocatechin gallate (EGCG), 172
galantamine, 173
ginkgolides, 173
huperzine A, 172
quercetin, 170
rivastigmine, 173
Multiple sclerosis, 163
neuroprotective phytochemicals, 173
clinical trials, 173te174t
neuroprotective plants, 167e168
alkaloids, 168
fatty acids, 168
ﬂavonoids, 168
lignin, 168
polysaccharides, 168
terpenes, 168
terpenoids, 168
Parkinson’s disease, 162
therapeutic strategies, 164e167
apoptosis, 166
enzymes, 166
excitotoxicity, 167
inﬂammatory pathway mediators,
164e166
mitochondrial dysfunction, 166
neurotrophins, 166
oxidative stress pathway mediators, 166
Neuroprotective activity, 352e353
Neurotropic viruses, 246
Neutral polysaccharides, 261
Neutrophils, 335
New antimalarial compounds, ligandeprotein
interaction of, 309
Nicotinamide adenine dinucleotide phosphate
(NADPH), 253
Nimbolide, 120
Nonsulfonylureas/biguanides, 136
Nostoc ﬂagelliforme, 264
Novel lead compounds, 311
Novel targets for male infertility, 337e338
Nutrition, male fertility, 337

O
Obesity, 187
Ochnaceae, 297
Ochna integerrima (Ochnaceae), 297
Ocimum basilicum, 250
Ocular viral infection, 246
Odonthalia corymbifera, 264
Oligosaccharides, 262
Oligospermia, 334
Ookinete, 306
Organosulfur phytochemicals
balanced viewpoints, 189e190
cardiovascular disease, 187e188
chemistry, 179e191
classiﬁcation, 179e191, 181te182t
complex human system, 183e184
diabetes mellitus, 187
dyslipidemia, 187e188
European Food Safety Authority
(EFSA), 183

Index

features, 181te182t
hypertension, 188
long-term responses, 184
methylsulfonylmethane (MSM), 186e190
neurodegenerative diseases, 188e189
obesity, 187
panacea, 185e186
physiological vs. pharmacological levels,
183
phytochemicalegene interaction, 185
reactive oxygen species (ROS), 180
responsible media, 190
risks, high dose consumptions, 189
scientiﬁc temper, 184e185
short-term responses, 184
synthetic antioxidants, 180
Orotidine 5’-monophosphate decarboxylase
(OMPDC), 308
Oseltamivir, 248e249, 251, 253, 255
mechanism of, 255
Oseltamivir phosphate, 12
Osteogenic effects, 353
Oxaprozin, 328
Oxidative stress
infertility, 334
Ozenoxacin, 283e284

P
Palytoxin, 18f
Panacea, 185e186
Papaver somniferum, 259, 282
Paragrantia cf. waguensis, 263
Parasites mitochondrion, 349
Pathogenesis, 295
Pemphigus Vulgaris, 214
Peptides, 260e261
Peramivir, 249
Periodontal disease, 319
Peroxidoxins (PRDXs), 336e337
PfATP6, 308
Phaeodactylum tricornutum, 263
Pharmaceutical medications,
342e343
Phenolic acids
caffeic acid, 77
ferulic acid, 77
magnolol, 78
a-mangostins, 77
salvianolic acid A, 77
salvianolic acid B, 77
Phenolic compounds,
264e265, 280
Phenolic hydroxyl group act, 11
Phosphoenolpyruvate, 251e253
Photodynamic therapy, 217
Phytoalexins, 347
Phytochemicalegene interaction, 185
Phytochemicals, in silico antimalarial
potential of, 309
Pilocarpine, 26f
Piroxicam, 328
Plantago ovata, 334
Plant-derived phytochemicals with antiviral
effects, 250

immunomodulators, 250
modiﬁers of viral genome and protein
processing, 250e251
virus assembly and release inhibitors, 251
virus attachment and entry inhibitors, 250
Plant products, 334
Plant raw materials, shikimic acid isolation
from, 254e255
Plants, biosynthesis of shikimic acid in,
251e253
Plant sources of shikimic acid, 251,
252te253t
Plasmodium falciparum, 259, 296,
305e306, 306f
Plasmodium malariae, 295
Plasmodium ovale, 295
Plasmodium sugar transporters, 349e350
Plasmodium vivax, 266
Platelet-derived growth factor (PDGF), 352
Pneumotropic viruses, 246
Podophyllotoxin derivatives, 103e104
administration, 104
chemical structure, 103, 103f
clinical use, 104
mechanism, 103
pharmacokinetics, 104
Poliovirus, 242
Polycitone A, 250
Polyketides, 264
Polypeptides, 283
Polyphenols, 105e107
curcumin, 105e106
ﬂavonoids, 107
genistein, 106
gingerol, 106
resveratrol, 106e107
tea polyphenols, 106
Poly (ADP-ribose) polymerase
(PARP), 121
Polysaccharides, 264
Polysyphorin, 299
Potassium channels, 350e351
Prenylated ﬂavonoids, 347
antidiabetic activity, 348e349
antimalarial activity, 349e350
antimicrobial activity, 350
antioxidant activity, 350
apoptosis induction and anticancer
activity, 348
calcium and potassium channels, 350e351
cardiovascular disease, 351
chronic inﬂammatory skin diseases,
351e352
isolation, 348
liver ailments, 352
melanogenesis, 352
metabolism, 348
neuroprotective activity, 352e353
osteogenic effects, 353
renal interstitial ﬁbrosis, 352
Primaquine, 296e297
Programmed Cell Death, 215
Propionibacterium acnes, 259
Proteineligand interaction, 309e311

363

Protein preparation for antimalarial drug
discovery, 309
Protein processing, modiﬁers of, 250e251
Protein synthesis
aminoacyl t-RNA synthetases, 278
biosynthesis of cell wall, 278
DNA replication and repair, 277
Protein tyrosine phosphatases (PTPase), 133
Proteus vulgaris, 258
Pseudoalteromonas bacteriolytica, 258
Pseudoceratina purpurea, 259e260
Psoriasis, 213
Pyrethrum, 301

Q
QSAR. See Quantitative structureeactivity
relationships (QSAR)
Quantitative structureeactivity relationships
(QSAR), 29e31
Quinine, 26f, 296e297, 307
Quinones, 280

R
Rainfall, 21
Randomized clinical trial (RCT), 155
Reactive oxygen species (ROS), 180
Reactive oxygen species and infertility, 335
Regulatory approaches, botanical drug
development, 43e49
botanical raw materials, 45
carcinogenicity studies, 47
challenges, 43e44
clinical pharmacology, 47
Code of Federal Regulations (CFR), 47
description and documentation of
products, 44
efﬁcacy, 47e48
general toxicity studies, 46
genotoxicity studies, 47
labeling, 46
nonclinical safety assessment, 46e47
novel botanical drugs, 44
pharmacokinetic studies, 46
placebo, 46
quality control, 44e45
quality control systems, 45
record and document control, 45
reproductive toxicology, 47
safety, 47e48
safety tests, 45
therapeutic consistency, 48e49
Remijia ferruginea (Rubiaceae), 298
Renal interstitial ﬁbrosis, 352
Representational difference analysis
(RDA), 27
Resunab, 329
Resveratrol, 119e120
Reverse genetics, 28
Reverse pharmacology, 26e27, 27f
Rhaphidecurperoxin, 299
Ribavirin, 249
Rifampicin, 219
Rimantadine and amantadine, 249

364 Index

Rosmarinic acid (RA), 133
Rubiaceae, 298
Rubus idaeus, 148
Rutaceae, 298

S
Sargassum macrocarpum methanol, 259
Sargassum wightii species, 261
Scientiﬁc temper, 184e185
Seasonal inﬂuenza epidemics, 246e248
Seasonality, 20
Selective serotonin reuptake inhibitors
(SSRIs), 343
Semaglutide, 137
Serial analysis of gene expression (SAGE), 27
Sesquiterpene lactones, 308e309, 311
Sesquiterpenes, 308e309
Sesquiterpenoid hydroquinones, 258e259
Severe acute respiratory syndrome corona
virus (SARS-coV), 250
SGLT-2 inhibitors, 135
Shikimic acid, 251
chemical synthesis of, 253e254
Enzymatic synthesis of, 254
isolation from plant raw isolation from plant
raw, 254e255
mechanism of oseltamivir, 255
microbial synthesis of, 254
pathway, 254
in plants, biosynthesis of, 251e253
plant sources of, 251, 252te253t
Shikimic acid biosynthesis pathway, 253f
Short-term responses, 184
Sialadenitis, 246
Sigmosceptrellin B, 267
“Silent disease”, 353
Siliquariaspongia mirabilis, 260e261
Skin diseases
acne vulgaris, 213
albinism, 213
antihistamines drugs, 218
anti-leprosy resistant drugs, 219
auto-immune skin disease, 213
bacteria skin diseases, 212
dermatological disorders drugs, 217e218
topical drugs development, 219
disorders of pigmentation, 218
eczema skin diseases, 212
fungal skin infection, 212
green tea polyphenols, 216e217
isorhamnetin, 217
kaempferide, 217
kojicacid, 215
miscellaneous skin disease, 213
multi-drug therapy, 218e219

parasitic infections, 213
potential druggable targets, 213e215
resveratrol, 216
types, 212e213
viral skin diseases, 212e213
yeast skin infection, 212
Small-molecule inhibitor of tubulin
assembly, 8e10
Smart insulin, 137e138
Sodium glucose cotransporter (SGLT),
348e349
Solanum khasianum, 282
Solanum nigrescens, 286
Sophora ﬂavescens, 347
Sotagliﬂozin, 136e137
Staphylococcus aureus, 259
Steroids, 265
Stilbenoids, 281
Structure-based drug design (SBDD), 27
Sulfated Polymannuronate (SPM), 262
Sulfated polysaccarides, 261e262
Sulfono Quinovosyl Dipalmitoyl Glyceride
(SQDG), 263
Sulfonylureas, 135
Supercritical ﬂuid extraction (SFE), 16
Superoxide dismutase, 336
Suvarna bhasma, 342
Synthetic antioxidants, 180
Systemic antibiotics, 217
Syzygium claviﬂorum, 251

T
Tannins, 281e282
Target proteins, 311
Tea polyphenols, 106
Telithromycin, 286
Temperature, 21
Terbinaﬁne, 217
Terpenoids and essential oils, 282
Terpenoids/isoprenoids/modiﬁed terpenes,
258e259
Tetracyclines, 276e277
Thelenota ananas, 262
Thiazolidinediones, 135e136
Thiopeptides, 260e261
Ticodendraceae, 298
Ticodendron incognitum
(Ticodendraceae), 298
Toxicity, 21
Trans-fatty acid, 337
Triacylglycerol, 351
Trichoderma koningii, 264
Triterpene glycosides, 262e263
Triterpenoid acids, 108
Tubulin inhibitors, 8e10

Type A inﬂuenza, 248
Type 1 diabetes mellitus (T1DM), 128
Type 2 diabetes mellitus (T2DM), 128

U
Ulcerative colitis, 319
Uncoupling protein 1 (UCP1), 147e148
Unhealthy diet and infertility, 337

V
Vabomere, 285
Vinca alkaloids
administration, 97
chemical structure, 97, 97f
clinical use, 97
drug interactions, 100
mechanism, 97
mechanisms of resistance, 99e100
pharmacokinetics, 97
semysynthetic derivatives, 99e100, 99f
vindesine, 99
vinﬂunine, 99
vinorelbine, 99
vinblastine, 98
vincristine, 97e98
Viral genome, modiﬁers of, 250e251
Viral infections, 245e246
Viral neuraminidase (NA) enzyme, 255
Virion, 245
Virus assembly and release inhibitors, 251
Virus attachment and entry inhibitors, 250
Viruses, 245
classiﬁcation of, 246, 247t
inﬂuenza and its various forms, 246
epidemiology, 246e248
FDA-approved drugs for inﬂuenza,
248e250
types of inﬂuenza viruses, 248
various classes of, 246
Vitamin C, 336
Vitamin E, 335

W
Wild birds, 248
Withania somnifera, 334, 339

X
Xanthones, 153, 153t
X-ray crystallography, 26

Z
Zanamivir, 248e249

